

Venous thromboembolism in over 16s

Reducing the risk of hospital-acquired deep vein
thrombosis or pulmonary embolism

NICE guideline (volume 2)

Methods, evidence and recommendations

October 2017

Draft for consultation

*Developed by the National Guideline Centre,
hosted by the Royal College of Physicians*

Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and, where appropriate, their carer or guardian.

Local commissioners and providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© NICE 2017. All rights reserved. Subject to [Notice of rights](#).

Contents

23	Anaesthesia	9
23.1	Introduction	9
23.2	Clinical evidence on anaesthesia	9
23.2.1	Regional vs. general anaesthesia	9
23.2.2	Subgroup analysis of epidural vs spinal anaesthesia	10
23.2.3	Regional and general anaesthesia vs general anaesthesia only	10
23.2.4	Risk of haematoma in anticoagulated patients receiving a regional anaesthetic	11
23.3	Cost-effectiveness evidence	11
23.4	Recommendations and link to evidence.....	11
24	Lower limb immobilisation	15
24.1	Introduction	15
24.2	Review question: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) in people with lower limb immobilisation?.....	15
24.3	Clinical evidence.....	17
24.4	Economic evidence	27
24.5	Evidence statements	27
24.6	Recommendations and link to evidence.....	27
25	Fragility fractures of the pelvis, hip and proximal femur	30
25.1	Introduction	30
25.2	Review question: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people with fragility fractures of the pelvis, hip or proximal femur?	30
25.3	Clinical evidence.....	32
25.4	Economic evidence	52
25.5	Evidence statements	55
25.6	Recommendations and link to evidence.....	57
26	Elective hip replacement surgery	63
26.1	Introduction	63
26.2	Review question: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing elective hip replacement?.....	63
26.3	Clinical evidence.....	65
26.4	Economic evidence	131
26.5	Evidence statements	141
26.6	Recommendations and link to evidence.....	150
27	Elective knee replacement surgery	155

27.1	Introduction	155
27.2	Review question: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing elective knee replacement surgery?	155
27.3	Clinical evidence.....	157
27.4	Economic evidence	207
27.5	Evidence statements.....	217
27.6	Recommendations and link to evidence.....	224
28	Non-arthroplasty orthopaedic knee surgery	228
28.1	Introduction	228
28.2	Review question: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) in people having non-arthroplasty knee surgery?	228
28.3	Clinical evidence.....	230
28.3.1	Pairwise comparisons: overall population stratum	234
28.3.2	Pairwise comparisons: Major arthroscopic surgery stratum	238
28.3.3	Pairwise comparisons: Minor arthroscopic surgery stratum	239
28.4	Economic evidence	240
28.5	Evidence statements.....	240
28.5.1	Clinical	240
	LMWH compared with no prophylaxis	240
28.6	Recommendations and link to evidence.....	241
29	Foot and ankle orthopaedic surgery	244
29.1	Introduction	244
29.2	Review question: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) in people having foot and ankle surgery?	244
29.3	Clinical evidence.....	246
29.4	Economic evidence	246
29.5	Evidence statements.....	246
29.6	Recommendations and link to evidence.....	246
30	Upper limb orthopaedic surgery	248
30.1	Introduction	248
30.2	Review question: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) in people having upper limb surgery?.....	248
30.3	Clinical evidence.....	250
30.4	Economic evidence	250
30.5	Evidence statements.....	250
30.6	Recommendations and link to evidence.....	250

31 Elective spinal surgery.....	252
31.1 Introduction	252
31.2 Review question: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing spinal surgery?	252
31.3 Clinical evidence.....	254
31.4 Economic evidence	258
31.5 Evidence statements.....	258
31.6 Recommendations and link to evidence.....	258
32 Intracranial surgery.....	262
32.1 Introduction	262
32.2 Review question: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing intracranial surgery?	262
32.3 Clinical evidence.....	264
32.3.1 Strata: People undergoing intracranial surgery (non-tumour specific)	267
32.3.2 Strata: People with intracranial tumour having neurosurgery	268
32.4 Economic evidence	272
32.5 Evidence statements.....	272
32.6 Recommendations and link to evidence.....	273
33 Spinal injury	276
33.1 Introduction	276
33.2 Review question: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people with spinal injury?	276
33.3 Clinical evidence.....	278
33.4 Economic evidence	284
33.5 Evidence statements.....	284
33.6 Recommendations and link to evidence.....	284
34 Major trauma	287
34.1 Introduction	287
34.2 Review question: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people with major trauma?	287
34.3 Clinical evidence.....	289
34.4 Economic evidence	305
34.5 Evidence statements.....	308
34.6 Recommendations and link to evidence.....	309
35 Abdominal surgery (excluding bariatric surgery)	313
35.1 Introduction	313
35.2 Review question: What is the effectiveness of different pharmacological and	

mechanical prophylaxis strategies (alone or in combination) for people undergoing abdominal surgery (gastrointestinal, gynaecological, urological)?.....	314
35.3 Clinical evidence.....	316
35.4 Economic evidence	371
35.5 Evidence statements.....	375
35.6 Recommendations and link to evidence.....	381
36 Bariatric surgery	385
36.1 Introduction	385
36.2 Review question: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing bariatric surgery?	385
36.3 Clinical evidence.....	387
36.4 Economic evidence	391
36.5 Evidence statements.....	393
36.6 Recommendations and link to evidence.....	393
37 Cardiac surgery	396
37.1 Introduction	396
37.2 Review question: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing cardiac surgery?	396
37.3 Clinical evidence.....	398
37.4 Economic evidence	402
37.5 Evidence statements.....	402
37.6 Recommendations and link to evidence.....	402
38 Thoracic surgery	405
38.1 Introduction	405
38.2 Review question: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing thoracic surgery?.....	405
38.3 Clinical evidence.....	406
38.4 Economic evidence	407
38.5 Evidence statements.....	409
38.6 Recommendations and link to evidence.....	409
39 Vascular surgery	412
39.1 Introduction	412
39.2 Review question: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing vascular surgery?	412
39.3 Clinical evidence.....	414
39.3.1 Strata: overall (not specified).....	419
39.3.2 Strata: Varicose veins	420

39.3.3	Strata: Lower limb amputation	424
39.4	Economic evidence	426
39.5	Evidence statements	426
39.6	Recommendations and link to evidence.....	427
39.6.1	Open vascular surgery or endovascular aneurysm repair	427
39.6.2	Lower limb amputation	429
39.6.3	Varicose vein surgery	430
40	Head and neck surgery.....	432
40.1	Oral and maxillofacial surgery.....	432
40.1.1	Introduction	432
40.1.2	Review question: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing oral or maxillofacial surgery?.....	432
40.1.3	Clinical evidence.....	434
40.1.4	Economic evidence.....	434
40.1.5	Evidence statements	434
40.1.6	Recommendations and link to evidence.....	434
40.2	ENT surgery	436
40.2.1	Introduction	436
40.2.2	Review question: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing ear, nose or throat (ENT) surgery?	436
40.2.3	Clinical evidence.....	438
40.2.4	Economic evidence.....	438
40.2.5	Evidence statements	438
40.2.6	Recommendations and link to evidence.....	438
41	Acronyms and abbreviations.....	440
42	Glossary	441
42.1	Guideline-specific terms	441
42.2	General terms	443
	Reference list.....	454

23 Anaesthesia

23.1.2 Introduction

3
4 Anaesthesia is required for most operations and many investigations and other
5 procedures. A general anaesthetic results in a patient losing consciousness. A regional
6 anaesthetic technique involves injecting local anaesthetic into the epidural space (an
7 epidural anaesthetic) or the subarachnoid space (a spinal anaesthetic) to achieve a
8 sensory and/or motor block of the required area^a. Other drugs such as opioids may be
9 added to the local anaesthetic agents or used as sole agents. Spinal injections are
10 usually given as a single dose with a limited duration of action. Epidural anaesthesia
11 may be continued for hours or days by placing additional medication through a catheter
12 left in the epidural space. Regional techniques may be combined with sedation or a
13 general anaesthetic. Certain procedures such as caesarean section, some urological
14 operations or orthopaedic procedures on the lower limbs, are well suited to the use of
15 regional techniques. Other procedures such as intracranial neurosurgery are not suitable.
16 The use of regional anaesthesia is rare in cardiac surgery but may be used for thoracic
17 and vascular operations.

18 A concern with regional anaesthesia is that when neuroaxial blockades are used,
19 thromboprophylaxis agents will increase the risk of spinal haematoma. Therefore, the
20 timing of the use drugs that affect haemostasis or platelet function should be carefully
21 planned.

23.2.2 Clinical evidence on anaesthesia

23.2.2.3 Regional vs. general anaesthesia

24
25 We identified one systematic review of 11 RCTs of regional vs general anaesthesia²⁵⁶
26 and four additional RCTs giving a total of 15 studies with 1115 participants (Evidence
27 Table 64, Appendix D). Twelve studies were in elective orthopaedic surgery patients,
28 two urological and one in general surgery patients. Eleven studies used an epidural
29 regional anaesthetic and four administered a spinal anaesthetic. Eight of the 11 studies
30 using epidural anaesthesia continued the anaesthetic into the post-operative period for
31 pain relief (in the remaining three studies the duration of the epidural anaesthetic was
32 either unclear or not reported). In seven studies patients were given no prophylaxis for
33 VTE, patients wore stockings in three studies, and received a pharmacological method of
34 prophylaxis in five studies.

^a The committee note the following edit to the definition for regional and local anaesthesia in the introduction:

'A regional anaesthetic technique involves injecting local anaesthetic to achieve a sensory and/or motor block of the required area. Regional anaesthesia may include:

1. Central neuro-axial (CNA) blockade (which includes spinal, epidural and combined spinal and epidural (CSE) anaesthesia).
2. Peripheral regional nerve block (which includes single shot techniques and continuous blockade using indwelling catheters).

Local anaesthesia involves the local infiltration of anaesthetic to achieve a sensory and/or motor block of a more local area.'

1 Nine studies were conducted in the 1980s and six in the 1990s, with the most recent trial
2 published in 1996. It should be noted that general anaesthetic techniques and other
3 aspects of perioperative management have changed considerably over this period.

4 All included RCTs were either individually critically appraised to be of a high quality
5 (level 1+ or level 1++) or came from systematic reviews of RCTs which had been
6 critically appraised to be of a high quality (level 1+ or level 1++).

7 **Effect on DVT:** A significant risk reduction for DVT was found in patients receiving
8 regional compared with general anaesthesia (38%) (RR=0.62, 95% CI: 0.53 to 0.73, 15
9 studies) (Forest Plot 242, Appendix E).

10 **Effect on pulmonary embolism:** Regional anaesthesia was significantly more effective
11 in reducing risk of pulmonary embolism than general anaesthesia, with an overall
12 reduction of 43% (RR=0.57, 95% CI: 0.35 to 0.91) (Forest Plot 243, Appendix E).

13 **Effect on major bleeding:** Seven studies measured major bleeding events. Only one
14 study reported an event, (RR=0.10, 95% CI: 0.01 to 1.71). The difference was not
15 significant (Forest Plot 245, Appendix E).

23.2.26 Subgroup analysis of epidural vs spinal anaesthesia

17
18 We found no RCTs comparing spinal and epidural anaesthesia with regard to the
19 development of post-operative VTE. A subgroup analysis of the regional vs general
20 anaesthesia RCTs was carried out to look for a difference in the magnitude of effect
21 based on whether spinal or epidural regional anaesthesia was used. Eleven studies used
22 epidural and four studies used spinal regional anaesthesia.

23 For deep vein thrombosis, a random effects meta-analysis was used, due to the
24 heterogeneity within the results. Subgroup analyses were not possible for proximal DVT
25 and major bleeding as there were no studies using spinal anaesthesia that assessed
26 these variables.

27 **Effect on DVT:** A significantly reduced risk of DVT was found with both epidural
28 compared with general anaesthesia (RR=0.62, 95% CI: 0.51 to 0.75, 11 studies) and
29 spinal compared with general anaesthesia (RR=0.63, 95% CI: 0.48 to 0.83, 4 studies).
30 No significant difference in the magnitude of effect between epidural and spinal
31 anaesthesia was found (Chi-square on 1 df = 0.03, p=0.86) (Forest Plot 246, Appendix
32 E).

33 **Effect on pulmonary embolism:** We found a significantly reduced risk with epidural
34 compared to general anaesthesia (RR=0.61, 95% CI: 0.38 to 0.99, 5 studies). There was
35 a significant difference in risk of developing pulmonary embolism in a comparison of
36 spinal vs general anaesthesia (RR=0.47, 95% CI: 0.23 to 0.96). There was no significant
37 difference in the magnitude of effect between epidural and spinal anaesthesia Chi-
38 square on 1 df = 0.42, p=0.52) (Forest Plot 247, Appendix E).

23.2.39 Regional and general anaesthesia vs general anaesthesia only

40
41 One study in the systematic review mentioned above²⁵⁶ and one further study⁶⁹
42 compared the combined use of regional anaesthesia and general anaesthesia with
43 general anaesthesia alone (Evidence Table 65, Appendix D). One study⁶⁹ was in elective
44 hip surgery patients. All patients received vitamin K antagonists for VTE prophylaxis.
45 Patients receiving regional anaesthesia had an epidural for the duration of surgery only.

1 The study was small, with only 37 patients. The second study¹⁴² was of general surgery
2 (elective gall bladder) patients. No VTE prophylaxis was given to patients in the study.
3 For regional anaesthesia patients, the epidural was prolonged into the post-operative
4 period for pain relief. The studies did not report major bleeds or pulmonary embolism.
5 One study⁶⁹ reported the site of deep vein thrombosis. No patient had a DVT that was
6 situated above the knee and therefore the relative risk of proximal DVT was not
7 estimable.

8 **Effect on DVT:** No significant difference was found (RR=0.69, 95% CI: 0.26 to 1.82, two
9 studies) (Forest Plot 248, Appendix E).

23.2.40 Risk of haematoma in anticoagulated patients receiving a regional anaesthetic

11
12 Risk of haematoma at the injection site is increased with the concomitant use of
13 pharmacological prophylaxis agents. Removal of epidural catheter in the anticoagulated
14 patient has also been associated with the development of spinal haematoma. The
15 consequences of an epidural haematoma may be permanent paralysis below the level
16 of the haematoma. The diagnosis is difficult as patients may have weakness or block
17 because of the effects of the epidural. It would be extremely difficult to determine the
18 true incidence as a randomised study would require very large numbers of patients due
19 to the rarity of the event, however it has been estimated to be about 1 in 150,000
20 epidural blocks and 1 in 220,000 spinal anaesthetics.⁴⁰

23.3.1 Cost-effectiveness evidence

22
23 No cost effectiveness analysis was completed for this population.

23.4.4 Recommendations and link to evidence

25

Recommendation	75. Consider regional anaesthesia for individual patients, in addition to other methods of VTE prophylaxis, as it carries a lower risk of VTE than general anaesthesia. Take into account the person's preferences, their suitability for regional anaesthesia and any other planned method of VTE prophylaxis. [2010]
Relative values of different outcomes	The outcomes considered were thromboembolic events (asymptomatic and symptomatic DVT, symptomatic pulmonary embolism and fatal pulmonary embolism), bleeding events (major bleeding, fatal bleeding and stroke) and other long term events occurring as a result of VTE (chronic thromboembolic pulmonary hypertension and post thrombotic syndrome).
Trade off between clinical benefit and harms	The benefit of reducing the risk of venous thromboembolism and long term events occurring as a result of thromboembolism were considered against the risk of major bleeding. The timing of when pharmacological prophylaxis is started is particularly important because of the risk from bleeding.

Economic considerations

We found no evidence on the cost-effectiveness of regional anaesthesia compared with general anaesthesia in the context of VTE prophylaxis. However, there is a small body of literature that shows regional anaesthesia to be associated with faster recovery time and reduced cost for some types of surgery.^{215,311} This would suggest that, when it can be performed safely, regional anaesthesia is likely to be a highly cost-effective form of VTE prophylaxis.

Quality of evidence

All included RCTs were either individually critically appraised to be of a high quality (level 1+ or level 1++) or came from systematic reviews of RCTs which had been critically appraised to be of a high quality (level 1+ or level 1++).

Evidence from RCTs shows that regional anaesthesia compared with general anaesthesia reduces the risk of developing postoperative VTE. There was not enough evidence to determine differences in effect for major bleeding.

Other considerations

The evidence is limited to certain surgical procedures and there are other considerations involved when selecting an anaesthetic technique. Patient preferences are also an important consideration.

Regional anaesthesia alone should not be considered a suitable method of VTE prophylaxis. There are effective alternative techniques to prevent these complications and other matters to be taken into account when deciding on the most appropriate anaesthetic for a patient. In the absence of data on bleeding and the practical implications for different surgical procedures the guideline development group decided to recommend that its use be considered where practical in addition to other methods of prophylaxis.

Neuroaxial blockade should be avoided in those patients with significant bleeding disorders or receiving certain drugs that affect haemostasis or platelet function. The summary of product characteristics for each agent should be consulted for the latest guidance.

1 **1.1.1 Supporting recommendation based on Guideline Development Group consensus**
2 **opinion**

Recommendation	76. If regional anaesthesia is used, plan the timing of pharmacological VTE prophylaxis to minimise the risk of epidural haematoma. If antiplatelet or anticoagulant agents are being used, or their use is planned, refer to the summary of product characteristics for guidance about the safety and timing of these in relation to the use of regional anaesthesia. [2010]
Trade off between clinical benefit and harms	The benefit of reducing the risk of venous thromboembolism and long term events occurring as a result of thromboembolism were considered against the risk of major bleeding. An additional concern is the risk of developing an epidural haematoma as a result of the regional anaesthetic technique. Consequently, the Guideline Development Group recommends that the timing of pharmacological prophylaxis should be carefully planned to minimise the risk of spinal haematoma if a regional anaesthetic technique is used. Patients using antiplatelets or anticoagulant agents may be at increased risk of bleeding.
Economic considerations	We found no evidence on the cost-effectiveness of the timing of regional anaesthesia. However, it seems logical that the careful consideration of timing will improve the cost-effectiveness of regional anaesthesia.
Other considerations	<p>The type of anticoagulant used may affect the timing of insertion and removal of the catheter. Such procedures should be delayed until the anticoagulant effect of the agent is minimal. For example, this may involve removing the catheter just before the next dose of thromboprophylaxis and delaying any further thromboprophylaxis for 2 hours after epidural catheter removal.</p> <p>The requirements for each antiplatelet agent or anticoagulant will be different. The guideline development group recommends that clinicians refer to information within the summary of product characteristics for each agent and seek advice from experienced anaesthetists if uncertainty remains.</p> <p>The balance of risks and benefits should be individualised for each patient and will depend on the type of regional anaesthesia, patient risk factors (including bleeding risks), and the type and dose of anticoagulant or use of other drugs affecting haemostasis or platelet function. An additional concern is the risk of developing an epidural haematoma as a result of a regional anaesthetic technique.</p>

3

1

Recommendation	77. Do not routinely offer pharmacological or mechanical VTE prophylaxis to people undergoing a surgical procedure with local anaesthesia by local infiltration with no limitation of mobility. [2010]
Trade off between clinical benefit and harms	The benefit of reducing the risk of venous thromboembolism and long term events occurring as a result of thromboembolism were considered against the risk of major bleeding.
Economic considerations	None
Other considerations	The guideline development group decided that although a risk assessment for VTE should still be required upon admission to hospital, patients undergoing minor procedures under local anaesthesia without reduced mobility were likely to be at a low risk of VTE and as such routine prophylaxis was not likely to be beneficial.

24 Lower limb immobilisation

24.1.2 Introduction

3 The use of lower limb immobilisation techniques in trauma and elective orthopaedic surgery affects a
4 significant number of patients. The populations involved include trauma patients who do not require
5 surgery, trauma patients who have had operative fixation and elective cases usually involving the
6 knee, foot and ankle. Immobilisation (such as with a plaster cast or brace) may be used for three
7 months or more following the intervention. Certain groups may be at greater risk for VTE, for
8 example, those undergoing conservative or operative treatment for rupture of the tendoachilles and
9 those patients undergoing more complex procedures with longer immobilisation.

24.2.0 Review question: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) in people with lower limb immobilisation?

13 For full details see review protocol in Appendix C.

14 **Table 1: PICO characteristics of review question**

Population	<p>Adults and young people (16 years and older) with lower limb immobilisation who are:</p> <ul style="list-style-type: none"> • Admitted to hospital • Having day procedures • Outpatients post-discharge <p>Immobilisation is defined as any clinical decision taken to manage the affected limb in such a way as to prevent normal weight bearing status and/or use of that limb.</p>
Intervention(s)	<p>Mechanical:</p> <ul style="list-style-type: none"> • Anti-embolism stockings (AES) (above or below knee) • Intermittent pneumatic compression (IPCD) devices (full leg or below knee) • Foot pumps or foot impulse devices (FID) • Electrical stimulation (including Geko devices) <p>Pharmacological:</p> <ul style="list-style-type: none"> • Unfractionated heparin (UFH) (low dose, administered subcutaneously) • Low molecular weight heparin (LMWH), licensed in UK: <ul style="list-style-type: none"> ○ enoxaparin (standard prophylactic dose 40mg daily; minimum 20mg daily* to maximum 60mg twice daily*) ○ dalteparin (standard prophylactic dose 5000 units once daily; minimum 1250 units once daily* to maximum 5000 units twice daily*; obese patients – maximum 7500 twice units daily*) ○ tinzaparin (standard prophylactic dose 4500 units once daily; minimum 2500 units once daily* to maximum 4500 units twice daily*; obese patients – maximum 6750 twice daily*) • LMWH, licensed in countries other than UK: <ul style="list-style-type: none"> ○ Bemiparin (standard 2500 units daily; minimum 2500 units daily to maximum 3500 units daily) ○ Certoparin (3000 units daily) ○ Nadroparin (standard 2850 units once daily; minimum 2850 units once daily to maximum up to 57 units/kg once daily) ○ Parnaparin (standard 3200 units once daily; minimum 3200 units once daily to maximum 4250 units once daily) ○ Reviparin (minimum 1750 units once daily to maximum 4200 units once daily)

	<ul style="list-style-type: none"> • Vitamin K Antagonists: <ul style="list-style-type: none"> ○ warfarin (variable dose only) ○ acenocoumarol (all doses) ○ phenindione (all doses) • Fondaparinux (all doses)* • Apixaban (all doses)* • Dabigatran (all doses)* • Rivaroxaban (all doses)* • Aspirin (up to 300mg)* <p>*off-label</p>
Comparison(s)	<p>Compared to:</p> <ul style="list-style-type: none"> • Other VTE prophylaxis treatment, including monotherapy and combination treatments (between class comparisons for pharmacological treatments only) • No VTE prophylaxis treatment (no treatment, usual care, placebo) <p>Within intervention (including same drug) comparisons, including:</p> <ul style="list-style-type: none"> • Above versus below knee stockings • Full leg versus below knee IPC devices • Standard versus extended duration prophylaxis • Low versus high dose for LMWH • Preoperative versus post-operative initiation of LMWH
Outcomes	<p>Critical outcomes:</p> <ul style="list-style-type: none"> • All-cause mortality (up to 90 days from hospital discharge) • Deep vein thrombosis (symptomatic and asymptomatic) (7-90 days from hospital discharge. Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) • Pulmonary embolism (7-90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE • Major bleeding (up to 45 days from hospital discharge). A major bleeding event meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood ; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event. Includes unplanned visit to theatre for control of bleeding • Fatal PE (7- 90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE <p>Important outcomes:</p> <ul style="list-style-type: none"> • Clinically relevant non-major bleeding (up to 45 days from hospital discharge): bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy. • Health-related quality of life (validated scores only)(up to 90 days from hospital discharge) • Heparin-induced thrombocytopenia (HIT) (duration of study) • Technical complications of mechanical interventions (duration of study) • Unplanned return to theatre (up to 45 days from hospital discharge)
Study design	Randomised controlled trials (RCTs), systematic reviews of RCTs

24.3.1 Clinical evidence

2 Twelve studies were included in the review^{41,77,78,155,168,172,178,179,185,263,269,301}; these are summarised
3 in Table 2 below. Six studies were included from the previous guideline (CG92)^{155,168,172,178,179,185}. Six
4 studies were added in the update^{41,77,78,263,269,301}. Evidence from these studies is summarised in the
5 clinical evidence summary below (Table 3, Table 4, Table 5, Table 6). See also the study selection flow
6 chart in Appendix E, forest plots in Appendix L, study evidence tables in Appendix H, GRADE tables in
7 Appendix K and excluded studies list in Appendix N.

8 The included studies cover a heterogeneous population of surgically and non-surgically treated
9 patients with injuries as diverse as simple ankle fractures to those with Achilles tendon ruptures. The
10 evidence features a number of different immobilisation techniques (for example plaster cast or
11 brace), and there is large variation in the duration of immobilisation, ranging from 2 weeks to 6
12 weeks.

13 **Table 2: Summary of studies included in the review**

Study	Intervention and comparison	Population	Outcomes	Comments
Bruntink 2017 PROTECT trial ⁴¹	<p>Intervention (n=154): LMWH, standard dose (nadroparin, 0.3ml). For the duration of immobilisation, mean (SD) 40.2 (8.5) days</p> <p>Intervention (n=157): Fondaparinux 2.5mg. For the duration of immobilisation, mean (SD) 38.0 (8.7) days</p> <p>Comparison (n=156): no VTE prophylaxis. For the duration of immobilisation, mean (SD) 40.3 (8.6) days</p>	<p>n=467</p> <p>People with a fracture of the ankle or foot who required non-surgical treatment with immobilisation in a below-knee plaster cast for a minimum of four weeks.</p> <p>Adults (mean age LMWH 47.7, fondaparinux 49.7, control 44.5)</p> <p>Male to female ratio 118:160</p> <p>The Netherlands</p>	<p>DVT (40 days): verified by duplex sonography</p> <p>PE (40 days): verified by CT angiography</p> <p>Major bleeding (40 days): no definition</p>	
Domeij-arverud 2013 ⁷⁸	<p>Intervention (n=14): IPCD, foot. Fitted unilaterally beneath plaster cast. Duration 2 weeks post-op</p> <p>Comparison (n=12): no VTE</p>	<p>n=26</p> <p>People with plaster cast due to acute unilateral tendo Achillis rupture after open TA repair</p> <p>Adults (mean age intervention 39.8, control</p>	<p>DVT (42 days): confirmed with colour Doppler sonography</p>	

Study	Intervention and comparison	Population	Outcomes	Comments
	prophylaxis	40.4; range 27-50 years) Male to female ratio 1:1 Sweden		
Domeij-arverud 2015 ⁷⁷	Intervention (n=74): IPCD, calf. Fitted bilaterally, beneath plaster cast on operated leg. Duration 2 weeks post-op Comparison (n=74): no VTE prophylaxis	n=148 People with plaster cast due to acute unilateral tendo Achillis rupture Adults (mean 40.9 years; range 26-62) Male to female ratio 88:21 Sweden	PE (42 days): CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography DVT (42 days): in operated leg confirmed by compression duplex ultrasound	
Jorgensen 2002 ¹⁵⁵	Intervention (n=148): LMWH, standard dose (tinzaparin 3500U). Self-injected into abdominal wall once daily until plaster cast removed. Mean duration 5.5 weeks. Comparison (n=152): no VTE prophylaxis	n=300 People with below knee plaster casts on lower extremity. Reasons for plaster cast: fracture 73.3%, tendon rupture 20.3%, other 6.3% Adults (>18 years; mean 49 years) Male to female ratio 128:172 Denmark	PE (mean 38 days): method of confirmation not reported DVT (mean 38 days): diagnosed by ascending unilateral venography when plaster cast removed	Included in CG92
Kock 1995 ¹⁶⁸	Intervention (n=176 analysed): LMWH, standard dose (certoparin 3000U) until cast removed (mean immobilisation time 15 days [sd 12, no range reported]) Comparison (n=163 analysed): no VTE prophylaxis.	n=428 People with plaster cast (below knee 85.5%, above knee 14.55%). Reason for plaster cast: Grade II sprains and bruises 28.5%, Grade III sprains 30.4%, fractures 16.8%, other 3.5% Adults (mean intervention 34.1 years, comparison 33 years; range 18-63 years) Male to female ratio 208:131	DVT (until plaster cast removed). Confirmed by venography when plaster cast removed Major bleeding (until plaster cast removed): no definition reported	Included in CG92

Study	Intervention and comparison	Population	Outcomes	Comments
	(mean immobilisation time 18 days [sd 13, range 2-72 days])	Germany		
Kujath 1993 ¹⁷²	<p>Intervention (n=126): LMWH, standard dose (nadroparin, 0.3ml). Started on first day of treatment, continued until plaster cast removed (mean 15.6 [6.8] days, range 7-41)</p> <p>Comparison (n=127): no VTE prophylaxis. Mean period of plaster cast 15.8 [9.6] days, range 5-66)</p>	<p>n=306</p> <p>People with plaster cast. Reason for plaster cast: soft tissue injury 70%, fractures 30%</p> <p>Young people (aged >16 years; mean intervention 32.9±13.8, comparison 35.6±14.6)</p> <p>Male to female ratio 146:107</p> <p>Germany</p>	DVT (until plaster cast removed): diagnosed by ultrasound confirmed by venography	Included in CG92
Lapidus 2007A ¹⁷⁸	<p>Intervention (n=52): LMWH, standard dose (Dalteparin 5000U). Started within hours post-surgery, up to 6th week, or mobilisation</p> <p>Comparison (n=53): No VTE prophylaxis (placebo)</p>	<p>n=105</p> <p>People with below knee plaster cast due to Achilles tendon rupture</p> <p>Adults (mean 40 years, range 18-75)</p> <p>Male to female ratio 83:22</p> <p>Sweden</p>	<p>All-cause mortality (42 days)</p> <p>PE, fatal (42 days): method of confirmation not reported</p> <p>PE (42 days) : method of confirmation not reported</p> <p>DVT (42 days): confirmed by unilateral ascending phlebography of the affected legs, or colour duplex sonography (CDS) when phlebography fails at the 3rd week and 6th week, on the last day of the dose (or a day after), and when thrombosis is suspected, whichever earlier</p> <p>Major bleeding (42 days): requiring blood transfusion/ surgery, or at a critical site such as intracranial, intraocular, intraspinal, or retroperitoneal</p>	Included in CG92
Lapidus 2007B ¹⁷⁹	<p>Intervention (n=136): LMWH, standard dose</p>	<p>n=272</p> <p>People with lower limb</p>	<p>All-cause mortality (42 days)</p> <p>PE, fatal (42 days): method of</p>	Included in CG92

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>(Dalteparin 5000U). Started within hours post-surgery, up to 6th week, or mobilisation</p> <p>Comparison (n=136): No VTE prophylaxis (placebo)</p>	<p>immobilisation (82% plaster cast, 18% orthosis), due to acute ankle fracture</p> <p>Adults (mean years 48, range 18-76)</p> <p>Male to female ratio 124:148</p> <p>Sweden</p>	<p>confirmation not reported</p> <p>PE (42 days): confirmed by: ventilation perfusion scan or spiral CT if suspected</p> <p>DVT (42 days): screened for by unilateral ascending phlebography of the affected legs, or colour duplex sonography (CDS) when phlebography fails at 2nd and 6th week, on the last day of the dose (or a day after), and when thrombosis is suspected, whichever earlier</p> <p>Major bleeding (42 days): requiring blood transfusion/ surgery, or at a critical site such as intracranial, intraocular, intraspinal, or retroperitoneal</p>	<p>Both groups received LMWH for one week prior to randomisation.</p>
Lassen 2002 ¹⁸⁵	<p>Intervention (n=217): LMWH, standard dose (reviparin 1750U). Mean duration of immobilisation: 43 days.</p> <p>Comparison (n=223): no VTE prophylaxis. Mean duration of immobilisation: 44 days.</p>	<p>n=440</p> <p>People with plaster cast (84.3%) or brace, due to fracture of leg (80%) or rupture of Achilles tendon (20%)</p> <p>Adults (median 47 years; range 37-55)</p> <p>Male to female ratio 112:105</p> <p>Denmark</p>	<p>DVT (until plaster cast removed): diagnosed by unilateral venography within a week of plaster cast removal</p> <p>PE (until plaster cast removed): confirmed by ventilation perfusion scanning</p> <p>Major bleeding (until plaster cast removed): defined as clinically apparent bleeding associated with a decrease of at least 2.0g per deciliter in the haemoglobin level, requirement for transfusion of at least 2 units of packed red cells, or retroperitoneal or intracranial bleeding or other bleeding that investigators decided required permanent discontinuation of treatment</p>	<p>Included in CG92</p> <p>Some patients (31%) who underwent surgery had heparin treatment up to 4 days before randomisation.</p>
Samama 2013 ²⁶³	<p>Intervention 1 (n=675): Fondaparinux 2.5mg (or 1.5mg in people with a calculated creatinine clearance between 30-50mL min⁻¹). Duration 21-45</p>	<p>n=1349</p> <p>People with lower limb immobilisation (plaster cast 83.8%, brace 6.2%, other 10%), due to non-surgical, unilateral single or multiple below-knee injury including: Fracture (most commonly concerning the external</p>	<p>All-cause mortality (21-45 days)</p> <p>PE (21-45 days): confirmed by CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography</p> <p>DVT (21-45 days): confirmed by</p>	

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>days (until mobilisation). Mean duration of immobilisation 33.5 (9.4) days.</p> <p>Intervention 2 (n=674): LMWH, standard dose (nadroparin 2850 units). Duration 21-45 days (until mobilisation). Mean duration of immobilisation 33.9 (9.0) days.</p> <p>Concurrent medication: Free to take acetaminophen as needed. Use of aspirin or NSAIDs was allowed but discouraged</p>	<p>malleolus and the metatarsus) 89%; Achilles tendon rupture 2%; Other injury 11%</p> <p>Adults (≥ 18 years; mean 46)</p> <p>Male to female ratio 1:1</p> <p>Multicentre international</p>	<p>ultrasonography</p> <p>Major bleeding (21-45 days): overt and fatal, occurred in a critical organ, was associated with a fall in haemoglobin concentration ≥ 2g dL⁻¹, or led to a transfusion ≥ 2 units of packed red blood cells or whole blood</p> <p>Clinically-relevant major bleeding (21-45 days): bleeding not qualifying as major, including bleeding leading to treatment discontinuation, gastrointestinal bleeding, haemoptysis, cutaneous hematoma >100cm², epistaxis >5 minute, recurrent or leading to intervention, spontaneous macroscopic haematuria >24 hour</p> <p>Heparin-induced thrombocytopenia (21-45 days)</p>	
Selby 2015 ²⁶⁹	<p>Intervention (n=134): LMWH, standard dose (dalteparin 5000U). Duration 2 weeks. Mean immobilisation duration 44 (26) days.</p> <p>Comparison (n=131): no VTE prophylaxis. Mean immobilisation duration 42 (29) days.</p> <p>Concurrent medication: Aspirin and other antiplatelet agents were</p>	<p>n=265</p> <p>People with lower limb immobilisation in cast or splint (98.1%) due to unilateral (97.4%) or bilateral, closed or open fractures of the tibia, fibula, or ankle requiring surgical repair</p> <p>Adults (mean 48 years; range 18-87)</p> <p>Male to female ratio 139:126</p> <p>Canada</p>	<p>PE (90 days): confirmed by positive spiral computed tomography pulmonary angiogram, high probability V/Q lung scan, or leg imaging</p> <p>DVT (90 days): confirmed by bilateral Doppler ultrasound</p> <p>Major bleeding (90 days): defined as overt bleeding that was fatal, life threatening or involved a critical organ or major joint, required surgical intervention, transfusion of 1 or more units of blood cells within 48 hours or the bleeding event, or was associated with a drop in haemoglobin of at least 20g/L within 48 hours of the bleeding event</p> <p>Heparin-induced thrombocytopenia (90 days)</p>	

Study	Intervention and comparison	Population	Outcomes	Comments
	allowed if they had been used before the injury for cardiac or stroke prophylaxis. Nonsteroidal anti-inflammatory agents were allowed			
van Adrichem 2016 POT-CAST trial ³⁰¹	<p>Intervention (n=719): LMWH, standard dose (dalteparin 2500 IU or nadroparin 2850 IU if 100kg or less, and a double dose if over 100kg. Duration during immobilisation. Mean immobilisation duration 4.9 (2.5) weeks.</p> <p>Comparison (n=131): no VTE prophylaxis. Mean immobilisation duration 4.9 (2.5) weeks.</p> <p>Concurrent medication: none reported</p>	<p>n = 1435</p> <p>Patients who were treated with casting of the lower leg. Indication for casting: Fracture 89%, Achilles' tendon rupture 7%, ankle distortion 2%, antalgic gait 1%, contusion 1%</p> <p>Adults mean age (SD): LMWH 46.5 (16.5); no prophylaxis 45.6 (16.4) years</p> <p>Male to female ratio 716/719</p> <p>The Netherlands</p>	<p>PE (3 months): not defined</p> <p>Symptomatic DVT (3 months): not defined</p> <p>Major bleeding (3 months): not defined</p> <p>Clinically relevant non-major bleeding (3 months): not defined</p>	

1

1 **Table 3: Clinical evidence summary: IPCD (below knee) versus no VTE prophylaxis**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with IPCD (below knee) versus no VTE prophylaxis (95% CI)
PE	140 (1 study) 41 days	VERY LOW ^{2,3} due to risk of bias, imprecision	Not estimable	See comment ⁴	0 fewer per 1000 (from 30 fewer to 30 more) ¹
DVT	162 (2 studies) 42 days	VERY LOW ^{2,3} due to risk of bias, imprecision	RR 1.19 (0.88 to 1.61)	470 per 1000	89 more per 1000 (from 56 fewer to 287 more)

1 Risk difference calculated manually in RevMan

2 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

3 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs

4 Zero events in both arms

2 **Table 4: Clinical evidence summary: LMWH (standard prophylactic dose) versus no VTE prophylaxis**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with LMWH (standard dose) versus no VTE prophylaxis (95% CI)
All-cause mortality	377 (2 studies) 42 days	VERY LOW ^{2,3} due to risk of bias, imprecision	Not estimable	See comment ⁵	0 fewer per 1000 (from 10 fewer to 10 more) ¹
Fatal PE	582 (3 studies) 38-42 days	VERY LOW ^{2,3} due to risk of bias, imprecision	Not estimable	See comment ⁵	0 fewer per 1000 (from 10 fewer to 10 more) ¹
PE	2899 (7 studies)	VERY LOW ^{2,3,4}	Peto OR 0.37	6 per 1000	4 fewer per 1000 (from 5 fewer to 1 more)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with LMWH (standard dose) versus no VTE prophylaxis (95% CI)
	38-40 days	due to risk of bias, indirectness, imprecision	(0.12 to 1.14)		
DVT	1934 (8 studies) 38-40 days	MODERATE ² due to risk of bias	RR 0.53 (0.41 to 0.68)	152 per 1000	71 fewer per 1000 (from 49 fewer to 90 fewer)
Major bleeding	2761 (6 studies) 38-90 days	VERY LOW ^{2,3} due to risk of bias, imprecision	Peto OR 1.99 (0.21 to 19.23)	1 per 1000	1 more per 1000 (from 1 fewer to 13 more)
Heparin-induced thrombocytopenia	258 (1 study) 90 days	VERY LOW ^{2,3} due to risk of bias, imprecision	Peto OR 0.98 (0.06 to 15.83)	8 per 1000	0 fewer per 1000 (from 7 fewer to 103 more)
Clinically relevant non-major bleeding	1435 (1 study) 38 days	VERY LOW ^{2,3,4} due to risk of bias, indirectness, imprecision	Peto OR 7.36 (0.15 to 370.84)	0 per 1000	0 more per 1000 (from 2 fewer to 5 more) ¹
<p>1 Risk difference calculated manually in Review Manager 2 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias 3 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs 4 Downgraded by 1 or 2 increments due to intervention indirectness because the majority of the evidence was from a study that had mixed standard or high doses of LMWH 5 Zero events in both arms</p>					

1

2

1 Table 5: Clinical evidence summary: Fondaparinux versus LMWH (standard prophylactic dose)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with Fondaparinux versus LMWH (standard dose) (95% CI)
All-cause mortality	1243 (1 study) 21-45 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 7.4 (0.15 to 372.99)	0 per 1000	⁻³
PE	1429 (2 studies) 21-45 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 7.41 (0.46 to 118.65)	0 per 1000	⁻³
DVT	1351 (2 studies) 21-45 days	MODERATE ¹ due to risk of bias	RR 0.27 (0.15 to 0.51)	65 per 1000	47 fewer per 1000 (from 32 fewer to 55 fewer)
Major bleeding	1528 (2 studies) 21-45 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 7.35 (0.15 to 370.19)	0 per 1000	⁻³
Clinically relevant non-major bleeding	1344 (1 study) 21-45 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.36 (0.05 to 2.6)	4 per 1000	3 fewer per 1000 (from 4 fewer to 7 more)
Heparin-induced thrombocytopenia	1344 (1 study) 21-45 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.13 (0 to 6.78)	1 per 1000	1 fewer per 1000 (from 1 fewer to 9 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs
3 Absolute effects could not be calculated due to zero events in the control arm

1 **Table 6: Clinical evidence summary: Fondaparinux versus no VTE prophylaxis**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with Fondaparinux versus no VTE prophylaxis (95% CI)
PE	186 (1 study) 40 days	VERY LOW ¹ due to risk of bias, imprecision	Peto OR 0.14 (0.01 to 2.2)	21 per 1000	18 fewer per 1000 (from 21 fewer to 24 more)
DVT	186 (1 study) 40 days	MODERATE ³ due to risk of bias	RR 0.09 (0.01 to 0.71)	117 per 1000	106 fewer per 1000 (from 34 fewer to 116 fewer)
Major bleeding	186 (1 study) 40 days	MODERATE ³ due to risk of bias	Not estimable	See comment ⁴	0 fewer per 1000 (from 20 fewer to 20 more) ²

1 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs
2 Risk difference calculated manually in Review Manager
3 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
4 Zero events in both arms

2

3

24.4¹ Economic evidence

2 Published literature

- 3 No relevant health economic studies were identified.
- 4 See also the health economic study selection flow chart in Appendix F.

24.5⁵ Evidence statements

6 Clinical

7 Very low quality evidence from one study showed no difference in PE rates between IPCD and no
8 prophylaxis, however there was uncertainty around this result. Very low quality evidence from two
9 studies suggested an increased DVT risk when using IPCD although there was serious imprecision
10 around this effect estimate indicating that the true effect could be consistent with no clinical
11 difference.

12 When comparing either LMWH or Fondaparinux with no prophylaxis, moderate quality evidence
13 showed that both LMWH (8 studies) and Fondaparinux (1 study) provided a clinically important
14 reduction in DVT compared to no prophylaxis. In head to head comparisons, moderate quality
15 evidence from 2 studies showed a benefit for fondaparinux over LMWH with a clinically important
16 reduction in DVT. However on the basis of very low quality evidence, no clinical difference was
17 observed for all other critical outcomes (all-cause mortality, fatal PE, PE and major bleeding) when
18 comparing LMWH, fondaparinux, or no prophylaxis. There was very serious imprecision associated
19 with all of the outcomes apart from DVT.

20 Economic

21 No relevant economic evaluations were identified.

24.6² Recommendations and link to evidence

Recommendations	78. Consider pharmacological VTE prophylaxis with LMWH^b or fondaparinux sodium^c for people with lower limb immobilisation whose risk of VTE outweighs their risk of bleeding. Continue until lower limb immobilisation is stopped. [2018]
Research recommendation	6. What is the clinical and cost effectiveness of direct oral anticoagulants (DOACs) for preventing VTE in people with lower limb immobilisation?
Relative values of different outcomes	The guideline committee considered all-cause mortality (up to 90 days from hospital discharge), deep vein thrombosis (symptomatic and asymptomatic) (up to 90 days from hospital discharge), pulmonary embolism (up to 90 days from hospital discharge), fatal PE (up to 90 days from hospital discharge), and major bleeding (up to 90 days from hospital discharge).

^b At the time of consultation (October 2017), LMWH did not have a UK marketing authorisation for use in young people under 18 for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information.

^c At the time of consultation (October 2017), fondaparinux sodium did not have a UK marketing authorisation for use in young people under 18 for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information.

	<p>to 45 days from hospital discharge) as critical outcomes.</p> <p>The guideline committee considered clinically relevant non-major bleeding (up to 45 days from hospital discharge), health-related quality of life (up to 90 days from hospital discharge), heparin-induced thrombocytopenia (duration of study), and technical complications of mechanical interventions (duration of study) as important outcomes.</p> <p>Please see section 4.3.3 in the methods chapter for further detail explaining prioritisation of the critical outcomes.</p>
Quality of the clinical evidence	<p>The majority of the evidence is of very low quality due to high risk of bias and imprecision around the effect estimates. One study also provided indirect evidence due to a mix of standard and high doses of LMWH being used.</p> <p>For the comparison between IPCD and no prophylaxis the evidence for both DVT and PE was all of very low quality. For the comparison between LMWH and no prophylaxis, and for the comparison of fondaparinux with LMWH, all the evidence was of very low quality except for the DVT outcome where the evidence was of moderate quality (no imprecision).</p>
Trade-off between clinical benefits and harms	<p>The use of lower limb immobilisation following trauma and elective orthopaedic surgery affects a significant number of patients. This is also highly heterogeneous group of patients, represented by a wide variation of DVT rates reported in the no prophylaxis arms.</p> <p>Based on the clinical evidence presented, no clinically important difference was found between IPCD and no prophylaxis. Due to the imprecision associated with the results, the committee felt that the evidence base was not strong enough in this context to recommend IPCD in this population.</p> <p>LMWH showed a clinically important reduction in DVT. There was also a suggested reduction in PE and increase in major bleeding, however these differences were too small to be considered clinically important and there was considerable uncertainty around the results.</p> <p>Fondaparinux also showed a clinically important reduction in DVT alongside a suggested decrease in PE although this second finding was very imprecise and no major bleeding events were noted in either group. The studies comparing fondaparinux vs LMWH (standard dose) also showed a clinically important reduction in DVT when using fondaparinux compared to LMWH. However the point estimates for all-cause mortality and major bleeding all favoured LMWH, but these findings did not reach clinical importance and there was uncertainty around the effect. The committee felt that overall the evidence did not support one treatment over another so that either should be recommended for those at high risk of VTE in the population with lower limb immobilisation.</p> <p>There is a range of procedures and injuries which require the application of lower limb immobilisation. The length of the immobilisation/cast and the location of injury within the leg may also differ. Most patients are expected to remain mobile (although not weight bearing on the affected limb), while others may remain immobile, generally. These are the factors which may put patients at different levels of risks.</p> <p>The committee acknowledged that for the subgroup of patients with tendo-achilles rupture, who are at higher risk of VTE, prophylaxis should be offered. The 'consider' recommendation is a reflection of the very low to moderate quality evidence. However, it is the committee's belief that for this group of patients, prophylaxis with LMWH (standard dose) is likely to be most clinically and cost effective compared with subgroups with ankle fractures (whether operated or not operated on) and soft tissue injuries.</p>
Trade-off between net clinical effects	<p>No relevant economic studies were identified for this review. Unit costs were presented to the committee for discussion alongside the clinical evidence.</p>

and costs	<p>The committee discussed the duration of prophylaxis and acknowledged that in this population, the cost of prophylaxis is likely to be higher compared to other populations due to the longer duration for which prophylaxis is required which ranges from 2 to 6 weeks.</p> <p>The committee felt that LMWHs and fondaparinux are the only interventions with clinical evidence that show clinical benefit in terms of DVT prevention to support a recommendation. Studies that compared LMWH with fondaparinux, suggested a clinical benefit for fondaparinux over LMWH for the outcome of DVT but less clear evidence of benefit for other critical outcomes. Given the higher cost of fondaparinux (£4.4 per day compared to a range of £2.77 to 3.03 for LMWHs) it was felt that it may not be as cost-effective as LMWH but that it could be recommended as an option; as some individuals would have contraindication to LMWHs. The guideline committee acknowledged that in current practice; clinicians usually default to using LMWH, unless there are contraindications.</p>
Other considerations	<p>The committee noted the lack of evidence for the clinical and cost-effectiveness of DOACs in this population (rivaroxaban, apixaban and dabigatran) and suggested a research recommendation would be beneficial looking at these interventions in comparison with LMWH and/or fondaparinux; see Appendix R for more details.</p>

1

25 Fragility fractures of the pelvis, hip and proximal femur

25.1.3 Introduction

Fractures of the pelvis, hip and proximal femur are very common in the elderly population and carry significant morbidity and mortality. They occur mainly as osteoporotic or fragility fractures but a small proportion may result from major trauma in a younger age group. The latter is covered under the section on major trauma (Chapter 34).

The risk of VTE in people with fragility fractures of the pelvis, hip or proximal femur can be quite high with an additional impact from common comorbidities such as cardiovascular, respiratory and cerebrovascular disease.

Trauma and orthopaedic surgeons and orthogeriatricians recognise that people who sustain other fragility fractures of the lower limb, for example to the distal femur or tibia, are very similar to the population sustaining fragility fractures of the pelvis, hip and proximal femur. This review has been confined to a specific subgroup of this population due to difficulties in defining which injuries have a similar impact on patient's physiology and rehabilitation. Clinicians should interpret these recommendations more widely when considering how to manage VTE prophylaxis for people with similar major lower limb fragility fractures.

25.2.8 Review question: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people with fragility fractures of the pelvis, hip or proximal femur?

For full details see review protocol in Appendix C.

Table 7: PICO characteristics of review question

Population	<p>Adults and young people (16 years and older) with fragility fractures of the pelvis, hip or proximal femur who are:</p> <ul style="list-style-type: none"> • Admitted to hospital • Outpatients post-discharge
Intervention(s)	<p>Mechanical:</p> <ul style="list-style-type: none"> • Anti-embolism stockings (AES) (above or below knee) • Intermittent pneumatic compression (IPCD) devices (full leg or below knee) • Foot pumps or foot impulse devices (FID) • Electrical stimulation (including Geko devices) • Continuous passive motion <p>Pharmacological:</p> <ul style="list-style-type: none"> • Unfractionated heparin (UFH) (low dose, administered subcutaneously) • Low molecular weight heparin (LMWH), licensed in UK: <ul style="list-style-type: none"> ○ enoxaparin (standard prophylactic dose 40mg daily; minimum 20mg daily* to maximum 60mg twice daily*) ○ dalteparin (standard prophylactic dose 5000 units once daily;

	<p>minimum 1250 units once daily* to maximum 5000 units twice daily*; obese patients – maximum 7500 twice units daily*)</p> <ul style="list-style-type: none"> ○ tinzaparin (standard prophylactic dose 4500 units once daily; minimum 2500 units once daily* to maximum 4500 units twice daily*; obese patients – maximum 6750 twice daily*) ● LMWH, licensed in countries other than UK: <ul style="list-style-type: none"> ○ Bemiparin (standard 2500 units daily; minimum 2500 units daily to maximum 3500 units daily) ○ Certoparin (3000 units daily) ○ Nadroparin (standard 2850 units once daily; minimum 2850 units once daily to maximum up to 57 units/kg once daily) ○ Parnaparin (standard 3200 units once daily; minimum 3200 units once daily to maximum 4250 units once daily) ○ Reviparin (minimum 1750 units once daily to maximum 4200 units once daily) ● Vitamin K Antagonists: <ul style="list-style-type: none"> ○ warfarin (variable dose only) ○ acenocoumarol (all doses) ○ phenindione (all doses) ● Fondaparinux (all doses)* ● Apixaban (all doses)* ● Dabigatran (all doses)* ● Rivaroxaban (all doses)* ● Aspirin (up to 300mg)* <p>*off-label</p>
Comparison(s)	<p>Compared to:</p> <ul style="list-style-type: none"> ● Other VTE prophylaxis treatment, including monotherapy and combination treatments (between class comparisons for pharmacological treatments only) ● No VTE prophylaxis treatment (no treatment, usual care, placebo) <p>Within intervention (including same drug) comparisons, including:</p> <ul style="list-style-type: none"> ● Above versus below knee stockings ● Full leg versus below knee IPC devices ● Standard versus extended duration prophylaxis ● Low versus high dose for LMWH ● Preoperative versus post-operative initiation of LMWH
Outcomes	<p>Critical outcomes:</p> <ul style="list-style-type: none"> ● All-cause mortality (up to 90 days from hospital discharge) ● Deep vein thrombosis (symptomatic and asymptomatic) (7-90 days from hospital discharge). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) ● Pulmonary embolism (7-90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE ● Major bleeding (up to 45 days from hospital discharge). A major bleeding event meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood ; leads to a drop

Study design	<p>in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event. Includes unplanned visit to theatre for control of bleeding</p> <ul style="list-style-type: none"> Fatal PE (7- 90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE <p>Important outcomes:</p> <ul style="list-style-type: none"> Clinically relevant non-major bleeding (up to 45 days from hospital discharge): bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy. Health-related quality of life (validated scores only)(up to 90 days from hospital discharge) Heparin-induced thrombocytopenia (HIT) (duration of study) Technical complications of mechanical interventions (duration of study) Infection (duration of study)
Study design	Randomised controlled trials (RCTs), systematic reviews of RCTs.

25.3.1 Clinical evidence

2 Sixteen studies were included in the review, fourteen studies were included in CG92,^{85 89 90 94 107 129}
3 ^{154 174 218 220 221 248 285 ,324} and two new studies were identified;^{114 287}, these are summarised in Table 8
4 below. One study was published before CG92²⁴⁸ and was not previously included due to
5 methodological concerns; it has now been included in this review.

6 One study that was previously included in CG92 has been excluded from this review and is now
7 included in the major trauma review.²⁷⁹

8 Evidence from these studies is summarised in the clinical evidence summary below (Table 9, Table
9 10, Table 11, Table 12, Table 13, Table 14, Table 15, Table 16, Table 17, Table 18, Table 19, Table 20).
10 See also the study selection flow chart in Appendix E, forest plots in Appendix L, study evidence
11 tables in Appendix H, GRADE tables in Appendix K and excluded studies list in Appendix N.

12 **Table 8: Summary of studies included in the review**

Study	Intervention and comparison	Population	Outcomes	Comments
Eriksson 2001 ⁸⁵ : PENTHIFRA trial	<p><u>Intervention (n=862):</u> LMWH, enoxaparin, 40mg once daily (standard dose) subcutaneously given along with placebo (saline). From 12±2 hours preoperatively and continued for 5-9 days.</p> <p><u>Comparison (n=849):</u> Fondaparinux, 2.5mg, once daily, subcutaneously given along with placebo (saline). From 6±2</p>	<p>n=1711</p> <p>People undergoing standard surgery for fracture of the upper third of the femur, including femoral head and neck</p> <p>Age (mean): 79 years Gender (male to female ratio): 1:3</p> <p>Argentina, Australia/New Zealand, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Italy,</p>	<p>All-cause mortality (49 days)</p> <p>DVT (symptomatic and asymptomatic) (11 days): confirmed by systemic ascending bilateral contrast venography</p> <p>PE (11 days): confirmed by high-probability lung scanning, pulmonary angiography, helical</p>	Included in CG92

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>hours postoperatively and continued for 5-9 days.</p> <p><u>Concomitant treatment:</u> AES was permitted, 49% of patients used AES. Early mobilisation was strongly recommended.</p>	<p>Norway, Poland, Portugal, Spain, South Africa, Sweden, Switzerland, the Netherlands, UK</p>	<p>computed tomography</p> <p>Fatal PE (11 days): confirmed at autopsy</p> <p>Major bleeding (11 days): defined as fatal bleeding, retroperitoneal, intracranial, or intraspinal bleeding, bleeding that involved any other critical organ, bleeding leading to reoperation, and overt bleeding with a bleeding index of 2 or more.</p>	
<p>Eriksson 2003A ⁸⁹</p>	<p><u>Intervention (n=327):</u> Fondaparinux sodium, 2.5 mg, once daily, subcutaneously given up to 6-8 days after surgery then an additional 19-23 days (extended duration), total duration of 25-31 days.</p> <p><u>Comparison (n=329):</u> Fondaparinux sodium, 2.5 mg, once daily, subcutaneously given up to 6-8 days after surgery (standard duration). Followed by placebo, 0.5ml isotonic sodium chloride, once daily, subcutaneously for additional 19-23 days, total duration of 25-31 days.</p> <p><u>Concomitant treatment:</u> AES was permitted, 46% of patients used AES. Early mobilisation was strongly recommended.</p>	<p>n=656</p> <p>People undergoing standard surgery for fracture of the upper third of the femur, including femoral head and neck</p> <p>Age (median): 79 years Gender (male to female ratio): 1:2</p> <p>Argentina, Australia, Belgium, Czech Republic, Denmark, Finland, France, Greece, Italy, Poland, Portugal, Spain, Sweden, Switzerland, the Netherlands, UK</p>	<p>All-cause mortality (25-32 days)</p> <p>DVT (symptomatic and asymptomatic) (25-32 days): confirmed by systemic ascending bilateral contrast venography</p> <p>PE (25-31 days): confirmed by high-probability lung scanning, pulmonary angiography, spiral computed tomography</p> <p>Fatal PE (25-31 days): confirmed at autopsy</p> <p>Major bleeding (25-31 days): defined as fatal bleeding, retroperitoneal, intracranial, or intraspinal bleeding, bleeding that involved any</p>	<p>Included in CG92</p>

Study	Intervention and comparison	Population	Outcomes	Comments
			other critical organ, bleeding leading to reoperation, and overt bleeding with a bleeding index of 2 or more.	
Eskeland 1966 ⁹⁰	<p><u>Intervention (n=100):</u> Vitamin K antagonists, phenindione, doses controlled by PP-test or Thrombotest three times a week, dose reduced gradually to zero from 7-14 days.</p> <p><u>Comparison (n=100):</u> Control group, no prophylaxis, no further details reported.</p>	<p>n=200</p> <p>People admitted with sub-capital or pertrochanteric fracture of the femur</p> <p>Age (mean): 76 years Gender (male to female ratio): 1:5</p> <p>Norway</p>	<p>All-cause mortality (90 days)</p> <p>DVT (symptomatic and asymptomatic) (90 days): definition not reported</p> <p>PE (90 days): definition not reported</p> <p>Fatal PE (90 days): confirmed by necropsy</p>	Included in CG92
Fisher 1995 ⁹⁴	<p><u>Intervention (n=145):</u> IPCD, thigh-length, pressures varied from 25-45 mmHg according to location of the six chambers. Compression cycle was 71 seconds, each compression lasted 11 seconds.</p> <p><u>Comparison (n=159):</u> Control group, received same clinical care as the intervention group.</p> <p><u>Concomitant treatment:</u> Physiotherapy, active mobilisation regimen which started on postoperative day 1</p>	<p>n=304</p> <p>People admitted with pelvic, acetabular, femoral neck, intertrochanteric, or sub-trochanteric fractures</p> <p>Age: 80% >40 years Gender (male to female ratio): Not reported</p> <p>Canada</p>	<p>DVT (symptomatic and asymptomatic) (mean: 14 days): confirmed by Doppler ultrasonography</p> <p>PE (5-10 days): confirmed by ventilation perfusion (VQ) lung scan</p>	Included in CG92
Galasko 1976 ¹⁰⁷	<p><u>Intervention (n=50):</u> Unfractionated heparin, 5000IU, twice daily, subcutaneously given on admission to hospital and continued until patient was discharged, transferred</p>	<p>n=100</p> <p>People who admitted for intertrochanteric or transcervical femoral fractures</p> <p>Age (mean): not reported</p>	<p>All-cause mortality (time-point not reported)</p> <p>DVT (symptomatic and asymptomatic) (time-point not reported):</p>	Included in CG92

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>or fully mobilised (duration of hospital length of stay not reported)</p> <p><u>Comparison (n=50):</u> Control group, no prophylaxis (usual care)</p>	<p>Gender: 100% female</p> <p>UK</p>	<p>confirmed by venography</p> <p>PE (time-point not reported): confirmed by clinical and radiological examinations or at autopsy</p> <p>Wound infection/haematoma (time-point not reported)</p>	
Goel 2009 ¹¹⁴	<p><u>Intervention (n=157)</u> LMWH, dalteparin, 5000IU, once daily (standard dose) subcutaneously given. 2500IU was administered subcutaneously two hours pre-operatively, followed by 2500IU eight hours post-operatively, and 5000IU on following days each morning up to and including the 14th day.</p> <p><u>Comparison (n=148)</u> No prophylaxis, saline given subcutaneously once daily for 14 days</p>	<p>n=305</p> <p>People admitted with unilateral isolated fractures below the knee which require operative fixation</p> <p>Age (mean): 40.95 years Gender (male to female ratio): 1.6:1</p> <p>Canada</p>	<p>All-cause mortality (time-point not reported)</p> <p>DVT (symptomatic and asymptomatic) (14 days): confirmed by bilateral venography</p> <p>Major bleeding (time-point not reported): defined as fall in haemoglobin of ≥ 2 g/dl within a 24-hour period resulting in transfusion of ≥ 2 units of blood, intracranial, intraspinal, intra-ocular, retroperitoneal or pericardial bleeding, and causing death</p>	New study
Hamilton 1970 ¹²⁹	<p><u>Intervention (n=38):</u> Vitamin K antagonist, phenindione, prothrombin time to 2-2.5 times the control (prothrombin time not reported). Duration of intervention not clearly reported.</p>	<p>n=76</p> <p>People admitted for a hip fracture</p> <p>Age (mean): 77 years Gender (male to female ratio): 1:5</p>	<p>All-cause mortality (time-point not reported)</p> <p>DVT (symptomatic and asymptomatic) (5-12 days): confirmed by ascending phlebography</p>	Included in CG92

Study	Intervention and comparison	Population	Outcomes	Comments
	<u>Comparison (n=38):</u> Control group, no further details reported.	Canada	Major bleeding (time-point not reported): patients requiring blood transfusions Deep wound infection (time-point not reported)	
Jørgensen 1992 ¹⁵⁴	<u>Intervention (n=30):</u> LMWH, dalteparin, 5000IU (standard dose), subcutaneously given from 2 hours preoperatively. First and second injections contained 2500IU; second injection administered 12 hours postoperatively. 5000IU administered once daily thereafter for 6 days. <u>Comparison (n=38):</u> Placebo, isotonic sodium chloride, from 2 hours preoperatively. Second injection administered 12 hours postoperatively. Placebo administered once daily thereafter for 6 days.	n=68 People admitted for a hip fracture Age (mean): 80 years Gender (male to female ratio): 1:3 Denmark	All-cause mortality (84 days) DVT (symptomatic and asymptomatic) (9 days): confirmed by I ¹²⁵ fibrinogen uptake test and scans and ascending phlebography PE (84 days): definition not reported Superficial wound infection (84 days)	Included in CG92
Lahnborg 1980 ¹⁷⁴	<u>Intervention (n=71):</u> Unfractionated heparin, sodium heparin, 5000IU subcutaneously, every 12 hours for 10 days, started 2-3 hours after the operation. <u>Comparison (n=69):</u> Placebo, 0.5ml of 0.85% saline, subcutaneously every 12 hours for 10 days, started 2-3 hours after the operation	n=140 People admitted for nailing of a fractured neck of the femur Age (mean): 77 years Gender (male to female ratio): 1:2 Sweden	DVT (symptomatic and asymptomatic) (10 days): confirmed by I ¹²⁵ fibrinogen uptake test and scans PE (time-point not reported): 'diagnosed clinically'	Included in CG92
Monreal 1989 ²¹⁸	<u>Intervention (n=46):</u>	n=90	All-cause mortality (time-point not	

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>LMWH, dalteparin, 5000IU once daily (standard dose), subcutaneously given every evening for 9 days. 2500IU was administered 2 hours preoperatively. Placebo injections given in the evening.</p> <p><u>Comparison (n=44):</u> Unfractionated heparin, 5000IU, subcutaneously given every 8 hours for 9 days</p>	<p>People admitted for a hip fracture</p> <p>Age (mean): 77 years Gender (male to female ratio): 1:5</p> <p>Spain</p>	<p>reported)</p> <p>PE (8 days): confirmed by ventilation-perfusion lung scanning</p>	
Morris 1976 ²²⁰	<p><u>Intervention (n=80):</u> VKA, warfarin sodium, loading dose of 30mg within 24 hours of admission. No warfarin given next day, third day a thrombotest level was obtained. Dose adjusted to achieve modest degree of anticoagulation (a thrombotest level of 10%). Warfarin was continued until the patients was independently mobile or for 3 months.</p> <p><u>Comparison (n=80)</u> Control group, no prophylaxis. No further details reported</p>	<p>n=160</p> <p>People admitted to hospital with a fractured neck of femur (sub-capital or intertrochanteric)</p> <p>Age (mean): 78.3 years Gender (male to female ratio): 1:7</p> <p>UK</p>	<p>All-cause mortality (90 days)</p> <p>DVT (symptomatic and asymptomatic) (10 days): confirmed by I¹²⁵ fibrinogen uptake test and scans</p> <p>PE (time-point not reported): confirmed by clinical signs, chest X-rays and electrocardiograms</p> <p>Major bleeding (time-point not reported): definition not reported</p>	Included in CG92
Moskovitz 1978 ²²¹	<p><u>Intervention (n=29):</u> Unfractionated heparin, sodium heparin, 5000IU subcutaneously given every 8 hours for 7 days. Patients wore AES (length unspecified), length of time AES worn for not reported.</p> <p><u>Comparison (n=23):</u></p>	<p>n=52</p> <p>People admitted for a hip fracture</p> <p>Age: 61% ≥70 years Gender (male to female ratio): 1:2</p> <p>USA</p>	<p>All-cause mortality (time-point not reported)</p> <p>DVT (symptomatic and asymptomatic) (10 days): confirmed by I¹²⁵ fibrinogen uptake test and scans</p> <p>PE (time-point not</p>	Included in CG92

Study	Intervention and comparison	Population	Outcomes	Comments
	Placebo, saline, subcutaneously given every 8 hour for 7 days. Patients wore AES (length unspecified), length of time AES worn for not reported.		reported): confirmed by radionuclide perfusion lung-scanning Major bleeding (time-point not reported): definition not reported Fatal PE (time-point not reported): definition not reported	
Pulmonary Embolism Prevention Collaborative Group 2000: PEP trial ²⁴⁸	<u>Intervention (n=6679):</u> Aspirin, 160mg, orally once daily, for 35 days 44% also taking UFH or LMWH and 30% also wearing AES <u>Comparison (n=6677):</u> Placebo, orally once daily for 35 days 43% also taking UFH or LMWH and 29% also wearing AES	n=13356 People admitted for a femoral-neck fracture or other fracture of the proximal femur. Age (mean): 79 years Gender (male to female ratio): 1:4 Australia, New Zealand, South Africa, Sweden, UK	All-cause mortality (35 days) PE (35 days): confirmed by pulmonary angiogram, a high-probability ventilation-perfusion scan and at necropsy. Fatal PE (35 days): confirmed by necropsy Wound infection (35 days)	New study Additional heparin and stocking prophylaxis in some people in both the intervention and control groups. Sub-group details provided in the paper are presented in the forest plots in Appendix L for information only (not analysed due to not matching review protocol).
Svend-Hansen 1981 ²⁸⁵	<u>Intervention (n=65):</u> Unfractionated heparin, 5000IU, subcutaneously administered three times daily for 14 days.	n=130 People admitted with proximal femoral fractures Age (mean): 73 years Gender (male to female	All-cause mortality (time-point not reported) DVT (symptomatic and asymptomatic) (14 days):	Included in CG92

Study	Intervention and comparison	Population	Outcomes	Comments
	<u>Comparison (n=65):</u> Placebo, given for 14 days.	ratio): 1:3 Denmark	confirmed by I ¹²⁵ fibrinogen uptake test and scans Fatal PE (time-point not reported): definition not reported	
Tang 2017 ²⁸⁷	<u>Intervention 1 (n=96):</u> LMWH, enoxaparin, 40mg once daily (standard dose), subcutaneously given from 12 hours postoperatively for one week. Patients then received rivaroxaban, 10mg once daily, orally given for 28 days. <u>Intervention 2 (n=95):</u> LMWH, enoxaparin, 40mg once daily (standard dose), subcutaneously given from 12 hours postoperatively, duration of intervention not clearly reported. Assumption that duration was 28 days was made. <u>Comparison (n=96):</u> Rivaroxaban, 10mg, orally given from 6 hours postoperatively for 28 days <u>Concomitant treatment:</u> All patients were encouraged to perform passive movement training of the affected limbs at day 2 after the surgery.	n=287 People admitted with hip fractures Age (mean): Gender (male to female ratio): 1:1.6 China	All-cause mortality (30 days) DVT (symptomatic and asymptomatic) (30 days): confirmed by colour Doppler ultrasound. Doppler ultrasound was recommended for asymptomatic patients. PE (30 days): confirmed by CT pulmonary angiogram (CTPA) when PE was suspected and/or confirmed. Fatal PE (30 days):	New study
Xabregas	<u>Intervention (n=25):</u>	n=50	DVT (symptomatic	Included in

Study	Intervention and comparison	Population	Outcomes	Comments
1978 ³²⁴	<p>Unfractionated heparin, calcium, adjusted by weight, 100IU/kg, subcutaneously administered three times daily for 14 days.</p> <p><u>Comparison (n=25):</u> Placebo, saline solution, given for 14 days.</p>	<p>People admitted with a fractured neck of the femur</p> <p>Age (mean): 76 years Gender (male to female ratio): 1:3</p> <p>Australia</p>	<p>and asymptomatic) (time-point not reported): confirmed by I¹²⁵ fibrinogen uptake test and scans</p> <p>PE (time-point not reported): definition not reported</p> <p>Wound infection (time-point not reported)</p>	CG92

1

1 Table 9: Clinical evidence summary: LMWH (standard dose; standard duration) versus no prophylaxis

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with No prophylaxis	Risk difference with LMWH (standard dose) (95% CI)
All-cause mortality	305 (2 studies) 84 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 1.17 (0.33 to 4.19)	27 per 1000	5 more per 1000 (from 18 fewer to 86 more)
DVT (symptomatic and asymptomatic)	305 (2 studies) 14 days	LOW ^{1,2} due to risk of bias, imprecision	RR 0.59 (0.37 to 0.96)	242 per 1000	99 fewer per 1000 (from 10 fewer to 152 fewer)
PE	68 (1 study) 84 days	VERY LOW ^{1,2,3} due to risk of bias, indirectness, imprecision	Peto OR 0.17 (0 to 8.65)	26 per 1000	22 fewer per 1000 (from 26 fewer to 163 more)
Major bleeding	237 (1 study) time-point not reported	VERY LOW ^{1,2,3} due to risk of bias, indirectness, imprecision	Not estimable ⁴	Not estimable ⁴	0 fewer per 1000 (from 20 fewer to 20 more) ⁴
Wound infection	68 (1 study) 84 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 1.27 (0.19 to 8.47)	53 per 1000	14 more per 1000 (from 43 fewer to 393 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.

3 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol

4 Zero events in both arms. Risk difference calculated in Review Manager.

1 Table 10: Clinical evidence summary: LMWH (standard dose; standard duration) versus UFH

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with UFH	Risk difference with LMWH (standard dose) (95% CI)
All-cause mortality	90 (1 study) time-point not reported	VERY LOW ^{1,2,3} due to risk of bias, indirectness, imprecision	RR 0.64 (0.11 to 3.64)	68 per 1000	25 fewer per 1000 (from 61 fewer to 180 more)
PE	90 (1 study) 8 days	MODERATE ¹ due to risk of bias	Peto OR 7.95 (1.53 to 41.29)	0 per 1000	- ⁴

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol
3 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.
4 Absolute effects could not be calculated due to zero events in the control arm

2 Table 11: Clinical evidence summary: LMWH (standard dose; standard duration) versus fondaparinux

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Fondaparinux	Risk difference with LMWH (standard dose) (95% CI)
All-cause mortality	1673 (1 study) 49 days	LOW ¹ due to imprecision	RR 1.09 (0.71 to 1.67)	46 per 1000	4 more per 1000 (from 13 fewer to 31 more)
DVT (symptomatic and asymptomatic)	1247 (1 study) 11 days	MODERATE ² due to risk of bias	RR 2.39 (1.75 to 3.28)	79 per 1000	109 more per 1000 (from 59 more to 179 more)
PE	1671 (1 study) 11 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 1.01 (0.06 to 16.13)	1 per 1000	0 more per 1000 (from 1 fewer to 18 more)
Major bleeding	1673		RR 1.04	22 per 1000	1 more per 1000

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Fondaparinux	Risk difference with LMWH (standard dose) (95% CI)
	(1 study) 11 days	LOW ¹ due to imprecision	(0.55 to 1.97)		(from 10 fewer to 21 more)
Fatal PE	1671 (1 study) 11 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 0.99 (0.14 to 7.01)	2 per 1000	0 fewer per 1000 (from 2 fewer to 14 more)

1 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.
2 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

1 Table 12: LMWH (standard dose; standard duration) followed by rivaroxaban versus rivaroxaban

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Rivaroxaban	Risk difference with LMWH + rivaroxaban (95% CI)
All-cause mortality	192 (1 study) 30 days	LOW ² due to imprecision	Peto OR 7.39 (0.15 to 372.38)	0 per 1000	- ¹
DVT (symptomatic and asymptomatic)	192 (1 study) 30 days	VERY LOW ^{2,3} due to indirectness, imprecision	RR 1.8 (0.63 to 5.17)	52 per 1000	42 more per 1000 (from 19 fewer to 217 more)
PE	192 (1 study) 30 days	LOW ² due to imprecision	RR 2 (0.18 to 21.69)	10 per 1000	10 more per 1000 (from 9 fewer to 216 more)
Fatal PE	192 (1 study) 30 days	LOW ² due to imprecision	Peto OR 7.39 (0.15 to	0 per 1000	- ¹

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Rivaroxaban	Risk difference with LMWH + rivaroxaban (95% CI)
			372.38)		
1 Absolute effects could not be calculated due to zero events in one of the arms. 2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs. 3 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol					

1 Table 13: LMWH (standard dose; standard duration) followed by rivaroxaban versus LMWH (standard dose; extended duration)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with LMWH (extended duration)	Risk difference with LMWH + rivaroxaban (95% CI)
All-cause mortality	192 (1 study) 30 days	VERY LOW ^{1,2} due to indirectness, imprecision	RR 0.99 (0.06 to 15.59)	11 per 1000	0 fewer per 1000 (from 10 fewer to 154 more)
DVT (symptomatic and asymptomatic)	191 (1 study) 30 days	VERY LOW ^{1,2} due to indirectness, imprecision	RR 0.74 (0.33 to 1.68)	126 per 1000	33 fewer per 1000 (from 85 fewer to 86 more)
PE	191 (1 study) 30 days	VERY LOW ^{1,2} due to indirectness, imprecision	RR 0.49 (0.05 to 5.37)	21 per 1000	11 fewer per 1000 (from 20 fewer to 92 more)
Fatal PE	191 (1 study) 30 days	VERY LOW ^{1,2} due to indirectness, imprecision	RR 0.99 (0.06 to 15.59)	11 per 1000	0 fewer per 1000 (from 10 fewer to 154 more)
1 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs. 2 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol					

1 Table 14: LMWH (standard dose; extended duration) versus rivaroxaban

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Rivaroxaban	Risk difference with LMWH (extended duration) (95% CI)
All-cause mortality	191 (1 study) 30 days	VERY LOW ^{1,2} due to indirectness, imprecision	Peto OR 7.47 (0.15 to 376.35)	0 per 1000	– ¹
DVT (symptomatic and asymptomatic)	191 (1 study) 30 days	VERY LOW ^{1,2} due to indirectness, imprecision	RR 2.43 (0.89 to 6.62)	52 per 1000	74 more per 1000 (from 6 fewer to 293 more)
PE	191 (1 study) 30 days	VERY LOW ^{1,2} due to indirectness, imprecision	RR 2.02 (0.19 to 21.92)	10 per 1000	11 more per 1000 (from 8 fewer to 218 more)
Fatal PE	191 (1 study) 30 days	VERY LOW ^{1,2} due to indirectness, imprecision	Peto OR 7.47 (0.15 to 376.35)	0 per 1000	– ¹

1 Absolute effects could not be calculated due to zero events in one of the arms.

2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.

3 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol

2 Table 15: Clinical evidence summary: Fondaparinux (extended duration) versus fondaparinux (standard duration)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Fondaparinux (standard duration)	Risk difference with Fondaparinux (extended duration) (95% CI)
All-cause mortality	656 (1 study)	LOW ¹	RR 0.75 (0.26 to 2.15)	24 per 1000	6 fewer per 1000 (from 18 fewer to 28 more)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Fondaparinux (standard duration)	Risk difference with Fondaparinux (extended duration) (95% CI)
	25-31 days	due to imprecision			
DVT (symptomatic and asymptomatic)	426 (1 study) 25-32 days	MODERATE ² due to risk of bias	RR 0.04 (0.01 to 0.13)	339 per 1000	326 fewer per 1000 (from 295 fewer to 336 fewer)
PE	656 (1 study) 25-31 days	LOW ¹ due to imprecision	Peto OR 0.14 (0.01 to 2.19)	6 per 1000	5 fewer per 1000 (from 6 fewer to 7 more)
Major bleeding	656 (1 study) 25-31 days	MODERATE ¹ due to imprecision	RR 4.02 (0.86 to 18.81)	6 per 1000	18 more per 1000 (from 1 fewer to 108 more)
Fatal PE	656 (1 study) 25-31 days	LOW ¹ due to imprecision	Peto OR 0.14 (0 to 6.9)	3 per 1000	3 fewer per 1000 (from 3 fewer to 18 more)

1 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.
2 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

1 Table 16: Clinical evidence summary: UFH versus no prophylaxis

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with No prophylaxis	Risk difference with UFH (95% CI)
All-cause mortality	230 (2 studies) time-point not reported	VERY LOW ^{1,2,3} due to risk of bias, indirectness, imprecision	RR 1.76 (1.04 to 3.01)	148 per 1000	112 more per 1000 (from 6 more to 297 more)
DVT (symptomatic and	420		RR 0.53	378 per 1000	178 fewer per 1000

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with No prophylaxis	Risk difference with UFH (95% CI)
asymptomatic)	(4 studies) 14 days	MODERATE ¹ due to risk of bias	(0.38 to 0.73)		(from 102 fewer to 234 fewer)
PE	290 (3 studies) time-point not reported	VERY LOW ^{1,2,3} due to risk of bias, indirectness, imprecision	RR 1.16 (0.4 to 3.38)	35 per 1000	6 more per 1000 (from 21 fewer to 83 more)
Fatal PE	130 (1 study) time-point not reported	VERY LOW ^{1,2,3} due to risk of bias, indirectness, imprecision	Peto OR 1 (0.06 to 16.16)	15 per 1000	0 fewer per 1000 (from 14 fewer to 186 more)
Wound infection	150 (2 studies) time-point not reported	VERY LOW ^{1,2,3} due to risk of bias, indirectness, imprecision	RR 0.9 (0.39 to 2.08)	133 per 1000	13 fewer per 1000 (from 81 fewer to 144 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol
3 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.

1 Table 17: Clinical evidence summary: UFH + AES (length unspecified) versus AES (length unspecified)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with AES (length unspecified)	Risk difference with UFH + AES (length unspecified) (95% CI)
All-cause mortality	52 (1 study) time-point not reported	VERY LOW ^{1,2,3} due to risk of bias, indirectness, imprecision	Peto OR 0.1 (0.01 to 0.97)	130 per 1000	116 fewer per 1000 (from 3 fewer to 129 fewer)
DVT (symptomatic and	52 (1 study)	VERY LOW ^{1,3}	RR 0.99	348 per 1000	3 fewer per 1000

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with AES (length unspecified)	Risk difference with UFH + AES (length unspecified) (95% CI)
asymptomatic)	10 days	due to risk of bias, imprecision	(0.47 to 2.1)		(from 184 fewer to 383 more)
PE	52 (1 study) time-point not reported	VERY LOW ^{1,2,3} due to risk of bias, indirectness, imprecision	RR 1.59 (0.15 to 16.42)	43 per 1000	26 more per 1000 (from 37 fewer to 670 more)
Major bleeding	52 (1 study) time-point not reported	VERY LOW ^{1,2,3} due to risk of bias, indirectness, imprecision	Not estimable ⁴	Not estimable ⁴	0 fewer per 1000 (from 70 fewer to 70 more) ⁴
Fatal PE	52 (1 study) time-point not reported	VERY LOW ^{1,2,3} due to risk of bias, indirectness, imprecision	Peto OR 0.1 (0 to 5.39)	43 per 1000	39 fewer per 1000 (from 43 fewer to 153 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol
3 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.
4 Absolute effects could not be calculated due to zero events in the control arm

1 Table 18: Clinical evidence summary: VKA versus no prophylaxis

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with No prophylaxis	Risk difference with VKA (95% CI)
All-cause mortality	436 (3 studies) 90 days	LOW ^{1,2} due to risk of bias, imprecision	RR 0.75 (0.52 to 1.08)	239 per 1000	60 fewer per 1000 (from 114 fewer to 19 more)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with No prophylaxis	Risk difference with VKA (95% CI)
DVT (symptomatic and asymptomatic)	424 (3 studies) 10 days	MODERATE ¹ due to risk of bias	RR 0.47 (0.34 to 0.64)	351 per 1000	186 fewer per 1000 (from 126 fewer to 231 fewer)
PE	360 (2 studies) 90 days	VERY LOW ^{1,2,3} due to risk of bias, indirectness, imprecision	Peto OR 0.51 (0.1 to 2.55)	22 per 1000	11 fewer per 1000 (from 20 fewer to 33 more)
Major bleeding	236 (2 studies) time-point not reported	VERY LOW ^{1,2,3} due to risk of bias, indirectness, imprecision	RR 1.73 (0.88 to 3.37)	93 per 1000	68 more per 1000 (from 11 fewer to 221 more)
Fatal PE	200 (1 study) 90 days	LOW ^{1,2} due to risk of bias, imprecision	RR 0.14 (0.02 to 1.14)	70 per 1000	60 fewer per 1000 (from 69 fewer to 10 more)
Deep wound infection	76 (1 study) time-point not reported	VERY LOW ^{1,2,3} due to risk of bias, indirectness, imprecision	RR 0.75 (0.18 to 3.13)	105 per 1000	26 fewer per 1000 (from 86 fewer to 224 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.
3 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol

1 Table 19: Clinical evidence summary: Aspirin (± other prophylaxis) versus no aspirin (± other prophylaxis)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with No aspirin	Risk difference with Aspirin (95% CI)
All-cause mortality	13356		RR 0.97	69 per 1000	2 fewer per 1000

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with No aspirin	Risk difference with Aspirin (95% CI)
	(1 study) 35 days	MODERATE ² due to indirectness	(0.85 to 1.1)		(from 10 fewer to 7 more)
PE	13356 (1 study) 35 days	LOW ^{1,2} due to imprecision and indirectness	RR 0.74 (0.45 to 1.2)	6 per 1000	1 fewer per 1000 (from 3 fewer to 1 more)
Fatal PE	13356 (1 study) 35 days	MODERATE ² due to indirectness	RR 0.42 (0.24 to 0.72)	6 per 1000	4 fewer per 1000 (from 2 fewer to 5 fewer)
Wound infection	13356 (1 study) 35 days	LOW ^{1,2} due to imprecision and indirectness	RR 1.17 (0.87 to 1.56)	13 per 1000	2 more per 1000 (from 2 fewer to 7 more)

1 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.
2 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol

1 Table 20: Clinical evidence summary: IPCD (thigh-length) versus no prophylaxis

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with No prophylaxis	Risk difference with IPCD (95% CI)
DVT (symptomatic and asymptomatic)	304 (1 study) 14 days	MODERATE ¹ due to risk of bias	Peto OR 0.14 (0.04 to 0.53)	57 per 1000	48 fewer per 1000 (from 26 fewer to 54 fewer)
PE	304 (1 study) 5-10 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 0.37 (0.07 to 1.78)	38 per 1000	24 fewer per 1000 (from 35 fewer to 29 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with No prophylaxis	Risk difference with IPCD (95% CI)
risk of bias					
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.					

1

2

25.4¹ Economic evidence

2 Published literature

3 Two economic models were developed for this population in CG92 with the relevant comparison and
4 have been included in this review.²²⁴ These are summarised in the health economic evidence profiles
5 below (**Table 21** and Table 22) and the health economic evidence tables in Appendix J.

6 Two economic studies relating to this review question were identified but were excluded due to
7 limited applicability or methodological limitations.^{47,80} These are listed in Appendix O, with reasons
8 for exclusion given.

9 See also the health economic study selection flow chart in Appendix F.

10

1 **Table 21: Health economic evidence profile: pharmacological, mechanical or combination of prophylaxis strategies vs each other**

Study	Applicability	Limitations	Other comments	Incremental cost	Incremental effects	Cost-effectiveness	Uncertainty
NCGC 2010 [CG92] ²²⁴ [UK]	Partially applicable ^(a)	Potentially serious limitations ^(b)	<p>Study design: Decision analytic model</p> <p>Population: Adults admitted for hip fracture surgery in England.</p> <p>Interventions:</p> <ol style="list-style-type: none"> 1. Fondaparinux sodium (2.5 mg subcutaneously) 2. Warfarin variable dose (adjusted to INR range 2 to 3, average dose 4mg/day) 3. LMWH (average of dalteparin 5000 units subcutaneous daily) and enoxaparin (4000 units subcutaneous daily) 4. UFH (5000 units three times daily) 5. IPCD-FID 6. Aspirin (High dose) 7. No prophylaxis 	NR	NR	<p>Incremental net monetary benefit (INMB) (pa)</p> <ol style="list-style-type: none"> 1. Fondaparinux sodium: £2148 (rank 1) 2. Warfarin variable dose: £1830 (rank 2) 3. LMWH: 1711 (rank 3) 4. UFH: £1465 (rank 4) 5. IPCD-FID: £999 (rank 5) 6. Aspirin (high dose): £558 (rank 6) 7. No prophylaxis: £0 (rank 7) 	For patients with a very low bleeding risk fondaparinux was the most cost-effective strategy, with a probability of 85% of being the most cost-effective strategy. LMWH tended to be more cost-effective as the risk of major bleeding increased.

2 Abbreviations: FID: foot impulse device; ICER: incremental cost-effectiveness ratio; IPCD: intermittent pneumatic compression; LMWH : low molecular weight heparin; NR: not
3 reported; pa: probabilistic analysis

4 (a) Some uncertainty regarding the applicability of unit costs from 2009 to current NHS context. Some of the interventions are not included in the current clinical review, for
5 example: aspirin (high dose), warfarin (variable dose) and UFH.

6 (b) The relative treatment effect applied to all VTE events in the model is the relative treatment effect obtained from the DVT NMA.

7
8
9

1 **Table 22: Health economic evidence profile: fondaparinux (post-discharge) vs no post-discharge prophylaxis**

Study	Applicability	Limitations	Other comments	Incremental cost	Incremental effects	Cost-effectiveness	Uncertainty
NCGC 2010 [CG92] ²²⁴ (UK)	Directly applicable ^(a)	Potentially serious limitations ^(b)	<p>Study design: Decision analytic model</p> <p>Interventions:</p> <ol style="list-style-type: none"> No post discharge prophylaxis (it is not clear whether prophylaxis was given during the initial hospital stay) Post-discharge prophylaxis with fondaparinux for 10 days 	NR	NR	<p>Incremental net monetary benefit (INMB) (pa)</p> <ol style="list-style-type: none"> No prophylaxis: £0 (rank 2) Fondaparinux: £239 (rank 1) 	<p>Fondaparinux had 92% probability of being the cost-effective strategy at £20K threshold.</p> <p>In a threshold analysis, post-discharge fondaparinux was no longer cost-effective if greater than 55% of patients require district nurse visits to deliver their prophylaxis.</p>

2 Abbreviations: BNF: British National Formulary; 95% CI: 95% confidence interval; INMB: incremental net monetary benefit; NR: not reported; pa: probabilistic analysis.

3 (a) Some uncertainty regarding the applicability of unit costs from 2009 to current NHS context.

4 (b) The relative treatment effect applied to all VTE events in the model is the relative treatment effect obtained from the DVT MA.

5

6

7

25.5 1 Evidence statements

2 Clinical

3 Pharmacological and mechanical interventions versus no VTE prophylaxis

4 Four of the comparisons compared interventions with no VTE prophylaxis, three were
5 pharmacologically based comparisons. For the comparison of LMWH versus no prophylaxis, data
6 presented suggested possible clinical benefit of LMWH in terms of DVT (symptomatic and
7 asymptomatic) and PE and possible clinical harm in terms of all-cause mortality and wound infection,
8 although there was uncertainty associated with all of these results. There was no clinical difference
9 in terms of major bleeding. Quality of the evidence for this comparison ranged from very low to low
10 due to risk of bias, imprecision and indirectness. For the comparison of UFH versus no prophylaxis,
11 there was no clinical difference between UFH and no prophylaxis for the outcomes of PE, fatal PE and
12 wound infection. However the large uncertainty in these results means they could also be consistent
13 with both benefit and harm. Clinical benefit of UFH was reported in terms of DVT and possible clinical
14 harm in terms of all-cause mortality, although the mortality outcome could also have been consistent
15 with no difference when taking uncertainty into account. Quality of the evidence for this comparison
16 ranged from very low to moderate due to risk of bias, imprecision and indirectness. VKA compared
17 with no prophylaxis presented clinical benefit of DVT (symptomatic and asymptomatic) without any
18 imprecision. There was a possible clinical benefit due to imprecision in terms of the outcomes all-
19 cause mortality, PE and fatal PE. There was however, possible clinical harm of VKA in terms of major
20 bleeding and no clinical difference in regards to deep wound infection. Quality of the evidence for
21 this comparison ranged from very low to moderate due to risk of bias, imprecision and indirectness.

22 Lastly, for data reported for the mechanical intervention of IPCD versus no prophylaxis, there was a
23 possible clinical benefit of IPCD in terms of PE, although there was imprecision around this result and
24 clinical benefit of IPCD in terms of DVT (symptomatic and asymptomatic). Quality of the evidence for
25 this comparison ranged from very low to moderate due to risk of bias and imprecision.

26 LMWH at a standard dose for a standard duration versus other pharmacological interventions

27 When compared with UFH, LMWH has a possible clinical benefit in terms of all-cause mortality,
28 although the imprecision around this result was also consistent with no difference or harm.
29 Moderate quality evidence showed clinical harm in terms of PE. Quality of evidence for this
30 comparison ranged from very low to moderate due to risk of bias, indirectness and imprecision.
31 Compared with fondaparinux, there was no clinical difference in terms of all-cause mortality, PE,
32 major bleeding, and fatal PE, however very serious imprecision around these results presents
33 considerable uncertainty. Moderate quality, precise evidence showed clinical harm in terms of DVT
34 (symptomatic and asymptomatic). Quality of evidence for this comparison ranged from very low to
35 moderate due to risk of bias and imprecision.

36 LMWH at a standard dose for a standard duration followed by rivaroxaban compared with
37 rivaroxaban, the outcomes all-cause mortality, DVT (symptomatic and asymptomatic), PE and fatal PE
38 were reported in one study. There was possible clinical harm of LMWH followed by rivaroxaban in
39 terms of all-cause mortality, DVT (symptomatic and asymptomatic), PE and fatal PE. However there
40 was very serious imprecision around these effect estimates. The quality of the evidence ranged from
41 very low to low due to imprecision and indirectness.

42 LMWH at a standard dose for a standard duration followed by rivaroxaban was compared with
43 LMWH at a standard dose for an extended duration, the outcomes all-cause mortality, DVT
44 (symptomatic and asymptomatic), PE and fatal PE were reported in one study. There was possible
45 clinical benefit of LMWH followed by rivaroxaban in terms of DVT (symptomatic and asymptomatic)

1 and PE. However the uncertainty around these results was also associated with no difference or
2 clinical harm. There was no clinical difference in terms of all-cause mortality and fatal PE, although
3 again there was considerable uncertainty around these results too The quality of the evidence was
4 very low due to imprecision and indirectness.

5 **LMWH at a standard dose for an extended duration versus rivaroxaban**

6 LMWH at a standard dose for an extended duration compared with rivaroxaban, the outcomes all-
7 cause mortality, DVT (symptomatic and asymptomatic), PE and fatal PE were reported in one study.
8 There was possible clinical harm of LMWH followed by rivaroxaban in terms of all-cause mortality,
9 DVT (symptomatic and asymptomatic), PE and fatal PE. However there was considerable uncertainty
10 around all these results. The quality of the evidence was very low due to imprecision and
11 indirectness.

12 **Fondaparinux (extended duration) versus fondaparinux (standard duration)**

13 There was a reported clinical benefit of fondaparinux for an extended duration when compared to
14 fondaparinux for a standard duration. There was a possible clinical benefit in terms of PE and fatal
15 PE, although these results were uncertain. Moderate quality, precise evidence showed clinical
16 benefit in terms of DVT (symptomatic and asymptomatic). There was no clinical difference between
17 the two durations of fondaparinux in terms of all-cause mortality and there was possible clinical
18 harm of an extended duration of fondaparinux in terms of major bleeding, however this finding was
19 also consistent with no difference when taking uncertainty into account. Quality of evidence for this
20 comparison ranged from low to moderate due to risk of bias and imprecision.

21 **Aspirin (± other prophylaxis) versus no aspirin (± other prophylaxis)**

22 There was a clinical benefit of aspirin in terms of all-cause mortality and fatal PE. There was a
23 possible clinical benefit for PE although this finding was uncertain and could also have been
24 consistent with no difference. There was no clinical difference between aspirin and no aspirin in
25 terms of wound infection, however the uncertainty around this result could also have been
26 consistent with a harm with aspirin. Quality of evidence for this comparison ranged from low to
27 moderate due to indirectness and imprecision.

28 **Combination comparison: UFH + AES versus AES alone**

29 In this comparison, unfractionated heparin used with AES had possible clinical benefit over AES alone
30 in terms of all-cause mortality and fatal PE. Contrastingly, there was possible clinical harm of UFH
31 used with AES in terms of PE. There was no clinical difference between the two interventions in
32 terms of DVT (symptomatic and asymptomatic) and major bleeding. However results for all outcomes
33 had uncertainty. Quality of evidence for this comparison was all very low due to risk of bias,
34 indirectness and imprecision.

35 **Economic**

36 • One cost-utility analysis found that the following interventions were cost-effective (having
37 positive incremental net monetary benefit [INMB]) compared to no prophylaxis in patients with
38 fragility fractures of the hip: fondaparinux sodium (INMB: £2,148), warfarin variable dose (INMB:
39 £1,830), low molecular weight heparin (INMB: £1,711), unfractionated heparin (INMB: £1,465),
40 intermittent pneumatic compression-foot impulse devices (INMB: £999) and aspirin (high dose;
41 INMB: £558). This analysis was assessed as partially applicable with potentially serious
42 limitations.
43

- 1 • One cost–utility analysis found that, in people with fragility fractures of the hip, fondaparinux
- 2 (post-discharge) was cost effective (INMB: £239) compared to no post-discharge prophylaxis .
- 3 This analysis was assessed as directly applicable with potentially serious limitations.

25.6.4 Recommendations and link to evidence

Recommendations	<p>79. Offer VTE prophylaxis for 28-35 days to people with fragility fractures of the pelvis, hip or proximal femur. Choose either:</p> <ul style="list-style-type: none"> • LMWH^d, starting 6–12 hours after surgery or • fondaparinux sodium^e, starting 6 hours after surgery, providing there is low risk of bleeding. [2018] <p>80. Consider pre-operative VTE prophylaxis for people with fragility fractures of the pelvis, hip or proximal femur if surgery is delayed beyond the day after admission, stopping 12 hours before surgery. [2018]</p> <p>81. Consider intermittent pneumatic compression for people with fragility fractures of the pelvis, hip or proximal femur at the time of admission if pharmacological prophylaxis is contraindicated. Continue until the person no longer has significantly reduced mobility relative to their normal or anticipated mobility. [2018]</p>
Research recommendation	<p>7. What is the clinical and cost effectiveness of aspirin alone versus other pharmacological and/or mechanical prophylaxis strategies (alone or in combination) for people with fragility fractures of the pelvis, hip or proximal femur?</p> <p>8. What is the clinical and cost effectiveness of IPCD in combination with pharmacological prophylaxis strategies for people with fragility fractures of the pelvis, hip or proximal femur?</p>
Relative values of different outcomes	<p>The guideline committee considered all-cause mortality (up to 90 days from hospital discharge), deep vein thrombosis (symptomatic and asymptomatic) (7-90 days from hospital discharge), pulmonary embolism (7-90 days from hospital discharge), fatal PE (7-90 days from hospital discharge), and major bleeding (up to 45 days from hospital discharge) as critical outcomes.</p> <p>The guideline committee considered clinically relevant non-major bleeding (up to 45 days from hospital discharge), health-related quality of life (up to 90 days from hospital discharge), heparin-induced thrombocytopenia (duration of study), and technical complications of mechanical interventions (duration of study) and infection (duration of study) as important outcomes.</p> <p>Please see section 4.3.3 in the methods chapter for further detail explaining prioritisation of the critical outcomes.</p>

^d At the time of consultation (October 2017), LMWH did not have a UK marketing authorisation for use in young people under 18 for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information.

^e At the time of consultation (October 2017), fondaparinux sodium did not have a UK marketing authorisation for use in young people under 18 for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information.

Quality of the clinical evidence	<p>Fifteen studies were included in this review; thirteen of the relevant studies were randomised controlled trials identified from the previous guideline (CG92). One new study was identified and one study published before CG92 is now included in this review. One of the previously included studies in this evidence review was excluded and moved to the major trauma review due to more appropriate applicability of the study population.</p> <p>Nine comparisons were included; they evaluated both pharmacological and mechanical interventions. Pharmacological interventions included LMWH at standard dose and for a standard duration, UFH, fondaparinux (standard duration and extended duration), VKA and aspirin. Mechanical interventions included AES (length unspecified) and IPCD (thigh-length).</p> <p><i>Pharmacological and mechanical interventions versus no VTE prophylaxis</i></p> <p>Four of the comparisons compared prophylaxis strategies with no VTE prophylaxis, three were pharmacologically based comparisons. For the comparison of LMWH versus no prophylaxis data was presented for all-cause mortality, DVT (symptomatic and asymptomatic) and PE. Evidence quality ranged from very low to low due to risk of bias, indirectness and imprecision. For the comparison of UFH versus no prophylaxis data was reported for all-cause mortality, DVT (symptomatic and asymptomatic), PE, fatal PE and wound infection. Evidence quality ranged from very low to moderate due to risk of bias, indirectness and imprecision. VKA compared with no prophylaxis presented data for all-cause mortality, DVT (symptomatic and asymptomatic), PE and fatal PE, major bleeding and deep wound infection. The quality of the evidence ranged from very low to moderate due to risk of bias, indirectness and imprecision. Data for DVT (symptomatic and asymptomatic) and PE was reported for the mechanical intervention of IPCD versus no prophylaxis. The quality of the evidence ranged from very low to moderate due to risk of bias and imprecision.</p> <p><i>LMWH at a standard dose for a standard duration versus other pharmacological interventions</i></p> <p>For the comparison of LMWH versus UFH, data was reported for all-cause mortality and PE. Quality of evidence ranged from very low to moderate due to risk of bias, indirectness and imprecision. For LMWH compared with fondaparinux, data was reported for all-cause mortality, DVT (symptomatic and asymptomatic), PE, major bleeding and fatal PE. Evidence quality ranged from very low to moderate due to risk of bias and imprecision.</p> <p>LMWH at a standard dose for a standard duration followed by rivaroxaban compared with rivaroxaban, the outcomes all-cause mortality, DVT (symptomatic and asymptomatic), PE and fatal PE were not reported in one study. The quality of the evidence ranged from very low to low due to imprecision and indirectness.</p> <p>LMWH at a standard dose for a standard duration followed by rivaroxaban was compared with LMWH at a standard dose for an extended duration, the outcomes all-cause mortality, DVT (symptomatic and asymptomatic), PE and fatal PE were not reported in one study. The quality of the evidence was very low due to imprecision and indirectness.</p> <p><i>LMWH at a standard dose for an extended duration versus rivaroxaban</i></p> <p>LMWH at a standard dose for an extended duration compared with rivaroxaban, the outcomes all-cause mortality, DVT (symptomatic and asymptomatic), PE and fatal PE were not reported in one study. The quality of the evidence was very low due to imprecision and indirectness.</p> <p><i>Fondaparinux (extended duration) versus fondaparinux (standard duration)</i></p> <p>In the comparison of fondaparinux (extended duration) versus fondaparinux</p>
----------------------------------	---

	<p>(standard duration) data for all-cause mortality, PE, fatal PE and major bleeding was reported. Quality of evidence ranged from low to moderate due to imprecision and risk of bias.</p> <p><i>Aspirin (± other prophylaxis) versus no aspirin (± other prophylaxis)</i></p> <p>In this comparison data for all-cause mortality, PE, fatal PE and wound infection were reported. Quality of the evidence for all-cause mortality, PE and fatal PE ranged from low to moderate due to imprecision and indirectness.</p> <p><i>Combination comparison: UFH + AES versus AES alone</i></p> <p>In this comparison, all-cause mortality, DVT (symptomatic and asymptomatic), PE, major bleeding and fatal PE was reported. The quality of the evidence was all very low due to risk of bias, indirectness and imprecision.</p>
Trade-off between clinical benefits and harms	<p><i>Pharmacological and mechanical interventions versus no VTE prophylaxis</i></p> <p>The committee discussed the need of prophylaxis in this population and appreciated that in a majority of the evidence where pharmacological or mechanical prophylaxis was compared with no prophylaxis there were better outcomes in the group receiving an intervention. The committee noted that people with fragility fractures of the pelvis, hip and proximal femur tend to have a longer length of hospital stay around 21 days for acute spells and 23 for super-spells (may include hospitals differential capture of rehabilitation length-of-stay).²²⁷ Patients have reduced mobility whilst in hospital, a factor that contributes to risk of VTE.</p> <p>General consensus was that IPCD seemed effective as the clinical evidence presented showed clinical benefit for DVT (symptomatic and asymptomatic) and a possible clinical benefit for PE, although there was uncertainty associated with the PE result. The orthopaedic subgroup advised the committee that some hospitals using IPCD routinely in orthopaedic theatres and wards; the use of pharmacological interventions alongside IPCD is commonly used in practice but appreciated that there is absence of RCT evidence evaluating the clinical effectiveness of this combination intervention in this population. It was therefore suggested that a research recommendation be proposed in order to encourage this evaluation.</p> <p>Some members of the sub-group felt the use of IPCD may discourage mobilisation. Therefore the sub-group and committee agreed to recommend IPCD only when pharmacological prophylaxis was contra-indicated and only until people are able to mobilise themselves.</p> <p><i>LMWH at a standard dose for a standard duration versus other pharmacological interventions</i></p> <p>The committee felt that the evidence sufficiently supports the use of LMWH and fondaparinux, it was discussed that UFH is not commonly used in current practice. It was previously recommend for patients with renal failure, but low doses of LMWH are currently used in practice instead for these patients.</p> <p>The guideline committee discussed the evidence presented for LMWH versus fondaparinux and noted that the clinical evidence suggests a higher clinical benefit of fondaparinux over LMWH, as seen in moderate quality evidence for a clinically important reduction in the rate of DVT with fondaparinux compared to LMWH. The committee considered other aspects of the interventions that were not listed as outcomes in the review such as the half-life of each with regard to considering situations where prophylaxis would need to be reversed. Fondaparinux has a half-life of 17 hours whereas LMWH has a much shorter half-life ranging from 2-5 hours depending on which preparation is used (according to summary of product characteristics). The guideline committee decided to also recommend LMWH based on the effectiveness evidence showing a possible benefit when compared with no prophylaxis for DVT and PE, although there was uncertainty around these effect estimates. Recommending LMWH is in line with current context as it is already</p>

	<p>widely used in this population and is not associated with a high bleeding risk such is the case with fondaparinux. The committee discussed the major bleeding risk associated with fondaparinux and suggested that it only be used once haemostasis has been established and there is no risk of bleeding. The guideline committee discussed the length of prophylaxis and decided to adopt the recommendation for use of VTE prophylaxis for 28-35 days, The guideline committee noted the increased benefit of an extended duration of fondaparinux as reported in one of the studies included in this evidence review.</p> <p><i>Aspirin (± other prophylaxis) versus no aspirin (± other prophylaxis)</i></p> <p>One of the larger trials conducted in this population was the PEP trial that was published in 2000, evaluating the use of aspirin. The committee noted that the PEP trial allowed centres to include other prophylaxis. The data reported include just over 50% of patients with either LMWH or UFH, and around 30% using AES. It is not reported how many of these patients received both heparin and AES, or who had aspirin alone or no prophylaxis at all. The study also reported a post hoc analysis for the combined outcome of pulmonary embolism and symptomatic DVT. This showed that a reduction in symptomatic VTE events using aspirin (plus or minus AES) without the use of heparin and a reduction of symptomatic VTE events with AES (plus or minus the use of heparin). The outcomes of major bleeding or clinically relevant non-major bleeding were not adequately reported in the study and were excluded from the current review. Overall, it was believed that aspirin offers a beneficial effect in reducing symptomatic VTE, however, its effect on bleeding was unknown.</p> <p>The PEP trial was discussed at length. The committee were aware that some of the orthopaedic community believe aspirin is an appropriate form of prophylaxis, and that the PEP trial provides evidence for its use in this population. The committee were also aware that aspirin is recommended in the American College of Clinical Pharmacy (ACCP) as a method of VTE prophylaxis in this population. The orthopaedic sub-group believed the evidence showed that aspirin alone is an effective method of prophylaxis and advised it should be recommended for this population. However, the guideline committee was concerned about the lack of evidence for aspirin alone particularly around bleeding that is commonly associated with the use of aspirin. Therefore they did not believe it should be recommended in this population. A research recommendation was proposed to investigate the effectiveness and safety of aspirin compared with the other routinely used pharmacological prophylaxis – LMWH, in people with fragility fractures of the pelvis, hip or proximal femur.</p> <p><i>Combination comparison: UFH + AES versus AES alone</i></p> <p>The committee noted that combination prophylaxis has limited benefit so suggested that the CG92 recommendation which recommends combined prophylaxis should not be adopted unless mobility is reduced. The committee expressed concerns about the overuse of AES in current practice within this population with little evidence of clinical benefit. It was also noted that AES are difficult to fit, applying can be painful to the patient and they are not always worn properly. Therefore, it was agreed that the use of AES should not be specified in the recommendation. Although the committee believe that AES should not be routinely used they noted that they may be effective for patients with a high risk of bleeding.</p>
Trade-off between net clinical effects and costs	<p>Two economic models were developed for this population in CG92 and were included in this review. The first model compared all standard duration prophylaxis strategies. This analysis showed that fondaparinux (2.5 mg) was the most cost-effective strategy, with incremental net monetary benefit (INMB) of £2,148. This analysis was assessed as partially applicable, with potentially serious limitations.</p> <p>The second model compared fondaparinux initiated post-operatively and continued for 10 days to no post-discharge prophylaxis. This analysis showed that fondaparinux was cost -effective compared to no prophylaxis, with INMB of £239. This analysis was assessed as directly applicable with potentially serious limitations.</p>

	<p>Additionally, two studies were identified but were selectively excluded; due to the availability of the more applicable models from CG92.</p> <p>The committee discussed the relevance of the clinical evidence used in the CG92 model to the evidence included in the current review. It was acknowledged that there were differences between the interventions included in the model and those included in the current clinical review, where aspirin (high dose) is not used in clinical practice in the UK.</p> <p>The committee also highlighted that there was no evidence to support the use of AES for lower limb fragility fractures and that they are difficult to fit, necessitating time from the nurses to ensure they are properly fitted and monitored. Hence, it was concluded that the routine use of AES in this population represents a financial burden on the NHS without evidence of cost effectiveness. The committee discussed the evidence available for the use of IPCD and concluded that this is the only mechanical prophylaxis method that has clinical and cost-effectiveness evidence to support its use in the early post-operative period until mobilisation. It was acknowledged that although there might be an upfront cost of providing IPCDs in hospitals, this is likely to be off-set by the saving achieved from not using AES and the standardisation of practice. It was also highlighted that, in most cases, IPCDs are provided rent-free to hospitals and the only cost involved would be that of the sleeves. Additionally, IPCDs are used for a shorter period of time until mobilisation.</p> <p>The committee discussed the evidence for pharmacological prophylaxis in this population and noted that the CG92 model showed the cost effectiveness of LMWH (standard dose) and fondaparinux compared to no prophylaxis. Based on the clinical evidence in this update and the trade-off between clinical benefits and harms, the committee decided to retain the CG92 recommendation of these options giving clinicians the ability to choose between them based on clinical and individual factors.</p> <p>The orthopaedic sub-group discussed the evidence for aspirin, all of which came from the PEP trial and considered its lower cost compared to LMWH and fondaparinux. They concluded that it is very likely to be a cost-effective option in this population. However, the guideline committee considered the PEP trial to show evidence of clinical effectiveness of aspirin as an add-on prophylaxis option rather than stand-alone, and its cost effectiveness should be considered in this context. Hence, the guideline committee felt that the pharmacological options that could be recommended should be limited to LMWH and fondaparinux. However; the committee acknowledged the potential value for money that could be achieved if aspirin is proven to be effective as a stand-alone prophylaxis strategy. Hence, the committee made a research recommendation to assess the clinical and cost effectiveness of aspirin in this population.</p>
Other considerations	<p>There are 70,000 hip fractures a year in England, Wales and Northern Ireland (National Hip Fracture Database; http://www.nhfd.co.uk/). This population is associated with an older and frail population with the mean age of patients being 82 years (http://www.nhfd.co.uk/). Age is a significant risk factor for VTE and bleeding, thus important that prophylaxis is provided for these patients. There is an increasing trend to mobilise patients post-operation from day 0 in this population with can reduce the risk of VTE</p> <p>There was a lengthy discussion about the lack of evidence evaluating NOACs in this review population. NOACs are currently licensed in the orthopaedic populations of elective hip replacement surgery and elective knee replacement surgery. The subgroup understood that the absence of evidence about these interventions in this review population prohibited a suggested recommendation but appreciated that there may be some clinical benefit and cost saving from these interventions.</p> <p>The committee made a high-priority research recommendation on aspirin alone, and a research recommendation on IPCD, in this population group; see Appendix R for more details.</p>

1

26 Elective hip replacement surgery

26.1.2 Introduction

- 3 Elective total hip replacement may be associated with a higher risk of VTE compared with other
4 surgical populations. The population covered in this section of the guideline are those patients
5 undergoing elective hip replacement surgery for any indication. Emergent hip replacement surgery
6 following fracture of the proximal femur is covered in Chapter 25.
- 7 One objection of using pharmacological VTE prophylaxis is the increased risk of bleeding as a result of
8 anticoagulation. A balance of the benefit of VTE prophylaxis has to be weighed against the risks and
9 consequences of a post-operative bleed.
- 10 This guideline is aimed at providing guidance for the appropriate prophylaxis against VTE and its
11 sequelae following elective hip replacement.

26.2.2 Review question: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing elective hip replacement?

15 For full details see review protocol in Appendix C.

16 **Table 23: PICO characteristics of review question**

Population	Adults and young people (16 years and older) undergoing elective hip replacement admitted to and discharged from hospital
Intervention(s)	<p>Mechanical:</p> <ul style="list-style-type: none"> • Anti-embolism stockings (AES) (above or below knee) • Intermittent pneumatic compression (IPCD) devices (full leg or below knee) • Foot pumps or foot impulse devices (FID) • Electrical stimulation (including Geko devices) • Continuous passive motion <p>Pharmacological:</p> <ul style="list-style-type: none"> • Unfractionated heparin (UFH) (low dose, administered subcutaneously) • Low molecular weight heparin (LMWH), licensed in UK: <ul style="list-style-type: none"> ○ enoxaparin (standard prophylactic dose 40mg daily; minimum 20mg daily* to maximum 60mg twice daily*) ○ dalteparin (standard prophylactic dose 5000 units once daily; minimum 1250 units once daily* to maximum 5000 units twice daily*; obese patients – maximum 7500 twice units daily*) ○ tinzaparin (standard prophylactic dose 3500 units once daily; minimum 2500 units once daily* to maximum 4500 units twice daily*; obese patients – maximum 6750 twice daily*) • LMWH, licensed in countries other than UK: <ul style="list-style-type: none"> ○ Bemiparin (standard 2500 units daily; minimum 2500 units daily to maximum 3500 units daily) ○ Certoparin (3000 units daily) ○ Nadroparin (standard 2850 units once daily; minimum 2850 units once daily to maximum up to 57 units/kg once daily) ○ Parnaparin (standard 3200 units once daily; minimum 3200 units once daily to

	<p>maximum 4250 units once daily)</p> <ul style="list-style-type: none"> ○ Reviparin (minimum 1750 units once daily to maximum 4200 units once daily) ● Vitamin K Antagonists: <ul style="list-style-type: none"> ○ warfarin (variable dose only) ○ acenocoumarol (all doses) ○ phenindione (all doses) ● Fondaparinux (all doses)* ● Apixaban (2.5mg twice daily) ● Dabigatran (220mg once daily; 150mg once daily - patients with moderate renal impairment, interacting medicines, over 75 years old) ● Rivaroxaban (10mg once daily) ● Aspirin (up to 300mg)* <p>*off-label</p>
<p>Comparison(s)</p>	<p>Compared to:</p> <ul style="list-style-type: none"> ● Other VTE prophylaxis treatment, including monotherapy and combination treatments (between class comparisons for pharmacological treatments only) ● No VTE prophylaxis treatment (no treatment, usual care, placebo) <p>Within intervention (including same drug) comparisons, including:</p> <ul style="list-style-type: none"> ● Above versus below knee stockings ● Full leg versus below knee IPC devices ● Standard versus extended duration prophylaxis ● Low versus high dose for LMWH ● Preoperative versus post-operative initiation of LMWH
<p>Outcomes</p>	<p>Critical outcomes:</p> <ul style="list-style-type: none"> ● All-cause mortality (up to 90 days from hospital discharge) ● Deep vein thrombosis (symptomatic and asymptomatic) (7-90 days from hospital discharge). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) ● Pulmonary embolism (7-90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE ● Major bleeding (up to 45 days from hospital discharge). A major bleeding event meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood ; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event. Includes unplanned visit to theatre for control of bleeding ● Fatal PE (7- 90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE ● Surgical site haematoma (up to 45 days from hospital discharge) <p>Important outcomes:</p> <ul style="list-style-type: none"> ● Clinically relevant non-major bleeding (up to 45 days from hospital discharge): bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy. ● Health-related quality of life (validated scores only)(up to 90 days from hospital discharge)

	<ul style="list-style-type: none"> • Heparin-induced thrombocytopenia (HIT) (duration of study) • Technical complications of mechanical interventions (duration of study) • Infection (duration of study)
Study design	Randomised controlled trials (RCTs), systematic reviews of RCTs.

26.3.1 Clinical evidence

2 Fifty studies were included in the review, these are summarised in Table 24 below. Forty-one studies
3 were previously included in the previous guideline (CG92);^{12 14 23 62,63,66 67 84 83,97,99 100 105,106 108 130,145}
4 147 161 163 181 182 183 195 200 201 240 242 243 244 247 262 264 266,270 289 298 299 307 309,328 59 221 and nine studies were
5 added in the update;^{157 65 86 87 8 132 187 326 31}

6 Two technology appraisals were previously included in the previous guideline;^{228 229}. One of the
7 technology appraisals²²⁹; evaluated evidence from studies that were identified in the update^{86,157}.
8 Three systematic reviews that were previously included in CG92 have been included in this update;⁷
9^{146,167} these are summarised below in Table 24.

10 Twenty-eight studies that were previously included in CG92 have been excluded:^{3 27,270 71,72 96 101 110}
11 124 133 134,135 140 148 184 196 205 221 258 267 274 277 283 288 304 314 323,327, reasons for exclusion include incorrect
12 intervention, no relevant extractable outcomes and incorrect population. One study was previously
13 included in CG92, within the hip fracture evidence review⁵⁹, this has been included in this evidence
14 review as the population is more appropriate.

15 Two Cochrane reviews^{98 261} were identified which looked at low-molecular-weight heparin,
16 unfractionated heparin and vitamin-K antagonists for the prevention of venous thromboembolism
17 people undergoing elective hip replacement. The reviews included studies which were included in
18 the previous guideline (CG92) and in the update.

19 Evidence from these studies is summarised in the clinical evidence summary tables below (Table 25,
20 Table 26, Table 27, Table 28, Table 29, Table 30, Table 31, Table 32, Table 33, Table 34, Table 35,
21 Table 36, Table 37, Table 38, Table 39, Table 40, **Table 41**, Table 42, Table 43, Table 44, Table 45,
22 Table 46, Table 47, Table 48, Table 49, Table 50, Table 51, Table 52, Table 53, Table 54, Table 55,
23 Table 56, Table 57, Table 58, Table 59, Table 60, Table 61, Table 62, Table 63, Table 64, Table 65,
24 Table 66, Table 67, Table 68, Table 69, Table 70, Table 71, Table 72, Table 73, Table 74, Table 75,
25 Table 76, Table 77). See also the study selection flow chart in Appendix E, forest plots in Appendix L,
26 study evidence tables in Appendix H, GRADE tables in Appendix K and excluded studies list in
27 Appendix N.

28 In order to input the clinical effectiveness data of multiple possible interventions into the economic
29 model, it was proposed that a network meta-analysis be carried out on the outcome data for DVT, PE
30 and major bleeding. For full details on the NMA methodology and results, please see Appendix M.

31 **Table 24: Summary of studies included in the review**

Study	Intervention and comparison	Population	Outcomes	Comments
Anderson 2013 ⁸	Intervention (n=400): LMWH, extended duration, dalteparin, 5000 IU once daily (standard dose), subcutaneously given from the morning after surgery for 10 days.	n=785 People undergoing elective total hip replacement, mean duration of	All-cause mortality (90 days) PE (90 days): confirmed by compression ultrasonography (definition unclear)	New study

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>Continued course of dalteparin (combined with placebo aspirin tablets) for 28 more days</p> <p><u>Comparison (n=385):</u> LMWH, dalteparin, 5000 IU once daily (standard dose), subcutaneously given from the morning after surgery for 10 days followed by Aspirin, 81 mg orally for 28 more days</p>	<p>surgery 92 minutes</p> <p>Age (mean): 57.8 years</p> <p>Gender (male to female ratio): 1.3:1</p> <p>Multicentre, Canada</p>	<p>Fatal PE (90 days)</p> <p>Major bleeding (90 days): defined as fatal bleeding, symptomatic bleeding into a critical area or organ, or bleeding that caused 20g/L decrease or more in haemoglobin level or led to transfusion of 2 or more units of whole blood or red blood cells.</p> <p>Clinically relevant non-major bleeding: resulted in hospitalisation, reoperation, aspiration, or a wound hematoma complicated by infection.</p> <p>Heparin-induced thrombocytopenia (90 days)</p> <p>Wound infection (90 days)</p>	
Avikainen 1995 ¹²	<p><u>Intervention (n=83):</u> LMWH, enoxaparin, 40mg (standard dose), subcutaneously given preoperatively and repeated daily for 10 days.</p> <p><u>Comparison (n=84):</u> Unfractionated heparin, 5000IU. Begun 2 hours before the operation and repeated twice daily for 10 days</p>	<p>n=167</p> <p>People undergoing elective hip replacement surgery, mean duration of surgery not reported</p> <p>Age (mean): 65 years</p> <p>Gender (male to female ratio): 1:2</p> <p>Finland</p>	<p>DVT (symptomatic and asymptomatic) (10-14 days): confirmed by ultrasonography</p> <p>PE (time-point not clearly reported): confirmed by ventilation–perfusion</p>	Included in CG92
Bailey 1991 ¹⁴	<p><u>Intervention (n=50):</u> Intermittent pneumatic compression device (IPCD), applied from after surgery in recovery ward until day 7. AES applied on admission until discharge.</p>	<p>n=95</p> <p>People undergoing elective total hip replacement, mean duration of surgery 197 minutes</p> <p>Age (mean): 65</p>	<p>DVT (symptomatic and asymptomatic) (7 days): confirmed by venography or B-mode Doppler ultrasonography and technecium-pyrophosphate red-cell labelled nuclear venogram with impedance plethysmography.</p> <p>Clinically relevant non-major</p>	Included in CG92

Study	Intervention and comparison	Population	Outcomes	Comments
	<p><u>Comparison (n=45):</u> Warfarin, 10mg evening before surgery (7.5mg for women over 70 and patients with minor abnormalities of liver function tests). Doses given after surgery adjusted to maintain a prothrombin time at 14-16 seconds. Prothrombin times routinely obtained by postoperative day 2 or 3. AES applied on admission until discharge.</p>	<p>years Gender (male to female ratio): 1:1 USA</p>	<p>bleeding (7 days): defined as “clinically important bleeding”</p>	
Bergqvist 1996B ²³	<p><u>Intervention (n=131):</u> LMWH, enoxaparin, 40mg (standard dose), subcutaneously administered once daily. First dose was given 12±2 hours preoperatively until day 21.</p> <p><u>Comparison (n=131):</u> Placebo or single dose of 0.4ml saline</p>	<p>n=262 People undergoing elective total hip replacement surgery, mean duration of surgery was 1.9 hours. Age (mean): 70 years Gender (male to female ratio): 1:1.3 Sweden</p>	<p>DVT (symptomatic and asymptomatic) (90 days): confirmed by bilateral ascending phlebography PE (90 days): confirmed by ventilation-perfusion lung scan or a pulmonary angiography</p>	Included in CG92
Bern 2015 ³¹	<p><u>Intervention (n=64)</u> Fondaparinux, 2.5mg once daily, orally from 6 or more hours (no later than 6AM the next day) postoperatively, or 6-8 hours after epidural catheter removal, continued for 28±2 days. IPCD was worn for duration on stay in hospital. AES were prescribed for use after discharge.</p>	<p>n=118 People undergoing elective primary unilateral total knee replacement surgery, mean duration of surgery not reported Age (mean): 61 years Gender (male to female ratio): 1:1</p>	<p>All-cause mortality (30 days) DVT (symptomatic and asymptomatic) (30 days): confirmed by bilateral duplex sonography PE (30 days): confirmed by ventilation/perfusion lung scan or computerised axial tomography angiogram</p>	New study

Study	Intervention and comparison	Population	Outcomes	Comments
	<p><u>Comparison (n=54)</u> VKA, warfarin, dose of 5.0mg the night before surgery, followed by 5.0mg the evening of surgery, variable dose (target INR 2.0-2.5) until day 28±2 days. IPCD was worn for duration on stay in hospital. AES were prescribed for use after discharge.</p>	USA		
Cohen 2007 ⁵⁹	<p><u>Intervention (n=430):</u> Fondaparinux, 2.5 mg, once daily, subcutaneously given for 5-9 days. First dose of fondaparinux was given six hours after wound closure and the second dose 18-24 hours later. Subsequent doses were administered 22-26 hours. AES, above-knee, applied pre-operatively and worn for 35-49 days.</p> <p><u>Comparison (n=426):</u> Fondaparinux, 2.5 mg, once daily, subcutaneously given for 5-9 days. First dose of fondaparinux was given six hours after wound closure and the second dose 18-24 hours later. Subsequent doses were administered 22-26 hours.</p>	<p>n=856</p> <p>People undergoing elective total hip replacement</p> <p>Age (mean): 65 years Gender (male to female ratio): 1: 1.33</p> <p>Brazil, UK, Hong Kong and Spain</p>	<p>All-cause mortality (35-49 days)</p> <p>Major bleeding (35-49 days): defined as fatal bleeds; bleeding which lead to re-operation or into critical organs; clinically-overt bleeding associated with a fall in haemoglobin level of 2 g/dl or to transfusion of two or more units, or warranting cessation of treatment.</p> <p>Fatal PE (35-49 days): definition not reported</p> <p>Clinically relevant non-major bleeding (35-49 days): defined as non-major bleeding requiring intervention or unscheduled contact, or with patient discomfort</p> <p>Health-related quality of life (35-29 days): EQ-5D (medians reported, narratively reported)</p>	Included in CG92 – was in the hip fracture review
Colwell 1994A ⁶³	<p><u>Intervention 1 (n=203):</u> LMWH, enoxaparin, 40mg once daily (standard dose) subcutaneously administered, within 24 hours after surgery and continued for a maximum of 7 days.</p>	<p>n=610</p> <p>People undergoing elective hip replacement surgery, including primary and revision</p>	<p>All-cause mortality (7 days)</p> <p>DVT (symptomatic and asymptomatic) (7 days): confirmed by bilateral contrast venography</p> <p>PE (7 days): definition not</p>	Included in CG92

Study	Intervention and comparison	Population	Outcomes	Comments
	<p><u>Intervention 2 (n=195)</u> LMWH, enoxaparin, 30mg once daily (high dose), subcutaneously administered, within 24 hours after surgery and continued for a maximum of 7 days.</p> <p><u>Comparison (n=209):</u> Unfractionated heparin, 5000IU, administered every 8 hours, within 24 hours after surgery and continued for a maximum of 7 days</p>	<p>procedures, mean duration of surgery not reported</p> <p>Age (mean): 65.3 years</p> <p>Gender (male to female ratio): 1:1.04</p> <p>Multicentre, USA</p>	<p>reported</p> <p>Major bleeding (7 days): definition not reported</p>	
Colwell 1999 ⁶²	<p><u>Intervention (n=1516)</u> LMWH, enoxaparin, 30mg twice daily (high dose), every 12 hours subcutaneously given until discharge. Administered within 24 hours postoperatively.</p> <p><u>Comparison (n=1495)</u> Warfarin, started at 7.5mg, adjusted to maintain INR ratio between 2.0 to 3.0. Administered between 48 hours preoperatively and 24 hours postoperatively.</p> <p><u>Concomitant treatment</u> AES permitted, further details not reported</p>	<p>n=3011</p> <p>People undergoing elective total hip replacement, mean duration of surgery not reported</p> <p>Age (mean): 64 years</p> <p>Gender (male to female ratio): 1:1.25</p> <p>Multicentre, USA</p>	<p>All-cause mortality (90 days)</p> <p>PE (90 days): confirmed by ventilation perfusion scan or pulmonary angiography</p> <p>Major bleeding (time-point not reported)</p>	<p>Included in CG92</p> <p>Significantly more obese patients in the intervention arm</p>
Comp 2001 ⁶⁶	<p><u>Intervention (n=224):</u> LMWH, enoxaparin, 30 mg twice daily (high dose) subcutaneously for 7-10 days. Patients were then administered 40mg once daily subcutaneously for 3 weeks (extended duration).</p>	<p>n=435</p> <p>People undergoing elective total hip replacement, mean duration of surgery not reported</p> <p>Age (mean): 64</p>	<p>DVT (symptomatic and asymptomatic) (27-29 days): confirmed by segment-filling defects on lower-extremity ascending contrast venograms.</p> <p>PE (27-29 days): confirmed by high-probability ventilation-perfusion lung scan or pulmonary angiogram</p>	<p>Included in CG92</p>

Study	Intervention and comparison	Population	Outcomes	Comments
	<p><u>Comparison (n=211):</u> LMWH, enoxaparin, 30 mg twice daily (high dose) subcutaneously for 7-10 days (standard duration). Patients were then administered placebo, saline subcutaneously for 3 weeks.</p>	<p>years Gender (male to female ratio): 1:1 Multicentre, USA</p>	<p>Major bleeding (27-29 days): defined as clinically overt and resulted in death, transfusion of two or more units of blood products, a decrease in haemoglobin level of ≥ 2.0 g/dL (≥ 20 g/L) compared with the most recent preceding postoperative value, or a serious or life-threatening clinical event or one requiring surgical intervention or if it was retroperitoneal, intracranial, or intraocular in location.</p> <p>Heparin-induced thrombocytopenia (27-29 days)</p>	
Dahl 1997 ⁶⁷	<p><u>Intervention (n=117):</u> LMWH, dalteparin, 5000 IU once daily (standard dose), subcutaneously administered from the evening before the operation until 4 weeks after (extended duration). AES, below-knee on both legs before the operation and for the first post-operative week.</p> <p><u>Comparison (n=110):</u> LMWH, dalteparin, 5000 IU once daily (standard dose), subcutaneously administered from the evening before the operation until 7 days after (standard duration), then administered placebo (sodium chloride) in the evenings. AES, below-knee on both legs before the operation and for the first post-operative week.</p>	<p>n=227 People undergoing elective primary or secondary hip replacement, mean duration of surgery 107 minutes Age (mean): 71.2 years Gender (male to female ratio): 1:2.4 Norway</p>	<p>DVT (symptomatic and asymptomatic) (35 days): confirmed by bilateral ascending venography</p> <p>PE (35 days): confirmed by ventilation/perfusion scintigraphy (V/Q scan) and chest X-rays</p>	Included in CG92

Study	Intervention and comparison	Population	Outcomes	Comments
Eriksson 1991A ⁸⁴	<p><u>Intervention (n=67):</u> LMWH, dalteparin, 5000 IU once daily (standard dose) subcutaneously from the evening before the operation until 10 days post-operation. Placebo was also given twice daily.</p> <p><u>Comparison (n=69):</u> Unfractionated heparin, 5000 IU three times daily, subcutaneously from two hours pre-operation for 10 days. Placebo was only given on the pre-operative evening.</p> <p><u>Concomitant treatment:</u> Mobilisation and physiotherapy started on the first day after the operation</p>	<p>n=132</p> <p>People undergoing elective total hip replacement, mean duration of surgery 124 minutes</p> <p>Age (mean): 69 years</p> <p>Gender (male to female ratio): 1:1.4</p> <p>Sweden</p>	<p>DVT (symptomatic and asymptomatic) (12-14 days): confirmed by bilateral ascending phlebography</p> <p>PE (12-14 days): confirmed by pulmonary perfusion scintigraphy</p> <p>Major bleeding (10 days): definition not reported</p> <p>Heparin-induced thrombocytopenia (time-point not reported)</p> <p>Haematoma > 0.5 cm at site of injection (time-point not reported)</p>	Included in CG92
Eriksson 2007 ⁸³ :RENOVATE I study	<p><u>Intervention (n=1157):</u> Dabigatran etexilate, 220 mg once daily (started 1–4 hours after surgery with a half dose of 110 mg) subcutaneously. Intervention continued for 28-35 days.</p> <p><u>Comparison (n=1174):</u> LMWH, enoxaparin, 40 mg once daily (standard dose) subcutaneously, administered from the evening before the operation for 28-35 days.</p>	<p>n=2319</p> <p>People undergoing elective total hip replacement, mean duration of surgery not reported</p> <p>Age (mean): 65 years</p> <p>Gender (male to female ratio): 1:1</p> <p>Multinational – Europe, Australia and South Africa</p>	<p>DVT (symptomatic and asymptomatic) (28-35 days): confirmed by a consistent intraluminal filling defect on at least two venogram images.</p> <p>PE (28-35 days): confirmed by ventilation-perfusion scintigraphy, pulmonary angiography, spiral chest CT, or by autopsy.</p> <p>Major bleeding (28-35 days): defined as a bleeding event that meets at least one of the following criteria: fatal bleeding, critical bleeding (intracranial, intraocular, intraspinal, pericardial, retroperitoneal, in a non-operated joint, or intramuscular with compartment syndrome,</p>	Included in CG92 TA1572008 ²²⁹

Study	Intervention and comparison	Population	Outcomes	Comments
			<p>clinically overt bleeding (at surgical or extra-surgical site) associated with a decrease in the haemoglobin level of more than 2 g/dL (20 g/l; 1.24 mmol/L), clinically overt bleeding (at surgical or extra-surgical site) leading to transfusion of two or more units of whole blood or packed cells, bleeding located at the surgical site and leading to re-operation or to any unusual medical intervention or procedure for relief (e.g. draining or puncture of an haematoma at the surgical site, transfer to an ICU or emergency room)</p>	
<p>Eriksson 2008⁸⁶: RECORD I study</p>	<p><u>Intervention (n=2266):</u> LMWH, enoxaparin, 40mg once daily (standard dose), subcutaneously given from the evening before the surgery, restarted 6-8 hours after wound closure, continued to day 35 (extended duration). Placebo tablets were given.</p> <p><u>Comparison (n=2275):</u> Rivaroxaban, 10mg, orally administered from 6-8 hours after wound closure until day 35. Placebo injections were given.</p>	<p>n=4541</p> <p>People undergoing elective total hip replacement, mean duration of surgery 91 minutes</p> <p>Age (mean): 63 years</p> <p>Gender (male to female ratio): 1:1</p> <p>Austria, Australia, Argentina, Belgium, Brazil, Canada, Chile, Colombia, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Israel, Italy, Lithuania, Netherlands, Norway, Poland, Slovakia, South Africa, Spain, Sweden, Turkey, USA</p>	<p>All-cause mortality (36 days)</p> <p>DVT (symptomatic and asymptomatic) (36 days): confirmed by ascending bilateral venography using Rabinov and Paulin technique</p> <p>PE (36 days): confirmed by spiral computed tomography, perfusion-ventilation lung scintigraphy or pulmonary angiography</p> <p>Major bleeding (37 days): defined as bleeding that was fatal, occurred in a critical organ (e.g. retroperitoneal, intracranial, intraocular, and intraspinal bleeding), or required reoperation or extrasurgical-site bleeding that was clinically overt and was associated with a fall in the haemoglobin level of at least 2 g/dl or that required transfusion of 2 or more units of whole blood or packed cells</p> <p>Clinically relevant non-major bleeding (37 days):</p>	<p>New study</p> <p>TA1702009 229</p>

Study	Intervention and comparison	Population	Outcomes	Comments
			definition not reported	
			Wound infection (37 days)	
Eriksson 2011 ⁸⁷ : RE-NOVATE II trial	<p><u>Intervention (n=992):</u> LMWH, enoxaparin, 40 mg (standard dose) and placebo drug, subcutaneously given from the evening before surgery and continued for 28-35 days.</p> <p><u>Comparison (n=1001):</u> Dabigatran, 220mg (110 mg x2) once daily, orally administered from the evening before surgery and continued for 28-35 days.</p>	<p>n=1993</p> <p>People undergoing primary, unilateral, elective hip replacement, median duration 80 minutes</p> <p>Age (mean): 62 years</p> <p>Gender (male to female ratio): 1:1</p> <p>Multicentre in 19 countries; Australia, Belgium, Canada, Czech Republic, Denmark, Finland, Germany, Hungary, India, Italy, Netherlands, New Zealand, Norway, Poland, South Africa, Spain, Sweden, USA.</p>	<p>All-cause mortality (38 days)</p> <p>DVT (symptomatic and asymptomatic) (36 days): confirmed by ascending, bilateral venography using a modification of the Rabinov and Paulin technique.</p> <p>PE (36 days): confirmed by ventilation-perfusion scintigraphy and chest X-ray, pulmonary angiography, spiral chest computer tomography, or by autopsy</p> <p>Major bleeding (36 days): defined as a bleeding event that meets at least one of the following criteria: fatal bleeding, critical bleeding (intracranial, intraocular, intraspinal, pericardial, retroperitoneal, in a non-operated joint, or intramuscular with compartment syndrome, clinically overt bleeding (at surgical or extra-surgical site) associated with a decrease in the haemoglobin level of more than 2 g/dL (20 g/l; 1.24 mmol/L), clinically overt bleeding (at surgical or extra-surgical site) leading to transfusion of two or more units of whole blood or packed cells, bleeding located at the surgical site and leading to re-operation or to any unusual medical intervention or procedure for relief (e.g. draining or puncture of an haematoma at the surgical site, transfer to an ICU or emergency room). [taken from European Medicines Agency guideline]</p>	New study

Study	Intervention and comparison	Population	Outcomes	Comments
			Clinically relevant non-major bleeding (36 days): defined as any clinically overt bleeding that does not meet the criteria for major bleeding but requires medical attention (e.g. hospitalisation, medical treatment for bleeding) and/or change in antithrombotic therapy (including discontinuation or down-titration of study drug) and/or any other bleeding type considered to have clinical consequences for a patient. [taken from European Medicines Agency guideline]	
Fordyce 1992 ⁹⁷	<p><u>Intervention (n=39):</u> Foot pump, A-V Impulse System, rapid inflation and deflation for 3 seconds, cycle repeated every 20 seconds. Fitted to the foot of the operated limb, and using whenever the patient was in bed or sitting at rest. Duration of intervention unclear. AES was also applied to both legs</p> <p><u>Comparison (n=40):</u> AES on both legs alone. Duration of intervention unclear.</p> <p><u>Concomitant treatment:</u> Patients practiced active leg exercise and were mobilised on the 2nd postoperative day</p>	<p>n=79</p> <p>People undergoing elective primary total hip replacement, mean duration of surgery 109 minutes.</p> <p>Age (mean): 70 years</p> <p>Gender (male to female ratio): 1:1.7</p> <p>UK</p>	DVT (symptomatic and asymptomatic) (6-9 days): confirmed by ascending venography	Included in CG92
Francis 1992 ⁹⁹	<p><u>Intervention (n=98):</u> Intermittent pneumatic compression device (IPCD), bilateral thigh-calf, 35-55 mmHg.</p>	<p>n= 291</p> <p>People undergoing elective hip replacement,</p>	DVT (symptomatic and asymptomatic) (6-8 days): confirmed by venography	Included in CG92

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>Bilateral thigh-high AES. Applied immediately prior to surgery. Continued until outcome assessment at 6-8 days.</p> <p><u>Comparison (n=103):</u> Warfarin, low dose adjusted to achieve INR of 1.5 on day of surgery, and 2.5 post-operatively. Bilateral thigh-high AES. Applied immediately prior to surgery. Continued until outcome assessment at 6-8 days.</p> <p><u>Concomitant treatment:</u> Patients moved from bed to chair on 2nd day post-operation, began ambulation and physical therapy on 3rd day post-operation.</p>	<p>mean duration of surgery not reported.</p> <p>Age (mean): 64 years</p> <p>Gender (male to female ratio): 1:1.12</p> <p>USA</p>		
Francis 1997A ¹⁰⁰	<p><u>Intervention (n=271):</u> LMWH, dalteparin, 5000IU once daily (standard dose) subcutaneously for mean of 7 days from the first postoperative day. First dose of 2500IU was administered two hours before the operation; second dose of 25000IU was given on the evening of the operation.</p> <p><u>Comparison (n=279):</u> Warfarin, adjusted to an INR of approximately 2.5, orally. First dose administered evening before the operation and second dose administered evening</p>	<p>n=550</p> <p>People undergoing elective primary of revision total hip replacement, mean duration of surgery not reported</p> <p>Age (mean): 63 years</p> <p>Gender (male to female ratio): 1:1</p> <p>USA</p>	<p>DVT (symptomatic and asymptomatic) (9 days): confirmed by bilateral ascending venography</p> <p>Major bleeding (9 days): defined as fatal or if the patient required a transfusion, a reoperation or prolonged hospital stay</p> <p>Wound haematoma (9 days)</p>	Included in CG92

Study	Intervention and comparison	Population	Outcomes	Comments
	of the day of the operation. Dose for first and second dose: 5-7.5 mg, (depending on weight: 5mg for patients that weighed ≤57 kg; 7.5 for patients that weighed >57kg).			
Fuji 2008 ¹⁰⁵	<p><u>Intervention (n=81):</u> Fondaparinux, 2.5mg subcutaneously once daily. Administered 24±2 hours after surgery until 10-16 days. More than 50% received AES.</p> <p><u>Comparison (n=82):</u> Placebo, 0.25ml isotonic sodium chloride, subcutaneously once daily. Administered 24±2 hours after surgery until 10-16 days. More than 50% received AES.</p>	<p>n=163</p> <p>People undergoing primary elective total hip replacement or revision surgery, mean duration of surgery not reported</p> <p>Age (mean): 61.6 years</p> <p>Gender (male to female ratio):4.6:1</p> <p>Japan</p>	<p>All-cause mortality (11-17 days)</p> <p>Major bleeding (11-17 days): defined as fatal bleeding; bleeding that was retroperitoneal, intracranial, or intraspinal or that involved any other critical organ; bleeding leading to reoperation; and overt bleeding with bleeding index of 2 or more.</p>	Included in CG92
Fuji 2008A ¹⁰⁶	<p><u>Intervention 1 (n=81):</u> LMWH, enoxaparin, 20mg (low dose), subcutaneously once daily, administered 24-36 hours after surgery for 14 days. More than 50% received AES (length unspecified).</p> <p><u>Intervention 2 (n=80):</u> LMWH, enoxaparin, 40mg (standard dose) once daily, administered 24-36 hours after surgery for 14 days. More than 50% received AES (length unspecified).</p> <p><u>Comparison (n=86):</u> Placebo (saline). Administered 24-36 hours after surgery for 14 days. More than</p>	<p>n=247</p> <p>People undergoing primary elective hip replacement, mean duration of surgery not reported</p> <p>Age (mean): 62 years</p> <p>Gender (male to female ratio): 1:8</p> <p>Japan</p>	<p>DVT (symptomatic and asymptomatic) (14 days): confirmed by Doppler ultrasound</p> <p>PE (90 days): confirmed by ventilation perfusion lung scans or pulmonary angiography</p> <p>Major bleeding (15 days): defined as bleeding episode that was retroperitoneal, intracranial, or intraocular or if it was associated with: death; transfusion of ≥2 units of packed red blood cells or whole blood (except autologous); a reduction of ≥2 g/d; or a serious or life threatening clinical events that required medical intervention.</p>	Included in CG92

Study	Intervention and comparison	Population	Outcomes	Comments
	50% received AES (length unspecified).			
Gallus 1983 ¹⁰⁸	<p><u>Intervention (n=43):</u> Intermittent pneumatic compression device (IPCD), calf compression, 45 mmHg for 10 seconds each 2 minutes. Device was applied to both legs throughout surgery then day and night for 7 days.</p> <p><u>Comparison (n=47):</u> Control group, no further details reported</p>	<p>n=90</p> <p>People undergoing elective hip replacement, mean duration of surgery not reported</p> <p>Age (mean): 68 years</p> <p>Gender (male to female): 1:2</p> <p>Australia</p>	<p>DVT (symptomatic and asymptomatic) (7 days): confirmed by 125I fibrinogen leg scan or venography</p>	Included in CG92
Hampson 1974 ¹³⁰	<p><u>Intervention (n=48):</u> Unfractionated heparin (calcium heparin), 5000 I subcutaneously three times daily for 7-10 days after surgery</p> <p><u>Comparison (n=52):</u> Control group, saline, subcutaneously three times daily.</p>	<p>n=100</p> <p>People undergoing elective total hip replacement, mean duration of surgery not reported</p> <p>Age (mean): details not reported</p> <p>Gender (male to female ratio): details not reported</p> <p>UK</p>	<p>DVT (symptomatic and asymptomatic) (18 days): confirmed by 125I fibrinogen uptake test and ultrasound investigations</p> <p>Major bleeding (time-point not reported): definition not reported</p>	Included in CG92
Hardwick 2011 ¹³² ; Colwell 2010 ⁶⁵	<p><u>Intervention (n=194):</u> LMWH, enoxaparin, 30 mg twice daily (high dose) subcutaneously from the morning after surgery until discharge. Mean length of stay 3.2 days. LMWH, enoxaparin, 40 mg once daily (standard dose) until 10 days post-operation.</p> <p><u>Comparison (n=198):</u></p>	<p>n=392</p> <p>People undergoing elective primary unilateral total hip replacement, mean duration of surgery 94 minutes</p> <p>Age (mean): 63 years</p> <p>Gender (male to</p>	<p>DVT (symptomatic and asymptomatic): (84 days) confirmed by bilateral duplex ultrasonography</p> <p>PE (84 days): confirmed by spiral computed tomographic scans</p> <p>Major bleeding (10 days): definition not reported</p>	New study

Study	Intervention and comparison	Population	Outcomes	Comments
	IPCD, on both of the patient's calves, 50 mmHg for 8 seconds followed by 36-45 seconds of decompression. IPCD applied in the operating room and continued use for 10 days after surgery.	female): 1:1 USA		
Hull 1990 ¹⁴⁷	<p><u>Intervention (n=152):</u> IPCD, calf and thigh length, 50-65 mmHg, was applied postoperatively in the recovery room until hospital discharge or for 14 days</p> <p><u>Comparison (n=158):</u> Control group, no prophylaxis, no further details reported</p> <p><u>Concomitant treatment</u> Routine physiotherapy provided to all patients</p>	<p>n=310</p> <p>People undergoing elective total hip replacement, mean duration of surgery not reported.</p> <p>Age (mean): 65 years Gender (male to female ratio): 1:1.5</p> <p>Canada</p>	<p>DVT (symptomatic and asymptomatic) (14 days): confirmed by bilateral ascending venography</p> <p>PE (14 days): confirmed by ventilation-perfusion lung scanning and pulmonary angiography</p>	Included in CG92
Hull 2000 ¹⁴⁵	<p><u>Intervention 1 (n=496):</u> LMWH, dalteparin, 2500IU (low dose) subcutaneously 2 hours before surgery (pre-operatively), a second dose of 2500IU postoperatively. Patients also received placebo oral capsules.</p> <p><u>Intervention 2 (n=487):</u> LMWH, dalteparin, 2500IU (low dose) subcutaneously postoperatively, placebo administered before the operation. Patients also received placebo oral capsules.</p> <p><u>Comparison (n=489):</u> Warfarin, initial dose of 10mg</p>	<p>n=1472</p> <p>People undergoing elective unilateral total hip replacement, mean duration of surgery not reported</p> <p>Age (mean): 64 years Gender (male to female ratio): 1:1.08</p> <p>USA and Canada</p>	<p>All-cause mortality (8 days)</p> <p>DVT (symptomatic and asymptomatic) (8 days): confirmed by venography</p> <p>PE (8 days): confirmed by lung scanning or pulmonary angiography</p> <p>Major bleeding (8 days): defined as clinically overt and associated with a decrease in haemoglobin level of 20 g/L or more or required transfusion of 2 U of blood or more; if it was intracranial, intraocular, intraspinal or retroperitoneal; or if it occurred into a prosthetic joint</p>	Included in CG92

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>postoperatively in the evening of surgery day. Doses were adjusted daily to maintain an INR from 2.0 to 3.0. Patients also received subcutaneous placebo injections</p> <p><u>Concomitant treatment:</u> AES used in approximately 30% in intervention groups</p>		Wound haematoma (8 days)	
Kakkar 2000 ¹⁶¹	<p><u>Intervention (n=149):</u> LMWH, bempiparin, 35000IU (high dose) plus placebo injections of 0.9% saline subcutaneously, administered 2 hours before surgery and continued for at least 8 days post-operation (longer if person was still hospitalised)</p> <p><u>Comparison (n=149):</u> Unfractionated heparin (calcium heparin), 5000IU subcutaneously, administered 2 hours before surgery and continued for at least 8 days post-operation (longer if person was still institutionalised)</p>	<p>n=298</p> <p>People undergoing elective hip replacement surgery, mean duration of surgery 105 minutes</p> <p>Age (mean): 70.5 years</p> <p>Gender (male to female ratio): 1:2</p> <p>UK</p>	<p>DVT (symptomatic and asymptomatic) (28 days): confirmed by bilateral elective venography</p> <p>PE (28 days): confirmed by ventilation perfusion scan.</p> <p>Fatal PE (28 days): confirmed by ventilation perfusion scan.</p> <p>Wound haematoma (28 days)</p>	Included in CG92
Kakkar 2008 ¹⁵⁷ : RECORD II study	<p><u>Intervention (n=1257):</u> LMWH, enoxaparin, 40 mg once daily (standard dose) subcutaneously, administered from 12 hours before surgery, restarted 6-8 hours (with placebo tablets for 31-39 days) after wound closure and continued for 10-14 days (standard duration).</p>	<p>n=2509</p> <p>People undergoing elective total hip replacement, mean duration of surgery 94 minutes.</p> <p>Age (mean):61.6 years</p> <p>Gender (male to female): 1:1</p>	<p>All-cause mortality (30-42 days)</p> <p>DVT (symptomatic and asymptomatic) (32-40 days): confirmed by venography</p> <p>PE (32-40 days): confirmed by pulmonary angiography, perfusion/ventilation lung scintigraphy with chest radiography, or spiral computed tomography.</p> <p>Major bleeding (30-42</p>	<p>New study.</p> <p>TA1702009²²⁹</p>

Study	Intervention and comparison	Population	Outcomes	Comments
	<u>Comparison (n=1252):</u> Rivaroxaban, 10mg once daily, orally administered 6-8 hours after wound closure (with placebo injections for 10-14 days), continued for 31-39 days	Multicentre; 123 centres across 21 countries (details of countries not reported)	days): defined as bleeding that was fatal, was into a critical organ (retroperitoneal, intracranial, intraocular, intraspinal), required re-operation, or clinically overt extra surgical site bleeding associated with a fall in haemoglobin of 20 g/L or more, calculated from the day 1 post-operative baseline value, or requiring infusion of two or more units of whole blood or packed cells. Clinically relevant non-major bleeding (30-42 days): definition not reported. Wound infection (30-42 days)	
Kalodiki 1996 ¹⁶³	<u>Intervention 1 (n=32):</u> LMWH, enoxaparin, 40 mg, once daily subcutaneously for 8-12 days <u>Intervention 2 (n=32):</u> LMWH, enoxaparin, 40mg, once daily (standard dose) subcutaneously and AES for 8-12 days <u>Comparison (n=14):</u> Control group, placebo injections once daily subcutaneously	n=78 People undergoing elective total hip replacement, mean duration of surgery not reported Age (mean): details not reported Gender (male to female ratio): 1:1 USA	DVT (symptomatic and asymptomatic) (8-12 days): confirmed by bilateral ascending venography PE (8-12 days): confirmed by perfusion/ventilation scan	Included in CG92
Lassen 1991 ¹⁸³	<u>Intervention (n=93):</u> LMWH, tinzaparin, 50 IU/kg, once daily (low dose) subcutaneously, from 2 hours preoperatively and continued for 7 days. AES, thigh-length, both legs, from one hour before the operation until 7 days post-operation.	n=190 People undergoing elective hip replacement, mean duration of surgery 120 minutes Age (mean):67	DVT (symptomatic and asymptomatic) (8-10 days): confirmed by bilateral ascending phlebography PE (8-10 days): confirmed by ventilation/perfusion lung scintimetry Fatal PE (8-10 days): confirmed by	Included in CG92

Study	Intervention and comparison	Population	Outcomes	Comments
	<p><u>Comparison (n=97):</u> Placebo group, saline once daily subcutaneously. AES, thigh-length, both legs, from one hour before the operation until 7 days post-operation.</p>	<p>years Gender (male to female ratio): 1:1 Denmark</p>	<p>ventilation/perfusion lung scintimetry</p>	
Lassen 1998 ¹⁸²	<p><u>Intervention (n=140):</u> LMWH, dalteparin, 5000 IU once daily (standard dose) subcutaneously, from 12 hours before operation until 35 days after operation (extended duration).</p> <p><u>Comparison (n=141):</u> LMWH, dalteparin, 5000 IU once daily (standard dose) subcutaneously, from 12 hours before operation until 7 days post-operation (standard duration). Placebo, isotonic sodium chloride subcutaneously administered until 35 days</p> <p><u>Concomitant treatment:</u> AES permitted, no further details reported</p>	<p>n=281 People undergoing elective total hip replacement, mean duration of surgery 108 minutes Age (mean): 69 years Gender (male to female ratio): 1:1.3 Denmark</p>	<p>DVT (symptomatic and asymptomatic) (35 days): confirmed by ultrasonography or phlebography</p> <p>PE (35 days): confirmed by perfusion/ventilation lung scan or pulmonary angiography</p> <p>Major bleeding (35 days): definition not reported</p>	Included in CG92
Lassen 2002 ¹⁸¹	<p><u>Intervention (n=1154):</u> LMWH, enoxaparin, 40 mg (standard dose) once daily and placebo subcutaneously, administered from 12±2 hours preoperatively until day 5 to 9. Use of AES was recommended, 71% used AES.</p> <p><u>Comparison (n=1155):</u> Fondaparinux sodium,</p>	<p>n=2309 People undergoing primary elective total hip-replacement surgery or revision surgery, mean duration of surgery 2.4 hours Age (mean): 67 years</p>	<p>All-cause mortality (49 days)</p> <p>DVT (symptomatic and asymptomatic) (49 days): confirmed by systematic bilateral ascending venography</p> <p>PE (49 days): confirmed by lung scan, pulmonary angiography or helical computed tomography or at autopsy</p>	Included in CG92

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>2.5mg and placebo subcutaneously, administered 6±2 hours postoperatively until day 5 to 9. Use of AES was recommended, 71% used AES.</p> <p><u>Concomitant treatment:</u> Use of NSAIDs or aspirin intervention group 54%, comparison group 53%</p>	<p>Gender (male to female ratio): 1:1.23</p> <p>Country not reported</p>	<p>Major bleeding (49 days): defined as fatal bleeding; bleeding that was retroperitoneal, intracranial, or intraspinal or that involved any other critical organ; bleeding leading to reoperation; and overt bleeding with bleeding index of 2 or more.</p>	
<p>Lassen 2010¹⁸⁷: ADVANCE-3 trial</p>	<p><u>Intervention (n=2699):</u> LMWH, enoxaparin, 40mg once daily (standard dose) subcutaneously, administered 12 hours before surgery until after surgery (duration of intervention not clearly reported), plus placebo tablets twice daily</p> <p><u>Comparison (n=2708):</u> Apixaban, 2.5mg orally twice daily plus placebo injections once daily, from 12 to 24 hours after closure of the surgical wound until after surgery (duration of intervention not clearly reported)</p>	<p>n=5407</p> <p>People undergoing elective total hip replacement or revision of a previously inserted hip prosthesis, mean duration of surgery 90 minutes</p> <p>Age (mean): 61 years</p> <p>Gender (male to female ratio): 1:1</p> <p>Denmark</p>	<p>All-cause mortality (32-38 days)</p> <p>DVT (symptomatic and asymptomatic) (32-38 days): confirmed by bilateral venography</p> <p>PE (32-38 days): confirmed by bilateral venography</p> <p>Major bleeding (32-38 days): defined as acute, clinically overt bleeding accompanied by one or more of the following findings: a decrease in the haemoglobin level of 2g/dl or more over a 24 hour period; transfusion of 2 or more units of packed red cells; bleeding at a critical site (including intracranial, intraspinal, intraocular, pericardial, and retroperitoneal bleeding); bleeding into the operated joint, necessitating reoperation or intervention; intramuscular bleeding with the compartment syndrome; or fatal bleeding.</p> <p>Fatal PE (32-38 days)</p> <p>Clinically relevant non-major bleeding (32-38 days): acute, clinically overt</p>	<p>New study</p>

Study	Intervention and comparison	Population	Outcomes	Comments
			<p>episodes such as wound haematoma, bruising, or ecchymosis, gastrointestinal bleeding, haemotypsis, haematuria, or epistaxis that did not met the criteria for major bleeding</p> <p>Heparin-induced thrombocytopenia (32-38 days)</p>	
Levine 1991 ¹⁹⁵	<p><u>Intervention (n=332):</u> LMWH, enoxaparin, 30mg twice daily (high dose) subcutaneously, from 12-24 hours after surgery continued for 14 days or until discharge if sooner.</p> <p><u>Comparison (n=333):</u> Unfractionated heparin, 7500IU twice daily subcutaneously, from 12-24 hours after surgery continued for 14 days or until discharge if sooner.</p>	<p>n=665</p> <p>People undergoing elective hip replacement, mean duration of surgery not reported.</p> <p>Age (mean): details not reported</p> <p>Gender (male to female ratio): details not reported</p> <p>Country not reported</p>	<p>DVT (symptomatic and asymptomatic) (10-14 days): confirmed by 125I fibrinogen leg scanning, impedance plethysmography and venography</p> <p>PE (10-14 days): definition not reported</p> <p>Major bleeding (10-14 days): definition not reported</p>	Included in CG92
Manganelli 1998 ²⁰⁰	<p><u>Intervention (n=33):</u> Unfractionated heparin, 5000IU, from one day pre-operation, every 8 hours for 30 days (extended duration).</p> <p><u>Comparison (n=28):</u> Unfractionated heparin, 5000IU, from one day pre-operation every 8 hours until discharge (standard duration). Length of stay (mean): 12 days</p>	<p>n=61</p> <p>People undergoing elective total hip replacement, mean duration of surgery not reported</p> <p>Age (mean): 66 years</p> <p>Gender (male to female ratio): 1:1.5</p> <p>Italy</p>	<p>DVT (symptomatic and asymptomatic) (45 days): confirmed by unilateral ascending venography</p> <p>Major bleeding (45 days): defined as clinically overt and associated with a decrease in haemoglobin values of 2 g/dl or more, compared with the last post-op value, or a need for blood transfusion, or if it was retroperitoneal or intracranial.</p>	Included in CG92
Mannucci 1976 ²⁰¹	<p>Trial 1 <u>Intervention (n=45):</u> Unfractionated heparin</p>	<p>Trial 1: n=96 Trial 2: n=47</p>	<p>Trial 1 DVT (symptomatic and asymptomatic) (7 days):</p>	Included in CG92

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>(calcium heparin), 5000 IU subcutaneously, from 2 hours preoperatively and 8 hourly postoperatively until fully ambulatory on crutches.</p> <p><u>Comparison (n=51):</u> Control group, no further details reported</p> <p>Trial 2 <u>Intervention (n=23):</u> Unfractionated heparin (calcium heparin), 5000 IU subcutaneously, from 2 hours preoperatively and 8 hourly postoperatively until fully ambulatory on crutches. (Intervention not explicitly detailed, assumption that details are the same as trial 1)</p> <p><u>Comparison (n=24):</u> Control group, no further details reported</p>	<p>People undergoing elective hip replacement, mean duration of surgery for trial 1: 117 minutes, trial 2: 121 minutes</p> <p>Trial 1 and 2 Age (mean): 60 years Gender (male to female): 1:4 (Reported that age and gender is similar in both trials)</p> <p>Italy</p>	<p>confirmed by 125I fibrinogen test</p> <p>PE (time-point not reported): definition not reported</p> <p>Wound haematomas (time-point not reported)</p> <p>Trial 2 DVT (symptomatic and asymptomatic) (15 days): confirmed by 125I fibrinogen test</p> <p>PE (time-point not reported): definition not reported</p> <p>Wound haematomas (time-point not reported)</p>	<p>Data from both trials were combined in analysis</p>
Moskovitz 1978 ²²¹	<p><u>Intervention (n=35):</u> Unfractionated heparin, sodium heparin, 5000IU subcutaneously given every 8 hours. Patients wore AES (length unspecified), length of time AES worn for not reported.</p> <p><u>Comparison (n=32):</u> Placebo, saline, subcutaneously given every 8 hours. Patients wore AES (length</p>	<p>n=67</p> <p>People admitted for elective hip replacement surgery, mean duration of surgery not reported</p> <p>Age: 46% ≥60 years; 54% <59 years Gender (male to female ratio): 1:1</p>	<p>All-cause mortality (time-point not reported)</p> <p>DVT (symptomatic and asymptomatic) (10 days): confirmed by I¹²⁵ fibrinogen uptake test and scans</p> <p>PE (time-point not reported): confirmed by radionuclide perfusion lung-scanning</p> <p>Major bleeding (time-point not reported): definition not reported</p>	<p>Included in CG92</p>

Study	Intervention and comparison	Population	Outcomes	Comments
	unspecified), length of time AES worn for not reported.	USA		
Paiement 1987 ²⁴⁰	<p><u>Intervention (n=66):</u> Intermittent pneumatic compression device (IPCD, 45-55 mmHg, started one day before operation</p> <p><u>Comparison (n=72):</u> Warfarin, low dose, 10 mg pre-operation, 5 mg post-operation, thereafter adjusted to maintain PTT at 15 seconds for control at 11-12 seconds</p>	<p>n=138</p> <p>People undergoing elective total hip replacement, mean duration of surgery not reported</p> <p>Age (mean): not reported</p> <p>Gender (male to female ratio):1:1</p> <p>Canada</p>	<p>DVT (symptomatic and asymptomatic) (10 days): confirmed by venography</p> <p>PE (10 days): was not routinely screened for – confirmed by V/Q and angiogram if high probability</p> <p>Major bleeding (10 days): defined as overt and associated with decrease in haemoglobin level if ≥ 2 g/dl; required transfusion of 2 or more units; retroperitoneal or occurred in major prosthetic joint, intracranial; intraoperative and post-operative blood loss (weight of sponges; suction drainage blood loss; estimated of blood on wound drapes)</p>	Included in CG92
Pitto 2004 ²⁴²	<p><u>Intervention (n=100):</u> LMWH, nadroparin, dose adjusted to body weight, 0.2 to 0.6 ml (0.1ml = 950IU of anti Xa) (variable dose). Mean BMI: 28.1 \pm 2.9. Subcutaneously administered every 12 hours postoperatively, not stated when stopped but could be until discharge. Bilateral thigh-high AES also used.</p> <p><u>Comparison (n=100):</u> Foot pump, A-V Impulse System (slippers), patient in Trendelenburg position (head-high, feet-low), 130 mmHg for one second every 20 seconds. Started post-operation, not stated when stopped could be</p>	<p>n=200</p> <p>People with osteoarthritis undergoing elective total hip replacement, mean duration of surgery not reported</p> <p>Age (mean): 57.7 years</p> <p>Gender (male to female ratio): 1:2</p> <p>New Zealand</p>	<p>DVT (symptomatic and asymptomatic) (45 days): confirmed by serial bilateral duplex</p> <p>PE (45 days): definition not reported</p> <p>Fatal PE (45 days): definition not reported</p> <p>Major bleeding (45 days): definition not reported</p> <p>Heparin-induced thrombocytopenia (45 days)</p>	Included in CG92

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>used until discharge. Bilateral thigh-high AES also used.</p> <p><u>Concomitant treatment:</u> Physiotherapy and mobilisation with partial weight bearing usually started on postoperative day 2.</p>			
Planès 1990A ²⁴⁴	<p>Trial 1 <u>Intervention (n=50):</u> LMWH, enoxaparin, 40 mg once daily (standard dose) subcutaneously from 12 hours pre-operation. Duration of intervention unclear, possibly until discharge.</p> <p><u>Comparison (n=50):</u> LMWH, enoxaparin, 60 mg once daily (high dose) subcutaneously from 12 hours pre-operation. Duration of intervention unclear, possibly until discharge.</p> <p>Trial 2 <u>Intervention (n=124):</u> LMWH, enoxaparin, 40mg once daily (standard dose), subcutaneously from 12 hours pre-operatively for 14 days or until hospital discharge.</p> <p><u>Comparison (n=113):</u> Unfractionated heparin (calcium heparin), 5000 IU, subcutaneously every 8 hours from 2 hours pre-operation for 14 days or until hospital discharge.</p>	<p>Trial 1: n=100 Trial 2: n=237</p> <p>People undergoing elective hip replacement, mean duration of surgery not reported</p> <p>Trial 1 Age (mean): 65 years Gender (male to female ratio):1:1</p> <p>Trial 2 Age (mean): not reported Gender (male to female ratio): not reported</p> <p>Both trials conducted in France</p>	<p>Trial 1 DVT (symptomatic and asymptomatic) (12-15 days): confirmed by bilateral ascending venography</p> <p>Wound haematomas (12-15 days)</p> <p>Trial 2 DVT (symptomatic and asymptomatic) (time-point unclear): confirmed by bilateral ascending venography</p> <p>PE (time-point unclear): definition not reported</p> <p>Major bleeding (time-point unclear): definition not reported)</p>	Included in CG92

Study	Intervention and comparison	Population	Outcomes	Comments
Planes 1996 ²⁴³	<p><u>Intervention (n=90):</u> LMWH, enoxaparin, 40mg once daily (standard dose), subcutaneously from 12 hours pre-operatively, 12 hours postoperatively, until 21±2 days (extended duration)</p> <p><u>Comparison (n=89):</u> Placebo, isotonic saline, 0.4 ml</p> <p><u>Concomitant treatment:</u> Patients were advised to wear elastic bandages/AES on both legs (% of patients that used AES not reported), avoid other anticoagulant treatment, aspirin, ticlopidine and NSAIDS</p>	<p>n=179</p> <p>People undergoing elective total hip replacement surgery, mean duration of surgery not reported</p> <p>Age (mean): 69 years</p> <p>Gender (male to female ratio): 1.3:1</p> <p>France</p>	<p>All-cause mortality (21±2 days)</p> <p>DVT (symptomatic and asymptomatic) (21±2 days): confirmed by bilateral phlebographic examination.</p> <p>PE (21±2 days): confirmed by pulmonary angiography or by autopsy</p> <p>Major bleeding (21±2 days): defined as overt and associated with either a fall in haemoglobin level of ≥20 g/L or a need for transfusion of 2 or more units of blood, or if it was retroperitoneal or intracranial.</p> <p>Wound haematoma (21±2 days)</p>	Included in CG92
Prandoni 2002 ²⁴⁷	<p><u>Intervention (n=184):</u> Warfarin – extended duration, sodium warfarin, 5 mg once daily, starting on the second preoperative day, after the intervention the dosage was adjusted to increase the INR between 2.0 and 3.0. Continued intervention more 4 weeks post-discharge (extended duration).</p> <p><u>Comparison (n=176):</u> Warfarin - standard duration, sodium warfarin, 5 mg once daily, starting on the second preoperative day, after the intervention the dosage was adjusted to</p>	<p>n=360</p> <p>People undergoing elective hip replacement, duration of study not reported</p> <p>Age (mean): 69 years</p> <p>Gender (male to female ratio): 1:1.2</p> <p>Italy</p>	<p>All-cause mortality (28 days)</p> <p>DVT (symptomatic and asymptomatic) (28 days): confirmed by compression ultrasound or intraluminal filling defect on ascending phlebography</p> <p>PE (28 days): confirmed by a high-probability ventilation-perfusion lung scan, a spiral computed tomographic scan, or an abnormal finding on angiography or (in case of death) autopsy.</p> <p>Major bleeding (28 days): defined as clinically overt and associated with either a decrease in haemoglobin of at least 2.9 g/dL or a need for a transfusion of 2 of more units of red blood cells, was intracranial or</p>	Included in CG92

Study	Intervention and comparison	Population	Outcomes	Comments
	increase the INR between 2.0 and 3.0. Intervention stopped at discharge		retroperitoneal or resulted in the permanent discontinuation of anticoagulation.	
Samama 1997 ²⁶²	<p><u>Intervention (n=85):</u> LMWH, enoxaparin, 40 mg once daily (standard dose) subcutaneously, administered for 10±2 days</p> <p><u>Comparison (n=85):</u> Placebo, sodium chloride saline for 10±2 days</p>	<p>n=170</p> <p>People undergoing elective total hip replacement, mean duration of surgery 70 minutes</p> <p>Age (mean): 67.2 years</p> <p>Gender (male to female ratio): 1.4:1</p> <p>France</p>	<p>All-cause mortality (90 days)</p> <p>DVT (symptomatic and asymptomatic)(12 days): confirmed by ultrasonography or venography</p> <p>PE (90 days): confirmed by ventilation-perfusion lung scan or angiography</p> <p>Major bleeding (12 days): defined as overt and associated with either a decrease in haemoglobin of 2 g/dl or more, a need for transfusion of 2 units or more of packed red blood cells, if it was retroperitoneal or intracranial, or if it led to surgical re-intervention or death.</p> <p>Wound haematomas (12 days)</p>	Included in CG92
Samama 2002 ²⁶⁴	<p><u>Intervention (n=644):</u> LMWH, reviparin, 4200IU once daily (high dose) subcutaneously, initial dose 12 hours preoperatively for 3±1 days, continued for 6 weeks (extended duration).</p> <p><u>Comparison (n=645):</u> LMWH, reviparin, initial dose of 4200IU (high dose), 12 hours preoperatively, crossed over to acenocoumarol for 6 weeks after surgery (extended duration). The dose was adjusted to achieve an INR</p>	<p>n=1289</p> <p>People undergoing elective unilateral primary total hip replacement, mean duration of surgery not reported</p> <p>Age (mean): 66 years</p> <p>Gender (male to female): 1:1</p> <p>France</p>	<p>All-cause mortality (42-63 days)</p> <p>DVT (symptomatic and asymptomatic) (42-63 days): confirmed by venography or duplex scanning</p> <p>PE (42-63 days): confirmed by ventilation-perfusion scanning or angiography</p> <p>Major bleeding (42 -63 days): defined as clinically overt and met any of the following criteria: associated with a decrease in the haemoglobin level of more than 20 g/L compared with the pre-randomisation level;</p>	Included in CG92

Study	Intervention and comparison	Population	Outcomes	Comments
	between 2.0 and 3.0 for 2 consecutive days.		it required the transfusion of 2 units of more of packed red blood cells after randomisation; it was digestive, intracranial, retroperitoneal or intraocular; it was located at the surgical site and required a reoperation	
Santori 1994 ²⁶⁶	<p><u>Intervention (n=67):</u> Foot pump, intermittent plantar, on both feet immediately after the operation and used for 7-10 days. Foot pump only used when patients were in bed. AES on both legs, no further information about the length or duration.</p> <p><u>Comparison (n=65):</u> Unfractionated heparin (calcium heparin), 5000IU three times daily for 10 days starting the day before the operation. AES on both legs, no further information about the length of duration.</p> <p><u>Concomitant treatment:</u> Physiotherapy with mobilisation started on the 2nd postoperative day. Walking began on 4th or 5th postoperative day</p>	<p>n=132</p> <p>People undergoing elective total hip replacement, mean duration of surgery not reported</p> <p>Age (mean): 71.1 years</p> <p>Gender (male to female ratio): 1:2.5</p> <p>Italy</p>	DVT (symptomatic and asymptomatic) (42 days): confirmed by thermography and Doppler ultrasonography followed by phlebography	Included in CG92
Tørholm 1991 ²⁸⁹	<p><u>Intervention (n=58):</u> LMWH, dalteparin, 2500 IU, subcutaneously for the first two doses (2 hours before surgery and 12 hours postoperatively), then 5000 IU subcutaneously for the</p>	<p>n=112</p> <p>People undergoing elective hip replacement, mean duration of surgery 125 minutes</p>	<p>All-cause mortality (time-point not reported)</p> <p>DVT (symptomatic and asymptomatic) (9 days): confirmed by 125I fibrinogen test and ascending phlebography</p> <p>PE (time-point not</p>	Included in CG92

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>following six days</p> <p><u>Comparison (n=54):</u> Placebo, sodium chloride 9 g/l subcutaneously using same regimen as intervention group</p>	<p>Age (mean): 66 years</p> <p>Gender (male to female ratio): 1:1.24</p> <p>Denmark</p>	<p>reported): definition not reported</p> <p>Wound infection (time-point not reported)</p>	
Turpie 1986 ²⁹⁸	<p><u>Intervention (n=50):</u> LMWH, enoxaparin, 30 mg twice daily (high dose) subcutaneously, from 12 to 24 hours after surgery for 14 days or until discharge.</p> <p><u>Comparison (n=50):</u> Placebo, 0.3 ml saline, subcutaneously from 12 to 24 hours after surgery for 14 days</p>	<p>n=100</p> <p>People undergoing elective hip replacement, mean duration of surgery 126 minutes</p> <p>Age (mean): 67 years</p> <p>Gender (male to female ratio): 1:1</p> <p>Canada</p>	<p>All-cause mortality (14 days)</p> <p>DVT (symptomatic and asymptomatic) (14 days): venography or 125I fibrinogen scanning</p> <p>PE (14 days): definition not clearly reported (venography?)</p> <p>Major bleeding (14 days): defined as overt and associate with either a fall in the haemoglobin level of 2 g/dl or more or a need for transfusion of two or more units of blood, or if it was retroperitoneal or intracranial.</p>	Included in CG92
Turpie 2002 ²⁹⁹	<p><u>Intervention (n=1138):</u> LMWH, enoxaparin (high dose), 30mg twice daily subcutaneously, administered 4-8 hours post-operation, then 12 or more hours afterwards. Treatment was scheduled to continue unto day 5-9. AES used in 85% of patients.</p> <p><u>Comparison (n=1137):</u> Fondaparinux sodium, 2.5mg and a placebo subcutaneously, administered 4-8 hours post-operation, then 12 or more hours afterwards. Treatment was scheduled to continue unto day 5-9.</p>	<p>n=2275</p> <p>People undergoing primary elective total hip replacement surgery or revision surgery, mean duration of surgery 2.42 hours</p> <p>Age (mean): 67 years</p> <p>Gender (male to female ratio): 1:1</p> <p>Canada</p>	<p>All-cause mortality (49 days)</p> <p>DVT (symptomatic and asymptomatic) (49 days): confirmed by systematic bilateral ascending venography</p> <p>PE (49 days): confirmed by systematic bilateral ascending venography</p> <p>Fatal PE (49 days): no definition reported</p> <p>Major bleeding (49 days): defined as fatal bleeding; bleeding that was retroperitoneal, intracranial or intraspinal or that involved Any other critical organ, bleeding that lead to reoperation; and overt</p>	Included in CG92

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>AES used in 86% of patients.</p> <p><u>Concomitant treatment:</u> Physiotherapy was recommended. Anticoagulant/antiplatelet therapy was permitted; mean use 1.6%. NSAIDs or aspirin also permitted; mean use 14%</p>		bleeding with index of 2 or more	
Warwick 1995A ³⁰⁷	<p><u>Intervention (n=78):</u> LMWH, enoxaparin, 40mg once daily (standard dose) subcutaneously, administered from 12 hours before operation, then at 12 hours and 36 hours postoperatively. AES, bilateral thigh-length also used</p> <p><u>Comparison (n=78):</u> AES, bilateral thigh-length alone</p> <p><u>Concomitant treatment:</u> All patients were mobilised on the second postoperative day</p>	<p>n=156</p> <p>People undergoing elective total hip replacement, mean duration of surgery not reported</p> <p>Age (mean): no further details reported</p> <p>Gender (male to female ratio): no further details reported</p> <p>UK</p>	<p>DVT (symptomatic and asymptomatic) (8-10 days): confirmed by ipsilateral venography</p> <p>PE (8-10 days): confirmed by ventilation/perfusion scan</p>	Included in CG92
Warwick 1998 ³⁰⁹	<p><u>Intervention (n=143):</u> LMWH, enoxaparin, 40mg (standard dose), once daily subcutaneously for 7 days.</p> <p><u>Comparison (n=147):</u> Foot pump, A-V impulse system, for 7 days, not further details reported.</p>	<p>n=290</p> <p>People undergoing elective total hip replacement, mean duration of surgery not reported</p> <p>Age (mean): 68 years</p> <p>Gender (male to female ratio): 1.8:1</p>	<p>DVT (symptomatic and asymptomatic) (6-8 days): confirmed by venography</p> <p>PE (90 days): confirmed by ventilation perfusion scanning</p>	Included in CG92

Study	Intervention and comparison	Population	Outcomes	Comments
		UK		
Yokote 2011 ³²⁶	<p><u>Intervention 1 (n=86):</u> LMWH, enoxaparin, 40mg, (20mg twice daily) (standard dose), subcutaneously post-operation for 10 days. AES, thigh-length and IPCD was applied in the operating theatre before the procedure until post-operative day 2.</p> <p><u>Intervention 2 (n=85):</u> Fondaparinux, 2.5 mg once daily, subcutaneously given post-operation for 10 days. AES, thigh-length and IPCD was applied in the operating theatre before the procedure until post-operative day 2.</p> <p><u>Comparison (n=85):</u> Placebo, isotonic saline, 0.5 ml, subcutaneously given post-operation for 10 days. AES, thigh-length and IPCD was applied in the operating theatre before the procedure until post-operative day 2.</p> <p><u>Concomitant treatment:</u> All began mobilisation exercises under supervision of a physiotherapist within 24 hours after surgery.</p>	<p>n=255</p> <p>People undergoing elective primary total hip replacement, mean duration of surgery not reported</p> <p>Age (mean): 64 years</p> <p>Gender (male to female): 1:4</p> <p>Japan</p>	<p>DVT (symptomatic and asymptomatic) (84 days): confirmed by Duplex ultrasonography</p> <p>PE (84 days): confirmed by multi-detector CT scan</p> <p>Major bleeding (11 days): defined as retroperitoneal, intracranial or intraocular bleeding, or if it was associated with either death, transfusion or more than two units of packed red blood cells or whole blood (except autologous), a reduction in the level of haemoglobin of > 2g/dl, or a serious life-threatening clinical event requiring medical intervention.</p> <p>Haematoma: maximum size > 5 cm (11 days)</p>	New study
Zanasi 1988 ³²⁸	<p><u>Intervention (n=19):</u> Unfractionated heparin, 5000IU and placebo subcutaneously, administered one day before surgery and</p>	<p>n=44</p> <p>People undergoing elective hip surgery</p>	<p>DVT (7 days): confirmed by fibrinogen uptake test</p> <p>PE (7 days): definition not reported</p> <p>Fatal PE (7 days): definition</p>	Included in CG92

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>continued until 7 postoperative days.</p> <p><u>Comparison (n=25):</u> Aspirin, 100mg administered on alternate days, started one day before surgery and continued until 7 postoperative days.</p>	<p>Age (mean): 70.8 years</p> <p>Gender (male to female ratio): 1:4</p>	<p>not reported</p>	

1

1 Table 25: Clinical evidence summary: LMWH (standard dose; standard duration) versus no prophylaxis

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with No prophylaxis	Risk difference with LMWH (standard dose) (95% CI)
DVT (symptomatic and asymptomatic)	391 (3 studies) 90 days	LOW ¹ due to risk of bias	RR 0.46 (0.33 to 0.63)	408 per 1000	220 fewer per 1000 (from 151 fewer to 273 fewer)
PE	391 (3 studies) 90 days	VERY LOW ^{1,2,3} due to risk of bias, indirectness	RR 0.15 (0.04 to 0.58)	43 per 1000	37 fewer per 1000 (from 18 fewer to 42 fewer)
Major bleeding	914 (4 studies) 11-12 days	LOW ¹ due to risk of bias	Peto OR 5.92 (2.13 to 16.46)	2 per 1000	11 more per 1000 (from 2 more to 33 more)
Wound haematoma	319 (2 studies) 10-12 days	LOW ^{1,2} due to risk of bias, imprecision	RR 1.65 (1.06 to 2.59)	133 per 1000	86 more per 1000 (from 8 more to 211 more)
Wound infection	112 (1 study) timepoint not reported	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 7.02 (0.43 to 113.83)	0 per 1000	- ⁴

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.
3 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol
4 Absolute effects could not be calculated due to zero events in the control arm

2 Table 26: Clinical evidence summary: LMWH (standard dose; standard duration) versus UFH

Outcomes	No of	Quality of the evidence	Relative effect	Anticipated absolute effects
----------	-------	-------------------------	-----------------	------------------------------

	Participants (studies) Follow up	(GRADE)	(95% CI)	Risk with UFH	Risk difference with LMWH (standard dose) (95% CI)
All-cause mortality	278 (1 study) 7 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.14 (0.01 to 2.25)	14 per 1000	12 fewer per 1000 (from 14 fewer to 17 more)
DVT (symptomatic and asymptomatic)	784 (4 studies) 7-14 days	VERY LOW ^{1,3,4} due to risk of bias, inconsistency, indirectness	RR 0.74 (0.42 to 1.30)	199 per 1000	52 fewer per 1000 (from 116 fewer to 60 more)
PE	941 (4 studies) 7 days	VERY LOW ^{1,2,4} due to risk of bias, indirectness, imprecision	Peto OR 0.30 (0.09 to 1.04)	17 per 1000	12 fewer per 1000 (from 16 fewer to 1 more)
Major bleeding	774 (3 studies) 7 days	VERY LOW ^{1,2,3,4} due to risk of bias, inconsistency, indirectness, imprecision	Peto OR 0.36 (0.16 to 0.82)	47 per 1000	29 fewer per 1000 (from 8 fewer to 39 fewer)
Wound haematoma	135 (1 study) not reported	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 0.29 (0.06 to 1.35)	103 per 1000	73 fewer per 1000 (from 97 fewer to 36 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.

3 Downgraded by 1 or 2 increments because heterogeneity, I² = > 50%, p = > 0.04, unexplained by subgroup analysis.

4 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol

1

2

3 **Table 27: Clinical evidence summary: LMWH (standard dose; standard duration) versus VKA**

Outcomes	No of	Quality of the evidence	Relative effect	Anticipated absolute effects
----------	-------	-------------------------	-----------------	------------------------------

	Participants (studies) Follow up	(GRADE)	(95% CI)	Risk with VKA	Risk difference with LMWH (standard dose) (95% CI)
DVT (symptomatic and asymptomatic)	382 (1 study) 9 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 1.77 (1.16 to 2.69)	146 per 1000	112 more per 1000 (from 23 more to 246 more)
Major bleeding	550 (1 study) 9 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 1.54 (0.44 to 5.41)	14 per 1000	8 more per 1000 (from 8 fewer to 63 more)
Wound haematoma	550 (1 study) 9 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 1.77 (1.16 to 2.69)	7 per 1000	6 more per 1000 (from 1 more to 12 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.

1 **Table 28: Clinical evidence summary: LMWH (standard dose; standard duration) versus dabigatran**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Dabigatran	Risk difference with LMWH (standard dose) (95% CI)
All-cause mortality	1993 (1 study) 35 days	LOW ² due to imprecision	Peto OR 7.46 (0.15 to 375.79)	0 per 1000	⁻¹
DVT (symptomatic and asymptomatic)	3351 (2 studies) 35 days	LOW ^{2,3} due to risk of bias, imprecision	RR 1.18 (0.92 to 1.51)	63 per 1000	11 more per 1000 (from 5 fewer to 32 more)
PE	3770 (2 studies) 35 days	VERY LOW ^{2,3} due to risk of bias, imprecision	RR 0.82 (0.25 to 2.69)	3 per 1000	1 fewer per 1000 (from 2 fewer to 5 more)
Major bleeding	4313 (2 studies) 28-35 days	MODERATE ² due to imprecision	RR 0.73 (0.45 to 1.19)	17 per 1000	5 fewer per 1000 (from 9 fewer to 3 more)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Dabigatran	Risk difference with LMWH (standard dose) (95% CI)
Clinically relevant non-major bleeding	2013 (1 study) 28-35 days	LOW ² due to imprecision	RR 0.88 (0.48 to 1.58)	23 per 1000	3 fewer per 1000 (from 12 fewer to 13 more)
<p>1 Absolute effects could not be calculated due to zero events in the control arm</p> <p>2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.</p> <p>3 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p>					

1 Table 29: Clinical evidence summary: LMWH (standard dose; standard duration) versus apixaban

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Apixaban	Risk difference with LMWH (standard dose) (95% CI)
All-cause mortality	5407 (1 study) 32-38 days	LOW ¹ due to imprecision	Peto OR 0.37 (0.05 to 2.62)	1 per 1000	1 fewer per 1000 (from 1 fewer to 2 more)
DVT (symptomatic and asymptomatic)	3855 (1 study) 32-38 days	HIGH	RR 3.14 (1.95 to 5.06)	11 per 1000	24 more per 1000 (from 11 more to 46 more)
PE	5407 (1 study) 32-38 days	LOW ¹ due to imprecision	RR 1.67 (0.4 to 6.99)	1 per 1000	1 more per 1000 (from 1 fewer to 7 more)
Major bleeding	5332 (1 study) 32-38 days	LOW ¹ due to imprecision	RR 0.82 (0.44 to 1.53)	8 per 1000	1 fewer per 1000 (from 5 fewer to 4 more)
Fatal PE	5407 (1 study) 32-38 days	LOW ¹ due to imprecision	Peto OR 0.14 (0 to 6.84)	0 per 1000	0 fewer per 1000 (from 0 fewer to 2 more)
Clinically relevant non-major	5332	MODERATE ¹	RR 1.11	41 per	4 more per 1000

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Apixaban	Risk difference with LMWH (standard dose) (95% CI)
bleeding	(1 study) 32-38 days	due to imprecision	(0.86 to 1.43)	1000	(from 6 fewer to 18 more)
Heparin-induced thrombocytopenia	5332 (1 study) 32-38 days	LOW ¹ due to imprecision	RR 1.51 (0.25 to 9.02)	1 per 1000	0 more per 1000 (from 1 fewer to 6 more)

1 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.

1 Table 30: Clinical evidence summary: LMWH (standard dose; standard duration) versus rivaroxaban

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Rivaroxaban	Risk difference with LMWH (standard duration) (95% CI)
All-cause mortality	1733 (1 study) 30-42 days	MODERATE ¹ due to risk of bias	RR 4.74 (2.83 to 7.92)	20 per 1000	74 more per 1000 (from 36 more to 136 more)
DVT (symptomatic and asymptomatic)	1733 (1 study) 30-42 days	MODERATE ¹ due to risk of bias	RR 5.04 (2.86 to 8.87)	16 per 1000	65 more per 1000 (from 30 more to 128 more)
PE	1733 (1 study) 30-42 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 3.31 (0.57 to 19.15)	1 per 1000	3 more per 1000 (from 0 fewer to 21 more)
Major bleeding	2509 (1 study) 41 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 0.82 (0.45 to 1.50)	18 per 1000	3 fewer per 1000 (from 10 fewer to 9 more)
Clinically relevant non-major bleeding	2457 (1 study) 41 days	VERY LOW ^{1,2,3} due to risk of bias, indirectness, imprecision	RR 0.82 (0.52 to 1.3)	33 per 1000	6 fewer per 1000 (from 16 fewer to 10 more)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Rivaroxaban	Risk difference with LMWH (standard duration) (95% CI)
Wound infection	2457 (1 study) 41 days	LOW ² due to imprecision	RR 0.75 (0.26 to 2.15)	7 per 1000	2 fewer per 1000 (from 5 fewer to 7 more)
<p>1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p> <p>2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.</p> <p>3 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol</p>					

1 Table 31: Clinical evidence summary: LMWH (standard dose; standard duration) versus IPCD

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with IPCD	Risk difference with LMWH (standard dose) (95% CI)
DVT (symptomatic and asymptomatic)	386 (1 study) 84 days	LOW ¹ due to imprecision	RR 1.03 (0.4 to 2.69)	41 per 1000	1 more per 1000 (from 24 fewer to 69 more)
PE	390 (1 study) 84 days	LOW ¹ due to imprecision	RR 0.99 (0.14 to 6.96)	10 per 1000	0 fewer per 1000 (from 9 fewer to 61 more)
<p>1 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.</p>					

2 Table 32: Clinical evidence summary: LMWH (standard dose; standard duration) + AES versus no prophylaxis

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with No prophylaxis	Risk difference with LMWH + AES (95% CI)
DVT (symptomatic and asymptomatic)	46 (1 study) 8-12 days	HIGH	RR 0.27 (0.15 to 0.5)	929 per 1000	678 fewer per 1000 (from 464 fewer to 789 fewer)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with No prophylaxis	Risk difference with LMWH + AES (95% CI)
PE	46 (1 study) 8-12 days	MODERATE ¹ due to imprecision	RR 0.17 (0.04 to 0.80)	357 per 1000	296 fewer per 1000 (from 71 fewer to 343 fewer)

1 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.

1 **Table 33: Clinical evidence summary: LMWH (standard dose; standard duration) + AES versus AES alone**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with AES	Risk difference with LMWH + AES (95% CI)
All-cause mortality	153 (1 study) 90 days	LOW ² due to imprecision	Not estimable ¹	Not estimable ¹	0 fewer per 1000 (from 30 fewer to 30 more) ¹
DVT (symptomatic and asymptomatic)	475 (3 studies) 14 days	VERY LOW ^{2,3,4} due to risk of bias, inconsistency, imprecision	RR 0.62 (0.42 to 0.93)	406 per 1000	154 fewer per 1000 (from 28 fewer to 235 fewer)
PE	475 (3 studies) 90 days	VERY LOW ^{2,4} due to risk of bias, imprecision	Peto OR 1.02 (0.14 to 7.30)	8 per 1000	0 more per 1000 (from 7 fewer to 50 more)

1 Zero events in both arms. Risk difference calculated in Review Manager.
2 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
3 Downgraded by 1 or 2 increments because heterogeneity, I² > 50%, p = > 0.04, unexplained by subgroup analysis.
4 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.

2 **Table 34: Clinical evidence summary: LMWH (standard dose) + IPCD + AES versus IPCD + AES**

Outcomes	No of	Quality of the evidence	Relative effect	Anticipated absolute effects
----------	-------	-------------------------	-----------------	------------------------------

	Participants (studies) Follow up	(GRADE)	(95% CI)	Risk with IPCD + AES	Risk difference with LMWH + IPCD + AES (95% CI)
DVT (symptomatic and asymptomatic)	166 (1 study) 11 days	LOW ¹ due to imprecision	RR 0.83 (0.26 to 2.62)	72 per 1000	12 fewer per 1000 (from 53 fewer to 117 more)
PE	166 (1 study) 11 days	LOW ¹ due to imprecision	Not estimable ²	Not estimable ²	0 fewer per 1000 (from 20 fewer to 20 more) ²

1 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.
2 Zero events in both arms. Risk difference calculated in Review Manager.

1 Table 35: Clinical evidence summary: LMWH (standard dose; standard duration) + AES versus LMWH (standard dose; standard duration)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with LMWH	Risk difference with LMWH + AES (95% CI)
DVT (symptomatic and asymptomatic)	64 (1 study) 8-12 days	LOW ¹ due to imprecision	RR 0.67 (0.32 to 1.41)	375 per 1000	124 fewer per 1000 (from 255 fewer to 154 more)
PE	64 (1 study) 8-12 days	LOW ¹ due to imprecision	RR 0.67 (0.12 to 3.73)	94 per 1000	31 fewer per 1000 (from 83 fewer to 256 more)

1 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.

2 Table 36: Clinical evidence summary: LMWH (standard dose; standard duration) versus fondaparinux

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Fondaparinux	Risk difference with LMWH (standard dose) (95% CI)
Major bleeding	2440 (2 studies) 11-49 days	VERY LOW ^{1,2,3} due to risk of bias,	RR 0.69 (0.44 to 1.07)	38 per 1000	12 fewer per 1000 (from 22 fewer to 3 more)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Fondaparinux	Risk difference with LMWH (standard dose) (95% CI)
		indirectness, imprecision			
Wound haematoma	167 (1 study) 11 days	LOW ³ due to imprecision	RR 1.01 (0.21 to 4.87)	36 per 1000	0 more per 1000 (from 28 fewer to 138 more)
<p>1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p> <p>2 The majority of the evidence was based on indirect comparisons.</p> <p>3 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs</p>					

1 Table 37: Clinical evidence summary: LMWH (standard dose; standard duration) + AES versus fondaparinux + AES

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Fondaparinux + AES	Risk difference with LMWH + AES (95% CI)
All-cause mortality	2273 (1 study) 49 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 2.01 (0.37 to 10.96)	2 per 1000	2 more per 1000 (from 1 fewer to 17 more)
DVT (symptomatic and asymptomatic)	1826 (1 study) 49 days	MODERATE ¹ due to risk of bias	RR 2.28 (1.56 to 3.34)	40 per 1000	51 more per 1000 (from 22 more to 93 more)
PE	2252 (1 study) 49 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 1.01 (0.2 to 4.99)	3 per 1000	0 more per 1000 (from 2 fewer to 10 more)
Fatal PE	2252 (1 study) 49 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 1.01 (0.06 to 16.08)	1 per 1000	0 fewer per 1000 (from 1 more to 13 more)
Major bleeding	2273	VERY LOW ^{1,2,3}	RR 0.69	41 per 1000	13 fewer per 1000

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Fondaparinux + AES	Risk difference with LMWH + AES (95% CI)
	(1 study) 49 days	due to risk of bias, imprecision, indirectness	(0.44 to 1.07)		(from 23 fewer to 3 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.
3 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol

1 Table 38: Clinical evidence summary: LMWH (standard dose) + IPCD + AES versus fondaparinux + IPCD + AES

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Fondaparinux + IPCD + AES	Risk difference with LMWH + IPCD + AES (95% CI)
DVT (symptomatic and asymptomatic)	167 (1 study) 11 days	LOW ¹ due to imprecision	RR 0.84 (0.27 to 2.66)	71 per 1000	11 fewer per 1000 (from 52 fewer to 119 more)
PE	167 (1 study) 11 days	LOW ¹ due to imprecision	Not estimable ²	Not estimable ²	0 fewer per 1000 (from 20 fewer to 20 more) ²

1 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.
2 Zero events in both arms. Risk difference calculated in Review Manager.

2 Table 39: Clinical evidence summary: LMWH (standard dose; standard duration) versus foot pump

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Foot pump	Risk difference with LMWH (standard dose) (95% CI)
DVT (symptomatic and	274	VERY LOW ^{1,2}	RR 0.74	176 per 1000	46 fewer per 1000

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Foot pump	Risk difference with LMWH (standard dose) (95% CI)
asymptomatic)	(1 study) 90 days	due to risk of bias, imprecision	(0.42 to 1.3)		(from 102 fewer to 53 more)
PE	274 (1 study) 90 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.13 (0 to 6.72)	7 per 1000	6 fewer per 1000 (from 7 fewer to 40 more)
Fatal PE	274 (1 study) 90 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Not estimable ³	Not estimable ³	0 fewer per 1000 (from 10 fewer to 10 more) ³

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.
3 Zero events in both arms. Risk difference calculated in Review Manager.

1 Table 40: Clinical evidence summary: LMWH (standard dose; extended duration) versus LMWH (standard dose; standard duration)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with LMWH (standard duration)	Risk difference with LMWH (extended duration) (95% CI)
All-cause mortality	179 (1 study) 27-29 days	LOW ³ due to imprecision	Not estimable ¹	Not estimable ¹	0 fewer per 1000 (from 20 fewer to 20 more) ¹
DVT (symptomatic and asymptomatic)	678 (3 studies) 23-35 days	MODERATE ² due to risk of bias	RR 0.36 (0.23 to 0.55)	207 per 1000	133 fewer per 1000 (from 93 fewer to 160 fewer)
PE	750 (3 studies) 23-35 days	VERY LOW ^{2,3} due to risk of bias, imprecision	Peto OR 0.12 (0.00 to 6.19)	3 per 1000	2 fewer per 1000 (from 3 fewer to 14 more)
Major bleeding	895 (3 studies)	VERY LOW ^{2,3} due to risk of bias,	Peto OR 0.14	2 per 1000	2 fewer per 1000

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with LMWH (standard duration)	Risk difference with LMWH (extended duration) (95% CI)
	23-35 days	imprecision	(0.00 to 6.87)		(from 2 fewer to 13 more)
Heparin-induced thrombocytopenia	435 (1 study) 27-29 days	LOW ³ due to imprecision	RR 1.41 (0.24 to 8.37)	9 per 1000	4 more per 1000 (from 7 fewer to 70 more)
Wound haematoma	179 (1 study) 27-29 days	LOW ³ due to imprecision	Peto OR 0.99 (0.06 to 15.93)	11 per 1000	0 fewer per 1000 (from 11 fewer to 142 more)

1 Zero events in both arms. Risk difference calculated in Review Manager.
2 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
3 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.

1 Table 41: Clinical evidence summary: LMWH (standard dose; extended duration) + AES versus LMWH (standard dose; standard duration) + AES

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with LMWH (standard duration) + AES	Risk difference with LMWH (extended duration) + AES (95% CI)
DVT (symptomatic and asymptomatic)	218 (1 study) 35 days	LOW ^{1,2} due to risk of bias, imprecision	RR 0.61 (0.38 to 0.97)	317 per 1000	124 fewer per 1000 (from 10 fewer to 197 fewer)
PE	217 (1 study) 35 days	LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.13 (0.01 to 1.23)	28 per 1000	25 fewer per 1000 (from 28 fewer to 6 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.

1 Table 42: Clinical evidence summary: LMWH (standard dose; extended duration) versus rivaroxaban

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Rivaroxaban	Risk difference with LMWH (extended duration) (95% CI)
All-cause mortality	3153 (1 study) 70 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.14 (0 to 6.98)	1 per 1000	1 fewer per 1000 (from 1 fewer to 4 more)
DVT (symptomatic and asymptomatic)	3153 (1 study) 36 days	MODERATE ¹ due to risk of bias	RR 4.52 (2.43 to 8.43)	8 per 1000	26 more per 1000 (from 11 more to 56 more)
PE	3153 (1 study) 36 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.31 (0.05 to 1.78)	3 per 1000	2 fewer per 1000 (from 2 fewer to 2 more)
Major bleeding	4541 (1 study) 36 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 0.82 (0.52 to 1.30)	18 per 1000	3 fewer per 1000 (from 8 fewer to 5 more)
Clinically relevant non-major bleeding	4433 (1 study) 36 days	LOW ^{1,2} due to risk of bias, imprecision	RR 0.83 (0.58 to 1.18)	29 per 1000	5 fewer per 1000 (from 12 fewer to 5 more)
Wound infection	4433 (1 study) 36 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 0.99 (0.37 to 2.64)	4 per 1000	0 fewer per 1000 (from 2 fewer to 6 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.

2

3

**1 Table 43: Clinical evidence summary: LMWH (standard dose; extended duration) versus LMWH (standard dose; standard duration) followed by aspirin
2 (extended duration)**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with LMWH followed by Aspirin (extended duration)	Risk difference with LMWH (extended duration) (95% CI)
All-cause mortality	785 (1 study) 90 days	LOW ² due to imprecision	Peto OR 7.12 (0.14 to 358.94)	0 per 1000	- ¹
PE	778 (1 study) 90 days	VERY LOW ^{2,3} due to risk of bias, imprecision	Peto OR 7.1 (0.74 to 68.48)	0 per 1000	- ¹
Fatal PE	785 (1 study) 90 days	LOW ² due to imprecision	Not estimable ⁴	Not estimable ⁴	0 fewer per 1000 (from 0 fewer to 0 more) ⁴
Major bleeding	785 (1 study) 90 days	LOW ² due to imprecision	Peto OR 7.12 (0.14 to 358.94)	0 per 1000	- ¹
Clinically relevant non-major bleeding	785 (1 study) 90 days	LOW ² due to imprecision	Peto OR 1.88 (0.38 to 9.38)	5 per 1000	5 more per 1000 (from 3 fewer to 4 more)
Wound infection	785 (1 study) 90 days	LOW ² due to imprecision	RR 0.8 (0.35 to 1.83)	31 per 1000	6 fewer per 1000 (from 20 fewer to 26 more)

1 Absolute effect could not be calculated due to zero events in the intervention arm

2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.

3 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

4 Zero events in both arms. Risk difference calculated in Review Manager.

1 Table 44: Clinical evidence summary: LMWH (high dose; standard duration) versus no prophylaxis

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with No prophylaxis	Risk difference with LMWH (high dose) (95% CI)
DVT (symptomatic and asymptomatic)	76 (1 study) 11 days	MODERATE ¹ due to risk of bias	RR 0.21 (0.08 to 0.56)	513 per 1000	405 fewer per 1000 (from 226 fewer to 472 fewer)
PE	100 (1 study) 11 days	VERY LOW ^{1,3,4} due to risk of bias, indirectness, imprecision	Not estimable ²	Not estimable ²	0 fewer per 1000 (from 40 fewer to 40 more) ²
Major bleeding	100 (1 study) 11 days	VERY LOW ^{1,4} due to risk of bias, imprecision	Peto OR 0.51 (0.05 to 4.98)	40 per 1000	19 fewer per 1000 (from 38 fewer to 132 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

2 Zero events in both arms. Risk difference calculated in Review Manager.

3 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol

4 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.

2 Table 45: Clinical evidence summary: LMWH (high dose; standard duration) versus UFH

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with UFH	Risk difference with LMWH (high dose) (95% CI)
All-cause mortality	278 (1 study) 7 days	LOW ^{1,3} due to risk of bias, imprecision	RR 3.65 (0.77 to 17.28)	14 per 1000	37 more per 1000 (from 3 fewer to 229 more)
DVT (symptomatic and asymptomatic)	1016 (3 studies) 10-14 days	VERY LOW ^{1,2,3} due to risk of bias, inconsistency, imprecision	RR 0.57 (0.33 to 0.98)	203 per 1000	87 fewer per 1000 (from 4 fewer to 136 fewer)
PE	1328	VERY LOW ^{1,3,4}	Peto OR 0.31	10 per	7 fewer per 1000

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with UFH	Risk difference with LMWH (high dose) (95% CI)
	(3 studies) 10-14 days	due to risk of bias, indirectness, imprecision	(0.05 to 1.81)	1000	(from 10 fewer to 8 more)
Major bleeding	1069 (2 studies) 10-14 days	VERY LOW ^{1,3,4} due to risk of bias, indirectness, imprecision	RR 0.61 (0.35 to 1.06)	59 per 1000	23 fewer per 1000 (from 38 fewer to 4 more)
Fatal PE	298 (1 study) 10-14 days	VERY LOW ^{1,3} due to risk of bias, imprecision	Peto OR 1.00 (0.06 to 16.06)	7 per 1000	0 fewer per 1000 (from 6 fewer to 91 more)
Wound haematoma	274 (1 study) 28 days	VERY LOW ^{1,3} due to risk of bias, imprecision	RR 1.36 (0.51 to 3.65)	47 per 1000	17 more per 1000 (from 23 fewer to 124 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 or 2 increments because heterogeneity, I² > 50%, p = > 0.04, unexplained by subgroup analysis.
3 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.
4 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol

1 Table 46: Clinical evidence summary: LMWH (high dose; standard duration) versus LMWH (standard dose)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with LMWH (standard dose)	Risk difference with LMWH (high dose) (95% CI)
All-cause mortality	272 (1 study) 7 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 7.39 (0.15 to 372.38)	0 per 1000	⁻³
DVT (symptomatic and asymptomatic)	500 (2 studies)	VERY LOW ^{1,2,4} due to risk of bias,	RR 0.45 (0.17 to	140 per 1000	77 fewer per 1000 (from 116 fewer to 34 more)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with LMWH (standard dose)	Risk difference with LMWH (high dose) (95% CI)
	15 days	imprecision, inconsistency	1.24)		
PE	398 (1 study) 7 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.14 (0 to 7.10)	5 per 1000	4 fewer per 1000 (5 fewer to 29 more)
Major bleeding	398 (1 study) 7 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 2.78 (0.75 to 10.31)	15 per 1000	4 fewer per 1000 (from 5 fewer to 29 more)
Wound haematoma	100 (1 study) 15 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 2 (0.53 to 7.56)	60 per 1000	60 more per 1000 (from 28 fewer to 394 more)
<p>1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p> <p>2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.</p> <p>3 Absolute effects could not be calculated due to zero events in the control arm</p> <p>4 Downgraded by 1 or 2 increments because heterogeneity, I² > 50%, p = > 0.04, unexplained by subgroup analysis.</p>					

1 Table 47: Clinical evidence summary: LMWH (high dose; standard duration) versus fondaparinux

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Fondaparinux	Risk difference with LMWH (high dose) (95% CI)
Major bleeding	2257 (1 study) 49 days	LOW ^{1,2} due to risk of bias, imprecision	RR 0.55 (0.26 to 1.14)	18 per 1000	8 fewer per 1000 (from 13 fewer to 2 more)
<p>1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p>					

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Fondaparinux	Risk difference with LMWH (high dose) (95% CI)
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs					

1 Table 48: Clinical evidence summary: LMWH (high dose) + AES versus fondaparinux + AES

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Fondaparinux + AES	Risk difference with LMWH (high dose) + AES (95% CI)
All-cause mortality	2257 (1 study) 49 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 0.5 (0.13 to 1.99)	5 per 1000	3 fewer per 1000 (from 5 fewer to 5 more)
DVT (symptomatic and asymptomatic)	1580 (1 study) 49 days	LOW ^{1,2} due to risk of bias, imprecision	RR 1.46 (1.01 to 2.11)	56 per 1000	26 more per 1000 (from 1 more to 62 more)
PE	2254 (1 study) 49 days	LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.13 (0.02 to 0.78)	4 per 1000	4 fewer per 1000 (from 1 fewer to 4 fewer)
Fatal PE	2254 (1 study) 49 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 7.38 (0.15 to 371.73)	0 per 1000	- ⁴

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.
3 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol
4 Absolute effects could not be calculated due to zero events in one of the arms

2 Table 49: Clinical evidence summary: LMWH (high dose; standard duration) versus VKA

Outcomes	No of	Quality of the evidence	Relative	Anticipated absolute effects
----------	-------	-------------------------	----------	------------------------------

	Participants (studies) Follow up	(GRADE)	effect (95% CI)	Risk with VKA	Risk difference with LMWH (high dose) (95% CI)
All-cause mortality	3011 (1 study) 43-63 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 0.89 (0.36 to 2.18)	7 per 1000	1 fewer per 1000 (from 4 fewer to 8 more)
PE	3011 (1 study) 42-63 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 0.66 (0.23 to 1.84)	6 per 1000	2 fewer per 1000 (from 5 fewer to 5 more)
Major bleeding	3011 (1 study) time-point not reported	VERY LOW ^{1,2,3} due to risk of bias, indirectness, imprecision	RR 1.48 (0.42 to 5.23)	3 per 1000	1 more per 1000 (from 2 fewer to 11 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.
3 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol

1 Table 50: Clinical evidence summary: LMWH (high dose; extended duration) versus VKA

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with VKA	Risk difference with LMWH (high dose; extended duration) (95% CI)
All-cause mortality	1279 (1 study) 42-63 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 0.13 (0.01 to 2.14)	3 per 1000	3 fewer per 1000 (from 3 fewer to 4 more)
DVT (symptomatic and asymptomatic)	1279 (1 study) 42-63 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 0.74 (0.38 to 1.44)	31 per 1000	8 fewer per 1000 (from 19 fewer to 14 more)
PE	4280 (2 studies) 90 days	LOW ^{1,2} due to risk of bias, imprecision	RR 0.48 (0.19 to 1.21)	6 per 1000	3 fewer per 1000 (from 5 fewer to 1 more)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with VKA	Risk difference with LMWH (high dose; extended duration) (95% CI)
Major bleeding	1279 (1 study) 42-63 days	LOW ^{1,3} due to risk of bias, indirectness	RR 0.27 (0.13 to 0.53)	58 per 1000	42 fewer per 1000 (from 27 fewer to 51 fewer)
<p>1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p> <p>2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.</p> <p>3 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol</p>					

1 Table 51: Clinical evidence summary: LMWH (low dose; pre-operation) versus VKA

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with VKA	Risk difference with LMWH (low dose; pre-op) (95% CI)
All-cause mortality	985 (1 study) 8 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 0.99 (0.14 to 6.97)	4 per 1000	0 fewer per 1000 (from 4 fewer to 24 more)
DVT (symptomatic and asymptomatic)	675 (1 study) 8 days	LOW ¹ due to risk of bias	RR 0.45 (0.31 to 0.64)	240 per 1000	132 fewer per 1000 (from 86 fewer to 165 fewer)
PE	985 (1 study) 8 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Not estimable ³	Not estimable ³	0 fewer per 1000 (from 0 fewer to 0 more) ³
Major bleeding	985 (1 study) 8 days	LOW ^{1,2} due to risk of bias, imprecision	RR 1.97 (1.2 to 3.24)	45 per 1000	44 more per 1000 (from 9 more to 101 more)
Wound haematoma	985 (1 study)	VERY LOW ^{1,2} due to risk of bias,	Peto OR 1.92	2 per 1000	2 more per 1000 (from 2 fewer to 35 more)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with VKA	Risk difference with LMWH (low dose; pre-op) (95% CI)
	8 days	imprecision	(0.2 to 18.53)		
<p>1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p> <p>2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.</p> <p>3 Zero events in both arms. Risk difference calculated in Review Manager.</p>					

1 Table 52: Clinical evidence summary: LMWH (low dose; post-operation) versus VKA

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with VKA	Risk difference with LMWH (low dose; post-op) (95% CI)
All-cause mortality	976 (1 study) 8 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.14 (0.01 to 2.17)	4 per 1000	4 fewer per 1000 (from 4 fewer to 5 more)
DVT (symptomatic and asymptomatic)	674 (1 study) 8 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 0.55 (0.39 to 0.76)	240 per 1000	108 fewer per 1000 (from 58 fewer to 146 fewer)
PE	976 (1 study) 8 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Not estimable ³	Not estimable ³	0 fewer per 1000 (from 0 fewer to 0 more) ³
Major bleeding	976 (1 study) 8 days	LOW ^{1,2} due to risk of bias, imprecision	RR 1.46 (0.86 to 2.48)	45 per 1000	21 more per 1000 (from 6 fewer to 67 more)
Wound haematoma	976 (1 study) 8 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 1.96 (0.2 to 18.87)	2 per 1000	2 more per 1000 (from 2 fewer to 35 more)
<p>1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high</p>					

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with VKA	Risk difference with LMWH (low dose; post-op) (95% CI)
risk of bias					
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.					
3 Zero events in both arms. Risk difference calculated in Review Manager.					

1 Table 53: Clinical evidence summary: LMWH (low dose; pre-operation) versus LMWH (low dose; post-operation)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with LMWH (low dose; post-op)	Risk difference with LMWH (low dose; pre-op) (95% CI)
All-cause mortality	983 (1 study) 8 days	VERY LOW ^{2,3} due to risk of bias, imprecision	Peto OR 7.27 (0.45 to 116.42)	0 per 1000	-. ¹
DVT (symptomatic and asymptomatic)	673 (1 study) 8 days	VERY LOW ^{2,3} due to risk of bias, imprecision	RR 0.82 (0.54 to 1.23)	131 per 1000	24 fewer per 1000 (from 60 fewer to 30 more)
PE	983 (1 study) 8 days	VERY LOW ^{2,3} due to risk of bias, imprecision	Not estimable ⁴	Not estimable ⁴	0 fewer per 1000 (from 0 fewer to 0 more) ⁴
Major bleeding	983 (1 study) 8 days	LOW ^{2,3} due to risk of bias, imprecision	RR 1.35 (0.87 to 2.09)	66 per 1000	23 more per 1000 (from 9 fewer to 72 more)
Wound haematomas	983 (1 study) 8 days	VERY LOW ^{2,3} due to risk of bias, imprecision	Peto OR 0.98 (0.14 to 6.99)	4 per 1000	0 fewer per 1000 (from 4 fewer to 24 more)

1 Absolute effects could not be calculated due to zero events in the control arm

2 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with LMWH (low dose; post-op)	Risk difference with LMWH (low dose; pre-op) (95% CI)
3 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.					
4 Zero events in both arms. Risk difference calculated in Review Manager.					

1 Table 54: Clinical evidence summary: LMWH (low dose; standard duration) versus no prophylaxis

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with No prophylaxis	Risk difference with LMWH (low dose) (95% CI)
Major bleeding	201 (1 study) 15 days	VERY LOW ^{2,3} due to risk of bias, imprecision	Peto OR 7.46 (0.15 to 376.15)	Not estimable ¹	- ¹
1 Absolute effects could not be calculated due to zero events in one of the arms					
2 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias					
3 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.					

2 Table 55: Clinical evidence summary: LMWH (low dose; standard duration) + AES versus AES (above-knee)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with AES alone	Risk difference with LMWH (low dose) + AES (95% CI)
DVT (symptomatic and asymptomatic)	190 (1 study) 8-10 days	LOW ^{1,2} due to risk of bias, imprecision	RR 0.69 (0.47 to 1.00)	454 per 1000	141 fewer per 1000 (from 240 fewer to 0 more)
PE	190 (1 study) 8-10 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 1.04 (0.06 to 16.81)	5 per 1000	0 more per 1000 (from 5 fewer to 79 more)
Fatal PE	190	VERY LOW ^{1,2}	Peto OR	Not estimable ³	- ³

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with AES alone	Risk difference with LMWH (low dose) + AES (95% CI)
	(1 study) 8-10 days	due to risk of bias, imprecision	7.71 (0.15 to 398.09)		
<p>1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p> <p>2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.</p> <p>3 Absolute effects could not be calculated due to zero events in one of the arms</p>					

1 Table 56: Clinical evidence summary: LMWH (low dose; standard duration) + AES versus AES (length unspecified)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with AES (length unspecified)	Risk difference with LMWH (low dose) + AES (95% CI)
DVT (symptomatic and asymptomatic)	167 (1 study) 14 days	LOW ^{1,2} due to risk of bias, imprecision	RR 0.62 (0.40 to 0.97)	419 per 1000	159 fewer per 1000 (from 13 fewer to 251 fewer)
PE	167 (1 study) 90 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Not estimable ³	Not estimable ³	0 fewer per 1000 (from 20 fewer to 20 more) ³
<p>1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p> <p>2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.</p> <p>3 Zero events in both arms. Risk difference calculated in Review Manager.</p>					

2 Table 57: Clinical evidence summary: LMWH (low dose; standard duration) versus LMWH (standard dose; standard duration)

Outcomes	No of Participants	Quality of the evidence	Relative	Anticipated absolute effects
----------	--------------------	-------------------------	----------	------------------------------

	(studies) Follow up	(GRADE)	effect (95% CI)	Risk with LMWH (standard dose)	Risk difference with LMWH (low dose) (95% CI)
Major bleeding	202 (1 study) 15 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.52 (0.05 to 5.06)	20 per 1000	9 fewer per 1000 (from 19 fewer to 72 more)
<p>1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p> <p>2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.</p>					

1 Table 58: Clinical evidence summary: LMWH (low dose; standard duration) + AES versus LMWH (standard dose; standard duration) + AES

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with LMWH (standard dose) + AES	Risk difference with LMWH (low dose) + AES (95% CI)
DVT (symptomatic and asymptomatic)	161 (1 study) 90 days	LOW ^{1,2} due to risk of bias, imprecision	RR 0.77 (0.48 to 1.24)	338 per 1000	78 fewer per 1000 (from 176 fewer to 81 more)
PE	161 (1 study) 90 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.13 (0 to 6.74)	12 per 1000	11 fewer per 1000 (from 13 fewer to 66 more)
<p>1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p> <p>2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.</p>					

2 Table 59: Clinical evidence summary: LMWH (variable dose; standard duration) versus no prophylaxis

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with *LMWH (variable dose) versus no prophylaxis (95% CI)
Major bleeding	200 (1 study) 45 days	VERY LOW ^{3,4,5} due to risk of bias, indirectness,	Not estimable ²	Not estimable ²	0 fewer per 1000 (from 20 fewer to 20 more) ¹

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with *LMWH (variable dose) versus no prophylaxis (95% CI)
		imprecision			
1 Risk difference calculated in Review Manager 2 Zero events in both arms 3 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias 4 The majority of the evidence was based on indirect comparisons 5 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs					

1 Table 60: Clinical evidence summary: LMWH (variable dose; standard duration) + AES versus foot pump + AES

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Foot pump + AES	Risk difference with LMWH (variable dose) + AES (95% CI)
DVT (symptomatic and asymptomatic)	191 (1 study) 45 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 2.06 (0.53 to 8.01)	31 per 1000	33 more per 1000 (from 15 fewer to 217 more)
PE	200 (1 study) 45 days	VERY LOW ^{1,2,3} due to risk of bias, imprecision, indirectness	Not estimable ³	Not estimable ³	0 fewer per 1000 (from 20 fewer to 20 more) ³
Fatal PE	200 (1 study) 45 days	VERY LOW ^{1,2,3} due to risk of bias, imprecision, indirectness	Not estimable ³	Not estimable ³	0 fewer per 1000 (from 20 fewer to 20 more) ³
Heparin-induced thrombocytopenia (45 days)	200 (1 study)	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 7.39 (0.15 to 372.38)	0 per 1000	- ⁵

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Foot pump + AES	Risk difference with LMWH (variable dose) + AES (95% CI)
risk of bias 2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs. 3 Zero events in both arms. Risk difference calculated in Review Manager. 4 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol 5 Absolute effects could not be calculated due to zero events in control arm					

1 Table 61: Clinical evidence summary: UFH versus no prophylaxis

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with No prophylaxis	Risk difference with UFH (95% CI)
DVT (symptomatic and asymptomatic)	243 (2 studies) not reported	VERY LOW ^{1,2,3,4} due to risk of bias, inconsistency, indirectness, imprecision	RR 0.62 (0.31 to 1.23)	504 per 1000	191 fewer per 1000 (from 348 fewer to 116 more)
Major bleeding	167 (2 studies) not reported	VERY LOW ^{1,2,3} due to risk of bias, indirectness, imprecision	Peto OR 7.20 (0.72 to 71.86)	0 per 1000	⁵
Wound haematomas	143 (1 study) not reported	LOW ¹ due to risk of bias, indirectness	Peto OR 7.10 (2.28 to 22.15)	13 per 1000	74 more per 1000 (from 17 more to 217 more)
1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias 2 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol 3 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs. 4 Downgraded by 1 or 2 increments because heterogeneity, I ² > 50%, p = > 0.04, unexplained by subgroup analysis. 5 Absolute effects could not be calculated due to zero events in control arm					

1 Table 62: Clinical evidence summary: UFH (extended duration) versus UFH (standard duration)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with UFH (standard duration)	Risk difference with UFH (extended duration) (95% CI)
DVT (symptomatic and asymptomatic)	61 (1 study) 45 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 0.57 (0.18 to 1.81)	214 per 1000	92 fewer per 1000 (from 176 fewer to 174 more)
Major bleeding	66 (1 study) 45 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Not estimable ³	Not estimable ³	0 fewer per 1000 (from 60 fewer to 60 more) ³

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.
3 Zero events in both arms. Risk difference calculated in Review Manager.

2 Table 63: Clinical evidence summary: UFH versus aspirin

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Aspirin	Risk difference with UFH (95% CI)
DVT (symptomatic and asymptomatic)	37 (1 study) 7 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 0.24 (0.05 to 1.13)	333 per 1000	253 fewer per 1000 (from 317 fewer to 43 more)
PE	37 (1 study) 7 days	VERY LOW ^{1,2,3} due to risk of bias, indirectness, imprecision	Peto OR 0.10 (0 to 5.16)	83 per 1000	74 fewer per 1000 (from 83 fewer to 236 more)
Fatal PE	37 (1 study) 7 days	VERY LOW ^{1,2,3} due to risk of bias, indirectness, imprecision	RR 0.76 (0.05 to 11.39)	83 per 1000	20 fewer per 1000 (from 79 fewer to 866 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Aspirin	Risk difference with UFH (95% CI)
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.					
3 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol					

1 Table 64: Clinical evidence summary: UFH + AES (length unspecified) versus AES (length unspecified)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with AES	Risk difference with UFH + AES (95% CI)
All-cause mortality	67 (1 study) time-point not reported	VERY LOW ^{2,3} due to indirectness, imprecision	Not estimable ¹	Not estimable ¹	0 fewer per 1000 (from 60 fewer to 60 more) ¹
DVT (symptomatic and asymptomatic)	60 (1 study) 10 days	HIGH	RR 0.37 (0.19 to 0.71)	679 per 1000	427 fewer per 1000 (from 197 fewer to 550 fewer)
PE	67 (1 study) time-point not reported	VERY LOW ^{2,3} due to indirectness, imprecision	RR 2.74 (0.3 to 25.05)	31 per 1000	54 more per 1000 (from 22 fewer to 752 more)
Major bleeding	67 (1 study) time-point not reported	VERY LOW ^{2,3,5} due to risk of bias, indirectness, imprecision	OR 7.20 (0.72 to 71.86)	0 per 1000	- ⁴

1 Zero events in both arms. Risk difference calculated in Review Manager.

2 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol

3 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.

4 Absolute effects could not be calculated due to zero events in one of the arms

5 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

1 Table 65: Clinical evidence summary: Fondaparinux versus no prophylaxis

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with No prophylaxis	Risk difference with Fondaparinux (95% CI)
Major bleeding	330 (2 studies) 11-17 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 7.57 (0.47 to 122.16)	0 per 1000	-
Wound haematoma	167 (1 study) 11 days	LOW ² due to imprecision	RR 2.96 (0.31 to 27.92)	12 per 1000	24 more per 1000 (from 8 fewer to 324 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs

2 Table 66: Clinical evidence summary: Fondaparinux + AES versus AES alone

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with AES alone	Risk difference with Fondaparinux + AES (95% CI)
All-cause mortality	163 (1 study) 17 days	VERY LOW ^{2,4} due to risk of bias, imprecision	Not estimable ¹	Not estimable ¹	0 fewer per 1000 (from 20 fewer to 20 more) ¹

1 Zero events in both arms. Risk difference calculated in Review Manager.
2 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
3 Absolute effects could not be calculated due to zero events in the control arm
4 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.

3 Table 67: Clinical evidence summary: Fondaparinux + IPCD + AES versus IPCD + AES

Outcomes	No of	Quality of the evidence	Relative	Anticipated absolute effects
----------	-------	-------------------------	----------	------------------------------

	Participants (studies) Follow up	(GRADE)	effect (95% CI)	Risk with IPCD + AES	Risk difference with Fondaparinux + IPCD + AES (95% CI)
DVT (symptomatic and asymptomatic)	167 (1 study) 11 days	LOW ¹ due to imprecision	RR 0.99 (0.33 to 2.94)	72 per 1000	1 fewer per 1000 (from 48 fewer to 140 more)
PE	167 (1 study) 11 days	LOW ¹ due to imprecision	Not estimable ²	Not estimable ²	0 fewer per 1000 (from 20 fewer to 20 more) ²

1 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.
2 Zero events in both arms. Risk difference calculated in Review Manager.

1 Table 68: Clinical evidence summary: Fondaparinux + AES versus fondaparinux

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Fondaparinux	Risk difference with Fondaparinux + AES (95% CI)
All-cause mortality	795 (1 study) 35-49 days	VERY LOW ^{1,2} due to risk of bias, imprecision	OR 0.38 (0.05 to 2.7)	7 per 1000	5 fewer per 1000 (from 7 fewer to 12 more)
Major bleeding	795 (1 study) 35-49 days	VERY LOW ^{1,2} due to risk of bias, imprecision	OR 0.14 (0 to 7.05)	2 per 1000	2 fewer per 1000 (from 2 fewer to 15 more)
Fatal PE	795 (1 study) 35-49 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Not estimable ³	Not estimable ³	-. ³
Clinically relevant non-major bleeding	795 (1 study) 35-49 days	VERY LOW ^{1,2} due to risk of bias, imprecision	OR 0.14 (0 to 7.05)	50 per 1000	42 fewer per 1000 (from 50 fewer to 219 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Fondaparinux	Risk difference with Fondaparinux + AES (95% CI)
3 Zero events in both arms. Risk difference calculated in Review Manager.					

1 Table 69: Clinical evidence summary: Fondaparinux + IPCD + AES versus VKA + IPCD + AES

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with VKA + IPCD + AES	Risk difference with Fondaparinux + IPCD + AES (95% CI)
All-cause mortality	118 (1 study) 30 days	VERY LOW ^{2,3} due to risk of bias, imprecision	Not estimable ¹	Not estimable ¹	0 fewer per 1000 (from 30 fewer to 30 more) ¹
DVT (symptomatic and asymptomatic)	118 (1 study) 30 days	VERY LOW ^{2,3} due to risk of bias, imprecision	Not estimable ¹	Not estimable ¹	0 fewer per 1000 (from 30 fewer to 30 more) ¹
PE	118 (1 study) 30 days	VERY LOW ^{2,3} due to risk of bias, imprecision	Not estimable ¹	Not estimable ¹	0 fewer per 1000 (from 30 fewer to 30 more) ¹
1 Zero events in both arms. Risk difference calculated in Review Manager.					
2 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias					
3 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.					

2 Table 70: Clinical evidence summary: IPCD versus no prophylaxis

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with No prophylaxis	Risk difference with IPCD (95% CI)
DVT (symptomatic and asymptomatic)	400 (2 studies) 7-14 days	MODERATE ¹ due to risk of bias	RR 0.53 (0.4 to 0.69)	498 per 1000	234 fewer per 1000 (from 154 fewer to 299 fewer)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with No prophylaxis	Risk difference with IPCD (95% CI)
PE	310 (1 study) 14 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 1.04 (0.06 to 16.7)	6 per 1000	0 more per 1000 (from 6 fewer to 90 more)
<p>1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p> <p>2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.</p>					

1 Table 71: Clinical evidence summary: VKA versus no prophylaxis

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with *VKA versus no prophylaxis (95% CI)
Major bleeding	138 (1 study) 10 days	VERY LOW ^{2,3} due to risk of bias, imprecision	Not estimable ¹	Not estimable ¹	0 fewer per 1000 (from 30 fewer to 30 more) ¹
Clinically relevant non-major bleeding	95 (1 study) 7 days	VERY LOW ^{2,3} due to risk of bias, indirectness, imprecision	Not estimable ¹	Not estimable ¹	0 fewer per 1000 (from 40 fewer to 40 more) ¹
<p>1 Zero events in both arms. Risk difference calculated in Review Manager.</p> <p>2 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p> <p>3 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs</p> <p>4 The majority of the evidence was based on indirect comparisons</p>					

2 Table 72: Clinical evidence summary: VKA (extended duration) versus VKA (standard duration)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with VKA (standard duration)	Risk difference with VKA (extended duration) (95% CI)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with VKA (standard duration)	Risk difference with VKA (extended duration) (95% CI)
All-cause mortality	360 (1 study) 28 days	VERY LOW ^{2,3} due to risk of bias, imprecision	Not estimable ¹	Not estimable ¹	0 fewer per 1000 (from 10 fewer to 10 more) ¹
DVT (symptomatic and asymptomatic)	360 (1 study) 28 days	VERY LOW ^{2,3} due to risk of bias, imprecision	RR 0.36 (0.1 to 1.33)	45 per 1000	29 fewer per 1000 (from 41 fewer to 15 more)
PE	360 (1 study) 28 days	VERY LOW ^{2,3} due to risk of bias, imprecision	Peto OR 0.13 (0 to 6.52)	6 per 1000	5 fewer per 1000 (from 6 fewer to 30 more)
Major bleeding	360 (1 study) 28 days	VERY LOW ^{2,3} due to risk of bias, imprecision	Peto OR 7.07 (0.14 to 356.89)	0 per 1000	_ ⁴

1 Zero events in both arms. Risk difference calculated in Review Manager.
2 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
3 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.
4 Absolute effects could not be calculated due to zero events in the control arm.

1 Table 73: Clinical evidence summary: IPCD versus VKA

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with VKA	Risk difference with IPCD (95% CI)
DVT (symptomatic and asymptomatic)	138 (1 study) 10 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 1 (0.47 to 2.11)	167 per 1000	0 fewer per 1000 (from 88 fewer to 185 more)
PE	138 (1 study)	VERY LOW ^{1,2} due to risk of bias,	Not estimable ³	Not estimable ³	0 fewer per 1000 (from 30 fewer to 30 more) ³

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with VKA	Risk difference with IPCD (95% CI)
	10 days	imprecision			
<p>1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p> <p>2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.</p> <p>3 Zero events in both arms. Risk difference calculated in Review Manager.</p>					

1 **Table 74: Clinical evidence summary: IPCD + AES versus VKA + AES**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with VKA + AES	Risk difference with IPCD + AES (95% CI)
DVT (symptomatic and asymptomatic)	296 (2 studies) 8 days	VERY LOW ^{1,2,3} due to risk of bias, inconsistency, imprecision	RR 0.49 (0.13 to 1.83)	297 per 1000	152 fewer per 1000 (from 259 fewer to 247 more)
<p>1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p> <p>2 Downgraded by 1 or 2 increments because heterogeneity, I² = > 50%, p = > 0.04, unexplained by subgroup analysis.</p> <p>3 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.</p> <p>4 Zero events in both arms. Risk difference calculated in Review Manager.</p> <p>5 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol</p>					

2

3

4 **Table 75: Clinical evidence summary: Foot pump + AES versus AES alone**

Outcomes	No of	Quality of the	Relative	Anticipated absolute effects
----------	-------	----------------	----------	------------------------------

	Participants (studies) Follow up	evidence (GRADE)	effect (95% CI)	Risk with AES alone	Risk difference with Foot pump + AES (95% CI)
DVT (symptomatic and asymptomatic)	79 (1 study) 6-9 days	MODERATE ¹ due to risk of bias	RR 0.26 (0.09 to 0.7)	400 per 1000	296 fewer per 1000 (from 120 fewer to 364 fewer)
1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias					

1 **Table 76: Clinical evidence summary: Foot pump + AES versus UFH + AES**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with UFH + AES	Risk difference with Foot pump + AES (95% CI)
DVT (symptomatic and asymptomatic)	132 (1 study) 42 days	LOW ¹ due to risk of bias, imprecision	RR 0.38 (0.19 to 0.76)	354 per 1000	219 fewer per 1000 (from 85 fewer to 287 fewer)
1 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.					

2 **Table 77: Additional data that could not be meta-analysed: Fondaparinux + AES versus fondaparinux for people undergoing elective hip replacement**

Study	Outcome	Time-point	Fondaparinux + AES	Fondaparinux	Risk of bias
Cohen 2007 ⁵⁹	Quality of life; EQ-5D; Health state score	Screening (before surgery)	0.21 (-0.59-1.00)	0.16 (-0.59-1.00)	Very low risk of bias*
		Last day of treatment (5-9 days/35-49 days)	0.59 (-0.59-1.00)	0.59 (-0.43-1.00)	Very low risk of bias*
		Follow-up (35-49 days)	0.76 (-0.17-1.00)	0.71 (-0.09-1.00)	Very low risk of bias*
	Quality of life; EQ-5D; Overall health status	Screening (before surgery)	65 (0-100)	60 (0-100)	Very low risk of bias*
		Last day of treatment (5-9 days/35-49 days)	70 (20-100)	70 (6-100)	Very low risk of bias*
		Follow-up (35-49 days)	80 (0-100)	80 (3-100)	Very low risk of bias*

3 *This is not a formal GRADE assessment as results were not reported in a manner amenable to analysis.

- 1
- 2

26.4.1 Economic evidence

2 Published literature

3 Thirty-two economic studies, in 35 publications, relating to this review question were identified but
4 were excluded due limited applicability, methodological limitations, a combination of limited
5 applicability and methodological limitations or the availability of the newly developed economic
6 model for this update which was considered to be more applicable evidence.^{10,32,33,39,47,68,70,75,79,80}
7^{,117,119,126,128,197,206-208,214,224,226,228-230,246,253-255,259,281,282,305,320,321,329} These included 3 NICE TAs, 2
8 evidence review group [ERG] reports and the CG92 model for standard duration and post discharge
9 prophylaxis. Also, 10 of these publications were previously included in CG46.^{10,32,33,68,70,79,119,126,197}
10^{,253} All excluded studies are listed in Appendix O, with reasons for exclusion given.

11 See also the health economic study selection flow chart in Appendix F.

12 New cost-effectiveness analysis

13 The guideline committee considered the available evidence of cost effectiveness of prophylaxis
14 strategies for people admitted for elective hip replacement (eTHR). The original guideline (CG92)
15 model was considered but it was felt that it required updating given the availability of more recent
16 trial data and the exclusion of the some of the older studies that were included in the CG92 NMAs
17 from the current updated NMAs. The original model also included some interventions that are not
18 routinely used in current practice including high doses of aspirin, VKA and UFH. The guideline
19 committee also discussed that since the publication of CG92, three TAs covering the use of DOACs in
20 this population have also been published; the latest in 2012.²²⁸⁻²³⁰ It was felt that it would be more
21 convenient for clinicians to be able to consult a single source for recommendation regarding the
22 most cost-effective prophylaxis strategy for this population. Moreover, as the size of the population
23 covered by this review question is very large; which means that changes to more costly prophylaxis
24 options would lead to substantial resource implications, the guideline committee agreed that this
25 question should be prioritised for economic modelling. This was also felt to be necessary given the
26 current variation in clinical practice across the NHS in England. Hence, de-novo economic model was
27 developed to address the question about the cost-effectiveness of different VTE prophylaxis
28 strategies (alone or in combination) in people admitted for eTHR. A summary of the model is
29 presented below and a detailed description can be found in Appendix P in the full guideline.

30 Model overview

31 A cost-utility analysis was undertaken in Microsoft Excel® where costs and quality-adjusted life years
32 (QALYs) were considered from a UK NHS and personal social services (PSS) perspective. A Markov
33 model was constructed in order to estimate the costs and QALYs associated with different VTE
34 prophylaxis strategies. Both costs and QALYs were discounted at a rate of 3.5% per annum in line
35 with NICE methodological guidance²³¹ Uncertainty was explored through probabilistic and
36 deterministic sensitivity analyses. The time horizon used was lifetime.

37 Population

38 The population entering the model are adults who are admitted to hospital for an eTHR. The cohort
39 characteristics were based on the data reported in the National Joint Registry 13th annual report;³⁶
40 which represented data collected up to December 2015 in England, Wales, Northern Ireland and the
41 Isle of Man. The mean age of this population was 68.7 years and 40% were male.

42 Comparators

1 Sixteen prophylaxis strategies were selected for inclusion based on the availability of evidence from
2 the clinical review, direct and network meta-analyses (N)MAs and discussion with the guideline
3 committee around which regimens are considered to be relevant to current clinical practice in the
4 UK. These were:

- 5 1. LMWH (std,std) + AEs
- 6 2. LMWH (std,extd)+ AEs
- 7 3. Fondaparinux+ AES
- 8 4. Foot pump + AES
- 9 5. IPCD
- 10 6. AES (above knee)
- 11 7. Foot pump
- 12 8. AES
- 13 9. LMWH (std,std)
- 14 10. LMWH (std,extd)
- 15 11. Aspirin (std duration)
- 16 12. LMWH (std, std) + Aspirin (extd duration)
- 17 13. Dabigatran
- 18 14. Apixaban
- 19 15. Rivaroxaban
- 20 16. No prophylaxis

21

22 **Model structure**

23 The model consists of a simple decision tree covering the acute phase from admission up to 90 days
24 post-operatively, to cover the period included in the definition of hospital-acquired VTE, followed by
25 a Markov chain for the remaining model time horizon. The structure is repeated for each prophylaxis
26 strategy.

27 The acute phase of the model is represented by a decision tree consisting of the primary clinical
28 events: DVT (symptomatic proximal, symptomatic distal, asymptomatic proximal and asymptomatic
29 distal), non-fatal PE, fatal PE, Surgical site bleeding, non-surgical site bleeding (gastrointestinal (GI)
30 bleeding, intracranial haemorrhage (ICH)/haemorrhagic stroke, other major bleeding), fatal major
31 bleeding (MB), clinically-relevant non-major bleeding (CRNMB) and heparin-induced
32 thrombocytopenia (HIT). The structure of the decision tree is presented in **Figure 1**.

33

34 The long-term part is represented by a Markov cohort model. Individuals enter the model in one of
35 the following states; based on where they end up at the end of the 90 days post-operatively: Well,
36 post-symptomatic proximal DVT, post-symptomatic distal DVT, post-asymptomatic proximal DVT,
37 post-asymptomatic distal DVT, post-PE, amputated post-HIT, disabled post-stroke, post-revision for
38 infection. In the first two years, individuals in a post-VTE state can develop post-thrombotic
39 syndrome (PTS). Those in the post-PE state can also develop chronic thromboembolic pulmonary
40 hypertension (CTEPH). Transitioning to death is allowed from any state in the model. The structure of
41 the Markov cohort model is illustrated in **Figure 2**.

42

43 **Model inputs**

44 The relative effects of treatments on the baseline transition probabilities were derived from clinical
45 evidence identified in the systematic review undertaken for the guideline, the results of the NMA
46 and supplemented by additional data sources as required. Health utility data were obtained from the
47 literature. Cost inputs were obtained from recognized national sources such as the drug tariff, NHS
48 reference costs and Personal Social Services Research Unit (PSSRU) publications. All inputs and
49 assumptions made were validated by the guideline committee.

50

51 **Sensitivity analysis**

1 A probabilistic analysis was carried out whereby distributions were assigned to model inputs in order
2 to account for the uncertainty and capture its effect on model outputs. Additionally, a number of
3 one-way sensitivity analyses were conducted whereby for each analysis one key model input was
4 changed in order to explore the sensitivity of model results to changes in that parameter (Table 78).
5

6 **Table 78: One-way sensitivity analyses**

	description	Base case input value	Alternative value for sensitivity analysis
SA1	Cost-effectiveness threshold	£20,000	£30,000
SA2	Discount rate for costs and QALYs	3.5%	1.5%
SA3	Prophylaxis duration	Based on the RCTs included in the DVT NMA	based on summary of product characteristics (SmPC)
SA4	Cohort starting age	eTHR: 68.7 years (a)	40 years
SA5	Cohort body weight	NJR cohort mean body weight(a)	Cohort body weight distribution calculated based on the NJR cohort BMI distribution (a) and average height for a UK male (1.75m) and female (1.62 m) (b)
SA6	All costs +10%	See Appendix P	Costs increased by 10%
SA7	All costs -10%	See Appendix P	Costs decreased by 10%
SA8	Timing of VTE and MB events	Based on committee expert opinion	Based on data from Warwick 2007 ³⁰⁸
SA9	Risk of VTE recurrence after :	Assumption based on committee opinion	Calculated based on data from TA245 manufacturer submissions
	Treated DVT	0%	2.74%
	PE	0%	0.26%
SA10	Costs of pharmacological prophylaxis	Calculated assuming no wastage	Calculated taking possible wastage into account
SA11	Risk of DVT when using LMWH (std/std) followed by aspirin	Calculated using the odds ratio from the PE network	Calculated using the odds ratio from Anderson 2013 for the outcome Proximal DVT
		0.05%	3.68%


7 Abbreviations: eTHR: elective total hip replacement; NMA: network meta-analysis; SA: sensitivity analysis

8 (a) Source: national Joint Registry³⁶

9 (b) Source: ONS²³⁷


10

Figure 1: Model structure up to 90 days post-operatively (Decision tree part)



Abbreviations: Asympt: asymptomatic; Dist: distal; DVT: Deep vein thrombosis; GI: gastrointestinal; HIT: heparin-induced thrombocytopenia; ICH: intracranial haemorrhage; MB: major bleeding; PE: pulmonary embolism; Prox: proximal; RTT: return to theatre; SSB: surgical site bleeding, SSI: surgical site infection; Sympt: symptomatic

Figure 2: Model structure after 90 days post-operatively (Markov model part)



Abbreviations: Asympt: asymptomatic; CTEPH: chronic thrombo-embolic pulmonary hypertension; DVT: Deep vein thrombosis; HIT: heparin-induced thrombocytopenia; PE: pulmonary embolism; Prox: proximal; PTS: post-thrombotic syndrome; Sympt: symptomatic

1 **Results**

2 **Base case**

3 The results of the base case analysis are presented in Table 79 and Figure 3. These show that the
4 most effective strategy in terms of QALYs-gained is LMWH (standard dose, standard duration) for 10
5 days followed by aspirin for 28 days (extended duration), with mean discounted QALYs per patient of
6 10.293 (95% CI: 8.02 to 12.00) over life-time time horizon. The least effective strategy was aspirin
7 (standard duration); with 9.42 QALYs (95% CI: 6.50 to 11.59); which also had the highest mean
8 discounted total cost £1,687 (95% CI: £157 to £4,039) per person over life-time time horizon. The
9 least costly prophylaxis strategy was AES with mean discounted cost per person of £299 (95% CI:
10 £102 to £793) followed by LMWH (standard dose, standard duration) +aspirin (extended duration)
11 strategy with mean discounted cost of £311 (95% CI: £148 to £1437).

12

13 The incremental net monetary benefit (INMB) vs the comparator (LMWH [standard, dose, standard
14 duration]+ AES) was calculated for all strategies at a cost-effectiveness threshold of £20,000 per
15 QALY-gained. Based on the INMB, the most cost-effective strategy (the one with the highest INMB)
16 was found to be LMWH (standard dose, standard duration) for 10 days followed by aspirin for 28
17 days; with mean INMB of £530 (95% CI: -£784 to £1,103). This was followed by LMWH (standard
18 dose, extended duration) +AES (unspecified length) with mean INMB of £42.

19

20 The full ranking based on the mean INMB of each strategy; together with the 95% confidence
21 intervals, is presented in Table 79. Based on the mean rank; all strategies except AES (above knee),
22 foot pump and aspirin (standard duration) were more cost effective than no prophylaxis.

23

24 Extended duration LMWH, solely or in combination with AES, ranked higher compared to standard
25 duration. AES (unspecified length) were on average the most cost-effective mechanical intervention
26 in this population. The DOACs (rivaroxaban, apixaban and dabigatran) were dominant compared to
27 no prophylaxis but were dominated by the model comparator (LMWH [standard dose, standard
28 duration]+AES). Of the three DOACs, rivaroxaban was cost-effective compared to apixaban with an
29 ICER of £12,242 per QALY-gained and both rivaroxaban and apixaban were dominant (more effective
30 and less costly) compared to dabigatran.

31

32 **Sensitivity analysis**

33 In all the SAs undertaken, the most cost-effective option (LMWH [standard dose, standard duration)
34 followed by aspirin (extended duration) did not change.

35


1 **Table 79: Probabilistic base case analysis results for elective total hip replacement (eTHR) population**

Intervention	Mean discounted QALYs (95% CI)	Mean Discounted Costs (95% CI)	Incremental QALYs vs LMWH+ AEs (95% CI)	Incremental costs vs LMWH+ AEs (95% CI)	Mean INMB at £20K (95% CI)	Probability most CE option	Rank (95% CI)
LMWH (std,std) + AEs	10.28 (8.01 to 11.98)	£489 (£350 to £832)	0.000 (0.000 to 0.000)	£0 (£0 to £0)	£0 (£0 to £0)	0.1%	4 (3, 11)
LMWH (std,extd)+ AEs	10.29 (8.02 to 12.00)	£706 (£509 to £1,376)	0.013 (-0.004 to 0.030)	£217 (-£42 to £694)	£36 (-£745 to £484)	0.6%	2 (2, 12)
Fondaparinux+ AEs	10.26 (7.98 to 11.96)	£665 (£336 to £1,563)	-0.015 (-0.112 to 0.013)	£176 (-£92 to £800)	-£478 (-£2,618 to £278)	0.2%	6 (3, 15)
Foot pump + AEs	10.24 (7.99 to 11.94)	£445 (£209 to £926)	-0.036 (-0.182 to 0.012)	-£44 (-£329 to £398)	-£684 (-£3,930 to £478)	0.6%	9 (2, 15)
IPCD	10.16 (7.86 to 11.91)	£742 (£255 to £1,968)	-0.115 (-0.681 to 0.011)	£253 (-£246 to £1,455)	-£2,550 (-£14,733 to £396)	0.1%	12 (4, 15)
AEs (above knee)	10.04 (7.35 to 11.93)	£691 (£119 to £3,765)	-0.234 (-2.197 to 0.027)	£202 (-£424 to £3,310)	-£4,873 (-£46,725 to £861)	13.2%	14 (1, 16)
Foot pump	9.80 (6.96 to 11.77)	£1,150 (£161 to £4,054)	-0.472 (-2.681 to 0.015)	£661 (-£344 to £3,578)	-£10,104 (-£57,043 to £590)	1.4%	15 (2, 16)
AES	10.27 (8.01 to 11.97)	£299 (£102 to £793)	-0.009 (-0.103 to 0.022)	-£189 (-£460 to £261)	£5 (-£2,106 to £781)	8.4%	3 (1, 14)
LMWH (std,std)	10.23 (7.95 to 11.94)	£691 (£375 to £1,413)	-0.048 (-0.283 to 0.009)	£202 (-£44 to £767)	-£1,162 (-£6,266 to £197)	0.0%	10 (6, 13)
LMWH (std,extd)	10.27 (7.98 to 11.98)	£844 (£528 to £1,582)	0.000 (-0.070 to 0.025)	£356 (£24 to £954)	-£361 (-£2,042 to £349)	0.1%	5 (4, 13)
Aspirin (std duration)	9.42 (6.50 to 11.59)	£1,687 (£157 to £4,039)	-0.856 (-3.179 to 0.009)	£1,198 (-£390 to £3,610)	-£18,312 (-£66,988 to £479)	0.7%	16 (2, 16)
LMWH (std, std) + Aspirin (extd duration)	10.29 (8.02 to 12.00)	£311 (£148 to £1437)	0.018 (0.003 to 0.036)	-£178 (-£548 to £781)	£530 (-£784 to £1,103)	72.0%	1 (1, 11)
Dabigatran	10.20 (7.93 to 11.94)	£849 (£319 to £1,957)	-0.077 (-0.465 to 0.010)	£360 (-£122 to £1,331)	-£1,903 (-£10,144 to £254)	0.0%	11 (5, 15)
Apixaban	10.25 (7.96 to 11.97)	£497 (£163 to £1,588)	-0.030 (-0.270 to 0.022)	£8 (-£302 to £895)	-£598 (-£6,089 to £632)	2.2%	8 (2, 14)
Rivaroxaban	10.25 (7.97 to 11.97)	£606 (£227 to £1,452)	-0.021 (-0.190 to 0.019)	£117 (-£234 to £814)	-£529 (-£4,385 to £514)	0.4%	7 (2, 13)
No prophylaxis	10.08 (7.80 to 11.82)	£908 (£297 to £2,185)	-0.196 (-0.885 to -0.008)	£419 (-£195 to £1,677)	-£4,336 (-£19,297 to -£95)	0.0%	13 (10, 16)

3 Abbreviations: AEs: anti-embolism stockings; CE: cost effective; CI: confidence interval; eTHR: elective total hip replacement; extd: extended; IPCD: intermittent pneumatic compression devices; INMB: incremental

4 net monetary benefit; LMWH: low molecular weight heparin; QALYs: quality-adjusted life-years; std: standard

Figure 3: Incremental analysis (vs LMWH (std,std)+ AES) results presented on the cost effectiveness plane



Abbreviations: AES: anti-embolism stockings; CE: cost-effective; CI: confidence interval; eTHR: elective total hip replacement; extd: extended; INMB: incremental net monetary benefit; IPCD: intermittent pneumatic compression device; LMWH: low molecular weight heparin; std: standard; QALYs: quality-adjusted life-years.

1 **Discussion**

2 **Interpretation and limitations**

3 The results of this analysis support the conclusion of the clinical review, direct and network meta-
4 analyses that VTE prophylaxis is effective compared to no prophylaxis. However, the choice of a
5 prophylaxis strategy is not clear cut. This is likely to be the result of the uncertainty around the
6 relative effectiveness estimates for the different interventions; which was clearly shown in the
7 results of the NMAs that informed the economic model.

8

9 Nevertheless, based on the results of this economic model; combined prophylaxis, despite being
10 more costly in terms of intervention costs, is likely to be the most cost-effective option for individuals
11 undergoing eTHR with the two most cost-effective options representing a combination of either two
12 pharmacological or one pharmacological and one mechanical option. Of the DOACs considered;
13 rivaroxaban dominated dabigatran and was cost-effective compared to apixaban with an ICER of
14 £12,242 per QALY-gained. This was in line with the results of TA170 where rivaroxaban was found to
15 dominate dabigatran.²²⁹ A recent analysis funded by the NIHR found that rivaroxaban dominated
16 dabigatran and was cost-effective compared to apixaban with an ICER of £114 per QALY gained.²⁸¹
17 TA245 also found that dabigatran was dominated, apixaban was extendedly dominated and
18 rivaroxaban had an ICER of £22,123 per QALY-gained compared to fondaparinux.²³⁰

19

20 Of the mechanical prophylaxis options considered in the analysis; AES-based strategies were more
21 cost-effective compared to IPCD and foot pump. However, it was not possible to directly compare
22 the length of AES (knee vs thigh length) in terms of cost effectiveness as there were no effectiveness
23 data for the knee-length stockings to allow its inclusion in this analysis. Additionally, results were
24 conflicting for AES in general; with those where length was unspecified ranking better than no
25 prophylaxis while those with above-knee length being worse compared to no prophylaxis.

26

27 This model was an update of the CG92 model; so we attempted to address the limitations of that
28 model which were highlighted by the orthopaedic surgeons' community in a number of publications.
29 One limitation was the use of relative effectiveness from the DVT NMA for the PE outcomes. To
30 address this, we used the PE NMA results for all strategies except where the strategy was not in the
31 network (foot pump + AES). Nevertheless, we have verified the proportionality assumption with the
32 guideline committee and externally validated it using the published observational data analysis that
33 used NJR data;¹⁵³ where the ratio of the relative effectiveness of LMWH vs aspirin for the DVT
34 outcome was found to be the same as for the PE outcome.

35 Another issue was the lack of differentiation between proximal and distal DVT. We have addressed
36 this issue by differentiating between the proximal and distal DVT for both symptomatic and
37 asymptomatic events. We also allowed for different probabilities of progressing from each of these
38 DVT outcomes to PTS; to acknowledge the fact that progression from treated and untreated DVT to
39 PTS would occur with different probabilities. We emphasised the fact that asymptomatic DVT does
40 not have an impact on costs and outcomes in the short term as it is not diagnosed in practice and its
41 only consequence in the model is its future progression to PTS. There was also a concern regarding
42 the baseline risk used in the model which was based on data from the no prophylaxis arm in the
43 RCTs. This was criticised as it was not considered to be reflective of current incidence of VTE; with
44 some trials dating back to the 70s, especially as practice has changed in terms of encouraging early
45 mobilisation as well as the difference in surgical techniques. Based on this, we have used LMWH
46 +AES as our model comparator and obtained its baseline risk data from observational cohort studies
47 that used the UK NJR data.¹⁵³

48 However; this updated analysis may have some limitations. Due to lack of data on either DVT or PE
49 outcomes for some strategies, an assumption still had to be made about the equivalence of relative
50 effectiveness on the DVT and PE outcomes for these strategies. However, we have limited this only

1 to instances where data was available for one of these outcomes but not for the other; as explained
2 earlier. The relative effectiveness of the strategy LMWH (std, std)+ aspirin (extd duration) in relation
3 to the DVT outcome was based on its relative effectiveness obtained from the PE NMA. This
4 assumption could have affected the results but we have tested it in a sensitivity analysis which
5 showed that the model results were robust to this change.

6
7 Additionally; in this analysis, aspirin (standard duration) came as the least favourable option and
8 indeed, on average, worse than no prophylaxis. This is a highly uncertain conclusion as the relative
9 effectiveness of aspirin in this population was based on a single small and outdated trial that the
10 orthopaedic subgroup did not consider to be reflective of current clinical practice; nevertheless, this
11 was the only trial for aspirin in this population. It was also noted that the findings of this trial are at
12 odds with their clinical experience and the observational studies that used the NJR data in this
13 population ¹⁵³.

14 A limitation of this analysis is that the relative safety of aspirin compared to LMWH was based on an
15 observational cohort analysis based on NJR data. ¹⁵³ This was due to the lack of any randomised
16 controlled trials that report major bleeding outcomes for aspirin in these populations. However, as
17 the data for MB from trials are likely to be imprecisely estimated, due to the rarity of these events; it
18 was felt that this would be an appropriate source of relative effectiveness for a safety outcome.

19

20 **Generalisability to other populations/settings**

21 This analysis has been undertaken from a UK NHS and PSS perspective; hence its results might not be
22 generalisable beyond these settings. The population modelled also represents a cohort whose
23 characteristics might be different from eTHR cohorts in other countries.

24

25 **Conclusions**

26 In people undergoing elective total hip replacement (e[THR]), VTE prophylaxis appears to be cost-
27 effective compared to no prophylaxis. A strategy consisting of LMWH (standard dose) for 10 days
28 followed by aspirin for 28 days was the most cost-effective. This result was robust to changes in the
29 model input parameters. LMWH-based strategies that use extended duration LMWH or its
30 combination with AES are more cost effective compared to LMWH standard duration alone or in
31 combination with AES. Rivaroxaban was found to be the most cost-effective of the DOACs considered
32 in this analysis.

26.5 1 Evidence statements

2 Clinical

3 Pairwise meta-analysis statements

4 Pharmacological interventions versus pharmacological interventions

5 LMWH (standard dose; standard duration)

6 LMWH at a standard dose for a standard duration was compared with unfractionated heparin, with
7 the outcomes of all-cause mortality, DVT (symptomatic and asymptomatic), PE, major bleeding and
8 wound haematoma reported across four studies. There was a suggested possible clinical benefit of
9 LMWH in terms of all-cause mortality, DVT (symptomatic and asymptomatic), PE, major bleeding and
10 haematoma. However there was inconsistency surrounding all results with each also possibly being
11 consistent with no difference, and all-cause mortality, DVT and wound haematoma also being
12 consistent with clinical harm. All of the evidence was graded very low due to risk of bias,
13 inconsistency and indirectness.

14 LMWH at a standard dose for a standard duration was compared with VKA, with the outcomes of
15 DVT (symptomatic and asymptomatic), major bleeding and wound haematoma reported in one
16 study. There was a suggested possible clinical harm of LMWH for all these outcomes. However
17 inconsistency around the results means the result could also be no difference or in the case of major
18 bleeding, also clinical benefit. All of the evidence was graded very low due to risk of bias and
19 imprecision.

20 LMWH at a standard dose for a standard duration was compared with dabigatran, with the outcomes
21 of all-cause mortality, DVT (symptomatic and asymptomatic), PE, major bleeding and clinically
22 relevant non-major bleeding reported across two studies. There was a suggested possible clinical
23 benefit of LMWH in terms of major bleeding, however the imprecision around this estimate was also
24 consistent with no difference. There was a suggested possible clinical harm of LMWH in terms of all-
25 cause mortality and no clinical difference in terms of DVT (symptomatic and asymptomatic), PE and
26 clinically relevant non-major bleeding; however there was considerable uncertainty around these
27 results. The quality of the evidence ranged from very low to moderate due to risk of bias and
28 imprecision.

29 LMWH at a standard dose for a standard duration was compared with apixaban, with the outcomes
30 of all-cause mortality, DVT (symptomatic and asymptomatic), PE, major bleeding, fatal PE, clinically
31 relevant non-major bleeding and heparin-induced thrombocytopenia reported in one study. There
32 was suggested possible clinical benefit of LMWH in terms of all-cause mortality and fatal PE, although
33 these findings were very imprecise and therefore could also be consistent with no difference or
34 clinical harm. High quality evidence demonstrated clinical harm of LMWH in terms of DVT
35 (symptomatic and asymptomatic). Low quality evidence suggested possible clinical harm of LMWH in
36 terms of PE and heparin-induced thrombocytopenia, although these findings were very imprecise
37 and therefore could also be consistent with no difference or clinical benefit. There was no clinical
38 difference in terms of major bleeding and clinically relevant non-major bleeding. The quality of the
39 evidence ranged from low to high due to imprecision. The outcome with high-quality evidence was
40 DVT (symptomatic and asymptomatic).

41 LMWH at a standard dose for a standard duration was compared with rivaroxaban, with the
42 outcomes of all-cause mortality, DVT (symptomatic and asymptomatic), PE, major bleeding, clinically
43 relevant non-major bleeding and wound infection reported in one study. Moderate quality, precise
44 evidence demonstrated clinical harm of LMWH in terms of all-cause mortality and DVT (symptomatic
45 and asymptomatic). Very low quality evidence suggested possible clinical harm in terms of PE;

1 however this result was very imprecise. There was no clinical difference in terms of major bleeding,
2 clinically relevant non-major bleeding and wound infection, although the imprecision around these
3 results was also consistent with both benefit and harm. The quality of evidence ranged from very low
4 to moderate due to risk of bias, imprecision and indirectness.

5 LMWH at a standard dose for a standard duration was compared with fondaparinux, with the
6 outcomes of major bleeding and wound haematoma was reported in two studies. There was
7 suggested possible clinical benefit of LMWH in terms of major bleeding, although this finding was
8 also consistent with no difference. There was suggested no clinical difference in terms of wound
9 haematoma, however imprecision around this estimate was also consistent with both benefit and
10 harm. The quality of evidence ranged from very low to low due to risk of bias, indirectness and
11 imprecision.

12 LMWH at a standard dose for a standard duration was compared with no prophylaxis in four studies;
13 the outcomes DVT (symptomatic and asymptomatic), PE, major bleeding, wound haematoma and
14 wound infection were reported. Precise evidence showed clinical benefit of LMWH in terms of DVT
15 (symptomatic and asymptomatic) and PE; and clinical harm of LMWH in terms of major bleeding.
16 Possible clinical harm was suggested for LMWH in terms of wound haematoma and wound infection,
17 however these results were imprecise. The quality of evidence ranged from very low to low due to
18 risk of bias, indirectness and imprecision.

19 *LMWH (standard dose; extended duration)*

20 LMWH at a standard dose for an extended duration was compared with rivaroxaban, with the
21 outcomes of all-cause mortality, DVT (symptomatic and asymptomatic), PE, major bleeding, clinically
22 relevant non-major bleeding and wound infection reported in one study. There was suggested
23 possible clinical benefit of LMWH in terms of all-cause mortality and PE, however these results were
24 seriously imprecise meaning they could also be consistent with no difference or harm. Moderate
25 quality evidence showed clinical harm of LMWH in terms of DVT (symptomatic and asymptomatic).
26 No clinical difference was seen in terms of major bleeding, clinically relevant non-major bleeding and
27 wound infection, however there was uncertainty around these results. The quality of the evidence
28 ranged from very low to moderate due to risk of bias and imprecision.

29 LMWH at a standard dose for an extended duration was compared with LMWH at a standard dose
30 followed by aspirin for an extended duration, with the outcomes of all-cause mortality, PE, major
31 bleeding, fatal PE, clinically relevant non-major bleeding and wound infection reported in one study.
32 There was possible clinical harm of LMWH in terms of all-cause mortality, PE, major bleeding and
33 clinically relevant non-major bleeding, however these results were associated with very serious
34 imprecision and therefore could also be consistent with no difference or clinical benefit. No clinical
35 difference was noted for fatal PE and wound infection, although again these results were very
36 imprecise. The quality of the evidence ranged from very low to low due to risk of bias and
37 imprecision.

38 LMWH at a standard dose for an extended duration was compared with LMWH at a standard dose
39 for a standard duration, the outcomes all-cause mortality, DVT (symptomatic and asymptomatic), PE,
40 major bleeding, heparin-induced thrombocytopenia and wound haematoma were reported across
41 three studies. Moderate quality evidence showed clinical benefit of LMWH at an extended duration
42 in terms of DVT (symptomatic and asymptomatic). Very low quality evidence suggested a possible
43 clinical benefit of this same intervention in terms of PE and major bleeding, although these findings
44 were very imprecise and could also be associated with no difference and clinical harm. There
45 suggested possible clinical harm of LMWH at an extended duration in terms of heparin-induced
46 thrombocytopenia. Again these last three outcomes were imprecise. There was no clinical difference
47 in terms of all-cause mortality and wound haematoma. The quality of the evidence ranged from very
48 low to moderate due to risk of bias and imprecision.

1 *LMWH (high dose; standard duration)*

2 LMWH at a high dose for a standard duration was compared with unfractionated heparin, the
3 outcomes all-cause mortality, DVT (symptomatic and asymptomatic), PE, major bleeding, fatal PE and
4 wound haematoma, reported in one study. There was a suggested possible clinical benefit of LMWH
5 in terms of DVT (symptomatic and asymptomatic), PE, major bleeding. However the imprecision
6 around these results suggested they could also be associated with no difference. There was
7 suggested possible clinical harm of LMWH in terms of all-cause mortality, wound haematoma and no
8 clinical difference in terms of fatal PE. Again there was imprecision associated with these results. The
9 quality of the evidence ranged from very low to low due to risk of bias, inconsistency, indirectness
10 and imprecision.

11 LMWH at a high dose for a standard duration was compared with fondaparinux the outcome of
12 major bleeding was reported in one study. There was a reported possible clinical benefit of LMWH
13 for this outcome, but the imprecision around the result was also associated with no difference.
14 Quality of the evidence was low due risk of bias and imprecision.

15 LMWH at a high dose for a standard duration was compared with VKA, the outcomes of all-cause
16 mortality, PE and major bleeding reported in one study. There was a possible clinical benefit of
17 LMWH in regards to all-cause mortality and PE; and possible clinical harm of LMWH in terms of major
18 bleeding. However the evidence for all three outcomes was very uncertain and findings could have
19 been associated with no difference, benefit or harm. The quality of evidence was very low due to risk
20 of bias and imprecision.

21 LMWH at a high dose for a standard duration was compared with LMWH at a standard dose for a
22 standard duration, the outcomes reported were all-cause mortality, DVT (symptomatic and
23 asymptomatic), PE, major bleeding and wound haematoma reported in one study. There was a
24 suggested clinical benefit of LMWH at a high dose in terms of DVT (symptomatic and asymptomatic)
25 and PE and possible clinical harm in terms of all-cause mortality, major bleeding and wound
26 haematoma. However there was uncertainty surrounding the results for all five outcomes. The
27 quality of the evidence ranged from very low to low due to risk of bias, imprecision and
28 inconsistency.

29 LMWH at a high dose for a standard duration was compared to no prophylaxis, the outcomes DVT
30 (symptomatic and asymptomatic), PE and major bleeding were reported in one study. moderate
31 quality evidence showed clinical benefit of LMWH in terms of DVT (symptomatic and asymptomatic).
32 Very low quality evidence suggested possible clinical benefit of LMWH in terms of major bleeding
33 and no clinical difference for PE. However there was uncertainty associated with the PE and major
34 bleeding results. Quality of evidence ranged from very low to moderate due to risk of bias,
35 indirectness and imprecision.

36 *LMWH (high dose; extended duration)*

37 LMWH at a high dose for an extended duration was compared with VKA, the outcomes all-cause
38 mortality, DVT (symptomatic and asymptomatic), PE and major bleeding reported in one study. Low
39 quality evidence showed clinical benefit of LMWH in terms of major bleeding. Low to very low quality
40 evidence suggested possible clinical benefit in terms of all-cause mortality, DVT (symptomatic and
41 asymptomatic) and PE. There was considerable uncertainty around the mortality and VTE results.
42 The quality of the evidence ranged from very low to low due to risk of bias, indirectness and
43 imprecision.

44 *LMWH (low dose; standard duration; pre-operation)*

45 LMWH at a low dose for a standard duration from pre-operation was compared with VKA, all-cause
46 mortality, DVT (symptomatic and asymptomatic), PE, major bleeding and wound haematoma
47 reported in one study. Low quality evidence showed clinical benefit of LMWH in terms of DVT

1 (symptomatic and asymptomatic). There was possible clinical harm of LMWH in terms of major
2 bleeding and wound haematoma, however there was uncertainty around these results. There was no
3 clinical difference for all-cause mortality, although this finding was also consistent with both clinical
4 benefit and harm. The quality of the evidence ranged from very low to low due to risk of bias and
5 imprecision.

6 LMWH at a low dose for a standard duration from pre-operation was compared with LMWH at a low
7 dose at a standard duration from post-operation, all-cause mortality, DVT (symptomatic and
8 asymptomatic), PE, major bleeding and wound haematoma reported in one study. There was
9 reported possible clinical harm of LMWH at a low dose from pre-operation in terms of all-cause
10 mortality and major bleeding, although there was uncertainty around these results. There was no
11 clinical difference in terms of DVT (symptomatic and asymptomatic) and PE and wound haematoma,
12 although there was uncertainty around these results. The quality of the evidence ranged from very
13 low to low due to risk of bias and imprecision.

14 *LMWH (low dose; standard duration; post-operation)*

15 LMWH at a low dose for a standard duration from pre-operation was compared with VKA, all-cause
16 mortality, DVT (symptomatic and asymptomatic), PE, major bleeding and wound haematoma
17 reported in one study. There was reported possible clinical benefit LMWH in terms of all-cause
18 mortality and DVT (symptomatic and asymptomatic), possible clinical harm of LMWH in terms of
19 major bleeding and wound haematoma and no clinical difference in terms of PE. However all five
20 outcomes were imprecise and therefore there is uncertainty around these results. The quality of the
21 evidence ranged from very low to low due to risk of bias and imprecision.

22 *LMWH (low dose; standard duration)*

23 LMWH at a low dose for a standard duration was compared with LMWH at a standard dose for a
24 standard duration, major bleeding was reported in one study. There was reported possible clinical
25 benefit of LMWH, but the uncertainty around this result was also associated with no difference or
26 clinical harm. The quality of the evidence was very low due to risk of bias and imprecision.

27 LMWH at low dose for a standard duration was compared with no prophylaxis, major bleeding was
28 reported in one study. There was reported possible clinical harm of LMWH, but the uncertainty
29 around this result was also associated with no difference or clinical benefit. The quality of the
30 evidence was very low due to risk of bias and imprecision.

31 *LMWH (variable dose; standard duration)*

32 LMWH at a variable dose for a standard duration was compared with no prophylaxis, major bleeding
33 was reported in one study. There was reported no clinical difference, but there was imprecision
34 around this result. Quality of the evidence was very low due to risk of bias, indirectness and
35 imprecision.

36 *UFH (standard duration and extended duration)*

37 UFH was compared with no prophylaxis, the outcomes DVT (symptomatic and asymptomatic), major
38 bleeding and wound haematomas were reported across two studies. There was possible clinical
39 benefit of UFH in terms of DVT (symptomatic and asymptomatic), however the imprecision around
40 this result was also consistent with no difference. There was clinical harm of UFH in terms of wound
41 haematomas and possible clinical harm of UFH in terms of major bleeding, however the bleeding
42 result was associated with very serious imprecision. The quality of the evidence was very low to low
43 due to risk of bias, indirectness, inconsistency and imprecision.

44 UFH was compared with aspirin, outcomes DVT (symptomatic and asymptomatic), PE and fatal PE
45 were reported in one study. There was possible clinical benefit of UFH for all of the outcomes

1 reported. However the DVT outcome was also consistent with no difference, and the PE outcomes
2 were so uncertain that they were consistent with both no difference and clinical harm. The quality of
3 the evidence was very low due to risk of bias, imprecision and indirectness.

4 UFH for an extended duration was compared with standard duration course of UFH, outcomes DVT
5 (symptomatic and asymptomatic) and major bleeding were reported in one study. There was
6 possible clinical benefit of UFH for an extended duration in terms of DVT (symptomatic and
7 asymptomatic) and no clinical difference in terms of major bleeding, however both of these results
8 had serious uncertainty. The quality of the evidence was very low due to risk of bias and imprecision.

9 *VKA (standard duration and extended duration)*

10 VKA (standard duration) was compared with no prophylaxis, outcomes major bleeding and clinically
11 relevant non-major bleeding was reported in one study. There no clinical difference for these
12 outcomes, although the quality of the evidence was very low due to risk of bias, imprecision and
13 indirectness.

14 VKA at an extended duration was compared with VKA at a standard duration, outcomes all-cause
15 mortality, DVT (symptomatic and asymptomatic), PE and major bleeding were reported in one study.
16 There was possible clinical benefit of VKA at an extended duration in terms of DVT (symptomatic and
17 asymptomatic) and PE, possible clinical harm of VKA at an extended duration in terms of major
18 bleeding and no clinical difference in terms of all-cause mortality. However all four of these
19 outcomes had high uncertainty around the results. The quality of the evidence was all very low due
20 to risk of bias and imprecision.

21 *Fondaparinux*

22 Fondaparinux was compared to no prophylaxis; the outcomes major bleeding and wound
23 haematoma were reported across two studies. There was possible clinical harm of fondaparinux in
24 terms of major bleeding and wound haematoma. However both of these results had such high
25 uncertainty that they may have been consistent with no difference and clinical benefit. The quality of
26 the evidence ranged from very low to low due to risk of bias and imprecision.

27 **Pharmacological interventions versus mechanical interventions**

28 *LMWH (standard dose)*

29 LMWH at a standard dose for a standard duration was compared with IPCD, the outcomes DVT
30 (symptomatic and asymptomatic) and PE were reported in one study. There was suggested no clinical
31 difference between the two interventions for the reported outcomes. However imprecision was so
32 serious as to be consistent with both clinical benefit or clinical harm. The quality of the evidence was
33 low due to imprecision.

34 LMWH at a standard dose for a standard duration was compared with foot pump, the outcomes DVT
35 (symptomatic and asymptomatic), PE and fatal PE were reported in one study. There was suggested
36 possible clinical benefit of LMWH in terms of DVT (symptomatic and asymptomatic) and PE, however
37 there was uncertainty around these results. There was no clinical difference for the outcome of fatal
38 PE, although this outcome was also uncertain. The quality of the evidence was all graded very low
39 due to risk of bias and imprecision.

40 **Mechanical interventions versus mechanical interventions**

41 IPCD was compared with no prophylaxis, outcomes DVT (symptomatic and asymptomatic) and PE
42 were reported across two studies. There was suggested clinical benefit of IPCD in terms of DVT
43 (symptomatic and asymptomatic) and no clinical difference for PE, although there was uncertainty
44 around these results. The quality of the evidence ranged from very low to moderate due to risk of
45 bias and imprecision.

1 Mechanical interventions versus pharmacological interventions

2 IPCD was compared with VKA, outcomes DVT (symptomatic and asymptomatic) and PE. There no
3 clinical difference for these outcomes, although the quality of the evidence was very low due to risk
4 of bias and imprecision.

5 Combination interventions versus combination interventions or single-prophylaxis agents

6 *LMWH (standard dose)*

7 LMWH at a standard dose for a standard duration in combination with AES was compared with no
8 prophylaxis, the outcomes DVT (symptomatic and asymptomatic) and PE were reported in one study.
9 High quality evidence showed clinical benefit of LMWH in combination with AES in terms of DVT
10 (symptomatic and asymptomatic), and low quality evidence suggested possible clinical benefit of
11 LMWH in combination with AES in terms of PE, although this finding was very uncertain.

12 LMWH at a standard dose for a standard duration in combination with AES was compared with
13 LMWH at a standard dose for a standard duration, the outcomes DVT (symptomatic and
14 asymptomatic) and PE were reported in one study. There was suggested possible clinical benefit of
15 LMWH in combination with AES for both outcomes, although the very serious imprecision reflected
16 that the result could also be consistent with both no difference or clinical harm. The quality of the
17 evidence was low due to imprecision.

18 LMWH at a standard dose for a standard duration in combination with AES was compared with AES
19 alone, the outcomes all-cause mortality, DVT (symptomatic and asymptomatic) and PE were reported
20 across three studies. There was suggested possible clinical benefit of LMWH in combination AES in
21 terms of DVT (symptomatic and asymptomatic), although this finding could also be consistent with
22 no difference. No clinical difference was suggested in terms of all-cause mortality and PE, but these
23 results had considerable uncertainty. The quality of the evidence ranged from very low to low due to
24 risk of bias, inconsistency and imprecision.

25 LMWH at a standard dose for a standard duration in combination with IPCD and AES was compared
26 with IPCD and AES, the outcomes DVT (symptomatic and asymptomatic) and PE were reported in one
27 study. There was no clinical difference between the two interventions for both of the outcomes,
28 however there was uncertainty around these results. The quality of the evidence was low due to
29 imprecision.

30 LMWH at a standard dose for a standard duration in combination with AES was compared with
31 fondaparinux in combination with AES, the outcomes all-cause mortality, DVT (symptomatic and
32 asymptomatic), PE, fatal PE and major bleeding were reported in one study. There was clinical harm
33 of LMWH in combination with AES in terms of DVT (symptomatic and asymptomatic). Possible
34 clinical harm of LMWH in combination with AES was suggested in terms of all-cause mortality,
35 however this result was very uncertain. There was possible clinical benefit of LMWH in combination
36 with AES in terms of major bleeding and no clinical difference in terms of PE and fatal PE, however all
37 three of these outcomes were associated with harm, no difference and benefit due to uncertainty.
38 The quality of the evidence was very low due to risk of bias, imprecision and indirectness.

39 LMWH at a standard dose for a standard duration in combination with IPCD and AES was compared
40 with fondaparinux in combination with IPCD and AES, the outcomes DVT (symptomatic and
41 asymptomatic) and PE were reported in one study. There was reported no clinical difference
42 between the two interventions, however there was uncertainty around these results. The quality of
43 the evidence was low due to imprecision.

44 LMWH at a standard dose for an extended duration in combination with AES was compared with
45 LMWH at a standard dose for a standard duration in combination with AES, the outcomes DVT
46 (symptomatic and asymptomatic) and PE were reported in one study. There was reported possible

1 clinical benefit of LMWH for an extended duration in combination with AES for both of the outcomes,
2 however the uncertainty around these results was also consistent with no difference. The quality of
3 the evidence was low due to risk of bias and imprecision.

4 *LMWH (high dose)*

5 LMWH at a high dose for a standard duration in combination with AES was compared with
6 fondaparinux in combination with AES, the outcomes all-cause mortality, DVT (symptomatic and
7 asymptomatic), PE and fatal PE were reported in one study. There was reported possible clinical
8 benefit of LMWH at a high dose in combination with AES in terms of all-cause mortality and PE, but
9 possible clinical harm in terms of DVT (symptomatic and asymptomatic) and fatal PE. However all
10 four of these results were associated with considerable uncertainty. The quality of the evidence
11 ranged from very low to low due to risk of bias and imprecision.

12 *LMWH (low dose)*

13 LMWH at a low dose for a standard duration in combination with AES was compared with AES
14 (above-knee), the outcomes DVT (symptomatic and asymptomatic) and PE were reported in one
15 study. There was possible clinical benefit of LMWH at a low dose in combination with AES in terms of
16 DVT (symptomatic and asymptomatic) and no clinical difference for PE, however there was
17 uncertainty around these results. LMWH at a low dose for a standard duration in combination with
18 AES was also compared with AES (length unspecified) in one study, reporting the same outcomes of
19 DVT (symptomatic and asymptomatic). The clinical effects were the same for this comparison for the
20 outcomes reported for the comparison with AES (above-knee). The quality of the evidence ranged
21 from very low to low due to risk of bias and imprecision.

22 LMWH at a low dose for a standard duration in combination with AES was compared with LMWH at a
23 standard dose for a standard duration in combination with AES, the outcomes DVT (symptomatic and
24 asymptomatic) and PE were reported in one study. There was possible clinical benefit of LMWH at a
25 low dose in combination with AES in terms of PE and no clinical difference for DVT (symptomatic and
26 asymptomatic), however the uncertainty associated with both these results was large enough to be
27 consistent with benefit and harm. The quality of the evidence ranged from very low to low due to
28 risk of bias and imprecision.

29 *LMWH (variable dose)*

30 LMWH at a variable dose for a standard duration in combination with AES was compared with foot
31 pump in combination AES, the outcomes DVT (symptomatic and asymptomatic), PE, fatal PE and
32 heparin-induced thrombocytopenia were reported in one study. There was possible clinical harm of a
33 LMWH at a variable dose with AES in terms of DVT (symptomatic and asymptomatic) and heparin-
34 induced thrombocytopenia. There was no clinical difference in terms of PE and fatal PE. However the
35 variance associated with all of these results was very wide and could be consistent with either
36 benefit or harm. All the evidence was graded very low due to risk of bias, imprecision and
37 indirectness.

38 *UFH*

39 UFH in combination with AES was compared with AES (length unspecified), outcomes all-cause
40 mortality, DVT (symptomatic and asymptomatic), PE and major bleeding were reported in one study.
41 High quality evidence showed clinical benefit of UFH in combination with AES in terms of DVT
42 (symptomatic and asymptomatic). Very low quality evidence suggested possible clinical harm of UFH
43 in combination with AES in terms of PE and major bleeding. There was no clinical difference for all-
44 cause mortality. There was considerable uncertainty around all the non-DVT results. The quality of
45 the evidence ranged from very low to high due to risk of bias, indirectness and imprecision. The
46 outcome with evidence of high quality was DVT (symptomatic and asymptomatic).

1 *Fondaparinux*

2 Fondaparinux in combination with AES was compared with AES, outcome of all-cause mortality was
3 reported in one study. There was no clinical difference; however this result had considerable
4 uncertainty associated with it. One study evaluated the addition of IPCD to both interventions, the
5 outcomes were DVT (symptomatic and asymptomatic) and PE were reported. There was no clinical
6 difference for these two outcomes, although again these findings were considerably uncertain. One
7 study evaluated the use of fondaparinux in the comparator arm reporting the outcomes all-cause
8 mortality, major bleeding, fatal PE and clinically relevant non-major bleeding. There was possible
9 clinical benefit of fondaparinux in combination with AES in terms of all-cause mortality, major
10 bleeding and clinically relevant non-major bleeding, however the results were so uncertain as to also
11 consistent with no difference or clinical harm. There was no clinical difference for fatal PE. The
12 quality of the evidence across these three comparisons ranged from very low to low due to risk of
13 bias and imprecision.

14 Fondaparinux in combination with IPCD was compared with VKA in combination with IPCD, outcomes
15 all-cause mortality, DVT (symptomatic and asymptomatic) and PE were reported in one study. There
16 was no clinical difference for all of the outcomes, however there was uncertainty around these
17 results. The quality of the evidence was very low due to risk of bias and imprecision.

18 *Combination mechanical interventions*

19 IPCD in combination with AES was compared with VKA in combination with AES, the outcome DVT
20 (symptomatic and asymptomatic) was reported in two studies. There was possible clinical benefit of
21 IPCD in combination with AES for this outcome, however this was so uncertain that the result could
22 also be consistent with no difference or clinical harm. The quality of the evidence was very low due
23 to risk of bias, inconsistency and imprecision.

24 Foot pump in combination with AES was compared with AES (length unspecified), DVT (symptomatic
25 and asymptomatic) was reported in one study. Moderate quality, precise evidence showed clinical
26 benefit of foot pump with AES. One study evaluated similar interventions with UFH in combination
27 with AES in the comparator arm. The same outcome of DVT (symptomatic and asymptomatic) was
28 reported, with possible clinical benefit of foot pump in combination with AES in terms of this
29 outcome. However this finding was also consistent with no difference due to uncertainty. The quality
30 of evidence ranged from low to moderate due to risk of bias and imprecision.

31 **Additional study data**

32 One study that evaluated fondaparinux in combination with AES was compared with fondaparinux
33 and reported a quality of life measure (EQ-5D) outcome measuring from screening (before surgery)
34 to follow-up at 35-49 days. This data could not be meta-analysed but the outcome data reported
35 suggests a similar increase in quality of life between the various time-points in both intervention
36 groups.

37 **Network meta-analysis statements**

38 *DVT (symptomatic and asymptomatic)*

39 42 studies were included in the network meta-analysis (NMA) for the outcome of DVT (symptomatic
40 and asymptomatic), involving 26 treatments. Treatments included no VTE prophylaxis,
41 pharmacological and mechanical interventions as single agents as well as combination interventions
42 of both pharmacological and mechanical interventions. Results from the network meta-analysis
43 presented rivaroxaban, fondaparinux in combination with AES and LMWH at standard dose and high
44 dose for varying durations (standard duration and extended duration) in combination with AES as the
45 most clinically effective interventions in terms of the outcome of DVT (symptomatic and

1 asymptomatic). The least clinically effective interventions were no prophylaxis, UFH for an extended
2 duration, IPCD and foot pump. Eight inconsistencies were identified when relative risk values from
3 pairwise meta-analyses were compared with relative risk values from the NMA. There was also a
4 considerable amount of uncertainty around the rank-point estimates with very wide credible
5 intervals.

6 PE

7 30 studies were included in the NMA for the outcome of PE, involving 23 treatments. Treatments
8 included no VTE prophylaxis, pharmacological and mechanical interventions as single agents as well
9 as combination interventions of both pharmacological and mechanical interventions. Results from
10 the network meta-analysis presented LMWH at a standard dose for a standard duration followed by
11 a course of aspirin for an extended duration, LMWH at a high dose for an extended duration and
12 LMWH at standard dose and high dose for varying durations (standard duration and extended
13 duration) in combination with AES as the most clinically effective interventions in terms of the
14 outcome of PE. The least clinically effective interventions were aspirin for a standard duration, foot
15 pump and no prophylaxis. One inconsistency was identified when relative risk values from pairwise
16 meta-analyses were compared with relative risk values from the NMA. There was also a considerable
17 amount of uncertainty around the rank-point estimates with very wide credible intervals.

18 *Major bleeding*

19 24 studies were included in the NMA for the outcome of major bleeding, involving 15 treatments.
20 Treatments included no VTE prophylaxis and pharmacological interventions (mechanical
21 interventions were combined with no prophylaxis as the assumption was made that these
22 interventions do not contribute to bleeding risk). Results from the network meta-analysis presented
23 LMWH at a standard dose for a standard duration followed by a course of aspirin for an extended
24 duration, no prophylaxis, VKA at a standard duration as the most clinically effective interventions in
25 terms of major bleeding. The least clinically effective interventions were VKA at an extended
26 duration, fondaparinux and dabigatran. One inconsistency was identified when relative risk values
27 from pairwise meta-analyses were compared with relative risk values from the NMA. There was also
28 a high amount of uncertainty around the rank-point estimates with very wide credible intervals
29 across a majority of the interventions.

30

31 ***Economic***

32 • One original cost-utility analysis found that, in people admitted for elective total hip replacement
33 surgery, the following interventions were cost-effective (having positive incremental net monetary
34 benefit [INMB]) compared to LMWH (standard dose, standard duration) + AEs: LMWH (standard
35 dose, standard duration) + aspirin (extended duration) (INMB £530); LMWH (standard dose,
36 extended duration)+ AEs (INMB £36) and AES (INMB: £5). This analysis was assessed as directly
37 applicable with minor limitations.

26.6¹ Recommendations and link to evidence

<p>Recommendations</p>	<p>82. Offer VTE prophylaxis to people undergoing elective hip replacement surgery. Choose any one of^f:</p> <ul style="list-style-type: none"> • LMWH^g (for 10 days) followed by aspirin (for 28 days) • LMWH^h (for 28 days) combined with anti-embolism stockings (until discharge) • Rivaroxaban, within its marketing authorisation, is recommended as an option for the prevention of venous thromboembolism in adults having elective total hip replacement surgery. [This bullet text is from Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults (NICE technology appraisal guidance 170).]ⁱ. [2018] <p>83. Consider anti-embolism stockings until discharge from hospital if pharmacological interventions are contraindicated in people undergoing elective hip replacement surgery. [2018]</p>
<p>Research recommendation</p>	<p>9. What is the clinical and cost effectiveness of standard versus extended duration pharmacological prophylaxis for preventing VTE in people undergoing elective total hip replacement surgery?</p> <p>10. What is the clinical and cost effectiveness of aspirin alone for VTE prophylaxis in people undergoing elective total hip replacement surgery?</p>
<p>Relative values of different outcomes</p>	<p>The guideline committee considered all-cause mortality (up to 90 days from hospital discharge), deep vein thrombosis (symptomatic and asymptomatic) (7-90 days from hospital discharge), pulmonary embolism (7-90 days from hospital discharge), fatal PE (7-90 days from hospital discharge), major bleeding (up to 45 days from hospital discharge) and surgical site haematoma (up to 45 days from hospital discharge) as critical outcomes.</p> <p>The guideline committee considered clinically relevant non-major bleeding (up to 45 days from hospital discharge), health-related quality of life (up to 90 days from hospital discharge), heparin-induced thrombocytopenia (duration of study), and technical complications of mechanical interventions (duration of study) and infection (duration of study) as important outcomes.</p> <p>Three network meta-analyses were conducted for this population, evaluating the outcomes DVT (symptomatic and asymptomatic), PE and major bleeding across</p>

^f See also the NICE technology appraisal guidance on apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults and dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults.

^g At the time of consultation (October 2017), LMWH did not have a UK marketing authorisation for use in young people under 18 for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information.

^h At the time of consultation (October 2017), LMWH did not have a UK marketing authorisation for use in young people under 18 for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information.

ⁱ At the time of consultation (October 2017), rivaroxaban did not have a UK marketing authorisation for use in young people under 18 for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information.

	<p>numerous interventions.</p> <p>Please see section 4.3.3 in the methods chapter for further detail explaining prioritisation of the critical outcomes.</p>
Quality of the clinical evidence	<p>Evidence from direct pairwise comparisons was included in the network meta-analyses for the elective hip replacement population. The quality of the pairwise comparisons ranged from very low to high due to risk of bias, imprecision, indirectness and inconsistency.</p> <p>The DVT (symptomatic and asymptomatic) network evaluated 26 interventions, the PE network evaluated 23 interventions and major bleeding network evaluated 14 interventions. Inconsistencies were identified in the DVT (symptomatic and asymptomatic), PE and major bleeding networks between the direct pairwise evidence and the NMA evidence but there was good calibration for all the outcomes with small differences between the residual deviance and DIC values for the network meta-analysis models that were ran. Wide credible intervals around the median network meta-analyses values present some uncertainty around the NMA results for all of the NMA outcomes.</p>
Trade-off between clinical benefits and harms	<p>The clinical evidence presented to the guideline committee and orthopaedic subgroup informed the economic model that was developed. The guideline committee's discussions on the clinical evidence guided the recommendations alongside discussions on the results of the economic model. The model evaluated cost effectiveness using clinical data from the network-meta analyses undertaken on the committee-specified critical outcomes of DVT (symptomatic and asymptomatic), PE, and major bleeding. The model also captured data from the included trials on additional outcomes such as symptomatic DVT and asymptomatic DVT, and more detailed bleeding outcomes such as surgical site bleeding, gastrointestinal bleeding, and wound haematoma.</p> <p>When assessing the results of the analysis of the clinical data, the guideline committee noted that the credible intervals for the NMA rankings were considerably wide, representing large uncertainty around the effects. For the DVT network credible intervals for the top ranked interventions ranged from 1-13 for the tightest CI and 1-25 for the widest. Similarly for the PE network the highest ranked interventions ranged from 1-13 and 1-20. And the uncertainty around the results was even more pronounced in the major bleeding network where the top ranked intervention had a CI spanning the entire range (1-15).</p> <p>The committee noted that LMWH was often amongst the top ranked interventions when assessing only the clinical data for all three critical outcomes, particularly when used for an extended duration and often when combined with anti-embolism stockings. Rivaroxaban performed well when assessing DVT although less so for PE and major bleeding. Whilst discussing the data for rivaroxaban, the guideline committee and orthopaedic subgroup also evaluated the evidence for the other DOACS (apixaban and dabigatran). They showed potential value when considered for DVT and PE, but performed less well when assessed for major bleeding. This is in line with widespread clinical concern around the bleeding risk associated with DOACs in orthopaedic populations. While fondaparinux ranked highly in the DVT network, it was not amongst the top ranked interventions for the PE and major bleeding outcomes and the committee noted that it is not widely used in clinical practice. The top ranked intervention for the clinical outcomes of PE and major bleeding was a combined pharmacological option of LMWH initially followed by aspirin. The guideline committee and orthopaedic subgroup discussed the current concerns in regards to the bleeding risk associated with aspirin especially when used soon after surgery (when bleeding risk is highest). However they agreed that the use of aspirin after a ten day course of LMWH would take into account the high early bleeding risk whilst providing clinical benefit in terms of the evaluated outcomes of PE and major bleeding.</p> <p>The orthopaedic subgroup noted that current clinical practice by some orthopaedic</p>

	<p>surgeons includes the use of intermittent pneumatic compression devices post-operatively followed by the use of AES. The NMA results did not present any clear clinical benefit for using IPCDs. Modern developments in clinical practice include the encouragement of early mobilisation post-operation, and the use of IPCDs can potentially restrict mobility of patients who have undergone elective hip replacement surgery.</p>
<p>Trade-off between net clinical effects and costs</p>	<p>An original economic model was developed to assess the cost effectiveness of the prophylaxis options included in the clinical review NMAs. It models the outcomes from the NMAs and also differentiates between asymptomatic and symptomatic DVT. This takes into account that asymptomatic DVT does not have an impact on costs and outcomes in the short term as it is not diagnosed in practice and its only consequence in the model is its future progression to PTS.</p> <p>Sixteen options were included in this model:</p> <ul style="list-style-type: none"> • Anti-embolism stockings (AES) (above knee) • AES (length unspecified) • Apixaban • Aspirin (standard duration) • Dabigatran • Fondaparinux+ AES • Foot pump + AES • Foot pump • IPCD (sleeve length unspecified) • LMWH (standard dose, standard duration) • LMWH (standard dose, extended duration) • LMWH (standard dose, standard duration) followed by Aspirin (extended duration) • LMWH (standard dose, standard duration) + AES • LMWH (standard dose, extended duration)+ AES • No prophylaxis • Rivaroxaban <p>The model results showed that the most cost-effective option for this population is combined prophylaxis using LMWH (standard dose) for 10 days followed by aspirin for 28 days. This intervention had the highest mean incremental net monetary benefit (INMB) per patient compared to LMWH (standard dose, standard duration) + anti-embolism stockings (£530) at a cost-effectiveness threshold of £20,000 per QALY-gained. Compared to no prophylaxis, all prophylaxis options ranked higher except foot pump, anti-embolism stocking (above-knee) and aspirin (standard duration). A number of sensitivity analyses were presented to the committee including changing the cost effectiveness threshold to £30,000 per QALY gained; changing the discount rate for costs and QALYs to 1.5% and using the licensed duration where applicable rather than the average RCT duration.</p> <p>The guideline committee and the orthopaedic subgroup considered the results of the model and noted that the most cost-effective intervention, LMWH (standard dose, standard duration) followed by Aspirin (extended duration), had a high probability of being the most cost-effective (72%). It was also the most cost-effective option in all sensitivity analyses. This result was in line with the findings from the MB and PE NMAs; where this intervention was ranked at the top. However, this intervention was not included in the DVT NMA as the only trial that included this regimen did not report DVT (symptomatic and asymptomatic) as an outcome but reported data for proximal DVT. Hence, in the economic model an assumption had to be made that the odds ratio from the PE NMA would be the same for the DVT outcome; which may have influenced the results. This assumption has been tested in a sensitivity analysis</p>

	<p>where the relative effectiveness of LMWH followed by aspirin on the DVT (symptomatic and asymptomatic) outcome was assumed to be the same as that for the outcome “proximal DVT” which was reported in the included trial. In this analysis, LMWH followed by aspirin retained its first rank. However, the committee noted that the evidence of efficacy for this intervention is based on a single trial, the high uncertainty around the ranking of the interventions considered in the model with large and overlapping 95% confidence intervals around these ranks and the small differences in costs and QALYs among the included interventions. Hence, the committee opted to give a choice of prophylaxis options rather than only recommending this intervention as the most cost-effective intervention.</p> <p>Of the LMWH-based strategies in the model, those with extended duration and in combination with AES appeared to be more cost-effective compared to the LMWH alone used for standard duration in this population, despite their higher cost compared to the other strategies in the model. This appeared to be driven by the higher incidence of symptomatic DVT and PE in this population.</p> <p>The committee discussed that for patients who are unable to self-administer parenteral prophylaxis or may be needle-phobic, oral anticoagulants were considered to be the appropriate prophylaxis option. The committee and the orthopaedic subgroup noted that out of the three DOACs included in the model (rivaroxaban, apixaban and dabigatran), rivaroxaban dominated dabigatran and was cost-effective compared to apixaban (ICER: £12,242 per QALY-gained). Apixaban had higher probability of being the most cost-effective compared to rivaroxaban (2.2% vs <1%; respectively), however; there was more uncertainty around the rank of apixaban compared to that of rivaroxaban (95% CI around the mean rank 2 to 14 for apixaban and 2 to 13 for rivaroxaban). The committee took this decision uncertainty into account and noted that the conclusion that rivaroxaban is on average more cost-effective than apixaban for people undergoing total hip replacement largely agreed with the findings of most of the previously published economic evaluations which have been selectively excluded from this review. It was in line with the results of TA170 where rivaroxaban was found to dominate dabigatran.²²⁹ A recent analysis funded by the NIHR found that rivaroxaban dominated dabigatran and was cost-effective compared to apixaban with an ICER of £114 per QALY gained.²⁸¹ TA245 also found that dabigatran was dominated, apixaban was extendedly dominated and rivaroxaban had an ICER of £22,123 per QALY gained compared to fondaparinux.²³⁰ Hence; the committee felt that it would be beneficial to standardise practice and recommend the most cost-effective DOAC, rivaroxaban.</p> <p>For those with contraindications for pharmacological prophylaxis, the committee and the orthopaedic subgroup felt that AES appeared to be the more cost-effective option in this population compared to IPCDs or foot pumps alone. The committee, however, felt that this was contrary to the evidence from other populations (for example people with stroke and those undergoing elective knee replacements). The committee also noted the difficulty in using AES for the durations reported in the trials as this would not be practical in real world situations. Hence, there is considerable uncertainty about whether the effects observed in the trials can be replicated in real world settings. It was not possible to specify the length of the AES to recommend as the included trials in the NMAs did not have knee-length AES to allow its inclusion in the model. The committee acknowledged that thigh-length AES are more costly and more difficult to fit which would require close monitoring by the nurses to ensure adherence; which again calls into question the possibility of replicating their effect in real-world settings. However, the committee and orthopaedic subgroup decided where pharmacological options are contraindicated; AES offer an acceptable prophylaxis strategy.</p>
Other considerations	<p>Extended duration prophylaxis was recommended in the previous guideline (CG92) for the elective total hip replacement population. The duration of prophylaxis was discussed with the following definitions considered: 10-14 days for standard and 28-</p>

35 for extended. The guideline committee and orthopaedic subgroup noted that clinical trials and the network meta-analyses suggested possible clinical benefit of prophylaxis with an extended duration. The quality of this evidence was assessed to be very low, reporting data from comparatively few participants in a small number of trials. The estimates of the effect were consequently imprecise and the risk of bias assessed to be high. More modern trials are conducted with extended prophylaxis strategies since this has come to be the standard-of-care despite the uncertainty around the evidence from the earlier variable duration trials conducted with LMWH.

The committee also noted that the modern practice of early mobilisation for these patients called into question whether extended duration prophylaxis is effective in current practice. The committee believed that more up-to-date evidence based in the current context is needed to evaluate the effectiveness of extended duration pharmacological prophylaxis compared to standard duration. The committee prioritised this as a key research recommendation as it represents a large population and could have potential cost savings to the NHS.

The committee noted that the single trial that represented the evidence for aspirin (standard duration) effectiveness and was included in the NMAs was old and used a non-standard dosing regimen with aspirin administered on alternate days post-operatively. The economic model showed lack of cost effectiveness, with aspirin ranking last and worse than no prophylaxis. However, the experience of the orthopaedic surgeons in the orthopaedic subgroup suggests that aspirin may be a suitable prophylaxis options for some individuals. Hence, the committee suggested a research recommendation comparing aspirin to other prophylaxis options; as given its low cost, aspirin could be a cost-effective option, if proven to be clinically effective.

The committee made a high-priority research recommendation on duration of prophylaxis, and a research recommendation on aspirin, in this population group; see Appendix R for more details.

27 Elective knee replacement surgery

27.1.2 Introduction

- 3 Elective knee replacement surgery involves a large number of patients per annum, with an increasing
4 application in younger age groups. The general risks of this surgery including infection are well
5 documented.
- 6 An objection of using pharmacological VTE prophylaxis is the increased risk of bleeding as a result of
7 anticoagulation. A balance of the benefit of VTE prophylaxis has to be weighed against the risks and
8 consequences of a post-operative bleed.

27.2.9 Review question: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing elective knee replacement surgery?

13 For full details see review protocol in Appendix C.

14 **Table 80: PICO characteristics of review question**

Population	Adults and young people (16 years and older) undergoing elective knee replacement surgery admitted to and discharged from hospital
Intervention(s)	<p>Mechanical:</p> <ul style="list-style-type: none"> • Anti-embolism stockings (AES) (above or below knee) • Intermittent pneumatic compression (IPCD) devices (full leg or below knee) • Foot pumps or foot impulse devices (FID) • Electrical stimulation (including Geko devices) • Continuous passive motion (CPM) <p>Pharmacological:</p> <ul style="list-style-type: none"> • Unfractionated heparin (UFH) (low dose, administered subcutaneously) • Low molecular weight heparin (LMWH), licensed in UK: <ul style="list-style-type: none"> ○ enoxaparin (standard prophylactic dose 40mg daily; minimum 20mg daily* to maximum 60mg twice daily*) ○ dalteparin (standard prophylactic dose 5000 units once daily; minimum 1250 units once daily* to maximum 5000 units twice daily*; obese patients – maximum 7500 twice units daily*) ○ tinzaparin (standard prophylactic dose 3500 units once daily; minimum 2500 units once daily* to maximum 4500 units twice daily*; obese patients – maximum 6750 twice daily*) • LMWH, licensed in countries other than UK: <ul style="list-style-type: none"> ○ Bemiparin (standard 2500 units daily; minimum 2500 units daily to maximum 3500 units daily) ○ Certoparin (3000 units daily) ○ Nadroparin (standard 2850 units once daily; minimum 2850 units once daily to maximum up to 57 units/kg once daily) ○ Parnaparin (standard 3200 units once daily; minimum 3200 units once daily to maximum 4250 units once daily) ○ Reviparin (minimum 1750 units once daily to maximum 4200 units once daily)

	<ul style="list-style-type: none"> • Vitamin K Antagonists: <ul style="list-style-type: none"> ○ warfarin (variable dose only) ○ acenocoumarol (all doses) ○ phenindione (all doses) • Fondaparinux (all doses)* • Apixaban (2.5mg twice daily) • Dabigatran (220mg once daily; 150mg once daily - patients with moderate renal impairment, interacting medicines, over 75 years old) • Rivaroxaban (10mg once daily) • Aspirin (up to 300mg)* <p>*off-label</p>
Comparison(s)	<p>Compared to:</p> <ul style="list-style-type: none"> • Other VTE prophylaxis treatment, including monotherapy and combination treatments (between class comparisons for pharmacological treatments only) • No VTE prophylaxis treatment (no treatment, usual care, placebo) <p>Within intervention (including same drug) comparisons, including:</p> <ul style="list-style-type: none"> • Above versus below knee stockings • Full leg versus below knee IPC devices • Standard versus extended duration prophylaxis • Low versus high dose for LMWH • Preoperative versus post-operative initiation of LMWH
Outcomes	<p>Critical outcomes:</p> <ul style="list-style-type: none"> • All-cause mortality (up to 90 days from hospital discharge) • Deep vein thrombosis (symptomatic and asymptomatic) (7-90 days from hospital discharge). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) • Pulmonary embolism (7-90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE • Major bleeding (up to 45 days from hospital discharge). A major bleeding event meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood ; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event. Includes unplanned visit to theatre for control of bleeding • Fatal PE (7- 90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE • Surgical site haematoma (up to 45 days from hospital discharge) <p>Important outcomes:</p> <ul style="list-style-type: none"> • Clinically relevant non-major bleeding (up to 45 days from hospital discharge): bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy. • Health-related quality of life (validated scores only)(up to 90 days from hospital discharge) • Heparin-induced thrombocytopenia (HIT) (duration of study) • Technical complications of mechanical interventions (duration of study)

	• Infection (duration of study)
Study design	Randomised controlled trials (RCTs), systematic reviews of RCTs.

27.3.1 Clinical evidence

2 Twenty-eight studies were included in this evidence review, these are summarised in Table 81 below.
3 Fourteen studies were previously included in the previous guideline (CG92)^{17,34,64,66,88,93,95,105,106,191}
4^{,192,233,310,318} and fourteen studies were added in the update^{4,52,53,180,188,189,216,104,252,300,330,31,186,151}.

5 Two technology appraisals were previously included in the previous guideline;^{228,229}. These
6 technology appraisals²²⁹; evaluated evidence identified in the update^{252,300} and evidence included in
7 the CG92^{88,180}.

8 Six studies that were previously included in CG92, have been excluded from this evidence review due
9 to incorrect interventions and incorrect comparisons^{125,141,144,194,209,315}.

10 Three Cochrane reviews^{139,98,261} were identified which looked at continuous passive motion, heparin
11 and vitamin K antagonists for the prevention of venous thromboembolism people undergoing
12 elective hip replacement. The reviews included studies which were included in the previous guideline
13 (CG92) and this current update.

14 Evidence from these studies is summarised in the clinical evidence summary tables below (Table 82,
15 Table 83, Table 84, Table 85, Table 86, Table 87, Table 88, Table 89, Table 90, Table 91, Table 92,
16 Table 93, Table 94, Table 95, Table 96, Table 97, Table 98, Table 99, Table 100, Table 101, Table 102,
17 Table 103, Table 104, Table 105, Table 106, Table 107, Table 108, Table 109, Table 110, Table 111,
18 Table 112, Table 113, Table 114, Table 115, Table 116, Table 117 and Table 118). See also the study
19 selection flow chart in Appendix E, forest plots in Appendix L, study evidence tables in Appendix H,
20 GRADE tables in Appendix K and excluded studies list in Appendix N.

21 In order to input the clinical effectiveness data of multiple possible interventions into the economic
22 model, it was proposed that a network meta-analysis be carried out on the outcome data for DVT, PE
23 and major bleeding. For full details on the NMA methodology and results, please see Appendix M.

24 **Table 81: Summary of studies included in the review**

Study	Intervention and comparison	Population	Outcomes	Comments
Alkire 2010 ⁴	<u>Intervention (n=33):</u> Continuous passive motion, Danniflex 480 apparatus, used 3 times daily for 3 days. <u>Comparison (n=32):</u> No VTE prophylaxis <u>Concomitant treatment:</u> Physiotherapy given in both arms, twice daily	n=65 People undergoing elective knee replacement surgery, mean duration of surgery not reported Age (mean): 66 years Gender (male to female ratio): 1:1.46 USA	DVT (symptomatic and asymptomatic)(90 days): definition not reported	New study
Bauer 2001 ¹⁷	<u>Intervention (n=523):</u> LMWH, enoxaparin, 30mg twice daily (high dose) subcutaneously.	n=1049 People undergoing elective major knee	All-cause mortality (49 days) DVT (symptomatic and	Included in CG92

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>Administered postoperatively until day 5 to 9. Use of AES (length unspecified) in 81% of patients.</p> <p><u>Comparison (n=526):</u> Fondaparinux sodium, 2.5 mg once daily orally and a placebo once daily, subcutaneously. Administered postoperatively until day 5 to 9. Use of AES (length unspecified) in 83% of patients.</p>	<p>replacement surgery, mean duration of surgery 128 minutes</p> <p>Age (mean): 67.5 years</p> <p>Gender (male to female ratio): 1:1.4</p> <p>Multicentre, USA</p>	<p>asymptomatic) (49 days): confirmed by systematic bilateral ascending venography</p> <p>PE (49 days): confirmed by lung scan, pulmonary angiography or helical computed tomography or at autopsy</p> <p>Major bleeding (49 days): defined as fatal bleeding; bleeding that was retroperitoneal, intracranial or intraspinal or that involved any other critical organ, bleeding that lead to reoperation; and overt bleeding with index of 2 or more.</p> <p>Fatal PE (49 days)</p>	
Bern 2015 ³¹	<p><u>Intervention (n=54)</u> Fondaparinux, 2.5mg once daily, orally from 6 or more hours (no later than 6AM the next day) postoperatively, or 6-8 hours after epidural catheter removal, continued for 28±2 days. IPCD was worn for duration on stay in hospital. AES were prescribed for use after discharge.</p> <p><u>Comparison (n=64)</u> VKA, warfarin, dose of 5.0mg the night before surgery, followed by 5.0mg the evening of surgery, variable dose (target INR 2.0-2.5) until day 28±2 days. IPCD was worn for</p>	<p>n=118</p> <p>People undergoing elective primary unilateral total knee replacement surgery, mean duration of surgery not reported</p> <p>Age (mean): 64 years</p> <p>Gender (male to female ratio): 1:1</p> <p>USA</p>	<p>All-cause mortality (30 days)</p> <p>DVT (symptomatic and asymptomatic) (30 days): confirmed by bilateral duplex sonography</p> <p>PE (30 days): confirmed by ventilation/perfusion lung scan or computerised axial tomography angiogram</p>	New study

Study	Intervention and comparison	Population	Outcomes	Comments
	duration on stay in hospital. AES were prescribed for use after discharge.			
Blanchard 1999A ³⁴	<p><u>Intervention (n=67):</u> LMWH, nadroparin, dose adjusted to patient's body weight (<50kg, 2850 IU; 51-71kg, 3800 IU; 71-100kg, 5700 IU) (standard adjusted dose), subcutaneously administered 12 hours preoperatively then 12 hours postoperatively, once daily for 12 days</p> <p><u>Comparison (n=63):</u> Intermittent pneumatic compression device (IPCD), started 12 hours preoperatively, discontinued for surgery reapplied after surgery</p>	<p>n=130</p> <p>People undergoing elective knee replacement surgery, mean duration of surgery 135 minutes</p> <p>Age (mean): 73 years Gender (male to female ratio): 1:3</p> <p>Mean BMI in LMWH group: 43.6 Mean BMI in IPCD group: 44.7</p> <p>Switzerland</p>	<p>DVT (symptomatic and asymptomatic) (8-10 days): confirmed by phlebography or venous compression ultrasonography</p> <p>PE (8-10 days): definition not reported</p> <p>Major bleedings (8-10 days): definition not reported</p>	Included in CG92
Chin 2009 ⁵²	<p><u>Intervention 1 (n=110):</u> LMWH, enoxaparin, 40 mg once daily (standard dose), subcutaneously given for 5-7 days.</p> <p><u>Intervention 2 (n=110):</u> Intermittent pneumatic compression device (IPCD), one minute per inflation-deflation cycle with pressures ranging from 45-52mmHg, applied for 5-7 days</p> <p><u>Intervention 3 (n=110):</u> AES, length not specified, on both legs, applied for 5-7 days</p> <p><u>Comparison (n=110):</u> No prophylaxis, no</p>	<p>n=440</p> <p>People undergoing elective total knee replacement, median duration of surgery 94 minutes</p> <p>Age (mean): 66 years Gender (male to female ratio): 1:9</p> <p>Singapore</p>	<p>DVT (symptomatic and asymptomatic) (30 days): confirmed by bilateral duplex ultrasonography</p> <p>PE (30 days): confirmed by ventilation-perfusion scanning and spiral computed tomography</p> <p>Major bleeding (time-point not reported): major bleeding requiring intervention</p> <p>Technical complications of mechanical interventions (time-point not reported): examples given were skin rash, swelling above the appliance,</p>	New study

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>further details reported</p> <p><u>Concomitant treatment:</u> Standardised rehabilitation, continuous passive movements on day 2 then ambulation on day 3</p>		<p>pressure necrosis of the skin, peroneal nerve palsy</p> <p>Wound infection (30 days)</p>	
Cho 2013 ⁵³	<p><u>Intervention (n=74):</u> Fondaparinux, 2.5mg, once daily, subcutaneously given for 5 days. AES (length not specified) was applied also. First dose administered at 6-8 hours after the surgery, second dose given 24 hours after the first.</p> <p><u>Comparison (n=74):</u> AES (length not specified) and placebo, 0.25ml saline once daily. First dose administered at 6-8 hours after the surgery, second dose given 24 hours after the first</p>	<p>n=148</p> <p>People undergoing elective unilateral primary knee replacement surgery who were deemed low risk, mean duration of surgery not reported.</p> <p>Age (mean): 68.5 years</p> <p>Gender (male to female ratio): 1:11.3</p> <p>South Korea</p>	<p>All-cause mortality (90 days)</p> <p>DVT (symptomatic and asymptomatic)(7 days): confirmed by Doppler ultrasonography</p> <p>PE (7 days): confirmed by ventilation perfusion lung scan and CT pulmonary angiography</p>	New study
Colwell 1995D ⁶⁴	<p><u>Intervention (n=228):</u> LMWH, enoxaparin, 30 mg twice daily (high dose) subcutaneously given for 14 days postoperatively. No further details reported about how long after the operation the intervention started.</p> <p><u>Comparison (n=225):</u> Unfractionated heparin, 5000IU three times daily, subcutaneously given</p>	<p>n=453</p> <p>People undergoing elective knee replacement surgery, mean duration of surgery not reported</p> <p>Age (mean): 68 years</p> <p>Gender (male to female ratio): 1:1.3</p> <p>USA</p>	<p>DVT (symptomatic and asymptomatic) (15 days): confirmed by unilateral radiocontrast venography and bilateral venography</p> <p>PE (15 days): confirmed by ventilation perfusion lung scan</p> <p>Major bleeding (15 days): no definition reported</p>	Included in CG92

Study	Intervention and comparison	Population	Outcomes	Comments
	for 14 days postoperatively. No further details reported about how long after the operation the intervention started.			
Comp 2001 ⁶⁶	<p><u>Intervention (n=217):</u> Extended duration LMWH, enoxaparin, 30 mg twice daily (high dose) subcutaneously for 7-10 days. Patients were then administered 40mg once daily subcutaneously for 3 weeks</p> <p><u>Comparison (n=221):</u> Standard duration LMWH, enoxaparin, 30 mg twice daily (high dose) subcutaneously for 7-10 days. Patients were then administered placebo, saline subcutaneously for 3 weeks.</p>	<p>n=438</p> <p>People undergoing elective knee replacement surgery, duration of surgery not reported</p> <p>Age (mean): 66 years Gender (male to female ratio): 1:1.34</p> <p>Multicentre, USA</p>	<p>DVT (symptomatic and asymptomatic) (27-29 days): confirmed by segment-filling defects on lower-extremity ascending contrast venograms.</p> <p>PE (27-29 days): confirmed by high-probability ventilation-perfusion lung scan or pulmonary angiogram</p> <p>Major bleeding (27-29 days): defined as clinically overt and resulted in death, transfusion of two or more units of blood products, a decrease in haemoglobin level of ≥ 2.0 g/dL (≥ 20 g/L) compared with the most recent preceding postoperative value, or a serious or life-threatening clinical event or one requiring surgical intervention or if it was retroperitoneal, intracranial, or intraocular in location.</p> <p>Heparin-induced thrombocytopenia (27-29 days)</p>	Included in CG92
Eriksson 2007: RE-MODEL trial ⁸⁸	<p><u>Intervention (n=699):</u> LMWH, enoxaparin, 40mg, once daily (standard dose), subcutaneously given, administered from the evening before surgery, treatment was</p>	<p>n=1393</p> <p>People undergoing elective primary unilateral total knee replacement, mean duration of surgery</p>	<p>All-cause mortality (13 days)</p> <p>DVT (symptomatic and asymptomatic) (13 days): confirmed by bilateral venography</p>	<p>Included in CG92</p> <p>Third arm of this trial evaluated use of a</p>

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>continued for 6-10 days. Patients received two capsules (placebo) in the morning and a daily subcutaneous injection in the evening.</p> <p><u>Comparison (n=694):</u> Dabigatran, 220mg, once daily, orally. First dose was one-half (110mg) and was administered 1-4 hours after completion of surgery. Treatment was continued for 6-10 days. Patients received two capsules in the morning and a daily subcutaneous injection (placebo) in the evening.</p> <p><u>Concomitant treatment:</u> AES was permitted, no further details reported about the percentage of patients who used AES</p>	<p>91 minutes</p> <p>Age (mean): 68 years Gender (female to male): 1:1.8</p> <p>Multicentre, 105 centres in Europe, Australia and South Africa</p>	<p>PE (13 days): confirmed by ventilation/perfusion scintigraphy, pulmonary angiography, spiral computed tomography, or autopsy</p> <p>Fatal PE (13 days): confirmed by ventilation/perfusion scintigraphy, pulmonary angiography, spiral computed tomography, or autopsy</p> <p>Major bleeding (13 days): defined as fatal bleeding; clinically overt bleeding associated with a decrease in the haemoglobin level of more than 20 g/l compared with the pre-randomisation level; clinically overt bleeding leading to transfusion of two or more units of whole blood or packed cells; critical bleeding (intracerebral, intraocular, intraspinal, pericardial or retroperitoneal); bleeding warranting treatment cessation; bleeding located at the surgical site and leading to re-operation or to any unusual medical intervention or procedure for relief (e.g. draining or puncture of a haematoma at the surgical site, transfer to an ICU or</p>	<p>different dose of dabigatran (150mg/day)</p> <p>NICE Technology Appraisal TA157 2008²²⁸</p>

Study	Intervention and comparison	Population	Outcomes	Comments
			<p>emergency room)</p> <p>Clinically relevant non-major bleeding (13 days): defined as any clinically overt bleeding that does not meet the criteria for major bleeding but requires medical attention (e.g.: hospitalisation, medical treatment for bleeding) and/or a change in antithrombotic therapy (including discontinuation or downtitration of study drug) and/or any other bleeding type considered to have clinical consequences for a patient</p>	
Fauno 1994 ⁹³	<p><u>Intervention (n=92):</u> LMWH, enoxaparin, 40mg once daily (standard dose) subcutaneously. Administered from the evening before the operation, and continued for 7-10 days. AES, short, on the operated limb and long AES on the contralateral limb.</p> <p><u>Comparison (n=93):</u> Unfractionated heparin (UFH), 5000IU three times daily, subcutaneously. Administered from the evening before the operation, and continued for 7-10 days. AES, short, on the operated limb and long AES on the contralateral limb.</p>	<p>n=185</p> <p>People undergoing elective primary knee replacement surgery, mean duration of surgery 103 minutes</p> <p>Age (mean): 71 years Gender (male to female ratio): 1:1.5</p> <p>Denmark</p>	<p>DVT (symptomatic and asymptomatic) (7-9 days): confirmed by bilateral ascending venography</p> <p>PE (7-9 days): confirmed by ventilation-perfusion lung scintigraphy</p> <p>Wound haematoma (7-9 days)</p> <p>Wound infection (7-9 days)</p>	Included in CG92
Fitzgerald 2001 ⁹⁵	<p><u>Intervention (n=173):</u> LMWH, enoxaparin, 30mg twice daily (high</p>	<p>n=349</p> <p>People undergoing</p>	All-cause mortality (15 days)	Included in CG92

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>dose) subcutaneously. Intervention began on the day of surgery, was continued for 4-14 days.</p> <p><u>Comparison (n=176):</u> Warfarin, initial dose of 7.5mg, followed by daily adjustment of dose to maintain INR of 2-3. Intervention began on the day of surgery, was continued for 4-14 days.</p> <p><u>Concomitant treatment:</u> Use of AES was permitted, no further details about percentage of people who received AES</p>	<p>elective primary total knee replacement, mean duration of surgery not reported</p> <p>Age (mean): not reported</p> <p>Gender (male to female ratio): 1:1.3</p> <p>Multicentre, USA</p>	<p>DVT (symptomatic and asymptomatic) (15 days): confirmed by bilateral lower-extremity ultrasonography, unilateral venography.</p> <p>PE (15 days): confirmed by high-probability ventilation-perfusion lung scan or a positive pulmonary angiogram</p> <p>Major bleeding (15 days): defined as major if it fulfilled at least one of the following criteria: resulted in transfusion of at least two units of packed red blood cells; resulted in a decrease in the haemoglobin concentration of ≥ 20 g/L compared with the postoperative haemoglobin concentration before the administration of any study medication; was retroperitoneal, intracranial, or intraocular; or resulted in a serious life-threatening clinical event or death</p>	
Fuji 2008 ¹⁰⁵	<p><u>Intervention (n=84):</u> Fondaparinux, 2.5mg subcutaneously once daily. Administered 24±2 hours after surgery until 10-16 days. More than 50% received AES.</p> <p><u>Comparison (n=87):</u> More than 50% received AES. Placebo, 0.25ml isotonic sodium chloride, subcutaneously once</p>	<p>n=171</p> <p>People undergoing elective knee replacement surgery,</p> <p>Age (mean): 61.6 years</p> <p>Gender (male to female ratio):4.6:1</p> <p>Japan</p>	<p>All-cause mortality (11-17 days)</p> <p>Major bleeding (11-17 days): defined as fatal bleeding; bleeding that was retroperitoneal, intracranial, or intraspinal or that involved any other critical organ; bleeding leading to reoperation; and overt bleeding with bleeding index of 2 or more.</p>	Included in CG92

Study	Intervention and comparison	Population	Outcomes	Comments
	daily. Administered 24±2 hours after surgery until 10-16 days.			
Fuji 2008A ¹⁰⁶	<p><u>Intervention 1 (n=78):</u> LMWH, enoxaparin, 20mg (low dose), subcutaneously once daily, administered 24-36 hours after surgery for 14 days. More than 50% received AES</p> <p><u>Intervention 2 (n=74):</u> LMWH, enoxaparin, 40mg (standard dose) once daily, administered 24-36 hours after surgery for 14 days.</p> <p><u>Comparison (n=79):</u> Placebo (saline). Administered 24-36 hours after surgery for 14 days. More than 50% received AES</p>	<p>n=231</p> <p>People undergoing elective knee replacement surgery, duration of surgery not reported</p> <p>Age (mean): 69 years Gender (male to female ratio): 1:5</p> <p>Japan</p>	<p>DVT (symptomatic and asymptomatic) (14 days): confirmed by Doppler ultrasound</p> <p>PE (90 days): confirmed by ventilation perfusion lung scans or pulmonary angiography</p> <p>Major bleeding (15 days): retroperitoneal, intracranial, or intraocular or if it was associated with: death; transfusion of ≥2 units of packed red blood cells or whole blood (except autologous); a reduction in the haemoglobin level of ≥2 g/dl; or a serious or life-threatening clinical event that required medical intervention.</p>	Included in CG92
Fuji 2010 ¹⁰⁴	<p><u>Intervention (n=129):</u> Dabigatran, 220mg, once daily, orally given from 'as early as possible' or at least 2 hours after removing the indwelling catheter and confirming the absence of abnormal bleeding from the drainage sites for 11-14 days. Patients received two capsules per day.</p> <p><u>Comparison (n=124):</u> Placebo, no prophylaxis, orally given from 'as early as</p>	<p>n=253</p> <p>People undergoing elective primary unilateral knee replacement surgery, mean duration of surgery 109 minutes</p> <p>Age (mean): 72 years Gender (male to female ratio): 1:1.6</p> <p>Japan</p>	<p>All-cause mortality (14 days)</p> <p>DVT (symptomatic and asymptomatic) (14 days): confirmed by bilateral venography</p> <p>PE (14 days): confirmed by pulmonary scintigraphy, pulmonary angiography, or contrast computed tomography</p> <p>Major bleeding (14 days): defined as a</p>	New study

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>possible' or at least 2 hours after removing the indwelling catheter and confirming the absence of abnormal bleeding from the drainage sites for 11-14 days. Patients received two capsules per day.</p> <p><u>Concomitant treatment:</u> AES permitted (percentage of patients who received AES not reported).</p>		<p>bleeding event that meets at least one of the following criteria: fatal bleeding, critical bleeding (intracranial, intraocular, intraspinal, pericardial, retroperitoneal, in a non-operated joint, or intramuscular with compartment syndrome), clinically overt bleeding (at surgical or extrasurgical site) associated with a decrease in the haemoglobin level of more than 2 g/dL (20 g/l; 1.24 mmol/L) compared with the pre-randomisation level, clinically overt bleeding (at surgical or extrasurgical site) leading to transfusion of two or more units of whole blood or packed cells, bleeding located at the surgical site and leading to re-operation or to any unusual medical intervention or procedure for relief (e.g. draining or puncture of an haematoma at the surgical site, transfer to an ICU or emergency room)</p> <p>Clinically relevant non-major bleeding (14 days): defined as any clinically overt bleeding that does not meet the criteria for major bleeding but requires medical attention (e.g.: hospitalisation, medical treatment for bleeding) and/or a change in antithrombotic therapy</p>	

Study	Intervention and comparison	Population	Outcomes	Comments
			(including discontinuation or down-titration of study drug) and/or any other bleeding type considered to have clinical consequences for a patient.	
Ginsberg 2009: RE-MOBILIZE trial ²⁵²	<p><u>Intervention (n=876):</u> LMWH, enoxaparin, 30mg twice daily (high dose), subcutaneously given 12-24 hours after surgery for 12-15 days. Two placebo tablets given in the morning.</p> <p><u>Comparison (n=862):</u> Dabigatran, 110mg, 6-12 hours after surgery then 220mg once daily (standard dose) for 12-15 days. Placebo subcutaneously given also.</p>	<p>n=1738</p> <p>People undergoing elective primary unilateral knee replacement surgery, mean duration of surgery 91 minutes</p> <p>Age (mean): 66 years Gender (male to female ratio): 1:1.38</p> <p>Multicentre</p>	<p>All-cause mortality (18 days)</p> <p>DVT (symptomatic and asymptomatic) (18 days): confirmed by bilateral venography</p> <p>PE (18 days): confirmed by high-probability result on ventilation-perfusion scintigraphy, pulmonary angiography, spiral computed tomography or autopsy.</p> <p>Major bleeding (18 days): defined as a bleeding event that meets at least one of the following criteria: fatal bleeding, critical bleeding (intracranial, intraocular, intraspinal, pericardial, retroperitoneal, in a non-operated joint, or intramuscular with compartment syndrome), clinically overt bleeding (at surgical or extrasurgical site) associated with a decrease in the haemoglobin level of more than 2 g/dL (20 g/l; 1.24 mmol/L) compared with the pre-randomisation level, clinically overt bleeding (at surgical or extrasurgical site) leading to transfusion</p>	New study

Study	Intervention and comparison	Population	Outcomes	Comments
			<p>of two or more units of whole blood or packed cells, bleeding located at the surgical site and leading to re-operation or to any unusual medical intervention or procedure for relief (e.g. draining or puncture of an haematoma at the surgical site, transfer to an ICU or emergency room)</p> <p>Fatal PE (18 days): confirmed by autopsy</p> <p>Clinically relevant non-major bleeding (18 days): defined as any clinically overt bleeding that does not meet the criteria for major bleeding but requires medical attention (e.g.: hospitalisation, medical treatment for bleeding) and/or a change in antithrombotic therapy (including discontinuation or down-titration of study drug) and/or any other bleeding type considered to have clinical consequences for a patient.</p>	
Intiyanaravut 2017 ¹⁵¹	<p><u>Intervention (n=25):</u> LMWH, enoxaparin, 40mg, once daily (standard dose), subcutaneously given from 24 hours post-operation and continued for 10 days. Continuous passive motion was initiated on second day post-operation.</p>	<p>n=50</p> <p>People undergoing elective primary knee replacement surgery, mean duration of surgery 130 minutes</p> <p>Age (mean): 71 years Gender (male to female ratio): 1:5</p>	<p>DVT (symptomatic and asymptomatic) (6-10 days): confirmed by bilateral colour Doppler ultrasonography</p> <p>PE (time-point not reported): confirmed by clinical signs scoring system (sudden dyspnea, chest pain and cough of</p>	New study

Study	Intervention and comparison	Population	Outcomes	Comments
	<p><u>Comparison (n=25):</u> No prophylaxis. Continuous passive motion was initiated on second day post-operation.</p> <p><u>Concomitant treatment:</u> Compression dressing was used in the first 24 hours. Active mobilisation and full weight-bearing ambulation was initiated.</p>	Thailand	<p>haemoptysis)</p> <p>Major bleeding (time-point not reported): defined as the presence of grade three haematoma which requiring operative removal and bleeding that was fatal or involved a critical organ.</p>	
Lassen 2007: APROPOS trial	<p><u>Intervention 1 (n=152):</u> LMWH, enoxaparin, 30mg twice daily (high dose), subcutaneously given every 12 hours, began 12-24 hours postoperatively continued for 12±2 days. Placebo tablets also given.</p> <p><u>Intervention 2 (n=310)</u> Apixaban, 2.5mg twice daily or 5mg once daily orally, began 12-24 hours postoperatively continued for 12±2 days. Placebo injections also given.</p> <p><u>Comparison (n=153)</u> VKA, warfarin, orally given once daily, loading dose of 5mg (two 2.5mg tablets), then adjusted dose to maintain INR in the range of 1.8-3.0, from the evening of the day of surgery continued for 12±2 days.</p>	<p>n=615</p> <p>People undergoing elective total knee replacement, mean duration of surgery 90 minutes</p> <p>Age (mean): 68 years Gender (male to female ratio): 1:1.7</p> <p>97 centres in Argentina, Australia, Canada, Mexico, Denmark, Israel, Poland, USA</p>	<p>All-cause mortality (12±2 days)</p> <p>DVT (symptomatic and asymptomatic) (12±2 days): confirmed by bilateral ascending venogram</p> <p>PE (12±2 days): confirmed by computed tomography (CT), pulmonary angiography or a ventilation-perfusion lung scan.</p> <p>Major bleeding (12±2 days): defined as overt bleeding accompanied by a reduction in haemoglobin of $\geq 2 \text{ g dL}^{-1}$ (relative to the postsurgical value) and/or a requirement for transfusion of ≥ 2 units of blood product, or a need to discontinue study medication, or if it was intracranial or intraspinal, retroperitoneal, or in the operated joint necessitating re-operation or intervention, intrapericardial,</p>	<p>Pre-CG92 not included</p> <p>Two arms of apixaban doses combined (2.5mg twice daily and 5mg once daily) to reflect BNF approved dose</p>

Study	Intervention and comparison	Population	Outcomes	Comments
			<p>intraocular or fatal.</p> <p>Fatal PE (12±2 days): defined by autopsy</p> <p>Wound infections (12±2 days)</p>	
Lassen 2008: RECORD-3 trial ¹⁸⁰	<p><u>Intervention (n=1277):</u> LMWH, enoxaparin, 40mg once daily (standard dose), subcutaneously given 12 hours before surgery then 6-8 hours after wound closure, administered for 10-14 days. Placebo oral tablet was also given.</p> <p><u>Comparison (n=1254):</u> Rivaroxaban, 10mg, once daily, initiated 6-9 hours after closure, administered every 24 hours for 10-14 days. Placebo injection was also given.</p>	<p>n=2459</p> <p>People undergoing elective knee replacement, mean duration of surgery 97 minutes</p> <p>Age (mean): 67.6 years</p> <p>Gender (male to female ratio): 1:2.1</p> <p>Multicentre – Austria, Belgium, Canada, China, Colombia, Czech Republic, Denmark, Germany, France, Israel, Italy, the Netherlands, Mexico, Norway, Poland, Peru, South Africa, Spain and Sweden</p>	<p>All-cause mortality (35 days)</p> <p>DVT (symptomatic and asymptomatic) (17 days): confirmed by ascending bilateral venography</p> <p>PE (17 days): confirmed by ventilation-perfusion scintigraphy of the lung and chest radiography or spiral computed tomography, or pulmonary angiography.</p> <p>Major bleeding (17 days): defined as bleeding that was fatal, that involved a critical organ, or that required reoperation or clinically overt bleeding outside the surgical site that was associated with a decrease in the haemoglobin level of 2 g or more per decilitre or requiring infusion of 2 or more units of blood.</p> <p>Clinically relevant non-major bleeding (17 days): definition not reported</p> <p>Wound infection (17 days)</p>	<p>New study</p> <p>NICE Technology Appraisal TA170 2009²²⁹</p>
Lassen 2009: ADVANCE-1	<p><u>Intervention (n=1596):</u> LMWH, enoxaparin,</p>	<p>n=3195</p>	<p>All-cause mortality (60 days)</p>	<p>New study</p>

Study	Intervention and comparison	Population	Outcomes	Comments
trial ¹⁸⁹	<p>30mg every 12 hours (high dose), subcutaneously given from 12-24 hours post-surgery. Intervention administered from 10-14 days. Placebo apixaban tablets also given.</p> <p><u>Comparison (n=1599):</u> Apixaban, 2.5mg twice daily, orally given from 12-24 hours post-surgery. Intervention administered from 10-14 days. Placebo enoxaparin, subcutaneously given also.</p>	<p>People undergoing elective total knee replacement surgery, mean duration of surgery 114 minutes</p> <p>Age (median): 65.8 years</p> <p>Gender (male to female ratio): 1:1.64</p> <p>Multicentre – North America, Europe, Latin America, Asia and Pacific Islands</p>	<p>DVT (symptomatic and asymptomatic) (14 days): confirmed by ascending bilateral venography</p> <p>PE (14 days): confirmed by ventilation–perfusion scintigraphy of the lung and chest radiography or spiral computed tomography were performed, or pulmonary angiography was performed</p> <p>Major bleeding (14 days): defined as bleeding that was fatal, that involved a critical organ, or that required reoperation or clinically overt bleeding outside the surgical site that was associated with a decrease in the haemoglobin level of 2 g or more per decilitre or requiring infusion of 2 or more units of blood.</p> <p>Fatal PE (14 days): confirmed by autopsy</p> <p>Clinically relevant non-major bleeding (14 days): such bleeding included acute, clinically overt bleeding, such as wound hematoma, bruising or ecchymosis, Gastrointestinal bleeding, haemoptysis, haematuria, or epistaxis that did not meet the other criteria for major bleeding.</p>	

Study	Intervention and comparison	Population	Outcomes	Comments
Lassen 2010: ADVANCE-2 trial ¹⁸⁸	<p><u>Intervention (n=1529):</u> LMWH, enoxaparin, 40mg once daily (standard dose), subcutaneously given 12 hours before operation then resumed after surgery. Intervention administered for 10-14 days, placebo apixaban tablets given also.</p> <p><u>Comparison (n=1528):</u> Apixaban, 2.5mg twice daily, orally from 12-24 hours after wound closure. Intervention administered for 10-14 days, subcutaneous placebo injections of enoxaparin.</p>	<p>n=3057</p> <p>People undergoing elective total knee replacement surgery, mean duration of surgery 118 minutes</p> <p>Age (median): 67 years</p> <p>Gender (male to female ratio): 2.63:1</p> <p>Multicentre – Europe, Asia/Pacific, Latin America, South Africa</p>	<p>Wound haematoma (14 days)</p> <p>All-cause mortality (60 days)</p> <p>DVT (symptomatic and asymptomatic)(14 days): confirmed by ascending bilateral venography</p> <p>PE (60 days): confirmed by ventilation–perfusion scintigraphy of the lung and chest radiography or spiral computed tomography were performed, or pulmonary angiography was performed</p> <p>Major bleeding (14 days): defined as bleeding that was fatal, that involved a critical organ, or that required reoperation or clinically overt bleeding outside the surgical site that was associated with a decrease in the haemoglobin level of 2 g or more per decilitre or requiring infusion of 2 or more units of blood.</p> <p>Fatal PE: confirmed by autopsy</p> <p>Clinically relevant non-major bleeding (14 days): such bleeding included acute, clinically overt bleeding, such as wound hematoma, bruising or ecchymosis, Gastrointestinal</p>	New study

Study	Intervention and comparison	Population	Outcomes	Comments
			bleeding, haemoptysis, haematuria, or epistaxis that did not meet the other criteria for major bleeding Wound haematoma (14 days)	
Leclerc 1992 ¹⁹¹	<p><u>Intervention (n=66):</u> LMWH, enoxaparin, 30mg twice daily (high dose), subcutaneously given from the morning of the first post-operative day and was continued for 14 days or until discharge if sooner.</p> <p><u>Comparison (n=65):</u> Placebo, saline, 0.4ml saline twice daily</p>	<p>n=131</p> <p>People undergoing elective knee replacement surgery or tibial osteotomy, mean duration of surgery 145 minutes</p> <p>Age (mean): 69 years Gender (male to female ratio):1:1.5</p> <p>Canada</p>	<p>All-cause mortality (14 days)</p> <p>DVT (symptomatic and asymptomatic) (14 days): confirmed by bilateral contrast venography</p> <p>Major bleeding (14 days): defined by a drop in haemoglobin of 20 g/l or more, requiring transfusion with two or more units of packed red cells or occurring in any of these site: intracranial, intra-ocular, retroperitoneal space or intra-articular.</p>	Included in CG92
Leclerc 1996 ¹⁹²	<p><u>Intervention (n=336):</u> LMWH, enoxaparin, 30mg twice daily (high dose) subcutaneously administered on the morning of the first day after surgery. Administered for 14 days or until hospital discharge, whichever occurred first. Patients also received warfarin placebo once daily from the evening of the operation.</p> <p><u>Comparison (n=334):</u> Warfarin, initial dose not reported, treatment goal was to maintain the INR 2-3. Administered from the evening of the</p>	<p>n=670</p> <p>People undergoing elective knee replacement surgery, mean duration of surgery 125 minutes</p> <p>Age (mean): 69 years Gender (male to female ratio): 1:1.7</p> <p>Multicentre, USA</p>	<p>All-cause mortality (14 days)</p> <p>DVT (symptomatic and asymptomatic) (14 days): confirmed by venography</p> <p>PE (14 days): confirmed by perfusion scan and high-probability scan</p> <p>Major bleeding (14 days): defined as overt bleeding that decreased the haemoglobin level by 20 g/L or more or necessitated transfusion of 2 or more units of packed red cells,</p>	Included in CG92

Study	Intervention and comparison	Population	Outcomes	Comments
	operation for 14 days or until hospital discharge, whichever occurred first. Patients also received subcutaneous saline placebo twice daily (every 12 hours)		haemarthrosis requiring evacuation, discontinuation of prophylaxis, or interruption of physiotherapy for at least 24 hours. Wound haematomas (14 days)	
Mirdamidi 2014 ²¹⁶	<p><u>Intervention (n=45):</u> LMWH, enoxaparin, 40mg once daily (standard dose), subcutaneously given from 12 hours before surgery and continued for up to 15 days.</p> <p><u>Comparison (n=45):</u> Dabigatran, 150mg, 4 hours after surgery and continued daily at an increased dose of 225mg for up to 15 days.</p>	<p>n=90</p> <p>People undergoing elective primary total knee replacement, mean duration of surgery not reported</p> <p>Age (mean): 70 years Gender (male to female ratio): 1:1.37</p> <p>Iran</p>	<p>All-cause mortality (15 days)</p> <p>PE (15 days): confirmed by ventilation/perfusion scintigraphy, spiral computed tomography</p> <p>Major bleeding (15 days): defined as clinically overt bleeding associated with ≥ 20 g/l fall in haemoglobin; clinically overt bleeding leading to a transfusion of ≥ 2 units of packed cells or whole blood; fatal, retroperitoneal, intracranial, intraocular or intraspinal bleeding and bleeding warranting treatment cessation or leading to reoperation.</p> <p>Clinically relevant non-major bleeding (15 days): defined as bleeding that included spontaneous hematoma ≥ 25 cm³, wound hematoma ≥ 100 cm³, epistaxis > 5 min, spontaneous haematuria or a prolonged one after intervention, spontaneous rectal bleeding, gingival bleeding > 5 min</p>	New study

Study	Intervention and comparison	Population	Outcomes	Comments
Norgren 1998 ²³³	<p><u>Intervention (n=19):</u> LMWH, enoxaparin, 40mg once daily (standard dose) subcutaneously. No details reported about when first dose was administered. Intervention continued until full mobilisation, further details not reported.</p> <p><u>Comparison (n=21):</u> Foot pump, plus AES. Started evening before surgery, reapplied immediately after and continued until full mobilisation. A tourniquet was used during surgery.</p>	<p>n=40</p> <p>People undergoing elective knee replacement surgery, duration of surgery not reported</p> <p>Age (mean): 72 years Gender (male to female ratio): 1:1.6</p> <p>Country not reported</p>	<p>DVT (symptomatic and asymptomatic)(7-10 days): confirmed by venography</p> <p>Fatal PE (90 days): confirmed by autopsy</p>	<p>Included in CG92</p> <p>11 patients dropped out of the study, 5 in the LMWH group and 6 in the foot pump group</p>
Turpie 2009: RECORD-4 trial ³⁰⁰	<p><u>Intervention (n=1564):</u> LMWH, enoxaparin, 30mg twice daily (high dose), subcutaneously given from 12-24 hours after wound closure for 11-15 days. Placebo rivaroxaban oral tablets given also.</p> <p><u>Comparison (n=1584):</u> Rivaroxaban, 10mg, orally once daily, from 6-8 hours after wound closure for 11-15 days. Placebo enoxaparin subcutaneously injections given also.</p>	<p>n=3148</p> <p>People undergoing elective total knee replacement, mean duration of surgery 100 minutes</p> <p>Age (mean): 65 years Gender (male to female ratio):1:1.86</p> <p>Canada, USA</p>	<p>All-cause mortality (35 days)</p> <p>DVT (symptomatic and asymptomatic) (17 days): confirmed by venography</p> <p>PE (17 days): confirmed by pulmonary angiography, by ventilation-perfusion lung scintigraphy with chest radiography, or by contrast-enhanced spiral CT.</p> <p>Major bleeding (17 days): defined as defined as bleeding that was fatal, that involved a critical organ, or that required reoperation or clinically overt bleeding outside the surgical site that was associated with a decrease in the haemoglobin level of 2 g or more per decilitre</p>	<p>New study</p> <p>NICE Technology Appraisal TA170 2009²²⁹</p>

Study	Intervention and comparison	Population	Outcomes	Comments
			<p>or requiring infusion of 2 or more units of blood.</p> <p>Fatal PE (17 days): confirmed by pulmonary angiography, by ventilation-perfusion lung scintigraphy with chest radiography, or by contrast-enhanced spiral CT.</p> <p>Clinically relevant non-major bleeding (17 days): defined as multiple-source bleeding, unexpected haematoma (>25 cm²), excessive wound haematoma, nose bleeding, gingival (>5 minutes), macroscopic haematuria, rectal bleeding, coughing or vomiting blood, vaginal bleeding, blood in semen, intra-articular bleeding with trauma, or surgical-site bleeding</p> <p>Wound infection (time-point not reported)</p>	
<p>Warwick 2002³¹⁰</p>	<p><u>Intervention (n=112):</u> LMWH, enoxaparin 40mg once daily (standard dose), subcutaneously, administered from 12 hours before surgery and every 24 hours thereafter until discharge from hospital. AES fitted below the knee before surgery, stocking on operated side was removed for duration of surgery and for some time after, no further details reported about length</p>	<p>n=229</p> <p>People undergoing elective total knee replacement, mean duration of surgery not reported</p> <p>Age (mean): 72 years Gender (male to female ratio): 1:1.9</p> <p>UK</p>	<p>DVT (symptomatic and asymptomatic) (8 days): confirmed by ascending venography</p> <p>Fatal PE (time-point not reported): definition not reported</p> <p>Wound haematomas (time-point not reported)</p>	<p>Included in CG92</p>

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>of time AES worn for.</p> <p><u>Comparison (n=117):</u> Foot pump, pressure of 130mmHg applied for one second, every 20 seconds. Foot pump applied in the recovery room, controller was engaged, foot pump used whenever patients was not weight-bearing until discharge from hospital. AES fitted below the knee before surgery, stocking on operated side was removed for duration of surgery and for some time after, no further details reported about length of time AES worn for.</p>			
Wilson 1992 ³¹⁸	<p><u>Intervention (n=28):</u> Foot pump, A-V Impulse System, compressor rapidly inflates the pad (0.4 seconds), deflates after a period of 3 seconds, cycle repeated every 20 seconds. Foot pump was applied to operated limb on completion of surgery.</p> <p><u>Comparison (n=32):</u> No VTE prophylaxis, no further details reported.</p>	<p>n=60</p> <p>People undergoing elective total knee replacements, mean duration of surgery 136 minutes</p> <p>Age (mean): 71 years Gender (male to female ratio): 1:3</p> <p>UK</p>	<p>DVT (symptomatic and asymptomatic) (10 days): confirmed by ascending ipsilateral venography</p> <p>PE (time-point not reported): confirmed by ventilation perfusion lung scanning</p>	Included in CG92
Zou 2014 ³³⁰	<p><u>Intervention 1 (n=112):</u> LMWH, enoxaparin, 4000IU (0.4ml)/40mg once daily (standard dose) subcutaneously given. Administered from 12 hours after the operation and continued for 14 days.</p>	<p>n=324</p> <p>People undergoing elective unilateral total knee replacement, mean duration surgery 87 minutes</p>	<p>DVT (symptomatic and asymptomatic) (28 days): confirmed by colour Doppler ultrasonography</p> <p>PE (time-point not reported): definition not reported</p>	New study

Study	Intervention and comparison	Population	Outcomes	Comments
	<p><u>Intervention 2 (n=102):</u> Rivaroxaban, 10mg, once daily, subcutaneously given. Administered from 12 hours after the operation and continued for 14 days.</p> <p><u>Comparison (n=110):</u> Aspirin, 100mg, once daily, subcutaneously given. Administered from 12 hours after the operation and continued for 14 days.</p> <p><u>Concomitant treatment:</u> Mobilisation started 1 day after surgery, they practiced walking with walking aids two or three times a day 2 days after surgery for 10-20 minutes each time.</p>	<p>Age (mean): 64 years Gender (male to female ratio): 1:2.7</p> <p>China</p>		

1

1 Table 82: Clinical evidence summary: LMWH (standard dose; standard duration) versus no prophylaxis

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with No prophylaxis	Risk difference with LMWH (standard dose) (95% CI)
DVT (symptomatic and asymptomatic)	220 (1 studies) 30 days	MODERATE ¹ due to risk of bias	RR 0.25 (0.11 to 0.59)	218 per 1000	164 fewer per 1000 (from 89 fewer to 194 fewer)
PE	220 (1 studies) 30 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.14 (0.00 to 6.82)	9 per 1000	8 fewer more per 1000 (from 9 fewer to 50 more)
Major bleeding	530 (3 studies) 30 days	VERY LOW ^{1,2,4,6} due to risk of bias, indirectness, imprecision, inconsistency	Peto OR 0.98 (0.24 to 3.95)	15 per 1000	0 fewer per 1000 (from 12 fewer to 42 more)
Wound haematoma	219 (1 study) 8 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 7.67 (0.48 to 123.42)	0 per 1000	⁻⁴
Technical complications of mechanical interventions	220 (1 study) time-point not reported	VERY LOW ^{1,2,4} due to risk of bias, indirectness imprecision	Not estimable ⁵	Not estimable ⁵	0 fewer per 1000 (from 20 fewer to 20 more) ⁵
Wound infection	220 (1 study) 30 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.13 (0.01 to 2.16)	18 per 1000	16 fewer per 1000 (from 18 fewer to 20 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with No prophylaxis	Risk difference with LMWH (standard dose) (95% CI)
3 Absolute effects could not be calculated due to zero events in the control arm					
4 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol					
5 Zero events in both arms of one of the studies included. Risk difference calculated in Review Manager.					
6 Downgraded by 1 or 2 increments because heterogeneity, I2= > 50%, p= > 0.04, unexplained by subgroup analysis.					

1 Table 83: Clinical evidence summary: LMWH (standard dose; standard duration) versus apixaban

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Apixaban	Risk difference with LMWH (standard dose) (95% CI)
All-cause mortality	3057 (1 study) 60 days	LOW ¹ due to imprecision	Peto OR 0.37 (0.05 to 2.61)	2 per 1000	1 fewer per 1000 (from 2 fewer to 3 more)
DVT (symptomatic and asymptomatic)	1968 (1 study) 14 days	MODERATE ² due to risk of bias	RR 1.67 (1.38 to 2.01)	146 per 1000	98 more per 1000 (from 56 more to 148 more)
PE	3057 (1 study) 14 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 0.17 (0.02 to 1.38)	4 per 1000	3 fewer per 1000 (from 4 fewer to 1 more)
Major bleeding	3009 (1 study) 14 days	LOW ¹ due to imprecision	RR 1.55 (0.67 to 3.57)	6 per 1000	3 more per 1000 (from 2 fewer to 15 more)
Fatal PE	3057 (1 study) 14 days	LOW ¹ due to imprecision	Peto OR 0.14 (0 to 6.82)	1 per 1000	1 fewer per 1000 (from 1 fewer to 4 more)
Clinically relevant non-major bleeding	3009 (1 study) 14 days	MODERATE ¹ due to imprecision	RR 1.31 (0.89 to 1.93)	29 per 1000	9 more per 1000 (from 3 fewer to 27 more)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Apixaban	Risk difference with LMWH (standard dose) (95% CI)
Wound haematoma	3009 (1 study) 14 days	LOW ¹ due to imprecision	Peto OR 0.13 (0 to 6.79)	1 per 1000	1 fewer per 1000 (from 1 fewer to 4 more)

1 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.
2 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

1 Table 84: Clinical evidence summary: LMWH (standard dose; standard duration) versus dabigatran

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Dabigatran	Risk difference with LMWH (standard dose) (95% CI)
All-cause mortality	1450 (2 studies) 13 days	LOW ² due to imprecision	Peto OR 1.01 (0.06 to 16.24)	1 per 1000	0 more per 1000 (from 1 fewer to 20 more)
DVT (symptomatic and asymptomatic)	1360 (1 study) 13 days	HIGH	RR 1.04 (0.87 to 1.24)	270 per 1000	11 more per 1000 (from 35 fewer to 65 more)
PE	1450 (2 studies) 13 days	LOW ² due to imprecision	Not estimable ¹	Not estimable ¹	0 fewer per 1000 (from 0 fewer to 0 more) ¹
Major bleeding	1463 (2 studies) 13 days	LOW ² due to imprecision	RR 0.83 (0.38 to 1.84)	18 per 1000	3 fewer per 1000 (from 11 fewer to 15 more)
Fatal PE	1360 (1 study) 13 days	LOW ² due to imprecision	Peto OR 7.28 (0.14 to 367.03)	0 per 1000	- ³
Clinically relevant non-major bleeding	1463	LOW ²	RR 0.9	66 per 1000	7 fewer per 1000

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Dabigatran	Risk difference with LMWH (standard dose) (95% CI)
	(2 studies) 13 days	due to imprecision	(0.61 to 1.33)		(from 26 fewer to 22 more)

1 Zero events in both arms of studies included. Risk difference calculated in Review Manager.
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.
3 Absolute effects could not be calculated due to zero events in the control

1 Table 85: Clinical evidence summary: LMWH (standard dose; standard duration) versus rivaroxaban

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Rivaroxaban	Risk difference with LMWH (standard dose) (95% CI)
All-cause mortality	2418 (1 study) 35 days	LOW ^{2,3} due to risk of bias, imprecision	Peto OR 7.31 (1.03 to 51.96)	0 per 1000	⁻¹
DVT (symptomatic and asymptomatic)	1916 (2 studies) 28 days	MODERATE ² due to risk of bias	RR 1.99 (1.55 to 2.54)	89 per 1000	88 more per 1000 (from 49 more to 136 more)
PE	2632 (2 studies) 17 days	LOW ^{2,3} due to risk of bias, imprecision	Peto OR 7.31 (1.03 to 51.96)	0 per 1000	⁻¹
Major bleeding	2531 (1 study) 17 days	LOW ³ due to imprecision	RR 0.79 (0.42 to 1.50)	17 per 1000	4 fewer per 1000 (from 10 fewer to 8 more)
Clinically relevant non-major bleeding	2459 (1 study) 35 days	VERY LOW ^{2,3} due to risk of bias, imprecision	RR 0.84 (0.51 to 1.37)	27 per 1000	4 fewer per 1000 (from 13 fewer to 10 more)
Wound infection	2459 (1 study)	VERY LOW ^{2,3} due to risk of bias,	RR 1.55 (0.6 to 3.98)	6 per 1000	3 more per 1000 (from 2 fewer to 17 more)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Rivaroxaban	Risk difference with LMWH (standard dose) (95% CI)
	17 days	imprecision			
<p>1 Absolute effects could not be calculated due to zero events in the control arm</p> <p>2 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p> <p>3 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.</p>					

1 Table 86: Clinical evidence summary: LMWH (standard dose; standard duration) versus aspirin

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Aspirin	Risk difference with LMWH (standard dose) (95% CI)
DVT (symptomatic and asymptomatic)	222 (1 study) 28 days	VERY LOW ^{1,3} due to risk of bias, imprecision	RR 0.76 (0.4 to 1.46)	164 per 1000	39 fewer per 1000 (from 98 fewer to 75 more)
PE	222 (1 study) 28 days	VERY LOW ^{1,2,3} due to risk of bias, indirectness, imprecision	Not estimable ⁴	Not estimable ⁴	0 fewer per 1000 (from 20 fewer to 20 more) ⁴
<p>1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p> <p>2 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol</p> <p>3 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.</p> <p>4 Zero events in both arms of one of the studies included. Risk difference calculated in Review Manager.</p>					

2 Table 87: Clinical evidence summary: LMWH (standard dose; standard duration) versus AES

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with AES	Risk difference with LMWH (standard dose) (95% CI)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with AES	Risk difference with LMWH (standard dose) (95% CI)
DVT (symptomatic and asymptomatic)	220 (1 study) 30 days	LOW ^{1,2} due to risk of bias, imprecision	RR 0.43 (0.17 to 1.07)	127 per 1000	73 fewer per 1000 (from 106 fewer to 9 more)
PE	220 (1 study) 30 days)	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.14 (0.00 to 6.82)	9 per 1000	8 fewer per 1000 (from 9 fewer to 50 more)
Technical complications of mechanical interventions	220 (1 study) time-point not reported	VERY LOW ^{1,2,4} due to risk of bias, indirectness imprecision	Not estimable ⁵	Not estimable ⁵	0 fewer per 1000 (from 20 fewer to 20 more) ⁵
Wound infection	220 (1 study) 30 days)	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.13 (0.01 to 2.16)	18 per 1000	16 fewer per 1000 (from 18 fewer to 20 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.
3 Absolute effects could not be calculated due to zero events in the control arm
4 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol
5 Zero events in both arms of one of the studies included. Risk difference calculated in Review Manager.

1 Table 88: Clinical evidence summary: LMWH (standard dose; standard duration) versus IPCD

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with IPCD	Risk difference with LMWH (standard dose) (95% CI)
DVT (symptomatic and asymptomatic)	350 (2 studies) 30 days	LOW ^{1,2} due to risk of bias, imprecision	RR 0.49 (0.32 to 0.76)	249 per 1000	127 fewer per 1000 (from 60 fewer to 169 fewer)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with IPCD	Risk difference with LMWH (standard dose) (95% CI)
PE	350 (2 studies) 30 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Not estimable ³	Not estimable ³	0 fewer per 1000 (from 20 fewer to 20 more) ³
Technical complications of mechanical interventions	220 (1 study) time-point not reported	VERY LOW ^{1,2,4} due to risk of bias, indirectness imprecision	Not estimable ³	Not estimable ³	0 fewer per 1000 (from 20 fewer to 20 more) ⁵
Wound infection	220 (1 study) 30 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.14 (0.00 to 6.82)	9 per 1000	8 fewer per 1000 (from 9 fewer to 50 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.
3 Zero events in both arms. Risk difference calculated in Review Manager.
4 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol
5 Absolute effects could not be calculated due to zero events in the control arm

1 Table 89: Clinical evidence summary: LMWH (standard dose; standard duration) versus foot pump + AES

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Foot pump + AES	Risk difference with LMWH (standard dose) (95% CI)
DVT (symptomatic and asymptomatic)	29 (1 study) 10 days	LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.11 (0.01 to 0.91)	267 per 1000	228 fewer per 1000 (from 18 fewer to 263 fewer)
Fatal PE	29 (1 study)	VERY LOW ^{1,2,3} due to risk of bias,	Peto OR 0.14 (0 to 7.31)	67 per 1000	57 fewer per 1000 (from 67 fewer to 276 more)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Foot pump + AES	Risk difference with LMWH (standard dose) (95% CI)
	time-point not reported	indirectness, imprecision			
1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias 2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs. 3 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol					

1

2 **Table 90: Clinical evidence summary: LMWH (standard dose; standard duration) + AES versus foot pump + AES**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Foot pump + AES	Risk difference with LMWH (standard dose) + AES (95% CI)
DVT (symptomatic and asymptomatic)	188 (1 study) 8 days	LOW ^{1,2} due to risk of bias, imprecision	RR 0.94 (0.73 to 1.21)	576 per 1000	35 fewer per 1000 (from 155 fewer to 121 more)
Fatal PE	188 (1 study) 8 days	VERY LOW ^{1,2,3} due to risk of bias, indirectness, imprecision	Peto OR 0.15 (0.01 to 2.40)	20 per 1000	17 fewer per 1000 (from 20 fewer to 27 more)
1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias 2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs. 3 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol 4 Absolute effects could not be calculated due to zero events in the control arm					

3 **Table 91: Clinical evidence summary: LMWH (standard dose; standard duration) versus UFH**

Outcomes	No of	Quality of the evidence	Relative	Anticipated absolute effects
----------	-------	-------------------------	----------	------------------------------

	Participants (studies) Follow up	(GRADE)	effect (95% CI)	Risk with UFH	Risk difference with LMWH (standard dose) (95% CI)
Wound haematoma	184 (1 study) 7-9 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 0.68 (0.29 to 1.59)	129 per 1000	41 fewer per 1000 (from 92 fewer to 76 more)
<p>1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p> <p>2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.</p>					

1 Table 92: Clinical evidence summary: LMWH (standard dose; standard duration) + AES versus UFH + AES

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with UFH + AES	Risk difference with LMWH (standard dose) + AES (95% CI)
DVT (symptomatic and asymptomatic)	184 (1 study) 7-9 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 0.86 (0.52 to 1.42)	269 per 1000	38 fewer per 1000 (from 129 fewer to 113 more)
PE	184 (1 study) 7-9 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Not estimable ³	Not estimable ³	0 fewer per 1000 (from 20 fewer to 20 more) ³
Wound infection	184 (1 study) 7-9 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 0.34 (0.04 to 3.21)	32 per 1000	21 fewer per 1000 (from 31 fewer to 71 more)
<p>1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p> <p>2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.</p> <p>3 Zero events in both arms. Risk difference calculated in Review Manager.</p>					

2 Table 93: Clinical evidence summary: LMWH (standard dose; extended duration) versus LMWH (standard dose; standard duration)

Outcomes	No of	Quality of the	Relative effect	Anticipated absolute effects
----------	-------	----------------	-----------------	------------------------------

	Participants (studies) Follow up	evidence (GRADE)	(95% CI)	Risk with LMWH (standard duration)	Risk difference with LMWH (extended duration) (95% CI)
DVT (symptomatic and asymptomatic)	299 (1 study) 27-29 days	LOW ¹ due to imprecision	RR 0.83 (0.55 to 1.25)	257 per 1000	44 fewer per 1000 (from 116 fewer to 64 more)
PE	438 (1 study) 27-29 days	LOW ¹ due to imprecision	Peto OR 0.14 (0.01 to 2.20)	9 per 1000	8 fewer per 1000 (from 9 fewer to 11 more)
Major bleeding	438 (1 study) 27-29 days	LOW ¹ due to imprecision	Peto OR 0.14 (0 to 6.95)	5 per 1000	4 fewer per 1000 (from 5 fewer to 26 more)
Heparin-induced thrombocytopenia	438 (1 study) 27-29 days	LOW ¹ due to imprecision	RR 1.02 (0.14 to 7.17)	9 per 1000	0 more per 1000 (from 8 fewer to 56 more)

1 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.

1 Table 94: Clinical evidence summary: LMWH (standard dose; standard duration) + AES versus LMWH (low dose; standard duration) + AES

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with LMWH (low dose) + AES	Risk difference with LMWH (standard dose) (95% CI) + AES
DVT (symptomatic and asymptomatic)	152 (1 study) 14 days	LOW ^{1,2} due to risk of bias, imprecision	RR 0.78 (0.52 to 1.16)	436 per 1000	96 fewer per 1000 (from 209 fewer to 70 more)
PE	152 (1 study) 90 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 1.05 (0.07 to 16.55)	13 per 1000	1 more per 1000 (from 12 fewer to 199 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.

1 Table 95: Clinical evidence summary: LMWH (standard dose; standard duration) + AES versus AES

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with AES	Risk difference with LMWH (standard dose) + AES (95% CI)
DVT (symptomatic and asymptomatic)	153 (1 study) 14 days	LOW ^{1,2} due to risk of bias, imprecision	RR 0.56 (0.39 to 0.80)	608 per 1000	267 fewer per 1000 (from 122 fewer to 371 fewer)
PE	153 (1 study) 90 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 1.07 (0.07 to 16.76)	13 per 1000	1 more per 1000 (from 12 fewer to 199 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.

2 Table 96: Clinical evidence summary: LMWH (standard dose; standard duration) versus LMWH (low dose; standard duration)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with LMWH (low dose)	Risk difference with LMWH (standard dose) (95% CI)
Major bleeding	180 (1 study) 14 days	VERY LOW ^{2,3} due to risk of bias, imprecision	Peto OR 7.23 (0.14 to 364.38)	0 per 1000	⁻¹

1 Absolute effects could not be calculated due to zero events in the control arm
2 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
3 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.

3 Table 97: Clinical evidence summary: LMWH (standard dose; standard duration) + CPM versus CPM

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with CPM	Risk difference with LMWH (standard dose) + CPM (95% CI)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with CPM	Risk difference with LMWH (standard dose) + CPM (95% CI)
DVT (symptomatic and asymptomatic)	50 (1 study) 6-10 days	LOW ² due to imprecision	OR 0.14 (0.00 to 6.82)	40 per 1000	34 fewer per 1000 (from 40 fewer to 181 more)
PE	50 (1 study) time-point not reported	VERY LOW ^{1,2,4} due to risk of bias, indirectness, imprecision	Not estimable ³	Not estimable ³	0 fewer per 1000 (from 70 fewer to 70 more) ³
Major bleeding	50 (1 study) time-point not reported	VERY LOW ^{1,2,4} due to risk of bias, indirectness, imprecision	Not estimable ³	Not estimable ³	0 fewer per 1000 (from 70 fewer to 70 more) ³

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.
3 Zero events in both arms. Risk difference calculated in Review Manager.
4 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol

1

2

3 **Table 98: Clinical evidence summary: LMWH (low dose; standard duration) versus no pharmacological prophylaxis**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with No pharmacological prophylaxis	Risk difference with LMWH (low dose) (95% CI)
Major bleeding	178 (1 study) 14 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.13 (0.02 to 0.94)	45 per 1000	39 fewer per 1000 (from 3 fewer to 44 fewer)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with No pharmacological prophylaxis	Risk difference with LMWH (low dose) (95% CI)
1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias					
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.					

1 Table 99: Clinical evidence summary: LMWH (low dose; standard duration) + AES versus AES

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with AES	Risk difference with LMWH (low dose) + AES (95% CI)
DVT (symptomatic and asymptomatic)	157 (1 study) 14 days	LOW ^{1,2} due to risk of bias, imprecision	RR 0.72 (0.53 to 0.98)	608 per 1000	170 fewer per 1000 (from 12 fewer to 286 fewer)
PE	157 (1 study) 90 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 1.01 (0.06 to 15.91)	13 per 1000	0 more per 1000 (from 12 fewer to 189 more)
1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias					
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.					

2 Table 100: Clinical evidence summary: LMWH (high dose; standard duration) versus no prophylaxis

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with No prophylaxis	Risk difference with LMWH (high dose) (95% CI)
All-cause mortality	131 (1 study) 14 days	LOW ² due to imprecision	Not estimable ¹	Not estimable ¹	0 fewer per 1000 (from 30 fewer to 30 more) ¹
DVT (symptomatic and	129 (1 study)	HIGH	RR 0.29	578 per 1000	410 fewer per 1000

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with No prophylaxis	Risk difference with LMWH (high dose) (95% CI)
asymptomatic)	14 days		(0.16 to 0.52)		(from 278 fewer to 486 fewer)
Major bleeding	131 (1 study) 14 days	LOW ² due to imprecision	Peto OR 0.13 (0 to 6.72)	15 per 1000	13 fewer per 1000 (from 15 fewer to 80 more)

1 Zero events in both arms. Risk difference calculated in Review Manager.
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.

1 Table 101: Clinical evidence summary: LMWH (high dose; standard duration) versus UFH

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with UFH	Risk difference with LMWH (high dose) (95% CI)
DVT (symptomatic and asymptomatic)	288 (1 study) 15 days	LOW ^{1,2} due to risk of bias, imprecision	RR 0.72 (0.56 to 0.93)	538 per 1000	151 fewer per 1000 (from 38 fewer to 237 fewer)
PE	288 (1 study) 15 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.13 (0.00 to 6.73)	7 per 1000	6 fewer per 1000 (from 7 fewer to 38 more)
Major bleeding	453 (1 study) 15 days	VERY LOW ^{1,2,3} due to risk of bias, indirectness, imprecision	RR 0.99 (0.2 to 4.84)	13 per 1000	0 fewer per 1000 (from 11 fewer to 51 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.
3 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol

1 Table 102: Clinical evidence summary: LMWH (high dose; standard duration) versus VKA

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with VKA	Risk difference with LMWH (high dose) (95% CI)
All-cause mortality	1237 (3 studies) 15 days	LOW ¹ due to imprecision	Peto OR 0.37 (0.05 to 2.66)	5 per 1000	3 fewer per 1000 (from 5 fewer to 8 more)
DVT (symptomatic and asymptomatic)	984 (3 studies) 15 days	MODERATE ¹ due to imprecision	RR 0.63 (0.53 to 0.75)	438 per 1000	162 fewer per 1000 (from 109 fewer to 206 fewer)
PE	984 (3 studies) 15 days	LOW ¹ due to imprecision	Peto OR 0.76 (0.17 to 3.37)	8 per 1000	2 fewer per 1000 (from 7 fewer to 19 more)
Major bleeding	1319 (3 studies) 15 days	LOW ¹ due to imprecision	RR 1.61 (0.74 to 3.51)	15 per 1000	9 more per 1000 (from 4 fewer to 38 more)
Fatal PE	218 (1 study) 12±2 days	VERY LOW ^{1,3} due to risk of bias, imprecision	Not estimable ²	Not estimable ²	0 fewer per 1000 (from 20 fewer to 20 more) ²
Wound haematoma	670 (1 study) 14 days	LOW ¹ due to imprecision	RR 0.99 (0.06 to 15.83)	3 per 1000	0 fewer per 1000 (from 3 fewer to 44 more)
Wound infection	300 (1 study) 12±2 days	VERY LOW ^{1,3} due to risk of bias, imprecision	RR 0.34 (0.04 to 3.21)	20 per 1000	13 fewer per 1000 (from 19 fewer to 44 more)

1 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.

2 Zero events in both arms of one of the studies included. Risk difference calculated in Review Manager

3 Downgrades by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

1 Table 103: Clinical evidence summary: LMWH (high dose; standard duration) versus fondaparinux

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Fondaparinux	Risk difference with LMWH (high dose) (95% CI)
Major bleeding	1034 (1 study) 49 days	LOW ^{1,2} due to risk of bias, indirectness	RR 0.09 (0.01 to 0.70)	21 per 1000	19 fewer per 1000 (from 6 fewer to 21 fewer)
<p>1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p> <p>2 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol</p>					

2 Table 104: Clinical evidence summary: LMWH (high dose; standard duration) + AES versus fondaparinux + AES

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Fondaparinux + AES	Risk difference with LMWH (high dose) + AES (95% CI)
All-cause mortality	1034 (1 study) 49 days	LOW ^{1,2} due to risk of bias, imprecision	RR 1.5 (0.25 to 8.94)	4 per 1000	2 more per 1000 (from 3 fewer to 31 more)
DVT (symptomatic and asymptomatic)	722 (1 study) 49 days	LOW ^{1,2} due to risk of bias, imprecision	RR 2.18 (1.58 to 3)	125 per 1000	147 more per 1000 (from 72 more to 249 more)
PE	1034 (1 study) 49 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 4 (0.45 to 35.67)	2 per 1000	6 more per 1000 (from 1 fewer to 67 more)
Fatal PE	1034 (1 study) 49 days	VERY LOW ^{1,4} due to risk of bias, indirectness	Not estimable ³	Not estimable ³	0 fewer per 1000 (from 0 fewer to 0 more) ³
<p>1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p> <p>2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.</p> <p>3 Zero events in both arms. Risk difference calculated in Review Manager.</p>					

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Fondaparinux + AES	Risk difference with LMWH (high dose) + AES (95% CI)
4 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol					

1 Table 105: Clinical evidence summary: LMWH (high dose; standard duration) versus apixaban

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Apixaban	Risk difference with LMWH (high dose) (95% CI)
All-cause mortality	3485 (2 studies) 60 days	LOW ¹ due to imprecision	RR 1.68 (0.48 to 5.79)	2 per 1000	2 more per 1000 (from 1 fewer to 11 more)
DVT (symptomatic and asymptomatic)	2581 (2 studies) 14 days	MODERATE ¹ due to imprecision	RR 1.10 (0.85 to 1.41)	81 per 1000	8 more per 1000 (from 12 fewer to 33 more)
PE	3512 (2 studies) 14 days	LOW ^{1,2} due to imprecision, inconsistency	RR 0.87 (0.42 to 1.78)	8 per 1000	1 fewer per 1000 (from 5 fewer to 6 more)
Major bleeding	3638 (2 studies) 14 days	LOW ^{1,2} due to imprecision, inconsistency	RR 1.63 (0.83 to 3.19)	8 per 1000	5 more per 1000 (from 1 fewer to 17 more)
Fatal PE	3195 (2 studies) 14 days	LOW ¹ due to imprecision	Peto OR 0.14 (0.01 to 2.17)	1 per 1000	1 fewer per 1000 (from 1 fewer to 1 more)
Clinically relevant non-major bleeding	3184 (1 study) 14 days	MODERATE ¹ due to imprecision	RR 1.35 (0.88 to 2.08)	22 per 1000	8 more per 1000 (from 3 fewer to 24 more)
Wound infection	454 (1 study)	LOW ¹ due to imprecision	RR 0.34 (0.04 to	20 per 1000	13 fewer per 1000 (from 19 fewer to 36 more)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Apixaban	Risk difference with LMWH (high dose) (95% CI)
	14 days		2.81)		
1 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.					
2 Downgraded by 1 or 2 increments because heterogeneity, I ² = > 50%, p = > 0.04, unexplained by subgroup analysis.					

1 Table 106: Clinical evidence summary: LMWH (high dose; standard duration) versus dabigatran

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Dabigatran	Risk difference with LMWH (high dose) (95% CI)
All-cause mortality	1725 (1 study) 18 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.13 (0 to 6.73)	1 per 1000	1 fewer per 1000 (from 1 fewer to 7 more)
DVT (symptomatic and asymptomatic)	1736 (1 study) 18 days	LOW ^{1,2} due to risk of bias imprecision	RR 0.82 (0.68 to 0.98)	300 per 1000	54 fewer per 1000 (from 6 fewer to 96 fewer)
PE	1247 (1 study) 18 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 0.78 (0.24 to 2.55)	10 per 1000	2 fewer per 1000 (from 8 fewer to 15 more)
Major bleeding	1725 (1 study) 18 days	MODERATE ¹ due to imprecision	RR 2.37 (0.84 to 6.7)	6 per 1000	8 more per 1000 (from 1 fewer to 33 more)
Clinically relevant non-major bleeding	1725 (1 study) 18 days	LOW ¹ due to imprecision	RR 0.9 (0.5 to 1.62)	27 per 1000	3 fewer per 1000 (from 13 fewer to 17 more)
1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias					
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.					

1 Table 107: Clinical evidence summary: LMWH (high dose; standard duration) versus rivaroxaban

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Rivaroxaban	Risk difference with LMWH (high dose) (95% CI)
All-cause mortality	3034 (1 study) 35 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 0.76 (0.17 to 3.39)	3 per 1000	1 fewer per 1000 (from 2 fewer to 6 more)
DVT (symptomatic and asymptomatic)	1924 (1 study) 17 days	LOW ^{1,2} due to risk of bias, imprecision	RR 1.42 (1.03 to 1.95)	63 per 1000	27 more per 1000 (from 2 more to 60 more)
PE	3034 (1 study) 17 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 2.02 (0.61 to 6.71)	3 per 1000	3 more per 1000 (from 1 fewer to 15 more)
Major bleeding	3148 (1 study) 17 days	MODERATE ² due to imprecision	RR 0.60 (0.32 to 1.11)	17 per 1000	7 fewer per 1000 (from 12 fewer to 2 more)
Clinically relevant non-major bleeding	3034 (1 study) 17 days	LOW ^{1,2} due to risk of bias, imprecision	RR 0.78 (0.49 to 1.25)	26 per 1000	6 fewer per 1000 (from 13 fewer to 6 more)
Wound infection	3034 (1 study) 17 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 0.76 (0.17 to 3.39)	3 per 1000	1 fewer per 1000 (from 2 fewer to 6 more)
<p>1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p> <p>2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.</p>					

2 Table 108: Clinical evidence summary: Fondaparinux versus no pharmacological prophylaxis

Outcomes	No of	Quality of the evidence	Relative	Anticipated absolute effects
----------	-------	-------------------------	----------	------------------------------

	Participants (studies) Follow up	(GRADE)	effect (95% CI)	Risk with No pharmacological prophylaxis	Risk difference with Fondaparinux (95% CI)
Major bleeding	171 (1 study) 11-17 days	VERY LOW ^{2,3} due to risk of bias, imprecision	RR 1.04 (0.07 to 16.29)	11 per 1000	0 more per 1000 (from 11 fewer to 176 more)
<p>1 Zero events in both arms. Risk difference calculated in Review Manager. 2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs. 3 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p>					

1 Table 109: Clinical evidence summary: Fondaparinux + AES versus AES

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with AES	Risk difference with Fondaparinux + AES (95% CI)
All-cause mortality	319 (2 studies) 11-17 days	VERY LOW ^{2,3} due to risk of bias, imprecision	Not estimable ¹	Not estimable ¹	0 fewer per 1000 (from 20 fewer to 20 more) ¹
DVT (symptomatic and asymptomatic)	148 (1 study) 7 days	HIGH	RR 0.26 (0.1 to 0.67)	257 per 1000	190 fewer per 1000 (from 85 fewer to 231 fewer)
PE	148 (1 study) 7 days	LOW ² due to imprecision	Not estimable ¹	Not estimable	0 fewer per 1000 (from 30 fewer to 30 more) ¹
Major bleeding	171 (1 study) 11-17 days	VERY LOW ^{2,3} due to risk of bias, imprecision	RR 1.04 (0.07 to 16.29)	11 per 1000	0 more per 1000 (from 11 fewer to 176 more)
<p>1 Zero events in both arms. Risk difference calculated in Review Manager. 2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs. 3 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p>					

1 Table 110: Clinical evidence summary: Fondaparinux + IPCD + AES versus VKA + IPCD + AES

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with VKA + IPCD + AES	Risk difference with Fondaparinux + IPCD + AES (95% CI)
All-cause mortality	118 (1 study) 30 days	VERY LOW ^{2,3} due to risk of bias, imprecision	Not estimable ¹	Not estimable ¹	0 fewer per 1000 (from 30 fewer to 30 more) ¹
DVT (symptomatic and asymptomatic)	118 (1 study) 30 days	VERY LOW ^{2,3} due to risk of bias, imprecision	Not estimable ¹	Not estimable ¹	0 fewer per 1000 (from 30 fewer to 30 more) ¹
PE	118 (1 study) 30 days	VERY LOW ^{2,3} due to risk of bias, imprecision	Not estimable ¹	Not estimable ¹	0 fewer per 1000 (from 30 fewer to 30 more) ¹

1 Zero events in both arms. Risk difference calculated in Review Manager.
 2 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
 3 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.

2 Table 111: Clinical evidence summary: Apixaban versus VKA

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with VKA	Risk difference with Apixaban (95% CI)
All-cause mortality	317 (1 study) 14 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 4.59 (0.07 to 284.39)	0 per 1000	- ⁴
DVT (symptomatic and asymptomatic)	317 (1 study) 14 days	MODERATE ¹ due to risk of bias	RR 0.38 (0.23 to 0.63)	266 per 1000	165 fewer per 1000 (from 98 fewer to 205 fewer)
PE	317 (1 study)	VERY LOW ^{1,2} due to risk of bias,	Not estimable ³	Not estimable ³	0 fewer per 1000 (from 10 fewer to 10 more) ³

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with VKA	Risk difference with Apixaban (95% CI)
	14 days	imprecision			
Major bleeding	456 (1 study) 14 days	LOW ² due to imprecision	Peto OR 4.50 (0.56 to 36.39)	0 per 1000	- ⁴
Fatal PE	317 (1 study) 7 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 4.59 (0.07 to 284.39)	0 per 1000	- ⁴
Wound infection	456 (1 study) 14 days	LOW ² due to imprecision	RR 0.99 (0.25 to 3.90)	20 per 1000	0 fewer per 1000 (from 15 fewer to 58 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.
3 Zero events in both arms. Risk difference calculated in Review Manager.
4 Absolute effects could not be calculated due to zero events in the control arm.

1 Table 112: Clinical evidence summary: Dabigatran versus no prophylaxis

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with No prophylaxis	Risk difference with Dabigatran (95% CI)
All-cause mortality	253 (1 study) 14 days	LOW ² due to imprecision	Not estimable ¹	Not estimable ¹	0 fewer per 1000 (from 20 fewer to 20 more) ¹
DVT (symptomatic and asymptomatic)	197 (1 study) 14 days	MODERATE ³ due to risk of bias	RR 0.42 (0.29 to 0.63)	564 per 1000	327 fewer per 1000 (from 209 fewer to 401 fewer)
PE	253	LOW ²	Not	Not estimable ¹	0 fewer per 1000

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with No prophylaxis	Risk difference with Dabigatran (95% CI)
	(1 study) 14 days	due to imprecision	estimable ¹		(from 20 fewer to 20 more) ¹
Major bleeding	253 (1 study) 14 days	LOW ² due to imprecision	Peto OR 2.64 (0.37 to 19.00)	8 per 1000	13 more per 1000 (from 5 fewer to 126 more)
Clinically relevant non-major bleeding	253 (1 study) 14 days	LOW ² due to imprecision	RR 0.64 (0.11 to 3.77)	24 per 1000	9 fewer per 1000 (from 22 fewer to 67 more)

1 Zero events in both arms. Risk difference calculated in Review Manager.
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.
3 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

1 Table 113: Clinical evidence summary: Rivaroxaban versus aspirin

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Aspirin	Risk difference with Rivaroxaban (95% CI)
DVT (symptomatic and asymptomatic)	212 (1 study) 28 days	HIGH	RR 0.18 (0.05 to 0.59)	164 per 1000	134 fewer per 1000 (from 67 fewer to 155 fewer)
PE	212 (1 study) 28 days	VERY LOW ^{1,3,4} due to risk of bias, indirectness, imprecision	Not estimable ²	Not estimable ²	0 fewer per 1000 (from 20 fewer to 20 more) ²

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Zero events in both arms. Risk difference calculated in Review Manager.
3 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Aspirin	Risk difference with Rivaroxaban (95% CI)
4 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.					

1 **Table 114: Clinical evidence summary: Foot pump versus no prophylaxis**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with No prophylaxis	Risk difference with Foot pump (95% CI)
DVT (symptomatic and asymptomatic)	60 (1 study) 10 days	MODERATE ¹ due to risk of bias	RR 0.3 (0.13 to 0.7)	594 per 1000	416 fewer per 1000 (from 178 fewer to 517 fewer)
PE	60 (1 study) time-point not reported	VERY LOW ^{1,3,4} due to risk of bias, indirectness, imprecision	Not estimable ²	Not estimable ²	0 fewer per 1000 (from 60 fewer to 60 more) ²
<p>1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p> <p>2 Zero events in both arms. Risk difference calculated in Review Manager.</p> <p>3 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol</p> <p>4 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.</p>					

2 **Table 115: Clinical evidence summary: AES versus no prophylaxis**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with No prophylaxis	Risk difference with AES (95% CI)
DVT (symptomatic and asymptomatic)	220 (1 study) 30 days	LOW ^{1,2} due to risk of bias, imprecision	RR 0.58 (0.32 to 1.07)	218 per 1000	92 fewer per 1000 (from 148 fewer to 15 more)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with No prophylaxis	Risk difference with AES (95% CI)
PE	220 (1 study) 30 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 1.00 (0.06 to 16.09)	9 per 1000	0 fewer per 1000 (from 9 fewer to 120 more)
Major bleeding	220 (1 study) time-point not reported	VERY LOW ^{1,2,4} due to risk of bias, indirectness imprecision	Not estimable ³	Not estimable ³	0 fewer per 1000 (from 20 fewer to 20 more) ³
Technical complications of mechanical interventions	220 (1 study) time-point not reported	VERY LOW ^{1,2,4} due to risk of bias, indirectness imprecision	Not estimable ³	Not estimable ³	0 fewer per 1000 (from 20 fewer to 20 more) ³
Wound infection	220 (1 study) 30 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 1.00 (0.14 to 6.97)	18 per 1000	0 fewer per 1000 (from 16 fewer to 96 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.
3 Zero events in both arms. Risk difference calculated in Review Manager.
4 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol

1 Table 116: Clinical evidence summary: IPCD versus no prophylaxis

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with No prophylaxis	Risk difference with IPCD (95% CI)
DVT (symptomatic and asymptomatic)	220 (1 study) 7 days	LOW ^{1,2} due to risk of bias, imprecision	RR 0.38 (0.18 to 0.77)	218 per 1000	135 fewer per 1000 (from 50 fewer to 179 fewer)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with No prophylaxis	Risk difference with IPCD (95% CI)
PE	220 (1 study) 30 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.14 (0.00 to 6.82)	9 per 1000	8 fewer per 1000 (from 9 fewer to 50 more)
Major bleeding	220 (1 study) time-point not reported	VERY LOW ^{1,2,4} due to risk of bias, indirectness imprecision	Not estimable ³	Not estimable ³	0 fewer per 1000 (from 20 fewer to 20 more) ³
Technical complications of mechanical interventions	220 (1 study) time-point not reported	VERY LOW ^{1,2,4} due to risk of bias, indirectness imprecision	Not estimable ³	Not estimable ³	0 fewer per 1000 (from 20 fewer to 20 more) ³
Wound infection	220 (1 study) 30 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.51 (0.14 to 6.97)	18 per 1000	9 fewer per 1000 (from 17 fewer to 66 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.
3 Zero events in both arms. Risk difference calculated in Review Manager.
4 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol

1 Table 117: Clinical evidence summary: IPCD versus AES

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with AES	Risk difference with IPCD (95% CI)
DVT (symptomatic and asymptomatic)	220 (1 study) 30 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 0.64 (0.29 to 1.42)	127 per 1000	46 fewer per 1000 (from 90 fewer to 53 more)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with AES	Risk difference with IPCD (95% CI)
PE	220 (1 study) 30 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.14 (0.00 to 6.82)	9 per 1000	8 fewer per 1000 (from 9 fewer to 50 more)
Major bleeding	220 (1 study) time-point not reported	VERY LOW ^{1,2,4} due to risk of bias, indirectness imprecision	Not estimable ³	Not estimable ³	0 fewer per 1000 (from 20 fewer to 20 more) ³
Technical complications of mechanical interventions	220 (1 study) time-point not reported	VERY LOW ^{1,2,4} due to risk of bias, indirectness imprecision	Not estimable ³	Not estimable ³	0 fewer per 1000 (from 20 fewer to 20 more) ³
Wound infection	220 (1 study) 30 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.51 (0.05 to 4.96)	18 per 1000	9 fewer per 1000 (from 17 fewer to 66 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.
3 Zero events in both arms. Risk difference calculated in Review Manager.
4 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol

1 Table 118: Clinical evidence summary: CPM versus no prophylaxis

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with No prophylaxis	Risk difference with CPM (95% CI)
DVT (symptomatic and asymptomatic)	65 (1 study) 90 days	VERY LOW ^{2,3,4} due to risk of bias, indirectness, imprecision	Not estimable ¹	Not estimable ¹	0 fewer per 1000 (from 60 fewer to 60 more) ¹

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with No prophylaxis	Risk difference with CPM (95% CI)
1 Zero events in both arms. Risk difference calculated in Review Manager.					
2 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias					
3 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol					
4 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.					

1

2

27.4.1 Economic evidence

2 Published literature

3 Thirty economic studies, in 32 publications, relating to this review question were identified but were
4 excluded due limited applicability, methodological limitations, a combination of limited applicability
5 and methodological limitations or the availability of more applicable evidence.^{10,32,33,39,47,75,79,80,117}
6 ,119,126,128,197,207,208,214,224,226,228-230,246,253-255,259,281,282,305,320,321,329 Of these, 10 publications were
7 previously included in CG46.^{10,32,33,68,70,79,119,126,197,253} They also included 3 NICE TAs, 2 evidence
8 review group [ERG] reports and the CG92 model for standard duration and post discharge
9 prophylaxis. All excluded studies are listed in Appendix O, with reasons for exclusion given.

10 See also the health economic study selection flow chart in Appendix F.

11 New cost-effectiveness analysis

12 The guideline committee considered the available evidence of cost effectiveness of prophylaxis
13 strategies for people admitted for elective knee replacement (eTKR). The original guideline (CG92)
14 model was considered but it was felt that it required updating given the availability of more recent
15 trial data and the exclusion of the some of the older studies that were included in the CG92 NMAs
16 from the current updated NMAs. The original model also included some interventions that are not
17 routinely used in current practice including high doses of aspirin, VKA and UFH. The guideline
18 committee also discussed that since the publication of CG92, three TAs covering the use of DOACs in
19 this population have also been published the latest in 2012.²²⁸⁻²³⁰ It was felt that it would be more
20 convenient for clinicians to be able to consult a single source for recommendation regarding the
21 most cost- effective prophylaxis strategy for this population. This would also help in standardising
22 current practice. Moreover, as the size of the population covered by this review question is very
23 large; which means that changes to more costly prophylaxis options would lead to substantial
24 resource implications, the guideline committee agreed that this question should be prioritised for
25 economic modelling. Hence, the original economic model presented here sought to address the
26 question about the cost-effectiveness of different VTE prophylaxis strategies (alone or in
27 combination) in people admitted for eTKR. A summary of the analysis is presented below and a full
28 description can be found in Appendix P in the full guideline.

29 Model overview

30 A cost-utility analysis was undertaken in Microsoft Excel® where costs and quality-adjusted life years
31 (QALYs) were considered from a UK NHS and personal social services (PSS) perspective. A Markov
32 model was constructed in order to estimate the costs and QALYs associated with different VTE
33 prophylaxis strategies. Both costs and QALYs were discounted at a rate of 3.5% per annum in line
34 with NICE methodological guidance²³¹ Uncertainty was explored through probabilistic and sensitivity
35 analyses. The time horizon considered was lifetime.

36 Population

37 The population entering the model are adults who are admitted to hospital for an eTKR. The cohort
38 characteristics were based on the data reported in the National Joint Registry 13th annual report;³⁶
39 which represented data collected up to December 2015 in England, Wales, Northern Ireland and the
40 Isle of Man. The mean age of this population was 69.3 years and 44% were male.

41 Comparators

1 Thirteen prophylaxis strategies were selected for inclusion based on the availability of evidence from
2 the clinical review, direct and network meta-analyses (N)MAs and discussion with the guideline
3 committee around which regimens are considered to be relevant to current clinical practice in the
4 UK. These were:

- 5 1. LMWH (std,std) + AEs
- 6 2. Fondaparinux+ AES
- 7 3. Foot pump + AES
- 8 4. IPCD
- 9 5. Foot pump
- 10 6. AES
- 11 7. LMWH (std,std)
- 12 8. LMWH (std,extd)
- 13 9. Aspirin
- 14 10. Dabigatran
- 15 11. Apixaban
- 16 12. Rivaroxaban
- 17 13. No prophylaxis

18 **Model structure**

19 The model consists of a simple decision tree covering the acute phase from admission up to 90 days
20 post-operatively, to cover the period included in the definition of hospital-acquired VTE, followed by
21 a Markov chain for the remaining model time horizon. The structure is repeated for each prophylaxis
22 strategy.

23 The acute phase of the model is represented by a decision tree consisting of the primary clinical
24 events: DVT (symptomatic proximal, symptomatic distal, asymptomatic proximal and asymptomatic
25 distal), non-fatal PE, fatal PE, Surgical site bleeding, non-surgical site bleeding (gastrointestinal (GI)
26 bleeding, intracranial haemorrhage (ICH)/haemorrhagic stroke, other major bleeding), fatal major
27 bleeding (MB), clinically-relevant non-major bleeding (CRNMB) and heparin-induced
28 thrombocytopenia (HIT). The structure of the decision tree is presented in Figure 4.

29

30 The long-term part is represented by a Markov cohort model. Individuals enter the model in one of
31 the following states; based on where they end up at the end of the 90 days post-operatively: Well,
32 post-symptomatic proximal DVT, post-symptomatic distal DVT, post-asymptomatic proximal DVT,
33 post-asymptomatic distal DVT, post-PE, amputated post-HIT, disabled post-stroke, post-revision for
34 infection. In the first two years, individuals in a post-VTE state can develop post-thrombotic
35 syndrome (PTS). Those in the post-PE state can also develop chronic thromboembolic pulmonary
36 hypertension (CTEPH). Transitioning to death is allowed from any state in the model, to represent all-
37 cause mortality. The structure of the Markov cohort model is illustrated in Figure 5.

38

39 **Model inputs**

40 The relative effects of treatments on the baseline transition probabilities were derived from clinical
41 evidence identified in the systematic review undertaken for the guideline, the results of the NMA
42 and supplemented by additional data sources as required. Health utility data were obtained from the
43 literature. Cost inputs were obtained from recognized national sources such as the drug tariff, NHS
44 reference costs and Personal Social Services Research Unit (PSSRU) publications. All inputs and
45 assumptions made were validated by the guideline committee.

46

47 **Sensitivity analysis**

48 A probabilistic analysis was carried out whereby distributions were assigned to model inputs in order
49 to account for the uncertainty around the point estimates of these inputs and capture the effect of
50 this uncertainty on model outputs. Additionally, a number of one-way sensitivity analyses were
51 conducted whereby, for each analysis one key model input was changed in order to explore the
52 sensitivity of model results to changes in that parameter (Table 119).

1 **Table 119: One-way sensitivity analyses**


	description	Base case input value	Alternative value for sensitivity analysis
SA1	Cost effectiveness threshold	£20,000	£30,000
SA2	Discount rate for costs and QALYs	3.5%	1.5%
SA3	Prophylaxis duration	Based on the RCTs included in the DVT NMA	based on summary of product characteristics (SmPC)
SA4	Cohort starting age	eTKR: 69.3 years (a)	40 years
SA5	Cohort body weight	NJR cohort mean body weight(a)	Cohort body weight distribution calculated based on the NJR cohort BMI distribution (a) and average height for a UK male (1.75m) and female (1.62 m) (b)
SA6	All costs +10%	See Appendix P	Costs increased by 10%
SA7	All costs -10%	See Appendix P	Costs decreased by 10%
SA8	Timing of VTE and MB events	Based on committee expert opinion	Based on data from Warwick 2007 ³⁰⁸
SA9	Risk of VTE recurrence after :	Assumption based on committee opinion	Calculated based on data from TA245 manufacturer submissions
	Treated DVT	0%	2.74%
	PE	0%	0.26%
SA10	Costs of pharmacological prophylaxis	Calculated assuming no wastage	Calculated taking possible wastage into account

2 Abbreviations: eTKR: elective total knee replacement; NMA: network meta-analysis; SA: sensitivity analysis

3 (a) Source: National Joint Registry³⁶


4 (b) Source: ONS²³⁷

Figure 4: Model structure up to 90 days post-operatively (Decision tree part)



Abbreviations: Asympt: asymptomatic; Dist: distal; DVT: Deep vein thrombosis; GI: gastrointestinal; HIT: heparin-induced thrombocytopenia; ICH: intracranial haemorrhage; MB: major bleeding; PE: pulmonary embolism; Prox: proximal; RTT: return to theatre; SSB: surgical site bleeding, SSI: surgical site infection; Sympt: symptomatic

Figure 5: Model structure after 90 days post-operatively (Markov model part)



Abbreviations: Asympt: asymptomatic; CTEPH: chronic thrombo-embolic pulmonary hypertension; DVT: Deep vein thrombosis; HIT: heparin-induced thrombocytopenia; PE: pulmonary embolism; Prox: proximal; PTS: post-thrombotic syndrome; Sympt: symptomatic

1

2

1 **Results**

2 **Base case**

3 The results of the base case analysis are presented in Table 120 and Figure 6. These show that the
4 most effective intervention in terms of QALYs- gained is foot pump, with mean discounted QALYs per
5 patient of 9.814 (95% CI: 7.86 to 11.58) over life-time time horizon followed by aspirin, with mean
6 discounted QALYs per patient of 9.809 (95% CI: 7.86 to 11.58) and LMWH (standard dose, standard
7 duration)+AES with a mean of 9.807 (95% CI: 7.86 to 11.58) over life-time time horizon. The least
8 effective was dabigatran; with 9.71 QALYs (95% CI: 7.53 to 11.56). Aspirin had the lowest mean total
9 cost of £187 (95% CI: £118 to £304) followed by foot pump with a mean total cost of £219 (95% CI:
10 £119 to £473) and rivaroxaban with a mean total cost of £256 (95% CI: £82 to £1,205). The highest
11 mean total cost was seen for fondaparinux + AES; with mean total cost of £904 (95% CI: £358 to
12 £3,016).

13

14 The incremental net monetary benefit (INMB) vs the comparator (LMWH [standard, dose, standard
15 duration]+ AES) was calculated at a cost-effectiveness threshold of £20,000 per QALY gained. Based
16 on the INMB, the most cost-effective strategy (the one with the highest INMB) was found to be foot
17 pump; with mean INMB of £353 (95% CI: -£101 to £665); however, the probability of being the most
18 cost-effective was only 18%. It was followed by aspirin, with mean INMB of £281
19 (95% CI: -£195 to £703), then foot pump + AES (mean INMB £72 [95% CI: -£379 to £343]).

20

21 The full ranking based on the mean INMB of each strategy; together with the 95% confidence
22 intervals, is presented in Table 120. This shows that there is considerable uncertainty in relation to
23 the ranking of these interventions; with wide and overlapping 95% CIs. Based on the mean rank; all
24 interventions except dabigatran were more cost-effective than no prophylaxis. Foot pump and IPCD
25 were more cost-effective compared to AES in this population.

26

27 Of the DOACs included in the model; rivaroxaban dominated both apixaban and dabigatran.
28 However, the model comparator (LMWH [standard dose, standard duration]+AES) was more cost-
29 effective compared to rivaroxaban (ICER: £7,686).

30

31 **Sensitivity analysis**

32 In all the SAs undertaken, the most cost effective option (foot pump) and the ranking of all
33 interventions remained largely the same.

34

35

1 Table 120: Probabilistic base case analysis results for elective total knee replacement (eTKR) population


Intervention	Mean discounted QALYs (95% CI)	Mean Discounted Costs (95% CI)	Incremental QALYs vs LMWH+ AEs (95% CI)	Incremental costs vs LMWH+ AEs (95% CI)	Mean INMB at £20K (95% CI)	Probability most CE option (95% CI)	Rank (95% CI)
LMWH (std,std) + AEs	9.81 (7.86 to 11.58)	£448 (£364 to £613)	0.000 (0.000 to 0.000)	£0 (£0 to £0)	£0 (£0 to £0)	0.1%	4 (4, 12)
Fondaparinux+ AEs	9.75 (7.83 to 11.52)	£904 (£358 to £3016)	-0.054 (-0.183 to -0.009)	£457 (-£53 to £2466)	-£1,532 (-£6,183 to -£176)	0.0%	11 (6, 13)
Foot pump + AEs	9.80 (7.86 to 11.58)	£315 (£208 to £590)	-0.003 (-0.020 to 0.006)	-£132 (-£234 to £32)	£72 (-£379 to £343)	0.1%	3 (3, 12)
IPCD	9.78 (7.82 to 11.56)	£332 (£133 to £1246)	-0.029 (-0.367 to 0.019)	-£115 (-£304 to £698)	-£473 (-£8,223 to £635)	5.8%	7 (1, 13)
Foot pump	9.81 (7.86 to 11.58)	£219 (£119 to £473)	0.006 (-0.011 to 0.018)	-£228 (-£332 to -£65)	£353 (-£101 to £665)	18.1%	1 (1, 10)
AEs	9.76 (7.77 to 11.57)	£387 (£167 to £1397)	-0.043 (-0.420 to 0.014)	-£60 (-£271 to £876)	-£803 (-£9,251 to £520)	0.2%	9 (3, 13)
LMWH (std,std)	9.77 (7.79 to 11.55)	£468 (£287 to £1563)	-0.035 (-0.441 to 0.018)	£21 (-£105 to £989)	-£728 (-£10,057 to £445)	0.0%	8 (4, 11)
LMWH (std,extd)	9.80 (7.85 to 11.58)	£666 (£508 to £1302)	-0.009 (-0.111 to 0.023)	£218 (£34 to £832)	-£398 (-£3,013 to £397)	0.1%	6 (3, 12)
Aspirin	9.81 (7.86 to 11.58)	£187 (£118 to £304)	0.001 (-0.018 to 0.014)	-£260 (-£436 to -£125)	£281 (-£195 to £703)	9.0%	2 (1, 12)
Dabigatran	9.71 (7.53 to 11.56)	£406 (£100 to £2987)	-0.101 (-1.308 to 0.020)	-£42 (-£343 to £2524)	-£1,977 (-£28,720 to £707)	3.6%	13 (1, 13)
Apixaban	9.73 (7.62 to 11.54)	£322 (£69 to £2624)	-0.081 (-1.178 to 0.023)	-£125 (-£392 to £2166)	-£1,504 (-£25,838 to £802)	42.8%	10 (1, 13)
Rivaroxaban	9.78 (7.79 to 11.57)	£256 (£82 to £1205)	-0.025 (-0.333 to 0.021)	-£191 (-£360 to £634)	-£306 (-£6,975 to £747)	19.7%	5 (1, 11)
No prophylaxis	9.73 (7.68 to 11.53)	£453 (£137 to £2281)	-0.082 (-0.894 to 0.014)	£6 (-£298 to £1,715)	-£1,655 (-£20,058 to £540)	0.4%	12 (3, 13)

2 Abbreviations: AEs: anti-embolism stockings; CE: cost effective; CI: confidence interval; eTKR: elective total knee replacement; extd: extended; IPCD: intermittent pneumatic compression

3 devices; INMB: incremental net monetary benefit; LMWH: low molecular weight heparin; QALYs: quality-adjusted life-years; std: standard

1

Figure 6: Incremental analysis (vs LMWH (std,std)+ AES) results presented on the cost effectiveness plane



Abbreviations: AES: anti-embolism stockings; CE: cost-effective; CI: confidence interval; eTKR: elective total knee replacement; extd: extended; INMB: incremental net monetary benefit; IPCD: intermittent pneumatic compression device; LMWH: low molecular weight heparin; std: standard; QALYs: quality-adjusted life-years.

2

1 **Discussion**

2 **Interpretation and limitations**

3 The results of this analysis reflect the very large uncertainty seen in the eTKR NMAs and in particular
4 the uncertainty in the PE NMA which appeared to be driving the results of the economic model. This
5 has been reflected in the very small differences in QALYs gained, the very wide 95% CIs around the
6 ranks and the fact that the optimal intervention (foot pump) only had 16% probability of being the
7 most cost-effective option. On average, however, the results seem to support the conclusion that
8 VTE prophylaxis is cost-effective compared to no prophylaxis. However, the choice of a prophylaxis
9 strategy is not clear cut. This is likely to be the result of the uncertainty around the relative
10 effectiveness estimates for the different strategies.

11
12 Nevertheless, based on the results of this economic model; low intensity and lower cost strategies
13 appeared to be more cost-effective for individuals undergoing eTKR, which might be the result of the
14 lower risk of symptomatic DVT and PE in this population compared to the eTHR population. This has
15 been reflected in the most cost-effective options being foot pump, aspirin and a combination of foot
16 pump and AEs. Of the DOACs included in the model; rivaroxaban dominated both apixaban and
17 dabigatran. This was in line with the results of the economic models assessed as part of TA170 and
18 TA245 and a more recent analysis funded by the NIHR.^{229,230,281} Of the mechanical prophylaxis
19 options considered in the analysis, foot pumps and IPCD were more cost-effective compared to AES.
20 This supported the clinical experience that AES are not a practical option in this population.

21
22 Similar to the eTHR population, the model was an update of the CG92 model; so we attempted to
23 address the limitations of that model which were highlighted by the orthopaedic surgeons'
24 community in a number of publications. One limitation was the use of relative effectiveness from the
25 DVT NMA for the PE outcomes; where we used the PE NMA for all the interventions for which PE
26 data were available to avoid making this assumption unless absolutely necessary; where the strategy
27 was not included in the PE network. However, we have verified this assumption with the guideline
28 committee and externally validated it using the observational data analysis that used NJR data;¹⁵²
29 where the ratio of the relative effectiveness of LMWH vs aspirin for the DVT outcome was found to
30 be approximately the same as for the PE outcome.

31
32 Another issue was the lack of differentiation between proximal and distal DVT. We have addressed
33 this issue by differentiating between the proximal and distal DVT for both symptomatic and
34 asymptomatic events. We also allowed for different probabilities of progressing from each of these
35 DVT events to PTS; to acknowledge the fact that progression from treated and untreated DVT to PTS
36 would be different. We emphasised the fact that asymptomatic DVT also does not have an impact on
37 costs and outcomes in the short term as it is not diagnosed in practice and its only consequence in
38 the model is its future progression to PTS.

39
40 There was also a concern regarding the baseline risk used in the model which was based on data
41 from the "no prophylaxis" arm in the RCTs. This was not felt to be reflective of current incidence of
42 VTE with some trials dating back to the 70s, especially as practice has changed in terms of
43 encouraging early mobilisation as well as the difference in surgical techniques. Based on this, we
44 have used a strategy consisting of LMWH (standard dose, standard duration)+AES as our model
45 comparator and obtained its baseline risk data from observational cohort studies that used the UK
46 NJR data (see model write-up Appendix P).¹⁵²

47
48 However, this updated model may have some limitations. Due to lack of data on either DVT or PE
49 outcomes for some strategies, an assumption still had to be made about the equivalence of relative
50 effectiveness on the DVT and PE outcomes for these strategies. However, we have limited this only
51 to instances where data was available for one of these outcomes but not for the other. This

1 assumption may have affected the results. The relative effectiveness of foot pump, aspirin and foot
2 pump + AES in relation to the PE outcome was assumed to be the same as their relative effectiveness
3 obtained from the DVT NMA. This has resulted in a much lower PE rate for these interventions
4 compared to all the others.

5

6 Another limitation of this analysis is that the relative safety of aspirin compared to LMWH was based
7 on an observational cohort analysis based on NJR data.¹⁵² This was due to the lack of any
8 randomised controlled trials that report major bleeding outcomes for aspirin in these populations.
9 However, as the data for MB from trials are likely to be imprecisely estimated, due to the rarity of
10 these events; it was felt that the use of observational data would be appropriate.

11

12 **Generalisability to other populations/settings**

13 This analysis has been undertaken from a UK NHS and PSS perspective; hence its results might not be
14 generalisable beyond these settings. The population modelled also represents a cohort whose
15 characteristics might be different from eTKR cohorts in other settings.

16

17 **Conclusions**

18 In people undergoing elective total knee replacement (eTKR), VTE prophylaxis appears to be cost-
19 effective compared to no prophylaxis. Foot pump was found to be the most cost-effective option in
20 this population. This result was robust to changes in the model input parameters. LMWH-based
21 strategies that use standard duration are more cost-effective compared to extended duration
22 LMWH. Rivaroxaban was found to be the most cost-effective of the DOACs considered in this
23 analysis. These results, however, are subject to high uncertainty given the imprecise effectiveness
24 results from the NMAs that underpinned this analysis.

27.5 1 Evidence statements

2 Clinical

3 Pairwise meta-analysis statements

4 Pharmacological interventions versus pharmacological interventions

5

6 *LMWH (standard dose; standard duration)*

7

8 LMWH at a standard dose for a standard duration was compared with no prophylaxis, the outcomes
9 DVT (symptomatic and asymptomatic), PE, major bleeding, wound haematoma, technical
10 complications of mechanical interventions (examples given were skin rash, swelling above the
11 appliance, pressure necrosis of the skin and peroneal nerve palsy) and wound infection were
12 reported in one study. Moderate quality evidence showed clinical benefit of LMWH in terms of DVT
13 (symptomatic and asymptomatic). Very low quality evidence suggested possible clinical benefit of
14 LMWH in terms of PE and wound infection; however the uncertainty around this result was also
15 consistent with both no difference or clinical harm. There was possible clinical harm of LMWH in
16 terms of wound haematoma and no clinical difference in terms of major bleeding and technical
17 complications of mechanical interventions, however there was also considerable uncertainty around
18 these results. The quality of the evidence ranged from very low to moderate due to risk of bias,
19 imprecision, indirectness and inconsistency.

20 LMWH at a standard dose for a standard duration was compared with apixaban, the outcomes all-
21 cause mortality, DVT (symptomatic and asymptomatic), PE, major bleeding, fatal PE, clinically
22 relevant non-major bleeding and wound haematoma were reported in one study. There was possible
23 clinical benefit of LMWH in terms of all-cause mortality, PE, fatal PE and wound haematoma.
24 However the uncertainty around these results also related to no difference and clinical harm.
25 Moderate quality evidence showed clinical harm of LMWH in terms of DVT (symptomatic and
26 asymptomatic). There was possible clinical harm of LMWH in terms of major bleeding and clinically
27 relevant non-major bleeding, although these outcomes also had serious uncertainty. The quality of
28 the evidence ranged from very low to moderate due to risk of bias and imprecision.

29 LMWH at a standard dose for a standard duration was compared with dabigatran, the outcomes all-
30 cause mortality, DVT (symptomatic and asymptomatic), PE, major bleeding, fatal PE and clinically
31 relevant non-major bleeding were reported across two studies. High quality, precise evidence
32 showed no clinical difference between LMWH and dabigatran for DVT. There was a suggestion of
33 clinical harm of LMWH in terms of fatal PE and no clinical difference in terms of all-cause mortality,
34 PE, major bleeding and clinically relevant non-major bleeding, although all of these results were
35 associated with considerable uncertainty. The quality of the evidence ranged from low to high due to
36 imprecision. The outcome with evidence of high quality of was DVT (symptomatic and
37 asymptomatic).

38 LMWH at a standard dose for a standard duration was compared with rivaroxaban, the outcomes all-
39 cause mortality, DVT (symptomatic and asymptomatic), PE, major bleeding, clinically relevant non-
40 major bleeding and wound infection were reported across two studies. There was clinical harm of
41 LMWH in terms of DVT (symptomatic and asymptomatic). There was, possible clinical harm of LMWH
42 in terms of all-cause mortality, PE and wound infection, although these findings could also have been
43 consistent with no difference. There was no clinical difference in terms of major bleeding and
44 clinically relevant non-major bleeding, however the uncertainty around the bleeding results were
45 also consistent with both benefit and harm. The quality of the evidence ranged from very low to
46 moderate due to risk of bias and imprecision.

47

- 1 LMWH at a standard dose for a standard duration was compared with aspirin, the outcomes DVT
2 (symptomatic and asymptomatic) and PE were reported in one study. There was no clinical
3 difference between the two interventions for both of the outcomes reported, although there was
4 very serious imprecision around both results. The quality of the evidence was very low due to risk of
5 bias, imprecision and indirectness.
- 6 LMWH at a standard dose for a standard duration was compared with UFH, the outcome wound
7 haematoma was reported in one study. There was possible clinical benefit of LMWH in terms of this
8 outcome of wound haematoma, however the uncertainty around this result was also consistent with
9 no difference and clinical harm. The quality of the evidence was very low due to risk of bias and
10 imprecision.
- 11 LMWH at a standard dose for a standard duration was compared with LMWH at a low dose for a
12 standard duration, the outcome major bleeding was reported in one study. There was possible
13 clinical harm of LMWH at a standard dose in regards to this outcome, however there was very
14 serious uncertainty around the result. The quality of the evidence of the evidence was very low due
15 to risk of bias and imprecision.
- 16
- 17 *LMWH (standard dose; extended duration)*
- 18
- 19 LMWH at a standard dose for an extended duration was compared with LMWH at a standard dose
20 for a standard duration, the outcomes DVT (symptomatic and asymptomatic), PE, major bleeding and
21 heparin-induced thrombocytopenia were reported in one study. There was possible clinical benefit of
22 LMWH for an extended duration in terms of PE and major bleeding. There was no clinical difference
23 in terms of DVT (symptomatic and asymptomatic) and heparin-induced thrombocytopenia. However
24 for all four outcomes the results were considerably uncertain and could be associated with harm, no
25 difference and benefit. The quality of the evidence was low due to imprecision.
- 26
- 27 *LMWH (low dose; standard duration)*
- 28
- 29 LMWH at a low dose for a standard duration was compared with no prophylaxis, the outcome was
30 major bleeding was reported in one study. There was possible clinical harm of LMWH in terms of
31 major bleeding, however this result was uncertain and could also be consistent with no difference.
32 The quality of evidence was very low due to risk of bias and imprecision.
- 33
- 34 *LMWH (high dose; standard duration)*
- 35
- 36 LMWH at a high dose for a standard duration was compared with no prophylaxis, the outcomes all-
37 cause mortality, DVT (symptomatic and asymptomatic) and major bleeding were reported in one
38 study. High quality evidence showed clinical benefit of LMWH in terms of DVT (symptomatic and
39 asymptomatic). Low quality evidence suggested possible clinical benefit of LMWH in terms of major
40 bleeding and no clinical difference in terms of all-cause mortality, however there was uncertainty
41 around both of these results. The quality of evidence ranged from low to high due to imprecision.
- 42 LMWH at a high dose for a standard duration was compared with UFH, the outcomes DVT
43 (symptomatic and asymptomatic), PE and major bleeding were reported in one study. There was
44 possible clinical benefit of LMWH in terms of DVT (symptomatic and asymptomatic) and PE. There
45 was no clinical difference in terms of major bleeding. However all three of these outcomes were
46 associated with a high level of uncertainty. The quality of the evidence ranged from very low to low
47 due to risk of bias, indirectness and imprecision.
- 48 LMWH at a high dose for a standard duration was compared with VKA, the outcomes all-cause
49 mortality, DVT (symptomatic and asymptomatic), PE, major bleeding, fatal PE, wound haematoma

1 and wound infection were reported across three studies. There was possible clinical benefit of
2 LMWH in terms of all-cause mortality, DVT (symptomatic and asymptomatic), major bleeding and
3 wound infection, although these results were uncertain. There was no clinical difference in terms of
4 PE, fatal PE and wound haematoma, however these results were also uncertain. The quality of
5 evidence ranged from very low to moderate due to risk of bias and imprecision.

6 LMWH at a high dose for a standard duration was compared with fondaparinux, the outcome major
7 bleeding was reported in one study. Low quality, precise evidence showed clinical benefit of LMWH
8 in terms of this outcome. The quality of the evidence was low due to risk of bias and indirectness.

9 LMWH at a high dose for a standard duration was compared with apixaban, the outcomes all-cause
10 mortality, DVT (symptomatic and asymptomatic), PE, major bleeding, fatal PE, clinically relevant non-
11 major bleeding and wound infection were reported across two studies. There was possible clinical
12 benefit of LMWH in terms of fatal PE and wound infection. There was possible clinical harm of LMWH
13 in terms of all-cause mortality, major bleeding and clinically relevant non-major bleeding. There was
14 no clinical difference in terms of DVT (symptomatic and asymptomatic) and PE. There was
15 considerable uncertainty around all of the outcomes for this comparison. The quality of the evidence
16 ranged from low to moderate due to imprecision and inconsistency.

17 LMWH at a high dose for a standard duration was compared with dabigatran, the outcomes all-cause
18 mortality, DVT (symptomatic and asymptomatic), PE, major bleeding and clinically relevant non-
19 major bleeding were reported in one study. There was possible clinical benefit of LMWH in terms of
20 all-cause mortality, possible clinical harm in terms of major bleeding and no clinical difference in
21 terms of major bleeding and PE. There was considerable uncertainty around all of the outcomes for
22 this comparison. The quality of evidence ranged from very low to moderate due to risk of bias and
23 imprecision.

24 LMWH at a high dose for a standard duration was compared with rivaroxaban, the outcomes all-
25 cause mortality, DVT (symptomatic and asymptomatic), PE, major bleeding, clinically relevant non-
26 major bleeding and wound infection were reported in one study. There was possible clinical benefit
27 of LMWH in terms of all-cause mortality and major bleeding. There was possible clinical harm of
28 LMWH in terms of DVT (symptomatic and asymptomatic) and PE. There was no clinical difference in
29 terms of clinically relevant non-major bleeding and wound infection. There was considerable
30 uncertainty around all of the outcomes for this comparison. The quality of evidence ranged from very
31 low to moderate due to risk of bias and imprecision.

32

33 *Fondaparinux*

34

35 Fondaparinux was compared with no prophylaxis, the outcome major bleeding was reported in one
36 study. There was no clinical difference for this outcome; however the quality of the evidence was
37 very low due to risk of bias and very serious imprecision around the effect estimate, meaning the
38 result could also be consistent with clinical benefit or harm.

39

40 *Apixaban*

41

42 Apixaban was compared with VKA, the outcomes all-cause mortality, DVT (symptomatic and
43 asymptomatic), PE, major bleeding, fatal PE and wound infection were reported one study. Moderate
44 quality evidence showed clinical benefit of apixaban in terms of DVT (symptomatic and
45 asymptomatic). There was possible clinical harm of apixaban in terms of all-cause mortality, major
46 bleeding and fatal PE, however these results may also be consistent with no difference and clinical
47 benefit as they were so uncertain. There was no clinical difference in terms of PE and wound
48 infection. These results were similarly uncertain. The quality of the evidence ranged from very low to
49 moderate due to risk of bias and imprecision.

50

1 *Dabigatran*

2

3 Dabigatran was compared with no prophylaxis, the outcomes all-cause mortality, DVT (symptomatic
4 and asymptomatic), PE, major bleeding and clinically relevant non-major bleeding were reported in
5 one study. Moderate quality, precise evidence showed clinical benefit of dabigatran in terms of DVT
6 (symptomatic and asymptomatic). Low quality evidence suggested possible clinical benefit of
7 dabigatran in terms of clinically relevant non-major bleeding, possible clinical harm of dabigatran in
8 terms of major bleeding, and no clinical difference in terms of all-cause mortality and PE. There was
9 considerable uncertainty around these results. The quality of evidence ranged from low to moderate
10 due to risk of bias and imprecision.

11

12 *Rivaroxaban*

13

14 Rivaroxaban was compared with aspirin, the outcomes DVT (symptomatic and asymptomatic) and PE
15 were reported in one study. High quality evidence showed clinical benefit of rivaroxaban in terms of
16 DVT (symptomatic and asymptomatic). Very low quality evidence suggested no clinical difference in
17 terms of PE, however this was uncertain. The quality of the evidence ranged from very low to high
18 due to risk of bias, indirectness and imprecision. The outcome with evidence of high quality was DVT
19 (symptomatic and asymptomatic).

20

21 **Pharmacological interventions versus mechanical interventions**

22

23 LMWH at a standard dose for a standard duration was compared with AES, the outcomes DVT
24 (symptomatic and asymptomatic), PE, technical complications of mechanical interventions (examples
25 given were skin rash, swelling above the appliance, pressure necrosis of the skin and peroneal nerve
26 palsy) and wound infection in one study. There was possible clinical benefit of LMWH in terms of DVT
27 (symptomatic and asymptomatic), PE and wound infection. There was no clinical difference in terms
28 of technical complications of the mechanical intervention. The evidence for all four of these
29 outcomes exhibited considerable uncertainty. The quality of the evidence ranged from very low to
30 low due to risk of bias, indirectness and imprecision.

31 LMWH at a standard dose for a standard duration was compared with IPCD, the outcomes DVT
32 (symptomatic and asymptomatic), PE, technical complications of mechanical interventions (examples
33 given were skin rash, swelling above the appliance, pressure necrosis of the skin and peroneal nerve
34 palsy) and wound infection in one study. There was possible clinical benefit of LMWH in terms of DVT
35 (symptomatic and asymptomatic) and wound infection. There was no clinical difference in terms of
36 PE and technical complications of the mechanical intervention. The evidence for all four of these
37 outcomes exhibited considerable uncertainty. The quality of the evidence ranged from very low to
38 low due to risk of bias, indirectness and imprecision.

39

40 **Combination interventions versus single interventions**

41

42 LMWH at a standard dose for a standard duration was compared with foot pump in combination
43 with AES, the outcomes DVT (symptomatic and asymptomatic) and fatal PE were reported in one
44 study. There was possible clinical benefit of LMWH for both outcomes, however the DVT outcome
45 was also consistent with no difference, and the fatal PE outcome with both no difference and clinical
46 harm. The quality of the evidence ranged from very low to low due to risk of bias, indirectness and
47 imprecision.

48 LMWH at a standard dose for a standard duration in combination with AES was compared with AES,
49 the outcomes DVT (symptomatic and asymptomatic) and PE were reported in one study. There was

1 possible clinical benefit of LMWH in combination with AES in terms of DVT (symptomatic and
2 asymptomatic) and no clinical difference in terms of PE, however there was uncertainty associated
3 with both of these results. The quality of the evidence ranged from very low to low due to risk of bias
4 and imprecision.

5 LMWH at a standard dose for a standard duration in combination with CPM was compared with
6 CPM, the outcomes DVT (symptomatic and asymptomatic), PE and major bleeding were reported in
7 one study. There was possible clinical benefit in terms of DVT (symptomatic and asymptomatic).
8 There was no clinical difference in terms of PE and major bleeding. All three outcomes has
9 considerable uncertainty associated with them. The quality of the evidence ranged from very low to
10 low due to risk of bias, indirectness and imprecision.

11 LMWH at a low dose for a standard duration in combination with AES was compared with AES, the
12 outcomes DVT (symptomatic and asymptomatic) and PE were reported in one study. There was
13 possible clinical benefit of LMWH in combination with AES in terms of DVT (symptomatic and
14 asymptomatic), although this finding was also consistent with no difference. And no clinical
15 difference was suggested in terms of PE, although this finding was very uncertain and could also be
16 consistent with benefit and harm. The quality of the evidence ranged from very low to low due to
17 risk of bias and imprecision.

18 Fondaparinux in combination with AES was compared with AES, the outcomes all-cause mortality,
19 DVT (symptomatic and asymptomatic), PE and major bleeding were reported in one study. High
20 quality evidence showed clinical benefit of fondaparinux in combination with AES in terms of DVT
21 (symptomatic and asymptomatic). There was no clinical difference in terms of all-cause mortality, PE
22 and major bleeding. However the findings for these three outcomes were also consistent with
23 benefit and harm. The quality of the evidence ranged from very low to high due to risk of bias and
24 imprecision. The outcome with evidence of high quality was DVT (symptomatic and asymptomatic).

25

26 **Combination interventions versus combination interventions**

27

28 *LMWH (standard dose; standard duration) + AES*

29

30 LMWH at a standard dose for a standard duration in combination with AES was compared with UFH
31 in combination with AES, the outcomes DVT (symptomatic and asymptomatic), PE and wound
32 infection were reported in one study. There was possible clinical benefit of LMWH in combination
33 with AES in terms of wound infection and no clinical difference in terms of DVT (symptomatic and
34 asymptomatic) and PE. However all three of these outcomes were associated with considerable
35 uncertainty. The quality of the evidence was very low due to risk of bias and imprecision.

36 LMWH at a standard dose for a standard duration in combination with AES was compared with foot
37 pump in combination with AES, the outcomes DVT (symptomatic and asymptomatic) and fatal PE
38 were reported in one study. There was possible clinical benefit of LMWH in combination with AES in
39 terms of fatal PE, although this finding was very uncertain. There was no clinical difference suggested
40 for DVT (symptomatic and asymptomatic), however the uncertainty around this result was also
41 consistent with clinical benefit. The quality of evidence ranged from very low to low due to risk of
42 bias, indirectness and imprecision.

43 LMWH at a standard dose for a standard duration in combination with AES was compared with
44 LMWH at a low dose for a standard duration in combination with AES, the outcomes DVT
45 (symptomatic and asymptomatic) and PE were reported in one study. There was no clinical
46 difference for both of these outcomes, although there was considerable uncertainty associated with
47 both. The quality of evidence ranged from very low to low due to risk of bias and imprecision.

48

49 *LMWH (high dose; standard duration) + AES*

50

1 LMWH at a standard dose for a standard duration in combination with AES was compared with
2 fondaparinux in combination with AES, the outcomes all-cause mortality, DVT (symptomatic and
3 asymptomatic), PE and fatal PE were reported in one study. There was possible clinical harm of
4 LMWH in combination with AES in terms of all-cause mortality, DVT (symptomatic and
5 asymptomatic) and PE. However there was uncertainty around these results. There was no clinical
6 difference in terms of fatal PE. The quality of the evidence ranged from very low to low due to risk of
7 bias and imprecision and indirectness.

8

9 *Fondaparinux + IPCD + AES*

10

11 Fondaparinux in combination with IPCD and AES was compared with VKA in combination with IPCD
12 and AES, the outcomes all-cause mortality, DVT (symptomatic and asymptomatic) and PE were
13 reported in one study. There was no clinical difference for all the outcomes; although all outcomes
14 were very uncertain. The quality of the evidence was very low due to risk of bias and imprecision.

15

16 **Mechanical interventions versus mechanical interventions**

17

18 *Foot pump*

19

20 Foot pump was compared with no prophylaxis, the outcomes DVT (symptomatic and asymptomatic)
21 and PE were reported in one study. Moderate quality evidence showed clinical benefit of foot pump
22 in terms of DVT (symptomatic and asymptomatic) and very low quality evidence suggested no
23 clinical difference in terms of PE. There was uncertainty around the PE result. The quality of the
24 evidence ranged from very low to moderate due to risk of bias, indirectness and imprecision.

25

26 *AES*

27

28 AES was compared with no prophylaxis, the outcomes DVT (symptomatic and asymptomatic), PE,
29 major bleeding, technical complications of mechanical interventions and wound infections were
30 reported in one study. There was possible clinical benefit of AES in terms of DVT (symptomatic and
31 asymptomatic). There was no clinical difference in terms of PE, major bleeding, technical
32 complications of mechanical interventions and wound infection. There was considerable uncertainty
33 around the effect estimates for all five outcomes. The quality of the evidence ranged from very low
34 to low due to risk of bias, indirectness and imprecision.

35

36 *IPCD*

37

38 IPCD was compared with no prophylaxis, the outcomes DVT (symptomatic and asymptomatic), PE,
39 major bleeding, technical complications of mechanical interventions and wound infections were
40 reported in one study. There was possible clinical benefit of AES in terms of DVT (symptomatic and
41 asymptomatic), PE and wound infection, and no clinical difference in terms major bleeding and
42 technical complications of mechanical interventions. However these results were all very uncertain.
43 The quality of the evidence ranged from very low to low due to risk of bias, indirectness and
44 imprecision.

45 IPCD was compared with AES, the outcomes DVT (symptomatic and asymptomatic), PE, major
46 bleeding, technical complications of mechanical interventions and wound infections were reported in
47 one study. There was possible clinical benefit of AES in terms of DVT (symptomatic and
48 asymptomatic), PE and wound infection, and no clinical difference in terms major bleeding and

1 technical complications of mechanical interventions. However there was considerable uncertainty
2 around all these results. The quality of the evidence was very low due to risk of bias, indirectness and
3 imprecision.

4

5 *Continuous passive motion*

6

7 Continuous passive motion compared with no prophylaxis, the outcome DVT was reported in one
8 study. There was no clinical difference for this outcome, however it was associated with considerable
9 uncertainty. The quality of the evidence was very low due to risk of bias, indirectness and
10 imprecision.

11

12 **Network meta-analysis statements**

13 *DVT (symptomatic and asymptomatic)*

14 23 studies were included in the network meta-analysis (NMA) for the outcome of DVT (symptomatic
15 and asymptomatic), involving 19 treatments. Treatments included no VTE prophylaxis,
16 pharmacological and mechanical interventions as single agents as well as combination interventions
17 of both pharmacological and mechanical interventions. Results from the network meta-analysis
18 presented rivaroxaban, apixaban and LMWH at a high dose for a standard duration as the most
19 clinically effective interventions in terms of DVT (symptomatic and asymptomatic). The least clinically
20 effective interventions were no prophylaxis, AES (length unspecified) and LMWH at a high dose for a
21 standard duration in combination with AES (length unspecified). Three inconsistencies were
22 identified when relative risk values from pairwise meta-analyses were compared with relative risk
23 values from the NMA. There was also a fair amount of uncertainty around the rank-point estimates
24 with very wide credible intervals.

25 *PE*

26 12 studies were included in the NMA for the outcome of PE, involving 13 treatments. Treatments
27 included no VTE prophylaxis, pharmacological and mechanical interventions as single agents as well
28 as combination interventions of both pharmacological and mechanical interventions. Results from
29 the network meta-analysis presented LMWH at a standard dose for an extended duration,
30 rivaroxaban and IPCD (length unspecified) as the most clinically effective interventions in terms of
31 the outcome of PE. The least clinically effective interventions were UFH, LMWH at a standard dose
32 for standard duration in combination with AES and no prophylaxis. No inconsistencies were identified
33 when relative risk values from pairwise meta-analyses were compared with relative risk values from
34 the NMA. There was also a high amount of uncertainty around the rank-point estimates with very
35 wide credible intervals.

36 *Major bleeding*

37 19 studies were included in the NMA for the outcome of major bleeding, involving 11 treatments.
38 Treatments included no VTE prophylaxis and pharmacological interventions (mechanical
39 interventions were combined with no prophylaxis as the assumption was made that these
40 interventions do not contribute to bleeding risk). Results from the network meta-analysis presented
41 LMWH at a low dose for a standard duration, LMWH at a standard dose for an extended duration,
42 and VKA as the most clinically effective interventions in terms of the outcome of major bleeding. The
43 least clinically effective interventions were fondaparinux, rivaroxaban and LMWH at a standard dose
44 for a standard duration. No inconsistencies were identified when relative risk values from pairwise
45 meta-analyses were compared with relative risk values from the NMA. There was also a high amount
46 of uncertainty around the rank-point estimates with very wide credible intervals.

47

1

2 **Economic**

- 3 • One original cost-utility analysis found that, in people admitted for elective knee replacement
4 surgery, the following interventions were cost-effective (having positive incremental net
5 monetary benefit [INMB]) compared to LMWH (standard dose, standard duration) +AEs: Foot
6 pump (INMB £353), aspirin (INMB £281), foot pump+ AES (INMB £72). This analysis was assessed
7 as directly applicable with potentially serious limitations.

27.6 8 Recommendations and link to evidence

Recommendations	<p>84. Offer VTE prophylaxis to people undergoing elective knee replacement surgery. Choose any one of^{fi}:</p> <ul style="list-style-type: none"> • aspirin (for 14 days) • LMWH^k (for 14 days) combined with anti-embolism stockings (until discharge) • Rivaroxaban, within its marketing authorisation, is recommended as an option for the prevention of venous thromboembolism in adults having elective total knee replacement surgery. [This bullet text is from Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults (NICE technology appraisal guidance 170).]^l. [2018] <p>85. Consider intermittent pneumatic compression if pharmacological prophylaxis is contraindicated in people undergoing elective knee replacement surgery. Continue until the person is mobile. [2018]</p>
Research recommendation	None
Relative values of different outcomes	<p>The guideline committee considered all-cause mortality (up to 90 days from hospital discharge), deep vein thrombosis (symptomatic and asymptomatic) (7-90 days from hospital discharge), pulmonary embolism (7-90 days from hospital discharge), fatal PE (7-90 days from hospital discharge), major bleeding (up to 45 days from hospital discharge) and surgical site haematoma (up to 45 days from hospital discharge) as critical outcomes.</p> <p>The guideline committee considered clinically relevant non-major bleeding (up to 45 days from hospital discharge), health-related quality of life (up to 90 days from hospital discharge), heparin-induced thrombocytopenia (duration of study), and technical complications of mechanical interventions (duration of study) and infection (duration of study) as important outcomes.</p>

^j See also the NICE technology appraisal guidance on apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults and dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults.

^k At the time of consultation (October 2017), LMWH did not have a UK marketing authorisation for use in young people under 18 for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information.

^l At the time of consultation (October 2017), rivaroxaban did not have a UK marketing authorisation for use in young people under 18 for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information.

	<p>Three network meta-analyses were conducted for this population, evaluating the outcomes DVT (symptomatic and asymptomatic), PE and major bleeding across numerous interventions.</p> <p>Please see section 4.3.3 in the methods chapter for further detail explaining prioritisation of the critical outcomes.</p>
<p>Quality of the clinical evidence</p>	<p>Evidence from direct pairwise comparisons was included in the network meta-analyses for the elective knee replacement population. The quality of the pairwise comparisons ranged from very low to high due to risk of bias, imprecision, indirectness and inconsistency.</p> <p>The DVT (symptomatic and asymptomatic) network evaluated 19 interventions, the PE network evaluated 13 interventions and major bleeding network evaluated 11 interventions. Inconsistencies were identified in the DVT (symptomatic and asymptomatic) and PE networks between the direct pairwise evidence and the NMA evidence but there was good calibration for all the outcomes with small differences between the residual deviance and DIC values for the network meta-analysis models that were ran. Very wide credible intervals around the median network meta-analyses values present some uncertainty around the NMA results particularly for the PE and major bleeding networks.</p>
<p>Trade-off between clinical benefits and harms</p>	<p>The clinical evidence presented to the guideline committee and orthopaedic subgroup informed the economic model that was developed. The guideline committee's discussions on the clinical evidence guided the recommendations alongside discussions on the results of the economic model. The model evaluated cost effectiveness using clinical data from the network-meta analyses undertaken on the committee-specified critical outcomes of DVT (symptomatic and asymptomatic), PE, and major bleeding. The model also captured data from the included trials on additional outcomes such as symptomatic DVT and asymptomatic DVT, and more detailed bleeding outcomes such as surgical site bleeding, gastrointestinal bleeding, and wound haematoma.</p> <p>When assessing the results of the analysis of the clinical data, the guideline committee noted the wide credible intervals presented in the network meta-analyses, particularly in the PE and major bleeding networks and that the uncertainty in the clinical data would have a knock on effect for the certainty in the results of the economic modelling.</p> <p>The licenced DOACs (rivaroxaban, apixaban and dabigatran) ranked highly when considering the clinical data for DVT, with rivaroxaban and apixaban ranked as the top two interventions having relatively narrow credible intervals. Based on the point estimates in the ranking rivaroxaban also outperformed dabigatran and apixaban in the analysis of the clinical data for PE. However there was considerable overlap of the confidence intervals for all of the DOACs due to the large uncertainty around the ranking results. None of the DOACs performed as well with respect of major bleeding.</p> <p>The guideline committee and orthopaedic subgroup noted that the network meta-analyses suggest that combination prophylaxis may not be highly beneficial, but acknowledged that there is a lot of uncertainty as indicated by the wide credible intervals. The orthopaedic subgroup discussed that the use of AES is common within clinical practice in the eTKR population, without any presence of clinical benefit with AES showing low rankings in preventing VTE outcomes (DVT and PE). It was discussed whether mechanical prophylaxis may be used due to pharmacological contraindications, and if clinicians might consider IPCD as the intervention of choice as there is suggested clinical benefit of these interventions in terms of DVT (symptomatic and asymptomatic) and PE, with some uncertainty. The ranking for foot pump based on the clinical data was relatively high in the DVT NMA but it was discussed that the study which influenced the rank of this intervention was conducted during a time period when clinical practice was very different. Foot pumps are not commonly used by people undergoing elective knee replacement</p>

	surgery for very long in the post-operative period due to the fact that this device can limit early mobilisation.
Trade-off between net clinical effects and costs	<p>An original economic model was developed to assess the cost effectiveness of the prophylaxis options included in the clinical review NMAs. It models the outcomes from the NMAs and also differentiates between asymptomatic and symptomatic DVT. This takes into account that asymptomatic DVT does not have an impact on costs and outcomes in the short term as it is not diagnosed in practice and its only consequence in the model is its future progression to PTS.</p> <p>Thirteen options were included in this model:</p> <ul style="list-style-type: none"> • Anti-embolism stockings (AES) – length unspecified • Aspirin • Apixaban • Dabigatran • Fondaparinux+ AES • Foot pump • Foot pump + AES • IPCD • LMWH (standard dose, standard duration) • LMWH (standard dose, extended duration) • LMWH (standard dose, standard duration) + Anti-embolism stockings (AEs) • No prophylaxis • Rivaroxaban <p>The model results showed that the most cost-effective option for this population is foot pump. This intervention had the highest mean incremental net monetary benefit (INMB) per patient compared to LMWH (standard dose, standard duration) + anti-embolism stockings (£353) at a cost-effectiveness threshold of £20,000 per QALY gained. It was followed by aspirin with INMB of £281. Compared to no prophylaxis, all options ranked higher, except dabigatran. A number of sensitivity analyses were presented to the committee including changing the cost-effectiveness threshold to £30,000 per QALY gained; changing the discount rate for costs and QALYs to 1.5% and using the licensed duration where applicable rather than the average RCT duration.</p> <p>The guideline committee and the orthopaedic subgroup considered the results of the model and noted that there was considerable uncertainty in this analysis which is likely to be the result of the uncertainty in the NMAs that informed the model, particularly the PE NMA; where the results were very imprecise. However, the results overall suggested that low-intensity, single-component and low-cost interventions are the most likely to be cost-effective in this population; with foot pump and aspirin ranking first and second. This was thought to be a result of the lower PE and symptomatic DVT incidence in the modelled cohort for the eTKR population compared to the eTHR population.</p> <p>The committee and the orthopaedic subgroup noted that despite being the most cost-effective option, foot pump had a low probability of being the most cost-effective (18%). This further emphasised the fact that considerable uncertainty exists in the analysis, which was also reflected in the very wide 95% CIs around the mean ranks. Hence, the committee opted to give a choice of prophylaxis options noting that some people may have contra-indications.</p> <p>The committee and the orthopaedic subgroup noted that out of the three DOACs included in the model (rivaroxaban, apixaban and dabigatran), rivaroxaban was dominant (more effective and less costly) compared to both apixaban and dabigatran. The committee noted that this was in line with previously published</p>

	<p>economic evaluations, the economic models assessed as part of TA170 and TA245 and a more recent analysis funded by the NIHR.^{229,230,281} Dabigatran was also on average, worse than no prophylaxis. The orthopaedic subgroup also noted recent reports of increased risk of wound complications and subsequent increased length of hospital stay when using dabigatran.³⁵ The committee noted that despite being dominated and having low NMB, apixaban had high probability of being the most cost-effective (43%). This was a result of the higher uncertainty around its cost-effectiveness; with around 5% probability of being the worst compared to 0% for rivaroxaban and 95% CI around its mean rank of 1 to 13, compared to 1 to 11 for rivaroxaban. Hence, the committee recommended rivaroxaban as the most cost-effective DOAC with the aim of standardising practice.</p> <p>For those with contraindications for pharmacological prophylaxis, the committee and the orthopaedic subgroup felt that foot pump and IPCD appeared to be the more cost-effective options in this population compared to AES. This was in line with the evidence from other populations where AES tended to be less effective than previously thought. The committee also noted the difficulty in using AES in this specific population where application is only possible on the opposite leg. Given the very large cost impact of using AES in this population, the considerable time required for nurses to fit them and the considerable uncertainty about their effectiveness; the committee and the subgroup felt that the use of AES as a sole prophylaxis option in this population should be discouraged. However, AES still ranked higher than no prophylaxis and the committee therefore felt there was not enough evidence to recommend against their use as a sole means of prophylaxis.</p> <p>The committee also noted that in general it was not possible to include any side effects for the mechanical prophylaxis options in the model and hence, their cost effectiveness might be over-estimated. Additionally; the trials of all mechanical prophylaxis options have used them for longer durations than how they are currently used in practice; where early mobilisation is encouraged, so the efficacy levels seen in the trials may not be possible to replicate in practice. Hence, a weaker “consider” recommendation would be more appropriate.</p>
Other considerations	None.

1

28 Non-arthroplasty orthopaedic knee surgery

28.1.2 Introduction

3 Non-arthroplasty knee surgery can include knee arthroscopy, osteotomy and surgery for peri-
4 articular trauma. This population was previously covered in the 'other orthopaedic surgery' chapter
5 in CG92. The number of non-arthroplasty knee surgeries performed has increased over the years,
6 thus it is important that this population is evaluated separately. These surgeries are commonly
7 performed in relatively younger patients and may not be extensive. They are associated with a lower
8 VTE risk compared with elective total knee replacement, possibly due to the shorter surgery duration
9 and earlier mobilisation of patients.

28.2.0 Review question: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) in people having non-arthroplasty knee surgery?

13 For full details see review protocol in Appendix C.

14 **Table 121: PICO characteristics of review question**

Population	<p>Adults and young people (16 years and older) having non-arthroplasty knee surgery who are:</p> <ul style="list-style-type: none"> • Admitted to hospital • Having day procedures • Outpatients post-discharge
Interventions	<p>Mechanical:</p> <ul style="list-style-type: none"> • Anti-embolism stockings (AES) (above or below knee) • Intermittent pneumatic compression (IPCD) devices (full leg or below knee) • Foot pumps or foot impulse devices (FID) • Electrical stimulation (including Geko devices) • Continuous passive motion <p>Pharmacological:</p> <ul style="list-style-type: none"> • Unfractionated heparin (UFH) (low dose, administered subcutaneously) • Low molecular weight heparin (LMWH), licensed in UK: <ul style="list-style-type: none"> ○ enoxaparin (standard prophylactic dose 40mg daily; minimum 20mg daily* to maximum 60mg twice daily*) ○ dalteparin (standard prophylactic dose 5000 units once daily; minimum 1250 units once daily* to maximum 5000 units twice daily*; obese patients – maximum 7500 twice units daily*) ○ tinzaparin (standard prophylactic dose 4500 units once daily; minimum 2500 units once daily* to maximum 4500 units twice daily*; obese patients – maximum 6750 twice daily*) • LMWH, licensed in countries other than UK: <ul style="list-style-type: none"> ○ Bemiparin (standard 2500 units daily; minimum 2500 units daily to maximum 3500 units daily) ○ Certoparin (3000 units daily) ○ Nadroparin (standard 2850 units once daily; minimum 2850 units once daily to maximum up to 57 units/kg once daily)

	<ul style="list-style-type: none"> ○ Parnaparin (standard 3200 units once daily; minimum 3200 units once daily to maximum 4250 units once daily) ○ Reviparin (minimum 1750 units once daily to maximum 4200 units once daily) ● Vitamin K Antagonists: <ul style="list-style-type: none"> ○ warfarin (variable dose only) ○ acenocoumarol (all doses) ○ phenindione (all doses) ● Fondaparinux (all doses)* ● Apixaban (all doses)* ● Dabigatran (all doses)* ● Rivaroxaban (all doses)* ● Aspirin (up to 300mg)* <p>*off-label</p>
Comparisons	<p>Compared to:</p> <ul style="list-style-type: none"> ● Other VTE prophylaxis treatment, including monotherapy and combination treatments (between class comparisons for pharmacological treatments only) ● No VTE prophylaxis treatment (no treatment, usual care, placebo) <p>Within intervention (including same drug) comparisons, including:</p> <ul style="list-style-type: none"> ● Above versus below knee stockings ● Full leg versus below knee IPC devices ● Standard versus extended duration prophylaxis ● Low versus high dose for LMWH ● Preoperative versus post-operative initiation of LMWH
Outcomes	<p>Critical outcomes:</p> <ul style="list-style-type: none"> ● All-cause mortality (up to 90 days from hospital discharge) ● Deep vein thrombosis (symptomatic and asymptomatic) (7-90 days from hospital discharge. Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) ● Pulmonary embolism (7-90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE ● Major bleeding (up to 45 days from hospital discharge). A major bleeding event meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood ; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event. Includes unplanned visit to theatre for control of bleeding ● Fatal PE (7- 90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE <p>Important outcomes:</p> <ul style="list-style-type: none"> ● Clinically relevant non-major bleeding (up to 45 days from hospital

	<p>discharge): bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy.</p> <ul style="list-style-type: none"> • Health-related quality of life (validated scores only)(up to 90 days from hospital discharge) • Heparin-induced thrombocytopenia (HIT) (duration of study) • Technical complications of mechanical interventions (duration of study) • Unplanned return to theatre (up to 45 days from hospital discharge)
Study design	Randomised controlled trials (RCTs), systematic reviews of RCTs
Stratification	<ul style="list-style-type: none"> • People who are contraindicated for pharmacological prophylaxis • People who are contraindicated for mechanical prophylaxis • Major arthroscopic surgery (combined anaesthetic and surgery longer than 1 hour) • Minor arthroscopic surgery (combined anaesthetic and surgery less than 1 hour) • Osteotomy • Peri-articular trauma

28.3.1 Clinical evidence

2 A search was conducted for randomised trials comparing the effectiveness of mechanical and
3 pharmacological prophylaxis strategies (alone or in combination) in people with non-arthroplasty
4 knee surgery. Five studies were included in the review;^{45,46,203,301,319} these are summarised in Table
5 122 below. Of the four studies included in the previous guideline (CG92), three were included ^{46,203}
6 ³¹⁹, and one was excluded due to the intervention arm including both low and standard doses of
7 LMWH.²¹³ Two new studies were identified for inclusion for this update. ^{301,45} Evidence from these
8 studies is summarised in the clinical evidence summary below (**Table 123, Table 124, Table 125, Table**
9 **126, Table 127, Table 128, Table 129**). See also the study selection flow chart in Appendix E, forest
10 plots in Appendix L, study evidence tables in Appendix H, GRADE tables in Appendix K and excluded
11 studies list in Appendix N.

12 The five included studies all included an arthroscopy surgery population. Although other types of
13 non-arthroplasty knee surgery were searched for, including osteotomy, fracture surgery and peri-
14 articular trauma, no studies involving these populations were identified for inclusion in this review.

15 As per the review protocol, studies were stratified according to the population. As a result, three
16 strata exist in the current review. The major arthroscopic surgery stratum includes studies where the
17 population had a mean combined anaesthetic and surgery time of over 1 hour. The minor
18 arthroscopic surgery stratum includes studies where the population had a mean combined
19 anaesthetic and surgery time of less than 1 hour. The overall population stratum includes studies
20 where combined anaesthetic and surgery time was not sufficiently reported. The included studies did
21 not report on the other specified stratification populations and therefore no other strata are
22 included.

23 **Table 122: Summary of studies included in the review**

Study	Intervention and comparison	Population	Outcomes	Comments
Overall population stratum				
Camporese 2008 ⁴⁶	Intervention 1 (n=660): AES, full length	n=1761 People having diagnostic	All-cause mortality (8 days)	

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>Applied to the operated leg before weight bearing, and worn for 7 days</p> <p>Intervention 2 (n=444): LMWH, high dose, extended duration (nadroparin, 3800U, once daily) Administered 8 hours after procedure, for 14 days</p> <p>Comparison (n=657): LMWH, high dose, standard duration (nadroparin, 3800U, once daily) Administered 8 hours after procedure, for 7 days</p>	<p>arthroscopy or arthroscopy assisted knee surgery</p> <p>Duration of operation not reported (overall strata)</p> <p>Males and females: AES group 1.66:1, LMWH extended group 1.60:1, LMWH standard group 1.62:1</p> <p>Italy</p>	<p>DVT (8 days): confirmed by ultrasonography</p> <p>PE (8 days): confirmed by ventilation perfusion lung scan</p> <p>Major bleeding (8 days): defined as a clinically overt haemorrhage associated with a haemoglobin decrease of at least 20g/L or requiring transfusion of 2 or more units of packed red blood cells, a retroperitoneal or intracranial event, a bleeding event requiring reintervention or a hemarthrosis with joint drainage of more than 450ml.</p>	
Camporese 2016 ⁴⁵	<p>Intervention (n=122): Rivaroxaban (10mg, once daily)</p> <p>Comparison (n=119): no VTE prophylaxis (placebo)</p> <p>Started 8-10 hours postoperatively, for 6 days</p>	<p>n=241</p> <p>People having non-diagnostic arthroscopy assisted knee surgery</p> <p>Duration of operation and/or anaesthesia not reported</p> <p>Age >18 years</p> <p>Males and females (162:79)</p> <p>Italy</p>	<p>All-cause mortality (90 days)</p> <p>DVT (90 days): confirmed by Doppler ultrasonography</p> <p>PE (90 days): confirmed by CT angiography</p> <p>Fatal PE (90 days): confirmed by autopsy, or on clinical grounds according to the treating physician</p>	
Marlovits 2007 ²⁰³	<p>Intervention (n=87): LMWH, standard dose, extended duration (enoxaparin, 40mg, once daily) Administered 12-18 hours preoperatively</p>	<p>n=175</p> <p>People having arthroscopic anterior cruciate ligament (ACL) surgery</p>	<p>DVT (23-28 days): confirmed by magnetic resonance venography</p> <p>PE (23-28 days): confirmed by lung</p>	

Study	Intervention and comparison	Population	Outcomes	Comments
	and continued for 23-28 days Comparison (n=88): LMWH, standard dose, standard duration (enoxaparin, 40mg, once daily) Administered 12-18 hours preoperatively and continued for 3-8 days plus placebo for the following 20 days	Duration of operation >2 hours: 50% Age >19 years Males and females (108:67) Austria	scan Major bleeding (23-28 days): defined as fatal bleeding, bleeding that was retroperitoneal, intracranial, intraspinal or involving any critical organ, bleeding leading to reoperation, transfusion of 2 units of packed red blood cells or whole blood, or overt bleeding with a bleeding index of 2 or more	
Major arthroscopic surgery stratum				
Wirth 2001 ³¹⁹	Intervention (n=117): LMWH, low dose (reviparin, 1750U, once daily) Comparison (n=122): no VTE prophylaxis	n=239 People having diagnostic arthroscopy or arthroscopy assisted knee surgery Duration of surgery (mean, SD): 34 (38) minutes Duration of anaesthesia (mean, SD): 68 (46) minutes Age >18 years Males and Females (179:60) Germany	DVT (10 days): confirmed by compression ultrasonography PE (10 days): confirmed by compression ultrasonography Major bleeding (10 days): defined as transfusion or reoperation due to bleeding Clinically relevant non-major bleeding (10 days): defined as wound haematoma (>2cm and <2cm)	Duration of anaesthesia SD is very wide so may have been less than 1 hour for many patients
Minor arthroscopic surgery stratum				
Van Adrichem 2017 ³⁰¹	Intervention (n=773): LMWH, low dose (nadroparin 2850U or dalteparin 2500U, once daily) Administered for 8 days post operatively Comparison (n=770): no VTE prophylaxis	n=1543 People having meniscectomy, diagnostic arthroscopy or removal of corpora libera (meniscectomy 72.5%, removal of loose bodies 5.3%, diagnostic arthroscopy 7.4%, other	All-cause mortality (90 days) PE (90 days): method of confirmation not reported	Type of LMWH was dependent on hospital preference If the patient's weight is more than 100kg a double dose

Study	Intervention and comparison	Population	Outcomes	Comments
		22%) Total duration (time from receiving anaesthesia to leaving operating room): LMWH group, 26 (11) minutes; control group, 26 (11) minutes Age >18 years Males and females (810: 733) Netherlands		of LMWH was given

1

28.3.1.1 Pairwise comparisons: overall population stratum

2 Table 123: Clinical evidence summary: LMWH (standard dose, extended duration) versus LMWH (standard dose, standard duration)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with LMWH	Risk difference with LMWH (standard dose, extended duration) (95% CI)
DVT	140 (1 study) 23-28 days	MODERATE ¹ due to risk of bias	RR 0.07 (0.02 to 0.27)	412 per 1000	383 fewer per 1000 (from 301 fewer to 404 fewer)
PE	140 (1 study) 23-28 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Not estimable ³	Not estimable ³	0 fewer per 1000 (from 28 fewer to 28 more) ⁴
Major bleeding	140 (1 study) 23-28 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Not estimable ³	Not estimable ³	0 fewer per 1000 (from 28 fewer to 28 more) ⁴

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
 2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs
 3 Could not be calculated as there were no events in the intervention or comparison group
 4 Risk difference calculated in Review Manager

3
4
5

6 Table 124: Clinical evidence summary: LMWH (high dose, standard duration) versus AES (full length)

Outcomes	No of Participants	Quality of the	Relative effect	Anticipated absolute effects
----------	--------------------	----------------	-----------------	------------------------------

	(studies) Follow up	evidence (GRADE)	(95% CI)	Risk with AES	Risk difference with LMWH (95% CI)
All-cause mortality	1317 (1 study) 8 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Not estimable ³	Not estimable ³	0 fewer per 1000 (from 3 fewer to 3 more) ⁴
DVT	1317 (1 study) 8 days	MODERATE ¹ due to risk of bias	RR 0.35 (0.17 to 0.70)	44 per 1000	29 fewer per 1000 (from 13 fewer to 36 fewer)
PE	1317 (1 study) 8 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 1.00 (0.14 to 7.15)	3 per 1000	0 fewer per 1000 (from 3 fewer to 18 more)
Major bleeding	1317 (1 study) 8 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 1.96 (0.20 to 18.86)	2 per 1000	1 more per 1000 (from 1 fewer to 26 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs
3 Could not be calculated as there were no events in the intervention or comparison group
4 Risk difference calculated in Review Manager

1 Table 125: Clinical evidence summary: LMWH (high dose, extended duration) versus AES (full length)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with AES	Risk difference with LMWH (95% CI)
All-cause mortality	1104 (1 study) 8 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Not estimable ³	Not estimable ³	0 fewer per 1000 (from 4 fewer to 4 more) ⁴
DVT	1104 (1 study)	LOW ^{1,2}	RR 0.46 (0.22 to 0.97)	44 per 1000	24 fewer per 1000 (from 1 fewer to 34 fewer)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with AES	Risk difference with LMWH (95% CI)
	8 days	due to risk of bias, imprecision			
PE	1104 (1 study) 8 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 1.50 (0.20 to 11.13)	3 per 1000	2 more per 1000 (from 2 fewer to 30 more)
Major bleeding	1104 (1 study) 8 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 1.50 (0.09 to 25.41)	2 per 1000	1 more per 1000 (from 1 fewer to 36 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs
3 Could not be calculated as there were no events in the intervention or comparison group
4 Risk difference calculated in Review Manager

1 Table 126: Clinical evidence summary: LMWH (high dose, extended duration) versus LMWH (high dose, standard duration)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with LMWH	Risk difference with LMWH (high dose, extended duration) (95% CI)
All-cause mortality	1101 (1 study) 8 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Not estimable ³	Not estimable ³	0 fewer per 1000 (from 4 fewer to 4 more) ⁴
DVT	1101 (1 study) 8 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 1.33 (0.55 to 3.25)	15 per 1000	5 more per 1000 (from 7 fewer to 34 more)
PE	1101		Peto OR 1.5	3 per 1000	2 more per 1000

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with LMWH	Risk difference with LMWH (high dose, extended duration) (95% CI)
	(1 study) 8 days	VERY LOW ^{1,2} due to risk of bias, imprecision	(0.2 to 11.06)		(from 2 fewer to 30 more)
Major bleeding	1101 (1 study) 8 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.75 (0.07 to 7.52)	3 per 1000	1 fewer per 1000 (from 3 fewer to 19 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs
3 Could not be calculated as there were no events in the intervention or comparison group
4 Risk difference calculated in Review Manager

1

2 **Table 127: Clinical evidence summary: Rivaroxaban versus no prophylaxis**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with Rivaroxaban versus no prophylaxis (95% CI)
All-cause mortality	234 (1 study) 90 days	LOW ¹ due to imprecision	Not estimable ²	Not estimable ²	0 fewer per 1000 (from 17 fewer to 17 more) ³
DVT	234 (1 study) 90 days	MODERATE ¹ due to imprecision	RR 0.24 (0.05 to 1.09)	70 per 1000	53 fewer per 1000 (from 67 fewer to 6 more)
PE	234 (1 study) 90 days	LOW ¹ due to imprecision	Not estimable ²	Not estimable ²	0 fewer per 1000 (from 17 fewer to 17 more) ³

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with Rivaroxaban versus no prophylaxis (95% CI)
Fatal PE	234 (1 study) 90 days	LOW ¹ due to imprecision	Not estimable ²	Not estimable ²	0 fewer per 1000 (from 17 fewer to 17 more) ³

1 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs
2 Could not be calculated as there were no events in the intervention or comparison group
3 Risk difference calculated in Review Manager

28.3.2.1 Pairwise comparisons: Major arthroscopic surgery stratum

2 Table 128: Clinical evidence summary: LMWH (low dose, standard duration) versus no prophylaxis

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with no prophylaxis	Risk difference with LMWH (low dose) (95% CI)
DVT	239 (1 study) 10 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.27 (0.05 to 1.35)	41 per 1000	30 fewer per 1000 (from 39 fewer to 14 more)
PE	239 (1 study) 10 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Not estimable ³	Not estimable ³	0 fewer per 1000 (from 16 fewer to 16 more) ⁴
Major bleeding	239 (1 study) 10 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Not estimable ³	Not estimable ³	0 fewer per 1000 (from 16 fewer to 16 more) ⁴
CRNMB	239 (1 study) 10 days	LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.31 (0.05 to 1.80)	33 per 1000	22 fewer per 1000 (from 31 fewer to 25 more)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with no prophylaxis	Risk difference with LMWH (low dose) (95% CI)
1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias 2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs 3 Could not be calculated as there were no events in the intervention or comparison group 4 Risk difference calculated in Review Manager					

1

28.3.3.2 Pairwise comparisons: Minor arthroscopic surgery stratum

3 Table 129: Clinical evidence summary: LMWH (low dose, standard duration) versus no prophylaxis

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with no prophylaxis	Risk difference with LMWH (low dose) (95% CI)
All-cause mortality	1451 (1 study) 90 days	LOW ¹ due to imprecision	Not estimable ³	Not estimable ³	0 fewer per 1000 (from 3 fewer to 3 more) ⁴
PE	1451 (1 study) 90 days	VERY LOW ^{1,2} due to indirectness, imprecision	Peto OR 0.98 (0.06 to 15.76)	1 per 1000	0 fewer per 1000 (from 1 fewer to 20 more)
1 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs 2 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol 3 Could not be calculated as there were no events in the intervention or comparison group 4 Risk difference calculated in Review Manager					

4

5

28.4₁ Economic evidence

- 2 No relevant health economic studies were identified.
- 3 See also the health economic study selection flow chart in Appendix F.

28.5₄ Evidence statements

28.5.15 Clinical

6 LMWH compared with no prophylaxis

7 In the major arthroscopic surgery stratum, one study compared LMWH at a low dose with no
8 prophylaxis. The evidence suggested clinical benefit of LMWH for both DVT and clinically relevant
9 non-major bleeding (low to very low quality, n=239), but no clinical difference in terms of PE or major
10 bleeding (very low quality, n=239), however there was considerable uncertainty around these
11 results.

12 Evidence from a single study in the minor arthroscopic surgery stratum demonstrated no clinical
13 difference between treatments in terms of all-cause mortality and PE (very low to low quality,
14 n=1451), although the uncertainty around these results could also have been associated with both
15 benefit and harm.

16 LMWH compared with AES

17 In the overall population stratum, evidence from a single study suggested that LMWH at a high dose
18 and standard duration had no clinically important benefit over AES (full length) in terms of all-cause
19 mortality or PE (very low quality, n=1317). In terms of DVT, evidence suggested a clinical benefit of
20 LMWH compared to AES, however there was a possible clinical harm of LMWH in terms of major
21 bleeding (very low to moderate quality, n=1317). However all of the results were associated with
22 considerable uncertainty.

23 When LMWH at a high dose and extended duration was compared to AES (full length) in a single
24 study in the overall population stratum, there was no clinical difference between treatments in terms
25 of all-cause mortality. The evidence suggested a clinical benefit of LMWH in terms of DVT, however
26 there was a possible clinical harm of LMWH compared to AES in terms of both PE and major bleeding
27 (low to very low quality, n=1104). However all of the results were associated with considerable
28 uncertainty.

29 LMWH extended duration compared with LMWH standard duration

30 In the overall population stratum, a single study (n=140) compared LMWH at a standard dose and
31 extended duration to LMWH at a standard dose and standard duration. Evidence from this study
32 demonstrated a clinical benefit for extended duration LMWH in terms of DVT (moderate quality), and
33 suggested no clinical difference was seen for PE or major bleeding. However there was very serious
34 imprecision associated with the PE and major bleeding outcomes.

35 In the overall population, LMWH at a high dose and extended duration was compared to LMWH at a
36 high dose and standard duration, in a single study (n=1101). No clinical difference was seen between
37 the treatments in terms of all-cause mortality and major bleeding, however there was a possible
38 clinical harm of extended duration LMWH in terms of DVT and PE (very low quality). However there
39 was very serious imprecision associated with all these results.

1 Rivaroxaban versus no prophylaxis

2 In the overall population stratum, a single study (n=234) compared rivaroxaban with no prophylaxis.
3 Evidence from this study suggested a clinical benefit in terms of DVT for rivaroxaban, however there
4 was no clinical difference between treatments in terms of all-cause mortality, PE and fatal PE (low to
5 moderate quality) and there was considerable uncertainty around these results.

6 Economic

7 • No relevant economic evaluations were identified.

28.6.8 Recommendations and link to evidence

Recommendations	<p>86. Be aware that VTE prophylaxis is generally not needed for people undergoing arthroscopic knee surgery where:</p> <ul style="list-style-type: none"> • total anaesthesia time is less than 1 hour and • the person is at low risk of VTE. [2018] <p>87. Consider LMWH^m 6–12 hours after surgery for 14 days for people undergoing arthroscopic knee surgery if:</p> <ul style="list-style-type: none"> • total anaesthesia time is more than 1 hour or • the person’s risk of VTE outweighs their risk of bleeding. [2018] <p>88. Consider VTE prophylaxis for people undergoing other knee surgery (for example, osteotomy or fracture surgery) whose risk of VTE outweighs their risk of bleeding. [2018]</p>
Research recommendation	None
Relative values of different outcomes	<p>The guideline committee considered all-cause mortality (up to 90 days from hospital discharge), deep vein thrombosis (symptomatic and asymptomatic) (up to 90 days from hospital discharge), pulmonary embolism (up to 90 days from hospital discharge), fatal PE (up to 90 days from hospital discharge), and major bleeding (up to 45 days from hospital discharge) as critical outcomes.</p> <p>The guideline committee considered clinically relevant non-major bleeding (up to 45 days from hospital discharge), health-related quality of life (up to 90 days from hospital discharge), heparin-induced thrombocytopenia (duration of study), and technical complications of mechanical interventions (duration of study) as important outcomes.</p> <p>Please see section 4.3.3 in the methods chapter for further detail explaining prioritisation of the critical outcomes.</p>
Quality of the clinical evidence	<p>Five studies were included in this review. Three of these were randomised controlled trials identified from the previous guideline (CG92). One study that was included in CG92 was excluded from this review due to the intervention arm including both low and standard doses of LMWH.</p> <p>Seven comparisons were included in the three strata; five in the overall population strata and one each in the major arthroscopic surgery and minor arthroscopic</p>

^m At the time of consultation (October 2017), LMWH did not have a UK marketing authorisation for use in young people under 18 for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council’s Prescribing guidance: prescribing unlicensed medicines for further information.

	<p>surgery strata. The comparisons evaluated both pharmacological and mechanical interventions. Pharmacological interventions included LMWH (at low, standard and high doses and standard and extended durations) and rivaroxaban. The committee noted that there was no evidence for UFH or other types of pharmacological prophylaxis. The only mechanical intervention was AES (full length). No evidence for other mechanical interventions was identified.</p> <p>All of the evidence in this review had a GRADE quality rating that ranged from very low to moderate. This was due to inadequate outcome reporting, lack of allocation concealment, lack of adequate blinding and sequence generation, and high dropout rates, resulting in a high risk of bias rating. Additionally, the majority of the evidence had serious or very serious imprecision, which further downgraded the quality of the evidence. Evidence for PE and DVT outcome in the minor arthroscopic stratum was also downgraded due to indirectness, which also reduced the quality rating. This was because the method of confirmation of PE and DVT was not reported. The committee noted the poor quality of the evidence and also that for each comparison there was only one study, therefore limiting the confidence that could be put in the findings.</p>
Trade-off between clinical benefits and harms	<p>The committee noted that all studies included in the review all involved an arthroscopy procedure. Although other types of non-arthroplasty knee surgery were searched for, including osteotomy and fractures, no relevant RCTs that could be included were identified. Therefore, the committee made recommendations in terms of the population in the evidence presented and other knee surgery.</p> <p>The committee discussed that although the studies included in the review were all arthroscopy related procedures, there was great variation in the types of arthroscopic operations, which differ substantially in terms of surgery and immobilisation time, and complexity of the procedure. For instance, it was noted that a diagnostic arthroscopy would be a much quicker and less complex procedure compared to other forms of non-arthroplasty knee surgery.</p> <p>The guideline committee also noted that although the study included in the major arthroscopic surgery stratum reported a mean anaesthetic time of over one hour, there was some concern that many of the patients in the study may have had surgery for less than one hour, given the large standard deviation and the type of surgery patients received. The committee noted their concern and took this into account when considering the evidence and recommendations.</p> <p>The orthopaedic subgroup advised the committee that the risk of VTE will be minimal if the surgery total anaesthesia time is less than one hour and the individuals undergoing the surgery have been assessed to be at low risk of VTE.</p> <p>The committee discussed the increased risk of VTE events if the surgery is performed under general anaesthesia and the total time is more than one hour. It was felt that in this group prophylaxis need to be considered based on individual VTE and bleeding risk assessment.</p>
Trade-off between net clinical effects and costs	<p>No relevant economic studies were identified for this population and no studies were previously included in CG92. Relevant unit costs were presented to the committee.</p> <p>The committee, on the advice of the orthopaedic subgroup, felt that people undergoing non-arthroplasty procedures are generally at low risk of VTE. Factors that contribute to increasing the risk were reported to include the use of general anaesthesia and surgery time. Only in these circumstances, the risk of VTE will be high enough to justify the use of the prophylaxis. The committee felt that LMWH was the prophylaxis option supported by the presented clinical evidence. This was also reported to be in line with current practice. Although rivaroxaban showed clinical benefit for the outcome of DVT when compared to no prophylaxis; it was acknowledged that it is not licensed for use in this population. Overall, the committee considered that the provision of prophylaxis in this population should be</p>

	based on individual VTE and bleeding risk assessment to ensure adequate targeting of those most likely to benefit and, hence, justify its cost.
Other considerations	None.

1

29 Foot and ankle orthopaedic surgery

29.1.2 Introduction

3 The risk of VTE in the foot and ankle surgery population is heterogeneous. However, there are
4 several known risk factors that can increase the risk of VTE, including type and duration of surgery
5 and period of immobilisation. Some patients who have foot or ankle surgery may be immobilised and
6 require the use of a plaster cast or orthosis, these patients are evaluated in the lower limb
7 immobilisation review (chapter 24). This guidance is for the totality of patients treated with lower
8 limb immobilisation; clinicians should consider individual patient risk, such as people with
9 tendoachilles rupture, when determining which VTE prophylaxis intervention is appropriate for a
10 patient.

29.2.1 Review question: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) in people having foot and ankle surgery?

14 For full details see review protocol in Appendix C.

15 **Table 130: PICO characteristics of review question**

Population	Adults and young people (16 years and older) having foot and ankle surgery who are: <ul style="list-style-type: none"> • Admitted to hospital • Having day procedures • Outpatients post-discharge
Interventions	<p>Mechanical:</p> <ul style="list-style-type: none"> • Anti-embolism stockings (AES) (above or below knee) • Intermittent pneumatic compression (IPCD) devices (full leg or below knee) • Foot pumps or foot impulse devices (FID) • Electrical stimulation (including Geko devices) <p>Pharmacological:</p> <ul style="list-style-type: none"> • Unfractionated heparin (UFH) (low dose, administered subcutaneously) • Low molecular weight heparin (LMWH), licensed in UK: <ul style="list-style-type: none"> ○ enoxaparin (standard prophylactic dose 40mg daily; minimum 20mg daily* to maximum 60mg twice daily*) ○ dalteparin (standard prophylactic dose 5000 units once daily; minimum 1250 units once daily* to maximum 5000 units twice daily*; obese patients – maximum 7500 twice units daily*) ○ tinzaparin (standard prophylactic dose 4500 units once daily; minimum 2500 units once daily* to maximum 4500 units twice daily*; obese patients – maximum 6750 twice daily*) • LMWH, licensed in countries other than UK: <ul style="list-style-type: none"> ○ Bemiparin (standard 2500 units daily; minimum 2500 units daily to maximum 3500 units daily) ○ Certoparin (3000 units daily) ○ Nadroparin (standard 2850 units once daily; minimum 2850 units once daily to maximum up to 57 units/kg once daily) ○ Parnaparin (standard 3200 units once daily; minimum 3200 units once daily to maximum 4250 units once daily) ○ Reviparin (minimum 1750 units once daily to maximum 4200 units once daily)

	<ul style="list-style-type: none"> • Vitamin K Antagonists: <ul style="list-style-type: none"> ○ warfarin (variable dose only) ○ acenocoumarol (all doses) ○ phenindione (all doses) • Fondaparinux (all doses)* • Apixaban (all doses)* • Dabigatran (all doses)* • Rivaroxaban (all doses)* • Aspirin (up to 300mg)* <p>*off-label</p>
Comparisons	<p>Compared to:</p> <ul style="list-style-type: none"> • Other VTE prophylaxis treatment, including monotherapy and combination treatments (between class comparisons for pharmacological treatments only) • No VTE prophylaxis treatment (no treatment, usual care, placebo) <p>Within intervention (including same drug) comparisons, including:</p> <ul style="list-style-type: none"> • Above versus below knee stockings • Full leg versus below knee IPC devices • Standard versus extended duration prophylaxis • Low versus high dose for LMWH • Preoperative versus post-operative initiation of LMWH
Outcomes	<p>Critical outcomes:</p> <ul style="list-style-type: none"> • All-cause mortality (up to 90 days from hospital discharge) • Deep vein thrombosis (symptomatic and asymptomatic) (7-90 days from hospital discharge. Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) • Pulmonary embolism (7-90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE • Major bleeding (up to 45 days from hospital discharge). A major bleeding event meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood ; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event. Includes unplanned visit to theatre for control of bleeding • Fatal PE (7- 90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE <p>Important outcomes:</p> <ul style="list-style-type: none"> • Clinically relevant non-major bleeding (up to 45 days from hospital discharge): bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy. • Health-related quality of life (validated scores only)(up to 90 days from hospital discharge) • Heparin-induced thrombocytopenia (HIT) (duration of study) • Technical complications of mechanical interventions (duration of study) • Unplanned return to theatre (up to 45 days from hospital discharge)
Study design	Randomised controlled trials (RCTs), systematic reviews of RCTs

29.3.1 Clinical evidence

- 2 No relevant clinical studies comparing different pharmacological and mechanical prophylaxis
- 3 strategies for people who are undergoing foot and ankle surgery were identified. See the study
- 4 selection flow chart in Appendix E and excluded studies list in Appendix N.

29.4.5 Economic evidence

- 6 **Published literature**
- 7 No relevant health economic studies were identified.
- 8 See also the health economic study selection flow chart in Appendix F.

29.5.9 Evidence statements

- 10 **Clinical**
- 11 No relevant clinical studies were identified.
- 12 **Economic**
- 13 No relevant economic evaluations were identified.

29.6.4 Recommendations and link to evidence

Recommendations	<p>89. Consider pharmacological VTE prophylaxis for people undergoing foot or ankle surgery:</p> <ul style="list-style-type: none"> • that requires immobilisation (for example, arthrodesis or arthroplasty) (see recommendation 81) or • when total anaesthesia time is greater than 1 hour or • the person's risk of VTE outweighs their risk of bleeding. [2018]
Research recommendation	None
Relative values of different outcomes	<p>The guideline committee considered all-cause mortality (up to 90 days from hospital discharge), deep vein thrombosis (symptomatic and asymptomatic) (up to 90 days from hospital discharge), pulmonary embolism (up to 90 days from hospital discharge), fatal PE (up to 90 days from hospital discharge), and major bleeding (up to 45 days from hospital discharge) as critical outcomes.</p> <p>The guideline committee considered clinically relevant non-major bleeding (up to 45 days from hospital discharge), health-related quality of life (up to 90 days from hospital discharge), heparin-induced thrombocytopenia (duration of study), and technical complications of mechanical interventions (duration of study) as important outcomes.</p> <p>Please see section 4.3.3 in the methods chapter for further detail explaining prioritisation of the critical outcomes.</p>
Quality of the clinical evidence	No clinical evidence was identified for inclusion in this review.
Trade-off between	In the absence of any clinical evidence, the committee considered advice from the

clinical benefits and harms	<p>orthopaedic subgroup and discussed that for those undergoing foot and ankle surgery prophylaxis is not indicated in those whose surgery lasts less than one hour, are not subsequently immobilised and are assessed as low risk for VTE.</p> <p>Where patients are immobilised after their foot or ankle surgery the risk of VTE is the same as the population reviewed for lower limb immobilisation and therefore the same recommendations apply.</p>
Trade-off between net clinical effects and costs	<p>No relevant economic studies were identified for this population. Relevant unit costs were presented to the committee.</p> <p>The committee acknowledged that the risk of VTE will be minimal if the surgery total anaesthesia time is less than one hour and the individuals undergoing the surgery have been assessed to be at low risk of VTE. This means that provision of prophylaxis for this group is unlikely to be cost-effective. Where immobilisation is required, the risk of VTE will be higher; which would justify the cost of provision of prophylaxis. For this group, LMWH has been recommended based on the evidence considered specifically for people discharged with lower limb immobilisation in a separate chapter in this update. This was also reported to be in line with current practice.</p>
Other considerations	<p>The 'consider' recommendation is a reflection of the lack of evidence in this population. However, it is the committee's belief that for this group of patients, prophylaxis is likely to be most clinically and cost effective when immobilisation is required or anaesthesia time is longer than an hour.</p>

- 1
- 2
- 3

30 Upper limb orthopaedic surgery

30.1.2 Introduction

3 It has been reported that over 4,000 shoulder and elbow replacements are performed in the UK each
4 year. The risk of VTE in this population is thought to be very low. However, there are some known
5 risk factors associated with upper limb surgery that can increase the risk of VTE. Similar to some
6 other surgical populations, the two main risk factors are duration of surgery and use of the general
7 anaesthesia.

30.2.8 Review question: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) in people having upper limb surgery?

11 For full details see review protocol in Appendix C.

12 **Table 131: PICO characteristics of review question**

Population	Adults and young people (16 years and older) having upper limb surgery who are: <ul style="list-style-type: none"> • Admitted to hospital • Having day procedures • Outpatients post-discharge
Interventions	<p>Mechanical:</p> <ul style="list-style-type: none"> • Anti-embolism stockings (AES) (above or below knee) • Intermittent pneumatic compression (IPCD) devices (full leg or below knee) • Foot pumps or foot impulse devices (FID) • Electrical stimulation (including Geko devices) <p>Pharmacological:</p> <ul style="list-style-type: none"> • Unfractionated heparin (UFH) (low dose, administered subcutaneously) • Low molecular weight heparin (LMWH), licensed in UK: <ul style="list-style-type: none"> ○ enoxaparin (standard prophylactic dose 40mg daily; minimum 20mg daily* to maximum 60mg twice daily*) ○ dalteparin (standard prophylactic dose 5000 units once daily; minimum 1250 units once daily* to maximum 5000 units twice daily*; obese patients – maximum 7500 twice units daily*) ○ tinzaparin (standard prophylactic dose 4500 units once daily; minimum 2500 units once daily* to maximum 4500 units twice daily*; obese patients – maximum 6750 twice daily*) • LMWH, licensed in countries other than UK: <ul style="list-style-type: none"> ○ Bemiparin (standard 2500 units daily; minimum 2500 units daily to maximum 3500 units daily) ○ Certoparin (3000 units daily) ○ Nadroparin (standard 2850 units once daily; minimum 2850 units once daily to maximum up to 57 units/kg once daily) ○ Parnaparin (standard 3200 units once daily; minimum 3200 units once daily to maximum 4250 units once daily) ○ Reviparin (minimum 1750 units once daily to maximum 4200 units once daily) • Vitamin K Antagonists: <ul style="list-style-type: none"> ○ warfarin (variable dose only) ○ acenocoumarol (all doses) ○ phenindione (all doses) • Fondaparinux (all doses)*

	<ul style="list-style-type: none"> • Apixaban (all doses)* • Dabigatran (all doses)* • Rivaroxaban (all doses)* • Aspirin (up to 300mg)* <p>*off-label</p>
Comparisons	<p>Compared to:</p> <ul style="list-style-type: none"> • Other VTE prophylaxis treatment, including monotherapy and combination treatments (between class comparisons for pharmacological treatments only) • No VTE prophylaxis treatment (no treatment, usual care, placebo) <p>Within intervention (including same drug) comparisons, including:</p> <ul style="list-style-type: none"> • Above versus below knee stockings • Full leg versus below knee IPC devices • Standard versus extended duration prophylaxis • Low versus high dose for LMWH • Preoperative versus post-operative initiation of LMWH
Outcomes	<p>Critical outcomes:</p> <ul style="list-style-type: none"> • All-cause mortality (up to 90 days from hospital discharge) • Deep vein thrombosis (symptomatic and asymptomatic) (7-90 days from hospital discharge. Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) • Pulmonary embolism (7-90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE • Major bleeding (up to 45 days from hospital discharge). A major bleeding event meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood ; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event. Includes unplanned visit to theatre for control of bleeding • Fatal PE (7- 90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE <p>Important outcomes:</p> <ul style="list-style-type: none"> • Clinically relevant non-major bleeding (up to 45 days from hospital discharge): bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy. • Health-related quality of life (validated scores only)(up to 90 days from hospital discharge) • Heparin-induced thrombocytopenia (HIT) (duration of study) • Technical complications of mechanical interventions (duration of study) • Unplanned return to theatre (up to 45 days from hospital discharge) • Upper limb DVT (7-90 days from hospital discharge. Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool)
Study design	Randomised controlled trials (RCTs), systematic reviews of RCTs

30.3.1 Clinical evidence

- 2 No relevant clinical studies comparing difference pharmacological and mechanical prophylaxis
- 3 strategies for people who are undergoing upper limb surgery. See the study selection flow chart in
- 4 Appendix E and excluded studies list in Appendix N.

30.4.5 Economic evidence

- 6 **Published literature**
- 7 No relevant health economic studies were identified.
- 8 See also the health economic study selection flow chart in Appendix F.

30.5.9 Evidence statements

- 10 **Clinical**
- 11 No relevant clinical studies were identified.
- 12 **Economic**
- 13 No relevant economic evaluations were identified.

30.6.4 Recommendations and link to evidence

Recommendations	<p>90. Be aware that VTE prophylaxis is generally not needed if giving local or regional anaesthetic for upper limb surgery. [2018]</p> <p>91. Consider VTE prophylaxis for people undergoing upper limb surgery if the person's total time under general anaesthetic is over 90 minutes or where their operation is likely to make it difficult for them to mobilise. [2018]</p>
Research recommendation	None
Relative values of different outcomes	<p>The guideline committee considered all-cause mortality (up to 90 days from hospital discharge), deep vein thrombosis (symptomatic and asymptomatic) (up to 90 days from hospital discharge), pulmonary embolism (up to 90 days from hospital discharge), fatal PE (up to 90 days from hospital discharge), and major bleeding (up to 45 days from hospital discharge) as critical outcomes.</p> <p>The guideline committee considered clinically relevant non-major bleeding (up to 45 days from hospital discharge), health-related quality of life (up to 90 days from hospital discharge), heparin-induced thrombocytopenia (duration of study), and technical complications of mechanical interventions (duration of study) as important outcomes.</p> <p>Please see section 4.3.3 in the methods chapter for further detail explaining prioritisation of the critical outcomes.</p>
Quality of the clinical evidence	No clinical evidence was identified for this review.
Trade-off between	The committee acknowledged that the risk of VTE is minimal in this population;

clinical benefits and harms	<p>particularly if the surgery is performed under local anaesthetic and the individuals undergoing the surgery have been assessed to be at low risk of VTE.</p> <p>The committee discussed that the increased risk of VTE events for people undergoing upper limb surgery is associated with surgery with a total general anaesthetic time over 90 minutes. The committee noted that this 90 minutes time-point is longer than the minimum time-point recommended for consideration of VTE prophylaxis in the lower limb surgery populations (60 minutes). This is due to the lower risk of developing VTE in upper limb surgeries compared to that of lower limb surgeries.</p> <p>In this group, the committee believed that prophylaxis should be considered based on individual VTE and bleeding risk assessment.</p>
Trade-off between net clinical effects and costs	<p>No relevant economic studies were identified for this population. Unit costs were presented to the committee.</p> <p>Given the lack of evidence, the committee considered that the provision of prophylaxis is likely to be cost effective only for individuals at higher risk of VTE where the cost of prophylaxis is likely to be off-set by the cost of averted VTE events.</p>
Other considerations	<p>The committee highlighted that some older people use their arms to support mobilisation (e.g. with a walking stick or frame). Therefore arm surgery would render this population partially immobilised until they recover from the upper limb surgery and their arm is no longer being used to support mobilisation.</p> <p>The 'consider' recommendation is a reflection of the lack of evidence in this population. However, it is the committee's belief that for this group of patients, prophylaxis is likely to be most clinically and cost effective when total time under general anaesthesia is longer than 90 minutes.</p>

1

31 Elective spinal surgery

31.1.2 Introduction

3 Elective spinal surgery is a subspecialty of both orthopaedic surgery and neurosurgery. It includes
 4 acute spinal injury surgery and elective spinal surgery (this evidence review will focus on elective
 5 spinal surgery). There is a considerable amount of uncertainty around the incidence of VTE events in
 6 the spinal surgery population. Despite this uncertainty the impact that a bleeding or VTE event can
 7 have is widely appreciated. In particular, the catastrophic long-term neurological consequences of
 8 extradural bleeding need to be balanced against the risk to life of VTE. Due to the potential life-
 9 changing effect a bleeding event can cause, it is important that the patient process involves the
 10 active recording of the clinical decision rather than a passive default position of no treatment.

31.2.1 Review question: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing spinal surgery?

14 For full details see review protocol in Appendix C.

15 **Table 132: PICO characteristics of review question**

Population	Adults and young people (16 years and older) undergoing spinal surgery admitted to hospital, having day procedures or outpatients post-discharge
Intervention(s)	<p>Mechanical:</p> <ul style="list-style-type: none"> • Anti-embolism stockings (above or below knee) • Intermittent pneumatic compression (IPCD) devices (full leg or below knee) • Foot pumps or foot impulse devices (FID) • Electrical stimulation (including Geko devices) • Continuous passive motion <p>Pharmacological:</p> <ul style="list-style-type: none"> • Unfractionated heparin (UFH) (low dose, administered subcutaneously) • Low molecular weight heparin (LMWH), licensed in UK: <ul style="list-style-type: none"> ○ enoxaparin (standard prophylactic dose 40mg daily; minimum 20mg daily* to maximum 60mg twice daily*) ○ dalteparin (standard prophylactic dose 5000 units once daily; minimum 1250 units once daily* to maximum 5000 units twice daily*; obese patients – maximum 7500 twice units daily*) ○ tinzaparin (standard prophylactic dose 3500 units once daily; minimum 2500 units once daily* to maximum 4500 units twice daily*; obese patients – maximum 6750 twice daily*) • LMWH, licensed in countries other than UK: <ul style="list-style-type: none"> ○ Bemiparin (standard 2500 units daily; minimum 2500 units daily to maximum 3500 units daily) ○ Certoparin (3000 units daily) ○ Nadroparin (standard 2850 units once daily; minimum 2850 units once daily to maximum up to 57 units/kg once daily) ○ Parnaparin (standard 3200 units once daily; minimum 3200 units once daily to maximum 4250 units once daily) ○ Reviparin (minimum 1750 units once daily to maximum 4200 units once daily)

	<ul style="list-style-type: none"> • Vitamin K Antagonists: <ul style="list-style-type: none"> ○ warfarin (variable dose only) ○ acenocoumarol (all doses) ○ phenindione (all doses) • Fondaparinux (all doses)* • Apixaban (2.5mg twice daily) • Dabigatran (220mg once daily; 150mg once daily - patients with moderate renal impairment, interacting medicines, over 75 years old) • Rivaroxaban (10mg once daily) • Aspirin (up to 300mg)* <p>*off-label</p>
Comparison(s)	<p>Compared to:</p> <ul style="list-style-type: none"> • Other VTE prophylaxis treatment, including monotherapy and combination treatments (between class comparisons for pharmacological treatments only) • No VTE prophylaxis treatment (no treatment, usual care, placebo) <p>Within intervention (including same drug) comparisons, including:</p> <ul style="list-style-type: none"> • Above versus below knee stockings • Full leg versus below knee IPC devices • Standard versus extended duration prophylaxis • Low versus high dose for LMWH • Preoperative versus post-operative initiation of LMWH
Outcomes	<p>Critical outcomes:</p> <ul style="list-style-type: none"> • All-cause mortality (up to 90 days from hospital discharge) • Deep vein thrombosis (symptomatic and asymptomatic) (7-90 days from hospital discharge). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) • Pulmonary embolism (symptomatic and asymptomatic) (7- 90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE • Major bleeding (up to 45 days from hospital discharge). A major bleeding event meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood ; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event. Includes returning to theatre for surgery for control of bleeding • Fatal PE (7-90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE <p>Important outcomes:</p> <ul style="list-style-type: none"> • Clinically relevant non-major bleeding (up to 45 days from hospital discharge): bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy. • Health-related quality of life (validated scores only)(up to 90 days from hospital discharge) • Heparin-induced thrombocytopenia (HIT) (duration of study) • Technical complications of mechanical interventions (duration of study) • Unplanned return to theatre (up to 45 days from hospital discharge)

Study design Randomised controlled trials (RCTs), systematic reviews of RCTs.

31.3 1 Clinical evidence

- 2 Two studies were included in the review ^{81 322}; these are summarised in Table 133 below. One study
3 was previously included in the previous guideline (CG92), ³²² and one study was added in the update.
- 4 One study that was previously included in CG92, has been excluded as the outcomes were measured
5 at 5 days (the minimum time-point is 7 days, as reported in the protocol (Appendix C) ²⁵⁷.
- 6 Evidence from these studies is summarised in the clinical evidence summary below (Table 134 and
7 Table 135). See also the study selection flow chart in Appendix E, forest plots in Appendix L, study
8 evidence tables in Appendix H, GRADE tables in Appendix K and excluded studies list in Appendix N.

9 **Table 133: Summary of studies included in the review**

Study	Intervention and comparison	Population	Outcomes	Comments
Du 2015 ⁸¹	<p><u>Intervention (n=324):</u> LMWH, parnaparin, 40mg once daily (standard dose), subcutaneously administered from 6-8 hours after surgery for 14 days when patients could fully ambulate.</p> <p><u>Comparison (n=341):</u> Rivaroxaban, 10mg, once daily, orally from 6-8 hours after surgery for 14 days when the patients could fully ambulate.</p>	<p>n=665</p> <p>People undergoing lumbar spinal surgery</p> <p>Age (mean): ≥60 years, 40% (no further details reported)</p> <p>Gender (male to female ratio): not reported</p> <p>China</p>	<p>All-cause mortality (14 days)</p> <p>DVT (symptomatic and asymptomatic) (14 days): confirmed by Doppler ultrasonography</p> <p>PE (14 days): confirmed by spiral computed tomography (CT) was conducted as soon as possible to determine pulmonary angiography</p> <p>Major bleeding (14 days): defined as fatal bleeding, bleeding in inflow critical organs (such as the posterior peritoneum, intracranial, intraocular, and intraspinal canal), bleeding-induced reoperation, or clinically significant bleeding outside the surgical site with a decrease of ≥20 g/L in haemoglobin level</p>	New study

Study	Intervention and comparison	Population	Outcomes	Comments
			<p>(with the level from the first postoperative day as the reference value), or the need to transfuse ≥ 2 units of whole blood or packed red blood cells.</p> <p>Clinically relevant non-major bleeding(14 days): included multi-sites bleeding, spontaneous haematoma, big incision haematoma</p>	
Wood 1997 ³²²	<p><u>Intervention (n=75):</u> Foot pump, inflatable wraps connected through tubing to a pneumatic control unit, inflation <0.4 seconds, cycle repeated every 20 seconds worn during and after surgery until patients were ambulant. Patients also wore AES, thigh-length, until discharge. No details reported about length of stay.</p> <p><u>Comparison (n=59):</u> IPCD, pneumatic compression wrap, thigh-length until patients were ambulant. AES, thigh-length (above-knee), placed on patients shortly before and during surgery and were worn until discharge. No details reported about length of stay.</p>	<p>n=134</p> <p>People undergoing spinal surgery, anterior lumbar interbody fusion, posterior lumbar and interbody fusion</p> <p>Age (mean): 39.5 years Gender (male to female ratio): 1.4:1</p> <p>USA</p>	<p>DVT (symptomatic and asymptomatic) (5-7 days): confirmed by duplex ultrasonography</p> <p>PE (5-7 days): definition not reported</p> <p>Visual analogue comfort scale (hospital discharge - time-point not reported)</p>	Included in CG92

1 Table 134: Clinical evidence summary: LMWH (standard dose; standard duration) versus rivaroxaban

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with rivaroxaban	Risk difference with LMWH (standard dose) (95% CI)
All-cause mortality	665 (1 study) 14 days	VERY LOW ^{2,3} due to risk of bias, imprecision	Peto OR 7.79 (0.15 to 392.95)	0 per 1000	- ¹
DVT (symptomatic and asymptomatic)	665 (1 study) 14 days	VERY LOW ^{2,3} due to risk of bias, imprecision	RR 1.4 (0.49 to 4)	18 per 1000	7 more per 1000 (from 9 fewer to 53 more)
PE	665 (1 study) 14 days	VERY LOW ^{2,3} due to risk of bias, imprecision	Peto OR 1.05 (0.07 to 16.88)	3 per 1000	0 more per 1000 (from 3 fewer to 44 more)
Major bleeding	665 (1 study) 14 days	VERY LOW ^{2,3} due to risk of bias, imprecision	Peto OR 0.54 (0.06 to 5.2)	6 per 1000	3 fewer per 1000 (from 6 fewer to 24 more)
Clinically relevant non-major bleeding	665 (1 study) 14 days	VERY LOW ^{2,3} due to risk of bias, imprecision	RR 1.05 (0.34 to 3.23)	18 per 1000	1 more per 1000 (from 12 fewer to 39 more)

1 Absolute effects could not be calculated due to zero events in the control arm

2 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

3 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.

2 Table 135: Clinical evidence summary: Foot pump + AES (above-knee) versus IPCD (above-knee) + AES (above-knee)

Outcomes	No of	Quality of the evidence	Relative	Anticipated absolute effects
----------	-------	-------------------------	----------	------------------------------

	Participants (studies) Follow up	(GRADE)	effect (95% CI)	Risk with IPCD + AES (above-knee)	Risk difference with Foot pump + AES (above-knee) (95% CI)
DVT (symptomatic and asymptomatic)	134 (1 study) 5-7 days	VERY LOW ^{1,2,3} due to risk of bias, indirectness, imprecision	Not estimable ⁴	Not estimable ⁴	0 fewer per 1000 (from 30 fewer to 30 more) ⁴
PE	134 (1 study) 5-7 days	VERY LOW ^{1,2,3} due to risk of bias, indirectness, imprecision	Not estimable ⁴	Not estimable ⁴	0 fewer per 1000 (from 30 fewer to 30 more) ⁴
Visual analogue comfort scale Scale from: 0 to 10.	134 (1 study) Hospital discharge; time-point not reported	VERY LOW ^{1,2,3} due to risk of bias, indirectness, imprecision	-	The mean visual analogue comfort scale (hospital discharge) in the control groups was 5.56	The mean visual analogue comfort scale (hospital discharge) in the intervention groups was 0.28 higher (0.69 lower to 1.25 higher)
<p>1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p> <p>2 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol</p> <p>3 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.</p> <p>4 Zero events in both arms. Risk difference calculated in Review Manager.</p>					

1
2
3

31.4.1 Economic evidence

2 Published literature

3 No relevant health economic studies were identified.

4 See also the health economic study selection flow chart in Appendix F.

31.5.5 Evidence statements

6 Clinical

7 There was possible clinical harm of LMWH in terms of all-cause mortality, DVT (symptomatic and
8 asymptomatic) and possible clinical benefit of LMWH in terms of major bleeding, however there was
9 imprecision around these estimates. There was no clinical difference between LMWH and
10 rivaroxaban in terms of PE and clinically relevant non-major bleeding. Quality of the all evidence in
11 this comparison was very low due to imprecision and indirectness.

12 There was no clinical difference between foot pump plus AES and IPCD plus AES in terms of DVT
13 (symptomatic and asymptomatic) and PE. There was reported possible clinical harm of foot pump
14 plus AES in terms of the quality of life measure of VAS, however there is uncertainty around this
15 result. Quality of the all evidence in this comparison was very low due to risk of bias, imprecision and
16 indirectness.

17 Economic

18 • No relevant economic evaluations were identified.

31.6.9 Recommendations and link to evidence

Recommendations	<p>92. Offer mechanical VTE prophylaxis on admission to people undergoing elective spinal surgery. Choose either:</p> <ul style="list-style-type: none">• anti-embolism stockings or• intermittent pneumatic compression. <p>Continue until the person no longer has significantly reduced mobility relative to their normal or anticipated mobility. [2018]</p> <p>93. Consider adding pharmacological VTE prophylaxis with LMWHⁿ for people undergoing elective spinal surgery whose risk of VTE outweighs their risk of bleeding, taking into account individual patient and surgical factors (major or complex surgery) and</p>
------------------------	--

ⁿ At the time of consultation (October 2017), LMWH did not have a UK marketing authorisation for use in young people under 18 for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information.

	<p>according to clinical judgement. [2018]</p> <p>94. If using LMWH^o for people undergoing elective spinal surgery, start giving it 24–48 hours postoperatively according to clinical judgement, taking into account patient characteristics and surgical procedure. Continue until the person no longer has significantly reduced mobility. [2018]</p> <p>95. If needed, start LMWH^p earlier than 24 hours after the operation for people undergoing elective spinal surgery. Base the decision on multidisciplinary or senior opinion, or locally agreed protocol. [2018]</p>
Research recommendation	None
Relative values of different outcomes	<p>The guideline committee considered all-cause mortality (up to 90 days from hospital discharge), deep vein thrombosis (symptomatic and asymptomatic) (7-90 days from hospital discharge), pulmonary embolism (7- 90 days from hospital discharge), major bleeding (up to 45 days from hospital discharge) and fatal PE (7- 90 days from hospital discharge) as critical outcomes.</p> <p>The guideline committee considered health-related quality of life (up to 90 days from hospital discharge), clinically relevant non-major bleeding (up to 45 days from hospital discharge), heparin-induced thrombocytopenia (duration of study), technical complications of mechanical interventions (duration of study) and unplanned return to theatre (up to 45 days from hospital discharge) as important outcomes.</p> <p>Please see section 4.3.3 in the methods chapter for further detail explaining prioritisation of the critical outcomes.</p>
Quality of the clinical evidence	<p>Two randomised controlled trials were included in this review. One study was previously included in CG92 and the other study was added in the update. The evidence evaluated pharmacological (LMWH and rivaroxaban) and mechanical interventions (foot pump, IPCD and AES).</p> <p>The comparison of LMWH at a standard dose for a standard duration versus rivaroxaban reported data for all-cause mortality, DVT (symptomatic and asymptomatic), PE, major bleeding and clinically relevant non-major bleeding. All of the evidence was graded very low due to risk of bias and imprecision. The comparison of foot pump with AES (above-knee) versus IPCD (above-knee) with AES above-knee reported outcome data for DVT (symptomatic and asymptomatic), PE and visual analogue comfort scale (VAS). All of the evidence was graded very low due to risk of bias, indirectness and imprecision.</p> <p>The committee noted the lack of evidence for this population and the poor quality of the literature.</p>
Trade-off between clinical benefits and harms	<p>The committee discussed that this population is at increased risk due to their high immobility associated with the surgical procedure. With both the induction process and the procedure itself the person is often under general anaesthetic and immobilised for at least 60 minutes.. The orthopaedic subgroup and guideline</p>

^o At the time of consultation (October 2017), LMWH did not have a UK marketing authorisation for use in young people under 18 for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information.

^p At the time of consultation (October 2017), LMWH did not have a UK marketing authorisation for use in young people under 18 for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information.

committee discussed that in current practice mechanical interventions are the preferred choice for VTE prophylaxis for spinal surgery patients and LMWH for those patients with a low risk of bleeding. Therefore, it was agreed that a similar prophylaxis strategy as that recommended in CG92 should be adopted; this indicates the use of mechanical VTE prophylaxis from admission for all spinal surgery patients and considering the addition of pharmacological prophylaxis in high VTE risk patients with a low risk of bleeding.

The guideline committee discussed that the results of the comparison between LMWH and rivaroxaban showed little clinical difference between the two interventions in terms of the VTE-related outcomes reported with uncertainty around the results due to imprecision. The guideline committee noted that although rivaroxaban is licensed in other orthopaedic populations (elective hip replacement and elective knee replacement) it is not licensed in a spinal surgery population. LMWH was previously recommended in CG92 and is currently used in standard practice; the guideline committee therefore felt that LMWH would be an effective pharmacological intervention to recommend for patients with low risk of bleeding.

There was an in-depth discussion about the starting time for LMWH and the lack of evidence in this area. The guideline committee discussed that there is a spectrum of opinion and practice around this, with initiation of LMWH ranging from 6-48 hours postoperatively. One of the studies included in this evidence review evaluated the initiation of LMWH from 6-8 hours postoperatively. The orthopaedic subgroup stated that this is not conventional practice. The guideline committee felt that it was important to give surgeons flexibility to start prophylaxis depending on the complexity of the surgery and patient factors. The guideline committee noted that the presence of postoperative bleeding complications are uncommon in spinal surgery, but emphasised that despite the low event rate when the complication does occur (such as bleeding in the spinal canal) it can be very serious. The committee believed that if the patient was going to develop a bleed this would usually be expected to occur within the first 24 hours post-surgery. Starting LMWH at 24 hours post-surgery was deemed acceptable taking into consideration, patient characteristics and bleeding risk. However due to the complex nature of orthopaedic spinal surgery, those being more cautious may wait longer than 24 hours (up to 48 hours) before initiating LMWH.

The guideline committee and orthopaedic subgroup discussed that some surgeons may feel that it is appropriate to start LMWH before 24 hours, e.g. if a patient has a history of VTE. It was stated that if LMWH is started before 24 hours post-operatively, it is essential that this is initiated only after an assessment by a senior clinician/consultant. This is to ensure that a low bleeding risk is accurately identified for the patient. The committee emphasised that this responsibility should not be given to junior clinicians. The committee acknowledged that the decision to commence LMWH earlier than 24 hours may be based on agreed local protocols for junior doctors to follow regarding when to seek multidisciplinary team and/or senior opinion.

The orthopaedic subgroup and guideline committee noted that the following factors should be considered when deciding a time-point for post-operative initiation of LMWH: the risk of haemorrhage, amount of blood loss (high blood loss and the use of LMWH can distort the blood mechanism and increase bleeding) and risk of a VTE event.

The majority of spinal surgery is lumbar with no instrumentation (such as discectomies) which would be expected to take approximately 60 minutes. Discectomy patients are usually younger, generally fitter and mobilise within 24 hrs and therefore very rarely require chemoprophylaxis. However it is important for clinicians to be aware that not every spinal surgery for disc prolapse is simple even in primary cases. Discectomies whether performed open or microscopically are at risk of hematoma formation.

More complex operations involving instrumentation can take much longer (4-5

	<p>hours). Duration of surgery is one of the three highly important risk factors for VTE listed by the guideline committee, alongside immobilisation and surgical position. The guideline committee noted that the duration of surgery cannot always be predicted thus a patient's risk of developing VTE can change during the procedure. The second risk factor is post-surgical immobilisation which may be due to paralysis, deficit or pain. Most fixations allow for mobilisation, as most fixation is to stabilise the spine and mobilise the patient early. The third risk factor is the position of the patient during surgery. For lumbar surgeries, a majority of patients are placed in a prone position where the legs are lower level than the body (specifically the inferior vena cava), increasing the risk of thrombosis the longer the patient is in this position.</p>
Trade-off between net clinical effects and costs	<p>No relevant economic studies were identified for this population. Unit costs were presented to the committee.</p> <p>The committee acknowledged the high risk of both VTE and bleeding in this population and the high cost of these events. The orthopaedic subgroup felt that based on the competing risks of these events, using mechanical prophylaxis would be the most clinically and economically justifiable option as the cost of mechanical prophylaxis provision would be off-set by the saving from the averted VTE events, while avoiding causing any increase in the risk of bleeding.</p> <p>The committee acknowledged that in people with low risk of bleeding, the cost of adding pharmacological prophylaxis with LMWH (standard dose) would be justified given the high downstream costs of the VTE events that would be averted. However, the subgroup felt that in absence of any economic evidence, the use of pharmacological prophylaxis should only be considered on individual basis based on proper risk assessment to ensure that the incremental cost of providing this extra prophylaxis is likely to be off-set in the longer term.</p>
Other considerations	None.

1

32 Intracranial surgery

32.1.2 Introduction

3 Intracranial surgery is usually completed by neurosurgeons and includes a range of operations
4 including craniotomies for brain tumours, subarachnoid haemorrhages and aneurysms. The majority
5 of these procedures would be less than 6 hours duration but there are some that would last longer.

6 The various intracranial surgical procedures can in some cases be associated with different risks of
7 developing VTE and bleeding events. For example, people undergoing intracranial surgery for brain
8 tumours can be at increased risk developing VTE due to risk factors including leg paresis, presence of
9 hypercoagulable states and previous history of neurosurgery. The risk of bleeding is particularly an
10 area of concern for patients requiring emergency cranial surgery.

11 It is crucial that clinicians weigh the risk of VTE and risk of bleeding in this population, taking into
12 account the surgical procedure itself.

32.2.3 Review question: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing intracranial surgery?

16 For full details see review protocol in Appendix C.

17 Table 136: PICO characteristics of review question

Population	Adults and young people (16 years and older) who are having intracranial surgery who are admitted to hospital, having day procedures or outpatients post-discharge
Intervention(s)	<p>Mechanical:</p> <ul style="list-style-type: none"> • Anti-embolism stockings (AES) (above or below knee) • Intermittent pneumatic compression (IPCD) devices (full leg or below knee) • Foot pumps or foot impulse devices (FID) • Electrical stimulation (including Geko devices) • Continuous passive motion <p>Pharmacological (no minimum duration):</p> <ul style="list-style-type: none"> • Unfractionated heparin (UFH) (low dose, administered subcutaneously) • Low molecular weight heparin (LMWH), licensed in UK: <ul style="list-style-type: none"> ○ enoxaparin (standard prophylactic dose 40 mg daily; minimum 20 mg daily* to maximum 60 mg twice daily*) ○ dalteparin (standard prophylactic dose 5000 units once daily; minimum 1250 units once daily* to maximum 5000 units twice daily*; obese patients – maximum 7500 twice units daily*) ○ tinzaparin (standard prophylactic dose 3500 units once daily; minimum 2500 units once daily* to maximum 4500 units twice daily*; obese patients – maximum 6750 twice daily*) • LMWH, licensed in countries other than UK: <ul style="list-style-type: none"> ○ Bemiparin (standard 2500 units daily; minimum 2500 units daily to maximum 3500 units daily) ○ Certoparin (3000 units daily) ○ Nadroparin (standard 2850 units once daily; minimum 2850 units once daily to

	<p>maximum up to 57 units/kg once daily)</p> <ul style="list-style-type: none"> ○ Parnaparin (standard 3200 units once daily; minimum 3200 units once daily to maximum 4250 units once daily) ○ Reviparin (minimum 1750 units once daily to maximum 4200 units once daily) ● Vitamin K Antagonists: warfarin (variable dose), acenocoumarol (all doses), phenindione (all doses) ● Fondaparinux (all doses) ● Apixaban (all doses) ● Dabigatran (all doses) ● Rivaroxaban (all doses) ● Aspirin (up to 300 mg)
Comparison(s)	<p>Compared to:</p> <ul style="list-style-type: none"> ● Other VTE prophylaxis treatment, including monotherapy and combination treatments (between class comparisons for pharmacological treatments only) ● No VTE prophylaxis treatment (no treatment, usual care, placebo) <p>Within intervention (including same drug) comparisons, including:</p> <ul style="list-style-type: none"> ● Above versus below knee stockings ● Full leg versus below knee IPC devices ● Standard versus extended duration prophylaxis. Extended duration = extended beyond discharge ● Low versus high dose for LMWH only ● Preoperative versus post-operative initiation of LMWH
Outcomes	<p>Critical outcomes:</p> <ul style="list-style-type: none"> ● All-cause mortality (up to 90 days from hospital discharge) ● Deep vein thrombosis (symptomatic and asymptomatic) (7–90 days from hospital discharge). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) ● Pulmonary embolism (symptomatic and asymptomatic) (7–90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE ● Major bleeding (up to 45 days from hospital discharge). A major bleeding event meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood ; leads to a drop in haemoglobin of ≥ 2 g/dl; a serious or life threatening clinical event. Includes unplanned visit to theatre for control of bleeding ● Fatal PE (7–90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE <p>Important outcomes:</p> <ul style="list-style-type: none"> ● Clinically relevant non-major bleeding (up to 45 days from hospital discharge): bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy ● Health-related quality of life (validated scores only)(up to 90 days from hospital discharge) ● Heparin-induced thrombocytopenia (HIT) (duration of study) ● Technical complications of mechanical interventions (duration of study)
Study design	Randomised controlled trials (RCTs), systematic reviews of RCTs.

Strata	People who are contraindicated for pharmacological prophylaxis People who are contraindicated for mechanical prophylaxis People with intracranial tumour having neurosurgery
---------------	--

32.3.1 Clinical evidence

2 Five studies were included in the review^{49,76,115,199,312}; these are summarised in Table 137 below.
 3 Fourteen studies were included in the previous guideline (CG92)^{2,43,49,76,115,199,211,234,271,295-297,312,313}.
 4 Six studies were excluded as they did not fit the population inclusion criteria for this review^{2,234,271}.
 5²⁹⁵⁻²⁹⁷. One study was excluded due to having an inappropriate comparison⁴³. One paper was
 6 excluded as it did not report any relevant outcomes³¹³. One paper was excluded as it was an abstract
 7 only²¹¹. One new study was included in the update²⁴¹. Evidence from the included studies is
 8 summarised in the clinical evidence summary tables below (Table 138, Table 139, Table 140, Table
 9 141, Table 142, Table 143). See also the study selection flow chart in Appendix E, forest plots in
 10 Appendix L, study evidence tables in Appendix H, GRADE tables in Appendix K and excluded studies
 11 list in Appendix N.

12 **Table 137: Summary of studies included in the review**

Study	Intervention and comparison	Population	Outcomes	Comments
Cerrato 1978 ⁴⁹	<p><u>Intervention (n=50):</u> UFH 5000U, given 2 hours before surgery and 3x daily after for at least 7 days</p> <p><u>Comparison (n=50):</u> No VTE prophylaxis</p>	<p>n=100</p> <p>People having elective neurosurgery (meningiomas 31%, gliomas 29%, arterial aneurysms 13%, metastatic tumours 7%, angiomas 5%, neurinomas 4%, hemangioblastomas 3%, craniopharyngiomas 2%, pituitary adenomas 1%, cavernous angiomas 1%, arachnoid cysts 1%, chemodectomas 1%, epidurmoid tumours 1%)</p> <p>Age: 40 years or over; mean intervention 53±9, control 51±7</p> <p>Male to female ratio 1:1</p> <p>Italy</p>	DVT (8 days): 125I-labeled fibrinogen test	Strata: people with intracranial tumour having neurosurgery
Dickinson 1998 ⁷⁶	<p><u>Intervention 1 (n=23):</u> LMWH, high dose (enoxaparin 30 mg pre-op, 30 mg 2x daily post-op), administered subcutaneously + sequential</p>	<p>n=66</p> <p>People having neurosurgery for intracranial neoplasms</p>	<p>Mortality (30 days)</p> <p>DVT (30 days): confirmed by duplex imaging (on four occasions in the first 1 month after surgery)</p>	Strata: people with intracranial tumour having neurosurgery

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>compression device, thigh length</p> <p><u>Intervention 2 (n=21):</u> LMWH, high dose (enoxaparin 30mg pre-op, 30 mg 2x daily post-op), administered subcutaneously</p> <p><u>Intervention 3 (n=22):</u> Sequential compression device, thigh length</p>	<p>Age: range 50-100 Male and female</p> <p>USA</p>	<p>PE (30 days): symptomatic</p> <p>Major bleeding(30 days): intra-cerebral haemorrhage or epidural haematoma</p>	
Goldhaber 2002 ¹¹⁵	<p><u>Intervention (n=75):</u> LMWH, standard dose (enoxaparin 40 mg 1x daily) + IPCD</p> <p><u>Comparison (n=75):</u> UFH 5000IU 2x daily + IPCD</p>	<p>n=150</p> <p>People undergoing craniotomy with suspected or metastatic brain tumour</p> <p>Age: mean intervention 48.33±15.07 years, comparison: 48.87±12.52 years</p> <p>Male to female ratio 79:71</p> <p>USA</p>	<p>Mortality (30 days)</p> <p>DVT (30 days): confirmed by duplex ultrasonography</p> <p>Major bleeding (30 days): major postoperative bleeding complications</p>	Strata: people with intracranial tumour having neurosurgery
Macdonald 2003 ¹⁹⁹	<p><u>Intervention (n=51):</u> LMWH, low dose (Dalteparin 2500 IU 1x daily)</p> <p><u>Comparison (n=49):</u> UFH 5000 IU 2x daily</p>	<p>n=100</p> <p>People undergoing craniotomy for brain neoplasm, including trans-sphenoidal surgery, intracranial aneurysm, vascular malformation, infection, spontaneous intracranial hematoma, closed head injury or cortical resection for epilepsy</p> <p>Diagnosis: Brain tumour 63% Aneurysm 15% Microvascular decompression 6% Chiari malformation 6%</p>	<p>Mortality (30 days)</p> <p>DVT (7 days): confirmed by Doppler US</p> <p>PE (30 days): symptomatic, confirmed by ventilation perfusion scan or spiral CT</p> <p>Major bleeding (30 days): intracranial haemorrhage confirmed by CT scan and MRI</p> <p>Thrombocytopenia (30 days)</p>	Strata: People having intracranial surgery (non-tumour) as tumour <80%

Study	Intervention and comparison	Population	Outcomes	Comments
		Vascular malformation 3% Age: mean 51 ±15 years Male to female ratio 23:28 USA		
Wautrecht 1996 ³¹²	<u>Intervention (n=25):</u> IPCD (thigh-length), from the night prior to the operation until at least 72 hours after the operation. AES, thigh-length pre-op continued for 10 days or until ambulant <u>Comparison (n=10):</u> AES alone, from admission until discharge (hospital stay duration not reported)	n=35 People undergoing neurosurgery for brain tumours No further details reported	DVT (8-10 days): confirmed by venography PE (8-10 days): confirmed by pulmonary scintigraphy Fatal PE (8-10 days): definition not reported	Strata: people with intracranial tumour having neurosurgery

32.3.1.1 Strata: People undergoing intracranial surgery (non-tumour specific)

2 Table 138: Clinical evidence summary: LMWH (low dose; standard duration) versus UFH

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with LMWH (low dose) versus UFH (95% CI)
All-cause mortality	100 (1 study) 30 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.13 (0 to 6.55)	20 per 1000	18 fewer per 1000 (from 20 fewer to 100 more)
DVT (symptomatic and asymptomatic)	100 (1 study) 7 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 7.25 (0.45 to 117.6)	0 per 1000	Not estimable ⁵
PE	100 (1 study) 30 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Not estimable ⁴	Not estimable ⁴	0 fewer per 1000 (from 40 fewer to 40 more) ³
Fatal PE	100 (1 study) 30 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Not estimable ⁴	Not estimable ⁴	0 fewer per 1000 (from 40 fewer to 40 more) ³
Major bleeding	100 (1 study) 30 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 1.9 (0.19 to 18.67)	20 per 1000	18 more per 1000 (from 16 fewer to 260 more)
Thrombocytopenia	100 (1 study) 30 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 1.9 (0.19 to 18.67)	20 per 1000	18 more per 1000 (from 16 fewer to 260 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs
3 Risk difference calculated in Review Manager
4 Zero events in both arms
5 Zero events in control arm

32.3.2.1 Strata: People with intracranial tumour having neurosurgery

2 Table 139: Clinical evidence summary: UFH versus no prophylaxis

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with UFH versus no VTE prophylaxis (95% CI)
DVT (symptomatic and asymptomatic)	100 (1 study) 8 days	MODERATE ¹ due to risk of bias	RR 0.18 (0.06 to 0.56)	340 per 1000	279 fewer per 1000 (from 150 fewer to 320 fewer)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

3 Table 140: Clinical evidence summary: LMWH (standard dose; standard duration) + IPCD versus UFH + IPCD

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with LMWH (standard) + IPCD versus UFH + IPCD (95% CI)
All-cause mortality	150 (1 study) 30 days	VERY LOW ^{3,4} due to risk of bias, imprecision	Not estimable ²	Not estimable ²	0 fewer per 1000 (from 30 fewer to 30 more) ¹
DVT (symptomatic and asymptomatic)	140 (1 study) 30 days	VERY LOW ^{3,4} due to risk of bias, imprecision	Peto OR 2.21 (0.73 to 6.65)	67 per 1000	70 more per 1000 (from 17 fewer to 255 more)
Major bleeding	150 (1 study) 30 days	VERY LOW ^{3,4,5} due to risk of bias, indirectness, imprecision	Peto OR 1.97 (0.2 to 19.19)	13 per 1000	13 more per 1000 (from 11 fewer to 193 more)

1 Risk difference calculated in Review Manager
 2 Zero events in both arms
 3 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
 4 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with LMWH (standard) + IPCD versus UFH + IPCD (95% CI)
5 Downgraded by 1 or 2 increments because the majority of the evidence had indirect outcomes					

1 Table 141: Clinical evidence summary: LMWH (high dose; standard duration) +IPCD versus IPCD

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with LMWH (high dose)+IPCD versus IPCD (95% CI)
All-cause mortality	45 (1 study) 30 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.96 (0.06 to 15.78)	45 per 1000	2 fewer per 1000 (from 43 fewer to 384 more)
DVT (symptomatic and asymptomatic)	45 (1 study) 30 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 1.28 (0.32 to 5.06)	136 per 1000	38 more per 1000 (from 93 fewer to 554 more)
PE	45 (1 study) 30 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Not estimable ⁴	Not estimable ⁴	0 fewer per 1000 (from 80 fewer to 80 more) ³
Fatal PE	45 (1 study) 30 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Not estimable ⁴	Not estimable ⁴	0 fewer per 1000 (from 80 fewer to 80 more) ³
Major bleeding	45 (1 study) 30 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 7.77 (0.77 to 78.78)	0 per 1000	Not estimable ⁵

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs
3 Risk difference calculated in Review Manager
4 Zero events in both arms
5 Zero events in control arm

1 Table 142: Clinical evidence summary: LMWH (high dose; standard duration) versus IPCD

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with LMWH (high dose) versus IPCD (95% CI)
All-cause mortality	43 (1 study) 30 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.14 (0 to 7.15)	45 per 1000	39 fewer per 1000 (from 45 fewer to 209 more)
DVT (symptomatic and asymptomatic)	43 (1 study) 30 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.36 (0.05 to 2.74)	136 per 1000	83 fewer per 1000 (from 129 fewer to 166 more)
PE	43 (1 study) 30 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Not estimable ⁴	Not estimable ⁴	0 fewer per 1000 (from 40 fewer to 40 more) ³
Fatal PE	43 (1 study) 30 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Not estimable ⁴	Not estimable ⁴	0 fewer per 1000 (from 40 fewer to 40 more) ³
Major bleeding	43 (1 study) 30 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 8.15 (0.49 to 134.79)	0 per 1000	Not estimable ⁵

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs

3 Risk difference calculated in Review Manager

4 Zero events in both arms

5 Zero events in control arm

2 Table 143: Clinical evidence summary: IPCD + AES versus AES alone

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with IPCD + AES versus AES (95% CI)
DVT (symptomatic and	23	VERY LOW ^{1,2}	Peto OR 0.01	400 per 1000	393 fewer per 1000

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with IPCD + AES versus AES (95% CI)
asymptomatic)	(1 study) 8-10 days	due to risk of bias, imprecision	(0 to 0.25)		(from 257 fewer to 400 fewer)
PE	35 (1 study) 8-10 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Not estimable ⁴	Not estimable ⁴	0 fewer per 1000 (from 130 fewer to 130 more) ³
Fatal PE	35 (1 study) 8-10 days	VERY LOW ^{1,2,5} due to risk of bias, indirectness, imprecision	Not estimable ⁴	Not estimable ⁴	0 fewer per 1000 (from 130 fewer to 130 more) ³

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs
3 Risk difference calculated in Review Manager
4 Zero events in both arms
5 Downgraded by 1 or 2 increments because the majority of the evidence had indirect outcomes

1

2

32.4¹ Economic evidence

- 2 No relevant health economic studies were identified.
- 3 See also the health economic study selection flow chart in Appendix F.

32.5⁴ Evidence statements

5 Clinical

6 *People undergoing intracranial surgery (non-tumour surgery)*

7 LMWH at a low dose for a standard duration was compared with UFH, the outcomes all-cause
8 mortality, DVT (symptomatic and asymptomatic), PE, fatal PE, major bleeding and heparin-induced
9 thrombocytopenia were reported in one study. There was possible clinical benefit of LMWH in terms
10 of all-cause mortality, however the result may also have been consistent with no difference. There
11 was possible clinical harm in terms of DVT (symptomatic and asymptomatic), major bleeding and
12 heparin-induced thrombocytopenia, however the large uncertainty around these results was also
13 consistent with no difference or benefit. There was no clinical difference in terms of PE and fatal PE,
14 although again there was large uncertainty around these results. The quality of the evidence was
15 very low due to risk of bias and imprecision.

16 *People with intracranial tumour having neurosurgery*

17 UFH was compared with no prophylaxis, the outcome DVT (symptomatic and asymptomatic) was
18 reported in one study. There was clinical benefit of UFH in terms of DVT (symptomatic and
19 asymptomatic). The quality of the evidence was moderate due to risk of bias.

20 LMWH at a standard dose for a standard duration in combination with IPCD was compared with UFH
21 in combination with IPCD, the outcomes all-cause mortality, DVT (symptomatic and asymptomatic)
22 and major bleeding were reported in one study. There was possible clinical harm of LMWH in
23 combination with IPCD in terms of DVT and major bleeding, although there was uncertainty around
24 these results. There was no clinical difference in terms of all-cause mortality. The quality of the
25 evidence was very low due to risk of bias, imprecision and indirectness.

26 LMWH at a high dose for a standard duration in combination with IPCD was compared with IPCD, the
27 outcomes all-cause mortality, DVT (symptomatic and asymptomatic), PE, fatal PE and major bleeding
28 were reported in one study. There was possible clinical benefit of LMWH in combination with IPCD in
29 terms of all-cause mortality and DVT (symptomatic and asymptomatic). There was possible clinical
30 harm of LMWH in terms of major bleeding and there was no clinical difference in terms of PE and
31 fatal PE. All these results were associated with large confidence intervals and therefore are
32 considerable uncertain. The quality of the evidence was very low due to risk of bias and imprecision.

33 LMWH at a high dose for a standard duration was compared with IPCD, the outcomes all-cause
34 mortality, DVT (symptomatic and asymptomatic), PE, fatal PE and major bleeding were reported in
35 one study. There was possible clinical benefit of LMWH in combination with IPCD in terms of all-
36 cause mortality and DVT (symptomatic and asymptomatic). There was possible clinical harm of
37 LMWH in terms of major bleeding and there was no clinical difference in terms of PE and fatal PE. All
38 these results were associated with large confidence intervals and therefore are considerable
39 uncertain. The quality of the evidence was very low due to risk of bias and imprecision.

40 IPCD in combination with AES was compared with AES alone, the outcomes DVT (symptomatic and
41 asymptomatic), PE and fatal PE. There was clinical benefit of IPCD in terms of DVT (symptomatic and

- 1 asymptomatic), and no clinical difference in terms of PE and fatal PE, although the PE outcomes were
- 2 very uncertain. The quality of the evidence was very low due to risk of bias, indirectness and
- 3 imprecision.

4 Economic

- 5 • No relevant economic evaluations were identified.

32.6.6 Recommendations and link to evidence

Recommendations	<p>96. Consider mechanical VTE prophylaxis for people undergoing cranial surgery. [2018]</p> <p>97. If using mechanical VTE prophylaxis for people undergoing cranial surgery, start it on admission. Choose either:</p> <ul style="list-style-type: none"> • anti-embolism stockings or • intermittent pneumatic compression. <p>Continue until the person no longer has significantly reduced mobility relative to their normal or anticipated mobility. [2018]</p> <p>98. Consider adding pharmacological VTE prophylaxis with LMWH^q up to 24 hours before surgery for people undergoing cranial surgery whose risk of VTE outweighs their risk of bleeding. [2018]</p> <p>99. Consider adding pharmacological VTE prophylaxis with LMWH^r after surgery for people undergoing cranial surgery whose risk of VTE outweighs their risk of bleeding. Continue for a minimum of 7 days. [2018]</p> <p>100. Be aware that cerebrospinal fluid drains and intracranial pressure monitors may increase the risk of intracranial bleeding. [2018]</p> <p>101. Do not offer pharmacological VTE prophylaxis to people with ruptured cranial vascular malformations (for example, brain aneurysms) or people with intracranial haemorrhage (spontaneous or traumatic) until the lesion has been secured or the condition has stabilised. [2018]</p>
Research recommendation	None
Relative values of	The guideline committee considered all-cause mortality (up to 90 days from hospital

^q At the time of consultation (October 2017), LMWH did not have a UK marketing authorisation for use in young people under 18 for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information.

^r At the time of consultation (October 2017), LMWH did not have a UK marketing authorisation for use in young people under 18 for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information.

different outcomes	<p>discharge), deep vein thrombosis (symptomatic and asymptomatic) (7-90 days from hospital discharge), pulmonary embolism (7- 90 days from hospital discharge), major bleeding (up to 45 days from hospital discharge) and fatal PE (7- 90 days from hospital discharge) as critical outcomes.</p> <p>The guideline committee considered health-related quality of life (up to 90 days from hospital discharge), clinically relevant non-major bleeding (up to 45 days from hospital discharge), heparin-induced thrombocytopenia (duration of study) and technical complications of mechanical interventions (duration of study) as important outcomes.</p> <p>Please see section 4.3.3 in the methods chapter for further detail explaining prioritisation of the critical outcomes.</p>
Quality of the clinical evidence	<p>Five randomised controlled trials were included in this review. All of the studies were included in the previous guideline (CG92). The committee pre-specified a stratum of people with intracranial tumour having neurosurgery, four studies were included in this stratum and one study was non-tumour specific (a combined population covering all intracranial surgery). A total of six intervention comparisons were identified from the five studies included, with one of the studies being a three-arm trial. These comparisons evaluated the use of pharmacological (different doses of LMWH and UFH) and mechanical prophylaxis (IPCD and AES) in people undergoing intracranial surgery.</p> <p>The one study in a non-tumour specific intracranial population evaluated the use of LMWH (low prophylactic dose) versus UFH. This study reported data for all of the critical outcomes and heparin-induced thrombocytopenia. All of the evidence in this comparison was graded very low due to risk of bias and imprecision.</p> <p>Within the stratum of people with intracranial tumour having neurosurgery, a study evaluated UFH versus no VTE prophylaxis. DVT (symptomatic and asymptomatic) was the only relevant outcome reported. This outcome was graded moderate due to risk of bias. Another study evaluated LMWH (standard dose) with IPCD versus UFH with IPCD and reported data for all-cause mortality, DVT (symptomatic and asymptomatic) and major bleeding. The evidence was graded very low due to risk of bias, imprecision and indirectness. A study compared LMWH (high dose) with IPCD versus IPCD alone and reported data for all of the critical outcomes. The evidence was graded very low due to risk of bias and imprecision. This same study evaluated LMWH (high dose) versus IPCD, reporting the same relevant outcomes for this comparison and graded with same quality due to risk of bias and imprecision.</p>
Trade-off between clinical benefits and harms	<p>It was suggested that this section encompass all cranial surgery on the understanding that this involves procedures carried out by a neurosurgeon. This was chosen as a more generic term than intracranial surgery as some operations to remove tumours do not necessarily involve opening the dura. For example, if a tumour is at the base of the skull it will still be dealt with by a neurosurgeon. There may be multidisciplinary involvement with oral and ENT surgeons but this will usually be for assistance with access, with the condition itself still sitting within neurosurgery. The committee acknowledge that this definition encompasses minor cranial surgeries (bony lumps) as well as other relatively minor operations undertaken by neurosurgeons on nerves in the arms and legs (peripheral nerve surgery) such as carpal tunnel decompression. However the committee reiterate that the guideline cannot pragmatically cover every different surgery separately and that these patients will likely be assessed as low or very low risk for VTE at the risk assessment stage due to usually being short (<60-90 mins) day case surgeries.</p> <p>There are different levels of VTE risk associated with neurosurgery to remove intracranial tumours based on the type of tumour. Surgery for benign tumours (meningioma's and acoustic tumours) tends to last longer (3-8+ hours) than surgery for malignant tumours (primarily gliomas and metastases) which usually involves biopsy which may take 1.5-2 hours or open operation of ~4 hours. However those</p>

	<p>people undergoing cranial surgery for malignant tumours will usually be assessed as at increased risk of VTE due to the ‘active cancer’ risk factor. Given that all people undergoing cranial surgery would have at first been assessed for risk of VTE based on these factors the committee did not deem it necessary to write separate prophylaxis recommendations based on the tumour type.</p> <p>The committee discussed the evidence alongside the previous recommendation made in CG92. In CG92 this population was merged with recommendations for people undergoing spinal surgery (jointly termed neurological surgery). While the evidence in the more specific cranial surgery population included in this update was mostly of very low quality due largely to imprecision around the effect estimates, the committee believed the evidence generally supported the recommendations made in the previous guideline – use of mechanical prophylaxis as first option with the addition of pharmacological prophylaxis for those at increased risk of VTE above their risk of bleeding. However the committee believed that a softer ‘consider’ recommendation was more appropriate for this population to reflect the uncertainty of the evidence.</p>
<p>Trade-off between net clinical effects and costs</p>	<p>No economic studies have been included in this review. Relevant unit costs were presented. The committee acknowledged that this is a population at high risk of bleeding and hence; mechanical prophylaxis options (for example IPCD) would be preferable in terms of safety and avoidance of major bleeding. For those at low risk of bleeding, LMWHs (standard dose) were considered to have the most favourable benefit-harm balance. This was supported by their slightly lower total drug and monitoring costs compared to UFH, making them the likely cost effective option among the pharmacological prophylaxis options considered.</p>
<p>Other considerations</p>	<p>Clinical practice has changed within this population since the last guideline has been published. Less invasive surgeries are being used and more clinicians are encouraging earlier mobilisation and hydration. Whilst these factors reduce VTE risk, not all patients mobilise soon after surgery and co-morbidities remain common in this population.</p> <p>The recommendation against pharmacological prophylaxis for people with haemorrhage is also expected to encompass people with traumatic brain injury or head injury. This recommendation is also cross-referred to from the major trauma section. While people with head injury may have suspected haemorrhage and the wording of the recommendation suggests that the haemorrhage has already been identified, the committee suggested that once a person has been admitted following trauma, standard practice is to have a scan to identify or exclude the presence of haemorrhage, and therefore it was acceptable to cross-refer to the recommendation in this cranial surgery population.</p> <p>The committee decided to make a cautionary recommendation for people fitted with intracranial devices as it is believed that people fitted with the two most common devices listed in the recommendation may be at increased risk of bleeding.</p>

33 Spinal injury

33.1.2 Introduction

3 Spinal injury and, in particular, spinal cord injury is a significant cause of morbidity and mortality with
4 younger age groups frequently affected. Spinal injury can occur with or without injury to the spinal
5 cord or cauda equina. Even without injury to the spinal cord or cauda equina, patients with spinal
6 injury may be at increased risk of VTE for reasons of prolonged immobility.

7 Non-traumatic causes of spinal cord compression are covered in other guidelines, for example, in the
8 NICE Metastatic spinal cord compression guideline CG75²²⁵. However, further evidence is evaluated
9 in the palliative care (Chapter 19) and critical care (Chapter 20) sections of this guideline. The
10 evidence for patients undergoing elective spinal surgery is presented in chapter 31.

11 The major concern in this population is the constantly changing balance between the initial risk of
12 bleeding (potentially a catastrophic complication within the enclosed space of the spine) and the
13 subsequent increased risk of thrombotic events, particularly, with prolonged immobilisation.

33.2.4 Review question: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people with spinal injury?

17 For full details see review protocol in Appendix C.

18 **Table 144: PICO characteristics of review question**

Population	Adults and young people (16 years and older) with cord or spinal column injury who are: <ul style="list-style-type: none"> • Admitted to hospital • Outpatients post-discharge
Intervention(s)	<p>Mechanical:</p> <ul style="list-style-type: none"> • Anti-embolism stockings (AES) (above or below knee) • Intermittent pneumatic compression (IPCD) devices (full leg or below knee) • Foot pumps or foot impulse devices (FID) • Electrical stimulation (including Geko devices) • Continuous passive motion <p>Pharmacological:</p> <ul style="list-style-type: none"> • Unfractionated heparin (UFH) (low dose, administered subcutaneously) • Low molecular weight heparin (LMWH), licensed in UK: <ul style="list-style-type: none"> ○ enoxaparin (standard prophylactic dose 40 mg daily; minimum 20 mg daily* to maximum 60 mg twice daily*) ○ dalteparin (standard prophylactic dose 5000 units once daily; minimum 1250 units once daily* to maximum 5000 units twice daily*; obese patients – maximum 7500 twice units daily*) ○ tinzaparin (standard prophylactic dose 3500-4500 units once daily; minimum 2500 units once daily* to maximum 4500 units twice daily*; obese patients – maximum 6750 twice daily*) • LMWH, licensed in countries other than UK: <ul style="list-style-type: none"> ○ Bemiparin (standard 2500 units daily; minimum 2500 units daily to maximum 3500 units daily)

	<ul style="list-style-type: none"> ○ Certoparin (3000 units daily) ○ Nadroparin (standard 2850 units once daily; minimum 2850 units once daily to maximum up to 57 units/kg once daily) ○ Parnaparin (standard 3200 units once daily; minimum 3200 units once daily to maximum 4250 units once daily) ○ Reviparin (minimum 1750 units once daily to maximum 4200 units once daily) ● Vitamin K Antagonists: <ul style="list-style-type: none"> ○ warfarin (variable dose only) ○ acenocoumarol (all doses) ○ phenindione (all doses) ● Fondaparinux (all doses)* ● Apixaban (all doses)* ● Dabigatran (all doses)* ● Rivaroxaban (all doses)* ● Aspirin (up to 300 mg)* <p>*off-label</p>
<p>Comparison(s)</p>	<p>Compared to:</p> <ul style="list-style-type: none"> ● Other VTE prophylaxis treatment, including monotherapy and combination treatments (between class comparisons for pharmacological treatments only) ● No VTE prophylaxis treatment (no treatment, usual care, placebo) <p>Within intervention (including same drug) comparisons, including:</p> <ul style="list-style-type: none"> ● Above versus below knee stockings ● Full leg versus below knee IPC devices ● Standard versus extended duration prophylaxis. Extended duration = extended beyond discharge ● Low versus high dose for LMWH ● Preoperative versus post-operative initiation of LMWH
<p>Outcomes</p>	<p>Critical outcomes:</p> <ul style="list-style-type: none"> ● All-cause mortality (up to 90 days from hospital discharge) ● Deep vein thrombosis (symptomatic and asymptomatic) (7-90 days from hospital discharge). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) ● Pulmonary embolism (symptomatic and asymptomatic) (7- 90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE ● Major bleeding (up to 45 days from hospital discharge). A major bleeding event meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood ; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event. Includes returning to theatre for surgery for control of bleeding and epidural bleeding ● Fatal PE (7- 90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE <p>Important outcomes:</p> <ul style="list-style-type: none"> ● Clinically relevant non-major bleeding (up to 45 days from hospital discharge): bleeding that does not meet the criteria for major bleed but requires medical

	<p>attention and/or a change in antithrombotic therapy.</p> <ul style="list-style-type: none"> • Health-related quality of life (validated scores only)(up to 90 days from hospital discharge) • Heparin-induced thrombocytopenia (HIT) (duration of study) • Technical complications of mechanical interventions (duration of study)
Study design	Randomised controlled trials (RCTs), systematic reviews of RCTs.

33.3.1 Clinical evidence

2 Four studies were included in the review^{122,212,276}; these are summarised in Table 145 below. Four
3 studies were included in the previous guideline (CG92)^{122,123,212,276}, one of which was excluded due
4 to having an inappropriate adjunct to the intervention¹²³. One new study¹²⁷ was identified during
5 the update. Evidence from these studies is summarised in the clinical evidence summary below
6 (Table 146, Table 147, Table 148, Table 149). See also the study selection flow chart in Appendix E,
7 forest plots in Appendix L, study evidence tables in Appendix H, GRADE tables in Appendix K and
8 excluded studies list in Appendix N.

9 **Table 145: Summary of studies included in the review**

Study	Intervention and comparison	Population	Outcomes	Comments
Green 1990 ¹²²	<p>Intervention (n=20): LMWH - standard dose (tinzaparin 3500U 1x daily), administered subcutaneously</p> <p>Comparison (n=21): UFH 5000U 3x daily, administered subcutaneously</p>	<p>n=41</p> <p>People with complete motor paralysis after spinal cord injury, sustained with previous 72 hours</p> <p>Age: intervention mean 28.3±11.8; comparison 31.4±15.5</p> <p>Male to female ratio 34:7</p> <p>USA</p>	<p>All-cause mortality (56 days)</p> <p>Fatal PE (56 days). Confirmed by: autopsy</p> <p>DVT (56 days). Screened with impedance plethysomography, Doppler flow measurement and DUS, 2 patients confirmed by venography, 1 patient confirmed by symptom and abnormal flow study</p> <p>Major bleeding (56 days): reported fatal bleeding only</p>	
Halim 2014 ¹²⁷	<p>Intervention (n=37): LMWH, standard dose (enoxaparin 40mg 1x daily), started on day of admission and continued for 8 weeks</p> <p>Comparison (n=37): no pharmacological VTE prophylaxis</p> <p>Both groups received concomitant</p>	<p>n=74</p> <p>People with acute spinal cord injury (≤5 days)</p> <p>Age not reported</p> <p>Male to female ratio 60:14</p> <p>Ethnicity: Indian</p> <p>India</p>	<p>DVT (12-16 days): colour Doppler venous ultrasonography</p> <p>PE (12-16 days): symptomatic, identified by clinical assessment</p>	

Study	Intervention and comparison	Population	Outcomes	Comments
	mechanical prophylaxis such as AES			
Merli 1988 ²¹²	Intervention (n=19): UFH 5000U 3x daily, administered subcutaneously Comparison (n=17): placebo	n=53 People with acute spinal cord injury (classified as having either motor complete or incomplete-preserved motor, non-functional C2 to T11 lesions), injured <2 weeks before initial evaluation Age: >16 years old Gender not reported USA	DVT (28-42 days). Diagnosed by fibrinogen uptake test confirmed by venography.	Treatment reduced from 42 to 28 days once it was found that patients were being discharged earlier. Unclear how many received 42 days treatment.
Spinal Cord Injury Thromboprophylaxis Investigators 2003 ²⁷⁶	Intervention (n=230): LMWH – high dose (Enoxaparin 30mg 2x daily), administered subcutaneously Comparison (n=246): UFH 5000U 3x daily, administered + IPCD used at least 22 hours/day Start time: within 72 hours of injury Duration: 2 weeks	n=476 People with acute spinal cord injury (from spinal cord level C2 to T12), sustained within previous 72 hours Age: mean 36.9 years Male to female ratio 389/87 USA, Canada	All-cause mortality (56 days) Fatal PE (56 days). Confirmed by: ventilation-perfusion lung scan, spiral CT or pulmonary angiography at 2 weeks or 2 days after last dose PE (56 days). Confirmed by: ventilation-perfusion lung scan, spiral CT or pulmonary angiography at 2 weeks or 2 days after last dose DVT (56 days). Confirmed by: proximal and distal venography or proximal Doppler Ultrasound 2 weeks or 2 days after last dose Major bleeding (56 days): definition not reported	Over 3/4 of patients randomised were excluded from efficacy analysis because they either failed to receive adequate proximal and distal imaging, or discontinued study due to bleeding or platelet counts <100 x 10 ⁹ /L

1

2 **Table 146: Clinical evidence summary: UFH versus no VTE prophylaxis**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with placebo	Risk difference with UFH (95% CI)
DVT	33 (1 study)	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 1.06 (0.53 to 2.15)	471 per 1000	28 more per 1000 (from 221 fewer to 541 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs

3 **Table 147: Clinical evidence summary: LMWH (standard dose; standard duration) versus no VTE prophylaxis**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with no VTE prophylaxis	Risk difference with LMWH (standard dose) (95% CI)
DVT	74 (1 study) 12-16 days	MODERATE ¹ due to imprecision	RR 0.25 (0.06 to 1.1)	216 per 1000	162 fewer per 1000 (from 203 fewer to 22 more)
PE	74 (1 study) 12-16 days	VERY LOW ^{1,4,5} due to risk of bias, indirectness, imprecision	Not estimable ³	Not estimable ³	0 fewer per 1000 (from 50 fewer to 50 more) ²
Fatal PE	74 (1 study) 12-16 days	VERY LOW ^{1,4,5} due to risk of bias, indirectness, imprecision	Not estimable ³	Not estimable ³	0 fewer per 1000 (from 50 fewer to 50 more) ²

1 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs
2 Risk difference calculated in Review Manager
3 Zero events in both arms

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with no VTE prophylaxis	Risk difference with LMWH (standard dose) (95% CI)
4 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias					
5 Downgraded by 1 or 2 increments because the majority of the evidence had indirect outcomes					

1

2 Table 148: Clinical evidence summary: LMWH (standard dose; standard duration) versus UFH

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with UFH	Risk difference with LMWH (standard dose) (95% CI)
All-cause mortality	41 (1 study) 56 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.14 (0.01 to 2.24)	95 per 1000	81 fewer per 1000 (from 94 fewer to 96 more)
Fatal PE	41 (1 study) 56 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.14 (0.01 to 2.24)	95 per 1000	81 fewer per 1000 (from 94 fewer to 96 more)
DVT	41 (1 study) 56 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.13 (0.01 to 1.31)	143 per 1000	122 fewer per 1000 (from 141 fewer to 36 more)
Major bleeding	41 (1 study) 56 days	VERY LOW ^{1,2,5} due to risk of bias, indirectness, imprecision	Not estimable ⁴	Not estimable ⁴	0 fewer per 1000 (from 90 fewer to 90 more) ³
1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias					
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs					
3 Risk difference calculated in Review Manager					
4 Zero events in both arms					
5 Downgraded by 1 or 2 increments because the majority of the evidence had indirect outcomes					

1

2 **Table 149: Clinical evidence summary: LMWH (high dose; standard duration) versus UFH+ICPD**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with UFH+ICPD	Risk difference with LMWH (standard dose) (95% CI)
All-cause mortality	476 (1 study) 56 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 1.07 (0.15 to 7.53)	8 per 1000	1 more per 1000 (from 7 fewer to 53 more)
Fatal PE	107 (1 study) 56 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Not estimable ⁴	Not estimable ⁴	0 fewer per 1000 (from 40 fewer to 40 more) ³
PE	107 (1 study) 56 days	LOW ^{1,2} due to risk of bias, imprecision	RR 0.28 (0.08 to 0.98)	184 per 1000	132 fewer per 1000 (from 4 fewer to 169 fewer)
DVT	107 (1 study) 56 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 1.34 (0.92 to 1.95)	449 per 1000	153 more per 1000 (from 36 fewer to 427 more)
Major bleeding	476 (1 study) 56 days	VERY LOW ^{1,2,5} due to risk of bias, indirectness, imprecision	RR 0.49 (0.19 to 1.28)	53 per 1000	27 fewer per 1000 (from 43 fewer to 15 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs

3 Risk difference calculated in Review Manager

4 Zero events in both arms

5 Downgraded by 1 or 2 increments because the majority of the evidence had indirect outcomes

3

4

33.4₁ Economic evidence

2 Published literature

3 No relevant health economic studies were identified.

4 See also the health economic study selection flow chart in Appendix F.

33.5₅ Evidence statements

6 Clinical

7 UFH was compared with no prophylaxis, the outcome DVT (symptomatic and asymptomatic) was
8 reported in one study. There was no clinical difference in terms of this outcome; although the
9 inconsistency associated with the result means the outcome may also mean either a benefit or harm.
10 The quality of the evidence was very low due to risk of bias and imprecision.

11 LMWH at a standard dose for a standard duration was compared with no prophylaxis, DVT
12 (symptomatic and asymptomatic), PE and fatal PE was reported in one study. There was possible
13 clinical benefit of LMWH in terms of DVT (symptomatic and asymptomatic), however the uncertainty
14 means that this result may also be consistent with no difference. There was no clinical difference in
15 terms of PE and fatal PE. However these results were also very uncertain. The quality of the evidence
16 ranged from very low to moderate due to risk of bias, indirectness and imprecision.

17 LMWH at a standard dose for a standard duration was compared with UFH, all-cause mortality, DVT,
18 fatal PE and major bleeding were reported in one study. There was possible clinical benefit of LMWH
19 in terms of all-cause mortality, DVT (symptomatic and asymptomatic), fatal PE. There was no clinical
20 difference in terms of major bleeding. However all results were very uncertain and could be
21 consistent with harm, no difference, or benefit. The quality of the evidence was very low due to risk
22 of bias, imprecision and indirectness

23 LMWH at a high dose for a standard duration was compared with UFH in combination with IPCD, the
24 outcomes all-cause mortality, DVT (symptomatic and asymptomatic), PE, fatal PE and major bleeding.
25 There was possible clinical benefit of LMWH in terms of PE and major bleeding. There was possible
26 clinical harm of LMWH in terms of all-cause mortality and DVT (symptomatic and asymptomatic).
27 Although uncertainty means these results may also have been consistent with no difference. The
28 quality of the evidence ranged from very low to low due to risk of bias, imprecision and indirectness.

29 Economic

30 No relevant economic evaluations were identified.

33.6₁ Recommendations and link to evidence

Recommendations	102. Consider mechanical VTE prophylaxis on admission for people with spinal injury. Choose either: <ul style="list-style-type: none">• anti-embolism stockings or• intermittent pneumatic compression. [2018] 103. Reassess risk of bleeding 24 hours after initial admission in people with spinal injury. [2018]
------------------------	--

	<p>104. Consider adding pharmacological VTE prophylaxis with LMWH^s 24 hours after initial admission for people with spinal injury who are not having surgery in the next 24–48 hours, if the benefit of reducing the risk of VTE outweighs the risk of bleeding. [2018]</p> <p>105. Continue VTE prophylaxis in people with spinal injury until the increased risk of VTE is reduced (for example, when the person no longer has significantly reduced mobility relative to their normal or anticipated mobility). [2018]</p>
<p>Research recommendation</p>	<p>None</p>
<p>Relative values of different outcomes</p>	<p>The committee considered all-cause mortality, DVT, PE, fatal PE and major bleeding to be critical outcomes. The committee considered clinically relevant non-major bleeding, health-related quality of life, heparin-induced thrombocytopenia and technical complications of mechanical interventions to be important outcomes. Please see section 4.3.3 in the methods chapter for further detail explaining prioritisation of the critical outcomes.</p>
<p>Quality of the clinical evidence</p>	<p>The majority of evidence was of very low quality with a high risk of bias. All of the evidence had imprecision. Some of the evidence was downgraded for indirectness as the definition of the outcome of the study or the time point at which the outcome was measured did not match the protocol or was not reported.</p> <p>The committee noted that the majority of studies had low numbers of participants or with high missing data rates, in particular the largest study (n=476) where no endpoint data was collected for 75% of patients due to inadequate imaging to determine endpoint or discontinued the study due to bleeding or platelet counts <100 x 10⁹/L</p>
<p>Trade-off between clinical benefits and harms</p>	<p>People with spinal injury can be paraplegic or immobile for a period of time and so are at high risk of VTE. The committee felt that the greatest risk period is more than 3 days and up to a week. However most spinal patients are immobile for 3 months. The committee noted that some people will have comorbid brain injury. All people with spinal injuries will also have a degree of haematoma, and people with spinal fracture may have significant haematoma.</p> <p>Very little evidence was identified for forms of mechanical prophylaxis, with only one paper reporting use of IPCD in combination with UFH, and no evidence for the use of AES. The committee noted that there is a higher risk of technical complications of mechanical interventions in this population (e.g. bruising) due to lower mobility, which was not identified in the studies. The committee believed that there is a lot of confusion and variation in current practice in this area; that AES and IPCD are used initially and then, if there are no plans to operate, pharmacological prophylaxis is considered later on. The committee highlighted that bleeding in this population would have catastrophic consequences and therefore pharmacological prophylaxis has to be avoided in the early stages after admission. Due to the sensory neurological impairment in the legs and that fact that much of this population will be at increased risk of VTE due to immobilisation the committee agreed that mechanical</p>

^s At the time of consultation (October 2017), LMWH did not have a UK marketing authorisation for use in young people under 18 for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information.

	<p>prophylaxis should be considered on admission, but that due to the increased chances of complications such as skin damage, it is extremely important that AES are fitted correctly.</p> <p>The committee agreed that if there are no plans to operate, anticoagulation at prophylactic doses can start 24 hours after the spinal injury where there is a low bleeding risk (from the brain). The committee noted that as a clot takes roughly 2 hours to stabilise, the time frame of 24 hours for initiating anticoagulation at prophylactic doses was felt to be feasible and clinically sensible.</p> <p>The committee also discussed when prophylaxis should be stopped. The committee agreed that for paraplegic patients, pharmacological prophylaxis should be stopped when the patient is out of the immediate risk period. This is at the individual discretion of the clinician and would take account of the presence of bed/joint mobilisation exercises. The committee noted that for people with spinal cord injury, there is a chance that pre-morbid mobility may not be regained. In some cases prophylaxis may continue during rehabilitation under specialist supervision.</p>
<p>Trade-off between net clinical effects and costs</p>	<p>No economic studies have been included in this review. Relevant unit costs were presented. The committee acknowledged that this is a population at high risk of VTE due to long periods of immobilisation. The committee felt that the cost of prophylaxis is likely to be off-set by the avoidance of the costly VTE events. However, the committee highlighted that this population is also at high risk bleeding, particularly in the immediate 24-hour period following the injury. Hence; mechanical prophylaxis options would be preferable in terms of safety and avoidance of major bleeding during the early period after the event.</p> <p>Given the rapidly changing VTE and bleeding risk balance in this population; reassessment of these risks was considered essential for guiding the appropriate prescribing of prophylaxis and hence; maximising its value. The committee acknowledged that reassessment will involve extra use of resources in terms of staff time, however, this was considered to be justified as this cost will be off-set by the avoidance of the costly VTE and bleeding events that could result from under- or over-use of prophylaxis.</p> <p>Once bleeding risk is low enough, pharmacological prophylaxis could be prescribed. The committee agreed that, based on the clinical evidence, LMWHs (standard dose) were considered more effective compared to UFH. They also had slightly lower total drug and monitoring costs compared to UFH, making them the likely cost effective option among the pharmacological prophylaxis options considered.</p>
<p>Other considerations</p>	<p>None.</p>

34 Major trauma

34.1.2 Introduction

3 The majority of patients suffering major trauma require assessment and management by the
4 orthopaedic trauma service. There may be associated injury to the head, chest or abdomen in those
5 patients sustaining poly-trauma, most frequently occurring following road traffic collisions. However,
6 major pelvic and spinal injuries and multiple long bone fractures in isolation constitute significant
7 orthopaedic trauma. A proportion will require management in a critical care setting, in either an
8 intensive care or high dependency unit, for which additional guidance can be found in Chapter 20 of
9 this guideline.

10 For major trauma patients, the main concern is the constantly changing balance between the initial
11 risk of bleeding and the subsequent increased risk of thrombotic events. Trauma patients have been
12 identified to be at increased risk of venous thromboembolism.

13 More guidance related to VTE prophylaxis for patients with single injury musculoskeletal trauma can
14 be found in the chapters on lower limb immobilisation (chapter 24), fragility fractures of the pelvis,
15 hip and proximal femur (chapter 25), foot and ankle surgery (chapter 29) and spinal injury (chapter
16 33) of this guideline.

34.2.7 Review question: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people with major trauma?

20 For full details see review protocol in Appendix C.

21 Table 150: PICO characteristics of review question

Population	Adults and young people (16 years and older) who are attending hospital with major trauma
Interventions	<p>Mechanical:</p> <ul style="list-style-type: none"> • Anti-embolism stockings (AES) (above or below knee) • Intermittent pneumatic compression (IPCD) devices (full leg or below knee) • Foot pumps or foot impulse devices (FID) • Electrical stimulation (including Geko devices) • Continuous passive motion • Vena caval filters <p>Pharmacological:</p> <ul style="list-style-type: none"> • Unfractionated heparin (UFH) (low dose, administered subcutaneously) • Low molecular weight heparin (LMWH), licensed in UK: <ul style="list-style-type: none"> ○ enoxaparin (standard prophylactic dose 40 mg daily; minimum 20 mg daily* to maximum 60 mg twice daily*) ○ dalteparin (standard prophylactic dose 5000 units once daily; minimum 1250 units once daily* to maximum 5000 units twice daily*; obese patients – maximum 7500 twice units daily*) ○ tinzaparin (standard prophylactic dose 3500-4500 units once daily; minimum 2500 units once daily* to maximum 4500 units twice daily*; obese patients – maximum 6750 twice daily*) • LMWH, licensed in countries other than UK:

	<ul style="list-style-type: none"> ○ Bemiparin (standard 2500 units daily; minimum 2500 units daily to maximum 3500 units daily) ○ Certoparin (3000 units daily) ○ Nadroparin (standard 2850 units once daily; minimum 2850 units once daily to maximum up to 57 units/kg once daily) ○ Parnaparin (standard 3200 units once daily; minimum 3200 units once daily to maximum 4250 units once daily) ○ Reviparin (minimum 1750 units once daily to maximum 4200 units once daily) ● Vitamin K Antagonists: <ul style="list-style-type: none"> ○ warfarin (variable dose only) ○ acenocoumarol (all doses) ○ phenindione (all doses) ● Fondaparinux (all doses)* ● Apixaban (all doses)* ● Dabigatran (all doses)* ● Rivaroxaban (all doses)* ● Aspirin (up to 300 mg)* <p>*off-label</p>
<p>Comparisons</p>	<p>Compared to:</p> <ul style="list-style-type: none"> ● Other VTE prophylaxis treatment, including monotherapy and combination treatments (between class comparisons for pharmacological treatments only) ● No VTE prophylaxis treatment (no treatment, usual care, placebo) <p>Within intervention (including same drug) comparisons, including:</p> <ul style="list-style-type: none"> ● Above versus below knee stockings ● Full leg versus below knee IPC devices ● Standard versus extended duration prophylaxis. ● Low versus high dose for LMWH ● Preoperative versus post-operative initiation of LMWH
<p>Outcomes</p>	<p>Critical outcomes:</p> <ul style="list-style-type: none"> ● All-cause mortality (up to 90 days from hospital discharge) ● Deep vein thrombosis (symptomatic and asymptomatic) (up to 90 days from hospital discharge). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) ● Pulmonary embolism (symptomatic and asymptomatic) (up to 90 days from hospital discharge) (NMA outcome). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE ● Major bleeding (up to 45 days from hospital discharge). A major bleeding event meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood ; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event. Includes unplanned visit to theatre for control of bleeding ● Fatal PE (up to 90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE <p>Important outcomes:</p> <ul style="list-style-type: none"> ● Clinically relevant non-major bleeding (up to 45 days from hospital discharge):

	<p>bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy.</p> <ul style="list-style-type: none"> • Health-related quality of life (validated scores only)(up to 90 days from hospital discharge) • Heparin-induced thrombocytopenia (HIT) (duration of study) • Technical complications of mechanical interventions (duration of study)
Study design	Randomised controlled trials (RCTs), systematic reviews of RCTs.

1

34.3.2 Clinical evidence

3 A search was conducted for randomised trials comparing the effectiveness of mechanical and
4 pharmacological prophylaxis strategies (alone or in combination) in people with major trauma. Of the
5 five studies included in the previous guideline conducted in the major trauma population (CG92),
6 four studies were included^{112,113,166,278}, and one study was excluded.⁶⁰ Six new studies were also
7 included.^{9,74,82,103,165,173} Additionally the guideline committee decided that vena caval filters would
8 only be appropriate for consideration for VTE prophylaxis in the major trauma population, therefore
9 the studies included in the previous guideline on the effectiveness of vena caval filters were
10 considered here. There was one study⁷³ noted for consideration in CG92, however this was excluded
11 in this guideline as it looked at the effectiveness of vena caval filters for secondary prevention of VTE.
12 The included studies are summarised in Table 151 below. See also the study selection flow chart in
13 Appendix E, forest plots in Appendix L, study evidence tables in Appendix H, GRADE tables in
14 Appendix K and excluded studies list in Appendix N.

15 **Table 151: Summary of studies included in the review**

Study	Intervention and comparison	Population	Outcomes	Comments
Anglen 1998 ⁹	<p><u>Intervention (n=68):</u> IPCD, below knee</p> <p><u>Comparison (n=49):</u> foot pump, applied to both feet (intermittent plantar compression devices, Plexipulse foot pumps)</p> <p>Applied after surgery or in the case of significant preoperative delay, before surgery</p>	<p>n=117</p> <p>People with trauma (pelvis 10.3%, hip 6.8%, acetabulum 32.5%, femur 43.6%, combination 6.8% fracture, multi trauma 61.5%) ISS not reported</p> <p>Age >17 years Males and females (65:52)</p> <p>United States</p>	<p>DVT (up to 14 days): confirmed by duplex ultrasound</p> <p>PE (2 months): method of confirmation not reported</p>	Major trauma status not defined as no ISS data reported.
Dennis 1993 ⁷⁴	<p><u>Intervention 1 (n=189):</u> IPCD, full leg</p> <p>Device applied within 48 hours of injury, until discharge or fully ambulatory</p> <p><u>Intervention 2 (n=92):</u></p>	<p>n=395</p> <p>People with trauma (chest 29.9%, abdomen 23.3%, extremities 47.6%, head 23.3%, spinal cord 12.7%, paralysis</p>	<p>All-cause mortality (time-point not reported)</p> <p>DVT (time-point not reported): confirmed by duplex scanning or Doppler ultrasound</p>	<p>Trauma inclusion defined as ISS >9</p> <p>Patients had scanning at 48 hrs and then</p>

Study	Intervention and comparison	Population	Outcomes	Comments
	UFH (5000U 2 x daily) Started within 96 hours of injury, until discharge or fully ambulatory <u>Comparison (n=114):</u> no VTE prophylaxis	6.3%) ISS >9 Age >18 years Gender not reported United States	PE (time-point not reported): confirmed by duplex scanning or Doppler ultrasound Fatal PE (time-point not reported): confirmed by autopsy	every 5 days after injury for between 2-25 scans
Elliot 1999 ⁸²	<u>Intervention (n=74):</u> IPCD, full leg Duration not reported <u>Comparison (n=75):</u> foot pump (plantar venous intermittent pneumatic compression devices) Duration not reported	n = 149 People with major trauma (head 82.6%, face 24.8%, chest 55.7%, abdomen 26.2%, upper limb 13.4%, other 38.9%) ISS: intervention mean, SD = 31, 11.6; comparison mean, SD = 30.2, 13.1 Age >13 years Males and females (100:49) United States	All-cause mortality (time-point not reported) DVT (8 days): confirmed by compression duplex ultrasonography Major bleeding (time-point not reported): definition not reported	
Fuchs 2005 ¹⁰³	<u>Intervention (n=111):</u> <ul style="list-style-type: none"> Continual passive motion, 2 x daily UFH 5000U 3 x daily <u>Comparison (n=116):</u> UFH 5000U 3 x daily Treatment started on the evening before surgery or immediately following surgery in emergency cases, carried on until mobilisation	n = 227 People with bony or ligamentous trauma to the spine, pelvis, femur, tibia or ankle ISS not reported Age >18 years Males and females (131:96) Germany	All-cause mortality (3 months) DVT (3 months): confirmed by compression ultrasonography, Doppler and/or plethysmography, and venography PE (3 months): method of confirmation not reported	Major trauma status not defined as no ISS data reported.
Geerts 1996 ¹¹²	<u>Intervention (n=136):</u> UFH 5000U, given subcutaneously every 12 hours Duration: within 36 hours of the injury for up to 14 days.	n=265 People with major trauma (head 4.9%, face/chest/abdomen 37.7%, spine 15%, lower limb 54.3%)*	All-cause mortality (14 days) DVT (days 10-14): confirmed by venography	Trauma inclusion defined as ISS >9

Study	Intervention and comparison	Population	Outcomes	Comments
	<p><u>Comparison (n=129):</u> LMWH, high dose (enoxaparin), 30 mg, given subcutaneously every 12 hours Duration: within 36 hours of the injury for up to 14 days.</p>	<p>ISS >9</p> <p>Age (mean, SD): intervention group 37.0 (16.5), comparison group 39.1 (16.8)</p> <p>Males and females (192:73)</p> <p>Canada</p> <p>*some patients had injuries at more than one site</p>	<p>PE, symptomatic (14 days): confirmed by ventilation perfusion scan</p> <p>Major bleeding (14 days): defined as overt bleeding that was associated with a decrease in the haemoglobin level of at least 2g per decilitre, the transfusion of two or more units of packed red cells, an intracranial or retroperitoneal site of bleeding, or the need for surgical intervention</p> <p>Fatal PE (14 days): confirmed by autopsy</p>	
Ginzburg 2003 ¹¹³	<p><u>Intervention (n=224):</u> IPCD, below knee Duration: within 24hrs of trauma until walking independently or discharge from hospital. Maximum 8 consecutive hours disuse allowed</p> <p><u>Comparison (n=218):</u> LMWH, high dose (enoxaparin), 30 mg, given subcutaneously every 12 hours Duration: within 24 hours of the injury until walking independently or discharge from hospital</p>	<p>n=442</p> <p>People with high risk trauma (head 22.9%, spinal cord 7.5%, chest 37.3%, leg or pelvis fracture 35.1%)* ISS >9</p> <p>Age (mean): intervention group 40, comparison group 42)</p> <p>Males and females (327:115)</p> <p>United states</p> <p>*some patients had injuries at more than one site</p>	<p>All-cause mortality (30 days)</p> <p>DVT (30 days): confirmed by Doppler ultrasonography</p> <p>PE, symptomatic (30 days): confirmed by spiral computed tomography or ventilation-perfusion scintigraphy</p> <p>Major bleeding (30 days): defined as haemorrhage leading to a fall in haemoglobin conc. of 2 g/dl, transfusion of 2 or more of packed red blood cells, intracranial or retroperitoneal bleeding or bleeding requiring surgical intervention</p>	Includes moderately (ISS 9-19) and severely (ISS >19) injured people.

Study	Intervention and comparison	Population	Outcomes	Comments
Knudson 1994 ¹⁶⁵	<p>Group 1 (patients who could receive either methods of prophylaxis):</p> <p><u>Intervention 1 (n=44):</u> UFH (5000U, 2 x daily)</p> <p><u>Intervention 2 (n=32):</u></p> <ul style="list-style-type: none"> • IPCD, full leg • AES, undefined <p><u>Comparison (n=64):</u> No VTE prophylaxis</p> <p>Duration not reported</p> <p>Group 2 (patients who could not wear mechanical prophylaxis devices):</p> <p><u>Intervention (n=19):</u> UFH (5000U, 2 x daily)</p> <p><u>Comparison (n=27):</u> No VTE prophylaxis</p> <p>Duration not reported</p> <p>Group 3 (patients who had contraindication to heparin):</p> <p><u>Intervention (n=26):</u> IPCD, full leg</p> <p><u>Comparison (n=39):</u> No VTE prophylaxis Duration not reported</p>	<p>n=251</p> <p>People with trauma (laparotomy, thoracotomy, ventilated > 24 hours, spine, pelvic, femur fracture)</p> <p>Mean ISS 16 (range 10-66)</p> <p>Age > 18 years Males and females (200:51)</p> <p>United States</p>	<p>All-cause mortality</p> <p>DVT (3 weeks): confirmed by duplex imaging</p> <p>PE (3 weeks): confirmed by pulmonary angiography</p>	<p>Cause of major trauma unclear for all patients</p> <p>Unclear if patients in group 3 received AES</p>
Knudson 1996 ¹⁶⁶	<p><u>Intervention (n=120):</u> LMWH, high dose (enoxaparin) 30mg given subcutaneously every 12 hours Duration not reported</p> <p><u>Comparison (n=82):</u></p> <ul style="list-style-type: none"> • IPCD, length undefined • AES, length undefined <p>Or FID alone</p>	<p>n=202</p> <p>People with trauma injuries (venous injury, pelvic fracture, unstable spine, spinal fracture)</p> <p>ISS > 10</p> <p>Age (mean): 38.5 years Male and female (values not reported)</p>	<p>All-cause mortality (time-point not reported)</p> <p>DVT (time-point not reported): confirmed by venous duplex ultrasound</p> <p>PE (time-point not reported): method of confirmation not reported</p> <p>Fatal PE (time-point not reported): confirmed by</p>	<p>Trauma inclusion defined as ISS >10</p> <p>Different mechanical prophylaxis used depending on the condition of the lower extremity.</p>

Study	Intervention and comparison	Population	Outcomes	Comments
	Sequential gradient pneumatic compression sleeves worn over AES, or arteriovenous impulse device Duration not reported	United States	autopsy	
Kurtoglu 2004 ¹⁷³	<p><u>Intervention (n = 60):</u></p> <ul style="list-style-type: none"> LMWH, standard dose (enoxaparin) 40mg given once daily IPCD, below knee <p><u>Comparison (n = 60):</u> IPCD, below knee</p> <p>All patients received IPCD on admission, and initiation of LMWH was determined after CT within 24 hours of admission. Duration not reported</p>	<p>n = 120</p> <p>People with severe head/spinal trauma (head 90.1%, spinal 9.1%) ISS 4-35</p> <p>Age >14 years Male and female: 47:73</p> <p>Turkey</p>	<p>All-cause mortality (time-point not reported)</p> <p>DVT (time-point not reported): confirmed by duplex sonography</p> <p>PE (time-point not reported): confirmed by spiral CT</p> <p>Major bleeding (time-point not reported): defined as macroscopic hematuria without renal injury, overt bleeding, and a sudden drop in haemoglobin level (>2 g/dl)</p> <p>Fatal PE (time-point not reported): confirmed by spiral CT</p>	No definition of 'severe' trauma provided.
Stannard 2006 ²⁷⁸	<p><u>Intervention (n=97):</u> LMWH, high dose (enoxaparin), 30mg, given subcutaneously every 12 hours Duration: within 24-48 hours of the injury</p> <p><u>Comparison (n=103):</u> Pulsatile foot pumps at time of admission (patients asked to use it for at least 12 hours per day) combined with enoxaparin (high dose, 30mg every 12 hours) on a delayed basis (5 days after admission)</p>	<p>n=200</p> <p>People with recent blunt skeletal trauma (mean ISS 14.42, range 4-57)</p> <p>Age >18 years</p> <p>United States</p>	<p>All-cause mortality (time point not reported)</p> <p>DVT (24 hours before discharge): confirmed by bilateral magnetic resonance venography and ultrasonography</p> <p>PE, symptomatic (time point and method of confirmation not reported)</p> <p>Fatal PE (time point and method of confirmation not reported)</p>	Blunt trauma

1 Table 152: Clinical evidence summary: IPCD (full leg) versus no prophylaxis

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with IPCD (full leg) versus no prophylaxis (95% CI)
All-cause mortality	368 (2 studies) 7-90 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 0.3 (0.06 to 1.62)	26 per 1000	18 fewer per 1000 (from 25 fewer to 16 more)
DVT (symptomatic and asymptomatic)	368 (2 studies) 7-90 days	LOW ¹ due to risk of bias	RR 0.26 (0.1 to 0.7)	98 per 1000	73 fewer per 1000 (from 29 fewer to 88 fewer)
PE	368 (2 studies) 7-90 days	VERY LOW ² due to risk of bias, imprecision	Peto OR 0.07 (0 to 4.01)	7 per 1000	6 fewer per 1000 (from 7 fewer to 19 more)
Fatal PE	303 (1 study) 7-90 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.59 (0.03 to 10.34)	9 per 1000	4 fewer per 1000 (from 9 fewer to 75 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs

2 Table 153: Clinical evidence summary: IPCD (full leg) versus foot pump

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with IPCD (full leg) versus foot pump (95% CI)
All-cause mortality	149 (1 study) time-point not reported	VERY LOW ^{1,2,3} due to risk of bias, indirectness, imprecision	RR 1.22 (0.39 to 3.81)	67 per 1000	15 more per 1000 (from 41 fewer to 187 more)
DVT (symptomatic and asymptomatic)	124 (1 study)	VERY LOW ^{1,2,3} due to risk of bias,	RR 0.31 (0.11 to 0.89)	210 per 1000	145 fewer per 1000 (from 23 fewer to 187 fewer)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with IPCD (full leg) versus foot pump (95% CI)
	8 days	indirectness, imprecision			
Major bleeding	149 (1 study) time-point not reported	VERY LOW ^{1,2,3} due to risk of bias, indirectness, imprecision	Peto OR 7.49 (0.15 to 377.48)	0 per 1000	Not estimable ⁴

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs
3 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol
4 Could not be calculated as there were no events in the comparison group

1 Table 154: Clinical evidence summary: IPCD (below knee) versus foot pump

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with IPCD (below knee) versus foot pump (95% CI)
DVT (symptomatic and asymptomatic)	117 (1 study) up to 14 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.17 (0.02 to 1.76)	44 per 1000	36 fewer per 1000 (from 43 fewer to 31 more)
PE	117 (1 study) 2 months	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.18 (0 to 9.51)	15 per 1000	12 fewer per 1000 (from 15 fewer to 110 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs

2 Table 155: Clinical evidence summary: IPCD (full leg) + AES (undefined) versus no prophylaxis

Outcomes	No of	Quality of the evidence	Relative	Anticipated absolute effects
----------	-------	-------------------------	----------	------------------------------

	Participants (studies) Follow up	(GRADE)	effect (95% CI)	Risk with Control	Risk difference with IPCD full leg + AES versus no prophylaxis (95% CI)
All-cause mortality	96 (1 study) up to 3 weeks	VERY LOW ^{1,2} due to risk of bias, imprecision	Not estimable ³	Not estimable ³	0 fewer per 1000 (from 47 fewer to 47 more) ⁴
DVT (symptomatic and asymptomatic)	96 (1 study) up to 3 weeks	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 4 (0.77 to 20.69)	31 per 1000	94 more per 1000 (from 7 fewer to 615 more)
PE	96 (1 study) up to 3 weeks	VERY LOW _{1,2} due to risk of bias, imprecision	Peto OR 0.22 (0 to 14.26)	16 per 1000	12 fewer per 1000 (from 16 fewer to 169 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs
3 Could not be calculated as there were no events in the intervention or comparison group
4 Risk difference calculated in Review Manager

1 Table 156: Clinical evidence summary: Continual passive motion + UFH versus UFH

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with Continual passive motion + UFH versus UFH (95% CI)
All-cause mortality	227 (1 study) 3 months	VERY LOW ^{1,2} due to risk of bias, imprecision	Not estimable ³	Not estimable ³	0 fewer per 1000 (from 17 fewer to 17 more) ⁴
DVT (symptomatic and asymptomatic)	227 (1 study) 3 months	MODERATE ¹ due to risk of bias	RR 0.14 (0.05 to 0.4)	250 per 1000	215 fewer per 1000 (from 150 fewer to 237 fewer)
PE	227 (1 study) 3 months	VERY LOW ^{1,2} due to risk of bias, imprecision	Not estimable ³	Not estimable ³	0 fewer per 1000 (from 17 fewer to 17 more) ⁴

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with Continual passive motion + UFH versus UFH (95% CI)
1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias 2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs 3 Could not be calculated as there were no events in the intervention or comparison group 4 Risk difference calculated in Review Manager					

1 Table 157: Clinical evidence summary: UFH versus no prophylaxis

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with UFH versus no prophylaxis (95% CI)
All-cause mortality	360 (3 studies) up to 3 months	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 0.32 (0.06 to 1.64)	24 per 1000	17 fewer per 1000 (from 23 fewer to 16 more)
DVT (symptomatic and asymptomatic)	360 (3 studies) up to 3 months	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 0.47 (0.17 to 1.26)	68 per 1000	36 fewer per 1000 (from 57 fewer to 18 more)
PE	360 (3 studies) up to 3 month	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.17 (0.01 to 2.88)	10 per 1000	8 fewer per 1000 (from 10 fewer to 18 more)
Fatal PE	206 (1 study) 7-90 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 1.24 (0.08 to 20.32)	9 per 1000	2 more per 1000 (from 8 fewer to 144 more)
1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias 2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs					

1 Table 158: Clinical evidence summary: UFH versus IPCD (full leg)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with IPCD (full leg) versus UFH (95% CI)
All-cause mortality	281 (1 study) time-point not reported	VERY LOW ^{1,2,3} due to risk of bias, indirectness, imprecision	RR 1.03 (0.09 to 11.18)	11 per 1000	0 fewer per 1000 (from 10 fewer to 108 more)
DVT (symptomatic and asymptomatic)	281 (1 study) time-point not reported	VERY LOW ^{1,2,3} due to risk of bias, indirectness, imprecision	RR 1.23 (0.3 to 5.05)	33 per 1000	6 more per 1000 (from 19 fewer to 107 more)
PE	281 (1 study) time-point not reported	VERY LOW ^{1,2,3} due to risk of bias, indirectness, imprecision	Not estimable ³	Not estimable ³	0 fewer per 1000 (from 17 fewer to 17 more) ⁴
Fatal PE	281 (1 study) time-point not reported	VERY LOW ^{1,2,3} due to risk of bias, indirectness, imprecision	Peto OR 2.20 (0.11 to 42.32)	11 per 1000	6 more per 1000 (from 5 fewer to 178 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol
3 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs
3 Could not be calculated as there were no events in the intervention or comparison group
4 Risk difference calculated in Review Manager

2 Table 159: Clinical evidence summary: UFH versus IPCD (full leg) + AES (undefined)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with IPCD full leg + AES versus UFH (95% CI)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with IPCD full leg + AES versus UFH (95% CI)
All-cause mortality	76 (1 study) up to 3 weeks	VERY LOW ^{1,2} due to risk of bias, imprecision	Not estimable ³	Not estimable ³	0 fewer per 1000 (from 52 fewer to 52 more) ⁴
DVT (symptomatic and asymptomatic)	76 (1 study) up to 3 weeks	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 0.18 (0.02 to 1.55)	125 per 1000	102 fewer per 1000 (from 123 fewer to 69 more)
PE	76 (1 study) up to 3 weeks	VERY LOW ^{1,2} due to risk of bias, imprecision	Not estimable ³	Not estimable ³	0 fewer per 1000 (from 52 fewer to 52 more) ⁴

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
 2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs
 3 Could not be calculated as there were no events in the intervention or comparison group
 4 Risk difference calculated in Review Manager

1

2 **Table 160: Clinical evidence summary: LMWH (standard dose; standard duration) + IPCD (below knee) versus IPCD (below knee)**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with LMWH (standard dose) + IPCD versus IPCD (95% CI)
All-cause mortality	120 (1 study) time-point not reported	VERY LOW ^{1,2,3} due to risk of bias, indirectness, imprecision	RR 1.14 (0.44 to 2.95)	117 per 1000	16 more per 1000 (from 65 fewer to 228 more)
DVT (symptomatic and asymptomatic)	120 (1 study) time-point not reported	VERY LOW ^{1,2,3} due to risk of bias, indirectness, imprecision	RR 0.75 (0.18 to 3.21)	67 per 1000	17 fewer per 1000 (from 55 fewer to 147 more)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with LMWH (standard dose) + IPCD versus IPCD (95% CI)
	reported				
PE	120 (1 study) time point not reported	VERY LOW ^{1,2,3} due to risk of bias, indirectness, imprecision	Not estimable ⁴	Not estimable ⁴	0 fewer per 1000 (from 32 fewer to 32 more) ⁵
Major bleeding	120 (1 study) time point not reported	VERY LOW ^{1,2,3} due to risk of bias, indirectness, imprecision	Not estimable ⁴	Not estimable ⁴	0 fewer per 1000 (from 32 fewer to 32 more) ⁵
Fatal PE	120 (1 study) time point not reported	VERY LOW ^{1,2,3} due to risk of bias, indirectness, imprecision	RR 2 (0.38 to 10.51)	33 per 1000	33 more per 1000 (from 21 fewer to 317 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs
3 Downgraded by 1 increment if the outcome does not fit the protocol
4 Could not be calculated as there were no events in the intervention or comparison group
5 Risk difference calculated in Review Manager

1 Table 161: Clinical evidence summary: LMWH (high dose; standard duration) versus UFH

Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with LMWH versus UFH (95% CI)
All-cause mortality	344 (1 study) 14 days	LOW ¹ due to imprecision	Peto OR 7.52 (0.47 to 120.72)	0 per 1000	Not estimable ²
DVT (symptomatic and asymptomatic)	265 (1 study)	MODERATE ¹ due to imprecision	RR 0.7 (0.51 to 0.97)	441 per 1000	132 fewer per 1000 (from 13 fewer to 216 fewer)

Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with LMWH versus UFH (95% CI)
	10-14 days				
PE	265 (1 study) 14 days	LOW ¹ due to imprecision	Peto OR 7.8 (0.15 to 393.69)	0 per 1000	Not estimable ²
Major bleeding	344 (1 study) 14 days	MODERATE ¹ due to imprecision	Peto OR 3.92 (0.78 to 19.63)	6 per 1000	17 more per 1000 (from 1 fewer to 97 more)
Fatal PE	344 (1 study) 14 days	LOW ¹ Due to imprecision	Not estimable ³	Not estimable ³	0 more per 1000 (from 113 fewer to 113 more) ⁴
<p>1 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs</p> <p>2 Could not be calculated as there were no events in the comparison group</p> <p>3 Could not be calculated as there were no events in the intervention or comparison group</p> <p>4 Risk difference calculated in Review Manager</p>					

1 Table 162: Clinical evidence summary: LMWH (high dose; standard duration) versus IPCD (below knee)

Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with LMWH versus IPCD (95% CI)
All-cause mortality	442 (1 study) 30 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Not estimable ³	Not estimable ³	0 more per 1000 (from 88 fewer to 88 more) ⁴
DVT (symptomatic and asymptomatic)	442 (1 study) 30 days	LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.24 (0.05 to 1.07)	27 per 1000	20 fewer per 1000 (from 25 fewer to 2 more)
PE	442 (1 study)	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 1.03 (0.06 to 16.48)	4 per 1000	0 more per 1000 (from 4 fewer to 64 more)

Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with LMWH versus IPCD (95% CI)
	30 days				
Major bleeding	442 (1 study) 30 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 1.03 (0.26 to 4.06)	18 per 1000	1 more per 1000 (from 13 fewer to 55 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs
3 Could not be calculated as there were no events in the intervention or comparison group
4 Risk difference calculated in Review Manager

1 Table 163: Clinical evidence summary: LMWH (high dose; standard duration) versus (IPCD, undefined + AES, undefined) or FID

Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with LMWH versus (IPCD + AES) or FID (95% CI)
All-cause mortality	202 (1 study) time-point not reported	VERY LOW ^{1,2,3} due to risk of bias, imprecision, indirectness	Not estimable ³	Not estimable ³	0 per 1000 (from 202 fewer to 202 more) ⁴
DVT (symptomatic and asymptomatic)	202 (1 study) time-point not reported	VERY LOW ^{1,2,3} due to risk of bias, imprecision, indirectness	Peto OR 0.34 (0.03 to 3.40)	24 per 1000	16 fewer per 1000 (from 24 fewer to 54 more)
PE	202 (1 study) time-point not reported	VERY LOW ^{1,2,3} due to risk of bias, imprecision, indirectness	Not estimable ³	Not estimable ³	0 per 1000 (from 202 fewer to 202 more) ⁴

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs

Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with LMWH versus (IPCD + AES) or FID (95% CI)
3 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol					
4 Could not be calculated as there were no events in the intervention or comparison group					
5 Risk difference calculated in Review Manager					

1 Table 164: Clinical evidence summary: LMWH (high dose; standard duration) versus delayed LMWH (high dose; standard duration) + foot pump

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with LMWH versus LMWH + foot pump (95% CI)
All-cause mortality	200 (1 study) time-point not reported	VERY LOW ^{1,2} due to risk of bias, imprecision	Not estimable ⁴	Not estimable ⁴	0 per 1000 (from 194 fewer to 194 more) ⁵
DVT (symptomatic and asymptomatic)	200 (1 study) time-point not reported	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 1.53 (0.69 to 3.43)	87 per 1000	46 more per 1000 (from 27 fewer to 212 more)
PE	200 (1 study) time-point not reported	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 7.94 (0.49 to 128.04)	0 per 1000	Not estimable ³
Fatal PE	200 (1 study) time-point not reported	VERY LOW ^{1,2} due to risk of bias, imprecision	Not estimable ⁴	Not estimable ⁴	0 per 1000 (from 194 fewer to 194 more) ⁵
1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias					
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs					

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with LMWH versus LMWH + foot pump (95% CI)
3		Could not be calculated as there were no events in the comparison group			
4		Could not be calculated as there were no events in the intervention or comparison group			
5		Risk difference calculated in Review Manager			

1
2
3

34.4¹ Economic evidence

2 Published literature

3 Two health economic studies were identified with the relevant comparison, and have been included
4 in this review.^{51,198} One of these two studies was previously included in CG92.¹⁹⁸ The two studies are
5 summarised in the health economic evidence profiles below (Table 165 and Table 166) and the
6 health economic evidence tables in Appendix J.

7 See also the health economic study selection flow chart in Appendix F.

8

1 **Table 165: Health economic evidence profile: VCF vs IPCD**

Study	Applicability	Limitations	Other comments	Incremental cost	Incremental effects	Cost-effectiveness	Uncertainty
Carter Chiasson 2009 ⁵¹ [(Canada)]	Partially applicable ^(a)	Potentially serious limitations ^(b)	<p>-Study design: cost-utility analysis using decision analytic modelling.</p> <p>-Population: Adult (>= 15 years)Trauma patients with severe injuries admitted to the ICU who were believed to have a contraindication to pharmacological VTE prophylaxis for up to 2 weeks because of a risk of major bleeding.</p> <p>-Interventions</p> <ol style="list-style-type: none"> 1. Pneumatic compression devices (IPCD) and expectant management alone during the first 2 weeks. 2. IPCD as well as weekly Serial Doppler ultrasound (SDU) screening for the duration of hospitalisation beginning in the first week of ICU admission. (results not reported here) 3. Prophylactic insertion of vena-cava filter (VCF). 	3 vs 1 £975	3 vs 1 0.0 QALYs	IPCD less costly	A wide range of one-way sensitivity analyses was undertaken. None of the SAs changed the conclusion

2 Abbreviations: ICER: incremental cost-effectiveness ratio; ICU: intensive care unit; IPCD: pneumatic compression device; QALY: quality-adjusted life years; RCT: randomised controlled trial;
3 SAs: sensitivity analyses; VCF: vena-cava filter; VTE: venous thromboembolism.
4 (a) Uncertainty regarding the applicability of unit costs from Canada, in 2007 to current NHS context. The discount used is 5% for both costs and outcomes; however, this
5 was tested in a sensitivity analysis with a range of 0-6%. It is not clear which utility measure was used to derive the utility values used in the model.
6 (b) The health states included in the long term of the model does not seem to include CTEPH as a complication of PE. Baseline risks as well as relative effectiveness are
7 based on the results of an observational cohort and single RCT so by definition, not reflective of all the evidence in this area. Both local and national unit costs were
8 used in the analysis, so may not be generalisable. Utility values were not tested in sensitivity analysis.
9

1 Table 166: Health economic evidence profile: LMWH (low dose) vs UFH (low dose)

Study	Applicability	Limitations	Other comments	Incremental cost	Incremental effects	Cost-effectiveness	Uncertainty
Lynd 2007 ¹⁹⁸ ([Canada])	Partially applicable ^(a)	Potentially serious limitations ^(b)	<p>- Study design: cost-consequences analysis using decision analytic modelling.</p> <p>- Population: Patients with major trauma (trauma score of =>9)</p> <p>- Interventions:</p> <ol style="list-style-type: none"> 1. UFH 5000 units once daily. 2. LMWH (enoxaparin 30 mg once daily). 	<p>2 vs 1</p> <p>£47</p>	<p>2 vs 1</p> <p>LYG: 130 life-years lost per 1000</p> <p>DVT: 86 DVTs averted per 1000</p> <p>PE: 18 PEs averted per 1000 patients</p> <p>MB: 18 more MB events per 1000 patients</p> <p>Deaths: 7 fewer deaths per 1000 patients</p>	<p>2 vs 1</p> <p>LYG: Dominated (more costly and less effective)</p> <p>DVT: £553 per DVT averted</p> <p>PE: £2,611 per PE averted</p> <p>MB: Dominated (more costly and less effective)</p> <p>Deaths: £6,714 per death averted</p>	<p>Probabilistic and deterministic (one-way and two-way) sensitivity analyses were conducted. The model results were robust to all changes.</p>

2 Abbreviations: ICER: incremental cost-effectiveness ratio; QALY: quality-adjusted life years; RCT: randomised controlled trial; UFH: unfractionated heparin.

3 a) Uncertainty regarding the applicability of unit costs from Canada, in 2003 to current NHS context. The discount used is 5% for outcomes; however, this was tested in a sensitivity analysis with a range of 3-7%. QALYs were not used as outcome.

4
5 b) The health states included in the long term of the model do not include CTEPH and PTS. Baseline risks as well as relative effectiveness are based on the results of a
6 single RCT (Geerts 1996¹¹²) so by definition, not reflective of all the evidence in this area. Both local and national unit costs were used in the analysis, so may not be
7 generalisable.

1

34.5.2 Evidence statements

3 Clinical

4 Mechanical prophylaxis

5 When IPCD (full leg) was compared to no prophylaxis, there was a clinical benefit of IPCD for DVT.
6 And suggested benefit for all other outcomes including all-cause mortality, PE and fatal PE. However
7 the non-DVT outcomes were all associated with imprecision. The quality of the evidence ranged from
8 very low to low due to risk of bias and imprecision.

9 The study comparing IPCD (full leg) in combination with AES with no prophylaxis found a possible
10 clinical harm of IPCD + AES for DVT, and a possible clinical benefit for PE. However there was
11 imprecision associated with these results. There was no clinical difference for all-cause mortality. The
12 quality of the evidence was very low due to risk of bias and imprecision.

13 For the comparison of IPCD (full leg) versus foot pump, there was a suggested clinical benefit of IPCD
14 for DVT, but a possible clinical harm for major bleeding, however there was imprecision around these
15 results. There was no clinical difference in terms of all-cause mortality. For below knee IPCD
16 compared to foot pump, the evidence demonstrated a possible clinical benefit for IPCD for both DVT
17 and PE, but there was imprecision around the results. The quality of the evidence for both
18 comparisons ranged from very low to low due to risk of bias and imprecision.

19

20 *Mechanical versus pharmacological prophylaxis*

21 When IPCD (full leg) was compared to UFH, there was a suggested clinical benefit of IPCD for fatal PE,
22 and no clinical difference for all other reported outcomes including all-cause mortality, DVT and PE.
23 However there was uncertainty surrounding these results. The quality of the evidence was very low
24 due to risk of bias, imprecision and indirectness.

25 For the comparison of IPCD (full leg) in combination with AES versus UFH, there was a possible
26 clinical harm of IPCD in combination with AES for DVT, and no clinical difference for all-cause
27 mortality or PE. However this evidence was very low quality due largely to the very serious
28 imprecision surrounding the effect estimates.

29 For the comparison of continual passive motion in combination with UFH versus UFH alone, there
30 was clinical benefit of continual passive motion for DVT, and no clinical difference for all-cause
31 mortality and PE. The quality of the evidence ranged from very low to moderate due to risk of bias
32 and imprecision.

33 When LMWH (standard dose) in combination with IPCD (below-knee) was compared to IPCD (below-
34 knee), there was a suggested clinical benefit of LMWH for DVT, and a suggested clinical harm for fatal
35 PE. There was no clinical difference for all-cause mortality, PE and major bleeding. However for all
36 results there was uncertainty around the effect estimates. The quality of the evidence was very low
37 due to risk of bias, imprecision and indirectness.

38 When LMWH (high dose) was compared to IPCD (below-knee), there was a suggested clinical benefit
39 of LMWH for DVT, however no clinical difference for all-cause mortality, PE and major bleeding.
40 There was considerable uncertainty around all these results. The quality of the evidence ranged from
41 very low to low due to risk of bias and imprecision.

42 The study comparing LMWH (high dose) to (IPCD in combination with AES) or FID found a suggested
43 clinical benefit of LMWH for DVT, and no clinical difference for all-cause mortality and PE. There was
44 considerable uncertainty around all these results. The quality of the evidence was very low due to
45 risk of bias, imprecision and indirectness.

1 For the comparison of LWMH (high dose) versus delayed LMWH (high dose) in combination with foot
2 pump, the evidence suggested a possible clinical harm for LMWH for both DVT and PE, and no clinical
3 difference for all-cause mortality and fatal PE, however all these results had considerable
4 uncertainty.

5

6 **Pharmacological prophylaxis**

7 For the comparison of UFH versus no prophylaxis, there was a suggested clinical benefit of UFH for
8 all-cause mortality, DVT and PE. However these results were very seriously imprecise and associated
9 with both no difference and harm as well. No clinical difference was found for fatal PE. The quality of
10 the evidence was very low due to risk of bias and imprecision.

11 For the comparison of LWMH (high dose) versus UFH, the evidence suggested a possible clinical harm
12 of LMWH for all-cause mortality, PE and major bleeding, however the evidence was very imprecise
13 and also consistent with no difference and possible benefit. However there was a possible clinical
14 benefit of LMWH for DVT, although this was also consistent with no difference. There was no clinical
15 difference in terms of fatal PE. The quality of the evidence ranged from low to moderate due to
16 imprecision.

17 **Economic**

18 One cost–utility analysis found that in trauma patients with severe injuries admitted to the ICU,
19 pneumatic compression devices and expectant management alone was less costly and equally
20 effective, compared to prophylactic insertion of vena-cava filter for VTE prophylaxis. This analysis
21 was assessed as partially applicable with potentially serious limitations.

22

23 One cost-consequences analysis found that in patients with major trauma low molecular weight
24 heparin (low dose) was more costly (£47 more per patient) and had 0.086 fewer DVT events per
25 patient, 0.0018 fewer PE events per patient and 0.007 fewer deaths per patient but 0.0018 more
26 major bleeding events per patient and 0.013 fewer life-years gained per patient compared to
27 unfractionated heparin (low dose) for VTE prophylaxis. This analysis was assessed as partially
28 applicable with potentially serious limitations.

34.6.9 Recommendations and link to evidence

Recommendations	<p>106. Offer mechanical VTE prophylaxis with intermittent pneumatic compression on admission to people with serious or major trauma. Continue until the person no longer has significantly reduced mobility relative to their normal or anticipated mobility. [2018]</p> <p>107. Reassess risk of VTE and bleeding at least daily in people with serious or major trauma. [2018]</p> <p>108. Consider pharmacological VTE prophylaxis for people with serious or major trauma as soon as possible after the risk assessment when the risk of VTE outweighs the risk of bleeding. Continue for a minimum of 7 days. [2018]</p>
Research recommendation	None
Relative values of	The guideline committee considered all-cause mortality (up to 90 days from hospital

different outcomes	<p>discharge), deep vein thrombosis (symptomatic and asymptomatic) (up to 90 days from hospital discharge), pulmonary embolism (symptomatic and asymptomatic) (up to 90 days from hospital discharge), fatal PE (up to 90 days from hospital discharge), and major bleeding (up to 45 days from hospital discharge) as critical outcomes.</p> <p>The guideline committee considered clinically relevant non-major bleeding (up to 45 days from hospital discharge), health-related quality of life (up to 90 days from hospital discharge), heparin-induced thrombocytopenia (duration of study), and technical complications of mechanical interventions (duration of study) as important outcomes.</p> <p>Please see section 4.3.3 in the methods chapter for further detail explaining prioritisation of the critical outcomes.</p>
Quality of the clinical evidence	<p>Ten studies were included in this review. Four were included in the previous guideline (CG92) and six were new studies. A total of thirteen comparisons were identified from the ten included studies, evaluating mechanical (IPCD, AES, continual passive motion and foot pump) and pharmacological (UFH and LMWH) interventions for VTE prophylaxis.</p> <p>Mechanical prophylaxis</p> <p>Two studies included comparisons of IPCD (full leg), and one study included IPCD (full leg) plus AES, versus no VTE prophylaxis. Both comparisons had very low or low quality evidence, due to risk of bias and imprecision.</p> <p>One study evaluated the use of IPCD (full leg) compared to foot pump, and another compared IPCD (below knee) to foot pump. Evidence for the comparisons ranged from low to very low quality due to risk of bias and imprecision.</p> <p>Mechanical versus pharmacological</p> <p>One study compared IPCD (full leg) to UFH. Evidence was very low quality due to risk of bias and imprecision.</p> <p>One study looked at a combination of continual passive motion and UFH compared to UFH alone. Evidence range from very low to moderate quality, due to risk of bias and imprecision.</p> <p>One study included comparisons of IPCD (full length) and AES versus UFH. All outcomes had very low quality evidence, due to risk of bias and imprecision.</p> <p>One study evaluated the use of LMWH (high prophylactic dose) to IPCD, and another compared LMWH (standard prophylactic dose) to IPCD. The quality of the evidence for both studies was very low to low, due to risk of bias, imprecision, and for one major bleeding outcome, indirectness.</p> <p>One study evaluated the use of LMWH (high prophylactic dose) compared to (IPCD + AES) or FID. All of the evidence for these outcomes was very low, due to risk of bias and imprecision.</p> <p>One study compared LMWH (high prophylactic dose) to delayed LMWH (high prophylactic dose + foot pumps). The quality of evidence was very low, due to risk of bias and imprecision.</p> <p>Pharmacological prophylaxis</p> <p>Three studies compared UFH to no VTE prophylaxis. Evidence was very low quality due to risk of bias and imprecision.</p> <p>One study compared LMWH (high prophylactic dose) to UFH. The quality of the evidence was low to moderate, which was due to imprecision for all outcomes.</p>
Trade-off between clinical benefits and harms	<p>The committee noted that the high event rate for DVT and PE in this population compared to some of the other review populations is expected. This tallies with clinical experience, it is common for ICU populations to experience higher rates of DVT and PE. Therefore clinicians are likely to be comfortable with the idea of administering VTE prophylaxis in this population. The committee noted that the trauma population are likely to have significant immobilisation due to the nature of</p>

	<p>the injuries which would contribute to an increased risk for VTE.</p> <p>Evidence was identified for both mechanical and pharmacological prophylaxis both compared to each other and to no VTE prophylaxis. When considering the evidence for mechanical prophylaxis, the guideline committee noted that the evidence showed some possible clinical benefits of IPCD alone or in combination with AES for the outcomes of all-cause mortality, DVT and PE, however there was uncertainty around these results consistent with no different, or harm. There were seven comparisons of mechanical versus pharmacological prophylaxis. This evidence demonstrated conflicting findings, with some suggesting clinical benefits of mechanical prophylaxis or combined mechanical and pharmacological prophylaxis for DVT, PE and fatal PE, and other evidence demonstrating clinical benefits of pharmacological prophylaxis for DVT.</p> <p>The guideline committee discussed that for the major trauma population, the risk of bleeding is high, and therefore mechanical prophylaxis may be preferable. It was also noted that AES are not always practical in the major trauma population, due to the nature of the injuries which may prevent AES from being worn (for example injuries involving broken legs). The committee discussed different prophylaxis strategies including immediate combined mechanical and pharmacological prophylaxis or initial mechanical and then switching to pharmacological once bleeding risk had minimised. While the review sought to find any differences between the effectiveness of IPCD and foot-pumps, in practice foot-pumps are understood to be a subset (type) of intermittent pneumatic compression device, specifically shaped for the foot only. The committee believed that the evidence did not clearly demonstrate clinical superiority of half- or full-leg based IPCD compared to foot pumps and therefore believed it was reasonable to group all such devices under the more general term of intermittent pneumatic compression. The guideline committee concluded that mechanical prophylaxis such as IPCD and foot pumps should be recommended as initial treatment, until the risk of bleeding is reduced, at which time the risk of bleeding should be weighed against the risk of VTE. Given the lack of evidence for AES alone and the practical issues surrounding its use, the guideline committee concluded that AES would not be recommended.</p> <p>There were two pharmacological prophylaxis only comparisons. When UFH was compared to no prophylaxis, possible clinical benefits of UFH were seen for all-cause mortality, DVT and PE. However, when UFH was compared to LMWH, the evidence was mixed and therefore the guideline committee felt that there was insufficient evidence to specify which type of pharmacological prophylaxis was most effective for this population. It was highlighted that if necessary (e.g. reoperation) anticoagulation with UFH can be reversed, unlike with LMWH or fondaparinux. The guideline committee concluded that pharmacological prophylaxis should be considered for major trauma patients, but did not specify which type of pharmacological prophylaxis should be used. The particular prophylaxis preparation used would need to be based on clinical judgement on consideration of the individual patient factors. The committee also discussed whether pharmacological prophylaxis should be given in addition to or as an alternative to mechanical prophylaxis, however it was felt that this would need to depend on a clinical judgement taking into account the individual patient.</p>
<p>Trade-off between net clinical effects and costs</p>	<p>Two economic studies have been included in this review. One study comparing LMWH to UFH has been previously included in CG92. The second study compared VCFs to IPCDs in trauma patients who have contraindications to pharmacological prophylaxis. Both studies were assessed as partially applicable with potentially serious limitations.</p> <p>The guideline committee discussed the economic evidence alongside the clinical evidence. It was acknowledged that the serious and major trauma populations are at very high risk of bleeding, hence; mechanical prophylaxis options will have a more favourable benefit-harm balance, particularly in the early stages of the trauma event. The economic evidence presented supported the cost effectiveness of IPCD</p>

	<p>and showed that it was a cost saving option compared to VCFs in people who have contraindication to pharmacological prophylaxis. The committee felt that, based on the evidence presented and their collective clinical experience, the use of VCFs for primary prevention of VTE in this population is not a cost-effective use of resources. They also acknowledged that the removal of VCF incurs extra cost that has not been included in the economic evidence presented and this is likely to make VCFs even more costly. Hence, the committee chose to recommend against their use for the purpose of primary VTE prevention in this population. For people at low risk of major bleeding, the committee considered that the benefit of pharmacological prophylaxis in the prevention of VTE is likely to outweigh their risks. Hence; the committee considered the addition of pharmacological prophylaxis in this group to be a cost-effective use of resources and likely to be off-set through the prevention of costly VTE events.</p>
Other considerations	<p>It was noted that the studies included in this review include populations with varying degrees of injury severity. Initially the committee considered including only those papers with patients with major trauma defined as Injury Severity Score ≥ 16.¹⁵ However in keeping in line with the NICE Major Trauma guideline (https://www.nice.org.uk/guidance/ng39) this definition was extended to include major trauma by definition of included study. The committee discussed that in the UK context having an ISS of ≥ 9 gets patient details entered onto TARN (trauma audit and research network). Once the ISS is getting into the high teens this represents multi-system injuries.</p> <p>The committee highlighted that reassessment of VTE and bleeding risk needed to happen on an at least daily basis in this population due to the nature of their injuries and evolving risk profile.</p> <p>The committee also considered the use of vena caval filters, however due to the lack of clinical evidence and the presence of economic evidence demonstrating it not to be cost effective; it was decided to not recommend this method of prophylaxis.</p> <p>For people undergoing neurosurgery as a result of a head injury see the recommendation relating to cranial surgery.</p>

35 Abdominal surgery (excluding bariatric surgery)

35.1.2 Introduction

3 This section covers major abdominal surgery. It includes both open and laparoscopic surgery. Major
4 abdominal surgery covers inpatients undergoing gastrointestinal, gynaecological and urological
5 surgery.

6 Gastrointestinal surgery of its nature is heterogeneous in the age of patients, the pathological
7 conditions being dealt with and organs and systems operated upon. There remain a variety of
8 procedures retained within this category that are specialisations in themselves. These include upper
9 gastrointestinal surgery and lower intestinal surgery (or coloproctology). Factors that may alter the
10 risk of VTE:

- 11 • Patients having surgery for cancer will have an increased risk of developing a DVT or pulmonary
12 embolism.
- 13 • Patients having emergency procedures are often elderly and will consequently be at higher risk of
14 developing a DVT or pulmonary embolism.
- 15 • Some patients having emergency procedures may already be using anticoagulation or antiplatelet
16 therapy. This needs to be considered when deciding on the method of VTE prophylaxis.

17 Open gynaecological surgery includes abdominal and vaginal surgery excluding caesarean section.
18 Factors that may alter the risk of VTE:

- 19 • Patients may be using hormonal contraception and hormone replacement therapy, which will
20 increase their risk of developing a DVT or pulmonary embolism.
- 21 • Patients having surgery for cancer will have increased risk of developing a DVT or pulmonary
22 embolism.

23 Open urological surgery is divided into two major groups: pelvic cancer surgery and renal surgery.
24 Patients undergoing these procedures are usually between the ages of 65 and 75.

25 Factors that may alter the risk of VTE:

- 26 • Many urological surgery patients get spinal and epidural anaesthesia. This may reduce the risk of
27 developing a deep vein thrombosis.
- 28 • Renal surgery procedures may involve division of the renal vein where it drains into the inferior
29 vena cava possibly. This could potentially increase the risk of VTE.

30 There are no specific factors that increase the risk of bleeding or the hazard associated with it in
31 open gastrointestinal, gynaecological or urological surgery. There are no other special factors that
32 would affect the choice of, and use of, specific methods of VTE prophylaxis in these surgeries.

33 Laparoscopic surgery is used in gastrointestinal, gynaecological and urological surgery. Specific
34 considerations apply to it in all these specialities. Factors that may alter the risk of VTE:

- 35 • There is some concern that the increased pressure in the peritoneal cavity during laparoscopic
36 surgery causes venous stasis which may increase VTE risk.
- 37 • Some laparoscopic procedures also tend to last longer than open procedures.
- 38 • Being less invasive, most people will make a quicker return to mobility following laparoscopic
39 procedures compared to open procedures.

40 Factors that may alter the risk of bleeding:

- 41 • Laparoscopic procedures may be associated with less bleeding than open surgery.

- 1 • Bleeding may make laparoscopic surgery difficult or impossible and result in the need for
- 2 conversion to open surgery.
- 3 There are no other special factors that may affect the choice, and use of, specific methods of VTE
- 4 prophylaxis in laparoscopic surgery.

35.2.5 Review question: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing abdominal surgery (gastrointestinal, gynaecological, urological)?

9 For full details see review protocol in Appendix C.

10 **Table 167: PICO characteristics of review question**

Population	Adults and young people (16 years and older) undergoing abdominal surgery (including gastrointestinal, gynaecological, urological) who are admitted to hospital, and outpatients post-discharge
Interventions	<p>Mechanical:</p> <ul style="list-style-type: none"> • Anti-embolism stockings (AES) (above or below knee) • Intermittent pneumatic compression (IPCD) devices (full leg or below knee) • Foot pumps or foot impulse devices (FID) • Electrical stimulation (including Geko devices) • Continuous passive motion <p>Pharmacological (no minimum duration):</p> <ul style="list-style-type: none"> • Unfractionated heparin (UFH) (low dose, administered subcutaneously) • Low molecular weight heparin (LMWH), licensed in UK: • Low molecular weight heparin (LMWH), licensed in UK: <ul style="list-style-type: none"> ○ enoxaparin (standard prophylactic dose 40mg daily; minimum 20mg daily* to maximum 60mg twice daily*) ○ dalteparin (standard prophylactic dose 5000 units once daily; minimum 1250 units once daily* to maximum 5000 units twice daily*; obese patients – maximum 7500 twice units daily*) ○ tinzaparin (standard prophylactic dose 3500 units once daily; minimum 2500 units once daily* to maximum 4500 units twice daily*; obese patients – maximum 6750 twice daily*) • LMWH, licensed in countries other than UK: <ul style="list-style-type: none"> ○ Bemiparin (standard 2500 units daily; minimum 2500 units daily to maximum 3500 units daily) ○ Certoparin (3000 units daily) ○ Nadroparin (standard 2850 units once daily; minimum 2850 units once daily to maximum up to 57 units/kg once daily) ○ Parnaparin (standard 3200 units once daily; minimum 3200 units once daily to maximum 4250 units once daily) ○ Reviparin (minimum 1750 units once daily to maximum 4200 units once daily) • Vitamin K Antagonists: warfarin (variable dose), acenocoumarol (all doses), phenindione (all doses) • Fondaparinux (all doses) • Apixaban (all doses)

	<ul style="list-style-type: none"> • Dabigatran (all doses) • Rivaroxaban (all doses) • Aspirin (up to 300mg)* <p>*off-licence</p>
Comparisons	<p>Compared to:</p> <ul style="list-style-type: none"> • Other VTE prophylaxis treatment, including monotherapy and combination treatments (between class comparisons for pharmacological treatments only) • No VTE prophylaxis treatment (no treatment, usual care, placebo) <p>Within intervention (including same drug) comparisons, including:</p> <ul style="list-style-type: none"> • Above versus below knee stockings • Full leg versus below knee IPC devices • Standard versus extended duration prophylaxis. Extended duration = extended beyond discharge • Low versus high dose for LMWH • Preoperative versus post-operative initiation of LMWH
Outcomes	<p>Critical outcomes:</p> <ul style="list-style-type: none"> • All-cause mortality (up to 90 days from hospital discharge) (NMA outcome) • Deep vein thrombosis (symptomatic and asymptomatic) (7-90 days from hospital discharge). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) (NMA outcome) • Pulmonary embolism (7- 90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE (NMA outcome) • Major bleeding (up to 45 days from hospital discharge). A major bleeding event meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood ; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event (NMA outcome) • Fatal PE (up to 90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE <p>Important outcomes:</p> <ul style="list-style-type: none"> • Clinically relevant non-major bleeding (up to 45 days from hospital discharge): bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy • Health-related quality of life (validated scores only)(up to 90 days from hospital discharge) • Heparin-induced thrombocytopenia (HIT) (duration of study) <p>Technical complications of mechanical interventions (duration of study)</p>
Study design	Randomised controlled trials (RCTs), systematic reviews of RCTs.

35.3.1 Clinical evidence

2 Sixty-seven studies in 69 papers were included in the review these are summarised in Table 168
3 below. Sixty-two studies were previously included in the previous guideline (CG92);^{5, 317, 316, 292, 293, 6, 19,}
4 37, 38, 44, 29, 30, 28, 25, 26, 24, 22, 42, 50, 54, 56, 55, 57, 58, 92, 102, 109, 110, 118, 120, 131, 138, 136, 156, 160, 159, 169, 175-177, 193, 202, 204, 210,
5 232, 235, 238, 239, 236, 245, 250, 251, 268, 272, 284, 286, 291, 290, 294, 303, 137, 302 and five studies were added to the update;
6 111, 260, 223, 158, 273, 137. Evidence from these studies is summarised in the clinical evidence summary
7 tables below (Table 169, Table 170, Table 171, Table 172, Table 173, Table 174, Table 175, Table 176,
8 Table 177, Table 178, Table 179, Table 180, Table 181, Table 182, Table 183, Table 184, Table 185,
9 Table 186, Table 187, Table 188, Table 189, Table 190, Table 191, Table 192, Table 193, Table 194,
10 Table 195, Table 196, Table 197, Table 198, Table 199, Table 200, Table 201, Table 202, Table 203,
11 Table 204, Table 205, Table 206, Table 207). See also the study selection flow chart in Appendix E,
12 forest plots in Appendix L, study evidence tables in Appendix H, GRADE tables in Appendix K and
13 excluded studies list in Appendix N.

14 Based on the current review protocol, six systematic reviews that were included in CG92 were
15 excluded but checked for references. The studies from all of one systematic review¹¹ were excluded
16 due to having the incorrect intervention. Some of the studies from five systematic reviews^{7, 61, 167, 217,}
17 ²⁵⁶ were excluded due to having incorrect population, intervention or comparisons. For this update,
18 data from the original papers, rather than systematic review data, was used.

19 A large amount of people undergo major abdominal surgery, and where evidence for other
20 populations relating to torso surgery (e.g. thoracic surgery and cardiac surgery) is lacking, the
21 committee agreed to consider major abdominal surgery as indirect evidence. Therefore in order to
22 compare the clinical effectiveness data of multiple possible interventions, it was proposed that a
23 network meta-analysis be carried out on the outcome data for DVT, PE and major bleeding in this
24 population. These analyses provide estimates of effect (with 95% credible intervals) for each
25 intervention compared to one another and compared to a single baseline risk (in this case the
26 baseline treatment was no prophylaxis or in the case of the major bleeding outcome a combination
27 of no prophylaxis and mechanical prophylaxis). These estimates provide a useful clinical summary of
28 the results and facilitate the formation of recommendations based on the best available evidence.
29 For full details on the NMA methodology and results, please see Appendix M.

30 **Table 168: Summary of systematic reviews included in the review**

Included studies	Intervention and comparison	Population	Outcomes	Comments
Agnelli 2005 ¹	<p><u>Intervention (n=1433):</u> Fondaparinux (2.5 mg, 1 x daily). Duration: started 6 hours post-op and repeated daily for 5-9 days.</p> <p><u>Comparison (n=1425):</u> LMWH, standard dose, (dalteparin, 5000U, 1 x daily). Duration: started 2 hours before operation (2500U), and then given 12 hours later (2500U). 5000 units given once daily</p>	<p>n=2858</p> <p>People having high risk abdominal surgery (duration >45 minutes)</p> <p>Age >40 years</p> <p>Male and female (1584:629)</p> <p>Cancer 67.9%</p> <p>Multiple countries (131 hospitals in 22 countries)</p>	<p>All-cause mortality (32 days)</p> <p>DVT (32 days): confirmed by bilateral venography</p> <p>Symptomatic pulmonary embolism (32 days): confirmed by high probability lung scan, pulmonary angiography, helical computed tomography or</p>	

Included studies	Intervention and comparison	Population	Outcomes	Comments
	thereafter for 5-9 days.		autopsy Major bleeding (7-11 days): fatal, retroperitoneal, intracranial, intraspinal, or involved any other critical organ, bleeding leading to reoperation or intervention, or a bleeding index of 2.0 or more Fatal PE (32 days): confirmed by autopsy	
Allan 1983 ⁵	<u>Intervention (n=97):</u> AES, length not stated. Duration: evening before operation until 7 days post-op <u>Comparison (n=103):</u> no VTE prophylaxis	n=200 People having abdominal surgery (duration >30 minutes) Age >40 years Male and female UK	DVT (7 days): confirmed by fibrinogen uptake test	
Allen 1978 ⁶	<u>Intervention (n=30):</u> UFH (5000U 2 x daily) Duration: started 2 hours before surgery, until discharge <u>Comparison (n=30):</u> No VTE prophylaxis	n=60 People undergoing urologic surgery (transurethral prostatectomy) Age (average): intervention 71.9, comparison 71.2 UK	All-cause mortality (time-point not reported) Major bleeding (time-point not reported): defined as requiring a transfusion of two units of blood	
Bejjani 1983 ¹⁹	<u>Intervention (n=17):</u> UFH (5000U 2 x daily) Duration: started 3 hours before surgery or on admission, for 2 days <u>Comparison (n=17):</u> No VTE prophylaxis (placebo, 2ml saline 2 x daily).	n=34 People undergoing urologic surgery Cancer = 38% United States	PE (postoperatively): confirmed by ventilation perfusion lung scan Major bleeding (postoperatively): defined as bleeding requiring a transfusion of 2	

Included studies	Intervention and comparison	Population	Outcomes	Comments
	Duration: started 3 hours before surgery or on admission, for 2 days		units	
Bergqvist 1980 ²⁹	<u>Intervention (n=46):</u> UFH (5000U, 2 x daily) Duration: started 2 hours before surgery or on admission, for 5 days <u>Comparison (n=51):</u> No VTE prophylaxis	n=97 People having general surgery (abdominal surgery 56.7%, urologic surgery 38.1%) Male and female (63:34) Age >51 years 22% malignant disease Sweden	All-cause mortality (up to 7 days) DVT (up to 7 days): confirmed by I-fibrinogen test Fatal PE (up to 7 days): method of confirmation not reported	
Bergqvist 1986 ^{25,26}	<u>Intervention (n=215):</u> LMWH, standard dose (dalteparin, 5000U, 1 x daily) Duration: started 2 hours before operation, for 5-7 days <u>Comparison (n=217):</u> UFH 5000U 2 x daily Duration: started 2 hours before operation, for 5-7 days	n=432 People having general surgery (gastric surgery 7.9%, biliary tract surgery 29.6%, colonic surgery 37%, rectal surgery 18.2%, pancreatic surgery 0.5%, other 6.7%) Age > 40 45% malignancies Sweden	All-cause mortality (30 days) DVT (7 days): confirmed by I-labelled fibrinogen uptake test Major bleeding (30 days): defined as bleeding requiring reintervention	
Bergqvist 1988 ³⁰	<u>Intervention (n=505):</u> LMWH, standard dose (dalteparin 5000U, 1 x daily). Duration: started the evening before surgery, for 5-8 days <u>Comparison (n=497):</u> UFH (5000U), 2 x daily (the first injection contained placebo) Duration: started the evening before surgery, for 5-8 days	n=1002 People having general abdominal surgery (gastric surgery 10%, biliary tract surgery 8.6%, colonic surgery 56.6%, rectal surgery 17.6%, pancreatic surgery 2.4%, other 4.6%) Median duration: LMWH = 120 minutes, UFH = 125 minutes Aged > 41 years Male and female (488:514)	All-cause mortality (30 days) DVT (7 days days): confirmed by I-labelled fibrogen uptake test PE (30 days): confirmed by scintigraphy Fatal PE (30 days): confirmed by autopsy	

Included studies	Intervention and comparison	Population	Outcomes	Comments
Bergqvist 1995 ²⁴	<p><u>Intervention (n=1036):</u> LMWH, standard dose, (dalteparin, 5000U, 1 x daily). Duration: started 22 hours the day before surgery for 7 days postoperatively.</p> <p><u>Comparison (n=1034):</u> LMWH, low dose (dalteparin, 2500U, 1 x daily). Duration: started 22 hours the day before surgery for 7 days postoperatively.</p>	<p>Sweden</p> <p>n=2070</p> <p>People having abdominal surgery (duration, median: intervention 125 minutes, comparison 129 minutes)</p> <p>Age > 40 years Male and female (985:1085)</p> <p>Sweden</p>	<p>All-cause mortality (30 days post op): confirmed by autopsy</p> <p>DVT (7 days post-op): confirmed by fibrinogen uptake test</p> <p>PE (30 days): confirmed by perfusion/ventilation scintigraphy</p> <p>Major bleeding (30 days post-op): defined as those leading to death or reoperation, or as being intracranial, intraocular or intraspinal</p>	
Bergqvist 1996 ²⁸	<p><u>Intervention (n=39):</u> LMWH, standard dose (tinzaparin 3500U, 1 x daily). Duration: started post-operatively for >5 days</p> <p><u>Comparison (n=41):</u> No VTE prophylaxis (placebo)</p>	<p>n=80</p> <p>People having emergency abdominal surgery</p> <p>Age >40 years Males and females (37:43)</p> <p>13.8% malignant disease</p> <p>Sweden</p>	<p>All-cause mortality (30 days)</p> <p>DVT (30 days): confirmed by FUT and venography</p> <p>PE (30 days): method of confirmation not reported</p> <p>Major bleeding (30 days): defined as bleeding requiring re-operation, transfusion or other intervention, leading to death or intraocular, intracranial or intraspinal bleeding</p>	
Bergqvist 2002 ²¹	<p><u>Intervention (n=253):</u> extended LMWH, standard dose, (enoxaparin, 40mg, 1 x daily). Duration: started 10-14 hours</p>	<p>n=501</p> <p>People having abdominal surgery for cancer Duration >45 minutes</p>	<p>All-cause mortality (2 months)</p> <p>DVT (25-31 days): confirmed</p>	AES were allowed

Included studies	Intervention and comparison	Population	Outcomes	Comments
	<p>before operation, then once daily for 25-31 days.</p> <p><u>Comparison (n=248):</u> standard LMWH, standard dose, (enoxaparin, 40mg 1 x daily). Duration: started 10-14 hours before operation, then once daily for 6-10 days. Placebo for further 19-21 days.</p>	<p>Age >40 years</p> <p>Male and female (200:132)</p> <p>Cancer 100%</p> <p>Multiple countries</p>	<p>by bilateral venography</p> <p>PE (3 months): confirmed by V/Q scan or angiogram</p> <p>Major bleeding (3 months): bleeding resulting in death, a decrease in the haemoglobin concentration of 2 g per deciliter or more, or the transfusion of at least 2 units of blood; retroperitoneal, intracranial, or intraocular; resulted in a serious or life-threatening clinical event; or if surgical or medical intervention was required</p> <p>Fatal PE (3 months): confirmed by autopsy</p>	
Borstad 1988 ³⁷	<p><u>Intervention (n=105):</u> LMWH, standard dose (dalteparin 5000U, 1 x daily) Duration: started 1 hour preoperatively for 7 days</p> <p><u>Comparison (n=110):</u> UFH (5000U, 2 x daily) Duration: started 1 hour preoperatively for 7 days</p>	<p>n= 215</p> <p>People having major gynaecological surgery (laparotomy 52.6%, colposuspension 19.6%, vaginal repair 25.1%) Duration >30 minutes</p> <p>Age >40 years</p> <p>Cancer 6%</p> <p>Norway</p>	<p>DVT (7 days): confirmed by plethysmography and venography</p> <p>PE (7 days): confirmed by clinical examination</p> <p>Major bleeding (time-point not reported): defined as if the patient was reoperated, received blood transfusions or had prophylaxis stopped due to bleeding</p>	
Borstad 1992 ³⁸	<u>Intervention (n=77):</u> LMWH, low dose	n=152	All-cause mortality (1 month)	

Included studies	Intervention and comparison	Population	Outcomes	Comments
	<p>(dalteparin, 2500U, 1 x daily). Duration: started 1 hour before surgery for 7 days</p> <p><u>Comparison (n=75):</u> UFH (5000U 2 x daily). Duration: started 1 hour before surgery for 7 days</p>	<p>People having major gynaecological surgery (laparotomy, colposuspension, vaginal repair)</p> <p>Duration > 30 minutes</p> <p>Age > 40 years</p> <p>Norway</p>	<p>PE (1 month): confirmed by venography if thromboembolic complications suspected from clinical examination</p> <p>Major bleeding (5 days): defined as prophylaxis stopped because of bleeding, transfusions received, perioperative bleeding more than 1000 ml and pelvic haematoma</p>	
Butson 1981 ⁴²	<p><u>Intervention (n=62):</u> IPCD, knee length</p> <p>Duration: started immediately after anaesthesia and continued until fully ambulant (usually for 24-48 hours)</p> <p><u>Comparison (n=57):</u> No VTE prophylaxis</p>	<p>n=119</p> <p>People having general abdominal surgery</p> <p>Age >20 years</p> <p>Males and females (52:67)</p> <p>Canada</p>	<p>DVT (discharge or 14 days): confirmed by fibrinogen scanning, venography, or autopsy</p> <p>Fatal PE (discharge or 14-90 days): confirmed by autopsy</p>	
Caen 1988 ⁴⁴	<p><u>Intervention (n=195):</u> LMWH, low dose (dalteparin, 2500U, 1 x daily)</p> <p>Duration: 2 hours before operation until 7 days post-op</p> <p><u>Comparison (n=190):</u> UFH (5000U, 2 x daily)</p> <p>Duration: 2 hours before operation until 7 days post-op</p>	<p>n=385</p> <p>People having major abdominal surgery</p> <p>Duration of surgery >30 minutes</p> <p>Age >40 years</p> <p>Males and females (188:197)</p> <p>France</p>	<p>All-cause mortality (30 days)</p> <p>DVT (30 days): confirmed by I-fibrinogen uptake test</p> <p>PE (30 days): method of confirmation not reported</p> <p>Fatal PE (30 days): method of confirmation not reported</p>	
Caprini 1983 ⁴⁸	<p><u>Intervention (n=38):</u></p> <ul style="list-style-type: none"> • AES, above knee • IPCD, full leg 	<p>n=77</p> <p>People having general</p>	<p>DVT (time-point not reported): confirmed by venography,</p>	

Included studies	Intervention and comparison	Population	Outcomes	Comments
	<p>Duration: all patients wore bilateral AES preoperatively. IPCD was then applied prior to the onset of anaesthesia and maintained for at least 3 days postoperatively or until ambulant. When the IPCD was removed, AES was re-applied until discharge</p> <p><u>Comparison (n=39):</u> AES, above knee. Duration: started preoperatively, worn until discharge</p>	<p>surgery (abdominal 64.9, orthopaedic 13%, neurologic 10.4%, genitourinary 10.4%, thoracic 1.3%)</p> <p>Age 92.3% >40 years</p> <p>Males and females (31:46)</p> <p>16.7% malignant condition</p> <p>United States</p>	<p>plethysmography and Doppler</p> <p>PE (time-point not reported): confirmed by angiography</p> <p>Fatal PE (time-point not reported): method of confirmation not reported</p>	
Chandhoke 1992 ⁵⁰	<p><u>Intervention (n=47):</u> IPCD, full length</p> <p>Duration: applied intra-operatively and continued post-op for 5 days or until patient became fully ambulant</p> <p><u>Comparison (n=53):</u> VKA, (warfarin, variable dose). Duration: started on the night of the operation, until discharge</p>	<p>n=100</p> <p>People having urological surgery (radical prostatectomy 81%, radical cystectomy 9%, other pelvic surgery 3%, kidney surgery 7%)</p> <p>Duration of surgery >2 hours</p> <p>Age (mean, SD): intervention, 67.5 (7.1), comparison, 66.1 (6.4)</p> <p>Male and Female (99:1)</p> <p>Cancer 99%</p> <p>United States</p>	<p>All-cause mortality (1-2 weeks)</p> <p>DVT (5 days): confirmed by venography and ultrasound</p> <p>PE (1-2 weeks): confirmed by venography and ultrasound</p>	
Clarke-Pearson 1983 ⁵⁴	<p><u>Intervention (n=88):</u> UFH (5000U, 2 x daily) Duration: 2 hours before surgery, for 7 days</p> <p><u>Comparison (n=97):</u> No VTE prophylaxis</p>	<p>n=185</p> <p>People having gynaecological malignancy surgery</p> <p>Age >20 years Female</p> <p>Cancer 100%</p> <p>United States</p>	<p>DVT (42 days): confirmed by fibrinogen counting, impedance plethysmography and venography</p> <p>PE (42 days): confirmed by ventilation-perfusion scanning and/or pulmonary</p>	

Included studies	Intervention and comparison	Population	Outcomes	Comments
			arteriography Fatal PE (42 days): confirmed at autopsy	
Clarke-Pearson 1984A ⁵⁵	<u>Intervention (n=97):</u> IPCD, below knee. Duration: applied at time of anaesthesia, until discharge from recovery room or for 1 day <u>Comparison (n=97):</u> No VTE prophylaxis	n=194 People having major surgery for gynaecologic malignancies Duration of surgery (mean): 233 minutes Female Cancer 100% United states	DVT (42 days): confirmed by I-labelled fibrinogen counting and impedance plethysmography and ascending venography PE (42 days): ventilation perfusion lung scanning, and pulmonary arteriography Fatal PE (42 days): confirmed by autopsy	
Clarke-Pearson 1984B ⁵⁷	<u>Intervention (n=55):</u> IPCD, below knee Duration: applied at time of anaesthesia for 5 days <u>Comparison (n=52):</u> No VTE prophylaxis	n=107 People having major surgery for gynaecologic malignancies Duration of surgery >85 minutes Age >20 years Female Cancer 100% United states	All-cause mortality (42 days) DVT (42 days): confirmed by I-fibrinogen counting and impedance plethysmography PE (42 days): ventilation perfusion lung scanning, and pulmonary arteriography	
Clarke-Pearson 1993 ⁵⁶	<u>Intervention (n=107):</u> UFH (5000U), 3 x daily Duration: started 16 hours before surgery (3 doses given preoperatively), for 7 days, until fully ambulated or until discharge <u>Comparison (n=101):</u> IPCD, below knee. Duration: applied at	n=208 People having gynaecologic oncology surgery Duration >80 minutes Age >22 years Female Cancer 76.4%	DVT (until discharge): confirmed by fibrinogen uptake test, impedance plethysmography, duplex Doppler ultrasound and ascending contrast venography PE (30 days): ventilation perfusion lung	

Included studies	Intervention and comparison	Population	Outcomes	Comments
	induction of anaesthesia, for 5 days, until fully ambulant or until discharge	United States	scanning and pulmonary arteriography	
Coe 1978 ⁵⁸	<p>Intervention 1 (n= 28): UFH (5000 U, 2 x daily) Duration: 2 hours before surgery, until discharge</p> <p>Intervention 2 (n=29): Intermittent pneumatic compression device (IPCD), calf length. Duration: applied after induction of anaesthesia until discharge</p> <p>Comparison (n=24): No VTE prophylaxis (control group, no further details reported)</p>	<p>n=81</p> <p>People undergoing urologic surgery Duration of surgery (mean) 234 minutes</p> <p>Age (mean, SD): intervention 1 = 63 (16) intervention 2 = 55 (11), control = 51 (18) Gender not reported</p> <p>United States</p>	<p>DVT (until discharge): confirmed by I fibrinogen scan technique, phlebography</p> <p>PE (until discharge): confirmed by chest roentgenography, lung scan, or pulmonary angiography</p>	
Fasting 1985 ⁹²	<p>Intervention (n=52): AES, thigh length Duration: applied the evening before surgery and worn for at least five days until mobile</p> <p>Comparison (n=45): UFH, (5000U 2 x daily). Duration: started the evening before surgery for at least 5 days until mobile. All patients received a dose 2-3hrs before surgery</p>	<p>n=97</p> <p>People having general surgery (gastro-duodenal 14.4%, large intestine 9.3%, rectal 14.4%, biliary 36.1%, urological 19.6%, other 6.2%) Surgery duration >1hr</p> <p>Age (mean, range): intervention, 60 (39-87), comparison, 60 (39-80)</p> <p>Male and female (49:48)</p> <p>Cancer 31.9%</p> <p>Denmark</p>	<p>Major bleeding (time-point not reported): defined as major post-operative haemorrhagic complications</p> <p>Fatal PE (time-point not reported): confirmed by autopsy</p>	
Fricker 1988 ¹⁰²	<p>Intervention (n=40): LMWH, standard dose (dalteparin, 2500U, 2 x daily). Duration: started 2 hours before surgery</p>	<p>n=80</p> <p>People having surgery of a malignant tumour of the abdomen or pelvis Duration >30 minutes</p>	DVT (10 days): confirmed by I-fibrinogen uptake test and venography	

Included studies	Intervention and comparison	Population	Outcomes	Comments
	<p>and 12 hours after first administration, followed by LWMH, standard dose (dalteparin 5000U, 1 x daily) for 10 days</p> <p><u>Comparison (n=40):</u> UFH (5000U, 3 x daily). Duration: started 2 hours before surgery, for 10 days</p>	<p>Age >40 years Males and females (8:72)</p> <p>Cancer 100%</p> <p>France</p>	<p>PE (up to 8 weeks): confirmed by lung scintigraphy and arterial gazometry</p> <p>Major bleeding (4 weeks): defined as severe postoperative bleeding requiring withdrawal of treatment</p>	
Gallus 1973 ¹¹⁰	<p><u>Intervention (n=108):</u> UFH (5000U, 3 x daily) Duration: started 2 hours before surgery until ambulant</p> <p><u>Comparison (n=118):</u> No VTE prophylaxis</p>	<p>n=226</p> <p>People having general surgery (cholecystectomy 37.6%, gastric surgery 16.8%, large bowel surgery 15%, laparotomy 4%, pancreatic surgery 1.3%, abdominal aneurysm 1.3%, hernia repair 5.8%, thoracotomy 4%, laminectomy 6.6%, hip replacement 7.5%)*</p> <p>Cancer = 15.5%</p> <p>Age >40 years Males and Females (92:134)</p> <p>Canada</p> <p>*Data on emergency hip surgery and medical patients has been excluded</p>	<p>DVT (mean 8.5-9.8 days): confirmed by I-fibrinogen scanning and venography</p>	
Gallus 1976 ¹⁰⁹	<p><u>Intervention (n=408):</u> UFH (5000U, 3 x daily) Duration: started 2 hours before surgery, for 7 days or until discharge</p> <p><u>Comparison (n=412):</u> No VTE prophylaxis</p>	<p>n=820</p> <p>People having major abdominothoracic surgery (gallbladder 47.9%, stomach 12.8%, large bowel 11%, other intraabdominal 6%, hernia 9.8%, chest 4.8%. spine 9.1%)</p> <p>Duration of surgery (mean, range) 92, 18-310 minutes</p>	<p>DVT (mean 8.4-9.1 days): confirmed by I-labelled fibrinogen scanning, and phlebography</p>	

Included studies	Intervention and comparison	Population	Outcomes	Comments
		Age >40 years Cancer 17% Canada		
Gao 2012 ¹¹¹	<p><u>Intervention (n=52):</u></p> <ul style="list-style-type: none"> AES, length undefined circumference IPCD, thigh length <p>Duration: AES was applied pre-operatively and IPCD was applied intra and postoperatively until ambulant</p> <p><u>Comparison (n=56):</u> AES, length undefined Duration: applied pre-operatively until ambulant</p>	<p>n=108</p> <p>People gynaecological pelvic surgery (laparotomy 25%, laparoscopic surgery 55.6%, vaginal surgery 19.4%)</p> <p>Age >60 years Female</p> <p>Cancer 64.8%</p> <p>China</p>	<p>DVT (time-point not reported): confirmed by Doppler ultrasound</p> <p>PE (time-point not reported): confirmed by pulmonary angiography</p>	
Gonzalez 1996 ¹¹⁸	<p><u>Intervention (n=84):</u> LMWH, standard dose (bemiparin, 2500U, 1 x daily). Duration: started 2 hours before surgery for 7 days</p> <p><u>Comparison (n=82):</u> UFH (5000U, 2 x daily). Duration: started 2 hours before surgery for 7 days</p>	<p>n=166</p> <p>People having abdominal surgery (cholecystectomy 52.6%, herniotomy 20.5%, pilorotomy 5.2%, other 21.8%) Duration >30 minutes</p> <p>Age >40 years Males and females (65:101)</p> <p>Spain</p>	<p>All-cause mortality (8 days)</p> <p>DVT (8 days): confirmed by Doppler and plethysmography</p> <p>PE (8 days): confirmed by perfusion/ventilation lung scanning and angiography</p> <p>Major bleeding (8 days): defined as needing a transfusion of 2 or more units of whole blood, haemoglobin less than 2 g/l, central bleeding and reoperation because of bleeding</p>	
Gordon-Smith 1972 ¹²⁰	<p><u>Intervention (n=48):</u> UFH (5000U), injected subcutaneously every</p>	n=98	DVT (time-point not reported): confirmed by I-	

Included studies	Intervention and comparison	Population	Outcomes	Comments
	<p>12 hours. Duration: started one hour before surgery, for 5 days (a total of 10 doses)</p> <p><u>Comparison (n=50):</u> No VTE prophylaxis</p>	<p>People having general surgery (abdominal 87.8%, prostatectomy 4.1%, nephrectomy/ ureterolithotomy 4.1%, radical mastectomy 4.1%)</p> <p>Age >40 years Male and female (49:49)</p> <p>Cancer 32.7%</p> <p>UK</p>	<p>fibrinogen method</p> <p>PE (time-point not reported): confirmed by phlebography</p>	
Hartl 1990 ¹³⁶	<p><u>Intervention (n=126):</u> LMWH, low dose (dalteparin, 2500U, 1 x daily) Duration: started 2 hours before operations for at least 7 days post op and fully ambulant</p> <p><u>Comparison (n=124):</u> UFH (5000U, 2 x daily) Duration: started 2 hours before operations for at least 7 days post op and fully ambulant</p>	<p>n=250</p> <p>People having abdominal surgery Duration of surgery (mean): intervention 91.7, comparison 106.4 minutes</p> <p>Aged >40 years Males and females (144:106)</p> <p>Cancer 29.6%</p> <p>Austria</p>	<p>All-cause mortality (time-point not reported): confirmed by autopsy</p> <p>DVT (time-point not reported): confirmed by fibrinogen uptake test and venography</p> <p>Major bleeding (time-point not reported): defined as bleeding requiring transfusion >2 units of blood</p> <p>Fatal PE (time-point not reported): confirmed by autopsy</p>	
Hata 2016 ¹³⁷	<p><u>Intervention (n=152):</u></p> <ul style="list-style-type: none"> UFH (5000U) Fondaparinux (2.5mg, 1 x daily) Mechanical thromboprophylaxis (AES + IPCD) <p>UFH started 6 hours after wound closure and continued every 12 hours until the day after surgery. Fondaparinux started on postoperative day 2</p>	<p>n=298</p> <p>People with urological malignancy Duration of surgery >45 minutes</p> <p>Age >40 years</p> <p>Males and females 282:16</p> <p>Japan</p>	<p>PE (time-point not reported): method of confirmation not reported</p> <p>Major bleeding (time-point not reported): defined as fatal bleeding, bleeding at vital organs, bleeding or hematoma around the surgical beds necessitating</p>	<p>If eGFR ranged from 30-50 mL/min/1.73² and the risk of bleeding was high, prophylaxis could be reduced to 1.5mg (fondaparinux) or 2000U daily (enoxaparin), at the discretion of the physician</p>

Included studies	Intervention and comparison	Population	Outcomes	Comments
	<p>until day 5. Mechanical thromboprophylaxis used until full ambulatory</p> <p><u>Comparison (n=146):</u></p> <ul style="list-style-type: none"> UFH (5000U) LMWH, standard dose (enoxaparin, 2000U, 2 x daily) Mechanical thromboprophylaxis (AES + IPCD) <p>UFH started 6 hours after wound closure and continued every 12 hours until the day after surgery. LMWH started on postoperative day 2 until day 5. Mechanical thromboprophylaxis used until full ambulatory</p>		reoperation, or bleeding necessitating transfusion of >400mL red blood cells prepared from whole blood, or >2g/dL decrease in haemoglobin level within 48 hours after bleeding onset	
Hauch 1988 ¹³⁸	<p><u>Intervention (n=20):</u> LMWH, standard dose (tinzaparin, 3500U, 1 x daily). Duration: started 2 hours before operation, until postoperative day 7 or discharge</p> <p><u>Comparison (n=22):</u> LMWH, low dose, (tinzaparin, 2500U, 1 x daily). Duration: started 2 hours before operation, until postoperative day 7 or discharge</p>	<p>n=42</p> <p>People having major abdominal surgery (biliary tract surgery 17.1%, gastric surgery 14.3%, colorectal surgery 48.6%, other 20%)</p> <p>Duration of surgery >1 hour</p> <p>Age >40 years</p> <p>Male and female (13:22)</p> <p>Denmark</p>	<p>DVT (7 days): confirmed by venography</p> <p>PE, symptomatic (1 month): method of confirmation not reported</p> <p>Major bleeding (1 month): defined as major bleeding complications</p> <p>Fatal PE (1 month): confirmed by autopsy</p>	
Holford 1976 ¹⁴³	<p><u>Intervention (n=48):</u> AES, above knee Duration: applied 12 hours before operation until fully ambulant (4 or 5 days post op)</p>	<p>n=95</p> <p>People having major surgery (abdominal, pelvic, abdominal and pelvic or thoracic 9.5%)</p>	<p>All-cause mortality (time-point not reported)</p> <p>DVT (time-point not reported): confirmed by I-</p>	

Included studies	Intervention and comparison	Population	Outcomes	Comments
	<u>Comparison (47):</u> No VTE prophylaxis (control group, no further details reported)	Age >40 years Cancer 20.4% UK	fibrinogen test PE (time-point not reported): confirmed by lung scanning	
Kaaja 1992 ¹⁵⁶	<u>Intervention (n=37):</u> LMWH, low dose (enoxaparin, 20mg, 1 x daily). Duration: started 2 hours before surgery for 3 days <u>Comparison (n=31):</u> UFH, 5000U, 2 x daily). Duration: started 2 hours before surgery for 3 days	n=68 People having abdominal hysterectomy Age >35 years Female Cancer 25% Finland	PE (3-4 weeks): confirmed by lung scanning Major bleeding (time-point not reported): defined as bleeding necessitating reoperation and/or blood transfusion, and cessation of heparin administration	
Kakkar 1972 ¹⁶⁰	<u>Intervention (n=39):</u> UFH (5000U, 2 x daily) Duration: started 2 hours before surgery for 7 days <u>Comparison (n=39):</u> No VTE prophylaxis	n=78 People having major surgery (gastric 24.4%, colonic 16.7%, biliary, 33.3% thoracic 5.1%, urological 16.7%, laparotomy 3.8%) Age >40 years Male and female (45:33) United States	DVT (10 days): confirmed by I-labelled fibrinogen test PE (time-point not reported): method of confirmation not reported	
Kakkar 1993 ¹⁵⁹	<u>Intervention (n=1894):</u> LMWH, low dose (dalteparin, 2500U, 1 x daily) Duration: started 1-4 hours before operation, for at least 5 days and until fully mobile <u>Comparison (n=1915):</u> UFH (5000U), 2 x daily Duration: started 1-4 hours before operation, for at least 5 days and until fully mobile	n=3809 People having major abdominal surgery (colectomy 23.4%, abdominoperineal resection 4.5%, cholecystectomy 25%, other biliary procedures 1.3%, laparotomy 3.9%, gynaecological procedure 25.4%, oesophageal procedure 2.8%, gastric procedure 6.6%, urological procedure 2.7%, other 3.6%) Duration >30 minutes	All-cause mortality (4-8 weeks) PE (4-8 weeks): confirmed by ventilation/perfusion scanning or pulmonary angiography Major bleeding (4-8 weeks) defined as: blood loss during the perioperative period that required discontinuation of	

Included studies	Intervention and comparison	Population	Outcomes	Comments
		Age > 40 years Male and female (1314:2495) Cancer 36.9% UK	prophylaxis, when bleeding was clearly attributable to the trial drug, when bleeding required reoperation to control it, or when a wound haematoma developed whether or not it required evacuation. Fatal PE (4-8 weeks): confirmed by autopsy	
Kakkar 2010 ¹⁵⁸	<u>Intervention (n=315):</u> extended duration LMWH, high dose (bemiparin, 3500U, 1 x daily) Duration: before randomisation, all patients received LMWH for 8±2 days, starting 6 hours after surgery. Patients then received LMWH for 20 ±2 additional days <u>Comparison (n=310):</u> standard duration LMWH, high dose (bemiparin, 3500U) + placebo (0.9% sodium chloride 0.2mL). Duration: before randomisation, all patients received LMWH for 8±2 days, starting 6 hours after surgery. Patients then received placebo for 20±2 additional days	n=625 People having abdominal or pelvic surgery for cancer (gastrointestinal tract (colorectal, gastric and other) 80.6%, urologic 7.5%, female reproductive organs 11.4%, retroperitoneal 0.5%) Duration >30 minutes Age >40 years Males and females (330:295) 34 centres in 3 countries (UK, Spain, Italy)	All-cause mortality (90 days) DVT (28 days): confirmed by venography or Doppler ultrasound PE (28 days): confirmed by perfusion/ventilation lung scintigraphy, pulmonary arteriography or spiral computed tomography Major bleeding (22 days): defined as fatal bleeding, clinically overt bleeding, bleeding leading to a transfusion of 2 or more units of packed cells or whole blood, retroperitoneal or intracranial bleeding, or clinically overt bleeding warranting treatment cessation	
Koller	<u>Intervention (n=23):</u>	n=43	All-cause mortality	

Included studies	Intervention and comparison	Population	Outcomes	Comments
1986A ¹⁷⁰	<p>LMWH, high dose (dalteparin, 7500U, 1 x daily)</p> <p>Duration: started one hour before operation, for a minimum of 5 days</p> <p><u>Comparison (n=20):</u> UFH (5000U), 2 x daily</p> <p>Duration: started one hour before operation, for a minimum of 5 days</p>	<p>People having general surgery (herniotomy 51.2%, cholecystectomy 18.6% , breast operation 9.3%, vagotomy 4.7%, colon resection 9.3%, lung resection 2.3%, other 4.7%)</p> <p>Age >20 years</p> <p>Males and females (28:15)</p> <p>Switzerland</p>	<p>(time-point not reported)</p> <p>DVT (30 days): confirmed by fibrinogen uptake test and venography</p> <p>Major bleeding (time-point not reported): defined as bleeding requiring discontinuation of prophylaxis</p>	
Koller 1986B ¹⁷⁰	<p><u>Intervention (n=74):</u> LMWH, low dose (dalteparin, 2500U, 1 x daily)</p> <p>Duration: started one hour before operation, for at least 5 days</p> <p><u>Comparison (n=72):</u> UFH (5000U), 2 x daily</p> <p>Duration: started one hour before operation, for at least 5 days</p>	<p>n=146</p> <p>People having general surgery (herniotomy 60.3%, cholecystectomy 17.8%, prox. selective vagotomy 2.1%, colon resection 5.5%, breast operation 9.6%, other 4.5%)</p> <p>Age >20 and <80</p> <p>Males and females (89:57)</p> <p>Cancer 14.4%</p> <p>Switzerland</p>	<p>All-cause mortality (time-point not reported)</p> <p>DVT (30 days): confirmed by fibrinogen uptake test and venography</p> <p>PE (30 days): confirmed by pulmonary perfusion/ventilation scans</p> <p>Major bleeding (time-point not reported): defined as bleeding complications leading to discontinuation of prophylaxis, and transfusion >2 units of blood</p>	
Lahnborg 1975 ^{175,176}	<p><u>Intervention (n=58):</u> UFH (5000U, 2 x daily)</p> <p>Duration: started 2-5 hours before surgery, for 5 days</p> <p><u>Comparison (n=54):</u> No VTE prophylaxis</p>	<p>n=112</p> <p>People having major abdominal surgery</p> <p>Age >40 years</p> <p>Sweden</p> <p>No further details</p>	<p>All-cause mortality (5 days)</p> <p>PE (time-point not reported): confirmed by pulmonary photo scanning</p> <p>Major bleeding (time-point not reported)</p>	

Included studies	Intervention and comparison	Population	Outcomes	Comments
		reported	reported): not defined	
Liezorovicz 1991 ¹⁹³	<p><u>Intervention 1 (n=431):</u> LMWH, low dose (tinzaparin, 2500U, 1 x daily) Duration: started 2 hours before operation, for at least 7 days and maximum of 10 days</p> <p><u>Intervention 2 (n=430):</u> LMWH, standard dose (tinzaparin, 3500U, 1 x daily) Duration: started 2 hours before operation, for at least 7 days and maximum of 10 days</p> <p><u>Comparison (n=429):</u> UFH (5000U), 2 x daily Duration: started 2 hours before operation, for at least 7 days and maximum of 10 days</p>	<p>n=1290</p> <p>People having general surgery (abdominal 71.4%, gynaecological 13.5%, urological 9.8% or thoracic 5.3%) Duration > 30minutes</p> <p>Age >40 years Male and female (513:777)</p> <p>Cancer 38.5%</p> <p>France and UK</p>	<p>All-cause mortality (1 month)</p> <p>DVT (8 days): confirmed by fibrinogen uptake test and venography</p> <p>PE (1 month): confirmed by angiography</p> <p>Major bleeding (discharge – 1 month): defined as haemorrhage needing transfusion and/or reintervention and/or treatment discontinuation</p>	
Marassi 1993 ²⁰²	<p><u>Intervention (n=31):</u> LMWH, high dose (nadroparin, 3825U, 1 x daily). Duration: started 2 hours before operation, for 7 days</p> <p><u>Comparison (n=33):</u> No VTE prophylaxis</p>	<p>n=64</p> <p>People having cancer-related abdominal surgery</p> <p>Age > 40 years Males and females (36:25)</p> <p>Cancer surgery 100%</p> <p>Italy</p>	<p>DVT (7 days): confirmed by FUT and venography</p>	
Maxwell 2001 ²⁰⁴	<p><u>Intervention (n=106):</u> IPCD, length not reported. Duration: applied at induction of anaesthesia and continued for first 5 days postoperatively. Device stopped when patient was walking and restarted when</p>	<p>n=228</p> <p>People having gynaecological surgery (duration, median: intervention 199 minutes, comparison 197 minutes)</p> <p>Age >40 years Females</p>	<p>DVT (30 days): confirmed by real-time US compression technique with duplex and colour Doppler imaging</p> <p>PE (30 days): method of confirmation not</p>	

Included studies	Intervention and comparison	Population	Outcomes	Comments
	<p>back in bed.</p> <p><u>Comparison (n=105):</u> LMWH, standard dose, (dalteparin, 5000U, 1 x daily).</p> <p>Duration: 2500U given 1-2 hours before surgery and 12 hours after first dose. Then from postoperative day 1, 5000U was administered once daily up to post-operative day 5. If the patient was confined to bed after day 5, continued prophylaxis until day of discharge or ambulatory.</p>	<p>Cancer 74.9%</p> <p>United states</p>	<p>reported</p> <p>Thrombocytopenia (time-point not reported)</p>	
McLeod 2001 ²¹⁰	<p><u>Intervention (n=674):</u> LMWH, standard dose, (enoxaparin, 40mg, 1 x daily).</p> <p>Duration: started 2 hours before surgery, for 10 days</p> <p><u>Comparison (n=675):</u> UFH, (5000 units, 3 x daily)</p> <p>Duration: started 2 hours before surgery, for 10 days</p>	<p>n=1349</p> <p>People having abdominal (colorectal) surgery</p> <p>Duration >1 hour</p> <p>Age (mean, SD): intervention 52 (18), control 50 (17)</p> <p>Male and female (731:618)</p> <p>Cancer 35%</p> <p>Canada</p>	<p>PE (10 days): confirmed by lung scan or pulmonary angiogram</p> <p>Major bleeding (10 days): defined as intracranial, retroperitoneal, or clinically overt haemorrhage associated with a decrease in the haemoglobin level of more than 20 g/L, the transfusion of 2 or more units of packed cells, or the need for surgical intervention</p>	
Nagata 2015 ²²³	<p><u>Intervention (n=16):</u></p> <ul style="list-style-type: none"> • Foot impulse device (FID) • IPCD, below knee • LMWH, standard dose (enoxaparin, 20mg, 2x daily) <p>Duration: FID was applied immediately</p>	<p>n=30</p> <p>People having major abdominal or pelvic surgery (hysterectomy 53.3%, laparotomy 30%, debulking surgery 10%, tumour sampling 6.7%)</p> <p>Duration >45 minutes</p>	<p>DVT (11 days): confirmed by contrast CT</p> <p>PE (11 days): confirmed by contrast CT</p> <p>Major bleeding (11 days): defined as</p>	

Included studies	Intervention and comparison	Population	Outcomes	Comments
	<p>before surgery. Post operatively, patients switched to IPCD until after the first LMWH injection on postoperative day 2. LMWH commenced on postoperative day 2 for 7 days</p> <p><u>Comparison (n=14):</u></p> <ul style="list-style-type: none"> FID IPCD, below knee <p>Duration: FID was applied immediately prior to surgery. Post operatively, patients switched to IPCD until fully ambulated</p>	<p>Age >40 years</p> <p>Females</p> <p>100% cancer</p> <p>Japan</p>	<p>red blood cell transfusion of more than two units, a decrease in haemoglobin concentration of more than 2g/dL, intracranial, intraocular, gastrointestinal, epidural haemorrhage or bleeding from the wounds, the abdomen or retroperitoneal cavity that required surgical treatment</p> <p>Thrombocytopenia (6 days)</p>	
Nicolaides 1983 ²³²	<p><u>Intervention 1 (n=50):</u></p> <ul style="list-style-type: none"> IPCD, full leg AES, length not reported <p>Duration: IPCD worn during surgery and for 72 hours post-op or until ambulant, then AES applied until discharge</p> <p><u>Intervention 2 (n=50):</u></p> <p>UFH, (5000U, 2 x daily)</p> <p>Duration: started 2 hours before operation, until discharge</p> <p><u>Comparison (n=50):</u></p> <p>Electrical calf stimulation at 12 impulses/min.</p> <p>Duration: started after induction of anaesthesia and continued for duration of operation</p>	<p>n=150</p> <p>People having abdominal surgery</p> <p>Age >30 years</p> <p>Gender not reported</p> <p>Cancer 37.3%</p> <p>UK</p>	<p>DVT (until discharge): confirmed by 125I FUT</p>	
Nurmohamed 1995 ²³⁵	<p><u>Intervention (n=718):</u></p> <p>LMWH, low dose (enoxaparin, 20mg 1 x daily)</p> <p>Duration: started 2</p>	<p>n=1427</p> <p>People having general surgery (gastric 12.5%, cholecystectomy 23%,</p>	<p>All-cause mortality (time point not reported)</p> <p>DVT (10 days):</p>	

Included studies	Intervention and comparison	Population	Outcomes	Comments
	<p>hours before operation, for 10 days or until discharge</p> <p><u>Comparison (n=709):</u> UFH (5000U), 3 x daily Duration: started 2 hours before operation, for 10 days or until discharge</p>	<p>other biliary 2.4%, colon/rectum 28.9%, herniotomy 6%, hysterectomy 9.8%, other gynaecological 3.8%, urological 8%, other 4.2%)</p> <p>Duration of surgery >45 minutes</p> <p>Aged >40 years Males and females (670:734)</p> <p>Cancer 35.8%</p> <p>20 centres in Belgium, Germany, The Netherlands, Spain, UK, and New Zealand</p>	<p>confirmed by fibrinogen 1 125 uptake test and unilateral venography</p> <p>PE (time point not reported): clinical suspicion or autopsy</p> <p>Major bleeding (time point not reported): defined as clinically overt with either a fall of haemoglobin of 20g/L or when it led to a transfusion of 2 or more units of packed cells, or if it was retroperitoneal or intracranial</p> <p>Fatal PE (time-point not reported): confirmed by autopsy</p>	
Ockelford 1989 ²³⁶	<p><u>Intervention (n=102):</u> LMWH low dose, (dalteparin, 2500U, 1 x daily). Duration: started 1-2 hours before operation, for 5-9 days</p> <p><u>Comparison (n=95):</u> No VTE prophylaxis (placebo)</p>	<p>n=197</p> <p>People having abdominal surgery Duration >30 minutes</p> <p>Age >40 years Males and females</p> <p>Cancer surgery 43%</p> <p>New Zealand</p>	<p>All-cause mortality (42 days)</p> <p>DVT (42 days): confirmed by FUT</p> <p>PE (42 days): not reported</p> <p>Major bleeding (42 days): defined as when treatment discontinued because of excess bleeding</p> <p>Thrombocytopenia (42 days): not reported</p>	
Onarheim 1986 ²³⁸	<p><u>Intervention (n=25):</u> LMWH, standard dose (dalteparin, 5000U, 1 x daily). Duration: started 2</p>	<p>n=52</p> <p>People having major abdominal surgery for gastric, colonic, or rectal</p>	<p>All-cause mortality (30 days)</p> <p>DVT (30 days): confirmed by</p>	

Included studies	Intervention and comparison	Population	Outcomes	Comments
	<p>hours before surgery, for 6 days</p> <p><u>Comparison (n=27):</u> UFH 5000U, 2 x daily Duration: started 2 hours before surgery, for 6 days</p>	<p>malignancy</p> <p>Age >40 years</p> <p>Cancer 100%</p> <p>Norway</p>	<p>fibrinogen uptake test and phlebography</p> <p>PE (30 days): method of confirmation not reported</p> <p>Major bleeding (30 days): defined as bleeding requiring reoperation or interruption of prophylaxis</p>	
Osman 2007 ²³⁹	<p><u>Intervention 1 (n=25):</u> LMWH, standard dose, (tinzaparin, 3500U, 1 x daily) Duration: for 1 week post operatively. No further details reported</p> <p><u>Intervention 2 (n=25):</u> UFH, (5000U), 2 x daily Duration: for 1 week post operatively. No further details reported</p> <p><u>Comparison (n=25):</u> No VTE prophylaxis</p>	<p>n=75</p> <p>People having live-donor renal transplantation Duration not reported</p> <p>Age >16 years</p> <p>Male and female (52:23)</p> <p>Egypt</p>	<p>DVT (2 weeks): radiologically, ultrasonography, CT or MRI and isotope renography were used to diagnose postoperative complications</p> <p>PE (2 weeks): radiologically, ultrasonography, CT or MRI and isotope renography were used to diagnose postoperative complications</p> <p>Major bleeding (2 weeks): defined as massive haemorrhage necessitating exploration</p>	
Porteous 1989 ²⁴⁵	<p><u>Intervention (n=56):</u> AES, above knee. Duration: worn until discharge. No further details reported</p> <p><u>Comparison (n=58):</u> AES, below knee. Duration: worn until discharge. No further details reported</p>	<p>n=124</p> <p>People having major abdominal surgery Duration of surgery (mean, SD): intervention 110 (39), comparison 115 (44)</p> <p>Age >40 years</p> <p>Males and females (49:65)</p>	<p>DVT (time-point not reported): confirmed by I-labelled fibrinogen uptake test and phlebography</p>	

Included studies	Intervention and comparison	Population	Outcomes	Comments
		Malignant disease 40.4% UK		
Rasmussen 2006 ²⁵¹	<p><u>Intervention (n=205):</u></p> <ul style="list-style-type: none"> LMWH, standard dose, extended duration (dalteparin, 5000 U, 1 x daily). AES, length not reported <p>Duration: LMWH started the day before surgery, for 28 days. AES worn for 7 days</p> <p><u>Comparison (n=222):</u></p> <ul style="list-style-type: none"> LMWH, standard dose, standard duration (dalteparin, 5000 U, 1 x daily) AES length not reported <p>Duration: LMWH started the day before surgery, for 7 days. AES worn for 7 days</p>	<p>n=427</p> <p>People having major abdominal surgery Duration > 1 hour</p> <p>Age >18 years Male and female (174:169)</p> <p>Denmark and Norway</p>	<p>All-cause mortality (2 months)</p> <p>DVT (day 28): confirmed by bilateral venography</p> <p>PE (2 months): confirmed by ventilation/perfusion scanning</p> <p>Major bleeding (28 days): defined as bleeding that resulted in death, fall in haemoglobin $\geq 2\text{g/dl}$, transfusion ≥ 2 units of blood, retroperitoneal, intracranial, intraocular, resulted in life threatening event, or surgical/medical intervention required to stop it</p> <p>Fatal pulmonary embolism (up to 2 months): method of confirmation not reported</p>	
Rasmussen 1988 ²⁵⁰	<p><u>Intervention 1 (n=74):</u> AES, knee length Duration: applied the evening before surgery, for at least 5 days</p> <p><u>Intervention 2 (n=85):</u> UFH (5000U), administered subcutaneously every 12 hours. Duration: started the evening before</p>	<p>n=248</p> <p>People having major abdominal surgery (colon+rectum 21%, biliary 30.6%, gastric+pancreas 12%, urologic 14.9%, gynaecologic 14.1%, other 7.3%) Duration >1 hour</p> <p>Age >40 years Males and females (109:139)</p>	<p>All-cause mortality (time-point not reported)</p> <p>PE (time-point not reported): method of confirmation not reported</p> <p>Major bleeding (time-point not reported): defined as major postoperative</p>	

Included studies	Intervention and comparison	Population	Outcomes	Comments
	<p>surgery, for at least 5 days</p> <p><u>Comparison (n=89):</u></p> <ul style="list-style-type: none"> AES, knee length UFH (5000U) <p>Duration: as above</p>	Denmark	haemorrhage	
Sakon 2010 ²⁶⁰	<p><u>Intervention (n=113):</u></p> <ul style="list-style-type: none"> IPCD, length not reported LMWH, standard dose (enoxaparin 20mg 2 x daily) <p>Duration: all patients received at least one course of postsurgical IPCD before first LMWH dose. No further details on IPCD. LMWH started 24-36 hours after surgery and continued for 14 days (and for at least 7 consecutive days).</p> <p><u>Comparison (n=38):</u> IPCD length not reported Duration: left to the discretion of the investigator</p>	<p>n=151</p> <p>People having a laparotomy for cancer (stomach 42.1%, rectum 14.9%, colon 21.9%, prostate 4.4%, uterus 4.4%, ovary 2.6%, hepatic 2.6%, other 13.2%) *</p> <p>Duration >45 minutes</p> <p>Age >40 years Males and females (69:45)</p> <p>100% cancer</p> <p>Japan</p> <p>*total is more than 100% as some patients had surgery at multiple sites</p>	<p>DVT (14 days): confirmed by ultrasonography and venography</p> <p>PE (14 days): confirmed by ventilation/perfusion lung scan, pulmonary angiography or computerised tomography</p> <p>Major bleeding (14 days): defined as the event resulted in death, was clinically overt, was retroperitoneal, intracranial, or intraocular, or resulted in serious or life threatening clinical events, or required surgical or medical intervention to control the event</p>	
Scurr 1981 ²⁶⁸	<p><u>Intervention (n=33):</u> foot pump.</p> <p>Duration: applied from the beginning of the procedure until the patient regained consciousness</p> <p><u>Comparison (n=33):</u> No VTE prophylaxis</p>	<p>n=66</p> <p>People having major abdominal surgery Duration >20 minutes</p> <p>Age >40 years</p> <p>Cancer 77%</p> <p>UK</p>	<p>All-cause mortality (7 days)</p> <p>DVT (7 days): confirmed by fibrinogen scanning</p>	
Soderdahl 1997 ²⁷²	<p>Intervention (n=47): IPCD, thigh-length.</p> <p><u>Comparison (n=43):</u></p>	<p>n=90</p> <p>People having abdominal (urological) surgery</p>	DVT (3 months): confirmed by bilateral duplex ultrasound	

Included studies	Intervention and comparison	Population	Outcomes	Comments
	<p>IPCD, calf-length</p> <p>Duration: begun pre-anaesthetic and continued until patient fully ambulatory or until discharge</p>	<p>(duration not reported)</p> <p>Age (mean, range): intervention 64.8 (46-90), comparison 58.6 (24-77)</p> <p>Male and female</p> <p>United States</p>	<p>PE (3 months): confirmed by ventilation perfusion scan and pulmonary angiography</p> <p>Fatal PE (3 months): method of confirmation not reported</p>	
Song 2014 ²⁷³	<p><u>Intervention (n=108):</u></p> <ul style="list-style-type: none"> LMWH, standard dose (enoxaparin 40mg, 1 x daily) IPCD, length not reported <p>Duration: LMWH started post-operatively until discharge, IPCD applied pre-operatively until discharge</p> <p><u>Comparison (n=112):</u></p> <p>IPCD, length not reported</p> <p>Duration: applied pre-operatively until discharge</p>	<p>n=220</p> <p>People with cancer having gastrectomy (100% adenocarcinoma)</p> <p>Age >20 years</p> <p>Male to female (150:70)</p> <p>Cancer 100%</p> <p>South Korea</p>	<p>DVT (4 days): confirmed by duplex ultrasonography</p> <p>PE (30 days): 'detected'</p> <p>Major bleeding (30 days): definition not reported</p>	
Strand 1975 ²⁸⁴	<p><u>Intervention (n=50):</u></p> <p>UFH (5000U, 2 x daily)</p> <p>Duration: started 1-3 hours before surgery or on admission, for 7 days</p> <p><u>Comparison (n=50):</u></p> <p>No VTE prophylaxis (placebo)</p>	<p>n=100</p> <p>People having gastrointestinal or urinary tract surgery (stomach 16.7%, small intestine 2.9%, biliary 21.6%, colon 21.6%, rectum 4.9%, urinary 27.4%, other 6.9%)</p> <p>Age >30 years</p> <p>Males and females (49:51)</p> <p>Cancer 28%</p> <p>Denmark</p>	<p>DVT (10 weeks): confirmed by I fibrinogen method</p> <p>PE (10 weeks): method of confirmation not reported</p> <p>Fatal PE (10 weeks): confirmed by autopsy</p>	
Taberner 1978 ²⁸⁶	<p><u>Intervention 1 (n=49):</u></p> <p>UFH (5000U, 2 x daily)</p> <p>Duration: started 2</p>	<p>n=145</p> <p>People having abdominal</p>	<p>DVT (7 days): confirmed by fibrinogen scan</p>	

Included studies	Intervention and comparison	Population	Outcomes	Comments
	<p>hours before surgery on, for 7 days</p> <p><u>Intervention 2 (n=48):</u> VKA (acenocoumarol), 6mg Duration: started at least 5 days before surgery</p> <p><u>Comparison (n=48):</u> No VTE prophylaxis (placebo)</p>	<p>or vaginal surgery (hysterectomy or laparotomy 58.6%, pelvic floor repair 41.4.2%)</p> <p>Age >40 years</p> <p>Cancer 5.5%</p> <p>UK</p>		
Torngren 1978 ^{290,291}	<p><u>Intervention (n=63):</u> UFH (5000U, 2 x daily) Duration: started 2 hours before surgery or on admission, for 6-8 days</p> <p><u>Comparison (n=61):</u> No VTE prophylaxis</p>	<p>n=124</p> <p>People having abdominal surgery</p> <p>Duration of surgery >20 minutes</p> <p>Age >40 years</p> <p>Males and females (66:58)</p> <p>Cancer 24%</p> <p>Sweden</p>	<p>All-cause mortality (6-8 days): confirmed by autopsy</p> <p>DVT (up to 14 days): confirmed by I-fibrinogen test</p> <p>PE (6-8 days): confirmed by autopsy</p> <p>Major bleeding (6-8 days): defined at bleeding requiring a transfusion</p> <p>Fatal PE (6-8 days): confirmed by autopsy</p>	
Tsapogas 1971 ²⁹²	<p><u>Intervention (n=51):</u> AES, below knee. Duration: day of surgery until discharge</p> <p><u>Comparison (n=44):</u> No VTE prophylaxis</p>	<p>n=95</p> <p>People having major abdominal surgery</p> <p>Age >40 years</p> <p>Male and female (93:2)</p> <p>USA</p>	<p>DVT (7 days): confirmed by fibrinogen uptake test and phlebography</p>	
Turner 1984 ²⁹³	<p><u>Intervention (n=104):</u> AES, above knee Duration: started on day of admission, discontinuation point not reported</p>	<p>n=196</p> <p>People having elective gynaecological surgery</p> <p>Age >35 years</p> <p>Female</p>	<p>DVT (time-point not reported): confirmed by Fibrinogen Uptake Test</p> <p>PE (time-point not reported): method</p>	

Included studies	Intervention and comparison	Population	Outcomes	Comments
	<u>Comparison (n=92):</u> No VTE prophylaxis	UK	of confirmation not reported	
Turpie 2007 ²⁹⁴	<u>Intervention (n=650):</u> <ul style="list-style-type: none"> Fondaparinux (2.5mg, 1 x daily) IPCD, mixed length Duration: started 6-8 hours after surgery, provided that haemostasis was achieved, or 2 hours after removal of intrathecal or epidural catheter. Second injection given 16-28 h after 1st injection. Duration was 5-9 days. IPCD duration was left to the investigators discretion	n=1309 People having abdominal surgery Duration >45 minutes Age > 40 years Male and female (635:650) United States	All-cause mortality (32 days) DVT (days 5-10): confirmed by bilateral ascending contrast venography PE, symptomatic (32 days): confirmed by a high-probability lung scan, non-high probability lung scan defect plus confirmed DVT, pulmonary angiography, helical computed tomography, or autopsy) Major bleeding (day 32): defined as bleeding that was fatal, retroperitoneal, intracranial, or involved any other critical organ, led to intervention, or was associated with a bleeding index of 2.0 or more. Fatal PE (32 days): confirmed by: autopsy	The use of AES was left to the investigator's discretion
Van Vroonhove n 1974 ³⁰²	<u>Intervention (n=50):</u> UFH (dose not reported, 2x daily). Duration: begun 2 hours before operation, for 8 days <u>Comparison (n=50):</u> VKA (acenocoumarol, PTT 5-10% of normal).	n=100 People having general surgery (gastric 24%, biliary 28%, colonic 15%, herniotomy 16%, abdominal wall 6%, laparotomy 6%, other 5%)	DVT (time-point not reported): confirmed by I-fibrinogen test Major bleeding (time-point not reported): defined as overt bleeding complications	

Included studies	Intervention and comparison	Population	Outcomes	Comments
	Duration: Begun on evening of day of op, or 1st post-op day. Continued for 7 days	Age >40 years Cancer 18% Netherlands		
Vandendriess 1980 ³⁰³	<u>Intervention (n=31):</u> UFH (5000U, 3 x daily) Duration: started 2 hours before operation for 6 days <u>Comparison (n=33):</u> No VTE prophylaxis (placebo, 0.2 ml distilled water)	n=64 People having urologic surgery Age (mean): intervention 72.2, comparison 70 Belgium	DVT (time-point not reported): confirmed by I-labelled fibrinogen test and clinical examination PE (time-point not reported): confirmed by clinical examination	Patients with varicose veins wore AES during and after the operation
Wille-Jorgensen 1985 ³¹⁷	<u>Intervention (n=94):</u> <ul style="list-style-type: none"> AES, thigh length UFH (5000U 2 x daily) Duration: AES applied before surgery during the observation period. UFH administered 1 hour preoperatively for 7 days or until discharge <u>Comparison (n=102):</u> UFH (5000U, 2 x daily). Duration: administered 1 hour preoperatively for 7 days or until discharge	n=196 People having abdominal surgery Duration >45 minutes Age >39 years Male and female (105:71) Denmark	DVT (7 days): confirmed by Fibrinogen Uptake Test, and phlebography and perfusion lung scan if Fibrinogen Uptake Test was positive PE (30 days): confirmed by scintigraphy or autopsy Fatal PE (30 days): confirmed by scintigraphy	
Wille-Jorgensen 1991 ³¹⁶	<u>Intervention (n=94):</u> <ul style="list-style-type: none"> AES, above knee UFH (5000U 2 x daily) Duration: AES applied preoperatively and worn until full mobilisation. UFH administered on day of surgery for 7 days or until discharge.	n=178 People having abdominal surgery Duration >1 hour Age >39 years Male and female (58:102) Denmark	All-cause mortality (30 days) DVT (30 days): confirmed by I-fibrinogen uptake test and phlebography PE (30 days): confirmed by	

VTE prophylaxis

Abdominal surgery (excluding bariatric surgery)

Included studies	Intervention and comparison	Population	Outcomes	Comments
	<p><u>Comparison (n=84):</u> UFH (5000U 2 x daily) Duration: administered on day of surgery for 7 days or until discharge</p>		<p>perfusion pulmonary scintigram and roentgenogram</p>	

1 Table 169: Clinical evidence summary: AES (above knee) versus no prophylaxis

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with AES (above knee) versus no VTE prophylaxis (95% CI)
All-cause mortality	291 (2 studies) time-point not reported	VERY LOW ^{1,2} due to risk of bias, imprecision	Not estimable ³	Not estimable ³	0 fewer per 1000 (from 16 fewer to 16 more) ⁴
DVT	291 (2 studies) time-point not reported	MODERATE ¹ due to risk of bias	RR 0.41 (0.23 to 0.73)	194 per 1000	115 fewer per 1000 (from 52 fewer to 150 fewer)
PE	291 (2 studies) time-point not reported	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.13 (0 to 6.68)	7 per 1000	6 fewer per 1000 (from 7 fewer to 39 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs
3 Could not be calculated as there were no events in the intervention or comparison group
4 Risk difference calculated in Review Manager

2 Table 170: Clinical evidence summary: AES (below knee) versus no prophylaxis

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with AES (below knee) versus no VTE prophylaxis (95% CI)
DVT	95 (1 study) 7 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 0.29 (0.06 to 1.35)	136 per 1000	97 fewer per 1000 (from 128 fewer to 48 more)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with AES (below knee) versus no VTE prophylaxis (95% CI)
1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias					
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs					

1 **Table 171: Clinical evidence summary: AES (undefined) versus no prophylaxis**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with AES (undefined) versus no VTE prophylaxis (95% CI)
DVT	200 (1 study) 7 days	MODERATE ¹ due to risk of bias	RR 0.43 (0.25 to 0.73)	359 per 1000	205 fewer per 1000 (from 97 fewer to 269 fewer)
1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias					

2 **Table 172: Clinical evidence summary: AES (above knee) versus UFH**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with AES (above knee) versus UFH (95% CI)
Fatal PE	97 (1 study) time-point not reported	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.12 (0 to 5.9)	22 per 1000	20 fewer per 1000 (from 22 fewer to 96 more)
1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias					
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs					

1 Table 173: Clinical evidence summary: AES (below knee) versus UFH

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with AES (below knee) versus UFH (95% CI)
All-cause mortality	159 (1 study) time-point not reported	VERY LOW ^{1,2} due to risk of bias, imprecision	Not estimable ⁴	Not estimable ⁴	0 fewer per 1000 (from 24 fewer to 24 more) ⁵
PE	159 (1 study) time-point not reported	VERY LOW ^{1,2,3} due to risk of bias, imprecision, indirectness	Not estimable ⁴	Not estimable ⁴	0 fewer per 1000 (from 24 fewer to 24 more) ⁵

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs
3 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol
4 Could not be calculated as there were no events in the intervention or comparison group
5 Risk difference calculated in Review Manager

2 Table 174: Clinical evidence summary: AES (above knee) versus AES (below knee)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with AES above knee versus AES below knee (95% CI)
DVT	114 (1 study) time-point not reported	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 3.11 (0.33 to 28.99)	17 per 1000	36 more per 1000 (from 12 fewer to 483 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs

1 Table 175: Clinical evidence summary: AES (below knee) + UFH versus AES (below knee)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with AES	Risk difference with AES + UFH (95% CI)
All-cause mortality	163 (1 study) time-point not reported	VERY LOW ^{1,2} due to risk of bias, imprecision	Not estimable ⁴	Not estimable ⁴	0 fewer per 1000 (from 24 fewer to 24 more) ⁵
PE	163 (1 study) time-point not reported	VERY LOW ^{1,2,3} due to risk of bias, imprecision, indirectness	Not estimable ⁴	Not estimable ⁴	0 fewer per 1000 (from 24 fewer to 24 more) ⁵

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs
3 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol
4 Could not be calculated as there were no events in the intervention or comparison group
5 Risk difference calculated in Review Manager

2 Table 176: Clinical evidence summary: AES (above knee) + UFH versus UFH

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with AES (above knee) + UFH versus UFH (95% CI)
All-cause mortality	160 (1 study) up to 30 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 1.49 (0.74 to 3.01)	136 per 1000	67 more per 1000 (from 35 fewer to 273 more)
DVT	336 (2 studies) up to 30 days	MODERATE ¹ due to risk of bias	RR 0.16 (0.05 to 0.54)	111 per 1000	93 fewer per 1000 (from 51 fewer to 106 fewer)
PE	336		RR 0.35	34 per 1000	23 fewer per 1000

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with AES (above knee) + UFH versus UFH (95% CI)
	(2 studies) 30 days	VERY LOW ^{1,2} due to risk of bias, imprecision	(0.07 to 1.68)		(from 33 fewer to 24 more)
Fatal PE	176 (1 study) 30 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.14 (0 to 7.14)	11 per 1000	10 fewer per 1000 (from 11 fewer to 63 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs

1 Table 177: Clinical evidence summary: AES (below knee) + UFH versus UFH

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with AES (below knee) + UFH versus UFH (95% CI)
All-cause mortality	174 (1 study) time-point not reported	VERY LOW ^{1,2} due to risk of bias, imprecision	Not estimable ⁴	Not estimable ⁴	0 fewer per 1000 (from 22 fewer to 22 more) ⁵
PE	174 (1 study) time-point not reported	VERY LOW ^{1,2,3} due to risk of bias, imprecision, indirectness	Not estimable ⁴	Not estimable ⁴	0 fewer per 1000 (from 22 fewer to 22 more) ⁵

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol
3 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs
4 Could not be calculated as there were no events in the intervention or comparison group

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with AES (below knee) + UFH versus UFH (95% CI)
5 Risk difference calculated in Review Manager					

1 **Table 178: Clinical evidence summary: AES (above knee) + IPCD (full leg) versus AES (above knee)**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with AES (above knee) + IPCD versus AES (95% CI)
DVT	77 (1 study) time-point not reported	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 0.21 (0.03 to 1.68)	128 per 1000	101 fewer per 1000 (from 124 fewer to 87 more)
PE	77 (1 study) time-point not reported	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 1.03 (0.07 to 15.82)	26 per 1000	1 more per 1000 (from 24 fewer to 380 more)
Fatal PE	77 (1 study) time-point not reported	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.14 (0 to 7)	26 per 1000	22 fewer per 1000 (from 26 fewer to 130 more)
<p>1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p> <p>2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs</p>					

2

3 **Table 179: Clinical evidence summary: AES (undefined) + IPCD (full leg) versus AES (undefined)**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with AES (undefined) + IPCD versus AES (95% CI)
DVT	108		RR 0.38	250 per 1000	155 fewer per 1000

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with AES (undefined) + IPCD versus AES (95% CI)
	(1 study) time-point not reported	LOW ^{1,2} due to risk of bias, imprecision	(0.15 to 0.99)		(from 2 fewer to 213 fewer)
PE	108 (1 study) time-point not reported	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 1.08 (0.07 to 16.78)	18 per 1000	1 more per 1000 (from 17 fewer to 282 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs

1 Table 180: Clinical evidence summary: AES (undefined) + IPCD (full leg) versus UFH

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with AES + IPCD versus UFH (95% CI)
DVT	100 (1 study) time-point not reported	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 0.43 (0.12 to 1.56)	140 per 1000	80 fewer per 1000 (from 123 fewer to 78 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs

2 Table 181: Clinical evidence summary: AES (undefined) + IPCD (full leg) versus electrical stimulation

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with AES + IPCD versus electrical stimulation (95% CI)
DVT	100		RR 0.25	240 per 1000	180 fewer per 1000

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with AES + IPCD versus electrical stimulation (95% CI)
	(1 study) time-point not reported	LOW ^{1,2} due to risk of bias, imprecision	(0.08 to 0.83)		(from 41 fewer to 221 fewer)
1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias 2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs					

1 Table 182: Clinical evidence summary: Electrical stimulation versus UFH

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with Electrical stimulation versus UFH (95% CI)
DVT	100 (1 study) time-point not reported	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 1.71 (0.74 to 3.99)	140 per 1000	99 more per 1000 (from 36 fewer to 419 more)
1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias 2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs					

2 Table 183: Clinical evidence summary: Foot pump versus no prophylaxis

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with Foot pump versus no prophylaxis (95% CI)
All-cause mortality	66 (1 study) 7 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.14 (0 to 6.82)	30 per 1000	26 fewer per 1000 (from 30 fewer to 145 more)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with Foot pump versus no prophylaxis (95% CI)
DVT	66 (1 study) 7 days	LOW ^{1,2} due to risk of bias, imprecision	RR 0.4 (0.18 to 0.9)	455 per 1000	273 fewer per 1000 (from 45 fewer to 373 fewer)
<p>1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p> <p>2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs</p>					

1 **Table 184: Clinical evidence summary: FID + IPCD (below knee) + LMWH (low dose) versus FID + IPCD (below knee)**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with FID + IPCD + LMWH versus FID + IPCD (95% CI)
DVT	30 (1 study) 11 days	VERY LOW ^{1,2,3} due to risk of bias, imprecision, indirectness	RR 0.29 (0.03 to 2.5)	214 per 1000	152 fewer per 1000 (from 208 fewer to 321 more)
PE	30 (1 study) 11 days	LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.11 (0.01 to 1.13)	214 per 1000	185 fewer per 1000 (from 212 fewer to 21 more)
Thrombocytopenia	30 (1 study) 6 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Not estimable ⁴	Not estimable ⁴	0 fewer per 1000 (from 121 fewer to 121 more) ⁵
<p>1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p> <p>2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs</p> <p>3 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol</p>					

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with FID + IPCD + LMWH versus FID + IPCD (95% CI)
4 Could not be calculated as there were no events in the intervention or comparison group					
5 Risk difference calculated in Review Manager					

1 Table 185: Clinical evidence summary: IPCD (below knee) versus no prophylaxis

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with IPCD versus no prophylaxis (95% CI)
All-cause mortality	107 (1 study) 42 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Not estimable ⁴	Not estimable ⁴	0 fewer per 1000 (from 36 fewer to 36 more) ⁵
DVT	473 (4 studies) up to 90 days	VERY LOW ^{1,2,3} due to risk of bias, inconsistency, imprecision	RR 0.64 (0.26 to 1.59)	165 per 1000	59 fewer per 1000 (from 122 fewer to 97 more)
PE	354 (3 studies) 42 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 2.19 (0.58 to 8.24)	17 per 1000	21 more per 1000 (from 7 fewer to 126 more)
Fatal PE	313 (2 studies) up to 90 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.5 (0.05 to 4.81)	13 per 1000	6 fewer per 1000 (from 12 fewer to 47 more)
1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias					
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs					
3 Downgraded by 1 increment because heterogeneity, I ² =67%, p=0.03, unexplained by subgroup analysis.					
4 Could not be calculated as there were no events in the intervention or comparison group					
5 Risk difference calculated in Review Manager					

1 Table 186: Clinical evidence summary: IPCD (full leg) versus IPCD (below knee)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with IPCD full length versus IPCD below knee (95% CI)
DVT	90 (1 study) 90 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.12 (0 to 6.24)	23 per 1000	20 fewer per 1000 (from 23 fewer to 106 more)
PE	90 (1 study) 90 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 6.79 (0.13 to 343.33)	0 per 1000	Not estimable ³
Fatal PE	90 (1 study) 90 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.12 (0 to 6.24)	23 per 1000	20 fewer per 1000 (from 23 fewer to 106 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs
3 Could not be calculated as there were no events in the comparison group

2 Table 187: Clinical evidence summary: IPCD (full leg) versus VKA

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with IPCD versus warfarin (95% CI)
All-cause mortality	100 (1 study) 7-14 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Not estimable ⁴	Not estimable ⁴	0 fewer per 1000 (from 38 fewer to 38 more) ⁵
DVT	100 (1 study) 7-14 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 8.58 (0.53 to 139.81)	0 per 1000	Not estimable ⁶
PE	100 (1 study)	VERY LOW ^{1,2,3} due to risk of bias, imprecision,	Peto OR 8.4 (0.17 to 426.1)	0 per 1000	Not estimable ⁶

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with IPCD versus warfarin (95% CI)
	7-14 days	indirectness			
1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias 2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs 3 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol 4 Could not be calculated as there were no events in the intervention or comparison group 5 Risk difference calculated in Review Manager 6 Could not be calculated as there were no events in the comparison group					

1

2 **Table 188: Clinical evidence summary: IPCD (undefined) + LMWH (standard prophylactic dose) versus IPCD (undefined)**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with IPCD + LMWH standard dose versus IPCD (95% CI)
DVT	334 (2 studies) 14-30 days	LOW ¹ due to risk of bias	RR 0.07 (0.02 to 0.26)	63 per 1000	59 fewer per 1000 (from 47 fewer to 62 fewer)
PE	334 (2 studies) 14-30 days	VERY LOW ^{1,2,3} due to risk of bias, imprecision, indirectness	Not estimable ⁴	Not estimable ⁴	0 fewer per 1000 (from 12 fewer to 12 more) ⁵
1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias 2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs 3 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol 3 Could not be calculated as there were no events in the intervention or comparison group 4 Risk difference calculated in Review Manager					

1

2 **Table 189: Clinical evidence summary: UFH versus no prophylaxis/mechanical**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with UFH versus no prophylaxis (95% CI)
All-cause mortality	393 (4 studies) 5-8 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 0.36 (0.1 to 1.27)	46 per 1000	29 fewer per 1000 (from 41 fewer to 12 more)
DVT	1991 (12 studies) 7-70 days	MODERATE ¹ due to risk of bias	RR 0.40 (0.30 to 0.53)	138 per 1000	83 fewer per 1000 (from 65 fewer to 97 fewer)
PE	897 (10 studies) 7-70 days	LOW ^{1,2} due to risk of bias, imprecision	RR 0.60 (0.36 to 1.02)	62 per 1000	25 fewer per 1000 (from 40 fewer to 1 more)
Major bleeding	725 (7 studies) 6-14 days	LOW ^{1,2} due to risk of bias, imprecision	RR 1.30 (0.84 to 2.00)	75 per 1000	23 more per 1000 (from 12 fewer to 75 more)
Fatal PE	506 (4 studies) 7-70 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.15 (0 to 7.52)	4 per 1000	3 fewer per 1000 (from 4 fewer to 24 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs

3 **Table 190: Clinical evidence summary: UFH versus IPCD (below knee)**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with UFH versus IPCD (95% CI)
DVT	265 (2 studies)	LOW ^{1,2}	RR 2.36 (0.87 to 6.44)	38 per 1000	52 more per 1000 (from 5 fewer to 209 more)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with UFH versus IPCD (95% CI)
	30 days	due to risk of bias, imprecision			
PE	265 (2 studies) 30 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 1.04 (0.06 to 17)	8 per 1000	0 more per 1000 (from 7 fewer to 109 more)
<p>1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p> <p>2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs</p>					

1 Table 191: Clinical evidence summary: UFH versus VKA

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with UFH versus VKA (95% CI)
DVT	197 (2 studies) time-point not reported	LOW ^{1,2} due to risk of bias, imprecision	RR 0.33 (0.11 to 1)	122 per 1000	82 fewer per 1000 (from 109 fewer to 0 more)
Major bleeding	100 (1 study) time-point not reported	VERY LOW ^{1,2} due to risk of bias, imprecision	Not estimable ³	Not estimable ³	0 fewer per 1000 (from 38 fewer to 38 more) ⁴
<p>1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p> <p>2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs</p> <p>3 Could not be calculated as there were no events in the intervention or comparison group</p> <p>4 Risk difference calculated in Review Manager</p>					

1 Table 192: Clinical evidence summary: LMWH (low dose) versus no prophylaxis

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with LMWH low dose versus no prophylaxis (95% CI)
All-cause mortality	183 (1 study) 42 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.12 (0.01 to 1.99)	23 per 1000	20 fewer per 1000 (from 22 fewer to 22 more)
DVT	183 (1 study) 42 days	LOW ^{1,2} due to risk of bias, imprecision	RR 0.26 (0.09 to 0.77)	159 per 1000	118 fewer per 1000 (from 37 fewer to 145 fewer)
PE	183 (1 study) 42 days	VERY LOW ^{1,2,3} due to risk of bias, imprecision, indirectness	Peto OR 0.12 (0.01 to 1.99)	23 per 1000	20 fewer per 1000 (from 22 fewer to 22 more)
Major bleeding	183 (1 study) 42 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 0.93 (0.24 to 3.59)	45 per 1000	3 fewer per 1000 (from 35 fewer to 118 more)
Thrombocytopenia	183 (1 study) 42 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Not estimable ⁴	Not estimable ⁴	0 fewer per 1000 (from 21 fewer to 21 more) ⁵

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs
3 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol
4 Could not be calculated as there were no events in the intervention or comparison group
5 Risk difference calculated in Review Manager

1 Table 193: Clinical evidence summary: LMWH (low dose; standard duration) versus UFH

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with LMWH low dose versus UFH (95% CI)
All-cause mortality	7018 (7 studies) 6-56 days	LOW ^{1,2} due to risk of bias, imprecision	RR 1.27 (0.93 to 1.73)	19 per 1000	5 more per 1000 (from 1 fewer to 14 more)
DVT	3045 (5 studies) 6-30 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 1.91 (1.22 to 3.00)	18 per 1000	17 more per 1000 (from 4 more to 37 more)
PE	6836 (7 studies) 6-30 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.87 (0.41 to 1.83)	4 per 1000	1 fewer per 1000 (from 3 fewer to 4 more)
Major bleeding	6694 (7 studies) 5-30 days	VERY LOW ^{1,2,3} due to risk of bias, inconsistency, imprecision	RR 0.73 (0.49 to 1.11)	52 per 1000	14 fewer per 1000 (from 26 fewer to 6 more)
Fatal PE	5848 (5 studies) 6-30 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 1.75 (0.54 to 5.71)	1 per 1000	1 more per 1000 (from 1 fewer to 6 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs
3 Downgraded by 1 increment because heterogeneity, I²=55%, p=0.04, unexplained by subgroup analysis.

2

1

2 **Table 194: Clinical evidence summary: LMWH (standard dose; standard duration) versus no prophylaxis/mechanical**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with LMWH standard dose versus no prophylaxis (95% CI)
All-cause mortality	80 (1 study) 30 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.14 (0.01 to 2.26)	49 per 1000	42 fewer per 1000 (from 48 fewer to 55 more)
DVT	130 (2 studies) 7-30 days	LOW ^{1,2} due to risk of bias, imprecision	RR 0.35 (0.1 to 1.2)	136 per 1000	89 fewer per 1000 (from 123 fewer to 27 more)
PE	130 (2 studies) 14-30 days	VERY LOW ^{1,2,3} due to risk of bias, imprecision	Peto OR 0.14 (0 to 7.17)	15 per 1000	13 fewer per 1000 (from 15 fewer to 84 more)
Major bleeding	527 (5 studies) 11-30 days	LOW ^{1,2} due to risk of bias, imprecision	Peto OR 2.90 (0.9 to 9.34)	9 per 1000	16 more per 1000 (from 1 fewer to 67 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
 2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs
 3 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol

3

4

1 Table 195: Clinical evidence summary: LMWH (standard dose; standard duration) versus IPCD (undefined)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with LMWH low dose versus IPCD (95% CI)
DVT	211 (1 study) 30 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 1.98 (0.2 to 19.23)	9 per 1000	9 more per 1000 (from 8 fewer to 145 more)
PE	211 (1 study) 30 days	VERY LOW ^{1,2,3} due to risk of bias, imprecision, indirectness	Not estimable ⁴	Not estimable ⁴	0 fewer per 1000 (from 18 fewer to 18 more) ⁵
Thrombocytopenia	211 (1 study) time-point not reported	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 0.5 (0.09 to 2.7)	38 per 1000	19 fewer per 1000 (from 34 fewer to 64 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs
3 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol
4 Could not be calculated as there were no events in the intervention or comparison group
5 Risk difference calculated in Review Manager

2 Table 196: Clinical evidence summary: LMWH (standard dose; standard duration) versus UFH

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with LMWH standard dose versus UFH (95% CI)
All-cause mortality	2511 (5 studies) 8-30 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 1.04 (0.60 to 1.80)	19 per 1000	1 more per 1000 (from 8 fewer to 15 more)
DVT	2856		RR 0.85	40 per 1000	6 fewer per 1000

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with LMWH standard dose versus UFH (95% CI)
	(8 studies) 7-56 days	LOW ^{1,2} due to risk of bias, imprecision	(0.59 to 1.24)		(from 16 fewer to 10 more)
PE	3360 (8 studies) 7-56 days	MODERATE ¹ due to risk of bias	Peto OR 0.24 (0.08 to 0.73)	7 per 1000	5 fewer per 1000 (from 2 fewer to 6 fewer)
Major bleeding	3150 (8 studies) 8-30 days	LOW ^{1,2} due to risk of bias, imprecision	RR 1.69 (1.19 to 2.41)	28 per 1000	19 more per 1000 (from 5 more to 39 more)
Fatal PE	1002 (1 study) 30 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.13 (0.00 to 6.71)	2 per 1000	2 fewer per 1000 (from 2 fewer to 11 more)
<p>1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p> <p>2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs</p>					

1 Table 197: Clinical evidence summary: LMWH (high dose; standard duration) versus no prophylaxis

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with No prophylaxis	Risk difference with LMWH high dose (95% CI)
All-cause mortality	61 (1 study) 7 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Not estimable ³	Not estimable ³	0 fewer per 1000 (from 62 fewer to 62 more) ⁴
DVT	61 (1 study) 7 days	LOW ^{1,2} due to risk of bias, imprecision	RR 0.19 (0.05 to 0.78)	355 per 1000	287 more per 1000 (from 78 fewer to 337 fewer)
<p>1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high</p>					

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with No prophylaxis	Risk difference with LMWH high dose (95% CI)
risk of bias					
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs					
3 Could not be calculated as there were no events in the intervention or comparison group					
4 Risk difference calculated in Review Manager					

1 Table 198: Clinical evidence summary: LMWH (high dose; standard duration) versus UFH

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with LMWH high dose versus UFH (95% CI)
All-cause mortality	43 (1 study) time-point not reported	VERY LOW ^{1,2} due to risk of bias, imprecision	Not estimable ³	Not estimable ³	0 fewer per 1000 (from 87 fewer to 87 more) ⁴
DVT	43 (1 study) time-point not reported	VERY LOW ^{1,2} due to risk of bias, imprecision	Not estimable ³	Not estimable ³	0 fewer per 1000 (from 87 fewer to 87 more) ⁴
Major bleeding	43 (1 study) time-point not reported	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 5.22 (0.68 to 39.74)	50 per 1000	211 more per 1000 (from 16 fewer to 1000 more)
1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias					
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs					
3 Could not be calculated as there were no events in the intervention or comparison group					
4 Risk difference calculated in Review Manager					

1 Table 199: Clinical evidence summary: LMWH (low dose; standard duration) versus LMWH (standard dose; standard duration)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with LMWH low dose versus LMWH standard dose (95% CI)
All-cause mortality	2931 (2 studies) 8-30 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 1.07 (0.7 to 1.62)	29 per 1000	2 more per 1000 (from 9 fewer to 18 more)
DVT	2853 (3 studies) 7-30 days	MODERATE ¹ due to risk of bias	RR 1.98 (1.51 to 2.59)	50 per 1000	49 more per 1000 (from 26 more to 80 more)
PE	2853 (3 studies) 30 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 1.15 (0.42 to 3.16)	5 per 1000	1 more per 1000 (from 3 fewer to 10 more)
Major bleeding	2966 (3 studies) 30 days	VERY LOW ^{1,2,3,4} due to risk of bias, inconsistency, indirectness, imprecision	RR 0.58 (0.14 to 2.41)	16 per 1000	7 fewer per 1000 (from 14 fewer to 23 more)
Fatal PE	35 (1 study) 30 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Not estimable ⁵	Not estimable ⁵	0 fewer per 1000 (from 106 fewer to 106 more) ⁶

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
 2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs
 3 Downgraded by 1 increment because heterogeneity, I²=66%, p=0.05, unexplained by subgroup analysis
 4 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol
 5 Could not be calculated as there were no events in the intervention or comparison group
 6 Risk difference calculated in Review Manager

2 Table 200: Clinical evidence summary: LMWH (standard dose; extended duration) versus LMWH (standard dose; standard duration)

Outcomes	No of	Quality of the	Relative effect	Anticipated absolute effects
----------	-------	----------------	-----------------	------------------------------

	Participants (studies) Follow up	evidence (GRADE)	(95% CI)	Risk with Control	Risk difference with Extended duration LMWH standard dose versus standard duration LMWH standard dose (95% CI)
All-cause mortality	501 (1 study) 60 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 0.51 (0.13 to 1.99)	36 per 1000	18 fewer per 1000 (from 31 fewer to 36 more)
DVT	332 (1 study) 25-31 days	LOW ^{1,2} due to risk of bias, imprecision	RR 0.43 (0.18 to 0.89)	120 per 1000	68 fewer per 1000 (from 13 fewer to 98 fewer)
PE	332 (1 study) 90 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.14 (0.01 to 2.19)	12 per 1000	10 fewer per 1000 (from 12 fewer to 14 more)
Major bleeding	928 (2 studies) up to 90 days	VERY LOW= due to risk of bias, imprecision, inconsistency	Peto OR 0.83 (0.22 to 3.08)	11 per 1000	2 fewer per 1000 (from 8 fewer to 21 more)
Fatal PE	332 (1 study) 90 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.14 (0.00 to 6.90)	6 per 1000	5 fewer per 1000 (from 6 fewer to 34 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs
3 Downgraded by 1 increment because heterogeneity, I²=60%, p=0.12, unexplained by subgroup analysis.

1 Table 201: Clinical evidence summary: LMWH (high dose; extended duration) versus LMWH (high dose; standard duration)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with Extended duration LMWH high dose versus standard duration LMWH high dose (95% CI)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with Extended duration LMWH high dose versus standard duration LMWH high dose (95% CI)
All-cause mortality	488 (1 study) 90 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 1.29 (0.45 to 3.66)	25 per 1000	7 more per 1000 (from 14 fewer to 67 more)
DVT	488 (1 study) 28 days	LOW ^{1,2} due to risk of bias, imprecision	RR 0.63 (0.37 to 1.10)	121 per 1000	45 fewer per 1000 (from 76 fewer to 12 more)
PE	488 (1 study) 28 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Not estimable ³	Not estimable ³	0 fewer per 1000 (from 8 fewer to 8 more) ⁴
Major bleeding	625 (1 study) 22 days	LOW ² due to imprecision	Peto OR 1.92 (0.20 to 18.54)	3 per 1000	3 more per 1000 (from 3 fewer to 53 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs
3 Could not be calculated as there were no events in the intervention or comparison group
4 Risk difference calculated in Review Manager

1

2 **Table 202: Clinical evidence summary: LMWH (standard dose; extended duration) + AES (undefined) versus LMWH (standard dose; standard duration) +**
3 **AES (undefined)**

Outcomes	No of	Quality of the	Relative	Anticipated absolute effects
----------	-------	----------------	----------	------------------------------

	Participants (studies) Follow up	evidence (GRADE)	effect (95% CI)	Risk with LMWH standard dose standard duration + AES	Risk difference with LMWH standard dose extended duration + AES (95% CI)
All-cause mortality	427 (1 study) 60 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 1.27 (0.69 to 2.36)	77 per 1000	21 more per 1000 (from 24 fewer to 104 more)
DVT	340 (1 study) 60 days	LOW ^{1,2} due to risk of bias, imprecision	RR 0.50 (0.26 to 0.95)	149 per 1000	76 fewer per 1000 (from 9 fewer to 110 fewer)
PE	343 (1 study) 28 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 0.14 (0.01 to 1.40)	17 per 1000	14 fewer per 1000 (from 17 fewer to 7 more)
Fatal PE	427 (1 study) 28 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Not estimable ³	Not estimable ³	0 fewer per 1000 (from 9 fewer to 9 more) ⁴

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs

3 Could not be calculated as there were no events in the intervention or comparison group

4 Risk difference calculated in Review Manager

1 Table 203: Clinical evidence summary: Fondaparinux versus LMWH (standard dose; standard duration)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with Fondaparinux versus LMWH standard dose (95% CI)
All-cause mortality	2858 (1 study) 32 days	LOW ^{1,2} due to risk of bias,	RR 0.72 (0.48 to 1.08)	39 per 1000	11 fewer per 1000 (from 20 fewer to 3 more)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with Fondaparinux versus LMWH standard dose (95% CI)
		imprecision			
DVT	2042 (1 study) 32 days	LOW ^{1,2} due to risk of bias, imprecision	RR 0.72 (0.49 to 1.06)	58 per 1000	16 fewer per 1000 (from 30 fewer to 3 more)
PE	2927 (1 study) 32 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 7.38 (0.46 to 118.03)	0 per 1000	Not estimable ³
Major bleeding	2858 (1 study) 5-11 days	LOW ^{1,2} due to risk of bias, imprecision	RR 1.43 (0.93 to 2.21)	24 per 1000	10 more per 1000 (from 2 fewer to 29 more)
Fatal PE	2927 (1 study) 32 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 1 (0.2 to 4.95)	2 per 1000	0 fewer per 1000 (from 2 fewer to 8 more)
<p>1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p> <p>2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs</p> <p>3 Could not be calculated as there were no events in the comparison group</p>					

1 Table 204: Clinical evidence summary: Fondaparinux + IPCD (undefined) versus IPCD (undefined)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with Fondaparinux + IPCD versus IPCD (95% CI)
All-cause mortality	1285 (1 study)	LOW ²	Peto OR 1.63 (0.55 to 4.86)	8 per 1000	5 more per 1000 (from 3 fewer to 29 more)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with Fondaparinux + IPCD versus IPCD (95% CI)
	32 days	due to imprecision			
DVT	842 (1 study) 10 days	MODERATE ¹ due to risk of bias	RR 0.31 (0.14 to 0.73)	53 per 1000	36 fewer per 1000 (from 14 fewer to 45 fewer)
PE	1285 (1 study) 32 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.36 (0.05 to 2.57)	6 per 1000	5 fewer per 1000 (from 7 fewer to 11 more)
Fatal PE	1285 (1 study) 32 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 1.02 (0.06 to 16.39)	2 per 1000	0 more per 1000 (from 1 fewer to 23 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs

1 Table 205: Fondaparinux versus no prophylaxis/mechanical

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with Fondaparinux + IPCD versus IPCD (95% CI)
Major bleeding	1285 (1 study) 32 days	MODERATE ¹ due to risk of bias	Peto OR 5.33 (1.63 to 17.45)	2 per 1000	7 more per 1000 (from 1 more to 25 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

1 Table 206: Fondaparinux + UFH + mechanical (AES + IPCD) versus LMWH + UFH + mechanical (AES + IPCD)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with LMWH + UFH + mech	Risk difference with Fonda + UFH + mech (95% CI)
PE	258 (1 study) time-point not reported	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.13 (0.01 to 2.13)	16 per 1000	14 fewer per 1000 (from 15 fewer to 17 more)
Major bleeding	298 (1 study) time-point not reported	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 1.88 (0.19 to 18.21)	7 per 1000	6 more per 1000 (from 6 fewer to 105 more)

1 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs
2 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

2 Table 207: VKA versus no prophylaxis

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with VKA versus no prophylaxis (95% CI)
DVT	96 (1 study) 7 days	LOW ^{1,2} due to risk of bias, imprecision	RR 0.27 (0.08 to 0.92)	229 per 1000	167 fewer per 1000 (from 18 fewer to 211 fewer)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs

3

35.4¹ Economic evidence

2 Published literature

3 Two original economic models were developed for this population in CG92.²²⁴ Additionally, one
4 health economic study was also identified with the relevant comparison and have been included in
5 this review.³⁰⁵ These are summarised in the health economic evidence profiles below (Table 208,
6 Table 209 and Table 210) and the health economic evidence tables in Appendix J.

7 An economic model was developed for this population in CG46; for both standard duration and post-
8 discharge prophylaxis. Both these models were selectively excluded due to the availability of the
9 more applicable model from CG92.²²⁴ Additionally, three economic studies relating to this review
10 question were previously included in CG46,²²⁶ but one was excluded due to methodological
11 limitations,²¹⁹ and the other two were selectively excluded due to the availability of more applicable
12 evidence.^{121,253} These are listed in Appendix O, with reasons for exclusion given.

13 See also the health economic study selection flow chart in Appendix F.

14

1 **Table 208: Health economic evidence profile: LMWH (standard dose, standard duration) + AES (knee-length) vs LMWH (standard dose , standard duration) + AEs (thigh-length) vs LMWH (standard dose, standard duration)**
2

Study	Applicability	Limitations	Other comments	Incremental cost	Incremental effects	Cost-effectiveness	Uncertainty
Wade 2015 ³⁰⁵ ([UK])	Directly applicable ^(a)	Potentially serious limitations ^(b)	<p>- Study design: CUA using decision modelling</p> <p>- Population: Patients undergoing any general surgery (subgroups considered were high risk patients, medium risk patients and low risk patients).</p> <p>- Interventions:</p> <p>Intervention 1: LMWH (for duration of 7 days (standard duration).</p> <p>Intervention 2: Knee-length AES in addition to LMWH for a duration of 7 days (standard duration).</p> <p>Intervention 3: Thigh-length AES in addition to pharmacological prophylaxis (LMWH) for duration of 7 days (standard duration).</p>	<p>High risk patients:</p> <p>1 (vs 3) : £176 2 (vs 3): £177 3: comparator</p> <p>Intermediate risk patients:</p> <p>1 (vs 3) : £46 2 (vs 3): £76 3: comparator</p> <p>Low risk patients:</p> <p>1:comparator) 2 (vs 1) : £35 3 (vs 1): £5</p>	<p>High risk patients:</p> <p>1 (vs 3): 0.009 QALYs lost 2 (vs 3) : 0.007 QALYs lost 3: comparator</p> <p>Intermediate risk patients:</p> <p>1 (vs 3):0.004 QALYs lost 2 (vs 3): 0.003 QALYs lost 3 : comparator</p> <p>low risk patients:</p> <p>1: Comparator 2 (vs 1) : 0.002 QALYs lost 3 (vs 1): 0.002</p>	<p>High risk patients: LMWH + thigh-length AES (intervention 3) dominant (less costly and more effective)</p> <p>Intermediate risk patients: LMWH + thigh-length AES (intervention 3) dominant (less costly and more effective)</p> <p>Low risk patients: LMWH + thigh-length AES (intervention 3) cost effective (ICER: £2,632 per QALY gained vs LMWH alone [intervention 1])</p>	The results of all scenario and sensitivity analyses were largely consistent with the base case analysis for all subgroups

3 Abbreviations: AES: anti-embolism stockings; CUA: cost utility analysis; ICER: incremental cost-effectiveness ratio; LMWH: low molecular weight heparin; QALY: quality-adjusted life years;

4 RCT: randomised controlled trial

5 a) Mixed population of all surgery types, however subgroup analysis is also presented.

6 b) The model did not include some relevant health outcomes; e.g. clinically-relevant non-major bleeding , minor bleeding and surgical site infection.

1 **Table 209: Health economic evidence profile: pharmacological, mechanical or combination of prophylaxis strategies vs each other**

Study	Applicability	Limitations	Other comments	Incremental cost	Incremental effects	Cost-effectiveness	Uncertainty
National Guideline Centre 2010 ²²⁴ ([UK])	Partially applicable ^(a)	Potentially serious limitations ^(b)	<ul style="list-style-type: none"> - Study design: CUA using decision analytic model based on NMAs - Population: Adult (18 years or older) admitted for elective abdominal surgery to hospitals in England. - Interventions: <ol style="list-style-type: none"> 1. AES 2. IPCD-FID 3. UFH+ AES 4. LMWH+ AES 5. LMWH 6. Aspirin high dose 7. UFH 8. Fondaparinux+ IPCD-FID 9. Fondaparinux 10. VKA 11. No prophylaxis 12. UFH+ Aspirin high dose 	NR	NR	<p>Incremental net benefit:</p> <ul style="list-style-type: none"> Intervention 1: £488 Intervention 2: £464 Intervention 3: £408 Intervention 4: £348 Intervention 5: £347 Intervention 6: £314 Intervention 7: £241 Intervention 8: £127 Intervention 9: £104 Intervention 10: £75 Intervention 11: £0 Intervention 12: -£694 	High-dose aspirin alone was the most cost-effective strategy when the population-specific pulmonary embolism relative risks were used. The results were highly sensitive to baseline risk of major bleeding and baseline risk of pulmonary embolism. For patients at lowest risk of major bleeding, combination prophylaxis is cost-effective, rather than mechanical prophylaxis alone.

2 Abbreviations: AES: Anti-embolism stockings; CTEPH: chronic thromboembolic pulmonary hypertension; CUA: cost-utility analysis; DVT: deep vein thrombosis; FID: foot impulse devices; HD: high dose; HIT: Heparin induced thromboembolism; ICER: incremental cost-effectiveness ratio; IPCD: intermittent pneumatic compression device; LMWH: low molecular weight heparin; MB: major bleeding; NMA: network meta-analysis; PE: pulmonary embolism; QALY: quality-adjusted life years; RCT: randomised controlled trial; UFH: unfractionated heparin; VTE: venous thromboembolism; VKA: Vitamin K antagonists.

6 (a) Some uncertainty regarding the applicability of unit costs from 2009 to current NHS context. Some interventions are not included in our review protocol (aspirin (high dose))

7 (b) The relative treatment effect applied to all VTE events in the model is the relative treatment effect obtained from the DVT NMA.

1 **Table 210: Health economic evidence profile: LMWH (post-discharge) vs no post-discharge prophylaxis**

Study	Applicability	Limitations	Other comments	Incremental cost	Incremental effects	Cost-effectiveness	Uncertainty
National Guideline Centre 2010 ²²⁴ ([UK])	Directly applicable ^(a)	Potentially serious limitations ^(b)	<ul style="list-style-type: none"> - Study design: CUA using decision analytic model based on pairwise Meta-analysis - Population: Adult (18 years or older) admitted for elective abdominal surgery to hospitals in England ; randomised 10 to 12 days after surgery (mainly cancer surgery patients) - Interventions: Intervention 1: No post discharge prophylaxis Intervention 2: LMWH initiated post discharge and continued for 21 days. 	NR	NR	Incremental net benefit: No prophylaxis: £0 (comparator) LMWH (post-discharge): £49	The result was consistent for all deterministic sensitivity analyses. In the probabilistic sensitivity analysis, LMWH was more cost-effective in 77% of the 5000 simulations of the probabilistic sensitivity analysis. It was also found that life expectancy would have to be halved for it to no longer be cost-effective for these patients

2 Abbreviations: CUA: cost utility analysis; DVT: deep vein thrombosis; ICER: incremental cost-effectiveness ratio; LMWH: low molecular weight heparin; MB: major bleeding; MA: meta-analysis; PE: pulmonary embolism; QALY: quality-adjusted life years; RCT: randomised controlled trial; VTE: venous thromboembolism.
 3
 4 (a) Some uncertainty regarding the applicability of unit costs from 2009 to current NHS context.
 5 (b) The relative treatment effect applied to all VTE events in the model is the relative treatment effect obtained from the DVT MA.

6
7

35.5 1 Evidence statements

2 Clinical

3 Pairwise meta-analysis statements

4 **Mechanical prophylaxis versus mechanical prophylaxis**

5 AES

6 Two studies (n=291) evaluated the use of above knee AES compared to no prophylaxis. A clinical
7 benefit of AES was found for DVT, and a possible clinical benefit was found for PE, although for this
8 outcome there was very serious imprecision around the estimate. No clinical difference was found
9 for all-cause mortality. The evidence ranged from very low to moderate quality due to risk of bias
10 and imprecision.

11 One study (m=95) compared below knee AES to no prophylaxis and found a possible clinical benefit
12 of stockings in terms of DVT. However there was very serious imprecision, and therefore the
13 estimate is also consistent with no difference and clinical harm. The evidence was very low quality
14 due to risk of bias and imprecision.

15 One study compared AES at an undefined length to no VTE prophylaxis. The evidence showed that
16 for the outcome of DVT, there was a clinical benefit of AES. Evidence for this comparison was of
17 moderate quality due to risk of bias.

18 One study (n=114) compared above knee AES with below knee AES. For the only reported outcome
19 of DVT, there was a possible clinical harm of above knee AES, however there was very serious
20 imprecision around the estimate and therefore was also consistent with no difference and clinical
21 benefit. The evidence for this comparison was of very low quality due to risk of bias and imprecision.

22 *Foot pump*

23 One study of 66 participants evaluated the use of foot pumps compared to no prophylaxis. The
24 evidence demonstrated a possible clinical benefit of foot pumps in terms of both all-cause mortality
25 and DVT, however imprecision around these estimates was also consistent with no difference and in
26 the case of mortality, also possible harm as well. The quality of evidence for this comparison ranged
27 from low to very low due to risk of bias and imprecision.

28 *IPCD*

29 Four studies evaluated IPCD (below knee) versus no prophylaxis. A possible clinical benefit of IPCD
30 was found for both DVT and fatal PE, however for both of these outcomes there was very serious
31 imprecision around the estimate, and therefore was also consistent with no difference and clinical
32 harm. No clinical difference was found for all-cause mortality, and there was a suggested clinical
33 harm of IPCD in terms of PE. Again, both of these outcomes had serious imprecision around the
34 estimate. The evidence for this comparison was very low due to risk of bias, imprecision, and for the
35 DVT outcome, inconsistency.

36 One study (n=90) evaluated the use of IPCD (full leg) compared to IPCD (below knee). The evidence
37 showed a possible clinical benefit of full leg IPCD in terms DVT and fatal PE, but a suggested clinical
38 harm for full leg IPCD in terms of PE. Quality was very low due to risk of bias and imprecision.

39 **Pharmacological prophylaxis versus pharmacological prophylaxis**

40 *UFH*

41 Two studies evaluated the use UFH versus VKA in terms of DVT (n=197). A possible clinical benefit
42 was found for UFH, however there was serious imprecision around the estimate and therefore
43 evidence was also consistent with no difference. One study reported the outcome of major bleeding

1 (n=100). No clinical difference was found between UFH and VKA, however there was very serious
2 imprecision which meant that this was also consistent with clinical benefit and clinical harm. The
3 evidence quality ranged from low to very low due to risk of bias and imprecision.

4 *LMWH (low dose)*

5 One study compared LMWH at a low dose with no prophylaxis (n=183). There was a suggested
6 clinical benefit for LMWH for all-cause mortality, DVT and PE. There was no clinical difference for
7 major bleeding and thrombocytopenia. Quality ranged from very low to low due to risk of bias,
8 imprecision and for one outcome, indirectness.

9 LMWH at a low dose was compared to UFH. Seven studies reported the outcomes all-cause
10 mortality, PE and major bleeding (n=6694-7018). The evidence demonstrated a possible clinical harm
11 of LMWH for all-cause mortality, and a possible clinical harm for major bleeding. Both outcomes had
12 serious imprecision around the estimate, and therefore were also consistent with no difference.
13 There was no clinical difference between LMWH and UFH in terms of PE, with very serious
14 imprecision consistent with clinical benefit and clinical harm. Five studies reported the outcomes DVT
15 and fatal PE (n=3045-5848). Evidence from these studies showed a possible clinical harm for both
16 outcomes, however there was serious and very serious imprecision around the estimates. The quality
17 of the evidence ranged from very low to low due to risk of bias, imprecision and inconsistency.

18 LMWH at a low dose was compared to LMWH at a standard dose. Two studies reported the outcome
19 all-cause mortality (n=2931). The evidence demonstrated a possible clinical harm of low dose LMWH,
20 however there was very serious imprecision consistent with no difference and benefit. Three studies
21 reported the outcomes DVT, PE and major bleeding (n=2853-2966). There was a possible clinical
22 harm of low dose LMWH in terms of DVT, no clinical difference in terms of PE, and a possible clinical
23 benefit of low dose LMWH in terms of major bleeding. All outcomes had very serious imprecision.
24 One study reported the outcome fatal PE (n=35). This study demonstrated no clinical difference
25 between the two doses of LMWH, however there was very serious imprecision consistent with both
26 harm and benefit. Evidence for the comparison ranged from very low to moderate quality, due to risk
27 of bias, imprecision and, for the major bleeding outcome, indirectness and inconsistency.

28 *LMWH (standard dose)*

29 For the comparison of LMWH (standard dose) versus UFH, eight studies reported the outcomes DVT,
30 PE and major bleeding. There was a possible clinical benefit of LMWH for PE, no clinical difference for
31 DVT, and a suggested clinical harm of LMWH for major bleeding. The DVT outcome had serious
32 imprecision around the estimate consistent with benefit, whereas the major bleeding outcome
33 demonstrated serious imprecision consistent with no difference. Five studies reported the outcome
34 all-cause mortality. No clinical difference between LMWH and UFH was found, however there was
35 very serious imprecision around the estimate, and therefore was consistent with clinical harm and
36 clinical benefit. One study reported fatal PE, and found a possible clinical benefit of LMWH, however
37 this outcome had very serious imprecision consistent with no difference and clinical harm. The
38 evidence ranged from low to very low quality due to risk of bias, imprecision, and inconsistency.

39 Standard dose LMWH at an extended duration was compared to standard dose LMWH at a standard
40 duration. One study reported the outcomes all-cause mortality, DVT, PE and fatal PE (n=332-501). A
41 possible clinical benefit of extended duration LMWH was found for all-cause mortality, DVT, PE and
42 fatal PE, however all outcomes had either serious or very serious imprecision around the estimate.
43 Two studies reported the outcome major bleeding (n=928). There was no clinical difference for major
44 bleeding, however there was very serious imprecision around the estimate consistent with both
45 benefit and harm. The evidence ranged from very low to low quality due to risk of bias and
46 imprecision.

47 *LMWH (high dose)*

1 One study evaluated LMWH at a high dose versus no prophylaxis. The evidence demonstrated a
2 possible clinical benefit for LWMH was found for DVT. However there was serious imprecision
3 around the estimate, and therefore evidence was also consistent with no difference. No clinical
4 difference was found between LMWH and no prophylaxis in terms of all-cause mortality, however
5 again there was very serious imprecision around the estimate. The evidence was of low quality due
6 to risk of bias and imprecision.

7 For the comparison of LMWH at a high dose versus UFH, one study of 43 participants reported the
8 outcomes all-cause mortality, DVT and major bleeding. There was no clinical difference between the
9 two pharmacological prophylaxis methods for the all-cause mortality and DVT outcomes, although
10 there was very serious imprecision around the estimate for both outcomes, which therefore were
11 also consistent with benefit and harm. There was a possible clinical harm of LMWH in terms of major
12 bleeding, with very serious imprecision around the estimate. The quality of the evidence was very
13 low for all outcomes due to risk of bias and imprecision.

14 One study compared high dose LMWH at an extended duration versus high dose LMWH at a
15 standard duration (n=488-625). A possible clinical benefit of extended duration LMWH was found for
16 DVT, however there was serious imprecision around the estimate and therefore was also consistent
17 with no difference. A possible clinical harm was found for all-cause mortality and major bleeding
18 however there was very serious imprecision consistent with no difference and benefit. There was no
19 clinical difference for PE, with very serious imprecision consistent with both benefit and harm. The
20 evidence ranged from very low to low quality due to risk of bias and imprecision.

21 *Fondaparinux*

22 One study compared fondaparinux to LMWH at a standard dose (n=2042-2927). A possible clinical
23 benefit was found for fondaparinux in terms of all-cause mortality, and DVT. Both outcomes had
24 serious imprecision around the estimate and so were also consistent with no difference. A possible
25 clinical harm was found for PE and major bleeding. Very serious imprecision around the estimate for
26 PE meant that it is also consistent with no difference and benefit, and serious imprecision around the
27 estimate for major bleeding meant that the outcome is also consistent with no difference. No clinical
28 difference was found for fatal PE, with very serious imprecision. The evidence ranged from low to
29 very low quality due to risk o bias and imprecision.

30 *VKA*

31 One study compared VKA with no prophylaxis (n=96). For the outcome of DVT, there was a possible
32 clinical benefit of VKA, however there was serious imprecision around the estimate and therefore
33 this was also consistent with no difference. The evidence was low quality due to risk of bias and
34 imprecision.

35 **Mechanical prophylaxis versus pharmacological prophylaxis**

36 One study compared above knee AES with UFH (n=97). There was a possible clinical benefit of AES in
37 terms of fatal PE, however there was very serious imprecision around the estimate consistent with
38 no difference and harm. The evidence was very low quality due to risk of bias and imprecision.

39 One study compared below knee AES with UFH (n=159). No clinical difference was found for both all-
40 cause mortality and PE, with very serious imprecision consistent with both benefit and harm. The
41 evidence was of very low quality due to risk of bias, imprecision and, for the PE outcome,
42 indirectness.

43 One study of 100 participants compared electrical stimulation with UFH. There was a possible clinical
44 harm of electrical stimulation in terms of DVT, however there was very serious imprecision
45 consistent with benefit and no difference. The evidence was of very low quality due to risk of bias
46 and imprecision.

1 One study compared full leg IPCD versus VKA (n=100). A possible clinical harm of IPCD was found for
2 DVT and PE. For both outcomes there was very serious imprecision around the estimate consistent
3 with benefit and no difference. There was no clinical difference for all-cause mortality, again with
4 very serious imprecision. The evidence was very low quality due to risk of bias and imprecision.

5 **Pharmacological prophylaxis versus mechanical prophylaxis**

6 UFH was compared to no prophylaxis/mechanical prophylaxis. Twelve studies reported the outcome
7 DVT (n=1991), and the evidence demonstrated a clinical benefit for UFH. Ten studies reported the
8 outcome PE (n=897). There was a possible clinical benefit of UFH, however there was serious
9 imprecision, and was therefore also consistent with no clinical difference. Seven studies reported the
10 outcome major bleeding (n=725). This demonstrated a possible clinical harm of UFH, with serious
11 imprecision consistent with no difference. Four studies reported the outcomes all-cause mortality
12 and fatal PE (n=393-506). There was a possible clinical benefit of UFH for both outcomes, however
13 both outcomes also had very serious imprecision around the estimate and were consistent with no
14 difference and clinical harm. The evidence ranged from very low to moderate quality due to risk of
15 bias and imprecision.

16 Standard dose LMWH was compared to no prophylaxis/mechanical prophylaxis. One study reported
17 the outcome all-cause mortality (n=80). There was a possible clinical benefit of LMWH for this
18 outcome, however there was very serious imprecision around the estimate and so this was also
19 consistent with harm and no difference. Two studies reported DVT and PE (n=130). There was a
20 possible clinical benefit of LMWH for both outcomes, however there was serious and very serious
21 imprecision around the estimates, consistent with no difference, and no difference and clinical harm.
22 Five studies reported the outcome major bleeding (n=527). The evidence demonstrated a possible
23 clinical harm of LMWH for this outcome, however there was serious imprecision which was also
24 consistent with no difference. The evidence was very low to low quality due to risk of bias and
25 imprecision.

26 One study compared fondaparinux to no prophylaxis/mechanical prophylaxis (n=1285). There was a
27 clinical harm of fondaparinux in terms of DVT. No other outcomes were reported. The evidence was
28 high quality.

29 Two studies compared UFH and below knee IPCD (n=265). A possible clinical harm was found for UFH
30 in terms of DVT, however there was serious imprecision around the estimate and therefore was also
31 consistent with no difference. No clinical difference was found for PE, however there was very
32 serious imprecision around the estimate consistent with both benefit and harm. The evidence
33 ranged from very low to low quality due to risk of bias and imprecision.

34 One study compared standard dose LMWH to IPCD at an undefined length (n=211). The evidence
35 demonstrated a possible clinical harm of LMWH in terms of DVT, however there was very serious
36 imprecision around the estimate consistent with no difference and benefit. There was no clinical
37 difference in terms of PE, with very serious imprecision consistent with both benefit and harm. For
38 the outcome of thrombocytopenia, a possible clinical benefit of LWMH was found, however there
39 was also very serious imprecision consistent with no difference and harm. The evidence was very low
40 quality due to risk of bias and imprecision.

41 **Combination prophylaxis versus combination prophylaxis or single-prophylaxis agents**

42 *AES*

43 One study compared below knee AES in combination with UFH to below knee AES alone (n=163).
44 There was no clinical difference between the interventions for both all-cause mortality and PE,
45 however there was very serious imprecision for both outcomes consistent with both benefit and
46 harm. The evidence was very low quality due to risk of bias and inconsistency.

1 Above knee AES in combination with UFH was compared to UFH alone. One study reported the
2 outcomes all-cause mortality and fatal PE (n=160-176). A possible clinical harm was found for the
3 combination intervention in terms of all-cause mortality, however there was very serious imprecision
4 around the estimate, and therefore this was also consistent with no difference and benefit. A
5 possible clinical benefit was seen for the combination in terms of fatal PE, however again there was
6 very serious imprecision consistent with no difference and harm. Two studies reported the outcomes
7 DVT and PE (n=336). There was a clinical benefit of the combination intervention in terms of DVT,
8 and a possible clinical benefit in terms of PE, although this outcome estimate had very serious
9 imprecision and was consistent with no difference and harm. The evidence ranged from very low to
10 moderate quality due to risk of bias and imprecision.

11 One study compared below knee AES in combination with UFH to UFH alone (n=174). The evidence
12 showed no clinical difference for all-cause mortality or PE. Both outcomes had very serious
13 imprecision around the estimate and therefore were also consistent with both benefit and harm. The
14 evidence was very low quality due to risk of bias, imprecision and, for the PE outcome, indirectness.

15 One study compared the combination of above knee AES and full leg IPCD with above knee AES alone
16 (n=77). There was a possible clinical benefit of the combined interventions for DVT, however there
17 was very serious imprecision around the estimate and this was therefore also consistent with no
18 difference and harm. There was no clinical difference in terms of PE, however there was very serious
19 imprecision consistent with both benefit and harm. The evidence was very low quality due to risk of
20 bias and imprecision.

21 One study compared AES at an undefined length in combination with full leg IPCD to AES alone
22 (n=108). There was a possible clinical benefit of the combined interventions in terms of DVT,
23 however there was serious imprecision consistent with no difference. There was no clinical
24 difference in terms of PE, with very serious imprecision around the estimate, consistent with both
25 harm and benefit. The evidence ranged from very low to low quality due to risk of bias and
26 imprecision.

27 One study compared AES at an undefined length in combination with full leg IPCD to UFH alone
28 (n=100). There was a possible clinical benefit of the combined intervention in terms of DVT, however
29 there was very serious imprecision around the estimate and therefore was also consistent with no
30 difference and harm. No other outcomes were reported. The evidence was very low quality due to
31 risk of bias and imprecision.

32 One study compared AES at an undefined length in combination with full leg IPCD to electrical
33 stimulation alone (n=100). There was a possible clinical benefit of the combined intervention in
34 terms of DVT, however there was serious imprecision around the estimate consistent with no
35 difference. No other outcomes were reported. The evidence was low quality due to risk of bias and
36 imprecision.

37 *Foot impulse device*

38 One study compared the combination of FID, below knee IPCD and low dose LMWH to the
39 combination of FID and below knee IPCD. A possible clinical benefit was found for both DVT and PE,
40 however with very serious and serious imprecision around the estimates. No clinical difference was
41 found in terms of thrombocytopenia, however there was very serious imprecision consistent with
42 both benefit and harm. The evidence was very low to low quality due to risk of bias, imprecision and,
43 for the DVT outcome, indirectness.

44 *IPCD*

45 Two studies compared IPCD at an undefined length in combination with standard dose LMWH with
46 IPCD at an undefined length alone (n=334). The evidence showed a clinical benefit of the
47 combination intervention in terms of DVT. There was no clinical difference in terms of PE, however

1 there was very serious imprecision around the estimate for this outcome, and therefore was
2 consistent with both benefit and harm. The evidence ranged from very low to low quality due to risk
3 of bias, imprecision, and for the PE outcome, indirectness.

4 *LMWH*

5 One study compared standard dose and extended duration LMWH in combination with AES at an
6 undefined length, to standard dose and standard duration LMWH in combination with AES at an
7 undefined length (n=343-427). There was a possible clinical harm of the extended duration LMWH
8 combination in terms of all-cause mortality, however there was very serious imprecision around the
9 estimate and so this was also consistent with benefit and no difference. There was a possible clinical
10 benefit for both DVT and PE. Both outcomes also had serious and very serious imprecision around
11 the estimate. There was no clinical difference in terms of fatal PE. This outcome had very serious
12 imprecision around the estimate consistent with both harm and benefit. The evidence ranged from
13 very low to low quality due to risk of bias and imprecision.

14 *Fondaparinux*

15 One large study compared fondaparinux in combination with IPCD at an undefined length, to IPCD at
16 an undefined length alone (n=842-1285). There was a possible clinical harm of the fondaparinux +
17 IPCD combination in terms of all-cause mortality, however there was very serious imprecision around
18 the estimate and therefore this was also consistent with benefit and no difference. There was a
19 clinical benefit of the combined intervention in terms of DVT, and a possible benefit in terms of PE,
20 although this was also consistent with no difference and clinical harm. There was no clinical
21 difference in terms of fatal PE, although due to very serious imprecision around the estimate this was
22 also consistent with both benefit and harm. The evidence ranged from very low to moderate quality
23 due to risk of bias and imprecision.

24 One study compared fondaparinux in combination with UFH and mechanical prophylaxis (AES and
25 IPCD), to standard dose LMWH in combination with UFH and mechanical prophylaxis (AES and IPCD)
26 (n=258-298). There was a possible clinical benefit of the fondaparinux combination intervention in
27 terms of PE, however there was very serious imprecision consistent with no difference and clinical
28 harm. There was a possible clinical harm in terms of major bleeding, however there was very serious
29 imprecision around the estimate, and therefore was also consistent with no difference and benefit.
30 The evidence was very low quality due to risk of bias and imprecision.

31 **Network meta-analysis statements**

32 *DVT (symptomatic and asymptomatic)*

33 48 studies were included in the network meta-analysis (NMA) for the outcome of DVT (symptomatic
34 and asymptomatic), involving 22 treatments. Treatments included no VTE prophylaxis,
35 pharmacological and mechanical interventions as single agents as well as combination interventions
36 of both pharmacological and mechanical interventions. Results from the network meta-analysis
37 presented LMWH at a standard dose for a standard duration initiated post-operatively in
38 combination with IPCD, fondaparinux in combination with IPCD, and AES (above-knee) in
39 combination with IPCD (full leg) as the most clinically effective interventions in terms of the outcome
40 of DVT (symptomatic and asymptomatic). The least clinically effective interventions were no
41 prophylaxis, VKA and LMWH at a low dose for a standard duration initiated pre-operatively. One
42 inconsistency was identified when relative risk values from pairwise meta-analyses were compared
43 with relative risk values from the NMA. There was also a considerable amount of uncertainty around
44 the rank-point estimates with considerably wide credible intervals.

45 *PE*

1 26 studies were included in the NMA for the outcome of PE, involving 13 treatments. Treatments
2 included no VTE prophylaxis, pharmacological and mechanical interventions as single agents as well
3 as combination interventions of both pharmacological and mechanical interventions. Results from
4 the network meta-analysis presented LMWH at a standard dose for an extended duration initiated
5 pre-operatively, AES (above knee), LMWH at a standard dose for a standard duration initiated by
6 post-operatively as the most clinically effective interventions in terms of the outcome of PE. The least
7 clinically effective interventions were IPCD (full leg), fondaparinux and IPCD (below knee). No
8 inconsistencies were identified when relative risk values from pairwise meta-analyses were
9 compared with relative risk values from the NMA. There was also a high amount of uncertainty
10 around the rank-point estimates with very wide credible intervals.

11 *Major bleeding*

12 24 studies were included in the NMA for the outcome of major bleeding, involving 15 treatments.
13 Treatments included no VTE prophylaxis and pharmacological interventions (mechanical
14 interventions were combined with no prophylaxis as the assumption was made that these
15 interventions do not contribute to bleeding risk). Results from the network meta-analysis presented
16 no prophylaxis, LMWH at a low dose for a standard duration initiated pre-operatively and UFH as the
17 most clinically effective interventions in terms of major bleeding. The least clinically effective
18 interventions were LMWH at a high dose for a standard duration initiated pre-operatively,
19 fondaparinux and LMWH at a standard dose for a standard duration initiated post-operatively. One
20 inconsistency was identified when relative risk values from pairwise meta-analyses were compared
21 with relative risk values from the NMA. There was also a high amount of uncertainty around the
22 rank-point estimates with considerably wide credible intervals across a majority of the interventions.

23 **Economic**

- 24 • One cost-utility analysis found that for VTE prophylaxis:
- 25 o In low risk general surgery patients, LMWH (standard dose, standard duration) + thigh-length
26 AES was cost effective compared to LMWH (standard dose, standard duration) alone (ICER:
27 £2,632 per QALY gained)
 - 28 o In intermediate and high risk general surgery patients, LMWH (standard dose, standard
29 duration) + thigh-length AES was dominant (less costly and more effective) compared to
30 LMWH (standard dose, standard duration) alone
- 31 This analysis was assessed as directly applicable with potentially serious limitations
- 32 • One cost-utility analysis found that in people admitted for general surgery AES was the most cost-
33 effective intervention (having the highest incremental net monetary benefit [INMB]) compared to
34 no prophylaxis (INMB: £488). This analysis was assessed as partially applicable with potentially
35 serious limitations.
- 36 • One cost-utility analysis found that post-discharge LMWH (standard dose) was cost effective
37 (INMB: £49) compared to no post-discharge prophylaxis in patients admitted for general surgery.
38 This analysis was assessed as directly applicable with potentially serious limitations.

35.69 Recommendations and link to evidence

Recommendations	
	109. Offer VTE prophylaxis to people undergoing abdominal (gastrointestinal, gynaecological, urological) surgery who are at increased risk of VTE. For people undergoing bariatric surgery, follow recommendations 113 to 115.[2018]

	<p>110. Start mechanical VTE prophylaxis on admission for people undergoing abdominal surgery. Choose either:</p> <ul style="list-style-type: none"> • anti-embolism stockings or • intermittent pneumatic compression. [2018] <p>Continue until the person no longer has significantly reduced mobility relative to their normal or anticipated mobility. [2018]</p> <p>111. Add pharmacological VTE prophylaxis for a minimum of 7 days for people undergoing abdominal surgery whose risk of VTE outweighs their risk of bleeding, taking into account individual patient factors and according to clinical judgement. Choose either:</p> <ul style="list-style-type: none"> • LMWH or • fondaparinux sodium. [2018] <p>112. Consider extending pharmacological VTE prophylaxis to 28 days postoperatively for people who have had major cancer surgery in the abdomen. [2018]</p>
<p>Research recommendation</p>	<p>None</p>
<p>Relative values of different outcomes</p>	<p>The guideline committee considered all-cause mortality (up to 90 days from hospital discharge), deep vein thrombosis (symptomatic and asymptomatic) (up to 90 days from hospital discharge), pulmonary embolism (symptomatic and asymptomatic) (up to 90 days from hospital discharge), fatal PE (up to 90 days from hospital discharge), and major bleeding (up to 45 days from hospital discharge) as critical outcomes.</p> <p>The guideline committee considered clinically relevant non-major bleeding (up to 45 days from hospital discharge), health-related quality of life (up to 90 days from hospital discharge), heparin-induced thrombocytopenia (duration of study), and technical complications of mechanical interventions (duration of study) as important outcomes.</p> <p>Please see section 4.3.3 in the methods chapter for further detail explaining prioritisation of the critical outcomes.</p>
<p>Quality of the clinical evidence</p>	<p>Sixty-seven randomised controlled trials were included in this review. Sixty-two of these were included in the previous guideline (CG92). Five new studies were added to the review. A total of thirty-nine comparisons were included in this review, evaluating the use of pharmacological (UFH, LMWH, VKA and fondaparinux) and mechanical (AES, IPCD, foot pump, FID and electrical stimulation) interventions for VTE prophylaxis.</p> <p>For the majority of evidence in this review, the quality ranged from a GRADE rating of moderate to very low. This was due to a lack of blinding, presence of selection bias, incomplete outcome reporting due to the high number of drop outs in some included studies, and use of inadequate or unreported method of measurement, resulting in a high or very high risk of bias rating. Further, much of the evidence in the review had serious or very serious imprecision, leading to further downgrading to the quality of evidence. A high quality GRADE rating was seen for one outcome, in the fondaparinux versus no prophylaxis/mechanical prophylaxis comparison, for the DVT outcome.</p>
<p>Trade-off between clinical benefits and</p>	<p>The committee noted that the review contains both open and laparoscopic surgery populations, and noted that these populations were likely to have different</p>

harms	<p>mobilisation times and associated risks. The committee discussed creating separate recommendations for these populations but felt that it would be difficult to align a distinction in recommendations in line with the risk assessment recommendations, given that not all laparoscopic procedures are under 90 minutes, and given the fact that many of the included studies did not separate the two populations as they either used a mix of laparoscopic and open surgery procedures, or did not specify the type of procedure used.</p> <p>Mechanical prophylaxis</p> <p>The committee noted that there was no evidence for foot impulse devices as a standalone intervention and therefore a positive recommendation for the use of this intervention for VTE prophylaxis could not be made. The committee also discussed the evidence for the use of AES. It was felt that while there was no convincing evidence that above knee AES was better than below knee, the economic evidence suggested a slight benefit for above knee AES. Therefore, the committee agreed there was insufficient evidence to specify one particular option of above or below knee AES in the recommendations. In terms of IPCD the committee discussed the practical considerations that need to be taken into account with respect to mobilising the patient. IPCD are usually used only during the surgery.</p> <p>Pharmacological prophylaxis</p> <p>The committee considered the evidence for pharmacological prophylaxis. The committee noted that there was evidence to support LMWH and fondaparinux as being better than no prophylaxis. However there was not sufficient evidence to determine whether LMWH was better than fondaparinux. For prevention of DVT the evidence suggested that pharmacological prophylaxis (LMWH or fondaparinux) in combination with IPCD may be of most clinical benefit.</p> <p>The network meta-analysis (NMA) conducted presented that combination prophylaxis strategies with pharmacological and mechanical interventions are more clinically beneficial in terms of reducing DVT. These combination strategies had higher rankings compared to pharmacological or mechanical interventions as standalone interventions, particularly LMWH at a standard dose for a standard duration initiated post-operatively in combination with IPCD which was ranked as the most clinically effective prophylaxis in the NMA for DVT.</p>
Trade-off between net clinical effects and costs	<p>Two economic studies were included in this review. One is an economic evaluation recently published as part of an HTA funded study. This was assessed as directly applicable with minor limitations. The other was the economic model previously developed for CG92 which covered two comparisons; one for standard duration prophylaxis options and the second for post-discharge prophylaxis. The model comparing standard duration prophylaxis options was assessed as partially applicable with potentially serious limitations. The model for post-discharge prophylaxis was assessed as directly applicable with potentially serious limitations. Additionally, four studies were selectively excluded; one was excluded due to methodological limitations, three (including the model developed for CG46) were selectively excluded due to the availability of the more applicable included studies.</p> <p>The first of the two included studies was an economic model that compared above and below knee AES; each combined with LMWH (standard dose and standard duration), vs LMWH alone. The results were presented for three levels of baseline risk of VTE: high, intermediate and low. For people at high or intermediate risk of VTE, LMWH + thigh-length AES was the dominant option. For people at low risk, LMWH + thigh-length AES was the cost effective option with an ICER of £2,632 per QALY gained compared to LMWH alone.</p> <p>Two models were developed in CG92. The first was for standard duration prophylaxis and included the following interventions: AES, IPCD-FID, UFH (standard dose)+AES, LMWH (standard dose)+ AES, LMWH (standard dose), Aspirin (high dose), UFH (standard dose), Fondaparinux+ IPCD-FID, Fondaparinux, VKA (variable dose), UFH</p>

	<p>(standard dose) + Aspirin (high dose), and no prophylaxis. The guideline committee noted that not all of these interventions are still relevant to current practice (for example aspirin (high dose) and VKA). Mechanical prophylaxis with either AES or IPCD was the most cost effective options in the base case analysis with INMB of £488 and £464 respectively. However, in a two-way sensitivity analysis that varied the baseline risk of PE and MB; combined prophylaxis of LMWH+ stocking was the most cost- effective option for high baseline risk of PE and low risk of MB.</p> <p>The second model compared post-discharge prophylaxis with LMWH with no prophylaxis. The results showed that extending the duration of LMWH prophylaxis to continue post-discharge was cost effective compared to no prophylaxis with an INMB of £49.</p> <p>The guideline committee considered the economic evidence presented, alongside the clinical evidence. The committee noted that, in line with CG92 recommendation, combined prophylaxis for people at high risk of VTE is the most cost effective option. This was supported by the newly published HTA report that stratified surgical patients according to their level of VTE risk; where combined prophylaxis was the most cost effective option.</p> <p>The committee considered the recent clinical evidence and felt that both LMWH and fondaparinux were better compared to no prophylaxis; however, no clear conclusion could be made in terms of superiority of one over the other. However, as low quality clinical evidence for the DVT outcome suggested superiority of fondaparinux; the committee felt that this would justify the increased cost and choice of either as pharmacological prophylaxis options should be made based on the baseline bleeding risk.</p> <p>The committee discussed whether the evidence was enough to recommended either knee or thigh length AES. The economic evidence supported the cost effectiveness of combined prophylaxis that includes thigh length AES, however, the committee noted that thigh length AES are less convenient for people to wear and are more difficult to fit. Hence; the committee felt that the choice of the length of stocking should be made taking into account the preference of the individual and his/her ability to adhere to wearing them. No studies were identified that compared thigh vs knee length for IPCD, so the committee felt that, similar to AES, the choice of the length should be based on preference, likelihood of adherence and ease of fitting.</p> <p>The guideline committee also discussed the duration of prophylaxis and noted that the economic model developed for CG92 supported extending the duration of prophylaxis for those who are at increased risk of VTE. These were primarily people undergoing surgeries for cancer. For this population, continuing LMWH post discharge was found to be more cost effective than no post-discharge prophylaxis.</p>
Other considerations	None.

36 Bariatric surgery

36.1.2 Introduction

3 Bariatric or metabolic weight loss surgery is used as a treatment for people who are very obese with
 4 a BMI of 40 or more, or a BMI between 35 and 40 with an obesity-related condition. It can lead to
 5 significant weight loss and help improve many obesity-related conditions, such as type 2 diabetes or
 6 high blood pressure. Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT)
 7 and its complication, pulmonary embolism (PE), is a common cause of morbidity and mortality after
 8 bariatric surgery. There is a need to identify how to reduce this risk of VTE using mechanical or
 9 pharmacological prophylaxis.

10 Although part of gastrointestinal surgery, all patients undergoing bariatric surgery would already be
 11 considered at increased risk of VTE because they have a BMI of greater than 30 and are therefore
 12 classified as obese. Consequently, we have mentioned them separately. Most bariatric surgery is
 13 performed laparoscopically.

14 Factors that may increase the risk of bleeding or the hazard associated with it:

- 15 • Difficult access may result in poor views because of obesity
- 16 • There is a danger of converting from laparoscopic to open surgery if bleeding occurs.

17 Other factors that may affect the choice of prophylaxis:

- 18 • There may be a higher number of patients who are contraindicated to anti-embolism stockings in
 19 this group because of an unusual leg size and shape.

36.2.0 Review question: What is the effectiveness of different 21 pharmacological and mechanical prophylaxis strategies (alone or in 22 combination) for people undergoing bariatric surgery?

23 For full details see review protocol in Appendix C.

24 **Table 211: PICO characteristics of review question**

Population	Adults and young people (16 years and older) undergoing bariatric surgery who are admitted to hospital, and outpatients post-discharge
Intervention(s)	<p>Mechanical:</p> <ul style="list-style-type: none"> • Anti-embolism stockings (above or below knee) • Intermittent pneumatic compression (IPCD) devices (full leg or below knee) • Foot pumps or foot impulse devices (FID) • Electrical stimulation (including Geko devices) • Continuous passive motion <p>Pharmacological (no minimum duration):</p> <ul style="list-style-type: none"> • Unfractionated heparin (UFH) (low dose, administered subcutaneously) • Low molecular weight heparin (LMWH), licensed in UK: <ul style="list-style-type: none"> ○ enoxaparin (standard prophylactic dose 40mg daily; minimum 20mg daily* to maximum 60mg twice daily*) ○ dalteparin (standard prophylactic dose 5000 units once daily;

	<p>minimum 1250 units once daily* to maximum 5000 units twice daily*; obese patients – maximum 7500 twice units daily*)</p> <ul style="list-style-type: none"> ○ tinzaparin (standard prophylactic dose 3500 units once daily; minimum 2500 units once daily* to maximum 4500 units twice daily*; obese patients – maximum 6750 twice daily*) ● LMWH, licensed in countries other than UK: <ul style="list-style-type: none"> ○ Bemiparin (standard 2500 units daily; minimum 2500 units daily to maximum 3500 units daily) ○ Certoparin (3000 units daily) ○ Nadroparin (standard 2850 units once daily; minimum 2850 units once daily to maximum up to 57 units/kg once daily) ○ Parnaparin (standard 3200 units once daily; minimum 3200 units once daily to maximum 4250 units once daily) ○ Reviparin (minimum 1750 units once daily to maximum 4200 units once daily) ● Vitamin K Antagonists: warfarin (variable dose), acenocoumarol (all doses), phenindione (all doses) ● Fondaparinux (all doses) ● Apixaban (all doses) ● Dabigatran (all doses) ● Rivaroxaban (all doses) ● Aspirin (up to 300mg)
<p>Comparison(s)</p>	<p>Compared to:</p> <ul style="list-style-type: none"> ● Other VTE prophylaxis treatment, including monotherapy and combination treatments (between class comparisons for pharmacological treatments only) ● No VTE prophylaxis treatment (no treatment, usual care, placebo) <p>Within intervention (including same drug) comparisons, including:</p> <ul style="list-style-type: none"> ● Above versus below knee stockings ● Full leg versus below knee IPC devices ● Standard versus extended duration prophylaxis. Extended duration = extended beyond discharge ● Low versus high dose for LMWH licensed in UK only ● Preoperative versus post-operative initiation of LMWH
<p>Outcomes</p>	<p>Critical outcomes:</p> <ul style="list-style-type: none"> ● All-cause mortality (up to 90 days from hospital discharge) (NMA outcome) ● Deep vein thrombosis (symptomatic and asymptomatic) (7-90 days from hospital discharge). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool). (NMA outcome) ● Pulmonary embolism (symptomatic and asymptomatic) (7- 90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE (NMA outcome) ● Major bleeding (up to 45 days from hospital discharge). A major

	<p>bleeding event meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood ; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event (NMA outcome)</p> <ul style="list-style-type: none"> • Fatal PE (up to 90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE <p>Important outcomes:</p> <ul style="list-style-type: none"> • Clinically relevant non-major bleeding (up to 45 days from hospital discharge): bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy • Health-related quality of life (validated scores only)(up to 90 days from hospital discharge) • Heparin-induced thrombocytopenia (HIT) (duration of study) • Technical complications of mechanical interventions (duration of study)
Study design	Randomised controlled trials (RCTs), systematic reviews of RCTs.

36.3 1 Clinical evidence

- 2 Three studies were included in the review^{273,280 149,162}; these are summarised in Table 212 below.
- 3 Evidence from these studies is summarised in the clinical evidence summary below (**Table 213**, Table
- 4 214 and Table 215). See also the study selection flow chart in Appendix E, forest plots in Appendix L,
- 5 study evidence tables in Appendix H, GRADE tables in Appendix K and excluded studies list in
- 6 Appendix N.

7 **Table 212: Summary of studies included in the review**

Study	Intervention and comparison	Population	Outcomes
Imberti 2014 ¹⁴⁹	<p><u>Intervention (n=119):</u> LMWH, paraparin, 6400IU once daily (very high dose), subcutaneously administered from 12 hours pre-operatively for 9±2 days. IPCD and AES were worn by 62.2%</p> <p><u>Comparison (n=131):</u> LMWH, paraparin, 4250IU once daily (very high dose), subcutaneously administered from 12 hours pre-operatively for 9±2 days. IPCD and</p>	<p>n=250</p> <p>People undergoing open and laparoscopic primary or revisional bariatric surgery (laparoscopic gastric bypass 68%, laparoscopic sleeve gastrectomy 8.8%, laparoscopic gastric banding 8.4%, biliopancreatic diversion 9.6%, vertical gastropasty 0.4%)</p> <p>BMI (mean ± SD): 44.4 Age (mean): 40.9 years Gender (male to female ratio): 1:4</p> <p>Italy</p>	<p>All-cause mortality (90 days)</p> <p>DVT (symptomatic and asymptomatic) (11 days): confirmed by colour Doppler ultrasound</p> <p>PE (11 days): confirmed by perfusion lung scan matched with chest X-ray, ventilation/perfusion scan, computed tomography, angiography</p> <p>Heparin-induced thrombocytopenia (11 days)</p>

Study	Intervention and comparison	Population	Outcomes
	<p>AES were worn by 58%</p> <p><u>Concomitant treatment:</u> Early mobilisation was encouraged and accomplished with 96.4% of patients</p>		
Kalfarentzos 2001 ¹⁶²	<p><u>Intervention (n=30):</u> LMWH, nadroparin, 9500IU, once daily (very high dose) subcutaneously given from pre-operatively (time-point not reported) until discharge (mean 10.2 days).</p> <p><u>Comparison (n=30):</u> LMWH, nadroparin, 5700IU, once daily (high dose) subcutaneously given from pre-operatively (time-point not reported) until discharge (mean 9.4 days).</p>	<p>n=60</p> <p>People scheduled to undergo Roux-en-Y gastric bypass surgery</p> <p>BMI (mean ± SD): 48.7 Age (mean): 35 years Gender (male to female ratio): 1:4</p> <p>Greece</p>	<p>DVT (symptomatic and asymptomatic) (90 days): confirmed by</p> <p>Major bleeding (time-point unclear): defined as</p>
Steele 2015 ²⁸⁰ EFFORT trial	<p><u>Intervention 1 (n=98):</u> LMWH, standard dose pre-op and high dose post-op (enoxaparin 40mg 1x pre-op and 40mg x2 daily post-op). Given until discharge</p> <p><u>Intervention 2 (n=100):</u> Fondaparinux. 5mg once daily post-op. Given until discharge</p> <p><u>Concomitant care:</u> Sequential compression devices and antiembolic stockings 4-6 hours post-op, early mobilisation</p>	<p>n=198</p> <p>People having bariatric surgery (laproscopic vertical sleeve gastrectomy 37.9%; laproscopic Roux-en Y gastric bypass 62.1%)</p> <p>BMI (mean ± SD): 45.4±5.4 Age (mean): 41.1 years Gender (male to female ratio): 1:5</p> <p>USA</p>	<p>DVT (symptomatic and asymptomatic) (14 days): confirmed by magnetic resonance venography</p> <p>Thrombocytopenia (14 days)</p>

1 Table 213: Clinical evidence summary: LMWH (standard dose pre-op, high dose post-op; standard duration) versus fondaparinux

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with fondaparinux	Risk difference with LMWH (standard pre-op, high post-op) (95% CI)
DVT (symptomatic and asymptomatic)	177 (1 study) 14 days	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 1.13 (0.16 to 7.86)	21 per 1000	3 more per 1000 (from 18 fewer to 146 more)
Heparin-induced thrombocytopenia	177 (1 study) 14 days	VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 0.15 (0 to 7.73)	11 per 1000	9 fewer per 1000 (from 11 fewer to 66 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs

2 Table 214: Clinical evidence summary: LMWH (very high dose; standard duration) versus LMWH (high dose; standard duration)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with LMWH (high dose)	Risk difference with LMWH (very high dose) (95% CI)
DVT (symptomatic and asymptomatic)	60 (1 study) 90 days	VERY LOW ^{2,3,5} due to risk of bias, indirectness imprecision	Not estimable ¹	Not estimable ¹	0 fewer per 1000 (from 60 fewer to 60 more) ¹
Major bleeding	60 (1 study) time-point unclear	VERY LOW ^{2,3,5} due to risk of bias, indirectness, imprecision	OR 7.65 (0.47 to 125.22)	0 per 1000	-. ⁴

1 Zero events in both arms. Risk difference calculated in Review Manager.
2 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with LMWH (high dose)	Risk difference with LMWH (very high dose) (95% CI)
3 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.					
4 Absolute effects could not be calculated due to zero events in one of the arms					
5 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol					

1 **Table 215: Clinical evidence summary: LMWH (very high dose; standard duration) + IPCD + AES versus LMWH (high dose; standard duration) + IPCD + AES**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with LMWH (high dose) + IPCD + AES	Risk difference with LMWH (very high dose) + IPCD + AES (95% CI)
All-cause mortality	250 (1 study) 90 days	VERY LOW ^{2,3} due to indirectness, imprecision	Not estimable ¹	Not estimable ¹	0 fewer per 1000 (from 20 fewer to 20 more) ¹
DVT (symptomatic and asymptomatic)	250 (1 study) 11 days	VERY LOW ^{2,3} due to indirectness, imprecision	OR 1.1 (0.07 to 17.76)	8 per 1000	1 more per 1000 (from 7 fewer to 113 more)
PE	250 (1 study) 11 days	VERY LOW ^{2,3} due to indirectness, imprecision	OR 0.15 (0 to 7.51)	8 per 1000	6 fewer per 1000 (from 8 fewer to 47 more)
Heparin-induced thrombocytopenia	250 (1 study) 11 days	VERY LOW ^{2,3} due to indirectness, imprecision	OR 1.1 (0.07 to 17.76)	8 per 1000	1 more per 1000 (from 7 fewer to 113 more)
1 Zero events in both arms. Risk difference calculated in Review Manager					
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.					
3 Downgraded by 1 increment if the outcome definition reported did not meet definition of outcome in protocol					

36.4¹ Economic evidence

2 Published literature

3 One health economic study was identified with the relevant comparison and has been included in
4 this review.³⁰⁵ This is summarised in the health economic evidence profile below (Table 216) and the
5 health economic evidence table in Appendix J.

6 See also the health economic study selection flow chart in Appendix F.

7

1 **Table 216: Health economic evidence profile: LMWH (standard dose, standard duration) + AES (knee-length) vs LMWH (standard dose, standard duration) + AEs (thigh-length) vs LMWH (standard dose, standard duration)**
2

Study	Applicability	Limitations	Other comments	Incremental cost	Incremental effects	Cost-effectiveness	Uncertainty
Wade 2015 ³⁰⁵ ([UK])	Partially applicable ^(a)	Potentially serious limitations ^(b)	<p>- Study type: CUA using decision modelling</p> <p>- Population: Patients undergoing any general surgery (subgroups considered were high risk patients, medium risk patients and low risk patients).</p> <p>- Interventions:</p> <p>Intervention 1: LMWH (for duration of 7 days (standard duration).</p> <p>Intervention 2: Knee-length AES in addition to LMWH for a duration of 7 days (standard duration).</p> <p>Intervention 3: Thigh-length AES in addition to pharmacological prophylaxis (LMWH) for duration of 7 days (standard duration).</p>	<p>High risk patients:</p> <p>1 (vs 3) : £176</p> <p>2 (vs 3): £177</p> <p>3: comparator</p>	<p>High risk patients:</p> <p>1 (vs 3): 0.009 QALYs lost</p> <p>2 (vs 3) : 0.007 QALYs lost</p> <p>3: comparator</p>	<p>High risk patients:</p> <p>LMWH + thigh-length AES (intervention 3) dominant (less costly and more effective)</p>	The results of all scenario and sensitivity analyses were largely consistent with the base case analysis for all subgroups

3 Abbreviations: AES: anti-embolism stockings; CUA: cost utility analysis; ICER: incremental cost-effectiveness ratio; LMWH: low molecular weight heparin; QALY: quality-adjusted life years;

4 RCT: randomised controlled trial

5 (a) Mixed population of all surgery types, however subgroup analysis is also presented.

6 (b) The model did not include some relevant health outcomes; e.g. clinically-relevant non-major bleeding , minor bleeding and surgical site infection.

7

36.5.1 Evidence statements

2 Clinical

3 LMWH started pre-operatively at standard dose followed by LMWH at a high dose from post-
4 operatively for standard duration was compared with fondaparinux. The outcomes DVT
5 (symptomatic and asymptomatic) and heparin-induced thrombocytopenia were reported in one
6 study. There was possible clinical benefit of LMWH in terms of heparin-induced thrombocytopenia
7 and no clinical difference in terms of DVT (symptomatic and asymptomatic). There was very serious
8 imprecision around both of these results. The quality of the evidence was very low due to risk of bias
9 and imprecision.

10 LMWH at a very high dose for a standard duration was compared with LMWH at a high dose for a
11 standard duration. The outcomes DVT (symptomatic and asymptomatic) and major bleeding were
12 reported in one study. There was possible clinical harm of LMWH at a very high dose in terms of
13 major bleeding and no clinical difference in terms of DVT (symptomatic and asymptomatic). However
14 there was considerable uncertainty around both of these results. The quality of the evidence was
15 very low due to risk of bias, indirectness and imprecision. The outcomes were downgraded for
16 indirectness as the interventions dose exceeded the maximum dose as highlighted in the evidence
17 review protocol.

18 LMWH at a very high dose for a standard duration in combination with IPCD and AES was compared
19 with LMWH at a high dose for a standard duration in combination with IPCD and AES. The outcomes
20 all-cause mortality, DVT (symptomatic and asymptomatic), PE and heparin-induced
21 thrombocytopenia were reported in one study. There was possible clinical benefit of LMWH at a very
22 high dose in combination with IPCD and AES in terms of PE but no clinical difference for the other
23 outcomes reported in this study. There was considerable uncertainty around these results. The
24 quality of evidence was very low due to indirectness and imprecision. The outcomes were
25 downgraded for indirectness as the interventions dose exceeded the maximum dose as highlighted in
26 the evidence review protocol.

27 Economic

- 28 • One cost-utility analysis found that for VTE prophylaxis in high risk general surgery patients,
29 LMWH (standard dose, standard duration) + thigh-length AES was dominant (less costly and more
30 effective) compared to LMWH (standard dose, standard duration) alone. This analysis was
31 assessed as partially applicable with potentially serious limitations

36.6.2 Recommendations and link to evidence

Recommendations	
	<p>113. Offer VTE prophylaxis to people undergoing bariatric surgery. [2018]</p>
	<p>114. Start mechanical VTE prophylaxis on admission. Choose either:</p> <ul style="list-style-type: none"> • anti-embolism stockings or • intermittent pneumatic compression. <p>Continue until the person no longer has significantly reduced mobility relative to their normal or anticipated mobility. [2018]</p>
	<p>115. Add pharmacological VTE prophylaxis for people</p>

	<p>undergoing bariatric surgery for a minimum of 7 days for people whose risk of VTE outweighs their risk of bleeding. Choose either:</p> <ul style="list-style-type: none"> • LMWH or • fondaparinux sodium. [2018]
Research recommendation	None
Relative values of different outcomes	<p>The guideline committee considered all-cause mortality (up to 90 days from hospital discharge), deep vein thrombosis (symptomatic and asymptomatic) (up to 90 days from hospital discharge), pulmonary embolism (symptomatic and asymptomatic) (up to 90 days from hospital discharge), fatal PE (up to 90 days from hospital discharge), and major bleeding (up to 45 days from hospital discharge) as critical outcomes.</p> <p>The guideline committee considered clinically relevant non-major bleeding (up to 45 days from hospital discharge), health-related quality of life (up to 90 days from hospital discharge), heparin-induced thrombocytopenia (duration of study), and technical complications of mechanical interventions (duration of study) as important outcomes.</p> <p>Please see section 4.3.3 in the methods chapter for further detail explaining prioritisation of the critical outcomes.</p>
Quality of the clinical evidence	<p>Three studies were included in this evidence review. One of the studies included compared a standard dose of LMWH administered pre-operatively followed by a high dose post-operatively for a standard duration compared with fondaparinux. This study reported data for DVT (symptomatic and asymptomatic) and heparin-induced thrombocytopenia. For both the DVT outcome and the thrombocytopenia outcome the evidence was downgraded for risk of bias and imprecision.</p> <p>Another study compared a very high dose of LMWH for a standard duration versus LMWH at a high dose for a standard duration. The outcomes DVT (symptomatic and asymptomatic) and major bleeding were reported. The quality of the evidence was very low due to risk of bias, indirectness and imprecision.</p> <p>Another study reported similar interventions, evaluating LMWH at a very high dose versus LMWH at a high dose for a standard duration, however in combination with mechanical prophylaxis (IPCD and AES) in both arms of the trial. The outcomes all-cause mortality, DVT (symptomatic and asymptomatic), PE and heparin-induced thrombocytopenia were reported. The quality of the evidence was very low due to imprecision and indirectness.</p> <p>As the very high doses reported in two of the studies exceeded the maximum limit identified in the evidence review protocol the outcome data was downgraded for indirectness. The guideline committee agreed that this was appropriate (rather than excluding the papers) because due to the nature of the population evaluations using higher doses may be expected in studies. The committee pointed out that obese people may require higher doses of anticoagulants to achieve the same effect although there is no clear evidence for this (please refer to Chapter 11 for further discussion).</p>
Trade-off between clinical benefits and harms	<p>The guideline committee discussed the evidence presented and noted the poor quality of direct evidence and lack of clinically important effects for this population. The guideline committee agreed that bariatric surgery is a subset of abdominal surgery and therefore the abdominal surgery recommendations would apply in the absence of evidence to the contrary. The committee also noted that all people undergoing bariatric surgery would be considered at increased risk of VTE using the risk assessment tool because they are all obese.</p> <p>The committee discussed the choices of mechanical prophylaxis and believed that as there was no evidence of superiority of one over the other, it was best to offer</p>

	<p>clinicians the choice of IPC or anti-embolism stockings. The committee noted that stockings may be difficult to fit for some people who have had bariatric surgery due to the size and shape of the leg. It was also noted by the committee that as there is a higher incidence of diabetes in this population, a number of people may be contraindicated to stockings due to diabetic neuropathy. The committee believed that clinicians should be given the freedom to decide which would be the most appropriate form of mechanical prophylaxis for their individual patient.</p>
<p>Trade-off between net clinical effects and costs</p>	<p>No economic studies were identified to specifically cover bariatric surgery patients; however, one economic study that has been included in the major abdominal surgery review covered the general surgical population stratified according to the risk of VTE. The committee considered that this evidence can be applicable to the bariatric surgery population; specifically the “high risk” subgroup. The study is a cost-utility analysis for standard duration prophylaxis. It was assessed as partially applicable with potentially serious limitations.</p> <p>This analysis has shown that combined prophylaxis using LMWH + AES (thigh length) was dominant (more effective and less costly) compared to single prophylaxis with LMWH (standard dose, standard duration) only and combined prophylaxis of LMWH (standard dose, standard duration)+ AES (knee-length). The committee discussed whether the evidence was enough to recommended either knee or thigh length AES. The economic evidence supported the cost effectiveness of combined prophylaxis that includes thigh-length AES, however, the committee noted that thigh-length AES are less convenient for people to wear and are more difficult to fit; especially in the bariatric surgery population. Hence; the committee felt that the choice of the length of stocking should be made taking into account the preference of the individual and his/her ability to adhere to wearing them. As stockings may not generally be acceptable or feasible to use for many individuals undertaking bariatric surgery; due to the size or shape of the leg; IPCD was also recommended as an alternative option that requires less nursing time in terms of fitting and monitoring.</p> <p>The committee also felt that both LMWH and fondaparinux should be recommended as pharmacological options to address issues of contra-indications and individual preferences.</p>
<p>Other considerations</p>	<p>The guideline committee noted that the majority of bariatric operations are completed laparoscopically. Less invasive procedures such as laparoscopic procedures are in general associated with a lower risk of VTE than open surgery. However bariatric surgery may also result in venous compression and stasis due to the pneumoperitoneum and be prolonged.</p> <p>The studies identified for this population evaluated different doses of LMWH and presented the necessity to explore the issue of dose-adjustment for LMWH in obese people. The BAFLUX study¹⁵⁰ was not included in this evidence review as it did not reported any relevant outcomes as per protocol. However, this study evaluated the pharmacodynamics associated with using very high dose LMWH compared with a standard dose measuring anti-Xa activity. The study found that a standard dose in morbidly obese patients could be adequate prophylaxis based on this surrogate outcome. However there is no definitive evidence that anti-Xa levels are directly related to DVT/PE outcome.¹⁶ The guideline committee made a recommendation about dose-adjustment taking into account the lack of evidence (see section 11.6 obesity LETR re: dose-adjustment for LMWH).</p>

37 Cardiac surgery

37.1.2 Introduction

- 3 This section covers patients undergoing cardiac surgery.
- 4 Factors that may alter the risk of VTE in cardiac surgery include:
- 5 • Pacing wires and implantable cardioverter-defibrillator devices may lead to an increase in upper
6 limb deep vein thrombosis
- 7 Factors that increase the risk of bleeding or hazard associated with it:
- 8 • Many patients will be receiving antiplatelet medication, heparin or warfarin and will therefore have
9 an increased risk of bleeding.
- 10 Other special factors that would affect the choice of, and use of, specific methods of prophylaxis:
- 11 • Several procedures in cardiac surgery involve the use of anticoagulation or antiplatelet therapy:
- 12 - Full heparin anticoagulation is used during cardiopulmonary bypass which is typically one to
13 two hours of a two to five hour surgery.
- 14 - Surgeries performed "off pump" (surgeries performed without the use of heart lung
15 machines) are also covered by heparin anticoagulation.
- 16 - Most patients with coronary artery disease are given antiplatelet therapy up to shortly prior
17 to surgery and it is recommenced soon after.
- 18 - Many patients with valve disease have warfarin anticoagulation.
- 19 - Patients in atrial fibrillation will generally have warfarin or other anticoagulants.
- 20 • Many cardiac surgery patients have leg veins removed for use as grafts. This would preclude the
21 use of both AES and IPCD during the surgery but they could be used afterwards.

37.2.2 Review question: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing cardiac surgery?

25 For full details see the review protocol in Appendix C.

26 **Table 217: PICO characteristics of review question**

Population	Adults and young people (16 years and older) undergoing cardiac surgery who are: <ul style="list-style-type: none"> • Admitted to hospital • Discharged from hospital • Outpatients
Interventions	Mechanical: <ul style="list-style-type: none"> • Anti-embolism stockings (AES) (above or below knee) • Intermittent pneumatic compression (IPCD) devices (full leg or below knee) • Foot pumps or foot impulse devices (FID) • Electrical stimulation (including Geko devices)

	<ul style="list-style-type: none"> • Continuous passive motion <p>Pharmacological:</p> <ul style="list-style-type: none"> • Unfractionated heparin (UFH) (low dose, administered subcutaneously) • Low molecular weight heparin (LMWH), licensed in UK: <ul style="list-style-type: none"> ○ enoxaparin (standard prophylactic dose 40 mg daily; minimum 20 mg daily* to maximum 60mg twice daily*) ○ dalteparin (standard prophylactic dose 5000 units once daily; minimum 1250 units once daily* to maximum 5000 units twice daily*; obese patients – maximum 7500 twice units daily*) ○ tinzaparin (standard prophylactic dose 4500 units once daily; minimum 2500 units once daily* to maximum 4500 units twice daily*; obese patients – maximum 6750 twice daily*) • LMWH, licensed in countries other than UK: <ul style="list-style-type: none"> ○ bemiparin (standard 2500 units daily; minimum 2500 units daily to maximum 3500 units daily) ○ certoparin (3000 units daily) ○ nadroparin (standard 2850 units once daily; minimum 2850 units once daily to maximum up to 57 units/kg once daily) ○ parnaparin (standard 3200 units once daily; minimum 3200 units once daily to maximum 4250 units once daily) ○ reviparin (minimum 1750 units once daily to maximum 4200 units once daily) • Vitamin K Antagonists: <ul style="list-style-type: none"> ○ warfarin (variable dose only) ○ acenocoumarol (all doses) ○ phenindione (all doses) • Fondaparinux (all doses)* • Apixaban (all doses)* • Dabigatran (all doses)* • Rivaroxaban (all doses)* • Aspirin (up to 300 mg)* <p>*off-label</p>
<p>Comparisons</p>	<p>Compared to:</p> <ul style="list-style-type: none"> • Other VTE prophylaxis treatment, including monotherapy and combination treatments (between class comparisons for pharmacological treatments only) • No VTE prophylaxis treatment (no treatment, usual care, placebo) <p>Within intervention (including same drug) comparisons, including:</p> <ul style="list-style-type: none"> • Above versus below knee stockings • Full leg versus below knee IPC devices • Standard versus extended duration prophylaxis • Low versus high dose for LMWH • Preoperative versus post-operative initiation of LMWH
<p>Outcomes</p>	<p>Critical outcomes:</p> <ul style="list-style-type: none"> • All-cause mortality (up to 90 days from hospital discharge) • Deep vein thrombosis (symptomatic and asymptomatic) (up to 90 days from hospital discharge). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) • Pulmonary embolism (symptomatic and asymptomatic) (up to 90 days from hospital discharge) (NMA outcome). Confirmed by: CT scan with spiral or contrast; pulmonary

	<p>angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE</p> <ul style="list-style-type: none"> • Major bleeding (up to 45 days from hospital discharge). A major bleeding event meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood ; leads to a drop in haemoglobin of ≥ 2 g/dl; a serious or life threatening clinical event. Includes unplanned visit to theatre for control of bleeding • Fatal PE (up to 90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE <p>Important outcomes:</p> <ul style="list-style-type: none"> • Clinically relevant non-major bleeding (up to 45 days from hospital discharge): bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy. • Health-related quality of life (validated scores only)(up to 90 days from hospital discharge) • Heparin-induced thrombocytopenia (HIT) (duration of study) • Technical complications of mechanical interventions (duration of study) • Major adverse cardiac events (MACE) (duration of study): death, Q-wave myocardial infarction (MI) and the need for repeat revascularization by redo-CABG or repeat percutaneous intervention
Study design	Randomised controlled trials (RCTs), systematic reviews of RCTs

37.3.1 Clinical evidence

2 A search was conducted for randomised trials comparing the effectiveness of mechanical and
3 pharmacological prophylaxis strategies (alone or in combination) in people undergoing cardiac
4 surgery. Two new studies were identified (Kolluri 2016¹⁷¹; Myles 2016²²²). Of the three studies
5 included in the previous guideline (CG92), one study was included^{116,249}, and two studies were
6 excluded (Beghi 1993¹⁸; Ramos 1996²⁴⁹). The included study is summarised in Table 218 below. See
7 also the study selection flow chart in Appendix E, forest plots in Appendix L, study evidence tables in
8 Appendix H, GRADE tables in Appendix K and excluded studies list in Appendix N.

9 Summary of included studies

10 **Table 218: Summary of studies included in the review**

Study	Intervention and comparison	Population	Outcomes	Comments
Goldhaber 1995 ¹¹⁶	<p><u>Intervention (n = 172)</u> Thigh-length IPCD + AES (unknown length) + aspirin 325 mg/day. Started post-operatively</p> <p><u>Comparison (n=172)</u> AES (unknown length) + aspirin 325 mg/day. Started post-operatively</p>	<p>n=344</p> <p>People having coronary artery bypass</p> <p>Adults (mean age 63.2±9.7 years)</p> <p>Male to female ratio 229:112</p> <p>USA</p>	<p>All-cause mortality (until discharge)</p> <p>DVT (≥ 4 days post-op until discharge): confirmed by bilateral Doppler ultrasound</p> <p>PE (until discharge): confirmed by high probability V/Q scan</p> <p>Fatal PE: confirmed by:</p>	<p>First 98 patients enrolled had delayed initiation of prophylaxis with IPCD</p> <p>Significantly greater proportion of people in the comparison group had cancer</p>

Study	Intervention and comparison	Population	Outcomes	Comments
			assumed clinical evaluation (pulmonary embolectomy procedure)	(numbers not reported in CG92)
Kolluri 2016 ¹⁷¹	<p><u>Intervention (n = 41)</u> Fondapainux (2.5mg subcutaneously, once daily) starting at a mean of 12 hours after wound closure or in the morning of the first postoperative day. Administered for 9 days or until discharge.</p> <p><u>Comparison (n=37)</u> No VTE prophylaxis (subcutaneous injections of saline)</p> <p>Both groups routinely received AES and/or IPCD</p>	<p>n=78</p> <p>People having coronary artery bypass graft surgery</p> <p>Adults (mean age: intervention 64.4±8.9; comparison 62±8.9)</p> <p>Male to female ratio 57:21</p> <p>USA</p>	<p>DVT (9-11 days): confirmed by duplex ultrasound</p>	
Myles 2016 ²²²	<p><u>Intervention (n=1059):</u> Aspirin (100mg) starting 1-2 hours before surgery, with or without anxiolytic premedication</p> <p><u>Comparison (n=1068):</u> No VTE prophylaxis (matched placebo tablets 1 to 2 hours before surgery, with or without anxiolytic premedication)</p>	<p>n=2127</p> <p>People having coronary artery surgery who are at increased risk for complications</p> <p>Adults (mean age: intervention 66.5±9.7; comparison 66.2±10.2)</p> <p>Male to female ratio 1730:370</p> <p>Australia</p>	<p>All-cause mortality (30 days)</p> <p>PE (30 days): method of confirmation not reported</p> <p>Major bleeding (30 days): defined as any excessive bleeding leading to surgical reexploration</p>	<p>There was no limitation to the use or postoperative aspirin or other antiplatelet therapy, and such therapy was administered in accordance with local practices</p>

1 **Table 219: Clinical evidence summary: IPC + AES + aspirin compared to AES + aspirin**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with AES + aspirin	Risk difference with IPCD + AES + aspirin (95% CI)
All-cause mortality	330 (1 study) until discharge	VERY LOW ^{2,3} due to risk of bias, imprecision	Peto OR 7.53 (0.47 to 120.83)	0 per 1000	Not estimable ¹
DVT	330 (1 study) ≥4 days post-op until discharge	VERY LOW ^{2,3} due to risk of bias, imprecision	RR 0.87 (0.57 to 1.34)	217 per 1000	28 fewer per 1000 (from 93 fewer to 74 more)
PE	330 (1 study) until discharge	VERY LOW ^{2,3} due to risk of bias, imprecision	RR 1.01 (0.06 to 16.05)	6 per 1000	0 more per 1000 (from 6 fewer to 91 more)
PE, fatal	329 (1 study) until discharge	VERY LOW ^{2,3} due to risk of bias, imprecision	Peto OR 1.01 (0.06 to 16.15)	6 per 1000	0 more per 1000 (from 6 fewer to 84 more)

1 Zero events in control arm
2 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
3 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs

2

3 **Table 220: Clinical evidence summary: Aspirin versus no prophylaxis**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with Aspirin versus no prophylaxis (95% CI)
All-cause mortality	2100 (1 study)	LOW ¹ due to	RR 1.56 (0.68 to 3.6)	9 per 1000	5 more per 1000 (from 3 fewer to 22 more)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with Aspirin versus no prophylaxis (95% CI)
	30 days	imprecision			
PE	2100 (1 study) 30 days	LOW ¹ due to imprecision	RR 0.8 (0.32 to 2.03)	9 per 1000	2 fewer per 1000 (from 7 fewer to 10 more)
Major bleeding	2100 (1 study) 30 days	LOW ¹ due to imprecision	RR 0.87 (0.47 to 1.6)	21 per 1000	3 fewer per 1000 (from 11 fewer to 13 more)

1 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs

1
2 **Table 221: Clinical evidence summary: Fondaparinux + AES and/or IPCD versus AES and/or IPCD for VTE prophylaxis in people undergoing cardiac surgery**
3

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with Fonda + AES/IPCD versus AES/IPCD (95% CI)
DVT	67 (1 study) 9-11 days	LOW ¹ due to imprecision	Peto OR 0.12 (0 to 6.23)	31 per 1000	27 fewer per 1000 (from 31 fewer to 136 more)

1 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs

4

37.4₁ Economic evidence

2 Published literature

3 No relevant health economic studies were identified.

4 See also the health economic study selection flow chart in Appendix F.

37.5₅ Evidence statements

6 Clinical

7 In one study of very low quality, a possible clinical benefit of IPCD + AES + aspirin was found for the
8 outcome all-cause mortality, however there was very serious imprecision around the estimate, and
9 therefore was also associated with no difference and clinical harm (n=330). For the DVT outcome,
10 evidence from the same study showed a possible clinical harm of IPCD + AES + aspirin, however again
11 there was very serious imprecision around the estimate. There was no clinical difference between
12 the two interventions in terms of PE or fatal PE. The evidence for these outcomes also showed very
13 serious imprecision and was associated with both clinical benefit and clinical harm.

14 One study compared aspirin to no VTE prophylaxis. There was a possible clinical harm of aspirin
15 compared to no prophylaxis in terms of all-cause mortality, and no clinical difference between the
16 two interventions for the PE and major bleeding outcomes (low quality; n=2100). For all outcomes
17 there was very serious imprecision around the estimate.

18 One small study of 67 participants compared a combination of fondaparinux and mechanical
19 prophylaxis with mechanical prophylaxis alone. The evidence demonstrated a possible clinical benefit
20 for combined fondaparinux and mechanical prophylaxis in terms of DVT, however there was very
21 serious imprecision around the estimate and therefore was also associated with no difference or
22 clinical harm. No other outcomes were reported.

23 Economic

24 • No relevant economic evaluations were identified.

37.6₅ Recommendations and link to evidence

Recommendations	<p>116. Consider mechanical VTE prophylaxis on admission to people who are undergoing cardiac surgery who are at increased risk of VTE. Choose either:</p> <ul style="list-style-type: none">• anti-embolism stockings or• intermittent pneumatic compression. <p>Continue until the person no longer has significantly reduced mobility relative to their normal or anticipated mobility. [2018]</p> <p>117. Consider adding pharmacological VTE prophylaxis for a minimum of 7 days for people who are undergoing cardiac surgery</p>
------------------------	---

	<p>and are not having other anticoagulation therapy.</p> <ul style="list-style-type: none"> • Use LMWH^t as first-line treatment • If LMWH^u is contraindicated use fondaparinux sodium^v [2018]
Research recommendation	None
Relative values of different outcomes	<p>The guideline committee considered all-cause mortality (up to 90 days from hospital discharge), deep vein thrombosis (symptomatic and asymptomatic) (up to 90 days from hospital discharge), pulmonary embolism (symptomatic and asymptomatic) (up to 90 days from hospital discharge), fatal PE (up to 90 days from hospital discharge), and major bleeding (up to 45 days from hospital discharge) as critical outcomes.</p> <p>The guideline committee considered clinically relevant non-major bleeding (up to 45 days from hospital discharge), health-related quality of life (up to 90 days from hospital discharge), heparin-induced thrombocytopenia (duration of study), and technical complications of mechanical interventions (duration of study) as important outcomes.</p> <p>Please see section 4.3.3 in the methods chapter for further detail explaining prioritisation of the critical outcomes.</p>
Quality of the clinical evidence	<p>One study was identified which compared IPC+AES+ aspirin compared to AES+ aspirin. All of the evidence was of very low quality due to serious risk of bias and very serious imprecision.</p> <p>One study compared aspirin to no VTE prophylaxis. All evidence was of low quality due to very serious imprecision.</p> <p>One study compared fondaparinux + AES and/or IPCD versus AES and/or IPCD alone. This evidence was also of low quality due to very serious imprecision.</p>
Trade-off between clinical benefits and harms	<p>The key risks in this patient group are risk of bleeding as they are likely to already be receiving antiplatelet medication. Additionally this patient group has a high average age, and are likely to have undergone a long operation and a period of immobilisation.</p> <p>Cardiac surgery patients receive a large dose of heparin/anticoagulant during the surgery at the time of clamping, so any pharmacological VTE prophylaxis would not be initiated until after surgery.</p> <p>The committee noted the relatively small amount of evidence in this particular population. The committee pre-specified that if this was the case they would consider the evidence for the abdominal surgery population as indirect evidence. Both cardiac and abdominal surgery involves operations potentially lasting several hours and significant potential for post-operative immobility partly due to the presence of a large incision. The committee discussed the current evidence, considered the previous CG92 recommendations for the cardiac surgery population, as well as the recommendations for the abdominal surgery population. The committee believed that similar pharmacological VTE prophylaxis recommendations</p>

^t At the time of consultation (October 2017), LMWH did not have a UK marketing authorisation for use in young people under 18 for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information.

^u At the time of consultation (October 2017), LMWH did not have a UK marketing authorisation for use in young people under 18 for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information.

^v At the time of consultation (October 2017), fondaparinux sodium did not have a UK marketing authorisation for use in young people under 18 for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information.

	<p>could be made for this population as with abdominal surgery patients (LMWH and fondaparinux). The committee believed that the small amount of evidence for fondaparinux identified in the cardiac population suggested a benefit for reducing DVT and that this was a reasonable addition to the recommended options from CG92. However the use of fondaparinux sodium in the cardiac surgery population is off-label as fondaparinux sodium did not have a UK marketing authorisation for this indication at the time of consultation (October 2017). Therefore the committee recommend LMWH in the first instance and fondaparinux sodium only if LMWH is contraindicated.</p>
Trade-off between net clinical effects and costs	<p>No economic studies were identified for this review. Unit costs were presented.</p> <p>The committee highlighted that the VTE risk in people undergoing cardiac surgery is high. They discussed that current practice follows the recommendation of CG92, where combined prophylaxis (pharmacological and mechanical) was considered to be cost effective for this population. The clinical evidence presented limited their ability to draw a conclusion specific for this population and that extrapolation from the abdominal surgery population for which combined prophylaxis was recommended would be acceptable. Given the high baseline risk of VTE in this population; it was felt that the additional cost of combined prophylaxis would be offset by the savings from the averted VTE events. The choice of the mechanical and pharmacological prophylaxis options was considered. It was felt that the options given for the abdominal surgery population should be recommended for the cardiac surgery population to allow for tailoring prophylaxis prescribing; accommodating licence restrictions, the presence of contra-indications and patient preferences.</p>
Other considerations	<p>The committee noted that current practice is to use AES as opposed to graduated compression stockings. In terms of pharmacological prophylaxis, current practice is to give a large dose of heparin pre-operatively which is then reversed post-operatively and a lower dose is then offered. Therefore there is different risk of VTE in these two distinct stages.</p>

1

38 Thoracic surgery

38.1.2 Introduction

- 3 Thoracic surgery involves the repair of organs located in the thorax, or chest. Factors that may alter
4 the risk of VTE in people undergoing thoracic surgery include:
- 5 • After lung resection, pulmonary embolism to the remaining lung carries a commensurately higher
6 risk of death.
- 7 • Most patients having video-assisted thorascopic surgery (VATS), particularly for pneumothorax,
8 are young (less than 30 years) and are able to walk around the ward up to the time of surgery and
9 soon after and have short lengths of stay.
- 10 There are no special factors that increase the risk of bleeding or the hazard associated with it in
11 thoracic surgery. There are no other special factors that would affect the choice of, and use of,
12 specific methods of VTE prophylaxis in thoracic surgery.

38.2.3 Review question: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing thoracic surgery?

16 For full details see review protocol in Appendix C.

17 **Table 222: PICO characteristics of review question**

Population	Adults and young people (16 years and older) undergoing thoracic surgery who are admitted to hospital, and outpatients post-discharge
Intervention(s)	<p>Mechanical:</p> <ul style="list-style-type: none"> • Anti-embolism stockings (AES (above or below knee) • Intermittent pneumatic compression (IPCD) devices (full leg or below knee) • Foot pumps or foot impulse devices (FID) • Electrical stimulation (including Geko devices) • Continuous passive motion <p>Pharmacological (no minimum duration):</p> <ul style="list-style-type: none"> • Unfractionated heparin (UFH) (low dose, administered subcutaneously) • Low molecular weight heparin (LMWH), licensed in UK: <ul style="list-style-type: none"> o enoxaparin (standard prophylactic dose 40mg daily; minimum 20mg daily* to maximum 60mg twice daily*) o dalteparin (standard prophylactic dose 5000 units once daily; minimum 1250 units once daily* to maximum 5000 units twice daily*; obese patients – maximum 7500 twice units daily*) o tinzaparin (standard prophylactic dose 3500 units once daily; minimum 2500 units once daily* to maximum 4500 units twice daily*; obese patients – maximum 6750 twice daily*) • LMWH, licensed in countries other than UK: <ul style="list-style-type: none"> o Bemiparin (standard 2500 units daily; minimum 2500 units daily to maximum 3500 units daily) o Certoparin (3000 units daily) o Nadroparin (standard 2850 units once daily; minimum 2850 units once daily to maximum up to 57 units/kg once daily)

	<ul style="list-style-type: none"> o Parnaparin (standard 3200 units once daily; minimum 3200 units once daily to maximum 4250 units once daily) o Reviparin (minimum 1750 units once daily to maximum 4200 units once daily) • Vitamin K Antagonists: warfarin (variable dose), acenocoumarol (all doses), phenindione (all doses) • Fondaparinux (all doses) • Apixaban (all doses) • Dabigatran (all doses) • Rivaroxaban (all doses) • Aspirin (up to 300mg)* <p>*off-licence</p>
Comparison(s)	<ul style="list-style-type: none"> • Other VTE prophylaxis treatment, including monotherapy and combination treatments (between class comparisons for pharmacological treatments only) • No VTE prophylaxis treatment (no treatment, usual care, placebo)
Outcomes	<p>Critical outcomes:</p> <ul style="list-style-type: none"> • All-cause mortality (up to 90 days from hospital discharge) (NMA outcome) • Deep vein thrombosis (symptomatic and asymptomatic) (7-90 days from hospital discharge). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) (NMA outcome) • Pulmonary embolism (7- 90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE (NMA outcome) • Major bleeding (up to 45 days from hospital discharge). A major bleeding event meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood ; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event (NMA outcome) • Fatal PE (up to 90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE <p>Important outcomes:</p> <ul style="list-style-type: none"> • Clinically relevant non-major bleeding (up to 45 days from hospital discharge): bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy • Health-related quality of life (validated scores only)(up to 90 days from hospital discharge) • Heparin-induced thrombocytopenia (HIT) (duration of study) • Technical complications of mechanical interventions (duration of study)
Study design	Randomised controlled trials (RCTs), systematic reviews of RCTs

38.3.1 Clinical evidence

- 2 No relevant clinical studies comparing different pharmacological and mechanical prophylaxis
- 3 strategies for people undergoing thoracic surgery were identified. Papers included in the previous

- 1 guideline (CG92) in the major surgery review were considered for inclusion in addition to papers
- 2 identified in the update.

38.4³ Economic evidence

4 Published literature

- 5 One health economic study was identified with the relevant comparison and has been included in
- 6 this review.³⁰⁵ This is summarised in the health economic evidence profile below (Table 223) and the
- 7 health economic evidence tables in Appendix J.

- 8 See also the health economic study selection flow chart in Appendix F.

9

1 **Table 223: Health economic evidence profile: LMWH (standard dose, standard duration) + AES (knee-length) vs LMWH (standard dose , standard**
 2 **duration) + AEs (thigh-length) vs LMWH (standard dose, standard duration)**

Study	Applicability	Limitations	Other comments	Incremental cost	Incremental effects	Cost-effectiveness	Uncertainty
Wade 2015 ³⁰⁵ ([UK])	Partially applicable ^(a)	Potentially serious limitations ^(b)	<p>- Study type: CUA using decision modelling</p> <p>- Population: Patients undergoing any general surgery (subgroups considered were high risk patients, medium risk patients and low risk patients).</p> <p>- Interventions:</p> <p>Intervention 1: LMWH (for duration of 7 days (standard duration).</p> <p>Intervention 2: Knee-length AES in addition to LMWH for a duration of 7 days (standard duration).</p> <p>Intervention 3: Thigh-length AES in addition to pharmacological prophylaxis (LMWH) for duration of 7 days (standard duration).</p>	<p>High risk patients:</p> <p>1 (vs 3) : £176</p> <p>2 (vs 3): £177</p> <p>3: comparator</p>	<p>High risk patients:</p> <p>1 (vs 3): 0.009 QALYs lost</p> <p>2 (vs 3) : 0.007 QALYs lost</p> <p>3: comparator</p>	<p>High risk patients:</p> <p>LMWH + thigh-length AES (intervention 3) dominant (less costly and more effective)</p>	The results of all scenario and sensitivity analyses were largely consistent with the base case analysis for all subgroups

3 Abbreviations: AES: anti-embolism stockings; CUA: cost utility analysis; ICER: incremental cost-effectiveness ratio; LMWH: low molecular weight heparin; QALY: quality-adjusted life years;

4 RCT: randomised controlled trial

5 (c) Mixed population of all surgery types, however subgroup analysis is also presented.

6 (d) The model did not include some relevant health outcomes; e.g. clinically-relevant non-major bleeding , minor bleeding and surgical site infection.

7

8

38.5.1 Evidence statements

2 Clinical

3 No relevant clinical studies were identified.

4 Economic

- 5 • One cost-utility analysis found that for VTE prophylaxis in high risk general surgery patients,
6 LMWH (standard dose, standard duration) + thigh-length AES was dominant (less costly and more
7 effective) compared to LMWH (standard dose, standard duration) alone and to LMWH (standard
8 dose, standard duration)+ AES (knee-length). This analysis was assessed as partially applicable
9 with potentially serious limitations.

38.6.0 Recommendations and link to evidence

Recommendations	<p>118. Consider VTE prophylaxis for people undergoing thoracic surgery who are at increased risk of VTE. [2018]</p> <p>119. Start mechanical VTE prophylaxis on admission. Choose either:</p> <ul style="list-style-type: none"> • anti-embolism stockings or • intermittent pneumatic compression. <p>Continue until the person no longer has significantly reduced mobility relative to their normal or anticipated mobility. [2018]</p> <p>120. Consider adding pharmacological VTE prophylaxis for people undergoing thoracic surgery for a minimum of 7 days to people whose risk of VTE outweighs their risk of bleeding:</p> <ul style="list-style-type: none"> • Use LMWH^w as first-line treatment • If LMWH^x is contraindicated use fondaparinux sodium^y. [2018]
Research recommendation	None
Relative values of different outcomes	The guideline committee considered all-cause mortality (up to 90 days from hospital discharge), deep vein thrombosis (symptomatic and asymptomatic) (7-90 days from hospital discharge), pulmonary embolism (7- 90 days from hospital discharge), major bleeding (up to 45 days from hospital discharge) and fatal PE (7- 90 days from

^w At the time of consultation (October 2017), LMWH did not have a UK marketing authorisation for use in young people under 18 for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information.

^x At the time of consultation (October 2017), LMWH did not have a UK marketing authorisation for use in young people under 18 for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information.

^y At the time of consultation (October 2017), fondaparinux sodium did not have a UK marketing authorisation for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information.

	<p>hospital discharge) as critical outcomes.</p> <p>The guideline committee considered health-related quality of life (up to 90 days from hospital discharge), clinically relevant non-major bleeding (up to 45 days from hospital discharge), heparin-induced thrombocytopenia (duration of study) and technical complications of mechanical interventions (duration of study) as important outcomes.</p> <p>Please see section 4.3.3 in the methods chapter for further detail explaining prioritisation of the critical outcomes.</p>
Quality of the clinical evidence	No clinical evidence was identified for this review.
Trade-off between clinical benefits and harms	<p>In the previous guideline this group was considered together with other major abdominal surgery (gastrointestinal, bariatric, gynaecological, urological). For the update the committee wished to explore if there was any evidence specifically for the thoracic surgery population because it was felt to be different clinically to the abdominal surgery population both in terms of the procedures involved and the fact that the chest and not the abdomen or pelvis that was being operated on. In the absence of direct evidence the committee believed it would be reasonable to extrapolate the recommendations from the abdominal surgery population to this population, including the strength of the recommendation as this is a high risk group. However the use of fondaparinux sodium in the thoracic surgery population is off-label as fondaparinux sodium did not have a UK marketing authorisation for this indication at the time of consultation (October 2017). Therefore the committee recommend LMWH in the first instance and fondaparinux sodium only if LMWH is contraindicated.</p> <p>Following lung resection, the risk of PE in the remaining lung is higher. Some patients having certain types of thoracic surgery (for example video-assisted thorascopic surgery) are younger, are mobile up to the time of surgery and soon after.</p>
Trade-off between net clinical effects and costs	<p>No economic studies were identified to specifically cover thoracic surgery patients; however, one economic study that has been included in the major abdominal surgery review covered the general surgical population stratified according to the risk of VTE. The committee considered that this evidence can be applicable to the thoracic surgery population; specifically the “high risk” subgroup. The study is a cost-utility analysis for standard duration prophylaxis. It was assessed as partially applicable with potentially serious limitations.</p> <p>This analysis has shown that combined prophylaxis using LMWH + AES (thigh length) was dominant (more effective and less costly) compared to single prophylaxis with LMWH (standard dose, standard duration) only and combined prophylaxis of LMWH (standard dose, standard duration)+ AES (knee-length). The committee discussed whether the evidence was enough to recommended either knee or thigh length AES. The economic evidence supported the cost effectiveness of combined prophylaxis that includes thigh-length AES, however, the committee noted that thigh-length AES are less convenient for people to wear and are more difficult to fit. Hence; the committee felt that the choice of the length of stocking should be made taking into account the preference of the individual and his/her ability to adhere to wearing them. IPCD was also recommended as an alternative option that requires less nursing time in terms of fitting and monitoring.</p> <p>The committee also felt that both LMWH and fondaparinux should be recommended as pharmacological options to address issues of contra-indications and individual preferences. As fondaparinux use in this population is off-licence; it should only be considered where LMWH is contraindicated.</p>
Other considerations	The ‘consider’ recommendation is a reflection of the lack of evidence in this population. However, it is the committee’s belief that for this group of patients, prophylaxis is likely to be most clinically and cost effective for those assessed to be

at high risk for VTE.

1

39 Vascular surgery

39.1.2 Introduction

3 This section covers patients undergoing vascular surgery. Vascular surgery is a surgical specialty
4 dealing specifically with disorders of the arteries, veins and lymphatics around the body excluding
5 the heart and brain. It also includes dealing with the consequences of such vascular disease such as
6 limb amputation. Procedures range from these which can be long and involve interruption of flow in
7 vessels and reduce patient mobility to those which are more minor and can be done as day cases
8 such as varicose veins surgery. Often high doses of anticoagulation are given as part of the surgical
9 procedure on more major cases.

10 Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and its complication,
11 pulmonary embolism (PE), is a common cause of morbidity and mortality after vascular surgery
12 unless prophylaxis is given. However there are often also high risks of bleeding. There is a need to
13 identify how to best reduce this risk of VTE using mechanical or pharmacological prophylaxis.

14 Factors that may alter the risk of VTE:

- 15 • Arterial surgery patients are often elderly and immobile.
- 16 • Many arterial surgery patients will already be receiving antiplatelet therapy and some will be on
17 warfarin or other anticoagulants.
- 18 • Systemic heparin is frequently administered during surgery for arterial disease.
- 19 • Surgery for varicose veins is mostly in women, oral contraceptive use and hormone replacement
20 therapy are therefore more commonly associated with varicose veins surgery.

21 Factors that increase the risk of bleeding or hazard associated with it:

- 22 • Patients using anticoagulation or antiplatelet therapy not related to surgery will have an increased
23 risk of bleeding.

24 Other factors that may alter the choice of prophylaxis:

- 25 • The use of intermittent compression devices is contraindicated in patients with peripheral arterial
26 disease.
- 27 • The use of intermittent compression devices and anti-embolism / graduated compression
28 stockings will usually be inappropriate on the operated leg for a patient undergoing lower limb
29 arterial surgery.
- 30 • Anti-embolism / graduated compression stockings will be contraindicated for patients with lower
31 limb arterial disease.

39.2.2 Review question: What is the effectiveness of different 33 pharmacological and mechanical prophylaxis strategies (alone or in 34 combination) for people undergoing vascular surgery?

35 **Table 224: PICO characteristics of review question**

Population	Adults and young people (16 years and older) undergoing vascular surgery who are admitted to and discharged from hospital
Interventions	Mechanical: <ul style="list-style-type: none">• Anti-embolism stockings (AES) (above or below knee)• Intermittent pneumatic compression (IPCD) devices (full leg or below knee)• Foot pumps or foot impulse devices (FID)

	<ul style="list-style-type: none"> • Electrical stimulation (including Geko devices) • Continuous passive motion <p>Pharmacological:</p> <ul style="list-style-type: none"> • Unfractionated heparin (UFH) (low dose, administered subcutaneously) • Low molecular weight heparin (LMWH), licensed in UK: <ul style="list-style-type: none"> ○ enoxaparin (standard prophylactic dose 40mg daily; minimum 20mg daily* to maximum 60mg twice daily*) ○ dalteparin (standard prophylactic dose 5000 units once daily; minimum 1250 units once daily* to maximum 5000 units twice daily*; obese patients – maximum 7500 twice units daily*) ○ tinzaparin (standard prophylactic dose 4500 units once daily; minimum 2500 units once daily* to maximum 4500 units twice daily*; obese patients – maximum 6750 twice daily*) • LMWH, licensed in countries other than UK: <ul style="list-style-type: none"> ○ Bemiparin (standard 2500 units daily; minimum 2500 units daily to maximum 3500 units daily) ○ Certoparin (3000 units daily) ○ Nadroparin (standard 2850 units once daily; minimum 2850 units once daily to maximum up to 57 units/kg once daily) ○ Parnaparin (standard 3200 units once daily; minimum 3200 units once daily to maximum 4250 units once daily) ○ Reviparin (minimum 1750 units once daily to maximum 4200 units once daily) • Vitamin K Antagonists: <ul style="list-style-type: none"> ○ warfarin (variable dose only) ○ acenocoumarol (all doses) ○ phenindione (all doses) • Fondaparinux (all doses)* • Apixaban (all doses)* • Dabigatran (all doses)* • Rivaroxaban (all doses)* • Aspirin (up to 300mg)* <p>*off-label</p>
Comparison(s)	<p>Compared to:</p> <ul style="list-style-type: none"> • Other VTE prophylaxis treatment, including monotherapy and combination treatments (between class comparisons for pharmacological treatments only) • No VTE prophylaxis treatment (no treatment, usual care, placebo) <p>Within intervention (including same drug) comparisons, including:</p> <ul style="list-style-type: none"> • Above versus below knee stockings • Full leg versus below knee IPC devices • Standard versus extended duration prophylaxis. • Low versus high dose for LMWH • Preoperative versus post-operative initiation of LMWH
Outcomes	<p>Critical outcomes:</p> <ul style="list-style-type: none"> • All-cause mortality (up to 90 days from hospital discharge) • Deep vein thrombosis (symptomatic and asymptomatic) (up to 90 days from hospital discharge). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) • Pulmonary embolism (symptomatic and asymptomatic) (up to 90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy;

	<p>echocardiography; clinical diagnosis with the presence of proven VTE</p> <ul style="list-style-type: none"> Major bleeding (up to 45 days from hospital discharge). A major bleeding event meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood ; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event. Includes unplanned visit to theatre for control of bleeding Fatal PE (up to 90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE <p>Important outcomes:</p> <ul style="list-style-type: none"> Clinically relevant non-major bleeding (up to 45 days from hospital discharge): bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy. Health-related quality of life (validated scores only)(up to 90 days from hospital discharge) Heparin-induced thrombocytopenia (HIT) (duration of study) Technical complications of mechanical interventions (duration of study)
Study design	Randomised controlled trials (RCTs), systematic reviews of RCTs.
Strata	Open vascular surgery (major aortic/leg bypass) Varicose veins Lower limb amputation

39.3.1 Clinical evidence

2 A search was conducted for randomised trials comparing the effectiveness of mechanical and
3 pharmacological prophylaxis strategies (alone or in combination) in people undergoing vascular
4 surgery.

5 Eight RCTs reporting at least one of the three main outcomes were identified. Four studies were
6 identified from the search^{13,265,306,325} and five studies were included from the previous guideline
7 CG92^{20,91,190,275}. One of the studies included in CG92 was excluded (Killewich 1997¹⁶⁴) as the length of
8 follow up does not match the review protocol. Of the studies included from CG92, data for two
9 studies^{20,275} were extracted from a systematic review⁶¹. Evidence from all the studies is summarised
10 in the clinical evidence summary below (Table 225). See also the study selection flow chart in
11 Appendix E, forest plots in Appendix L, study evidence tables in Appendix H (details of the systematic
12 review are also reported in Appendix H), GRADE tables in Appendix K and excluded studies list in
13 Appendix N.

14 **Table 225: Summary of studies included in the review**

Study	Intervention and comparison	Population	Outcomes	Comments
Strata: overall (not specified)				
Belch 1980 ²⁰	Intervention (n = 24): UFH, 2,500UI pre-operatively then 5,000UI 2x daily for 7 days, administered subcutaneously	n=49 People undergoing elective aortic bifurcation graft surgery	DVT (timepoint not reported): confirmed by radiolabelled fibrinogen or scanning	The trial was terminated because of excess bleeding complications in patients receiving subcutaneous heparin
	Comparison (n= 25)	UK	PE (timepoint not	

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>Placebo, saline injections</p> <p>Concomitant treatment: All people received a routine dose of intravenous sodium heparin intra-operatively.</p>	<p>No further details reported</p>	<p>reported): no definition reported</p> <p>Major bleeding (timepoint not reported): no definition reported</p>	<p>Data extracted from systematic review (Collins 1988 ⁶¹)</p>
Farkas 1993 ⁹¹	<p>Intervention (n = 122): LMWH (Enoxaparin), 2100IU pre-op (standard dose), 4200IU post-op (high dose). Timing: Begun day pre-op and repeatedly daily until 7th day post- op</p> <p>Comparison (n=111): UFH 5000UI pre-op, 7500UI post-op. Timing: Begun day pre-op and repeated twice daily until 7th day post-op</p> <p>Concomitant treatment: Intraoperative use of UFH (94.4%) or protamine (7.9%) was authorised in both groups</p>	<p>n=223</p> <p>People undergoing vascular surgery (aortic or aortoiliac and aneurysmectomy; aorto- femoral bypass for atherosclerotic disease; and femoropopliteal or femorodistal bypass)</p> <p>Adults (mean age intervention 65±11 years, comparison 64±11 years)</p> <p>Male to female ratio 200:43</p>	<p>All-cause mortality (timepoint not reported)</p> <p>DVT (10 days): confirmed by Duplex US, confirmed by venography</p> <p>PE (timepoint not reported): confirmed by clinical suspicion investigated by angiogram</p> <p>Thrombocytopenia (timepoint not reported)</p>	<p>Numbers in each group for baseline data do not tally with text</p>
Spebar 1981 ²⁷⁵	<p>Intervention (n =24): UFH (no further details reported)</p> <p>Comparison (n=19): No VTE prophylaxis</p>	<p>n=43</p> <p>People undergoing peripheral vascular surgical procedures (including aortic reconstruction n=9, carotid artery reconstruction n=19, lumbar sympathectomy n=3, leg revascularisation n=4, psuedoaneurysm repair n=3, repair of artiovenous fistula n=2)</p> <p>No further details reported</p>	<p>DVT (timepoint not reported): indicated by iodine-125 fibrinogen scanning</p> <p>PE (timepoint not reported): no definition reported</p> <p>Major bleeding (timepoint not reported): no definition reported</p>	<p>Data extracted from systematic review (Collins 1988 ⁶¹)</p>

Study	Intervention and comparison	Population	Outcomes	Comments
Strata: limb amputation				
Lastoria 2006 ¹⁹⁰	<p>Intervention (n=41): LMWH (enoxaparin), 40mg 1x daily (standard dose). Timing: 12 hours before surgery or in emergency cases in the first postoperative day, until discharge.</p> <p>Comparison (n=34): UFH, 5000IU administered subcutaneously. Timing: 12 hours before surgery or in emergency cases in the first postoperative day, until discharge.</p>	<p>n=75</p> <p>People undergoing elective or emergency lower-limb amputation (n=30 above-knee; n=45 below-knee)</p> <p>Adults (age range 18 to 86)</p> <p>Male to female ratio 59:16</p>	<p>DVT (5-8 days after surgery): confirmed by duplex scanning</p> <p>Major bleeding (timepoint not reported): any 'bleeding complications'</p>	Strata: lower limb amputation
Strata: varicose veins				
Ayo 2017 ¹³	<p>Intervention (n = 39): AES (thigh high (30-40mmHg) for 24 hours post procedure and then daily during waking hours for 7 days)</p> <p>Comparison (n = 46): Usual care, 24 hours of post-procedural bandages (no compression therapy)</p>	<p>n=85</p> <p>People undergoing endovenous radiofrequency or laser ablation of great saphenous vein for valvular incompetence</p> <p>USA</p> <p>Mean age (SD not reported): compression: 52; usual care 49 years</p> <p>Male to female ratio 20:65</p>	<p>QOL: Venous clinical severity score (VCSS) at 7 days</p> <p>QOL: Chronic venous insufficiency questionnaire (CIVIQ-2) at 90 days</p>	<p>Strata: varicose vein surgery</p> <p>Some people were included in the study twice if they required bilateral treatment (number of people = 70, number of cases = 85)</p>
San Norberto Garcia 2013 ²⁶⁵	<p>Intervention (n=132): LMWH (Bemiparin, not UK licensed), 2500/3500IU 1x daily. Started 6 hours after wound closure, continued for 10 days +IPCD for first 7 days + AES (thigh length) + early mobilisation</p> <p>Comparison (n=130)</p>	<p>n=264</p> <p>People undergoing elective varicose vein surgery with moderate VTE risk (defined as having 2 risk factors for VTE)</p> <p>Adults (mean 67; range 18-75)</p>	<p>DVT (90 days): confirmed by duplex ultrasound</p> <p>PE (90 days): confirmed by duplex ultrasound</p> <p>Major bleeding (90 days): fatal bleeding, was into a critical organ (e.g.</p>	<p>Strata: varicose vein surgery</p> <p>Included people with moderate VTE risk (defined as having 2 risk factors for VTE); excluded people with high risk of bleeding</p>

Study	Intervention and comparison	Population	Outcomes	Comments
	IPCD for first 7 days then AES (thigh length) + early mobilisation	Male to female ratio 104:162 Spain	retroperitoneal, intracranial, intraocular, intraspinal), required reoperation, or was clinically over extrasurgical-site bleeding associated with a fall in haemoglobin of $\geq 20\text{g/L}$, calculated from preoperated baseline value, or requiring infusion of $\geq 2\text{U}$ of whole blood or packed cells	
Wang 2015 ³⁰⁶	Intervention 1 (n=531): UFH, 125U/kg, administered subcutaneously for 30 days Intervention 2(n=550): LMWH (Enoxaparin), 4000 IU, 1x daily (high dose) for 30 days Comparison (n=542) No VTE prophylaxis	n=1623 People undergoing varicose vein surgery (high ligation and stripping of the GSV, and removal of superficial varicosities) Adults (mean age 47.62 ± 10.37 ; range 23-68 years) Male to female ratio: intervention 1 - 1:1.01; 2 – 1: 1.04; 3 – 1.09 : 1 China	DVT, proximal (30 days): confirmed by ultrasound PE (30 days): computed tomography pulmonary angiography scan Major bleeding (30 days): haemorrhage followed by discontinuation of anticoagulation therapy	Strata: varicose vein surgery
Ye 2016 ³²⁵	Intervention (n = 200): AES. Elastic bandage placed after the procedure and left in position during the first night. Patients then wore a thigh-high AES (class II, ankle pressure of 23-32 mmHg), during the daytime for at least 2 weeks. Comparison (n = 200): Elastic bandage placed after the procedure and left in position during	n=400 People undergoing endovenous ablation for primary unilateral great saphenous vein incompetence China Age, median (IQR): Compression group 48 (37-59); usual care 49 (40-60)	All-cause mortality (14 days) DVT (14 days): confirmed by ultrasound duplex PE (14 days): definition not reported QOL: Aberdeen Varicose Vein Symptom Severity Score (AVVSS) (28	Strata: varicose vein surgery

Study	Intervention and comparison	Population	Outcomes	Comments
	the first night (as in the intervention group). Then AES were not recommended	Male to female ratio 165:235	days)	

39.3.1.1 Strata: overall (not specified)

2 Table 226: Clinical evidence summary: UFH compared to no prophylaxis

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with No prophylaxis	Risk difference with UFH (95% CI)
DVT	92 (2 studies) not reported	VERY LOW ^{1,2,3} due to risk of bias, indirectness, imprecision	RR 0.57 (0.22 to 1.46)	227 per 1000	98 fewer per 1000 (from 177 fewer to 105 more)
PE	43 (1 study) not reported	VERY LOW ^{1,2,3} due to risk of bias, indirectness, imprecision	– ⁴	– ⁴	0 fewer per 1000 (from 0 fewer to 0 more) ⁴
Major bleeding	92 (2 studies) not reported	VERY LOW ^{1,3} due to risk of bias, indirectness, imprecision	RR 8.33 (1.13 to 61.7)	23 per 1000	167 more per 1000 (from 3 more to 1000 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
 2 Downgraded by 1 or 2 increments because the majority of the evidence had indirect outcomes
 3 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs
 4 Zero events in both arms. Risk difference calculated in Review Manager

3

4 Table 227: Clinical evidence summary: LMWH (standard dose pre-op/high dose post-op) compared to UFH

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with UFH	Risk difference with LMWH (95% CI)
All-cause mortality	233		RR 4.55	0 per 1000	-

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with UFH	Risk difference with LMWH (95% CI)
	(1 study) not reported	VERY LOW ^{1,2,3} due to risk of bias, indirectness, imprecision	(0.22 to 93.81)		
DVT	233 (1 study) 10 days	VERY LOW ^{1,2,3} due to risk of bias, indirectness, imprecision	RR 2.27 (0.73 to 7.05)	36 per 1000	46 more per 1000 (from 10 fewer to 218 more)
PE	233 (1 study) not reported	VERY LOW ^{1,2,3} due to risk of bias, indirectness, imprecision	-. ⁴	-. ⁴	0 fewer per 1000 (from 20 fewer to 20 more) ⁴
Thrombocytopenia	233 (1 study) not reported	VERY LOW ^{1,2,3} due to risk of bias, indirectness, imprecision	Peto OR 6.81 (0.42 to 109.84)	0 per 1000	-

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
2 Downgraded by 1 or 2 increments because the majority of the evidence had indirect outcomes
3 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs
4 Zero events in both arms. Risk difference calculated in Review Manager

1

39.3.2.2 Strata: Varicose veins

3 Table 228: Clinical evidence summary: LMWH +AES + IPCD + mobilisation versus IPCD/AES + mobilisation

Outcomes	No of	Quality of the evidence	Relative	Anticipated absolute effects
----------	-------	-------------------------	----------	------------------------------

	Participants (studies) Follow up	(GRADE)	effect (95% CI)	Risk with IPCD/AES + mobilisation	Risk difference with LMWH +AES + IPCD mobilisation (95% CI)
DVT	262 (1 study) 90 days	VERY LOW ^{2,3} due to risk of bias, imprecision	-.1	-.1	0 fewer per 1000 (from 10 fewer to 10 more) ¹
PE	262 (1 study) 90 days	VERY LOW+ due to risk of bias, imprecision	-.1	-.1	0 fewer per 1000 (from 10 fewer to 10 more) ¹
Major bleeding	262 (1 study) 90 days	VERY LOW ^{2,3} due to risk of bias, imprecision	-.1	-.1	0 fewer per 1000 (from 10 fewer to 10 more) ¹

1 Zero events in both arms. Risk difference calculated in Review Manager
2 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
3 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs

1

2 **Table 229: Clinical evidence summary: LMWH (high dose) versus no prophylaxis**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with No prophylaxis	Risk difference with LMWH (high dose) (95% CI)
DVT	1092 (1 study) 30 days	HIGH	RR 0.07 (0.02 to 0.29)	52 per 1000	48 fewer per 1000 (from 37 fewer to 51 fewer)
PE	1092 (1 study) 30 days	HIGH	Peto OR 0.13 (0.03 to 0.53)	15 per 1000	13 fewer per 1000 (from 7 fewer to 14 fewer)
Major bleeding	1092		Peto OR 0.99	2 per 1000	0 fewer per 1000

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with No prophylaxis	Risk difference with LMWH (high dose) (95% CI)
	(1 study) 30 days	VERY LOW ^{1,2} due to indirectness, imprecision	(0.06 to 15.78)		(from 2 fewer to 26 more)

1 Downgraded by 1 or 2 increments because the majority of the evidence had indirect outcomes
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs

1

2 **Table 230: Clinical evidence summary: UFH versus no prophylaxis**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with No prophylaxis	Risk difference with UFH (95% CI)
DVT	1073 (1 study) 30 days	HIGH	RR 0.11 (0.03 to 0.36)	52 per 1000	46 fewer per 1000 (from 33 fewer to 50 fewer)
PE	1073 (1 study) 30 days	HIGH	Peto OR 0.14 (0.03 to 0.55)	15 per 1000	13 fewer per 1000 (from 7 fewer to 14 fewer)
Major bleeding	1073 (1 study) 30 days	VERY LOW ^{1,2} due to indirectness, imprecision	Peto OR 0.14 (0 to 6.96)	2 per 1000	2 fewer per 1000 (from 2 fewer to 11 more)

1 Downgraded by 1 or 2 increments because the majority of the evidence had indirect outcomes
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs

3

4 **Table 231: Clinical evidence summary: LMWH (high dose) versus UFH**

Outcomes	No of	Quality of the evidence	Relative	Anticipated absolute effects
----------	-------	-------------------------	----------	------------------------------

	Participants (studies) Follow up	(GRADE)	effect (95% CI)	Risk with UFH	Risk difference with LMWH (high dose) (95% CI)
DVT	1081 (1 study) 30 days	LOW ¹ due to imprecision	RR 0.64 (0.11 to 3.84)	6 per 1000	2 fewer per 1000 (from 5 fewer to 16 more)
PE	1081 (1 study) 30 days	LOW ¹ due to imprecision	-. ²	-. ²	0 fewer per 1000 (from 0 fewer to 0 more) ²
Major bleeding	1081 (1 study) 30 days	VERY LOW ^{1,3} due to indirectness, imprecision	Peto OR 0.29 (0.05 to 1.68)	8 per 1000	5 fewer per 1000 (from 7 fewer to 5 more)

1 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs
2 Zero events in both arms. Risk difference calculated in Review Manager
3 Downgraded by 1 or 2 increments because the majority of the evidence had indirect outcomes

1

2 Table 232: Clinical evidence summary: AES versus usual care

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Usual care	Risk difference with Varicose vein strata - AES (95% CI)
All-cause mortality	400 (1 study) 2 weeks	VERY LOW ^{1,2} due to risk of bias, imprecision	Not estimable	Moderate 0 per 1000	0 fewer per 1000 (from 10 fewer to 10 more) ¹
DVT ultrasound duplex	400 (1 study) 2 weeks	VERY LOW ^{1,2} due to risk of bias, imprecision	Not estimable	Moderate 0 per 1000	0 fewer per 1000 (from 10 fewer to 10 more) ¹
Symptomatic pulmonary	400		Not estimable	Moderate	

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Usual care	Risk difference with Varicose vein strata - AES (95% CI)
embolism	(1 study) 2 weeks	VERY LOW ^{1,2} due to risk of bias, imprecision		0 per 1000	0 fewer per 1000 (from 10 fewer to 10 more) ¹
HRQOL (AVVSS) Aberdeen Varicose Vein Symptoms Severity Score. Scale from: 0 to 100. Better=lower	400 (1 study) 4 weeks	MODERATE ² due to risk of bias		The mean HRQOL (AVVSS) in the control groups was 8	The mean HRQOL (AVVSS) in the intervention groups was 0.5 higher (0.19 lower to 1.19 higher)
HRQOL (VCSS) Venous clinical severity score. Scale from: 0 to 30. Better=lower	85 (1 study) 7 days	VERY LOW ^{2,3,4} due to risk of bias, indirectness, imprecision		The mean HRQOL (VCSS) in the control groups was 4.35	The mean HRQOL (VCSS) in the intervention groups was 1.23 lower (4.72 lower to 2.26 higher)
HRQOL (CIVIQ-2) Chronic venous insufficiency questionnaire. Scale from: 0 to 100. Better=lower	85 (1 study) 90 days	VERY LOW ^{2,3,4} due to risk of bias, indirectness, imprecision		The mean HRQOL (CIVIQ-2) in the control groups was 22.5	The mean HRQOL (CIVIQ-2) in the intervention groups was 6.6 higher (7.67 lower to 20.87 higher)
<p>1 Zero events in both arms. Risk difference calculated in Review Manager 2 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias 3 Some people were included in the study twice if they required bilateral treatment (number of people = 70, number of cases = 85) 4 Unable to calculate as standard deviations not reported</p>					

1

39.3.3.2 Strata: Lower limb amputation

3 Table 233: Clinical evidence summary: LMWH (standard dose) versus UFH

Outcomes	No of Participants	Quality of the evidence	Relative	Anticipated absolute effects
----------	--------------------	-------------------------	----------	------------------------------

	(studies) Follow up	(GRADE)	effect (95% CI)	Risk with UFH	Risk difference with LMWH (standard dose) (95% CI)
DVT	75 (1 study) 5-8 days post-op	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 0.83 (0.22 to 3.07)	118 per 1000	20 fewer per 1000 (from 92 fewer to 244 more)
Major bleeding	75 (1 study) not reported	VERY LOW ^{1,2,4} due to risk of bias, indirectness, imprecision	³	³	0 fewer per 1000 (from 50 fewer to 50 more) ³
<p>1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p> <p>2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs</p> <p>3 Zero events in both arms. Risk difference calculated in Review Manager</p> <p>4 Downgraded by 1 or 2 increments because the majority of the evidence had indirect outcomes</p>					

1

39.4₁ Economic evidence

2 Published literature

- 3 No relevant health economic studies were identified.
- 4 See also the health economic study selection flow chart in Appendix F.

39.5₅ Evidence statements

6 Clinical

7 *Strata: overall (no specific vascular population defined)*

8 Very low quality evidence from two studies (n=92) suggested a possible clinical benefit with
9 unfractionated heparin (UFH) compared to no prophylaxis for a reduction in DVT in people
10 undergoing vascular surgery, however this finding is seriously imprecise and could also be consistent
11 with an increase in DVT rates. A possible clinical harm with UFH was suggested with an increase in
12 major bleeding, although this too was an imprecise estimate that could also have been consistent
13 with no difference. No difference was noted between UFH and no prophylaxis for PE. Very low
14 quality evidence from one study (n=233) suggested that there were worse outcomes for all-cause
15 mortality, DVT and thrombocytopenia when using LMWH at a standard dose pre-operatively
16 followed by a high-dose post-operatively compared to using UFH. However there was considerable
17 uncertainty around these results with all of them also being consistent with possible benefit.

18 *Strata: People undergoing surgery for varicose veins*

19 High quality evidence from one study (n=1092) showed a clinically important reduction in DVT and PE
20 when using either high-dose LMWH or unfractionated heparin (UFH) compared to no prophylaxis.
21 Very low quality evidence from the same study suggested no difference between the LMWH and no
22 prophylaxis for major bleeding rates, and a possible benefit of UFH over no prophylaxis, although
23 these findings were imprecise. When comparing high-dose LMWH to no prophylaxis, there was low
24 quality evidence for a possible reduction in DVT and very low quality evidence for a possible
25 reduction in major bleeding when using LMWH. However there was uncertainty around these
26 results. No difference was found between the two for PE rates.

27 Very low quality evidence from one study (n=262) showed no difference in DVT, PE or major bleeding
28 rates when comparing either stockings or intermittent pneumatic compression and early
29 mobilisation with the same mechanical and mobilisation strategy plus the addition of LMWH.

30 Very low quality evidence from one study (n=400) found no difference in rates of DVT, PE and major
31 bleeding when using anti-embolism stockings compared to no prophylaxis. Moderate quality
32 evidence from the same study suggested no difference with respect of patient reported outcomes on
33 the Aberdeen Varicose Vein Symptoms Severity Score. Very low quality evidence also suggested no
34 difference in patient-reported scores on the Venous Clinical Severity Score and the Chronic Venous
35 Insufficiency Questionnaire, although these findings were imprecise.

36 *Strata: Lower limb amputation*

37 Very low quality evidence from one study (n=75) suggested there was no difference between LMWH
38 (standard dose) and UFH for the outcomes of DVT and major bleeding in those undergoing lower
39 limb amputation. These findings were imprecise.

- 1 **Economic**
- 2 No relevant economic evaluations were identified.

39.6.3 Recommendations and link to evidence

39.6.1.4 Open vascular surgery or endovascular aneurysm repair

Recommendations	<p>121. Consider pharmacological VTE prophylaxis with LMWH² for a minimum of 7 days for people who are undergoing open vascular surgery or major endovascular procedures, including endovascular aneurysm repair whose risk of VTE outweighs their risk of bleeding [2018]</p> <p>122. Consider mechanical VTE prophylaxis on admission for people who are undergoing open vascular surgery or major endovascular procedures, including endovascular aneurysm repair where pharmacological prophylaxis is contraindicated. Choose either:</p> <ul style="list-style-type: none"> • anti-embolism stockings (unless contraindicated) or • intermittent pneumatic compression. <p>Continue until the person no longer has significantly reduced mobility relative to their normal or anticipated mobility. [2018]</p> <p style="text-align: center;">a.</p>
Research recommendation	None
Relative values of different outcomes	<p>The guideline committee considered all-cause mortality (up to 90 days from hospital discharge), deep vein thrombosis (symptomatic and asymptomatic) (up to 90 days from hospital discharge), pulmonary embolism (symptomatic and asymptomatic) (up to 90 days from hospital discharge), fatal PE (up to 90 days from hospital discharge), and major bleeding (up to 45 days from hospital discharge) as critical outcomes.</p> <p>The guideline committee considered clinically relevant non-major bleeding (up to 45 days from hospital discharge), health-related quality of life (up to 90 days from hospital discharge), heparin-induced thrombocytopenia (duration of study), and technical complications of mechanical interventions (duration of study) as important outcomes.</p> <p>Please see section 4.3.3 in the methods chapter for further detail explaining prioritisation of the critical outcomes.</p>
Quality of the clinical evidence	<p><u>People undergoing vascular surgery (including major aortic/leg bypass):</u></p> <p>Three studies were included in this section, which were of different populations including people undergoing vascular surgery including aortic or aortoiliac aneurysm repair, aorto-femoral bypass for atherosclerotic disease, and femoropopliteal or femorodistal bypass; and people undergoing elective aortic bifurcation graft surgery; and people undergoing aortic reconstruction, carotid artery surgery, lumbar sympathectomy, leg revascularisation, pseudoaneurysm repair and repair of arteriovenous fistulae.</p> <p>All of the evidence was of very low quality for both UFH compared to no prophylaxis,</p>

² At the time of consultation (October 2017), LMWH did not have a UK marketing authorisation for use in young people under 18 for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information.

	<p>and for LMWH compared to UFH. This was due to risk of bias, indirectness and imprecision. The outcomes for both studies were downgraded for indirectness as the definition of the outcome of the study or the timepoint at which the outcome was measured did not match the protocol or was not reported. For DVT, both studies specified this was confirmed by fibrinogen scanning, which the committee did not consider to be an accurate measure of confirmation.</p>
Trade-off between clinical benefits and harms	<p>Many people having major arterial surgery are older and potentially immobile putting them at risk for VTE. However many will already be receiving anticoagulation or antiplatelet therapy and therefore be at greater risk of bleeding or admitted with bleeding as emergencies. In addition, full dose heparin is frequently administered during surgery for arterial disease prior to arterial clamping. Major aortic procedures are done either by open techniques or more minimally invasive endovascular techniques but both tend to be long procedures often lasting several hours and both are associated with a significant risk of VTE. Post-operatively return to full mobility can be significantly delayed after vascular surgery especially for open procedures. The committee noted that there was little RCT evidence in the open vascular surgery population but given their likelihood of extended immobility they believed it would be appropriate for clinicians to consider pharmacological prophylaxis with LMWH for those at low risk of bleeding. For those people whose risk of bleeding outweighs their risk of VTE, the committee believed mechanical prophylaxis could be considered. Given the lack of evidence identified for different forms of mechanical prophylaxis the committee believed it would best to offer clinicians choice between AES and IPC. Most people who are vascular patients will have peripheral arterial disease; this means they are not usually able to use AES. Intermittent compression can be used but may impair postoperative mobilisation and rehabilitation.</p>
Trade-off between net clinical effects and costs	<p>No economic studies were identified for this review. The unit costs were presented to the guideline committee. The guideline committee considered the clinical evidence presented for each stratum alongside the unit costs presented.</p> <p><u>People undergoing vascular surgery (including major aortic/leg bypass):</u></p> <p>Based on the doses reported in the included clinical studies, the cost of using UFH (Heparin sodium) ranged from £9 to £59. Using the BNF recommended dose; the cost was £24.6 (assuming administration for 7 days). For LMWH (enoxaparin sodium); the cost ranged from £24 to £91 (based on the included studies' doses). Using the BNF recommended dose; the cost was £24.2 (assuming administration for 7 days). The cost of nurse time required for administration was higher for UFH compared to LMWH due to the higher frequency of administration. UFH also required more monitoring tests (full blood count).</p> <p>Hence; LMWH was recommended as the preferred pharmacological prophylaxis modality as it was considered to be more cost effective; given the reduced frequency of administration and need for monitoring.</p> <p>For those with contraindications to pharmacological prophylaxis, it was noted that AES are unlikely to be suitable due to the likelihood having peripheral arterial disease. In absence of other suitable mechanical options; the committee considered that IPC would be the only potential option and is likely to be cost effective in this population given the high VTE risk.</p>
Other considerations	None.

39.6.2.1 Lower limb amputation

<p>Recommendations</p>	<p>123. Consider pharmacological VTE prophylaxis with LMWH^{aa} for a minimum of 7 days for people who are undergoing lower limb amputation whose risk of VTE outweighs their risk of bleeding. [2018]</p> <p>124. Consider mechanical VTE prophylaxis with intermittent pneumatic compression on the contralateral leg, on admission, for people who are undergoing lower limb amputation and where pharmacological prophylaxis is contraindicated.</p> <p>125. For people undergoing lower limb amputation, continue mechanical VTE prophylaxis until the person no longer has significantly reduced mobility relative to their anticipated mobility. [2018]</p>
<p>Research recommendation</p>	<p>None</p>
<p>Relative values of different outcomes</p>	<p>The guideline committee considered all-cause mortality (up to 90 days from hospital discharge), deep vein thrombosis (symptomatic and asymptomatic) (up to 90 days from hospital discharge), pulmonary embolism (symptomatic and asymptomatic) (up to 90 days from hospital discharge), fatal PE (up to 90 days from hospital discharge), and major bleeding (up to 45 days from hospital discharge) as critical outcomes.</p> <p>The guideline committee considered clinically relevant non-major bleeding (up to 45 days from hospital discharge), health-related quality of life (up to 90 days from hospital discharge), heparin-induced thrombocytopenia (duration of study), and technical complications of mechanical interventions (duration of study) as important outcomes.</p> <p>Please see section 4.3.3 in the methods chapter for further detail explaining prioritisation of the critical outcomes.</p>
<p>Quality of the clinical evidence</p>	<p><u>People undergoing lower limb amputation:</u></p> <p>One study comparing LMWH to UFH was included. The quality of the data for DVT as an outcome was very low due to risk of bias and imprecision, and very low for major bleeding as this was additionally downgraded for indirectness as this was defined as any 'bleeding complications'.</p>
<p>Trade-off between clinical benefits and harms</p>	<p>There was a lack of direct evidence for the amputation population but those undergoing lower limb amputation are known to have a very high risk of VTE in the amputated leg due to surgical trauma and ligation of the vein and they will be relatively immobile both before and after the surgery which also puts them at higher risk of VTE in the non-amputated leg. Most people who are vascular patients having amputation will have peripheral arterial disease; this means they are not usually able to use AES on the contralateral limb and not at all on the side of the amputation. Likewise intermittent pneumatic compression can only be used on the contralateral limb. In view of their high risk and the unsuitability of mechanical methods extrapolation from evidence in other high risk groups means it is likely that these patients will need pharmacological prophylaxis. If there is the occasional person who has a high bleeding risk such that pharmacological prophylaxis can't be used, then</p>

^{aa} At the time of consultation (October 2017), LMWH did not have a UK marketing authorisation for use in young people under 18 for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information.

	due to the high risk of VTE they should be getting mechanical prophylaxis on the contralateral leg.
Trade-off between net clinical effects and costs	No economic studies were identified for this review. The unit costs were presented to the guideline committee. The guideline committee considered the clinical evidence presented for each stratum alongside the unit costs presented. <u>People undergoing lower limb amputation:</u> The clinical evidence showed that there was no clinical difference for LMWH compared to UFH with regards to DVT and major bleeding. Given the lower cost of LMWH compared to UFH; it was considered to be the cost effective option; being equally effective and less costly.
Other considerations	None.

39.6.3.1 Varicose vein surgery

Recommendations	<p>126. Consider pharmacological VTE prophylaxis with LMWH^{bb} for a minimum of 7 days for people undergoing varicose vein surgery whose risk of VTE outweighs their risk of bleeding. [2018]</p> <p>127. Consider mechanical VTE prophylaxis with anti-embolism stockings, on admission, for people undergoing varicose vein surgery:</p> <ul style="list-style-type: none"> • who are at increased risk of VTE and • when pharmacological prophylaxis is contraindicated. [2018] <p>128. If using anti-embolism stockings for people undergoing varicose vein surgery, continue until the person no longer has significantly reduced mobility relative to their normal or anticipated mobility. [2018]</p>
Research recommendation	None
Relative values of different outcomes	The guideline committee considered all-cause mortality (up to 90 days from hospital discharge), deep vein thrombosis (symptomatic and asymptomatic) (up to 90 days from hospital discharge), pulmonary embolism (symptomatic and asymptomatic) (up to 90 days from hospital discharge), fatal PE (up to 90 days from hospital discharge), and major bleeding (up to 45 days from hospital discharge) as critical outcomes. The guideline committee considered clinically relevant non-major bleeding (up to 45 days from hospital discharge), health-related quality of life (up to 90 days from hospital discharge), heparin-induced thrombocytopenia (duration of study), and technical complications of mechanical interventions (duration of study) as important outcomes. Please see section 4.3.3 in the methods chapter for further detail explaining prioritisation of the critical outcomes.
Quality of the clinical evidence	Four studies were included that looked at prophylaxis in people undergoing varicose vein surgery.

^{bb} At the time of consultation (October 2017), LMWH did not have a UK marketing authorisation for use in young people under 18 for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information.

	<p>One study (San Noberto 2013) focused on comparing mechanical prophylaxis (IPCD then AES) with and without LMWH. All of the evidence was of very low quality due to risk of bias and imprecision.</p> <p>Another study (Wang 2015) compared both LMWH, UFH and no prophylaxis. Some evidence was of high quality; however the majority of evidence was of very low quality. The evidence for both LMWH versus no prophylaxis, and for UFH versus no prophylaxis with regards to DVT and PE was of high quality, however the evidence for major bleeding was of low quality due to indirectness of the outcome definition. The evidence for LMWH compared to UFH with regards to DVT, PE and major bleeding was all of low quality due to imprecision. The committee noted that Wang 2015 used open vein surgery for varicose veins, which is not a type of surgery recommended by NICE for this condition.</p> <p>Two further studies (Ayo 2017 and Ye 2016) compared anti-embolism stockings with no compression which were assessed as high risk of bias due to selection concerns and high rates of missing data. Some of the evidence was also downgraded due to intervention indirectness as patients were included in the study twice if they required bilateral treatment. Evidence was further downgraded due to imprecision around the effect estimates for the quality of life outcomes.</p>
<p>Trade-off between clinical benefits and harms</p>	<p>Varicose vein surgery is a relatively common procedure as varicose veins affect a large proportion of the population. The majority of people undergoing surgery for varicose veins are women; therefore oral contraceptive use and hormone replacement therapy use are common in this surgical population. Open varicose vein surgery is now becoming less common and more surgery is being performed using minimally invasive catheter techniques, often under local anaesthetic. People undergoing varicose vein surgery are considered to be at risk for VTE, and DVT and PE are the most common serious complications related to varicose vein surgery. The committee believed the risk was high enough that pharmacological prophylaxis should be considered for at risk persons undergoing varicose vein surgery. Anti-embolism stockings were considered to be the preferred mechanical prophylaxis strategy in this population as they are usually mobile and not suitable for IPC.</p>
<p>Trade-off between net clinical effects and costs</p>	<p>No economic studies were identified for this review. The unit costs were presented to the guideline committee. The guideline committee considered the clinical evidence presented for each stratum alongside the unit costs presented.</p> <p><u>People undergoing varicose vein surgery:</u></p> <p>The clinical evidence showed a possible benefit of LMWH for DVT and major bleeding but no difference for PE when compared with UFH. Given the lower cost of LMWH; it was considered to be the dominant pharmacological prophylaxis option in this population (more effective and less costly).</p>
<p>Other considerations</p>	<p>The committee noted that the rate of symptomatic DVT in varicose vein surgery is low, and that trials with large a number of participants are needed to reflect the true rate of DVT. This committee noted that the low number of participants in the included studies meant that the studies did not accurately represent the rate of DVT in this population.</p>

40 Head and neck surgery

40.1.2 Oral and maxillofacial surgery

40.1.1.3 Introduction

4 Oral and maxillofacial operations are common procedures that are usually undertaken as day cases.
5 Individuals undergoing these procedures are generally mobile. The risk of VTE in this population is,
6 hence, generally low. However; individual factors could increase this risk and need to be considered
7 when making a decision about the provision and choice of prophylaxis. Additionally some cases
8 undergo longer procedures and may have associated risk factors such as cancer. In the last version
9 of this guideline (CG92), this population was covered under “other surgeries”; however, a separate
10 review was necessary so that a specific recommendation for this population could be made.

40.1.2.1 Review question: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing oral or maxillofacial surgery?

14 For full details see review protocol in Appendix C.

15 Table 234: PICO characteristics of review question

Population	<p>Adults and young people (16 years and older) undergoing oral or maxillofacial surgery who are:</p> <ul style="list-style-type: none"> • Admitted to hospital • Having day procedures • Outpatients post-discharge
Intervention(s)	<p>Mechanical:</p> <ul style="list-style-type: none"> • Anti-embolism stockings (AES) (above or below knee) • Intermittent pneumatic compression (IPCD) devices (full leg or below knee) • Foot pumps or foot impulse devices (FID) • Electrical stimulation (including Geko devices) • Continuous passive motion <p>Pharmacological:</p> <ul style="list-style-type: none"> • Unfractionated heparin (UFH) (low dose, administered subcutaneously) • Low molecular weight heparin (LMWH), licensed in UK: <ul style="list-style-type: none"> ○ enoxaparin (standard prophylactic dose 40 mg daily; minimum 20 mg daily* to maximum 60 mg twice daily*) ○ dalteparin (standard prophylactic dose 5000 units once daily; minimum 1250 units once daily* to maximum 5000 units twice daily*; obese patients – maximum 7500 twice units daily*) ○ tinzaparin (standard prophylactic dose 3500 units once daily; minimum 2500 units once daily* to maximum 4500 units twice daily*; obese patients – maximum 6750 twice daily*) • LMWH, licensed in countries other than UK: <ul style="list-style-type: none"> ○ Bemiparin (standard 2500 units daily; minimum 2500 units daily to maximum 3500 units daily) ○ Certoparin (3000 units daily) ○ Nadroparin (standard 2850 units once daily; minimum 2850 units once daily to

	<p>maximum up to 57 units/kg once daily)</p> <ul style="list-style-type: none"> ○ Parnaparin (standard 3200 units once daily; minimum 3200 units once daily to maximum 4250 units once daily) ○ Reviparin (minimum 1750 units once daily to maximum 4200 units once daily) ● Vitamin K Antagonists: <ul style="list-style-type: none"> ○ warfarin (variable dose only) ○ acenocoumarol (all doses) ○ phenindione (all doses) ● Fondaparinux (all doses)* ● Apixaban (all doses)* ● Dabigatran (all doses)* ● Rivaroxaban (all doses)* ● Aspirin (up to 300 mg)* <p>*off-label</p>
Comparison(s)	<p>Compared to:</p> <ul style="list-style-type: none"> ● Other VTE prophylaxis treatment, including monotherapy and combination treatments (between class comparisons for pharmacological treatments only) ● No VTE prophylaxis treatment (no treatment, usual care, placebo) <p>Within intervention (including same drug) comparisons, including:</p> <ul style="list-style-type: none"> ● Above versus below knee stockings ● Full leg versus below knee IPC devices ● Standard versus extended duration prophylaxis ● Low versus high dose for LMWH ● Preoperative versus post-operative initiation of LMWH
Outcomes	<p>Critical outcomes:</p> <ul style="list-style-type: none"> ● All-cause mortality (up to 90 days from hospital discharge) ● Deep vein thrombosis (symptomatic and asymptomatic) (7-90 days from hospital discharge) (NMA outcome). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) ● Pulmonary embolism (7–90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE ● Major bleeding (up to 45 days from hospital discharge). A major bleeding event meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood ; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event. Includes unplanned visit to theatre for control of bleeding ● Fatal PE (7–90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE <p>Important outcomes:</p> <ul style="list-style-type: none"> ● Clinically relevant non-major bleeding (up to 45 days from hospital discharge): bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy. ● Health-related quality of life (validated scores only)(up to 90 days from hospital discharge)

	<ul style="list-style-type: none"> • Heparin-induced thrombocytopenia (HIT) (duration of study) • Technical complications of mechanical interventions (duration of study) • Cerebral sinus thrombosis (30 days)
Study design	Randomised controlled trials (RCTs), systematic reviews of RCTs.

40.1.3.1 Clinical evidence

- 2 No relevant clinical studies comparing difference pharmacological and mechanical prophylaxis
- 3 strategies for people who are undergoing oral or maxillofacial surgery. See the study selection flow
- 4 chart in Appendix E and excluded studies list in Appendix N.

40.1.4.5 Economic evidence

6 Published literature

- 7 No relevant health economic studies were identified.
- 8 See also the health economic study selection flow chart in Appendix F.

40.1.5.9 Evidence statements

10 Clinical

- 11 No relevant clinical studies were identified.

12 Economic

- 13 No relevant economic evaluations were identified.

40.1.6.4 Recommendations and link to evidence

Recommendations	<p>129. Consider pharmacological VTE prophylaxis with LMWH^{cc} for a minimum of 7 days for people undergoing oral or maxillofacial surgery whose risk of VTE outweighs their risk of bleeding. [2018]</p> <p>130. Consider mechanical VTE prophylaxis on admission for people undergoing oral or maxillofacial surgery who are at increased risk of VTE and high risk of bleeding. Choose either:</p> <ul style="list-style-type: none"> • anti-embolism stockings or • intermittent pneumatic compression. <p>Continue until the person no longer has significantly reduced mobility relative to their normal or anticipated mobility. [2018]</p>
Research recommendation	None
Relative values of	The guideline committee considered all-cause mortality (up to 90 days from hospital

^{cc} At the time of consultation (October 2017), LMWH did not have a UK marketing authorisation for use in young people under 18 for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information.

different outcomes	<p>discharge), deep vein thrombosis (symptomatic and asymptomatic) (up to 90 days from hospital discharge), pulmonary embolism (up to 90 days from hospital discharge), fatal PE (up to 90 days from hospital discharge), and major bleeding (up to 45 days from hospital discharge) as critical outcomes.</p> <p>The guideline committee considered clinically relevant non-major bleeding (up to 45 days from hospital discharge), health-related quality of life (up to 90 days from hospital discharge), heparin-induced thrombocytopenia (duration of study), technical complications of mechanical interventions (duration of study) and cerebral sinus thrombosis as important outcomes.</p> <p>Please see section 4.3.3 in the methods chapter for further detail explaining prioritisation of the critical outcomes.</p>
Quality of the clinical evidence	<p>No relevant clinical studies were identified.</p> <p>In the absence of evidence, the committee agreed to consider the evidence for specific prophylaxis choices from other surgery populations as indirect evidence to inform the recommendations for people undergoing oral or maxillofacial surgery, with particular reference to the abdominal surgery population.</p>
Trade-off between clinical benefits and harms	<p>No relevant clinical studies were identified. The committee noted that a person's risk of VTE needs to be considered when deciding if VTE prophylaxis is appropriate. VTE prophylaxis reduces the risk of VTE but pharmacological methods of prophylaxis can increase the risk of bleeding and mechanical methods prophylaxis can have technical complications, which need to be weighed against the reduction in VTE risk. The committee noted that whether pharmacological or mechanical prophylaxis is appropriate should be based on clinical judgement taking into account bleeding risk and individual circumstances. The committee agreed that pharmacological prophylaxis should be considered for those with a high risk of VTE and a low risk of bleeding, and that mechanical prophylaxis should be considered for those with a high risk of VTE and a high risk of bleeding, such as for people undergoing oral/maxillofacial surgery for cancer.</p> <p>Many people undergoing oral or maxillofacial surgery are day cases, or if not, are usually mobile fairly quickly following surgery (for example people having surgery for wisdom teeth or other dentoalveolar surgery procedures). Therefore these people are often low risk and may not require prophylaxis. However for some patients, such as those having major head and neck surgery or orthognathic surgery who are immobile after surgery; those with active cancer; or those assessed as at high risk for cerebral sinus thrombosis, prophylaxis may be necessary.</p> <p>In the absence of evidence the committee believed it would be appropriate to offer a softer 'consider' recommendation.</p>
Trade-off between net clinical effects and costs	<p>No relevant economic studies were identified. Unit costs were presented. In the absence of both clinical and economic evidence, the committee felt that the decision to prescribe prophylaxis should be made on an individual basis, taking into account the individual's risk of VTE and the benefit-harm balance of the proposed prophylaxis strategies. For those at high risk of VTE, the committee considered that prophylaxis is likely to be cost effective. The choice of the prophylaxis method will depend on the individual's risk of bleeding and the presence of contra-indications.</p>
Other considerations	<p>The committee noted that in current practice people undergoing oral or maxillofacial surgery generally do not have pharmacological prophylaxis as much of the minor surgery is performed under local anaesthesia in a fully ambulatory patient. In surgery requiring general anaesthesia, pharmacological prophylaxis is not used but all have mechanical prophylaxis with AES. In the more major maxillofacial procedures the full VTE prophylaxis algorithm is considered appropriate.</p>

40.2.1 ENT surgery

40.2.1.2 Introduction

3 Ear, Nose and throat (ENT) procedures are fairly common; however, the majority of ENT procedures
4 are usually undertaken as day cases. With the exception of major surgery such as those undertaken
5 for cancer; individuals undergoing these procedures are likely to be mobile. Current practice in terms
6 of risk assessment and prophylaxis provision for this population is variable. This population was
7 covered in the last version of this guideline (CG92) under “other surgeries”; however, a separate
8 review was necessary so that a specific recommendation for this population could be made.

40.2.2.9 Review question: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing ear, nose or throat (ENT) surgery?

12 For full details see review protocol in Appendix C.

13 Table 235: PICO characteristics of review question

Population	<p>Adults and young people (16 years and older) undergoing ear, nose or throat (ENT) who are:</p> <ul style="list-style-type: none"> • Admitted to hospital • Having day procedures • Outpatients post-discharge
Intervention(s)	<p>Mechanical:</p> <ul style="list-style-type: none"> • Anti-embolism stockings (AES) (above or below knee) • Intermittent pneumatic compression (IPCD) devices (full leg or below knee) • Foot pumps or foot impulse devices (FID) • Electrical stimulation (including Geko devices) • Continuous passive motion • Vena caval filters <p>Pharmacological:</p> <ul style="list-style-type: none"> • Unfractionated heparin (UFH) (low dose, administered subcutaneously) • Low molecular weight heparin (LMWH), licensed in UK: <ul style="list-style-type: none"> ○ enoxaparin (standard prophylactic dose 40 mg daily; minimum 20 mg daily* to maximum 60 mg twice daily*) ○ dalteparin (standard prophylactic dose 5000 units once daily; minimum 1250 units once daily* to maximum 5000 units twice daily*; obese patients – maximum 7500 twice units daily*) ○ tinzaparin (standard prophylactic dose 3500 units once daily; minimum 2500 units once daily* to maximum 4500 units twice daily*; obese patients – maximum 6750 twice daily*) • LMWH, licensed in countries other than UK: <ul style="list-style-type: none"> ○ Bemiparin (standard 2500 units daily; minimum 2500 units daily to maximum 3500 units daily) ○ Certoparin (3000 units daily) ○ Nadroparin (standard 2850 units once daily; minimum 2850 units once daily to maximum up to 57 units/kg once daily) ○ Parnaparin (standard 3200 units once daily; minimum 3200 units once daily to maximum 4250 units once daily)

	<ul style="list-style-type: none"> ○ Reviparin (minimum 1750 units once daily to maximum 4200 units once daily) ● Vitamin K Antagonists: <ul style="list-style-type: none"> ○ warfarin (variable dose only) ○ acenocoumarol (all doses) ○ phenindione (all doses) ● Fondaparinux (all doses)* ● Apixaban (all doses)* ● Dabigatran (all doses)* ● Rivaroxaban (all doses)* ● Aspirin (up to 300 mg)* <p>*off-label</p>
<p>Comparison(s)</p>	<p>Compared to:</p> <ul style="list-style-type: none"> ● Other VTE prophylaxis treatment, including monotherapy and combination treatments (between class comparisons for pharmacological treatments only) ● No VTE prophylaxis treatment (no treatment, usual care, placebo) <p>Within intervention (including same drug) comparisons, including:</p> <ul style="list-style-type: none"> ● Above versus below knee stockings ● Full leg versus below knee IPC devices ● Standard versus extended duration prophylaxis ● Low versus high dose for LMWH ● Preoperative versus post-operative initiation of LMWH
<p>Outcomes</p>	<p>Critical outcomes:</p> <ul style="list-style-type: none"> ● All-cause mortality (up to 90 days from hospital discharge) ● Deep vein thrombosis (symptomatic and asymptomatic) (7-90 days from hospital discharge). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) ● Pulmonary embolism (7-90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE ● Major bleeding (up to 45 days from hospital discharge). A major bleeding event meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood ; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event. Includes unplanned visit to theatre for control of bleeding ● Fatal PE (7- 90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE <p>Important outcomes:</p> <ul style="list-style-type: none"> ● Clinically relevant non-major bleeding (up to 45 days from hospital discharge): bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy. ● Health-related quality of life (validated scores only)(up to 90 days from hospital discharge) ● Heparin-induced thrombocytopenia (HIT) (duration of study) ● Technical complications of mechanical interventions (duration of study) ● Cerebral sinus thrombosis (up to 30 days from hospital discharge)

Study design

Randomised controlled trials (RCTs), systematic reviews of RCTs.

40.2.3.1 Clinical evidence

- 2 No relevant clinical studies comparing different pharmacological and mechanical prophylaxis
- 3 strategies for people who are undergoing ears, nose and throat (ENT) surgery were identified. See
- 4 the study selection flow chart in Appendix E and excluded studies list in Appendix N.

40.2.4.5 Economic evidence

6 Published literature

- 7 No relevant health economic studies were identified.
- 8 See also the health economic study selection flow chart in Appendix F.

40.2.5.9 Evidence statements

10 Clinical

- 11 No relevant clinical studies were identified.

12 Economic

- 13 No relevant economic evaluations were identified.

40.2.6.4 Recommendations and link to evidence

Recommendations	<p>131. Consider pharmacological VTE prophylaxis with LMWH^{dd} for a minimum of 7 days for people undergoing ENT surgery whose risk of VTE outweighs their risk of bleeding. [2018]</p> <p>132. Consider mechanical VTE prophylaxis on admission for people undergoing ENT surgery who are at increased risk of VTE and high risk of bleeding. Choose either:</p> <ul style="list-style-type: none"> • anti-embolism stockings or • intermittent pneumatic compression. <p>Continue until the person no longer has significantly reduced mobility relative to their normal or anticipated mobility. [2018]</p>
Research recommendation	None
Relative values of different outcomes	The guideline committee considered all-cause mortality (up to 90 days from hospital discharge), deep vein thrombosis (symptomatic and asymptomatic) (up to 90 days from hospital discharge), pulmonary embolism (up to 90 days from hospital discharge), fatal PE (up to 90 days from hospital discharge), and major bleeding (up to 45 days from hospital discharge) as critical outcomes.

^{dd} At the time of consultation (October 2017), LMWH did not have a UK marketing authorisation for use in young people under 18 for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information.

	<p>The guideline committee considered clinically relevant non-major bleeding (up to 45 days from hospital discharge), health-related quality of life (up to 90 days from hospital discharge), heparin-induced thrombocytopenia (duration of study), technical complications of mechanical interventions (duration of study) and cerebral sinus thrombosis as important outcomes.</p> <p>Please see section 4.3.3 in the methods chapter for further detail explaining prioritisation of the critical outcomes.</p>
Quality of the clinical evidence	<p>No relevant clinical studies were identified.</p> <p>In the absence of evidence, the committee agreed to consider the evidence for specific prophylaxis choices from other surgery populations as indirect evidence to inform the recommendations for people undergoing ENT surgery, with particular reference to the abdominal surgery population. However it was acknowledged that ENT surgery is different from abdominal surgery as it does not involve a body cavity.</p>
Trade-off between clinical benefits and harms	<p>No relevant clinical studies were identified. The committee noted that a person's risk of VTE needs to be considered when deciding if VTE prophylaxis is appropriate. VTE prophylaxis reduces the risk of VTE but pharmacological methods of prophylaxis can increase the risk of bleeding and mechanical methods prophylaxis can have technical complications, which need to be weighed against the reduction in VTE risk. The committee noted that whether pharmacological or mechanical prophylaxis is appropriate should be based on clinical judgement taking into account bleeding risk and individual circumstances. The committee agreed that pharmacological prophylaxis should be considered for those with a high risk of VTE and a low risk of bleeding, and that mechanical prophylaxis should be considered for those with a high risk of VTE and a high risk of bleeding, such as for people undergoing ENT surgery for cancer.</p> <p>Overall, the committee believed that most people undergoing ENT procedures are fully mobile day cases and therefore are often low risk for VTE and may not require prophylaxis. However, in high risk people, such as those with active cancer or those who are immobile after surgery, prophylaxis may be necessary.</p> <p>In the absence of evidence the committee believed it would be appropriate to offer a softer 'consider' recommendation.</p>
Trade-off between net clinical effects and costs	<p>No relevant economic studies were identified. Unit costs were presented. In the absence of both clinical and economic evidence, the committee felt that the decision to prescribe prophylaxis should be made on an individual basis, taking into account the individual's risk of VTE and the benefit-harm balance of the proposed prophylaxis strategies. For those at high risk of VTE, the committee considered that prophylaxis is likely to be cost effective. The choice of the prophylaxis method will depend on the individual's risk of bleeding and the presence of contra-indications.</p>
Other considerations	<p>The committee noted that in current practice the majority of people undergoing ENT surgery do not have pharmacological prophylaxis but all have mechanical prophylaxis with AES.</p>

1

2

41 Acronyms and abbreviations

Acronym or abbreviation	Description
ACS	Acute coronary syndrome
AES	Anti-embolism stockings
BNF	British National Formulary
CEA	Cost-effectiveness analysis
CI	Confidence interval
CPM	Continuous passive motion
CRT	Catheter related thrombosis
CUA	Cost-utility analysis
CVC	Central venous catheters
DOAC	Direct oral anticoagulant
DVT	Deep vein thrombosis
FID	Foot impulse devices
GCS	Graduated compression stockings
GRADE	Grading of Recommendations Assessment, Development and Evaluation
HD	High dose
HES	Hospital Episode Statistics
HIT	Heparin-induced thrombocytopenia
ICER	Incremental cost-effectiveness ratio
ICU	Intensive Care Unit
IPCD	Intermittent pneumatic compression devices
ISS	Injury severity score
IV	Intravenous
LD	Low dose
LMWH	Low molecular weight heparin
LOS	Length of stay
MB	Major bleeding
MHRA	Medicines and Healthcare Products Regulatory Agency
NMA	Network meta-analysis
NNT	Number needed to treat
OAC	Oral anticoagulants
PASA	NHS Purchasing and Supply Agency
PE	Pulmonary embolism
PHT	Chronic thromboembolic pulmonary hypertension
PTS	Post-thrombotic syndrome
SC	Subcutaneous
UKOSS	United Kingdom Obstetric Surveillance System
UFH	Unfractionated heparin
VKA	Vitamin K antagonist
VTE	Venous thromboembolism

42 Glossary

2 The NICE Glossary can be found at www.nice.org.uk/glossary.

42.1.3 Guideline-specific terms

Term	Definition
Acute medical admissions	A medical admission concerned with the immediate and early specialist management of adult patients suffering from a wide range of medical conditions who present to, or from within, hospitals, requiring urgent or emergency care.
Adherence	The extent to which the patient's behaviour matches the prescriber's recommendations. Adherence emphasises the need for agreement and that the patient is free to decide whether or not to adhere to the doctor's recommendation.
Anticoagulants	Any agent used to prevent the formation of blood clots. These include oral agents, such as warfarin, and others which are injected into a vein or under the skin, such as heparin.
Anti-embolism stockings	Hosiery which, when worn on the leg, exerts graduated compression on the leg surface and is intended to reduce the incidence of deep vein thrombosis. These should not be confused with "graduated compression stockings" which have a different pressure profile and are not used for the prevention of venous thromboembolism.
Chronic thromboembolic pulmonary hypertension	Abnormally elevated blood pressure within the pulmonary circuit (pulmonary artery).
Comorbidity	Co-existence of more than one disease or an additional disease (other than that being studied or treated) in an individual.
Continuous passive motion	Where a joint is moved continuously, either by another person bending it or by a machine.
Deep vein thrombosis (DVT)	Venous thrombosis that occurs in the "deep veins" in the legs, thighs, or pelvis.
Distal	Refers to a part of the body that is farther away from the centre of the body than another part.
Dosage	The prescribed amount of a drug to be taken, including the size and timing of the doses.
DVT	See 'Deep-vein thrombosis'.
Elective	Name for clinical procedures that are regarded as advantageous to the patient but not urgent.
Electrical stimulation	Designed to increase venous blood flow velocity out of the leg to reduce the incidence of post-surgical venous thrombosis.
Emergency admission	When admission is unpredictable and at short notice because of clinical need.
Fetal/fetus	A human being or animal in its later stages of development before it is born.
Foot impulse devices (FID)	The foot impulse device is designed to stimulate the leg veins (venous pump) artificially by compressing the venous plexus and mimicking normal walking and reducing stasis in immobilised patients.
Heparin-induced thrombocytopenia (HIT)	Low blood platelet count resulting from the administration of heparin (or heparin-like agents). Despite having a low platelet count, patients with this condition are at high risk of their blood clotting.
HIT	See 'Heparin-induced thrombocytopenia'.

Term	Definition
Indication	The defined use of a technology as licensed by the Medicines and Healthcare products Regulatory Agency (MHRA).
Intermittent pneumatic compression	A method of prophylaxis that includes an air pump and inflatable garments in a system designed to improve venous circulation in the lower limbs of people at risk of deep vein thrombosis or pulmonary embolism. The inflation-deflation cycle of IPC therapy simulates the thigh, calf and foot's normal ambulatory pump action increasing both the volume and rate of blood flow, eliminating venous stasis and replicating the effects of the natural muscle pump. Intermittent pneumatic compression devices can be thigh or knee length sleeves that are wrapped around the leg, or a garment that can be wrapped around or worn on the foot that is designed to mimic the actions of walking (foot-pump).
Intermittent pneumatic compression devices (IPCD)	A method of prophylaxis that comprises the use of inflatable garments wrapped around the legs, inflated by a pneumatic pump. The pump provides intermittent cycles of compressed air which alternately inflates and deflates the chamber garments, enhancing venous return.
Intervention	Healthcare action intended to benefit the patient, for example, drug treatment, surgical procedure, psychological therapy.
Intraoperative	The period of time during a surgical procedure.
Length of stay (LOS)	The total number of days a patient stays in hospital.
Licence	See 'Product licence'.
Lower limb immobilisation	Immobilisation is defined as any clinical decision taken to manage the affected limb in such a way as to prevent normal weight bearing status and/or use of that limb.
Mechanical	Physical (as opposed to chemical) agent used, in this context, to reduce likelihood of thrombosis. Mechanical methods of DVT prophylaxis work to combat venous stasis and include: anti-embolism stockings, intermittent pneumatic compression devices (IPCD), foot impulse devices, also known as foot pumps (FID).
Medical devices	All products, except medicines, used in healthcare for the diagnosis, prevention, monitoring or treatment of illness or handicap.
Medicines and Healthcare Products Regulatory Agency (MHRA)	The Executive Agency of the Department of Health protecting and promoting public health and patient safety by ensuring that medicines, healthcare products and medical equipment meet appropriate standards of safety, quality, performance and effectiveness, and are used safely.
Off-label	A drug or device used treat a condition or disease for which it is not specifically licensed.
Older people	People over the age of 65 years.
PE	See 'Pulmonary embolism'.
Perioperative	The period from admission through surgery until discharge, encompassing pre-operative and post-operative periods.
Post-thrombotic (Post-phlebotic) Syndrome	Chronic pain, swelling, and occasional ulceration of the skin of the leg that occur as a consequence of previous venous thrombosis.
Postoperative	Pertaining to the period after patients leave the operating theatre, following surgery.
Preoperative	Pertaining to the period before surgery commences.
Primary care	Healthcare delivered to patients outside hospitals. Primary care covers a range of services provided by GPs, nurses and other healthcare professionals, dentists, pharmacists and opticians.

Term	Definition
Product licence	An authorisation from the MHRA to market a medicinal product.
Prognosis	A probable course or outcome of a disease. Prognostic factors are patient or disease characteristics that influence the course. Good prognosis is associated with low rate of undesirable outcomes; poor prognosis is associated with a high rate of undesirable outcomes.
Prophylaxis	A measure taken for the prevention of a disease.
Proximal	Refers to a part of the body that is closer to the centre of the body than another part.
Pulmonary embolism (PE)	A blood clot that breaks off from the deep veins and travels round the circulation to block the pulmonary arteries (arteries in the lung). Most deaths arising from DVT are caused by PE.
Pulmonary hypertension	See 'Chronic thromboembolic pulmonary hypertension'.
Renal impairment	Patients with an estimated glomerular filtration rate (eGFR) of less than 30.
Significantly reduced mobility	Defined by the committee as: 'patients who are bed bound, unable to walk unaided or likely to spend a substantial proportion of their day in bed or in a chair'
Thrombophilia	The genetic or acquired prothrombotic states that increase the tendency to venous thromboembolism. It is a condition which leads to a tendency for a person's blood to clot inappropriately.
Thromboprophylaxis	A measure taken to reduce the risk of thrombosis.
Treatment options	The choices of intervention available.
Venous thromboembolism (VTE)	The blocking of a blood vessel by a blood clot dislodged from its site of origin. It includes both DVT and PE.
Venous thrombosis (VT)	A condition in which a blood clot (thrombus) forms in a vein.

42.2.1 General terms

Term	Definition
Abstract	Summary of a study, which may be published alone or as an introduction to a full scientific paper.
Allocation concealment	The process used to prevent advance knowledge of group assignment in an RCT. The allocation process should be impervious to any influence by the individual making the allocation, by being administered by someone who is not responsible for recruiting participants.
Applicability	How well the results of a study or NICE evidence review can answer a clinical question or be applied to the population being considered.
Arm (of a clinical study)	Subsection of individuals within a study who receive one particular intervention, for example placebo arm.
Association	Statistical relationship between 2 or more events, characteristics or other variables. The relationship may or may not be causal.
Base case analysis	In an economic evaluation, this is the main analysis based on the most plausible estimate of each input. In contrast, see Sensitivity analysis.
Baseline	The initial set of measurements at the beginning of a study (after run-in period where applicable), with which subsequent results are compared.
Bayesian analysis	A method of statistics, where a statistic is estimated by combining established information or belief (the 'prior') with new evidence (the 'likelihood') to give a revised estimate (the 'posterior').
Before-and-after study	A study that investigates the effects of an intervention by measuring

Term	Definition
	particular characteristics of a population both before and after taking the intervention, and assessing any change that occurs.
Bias	Influences on a study that can make the results look better or worse than they really are. (Bias can even make it look as if a treatment works when it does not.) Bias can occur by chance, deliberately or as a result of systematic errors in the design and execution of a study. It can also occur at different stages in the research process, for example, during the collection, analysis, interpretation, publication or review of research data. For examples see selection bias, performance bias, information bias, confounding factor, and publication bias.
Blinding	A way to prevent researchers, doctors and patients in a clinical trial from knowing which study group each patient is in so they cannot influence the results. The best way to do this is by sorting patients into study groups randomly. The purpose of 'blinding' or 'masking' is to protect against bias. A single-blinded study is one in which patients do not know which study group they are in (for example whether they are taking the experimental drug or a placebo). A double-blinded study is one in which neither patients nor the researchers and doctors know which study group the patients are in. A triple blind study is one in which neither the patients, clinicians or the people carrying out the statistical analysis know which treatment patients received.
Carer (caregiver)	Someone who looks after family, partners or friends in need of help because they are ill, frail or have a disability.
Clinical efficacy	The extent to which an intervention is active when studied under controlled research conditions.
Clinical effectiveness	How well a specific test or treatment works when used in the 'real world' (for example, when used by a doctor with a patient at home), rather than in a carefully controlled clinical trial. Trials that assess clinical effectiveness are sometimes called management trials. Clinical effectiveness is not the same as efficacy.
Clinician	A healthcare professional who provides patient care. For example, a doctor, nurse or physiotherapist.
Cochrane Review	The Cochrane Library consists of a regularly updated collection of evidence-based medicine databases including the Cochrane Database of Systematic Reviews (reviews of randomised controlled trials prepared by the Cochrane Collaboration).
Cohort study	A study with 2 or more groups of people – cohorts – with similar characteristics. One group receives a treatment, is exposed to a risk factor or has a particular symptom and the other group does not. The study follows their progress over time and records what happens. See also observational study.
Comorbidity	A disease or condition that someone has in addition to the health problem being studied or treated.
Comparability	Similarity of the groups in characteristics likely to affect the study results (such as health status or age).
Confidence interval (CI)	There is always some uncertainty in research. This is because a small group of patients is studied to predict the effects of a treatment on the wider population. The confidence interval is a way of expressing how certain we are about the findings from a study, using statistics. It gives a range of results that is likely to include the 'true' value for the population. The CI is usually stated as '95% CI', which means that the range of values has a 95 in a 100 chance of including the 'true' value. For example, a study may state that "based on our sample findings, we are 95% certain that the

Term	Definition
	<p>‘true’ population blood pressure is not higher than 150 and not lower than 110”. In such a case the 95% CI would be 110 to 150.</p> <p>A wide confidence interval indicates a lack of certainty about the true effect of the test or treatment – often because a small group of patients has been studied. A narrow confidence interval indicates a more precise estimate (for example, if a large number of patients have been studied).</p>
Confounding factor	<p>Something that influences a study and can result in misleading findings if it is not understood or appropriately dealt with.</p> <p>For example, a study of heart disease may look at a group of people that exercises regularly and a group that does not exercise. If the ages of the people in the 2 groups are different, then any difference in heart disease rates between the 2 groups could be because of age rather than exercise. Therefore age is a confounding factor.</p>
Consensus methods	<p>Techniques used to reach agreement on a particular issue. Consensus methods may be used to develop NICE guidance if there is not enough good quality research evidence to give a clear answer to a question. Formal consensus methods include Delphi and nominal group techniques.</p>
Control group	<p>A group of people in a study who do not receive the treatment or test being studied. Instead, they may receive the standard treatment (sometimes called ‘usual care’) or a dummy treatment (placebo). The results for the control group are compared with those for a group receiving the treatment being tested. The aim is to check for any differences.</p> <p>Ideally, the people in the control group should be as similar as possible to those in the treatment group, to make it as easy as possible to detect any effects due to the treatment.</p>
Cost–benefit analysis (CBA)	<p>Cost–benefit analysis is one of the tools used to carry out an economic evaluation. The costs and benefits are measured using the same monetary units (for example, pounds sterling) to see whether the benefits exceed the costs.</p>
Cost–consequences analysis (CCA)	<p>Cost–consequences analysis is one of the tools used to carry out an economic evaluation. This compares the costs (such as treatment and hospital care) and the consequences (such as health outcomes) of a test or treatment with a suitable alternative. Unlike cost–benefit analysis or cost-effectiveness analysis, it does not attempt to summarise outcomes in a single measure (like the quality-adjusted life year) or in financial terms. Instead, outcomes are shown in their natural units (some of which may be monetary) and it is left to decision-makers to determine whether, overall, the treatment is worth carrying out.</p>
Cost-effectiveness analysis (CEA)	<p>Cost-effectiveness analysis is one of the tools used to carry out an economic evaluation. The benefits are expressed in non-monetary terms related to health, such as symptom-free days, heart attacks avoided, deaths avoided or life years gained (that is, the number of years by which life is extended as a result of the intervention).</p>
Cost-effectiveness model	<p>An explicit mathematical framework, which is used to represent clinical decision problems and incorporate evidence from a variety of sources in order to estimate the costs and health outcomes.</p>
Cost–utility analysis (CUA)	<p>Cost–utility analysis is one of the tools used to carry out an economic evaluation. The benefits are assessed in terms of both quality and duration of life, and expressed as quality-adjusted life years (QALYs). See also utility.</p>
Credible interval (CrI)	<p>The Bayesian equivalent of a confidence interval.</p>
Decision analysis	<p>An explicit quantitative approach to decision-making under uncertainty, based on evidence from research. This evidence is translated into probabilities, and then into diagrams or decision trees which direct the</p>

Term	Definition
	clinician through a succession of possible scenarios, actions and outcomes.
Deterministic analysis	In economic evaluation, this is an analysis that uses a point estimate for each input. In contrast, see Probabilistic analysis
Discounting	Costs and perhaps benefits incurred today have a higher value than costs and benefits occurring in the future. Discounting health benefits reflects individual preference for benefits to be experienced in the present rather than the future. Discounting costs reflects individual preference for costs to be experienced in the future rather than the present.
Disutility	The loss of quality of life associated with having a disease or condition. See Utility
Dominance	A health economics term. When comparing tests or treatments, an option that is both less effective and costs more is said to be 'dominated' by the alternative.
Drop-out	A participant who withdraws from a trial before the end.
Economic evaluation	<p>An economic evaluation is used to assess the cost effectiveness of healthcare interventions (that is, to compare the costs and benefits of a healthcare intervention to assess whether it is worth doing). The aim of an economic evaluation is to maximise the level of benefits – health effects – relative to the resources available. It should be used to inform and support the decision-making process; it is not supposed to replace the judgement of healthcare professionals.</p> <p>There are several types of economic evaluation: cost–benefit analysis, cost–consequences analysis, cost-effectiveness analysis, cost-minimisation analysis and cost–utility analysis. They use similar methods to define and evaluate costs, but differ in the way they estimate the benefits of a particular drug, programme or intervention.</p>
Effect (as in effect measure, treatment effect, estimate of effect, effect size)	<p>A measure that shows the magnitude of the outcome in one group compared with that in a control group.</p> <p>For example, if the absolute risk reduction is shown to be 5% and it is the outcome of interest, the effect size is 5%.</p> <p>The effect size is usually tested, using statistics, to find out how likely it is that the effect is a result of the treatment and has not just happened by chance (that is, to see if it is statistically significant).</p>
Effectiveness	How beneficial a test or treatment is under usual or everyday conditions, compared with doing nothing or opting for another type of care.
Efficacy	How beneficial a test, treatment or public health intervention is under ideal conditions (for example, in a laboratory), compared with doing nothing or opting for another type of care.
EQ-5D (EuroQol 5 dimensions)	A standardised instrument used to measure health-related quality of life. It provides a single index value for health status.
Evidence	Information on which a decision or guidance is based. Evidence is obtained from a range of sources including randomised controlled trials, observational studies, expert opinion (of clinical professionals or patients).
Exclusion criteria (literature review)	Explicit standards used to decide which studies should be excluded from consideration as potential sources of evidence.
Exclusion criteria (clinical study)	Criteria that define who is not eligible to participate in a clinical study.
Extended dominance	If Option A is both more clinically effective than Option B and has a lower cost per unit of effect, when both are compared with a do-nothing alternative then Option A is said to have extended dominance over Option B. Option A is therefore cost effective and should be preferred, other

Term	Definition
	things remaining equal.
Extrapolation	An assumption that the results of studies of a specific population will also hold true for another population with similar characteristics.
Follow-up	Observation over a period of time of an individual, group or initially defined population whose appropriate characteristics have been assessed in order to observe changes in health status or health-related variables.
Generalisability	The extent to which the results of a study hold true for groups that did not participate in the research. See also external validity.
GRADE, GRADE profile	A system developed by the GRADE Working Group to address the shortcomings of present grading systems in healthcare. The GRADE system uses a common, sensible and transparent approach to grading the quality of evidence. The results of applying the GRADE system to clinical trial data are displayed in a table known as a GRADE profile.
Harms	Adverse effects of an intervention.
Health economics	Study or analysis of the cost of using and distributing healthcare resources.
Health-related quality of life (HRQoL)	A measure of the effects of an illness to see how it affects someone's day-to-day life.
Heterogeneity or Lack of homogeneity	The term is used in meta-analyses and systematic reviews to describe when the results of a test or treatment (or estimates of its effect) differ significantly in different studies. Such differences may occur as a result of differences in the populations studied, the outcome measures used or because of different definitions of the variables involved. It is the opposite of homogeneity.
Imprecision	Results are imprecise when studies include relatively few patients and few events and thus have wide confidence intervals around the estimate of effect.
Inclusion criteria (literature review)	Explicit criteria used to decide which studies should be considered as potential sources of evidence.
Incremental analysis	The analysis of additional costs and additional clinical outcomes with different interventions.
Incremental cost	The extra cost linked to using one test or treatment rather than another. Or the additional cost of doing a test or providing a treatment more frequently.
Incremental cost-effectiveness ratio (ICER)	The difference in the mean costs in the population of interest divided by the differences in the mean outcomes in the population of interest for one treatment compared with another.
Incremental net benefit (INB)	The value (usually in monetary terms) of an intervention net of its cost compared with a comparator intervention. The INB can be calculated for a given cost-effectiveness (willingness to pay) threshold. If the threshold is £20,000 per QALY gained then the INB is calculated as: (£20,000 × QALYs gained) – Incremental cost.
Indirectness	The available evidence is different to the review question being addressed, in terms of PICO (population, intervention, comparison and outcome).
Intention-to-treat analysis (ITT)	An assessment of the people taking part in a clinical trial, based on the group they were initially (and randomly) allocated to. This is regardless of whether or not they dropped out, fully complied with the treatment or switched to an alternative treatment. Intention-to-treat analyses are often used to assess clinical effectiveness because they mirror actual practice: that is, not everyone complies with treatment and the treatment people receive may be changed according to how they respond to it.
Intervention	In medical terms this could be a drug treatment, surgical procedure,

Term	Definition
	diagnostic or psychological therapy. Examples of public health interventions could include action to help someone to be physically active or to eat a more healthy diet.
Intraoperative	The period of time during a surgical procedure.
Length of stay	The total number of days a participant stays in hospital.
Licence	See 'Product licence'.
Life years gained	Mean average years of life gained per person as a result of the intervention compared with an alternative intervention.
Logistic regression or Logit model	In statistics, logistic regression is a type of analysis used for predicting the outcome of a binary dependent variable based on one or more predictor variables. It can be used to estimate the log of the odds (known as the 'logit').
Loss to follow-up	A patient, or the proportion of patients, actively participating in a clinical trial at the beginning, but whom the researchers were unable to trace or contact by the point of follow-up in the trial
Markov model	A method for estimating long-term costs and effects for recurrent or chronic conditions, based on health states and the probability of transition between them within a given time period (cycle).
Meta-analysis	A method often used in systematic reviews. Results from several studies of the same test or treatment are combined to estimate the overall effect of the treatment.
Multivariate model	A statistical model for analysis of the relationship between 2 or more predictor (independent) variables and the outcome (dependent) variable.
Negative predictive value (NPV)	In screening or diagnostic tests: A measure of the usefulness of a screening or diagnostic test. It is the proportion of those with a negative test result who do not have the disease, and can be interpreted as the probability that a negative test result is correct. It is calculated as follows: $TN/(TN+FN)$
Net monetary benefit (NMB)	The value in monetary terms of an intervention net of its cost. The NMB can be calculated for a given cost-effectiveness threshold. If the threshold is £20,000 per QALY gained then the NMB for an intervention is calculated as: $(£20,000 \times \text{mean QALYs}) - \text{mean cost}$. The most preferable option (that is, the most clinically effective option to have an ICER below the threshold selected) will be the treatment with the highest NMB.
Non-randomised intervention study	A quantitative study investigating the effectiveness of an intervention that does not use randomisation to allocate patients (or units) to treatment groups. Non-randomised studies include observational studies, where allocation to groups occurs through usual treatment decisions or people's preferences. Non-randomised studies can also be experimental, where the investigator has some degree of control over the allocation of treatments. Non-randomised intervention studies can use a number of different study designs, and include cohort studies, case-control studies, controlled before-and-after studies, interrupted-time-series studies and quasi-randomised controlled trials.
Observational study	Individuals or groups are observed or certain factors are measured. No attempt is made to affect the outcome. For example, an observational study of a disease or treatment would allow 'nature' or usual medical care to take its course. Changes or differences in one characteristic (for example, whether or not people received a specific treatment or intervention) are studied without intervening. There is a greater risk of selection bias than in experimental studies.

Term	Definition
Odds ratio	<p>Odds are a way to represent how likely it is that something will happen (the probability). An odds ratio compares the probability of something in one group with the probability of the same thing in another.</p> <p>An odds ratio of 1 between 2 groups would show that the probability of the event (for example a person developing a disease, or a treatment working) is the same for both. An odds ratio greater than 1 means the event is more likely in the first group. An odds ratio less than 1 means that the event is less likely in the first group.</p> <p>Sometimes probability can be compared across more than 2 groups – in this case, one of the groups is chosen as the ‘reference category’, and the odds ratio is calculated for each group compared with the reference category. For example, to compare the risk of dying from lung cancer for non-smokers, occasional smokers and regular smokers, non-smokers could be used as the reference category. Odds ratios would be worked out for occasional smokers compared with non-smokers and for regular smokers compared with non-smokers. See also confidence interval, risk ratio.</p>
Opportunity cost	<p>The loss of other healthcare programmes displaced by investment in or introduction of another intervention. This may be best measured by the health benefits that could have been achieved had the money been spent on the next best alternative healthcare intervention.</p>
Outcome	<p>The impact that a test, treatment, policy, programme or other intervention has on a person, group or population. Outcomes from interventions to improve the public’s health could include changes in knowledge and behaviour related to health, societal changes (for example, a reduction in crime rates) and a change in people’s health and wellbeing or health status. In clinical terms, outcomes could include the number of patients who fully recover from an illness or the number of hospital admissions, and an improvement or deterioration in someone’s health, functional ability, symptoms or situation. Researchers should decide what outcomes to measure before a study begins.</p>
P value	<p>The p value is a statistical measure that indicates whether or not an effect is statistically significant.</p> <p>For example, if a study comparing 2 treatments found that one seems more effective than the other, the p value is the probability of obtaining these results by chance. By convention, if the p value is below 0.05 (that is, there is less than a 5% probability that the results occurred by chance) it is considered that there probably is a real difference between treatments. If the p value is 0.001 or less (less than a 1% probability that the results occurred by chance), the result is seen as highly significant.</p> <p>If the p value shows that there is likely to be a difference between treatments, the confidence interval describes how big the difference in effect might be.</p>
Perioperative	<p>The period from admission through surgery until discharge, encompassing the preoperative and postoperative periods.</p>
Placebo	<p>A fake (or dummy) treatment given to participants in the control group of a clinical trial. It is indistinguishable from the actual treatment (which is given to participants in the experimental group). The aim is to determine what effect the experimental treatment has had – over and above any placebo effect caused because someone has received (or thinks they have received) care or attention.</p>
Polypharmacy	<p>The use or prescription of multiple medications.</p>
Posterior distribution	<p>In Bayesian statistics this is the probability distribution for a statistic based after combining established information or belief (the prior) with new evidence (the likelihood).</p>

Term	Definition
Positive predictive value (PPV)	In screening or diagnostic tests: A measure of the usefulness of a screening or diagnostic test. It is the proportion of those with a positive test result who have the disease, and can be interpreted as the probability that a positive test result is correct. It is calculated as follows: $TP/(TP+FP)$
Postoperative	Pertaining to the period after patients leave the operating theatre, following surgery.
Power (statistical)	The ability to demonstrate an association when one exists. Power is related to sample size; the larger the sample size, the greater the power and the lower the risk that a possible association could be missed.
Preoperative	The period before surgery commences.
Prior distribution	In Bayesian statistics this is the probability distribution for a statistic based on previous evidence or belief.
Primary care	Healthcare delivered outside hospitals. It includes a range of services provided by GPs, nurses, health visitors, midwives and other healthcare professionals and allied health professionals such as dentists, pharmacists and opticians.
Primary outcome	The outcome of greatest importance, usually the one in a study that the power calculation is based on.
Probabilistic analysis	In economic evaluation, this is an analysis that uses a probability distribution for each input. In contrast, see Deterministic analysis.
Product licence	An authorisation from the MHRA to market a medicinal product.
Prognosis	A probable course or outcome of a disease. Prognostic factors are patient or disease characteristics that influence the course. Good prognosis is associated with low rate of undesirable outcomes; poor prognosis is associated with a high rate of undesirable outcomes.
Prospective study	A research study in which the health or other characteristic of participants is monitored (or 'followed up') for a period of time, with events recorded as they happen. This contrasts with retrospective studies.
Publication bias	Publication bias occurs when researchers publish the results of studies showing that a treatment works well and don't publish those showing it did not have any effect. If this happens, analysis of the published results will not give an accurate idea of how well the treatment works. This type of bias can be assessed by a funnel plot.
Quality of life	See 'Health-related quality of life'.
Quality-adjusted life year (QALY)	A measure of the state of health of a person or group in which the benefits, in terms of length of life, are adjusted to reflect the quality of life. One QALY is equal to 1 year of life in perfect health. QALYS are calculated by estimating the years of life remaining for a patient following a particular treatment or intervention and weighting each year with a quality of life score (on a scale of 0 to 1). It is often measured in terms of the person's ability to perform the activities of daily life, freedom from pain and mental disturbance.
Randomisation	Assigning participants in a research study to different groups without taking any similarities or differences between them into account. For example, it could involve using a random numbers table or a computer-generated random sequence. It means that each individual (or each group in the case of cluster randomisation) has the same chance of receiving each intervention.
Randomised controlled trial (RCT)	A study in which a number of similar people are randomly assigned to 2 (or more) groups to test a specific drug or treatment. One group (the

Term	Definition
	<p>experimental group) receives the treatment being tested, the other (the comparison or control group) receives an alternative treatment, a dummy treatment (placebo) or no treatment at all. The groups are followed up to see how effective the experimental treatment was. Outcomes are measured at specific times and any difference in response between the groups is assessed statistically. This method is also used to reduce bias.</p>
RCT	See 'Randomised controlled trial'.
Receiver operated characteristic (ROC) curve	<p>A graphical method of assessing the accuracy of a diagnostic test. Sensitivity is plotted against 1 minus specificity. A perfect test will have a positive, vertical linear slope starting at the origin. A good test will be somewhere close to this ideal.</p>
Reporting bias	See 'Publication bias'.
Resource implication	The likely impact in terms of finance, workforce or other NHS resources.
Retrospective study	<p>A research study that focuses on the past and present. The study examines past exposure to suspected risk factors for the disease or condition. Unlike prospective studies, it does not cover events that occur after the study group is selected.</p>
Review question	<p>In guideline development, this term refers to the questions about treatment and care that are formulated to guide the development of evidence-based recommendations.</p>
Risk ratio (RR)	<p>The ratio of the risk of disease or death among those exposed to certain conditions compared with the risk for those who are not exposed to the same conditions (for example, the risk of people who smoke getting lung cancer compared with the risk for people who do not smoke).</p> <p>If both groups face the same level of risk, the risk ratio is 1. If the first group had a risk ratio of 2, subjects in that group would be twice as likely to have the event happen. A risk ratio of less than 1 means the outcome is less likely in the first group. The risk ratio is sometimes referred to as relative risk.</p>
Secondary outcome	An outcome used to evaluate additional effects of the intervention deemed a priori as being less important than the primary outcomes.
Selection bias	<p>Selection bias occurs if:</p> <ul style="list-style-type: none"> a) The characteristics of the people selected for a study differ from the wider population from which they have been drawn, or b) There are differences between groups of participants in a study in terms of how likely they are to get better.
Sensitivity	<p>How well a test detects the thing it is testing for.</p> <p>If a diagnostic test for a disease has high sensitivity, it is likely to pick up all cases of the disease in people who have it (that is, give a 'true positive' result). But if a test is too sensitive it will sometimes also give a positive result in people who don't have the disease (that is, give a 'false positive').</p> <p>For example, if a test were developed to detect if a woman is 6 months pregnant, a very sensitive test would detect everyone who was 6 months pregnant, but would probably also include those who are 5 and 7 months pregnant.</p> <p>If the same test were more specific (sometimes referred to as having higher specificity), it would detect only those who are 6 months pregnant, and someone who was 5 months pregnant would get a negative result (a 'true negative'). But it would probably also miss some people who were 6 months pregnant (that is, give a 'false negative').</p> <p>Breast screening is a 'real-life' example. The number of women who are recalled for a second breast screening test is relatively high because the</p>

Term	Definition
	test is very sensitive. If it were made more specific, people who don't have the disease would be less likely to be called back for a second test but more women who have the disease would be missed.
Sensitivity analysis	<p>A means of representing uncertainty in the results of economic evaluations. Uncertainty may arise from missing data, imprecise estimates or methodological controversy. Sensitivity analysis also allows for exploring the generalisability of results to other settings. The analysis is repeated using different assumptions to examine the effect on the results.</p> <p>One-way simple sensitivity analysis (univariate analysis): each parameter is varied individually in order to isolate the consequences of each parameter on the results of the study.</p> <p>Multi-way simple sensitivity analysis (scenario analysis): 2 or more parameters are varied at the same time and the overall effect on the results is evaluated.</p> <p>Threshold sensitivity analysis: the critical value of parameters above or below which the conclusions of the study will change are identified.</p> <p>Probabilistic sensitivity analysis: probability distributions are assigned to the uncertain parameters and are incorporated into evaluation models based on decision analytical techniques (for example, Monte Carlo simulation).</p>
Significance (statistical)	A result is deemed statistically significant if the probability of the result occurring by chance is less than 1 in 20 ($p < 0.05$).
Specificity	<p>The proportion of true negatives that are correctly identified as such. For example in diagnostic testing the specificity is the proportion of non-cases correctly diagnosed as non-cases.</p> <p>See related term 'Sensitivity'.</p> <p>In terms of literature searching a highly specific search is generally narrow and aimed at picking up the key papers in a field and avoiding a wide range of papers.</p>
Stakeholder	<p>An organisation with an interest in a topic that NICE is developing a guideline or piece of public health guidance on. Organisations that register as stakeholders can comment on the draft scope and the draft guidance. Stakeholders may be:</p> <ul style="list-style-type: none"> • manufacturers of drugs or equipment • national patient and carer organisations • NHS organisations • organisations representing healthcare professionals.
State transition model	See Markov model
Systematic review	A review in which evidence from scientific studies has been identified, appraised and synthesised in a methodical way according to predetermined criteria. It may include a meta-analysis.
Time horizon	The time span over which costs and health outcomes are considered in a decision analysis or economic evaluation.
Transition probability	In a state transition model (Markov model), this is the probability of moving from one health state to another over a specific period of time.
Treatment allocation	Assigning a participant to a particular arm of a trial.
Univariate	Analysis which separately explores each variable in a data set.
Utility	In health economics, a 'utility' is the measure of the preference or value that an individual or society places upon a particular health state. It is generally a number between 0 (representing death) and 1 (perfect health). The most widely used measure of benefit in cost–utility analysis is the

Term	Definition
	quality-adjusted life year, but other measures include disability-adjusted life years (DALYs) and healthy year equivalents (HYEs).

1

1 Reference list

- 2 1. Agnelli G, Bergqvist D, Cohen AT, Gallus AS, Gent M. Randomized clinical trial of
3 postoperative fondaparinux versus perioperative dalteparin for prevention of venous
4 thromboembolism in high-risk abdominal surgery. *British Journal of Surgery*. 2005;
5 92(10):1212-1220
- 6 2. Agnelli G, Piovella F, Buoncristiani P, Severi P, Pini M, D'Angelo A et al. Enoxaparin plus
7 compression stockings compared with compression stockings alone in the prevention of
8 venous thromboembolism after elective neurosurgery. *New England Journal of Medicine*.
9 1998; 339(2):80-85
- 10 3. Alfaro MJ, Paramo JA, Rocha E. Prophylaxis of thromboembolic disease and platelet-related
11 changes following total hip replacement: a comparative study of aspirin and heparin-
12 dihydroergotamine. *Thrombosis and Haemostasis*. 1986; 56(1):53-56
- 13 4. Alkire MR, Swank ML. Use of inpatient continuous passive motion versus no CPM in
14 computer-assisted total knee arthroplasty. *Orthopaedic Nursing*. 2010; 29(1):36-40
- 15 5. Allan A, Williams JT, Bolton JP, Le Quesne LP. The use of graduated compression stockings in
16 the prevention of postoperative deep vein thrombosis. *British Journal of Surgery*. 1983;
17 70(3):172-174
- 18 6. Allen NH, Jenkins JD, Smart CJ. Surgical haemorrhage in patients given subcutaneous heparin
19 as prophylaxis against thromboembolism. *British Medical Journal*. 1978; 1(6123):1326
- 20 7. Amaragiri SV, Lees TA. Elastic compression stockings for prevention of deep vein thrombosis.
21 *Cochrane Database of Systematic Reviews* 2000, Issue 1. Art. No.: CD001484. DOI:
22 10.1002/14651858.CD001484.pub2.
- 23 8. Anderson DR, Dunbar MJ, Bohm ER, Belzile E, Kahn SR, Zukor D et al. Aspirin versus low-
24 molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip
25 arthroplasty: a randomized trial. *Annals of Internal Medicine*. 2013; 158(11):800-806
- 26 9. Anglen JO, Bagby C, George R. A randomized comparison of sequential-gradient calf
27 compression with intermittent plantar compression for prevention of venous thrombosis in
28 orthopedic trauma patients: preliminary results. *American Journal of Orthopedics*. 1998;
29 27(1):53-58
- 30 10. Annemans L, Minjoulat-Rey MC, De Knock M, Vranckx K, Czarka M, Gabriel S et al. Cost
31 consequence analysis of fondaparinux versus enoxaparin in the prevention of venous
32 thromboembolism after major orthopaedic surgery in Belgium. *Acta Clinica Belgica*. 2004;
33 59(6):346-357
- 34 11. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of
35 antiplatelet therapy--III: Reduction in venous thrombosis and pulmonary embolism by
36 antiplatelet prophylaxis among surgical and medical patients. Antiplatelet Trialists'
37 Collaboration. *British Medical Journal*. 1994; 308(6923):235-246
- 38 12. Avikainen V, von Bonsdorff H, Partio E, Kaira P, Hakkinen S, Usenius JP et al. Low molecular
39 weight heparin (enoxaparin) compared with unfractionated heparin in prophylaxis of deep
40 venous thrombosis and pulmonary embolism in patients undergoing hip replacement.
41 *Annales Chirurgiae et Gynaecologiae*. 1995; 84(1):85-90

- 1 13. Ayo D, Blumberg SN, Rockman CR, Sadek M, Cayne N, Adelman M et al. Compression versus
2 no compression after endovenous ablation of the great saphenous vein: a randomized
3 controlled trial. *Annals of Vascular Surgery*. 2017; 38:72-77
- 4 14. Bailey JP, Kruger MP, Solano FX, Zajko AB, Rubash HE. Prospective randomized trial of
5 sequential compression devices vs low-dose warfarin for deep venous thrombosis
6 prophylaxis in total hip arthroplasty. *Journal of Arthroplasty*. 1991; 6(Suppl):S29-S35
- 7 15. Baker SP, O'Neill B, Haddon W, Jr., Long WB. The injury severity score: a method for
8 describing patients with multiple injuries and evaluating emergency care. *Journal of Trauma*.
9 1974; 14(3):187-196
- 10 16. Bartlett MA, Mauck KF, Daniels PR. Prevention of venous thromboembolism in patients
11 undergoing bariatric surgery. *Vascular Health and Risk Management*. 2015; 11:461-477
- 12 17. Bauer KA, Eriksson B, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for
13 the prevention of venous thromboembolism after elective major knee surgery. *New England*
14 *Journal of Medicine*. 2001; 345(18):1305-1310
- 15 18. Beghi C, Fragnito C, Antonelli A, Reverberi C, Ferrari P, Sacconi S et al. Prevention of deep
16 venous thrombosis by a new low molecular weight heparin (Fluxum) in cardiac surgery.
17 *International Angiology*. 1993; 12(4):383-386
- 18 19. Bejjani BB, Chen DC, Nolan NG, Edson M. Minidose heparin in transurethral prostatectomy.
19 *Urology*. 1983; 22(3):251-254
- 20 20. Belch JJ, Lowe GD, Pollock JG, Forbes CD, Prentice CR. Low dose heparin in the prevention of
21 deep-vein thrombosis after aortic bifurcation graft surgery. *Thrombosis and Haemostasis*.
22 1980; 42(5):1429-1433
- 23 21. Bergqvist D. Enoxaparin. A pharmacoeconomic review of its use in the prevention and
24 treatment of venous thromboembolism and in acute coronary syndromes.
25 *Pharmacoeconomics*. 2002; 20(4):225-243
- 26 22. Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A et al. Duration of
27 prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. *New*
28 *England Journal of Medicine*. 2002; 346(13):975-980
- 29 23. Bergqvist D, Benoni G, Björgell O, Fredin H, Hedlundh U, Nicolas S et al. Low-molecular-
30 weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip
31 replacement. *New England Journal of Medicine*. 1996; 335(10):696-700
- 32 24. Bergqvist D, Burmark US, Flordal PA, Frisell J, Hallböök T, Hedberg M et al. Low molecular
33 weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500
34 versus 5000 Xal units in 2070 patients. *British Journal of Surgery*. 1995; 82(4):496-501
- 35 25. Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B et al. Low molecular
36 weight heparin once daily compared with conventional low-dose heparin twice daily. A
37 prospective double-blind multicentre trial on prevention of postoperative thrombosis. *British*
38 *Journal of Surgery*. 1986; 73(3):204-208
- 39 26. Bergqvist D, Burmark US, Frisell J, Hallböök T, Lindblad B, Risberg B et al. Prospective double-
40 blind comparison between Fragmin and conventional low-dose heparin:
41 thromboprophylactic effect and bleeding complications. *Haemostasis*. 1986; 16(Suppl 2):11-
42 18

- 1 27. Bergqvist D, Efsing HO, Hallbook T, Hedlund T. Thromboembolism after elective and post-
2 traumatic hip surgery--a controlled prophylactic trial with dextran 70 and low-dose heparin.
3 *Acta Chirurgica Scandinavica*. 1979; 145(4):213-218
- 4 28. Bergqvist D, Flordal PA, Friberg B, Frisell J, Hedberg M, Ljungström KG et al.
5 Thromboprophylaxis with a low molecular weight heparin (tinzaparin) in emergency
6 abdominal surgery. A double-blind multicenter trial. *Vasa*. 1996; 25(2):156-160
- 7 29. Bergqvist D, Hallbook T. Prophylaxis of postoperative venous thrombosis in a controlled trial
8 comparing dextran 70 and low-dose heparin. *World Journal of Surgery*. 1980; 4(2):239-243
- 9 30. Bergqvist D, Matzsch T, Burmark US, Frisell J, Guilbaud O, Hallbook T et al. Low molecular
10 weight heparin given the evening before surgery compared with conventional low-dose
11 heparin in prevention of thrombosis. *British Journal of Surgery*. 1988; 75(9):888-891
- 12 31. Bern MM, Hazel D, Deeran E, Richmond JR, Ward DM, Spitz DJ et al. Low dose compared to
13 variable dose warfarin and to fondaparinux as prophylaxis for thromboembolism after
14 elective hip or knee replacement surgery; a randomized, prospective study. *Thrombosis*
15 *Journal*. 2015; 13:32
- 16 32. Bischof M, Leuppi JD, Sendi P. Cost-effectiveness of extended venous thromboembolism
17 prophylaxis with fondaparinux in hip surgery patients. *Expert Review of Pharmacoeconomics*
18 *and Outcomes Research*. 2006; 6(2):171-180
- 19 33. Bjorvatn A, Kristiansen F. Fondaparinux sodium compared with enoxaparin sodium: A cost-
20 effectiveness analysis. *American Journal of Cardiovascular Drugs*. 2005; 5(2):121-130
- 21 34. Blanchard J, Meuwly JY, Leyvraz PF, Miron MJ, Bounameaux H, Hoffmeyer P et al. Prevention
22 of deep-vein thrombosis after total knee replacement. Randomised comparison between a
23 low-molecular-weight heparin (nadroparin) and mechanical prophylaxis with a foot-pump
24 system. *Journal of Bone and Joint Surgery (British Volume)*. 1999; 81(4):654-659
- 25 35. Bloch BV, Patel V, Best AJ. Thromboprophylaxis with dabigatran leads to an increased
26 incidence of wound leakage and an increased length of stay after total joint replacement.
27 *Bone Joint J*. 2014; 96-B(1):122-126
- 28 36. Board NE. National Joint Registry 13th Annual Report. 2016. Available from:
29 [http://www.njrreports.org.uk/Portals/0/PDFdownloads/NJR%2013th%20Annual%20Report%](http://www.njrreports.org.uk/Portals/0/PDFdownloads/NJR%2013th%20Annual%20Report%202016.pdf)
30 [202016.pdf](http://www.njrreports.org.uk/Portals/0/PDFdownloads/NJR%2013th%20Annual%20Report%202016.pdf)
- 31 37. Borstad E, Urdal K, Handeland G, Abildgaard U. Comparison of low molecular weight heparin
32 vs. unfractionated heparin in gynecological surgery. *Acta Obstetrica et Gynecologica*
33 *Scandinavica*. 1988; 67(2):99-103
- 34 38. Borstad E, Urdal K, Handeland G, Abildgaard U. Comparison of low molecular weight heparin
35 vs. unfractionated heparin in gynecological surgery. II: Reduced dose of low molecular weight
36 heparin. *Acta Obstetrica et Gynecologica Scandinavica*. 1992; 71(6):471-475
- 37 39. Braidy N, Bui K, Bajorek B. Evaluating the impact of new anticoagulants in the hospital
38 setting. *Pharmacy Practice*. 2011; 9(1):1-10
- 39 40. Broadman LM. Non-steroidal anti-inflammatory drugs, antiplatelet medications and spinal
40 axis anesthesia. *Best Practice & Research Clinical Anaesthesiology*. 2005; 19(1):47-58
- 41 41. Bruntink MM, Groutars YM, Schipper IB, Breederveld RS, Tuinebreijer WE, Derksen RJ.
42 Nadroparin or fondaparinux versus no thromboprophylaxis in patients immobilised in a

- 1 below-knee plaster cast (PROTECT): A randomised controlled trial. *Injury*. 2017; 48(4):936-
2 940
- 3 42. Butson AR. Intermittent pneumatic calf compression for prevention of deep venous
4 thrombosis in general abdominal surgery. *American Journal of Surgery*. 1981; 142(4):525-527
- 5 43. Bynke O, Hillman J, Lassvik C. Does peroperative external pneumatic leg muscle compression
6 prevent post-operative venous thrombosis in neurosurgery? *Acta Neurochirurgica*. 1987;
7 88(1-2):46-48
- 8 44. Caen JP. A randomized double-blind study between a low molecular weight heparin Kabi
9 2165 and standard heparin in the prevention of deep vein thrombosis in general surgery. A
10 French multicenter trial. *Thrombosis and Haemostasis*. 1988; 59(2):216-220
- 11 45. Camporese G, Bernardi E, Noventa F, Bosco M, Monteleone G, Santoro L et al. Efficacy of
12 Rivaroxaban for thromboprophylaxis after Knee Arthroscopy (ERIKA). A phase II, multicentre,
13 double-blind, placebo-controlled randomised study. *Thrombosis and Haemostasis*. 2016;
14 116(2):349-355
- 15 46. Camporese G, Bernardi E, Prandoni P, Noventa F, Verlato F, Simioni P et al. Low-molecular-
16 weight heparin versus compression stockings for thromboprophylaxis after knee
17 arthroscopy: a randomized trial. *Annals of Internal Medicine*. 2008; 149(2):73-82
- 18 47. Capri S, Ageno W, Imberti D, Palareti G, Piovella F, Scannapieco G et al. Extended prophylaxis
19 of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic
20 surgery in Italy: a cost-effectiveness analysis. *Internal and Emergency Medicine*. 2010;
21 5(1):33-40
- 22 48. Caprini JA, Chucker JL, Zuckerman L. Thrombosis prophylaxis using external compression.
23 *Surgery, Gynecology and Obstetrics*. 1983; 156(5):599-604
- 24 49. Cerrato D, Ariano C, Fiacchino F. Deep vein thrombosis and low-dose heparin prophylaxis in
25 neurosurgical patients. *Journal of Neurosurgery*. 1978; 49(3):378-381
- 26 50. Chandhoke PS, Gooding GA, Narayan P. Prospective randomized trial of warfarin and
27 intermittent pneumatic leg compression as prophylaxis for postoperative deep venous
28 thrombosis in major urological surgery. *Journal of Urology*. 1992; 147(4):1056-1059
- 29 51. Chiasson TC, Manns BJ, Stelfox HT. An economic evaluation of venous thromboembolism
30 prophylaxis strategies in critically ill trauma patients at risk of bleeding. *PLoS Medicine*. 2009;
31 6(6)
- 32 52. Chin PL, Amin MS, Yang KY, Yeo SJ, Lo NN. Thromboembolic prophylaxis for total knee
33 arthroplasty in Asian patients: a randomised controlled trial. *Journal of Orthopaedic Surgery*.
34 2009; 17(1):1-5
- 35 53. Cho KY, Kim KI, Khurana S, Bae DK, Jin W. Is routine chemoprophylaxis necessary for
36 prevention of venous thromboembolism following knee arthroplasty in a low incidence
37 population? *Archives of Orthopaedic and Trauma Surgery*. 2013; 133(4):551-559
- 38 54. Clarke-Pearson DL, Coleman RE, Synan IS, Hinshaw W, Creasman WT. Venous
39 thromboembolism prophylaxis in gynecologic oncology: a prospective, controlled trial of low-
40 dose heparin. *American Journal of Obstetrics and Gynecology*. 1983; 145(5):606-613
- 41 55. Clarke-Pearson DL, Creasman WT, Coleman RE, Synan IS, Hinshaw WM. Perioperative
42 external pneumatic calf compression as thromboembolism prophylaxis in gynecologic

- 1 oncology: report of a randomized controlled trial. *Gynecologic Oncology*. 1984; 18(2):226-
2 232
- 3 56. Clarke-Pearson DL, Synan IS, Dodge R, Soper JT, Berchuck A, Coleman RE. A randomized trial
4 of low-dose heparin and intermittent pneumatic calf compression for the prevention of deep
5 venous thrombosis after gynecologic oncology surgery. *American Journal of Obstetrics and
6 Gynecology*. 1993; 168(4):1146-1153
- 7 57. Clarke-Pearson DL, Synan IS, Hinshaw WM, Coleman RE, Creasman WT. Prevention of
8 postoperative venous thromboembolism by external pneumatic calf compression in patients
9 with gynecologic malignancy. *Obstetrics and Gynecology*. 1984; 63(1):92-98
- 10 58. Coe NP, Collins RE, Klein LA, Bettmann MA, Skillman JJ, Shapiro RM et al. Prevention of deep
11 vein thrombosis in urological patients: a controlled, randomized trial of low-dose heparin and
12 external pneumatic compression boots. *Surgery*. 1978; 83(2):230-234
- 13 59. Cohen AT, Skinner JA, Warwick D, Brenkel I. The use of graduated compression stockings in
14 association with fondaparinux in surgery of the hip: a multicentre, multinational,
15 randomised, open-label, parallel-group comparative study. *Journal of Bone and Joint Surgery
16 (British Volume)*. 2007; 89-B(7):887-892
- 17 60. Cohn SM, Moller BA, Feinstein AJ, Burns GA, Ginzburg E, Hammers LW. Prospective trial of
18 low-molecular-weight heparin versus unfractionated heparin in moderately injured patients.
19 *Vascular Surgery*. 1999; 33(2):219-223
- 20 61. Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous
21 thrombosis by perioperative administration of subcutaneous heparin. Overview of results of
22 randomized trials in general, orthopedic, and urologic surgery. *New England Journal of
23 Medicine*. 1988; 318(18):1162-1173
- 24 62. Colwell CW, Jr., Collis DK, Paulson R, McCutchen JW, Bigler GT, Lutz S et al. Comparison of
25 enoxaparin and warfarin for the prevention of venous thromboembolic disease after total
26 hip arthroplasty. Evaluation during hospitalization and three months after discharge. *Journal
27 of Bone and Joint Surgery (American Volume)*. 1999; 81(7):932-940
- 28 63. Colwell CW, Jr., Spiro TE, Trowbridge AA, Morris BA, Kwaan HC, Blaha JD et al. Use of
29 enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention
30 of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy
31 and safety. Enoxaparin Clinical Trial Group. *Journal of Bone and Joint Surgery*. 1994; 76(1):3-
32 14
- 33 64. Colwell CW, Spiro TE, Trowbridge AA, Stephens JW, Gardiner GA, Ritter MA. Efficacy and
34 safety of enoxaparin versus unfractionated heparin for prevention of deep venous
35 thrombosis after elective knee arthroplasty. Enoxaparin Clinical Trial Group. *Clinical
36 Orthopaedics and Related Research*. 1995; 321:19-27
- 37 65. Colwell CWJ, Froimson MI, Mont MA, Ritter MA, Trousdale RT, Buehler KC et al. Thrombosis
38 prevention after total hip arthroplasty: a prospective, randomized trial comparing a mobile
39 compression device with low-molecular-weight heparin. *Journal of Bone and Joint Surgery -
40 American Volume*. 2010; 92(3):527-535
- 41 66. Comp PC, Spiro TE, Friedman RJ, Whitsett TL, Johnson GJ, Gardiner GA, Jr. et al. Prolonged
42 enoxaparin therapy to prevent venous thromboembolism after primary hip or knee
43 replacement. *Journal of Bone and Joint Surgery (American Volume)*. 2001; 83(3):336-345
- 44 67. Dahl OE, Andreassen G, Aspelin T, Müller C, Mathiesen P, Nyhus S et al. Prolonged
45 thromboprophylaxis following hip replacement surgery -- results of a double-blind,

- 1 prospective, randomised, placebo-controlled study with dalteparin (Fragmin). *Thrombosis*
2 and *Haemostasis*. 1997; 77(1):26-31
- 3 68. Dahl OE, Pleil AM. Investment in prolonged thromboprophylaxis with dalteparin improves
4 clinical outcomes after hip replacement. *Journal of Thrombosis and Haemostasis*. 2003;
5 1(5):896-906
- 6 69. Dauphin A, Raymer KE, Stanton EB, Fuller HD. Comparison of general anesthesia with and
7 without lumbar epidural for total hip arthroplasty: effects of epidural block on hip
8 arthroplasty. *Journal of Clinical Anesthesia*. 1997; 9(3):200-203
- 9 70. Davies LM, Richardson GA, Cohen AT. Economic evaluation of enoxaparin as postdischarge
10 prophylaxis for deep vein thrombosis (DVT) in elective hip surgery. *Value in Health*. 2000;
11 3(6):397-406
- 12 71. Dechavanne M, Saudin F, Viala JJ, Kher A, Bertrix L, de Mourgues G. Prevention of venous
13 thrombosis. Success of high doses of heparin during total hip replacement for osteoarthritis.
14 *La Nouvelle Presse Médicale*. 1974; 3(20):1317-1319
- 15 72. Dechavanne M, Ville D, Berruyer M, Trepo F, Dalery F, Clermont N et al. Randomized trial of a
16 low-molecular-weight heparin (Kabi 2165) versus adjusted-dose subcutaneous standard
17 heparin in the prophylaxis of deep-vein thrombosis after elective hip surgery. *Haemostasis*.
18 1989; 19(1):5-12
- 19 73. Decousus H, Leizorovicz A, Parent F, Page Y, Tardy B, Girard P et al. A clinical trial of vena
20 caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein
21 thrombosis: interruption cave study group. *New England Journal of Medicine*. 1998;
22 338(7):409-415
- 23 74. Dennis JW, Menawat S, Von Thron J, Fallon WF, Jr., Vinsant GO, Laneve LM et al. Efficacy of
24 deep venous thrombosis prophylaxis in trauma patients and identification of high-risk
25 groups. *Journal of Trauma*. 1993; 35(1):132-138
- 26 75. Diamantopoulos A, Lees M, Wells PS, Forster F, Ananthapavan J, McDonald H. Cost-
27 effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous
28 thromboembolism in Canada. *Thrombosis and Haemostasis*. 2010; 104(4):760-770
- 29 76. Dickinson LD, Miller LD, Patel CP, Gupta SK. Enoxaparin increases the incidence of
30 postoperative intracranial hemorrhage when initiated preoperatively for deep venous
31 thrombosis prophylaxis in patients with brain tumors. *Neurosurgery*. 1998; 43(5):1074-1081
- 32 77. Domeij-Arverud E, Labruto F, Latifi A, Nilsson G, Edman G, Ackermann PW. Intermittent
33 pneumatic compression reduces the risk of deep vein thrombosis during post-operative
34 lower limb immobilisation: a prospective randomised trial of acute ruptures of the Achilles
35 tendon. *Bone and Joint Journal*. 2015; 97-B(5):675-680
- 36 78. Domeij-Arverud E, Latifi A, Labruto F, Nilsson G, Ackermann PW. Can foot compression under
37 a plaster cast prevent deep-vein thrombosis during lower limb immobilisation? *Bone and*
38 *Joint Journal*. 2013; 95-B(9):1227-1231
- 39 79. Dranitsaris G, Kahn SR, Stumpo C, Paton TW, Martineau J, Smith R et al. Pharmacoeconomic
40 analysis of fondaparinux versus enoxaparin for the prevention of thromboembolic events in
41 orthopedic surgery patients. *American Journal of Cardiovascular Drugs*. 2004; 4(5):325-333
- 42 80. Dranitsaris G, Stumpo C, Smith R, Bartle W. Extended dalteparin prophylaxis for venous
43 thromboembolic events: cost-utility analysis in patients undergoing major orthopedic
44 surgery. *American Journal of Cardiovascular Drugs*. 2009; 9(1):45-58

- 1 81. Du W, Zhao C, Wang J, Liu J, Shen B, Zheng Y. Comparison of rivaroxaban and parnaparin for
2 preventing venous thromboembolism after lumbar spine surgery. *Journal of Orthopaedic*
3 *Surgery and Research*. 2015; 10:78
- 4 82. Elliott CG, Dudney TM, Egger M. Calf-thigh sequential pneumatic compression compared
5 with plantar venous pneumatic compression to prevent deep-vein thrombosis after non-
6 lower extremity trauma. *Journal of Trauma*. 1999; 47(1):25-32
- 7 83. Eriksson B, Dahl OE, Rosencher N, Kurth A, Niek van Dijk C, Frostick S et al. Dabigatran
8 etexilate versus enoxaparin for prevention of venous thromboembolism after total hip
9 replacement: a randomised, double-blind, non-inferiority trial. *Lancet*. 2007; 370(9591):949-
10 956
- 11 84. Eriksson B, I, Kälebo P, Anthymyr BA, Wadenvik H, Tengborn L, Risberg B. Prevention of deep-
12 vein thrombosis and pulmonary embolism after total hip replacement. Comparison of low-
13 molecular-weight heparin and unfractionated heparin. *Journal of Bone and Joint Surgery*.
14 1991; 73(4):484-493
- 15 85. Eriksson BI, Bauer KA, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for
16 the prevention of venous thromboembolism after hip-fracture surgery. *New England Journal*
17 *of Medicine*. 2001; 345(18):1298-1304
- 18 86. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK et al. Rivaroxaban versus
19 enoxaparin for thromboprophylaxis after hip arthroplasty. *New England Journal of Medicine*.
20 2008; 358(26):2765-2775
- 21 87. Eriksson BI, Dahl OE, Huo MH, Kurth AA, Hantel S, Hermansson K et al. Oral dabigatran versus
22 enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A
23 randomised, double-blind, non-inferiority trial. *Thrombosis and Haemostasis*. 2011;
24 105(4):721-729
- 25 88. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP et al. Dabigatran
26 etexilate versus enoxaparin for the prevention of venous thromboembolism after total knee
27 replacement: the RE-MODEL randomized trial. *Journal of Thrombosis and Haemostasis*. 2007;
28 5(11):2178-2185
- 29 89. Eriksson BI, Lassen MR. Duration of prophylaxis against venous thromboembolism with
30 fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled,
31 double-blind study. *Archives of Internal Medicine*. 2003; 163(11):1337-1342
- 32 90. Eskeland G, Solheim K, Skjorten F. Anticoagulant prophylaxis, thromboembolism and
33 mortality in elderly patients with hip fractures. A controlled clinical trial. *Acta Chirurgica*
34 *Scandinavica*. 1966; 131(1):16-29
- 35 91. Farkas JC, Chapuis C, Combe S, Silsiguen M, Marzelle J, Laurian C et al. A randomised
36 controlled trial of a low-molecular-weight heparin (Enoxaparin) to prevent deep-vein
37 thrombosis in patients undergoing vascular surgery. *European Journal of Vascular Surgery*.
38 1993; 7(5):554-560
- 39 92. Fasting H, Andersen K, Kraemmer-Nielsen H, Husted SE, Koopmann HD, Simonsen O et al.
40 Prevention of postoperative deep venous thrombosis. Low-dose heparin versus graded
41 pressure stockings. *Acta Chirurgica Scandinavica*. 1985; 151(3):245-248
- 42 93. Faunø P, Suomalainen O, Rehnberg V, Hansen TB, Krøner K, Soimakallio S et al. Prophylaxis
43 for the prevention of venous thromboembolism after total knee arthroplasty. A comparison
44 between unfractionated and low-molecular-weight heparin. *Journal of Bone and Joint*
45 *Surgery*. 1994; 76(12):1814-1818

- 1 94. Fisher CG, Blachut PA, Salvian AJ, Meek RN, O'Brien PJ. Effectiveness of pneumatic leg
2 compression devices for the prevention of thromboembolic disease in orthopaedic trauma
3 patients: a prospective, randomized study of compression alone versus no prophylaxis.
4 *Journal of Orthopaedic Trauma*. 1995; 9(1):1-7
- 5 95. Fitzgerald RH, Jr., Spiro TE, Trowbridge AA, Gardiner GA, Jr., Whitsett TL, O'Connell MB et al.
6 Prevention of venous thromboembolic disease following primary total knee arthroplasty. A
7 randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin.
8 *Journal of Bone and Joint Surgery*. 2001; 83-A(6):900-906
- 9 96. Flicoteaux H, Kher A, Jean N, Blery M, Judet T, Honnart F et al. Comparison of low dose
10 heparin and low dose heparin combined with aspirin in prevention of deep vein thrombosis
11 after total hip replacement. *Pathologie Biologie*. 1977; 25(Suppl):55-58
- 12 97. Fordyce MJ, Ling RS. A venous foot pump reduces thrombosis after total hip replacement.
13 *Journal of Bone and Joint Surgery (British Volume)*. 1992; 74(1):45-49
- 14 98. Forster R, Stewart M. Anticoagulants (extended duration) for prevention of venous
15 thromboembolism following total hip or knee replacement or hip fracture repair. *Cochrane*
16 *Database Syst Rev* 2016, Issue 3. Art. No.: CD004179. DOI:
17 10.1002/14651858.CD004179.pub2.
- 18 99. Francis CW, Pellegrini Jr V, Marder VJ, Totterman S, Harris CM, Gabriel KR et al. Comparison
19 of warfarin and external pneumatic compression in prevention of venous thrombosis after
20 total hip replacement. *JAMA*. 1992; 267(21):2911-2915
- 21 100. Francis CW, Pellegrini VD, Totterman S, Boyd AD, Marder VJ, Liebert KM et al. Prevention of
22 deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin.
23 *Journal of Bone and Joint Surgery (American Volume)*. 1997; 79(9):1365-1372
- 24 101. Freick H, Haas S. Prevention of deep vein thrombosis by low-molecular-weight heparin and
25 dihydroergotamine in patients undergoing total hip replacement. *Thrombosis Research*.
26 1991; 63(1):133-143
- 27 102. Fricker JP, Vergnes Y, Schach R, Heitz A, Eber M, Grunebaum L et al. Low dose heparin versus
28 low molecular weight heparin (Kabi 2165, Fragmin) in the prophylaxis of thromboembolic
29 complications of abdominal oncological surgery. *European Journal of Clinical Investigation*.
30 1988; 18(6):561-567
- 31 103. Fuchs S, Heyse T, Rudofsky G, Goshager G, Chylarecki C. Continuous passive motion in the
32 prevention of deep-vein thrombosis: a randomised comparison in trauma patients. *Journal of*
33 *Bone and Joint Surgery (British Volume)*. 2005; 87(8):1117-1122
- 34 104. Fuji T, Fujita S, Ujihira T, Sato T. Dabigatran etexilate prevents venous thromboembolism
35 after total knee arthroplasty in Japanese patients with a safety profile comparable to
36 placebo. *Journal of Arthroplasty*. 2010; 25(8):1267-1274
- 37 105. Fuji T, Fujita S, Ochi T. Fondaparinux prevents venous thromboembolism after joint
38 replacement surgery in Japanese patients. *International Orthopaedics*. 2008; 32(4):443-451
- 39 106. Fuji T, Ochi T, Niwa S, Fujita S. Prevention of postoperative venous thromboembolism in
40 Japanese patients undergoing total hip or knee arthroplasty: Two randomized, double-blind,
41 placebo-controlled studies with three dosage regimens of enoxaparin. *Journal of*
42 *Orthopaedic Science*. 2008; 13(5):442-451

- 1 107. Galasko CS, Edwards DH, Fearn CB, Barber HM. The value of low dosage heparin for the
2 prophylaxis of thromboembolism in patients with transcervical and intertrochanteric femoral
3 fractures. *Acta Orthopaedica Scandinavica*. 1976; 47(3):276-282
- 4 108. Gallus A, Raman K, Darby T. Venous thrombosis after elective hip replacement--the influence
5 of preventive intermittent calf compression and of surgical technique. *British Journal of*
6 *Surgery*. 1983; 70(1):17-19
- 7 109. Gallus AS, Hirsh J, O'Brien SE, McBride JA, Tuttle RJ, Gent M. Prevention of venous
8 thrombosis with small, subcutaneous doses of heparin. *JAMA*. 1976; 235(18):1980-1982
- 9 110. Gallus AS, Hirsh J, Tuttle RJ, Trebilcock R, O'Brien SE, Carroll JJ et al. Small subcutaneous doses
10 of heparin in prevention of venous thrombosis. *New England Journal of Medicine*. 1973;
11 288(11):545-551
- 12 111. Gao J, Zhang ZY, Li Z, Liu CD, Zhan YX, Qiao BL et al. Two mechanical methods for
13 thromboembolism prophylaxis after gynaecological pelvic surgery: a prospective,
14 randomised study. *Chinese Medical Journal*. 2012; 125(23):4259-4263
- 15 112. Geerts WH, Jay RM, Code KI. A comparison of low-dose heparin with low-molecular-weight
16 heparin as prophylaxis against venous thromboembolism after major trauma. *New England*
17 *Journal of Medicine*. 1996; 335(10):701-707
- 18 113. Ginzburg E, Cohn SM, Lopez J, Jackowski J, Brown M, Hameed SM. Randomized clinical trial
19 of intermittent pneumatic compression and low molecular weight heparin in trauma. *British*
20 *Journal of Surgery*. 2003; 90(11):1338-1344
- 21 114. Goel DP, Buckley R, deVries G, Abelseth G, Ni A, Gray R. Prophylaxis of deep-vein thrombosis
22 in fractures below the knee: a prospective randomised controlled trial. *Journal of Bone and*
23 *Joint Surgery (British Volume)*. 2009; 91(3):388-394
- 24 115. Goldhaber SZ, Dunn K, Gerhard-Herman M, Park JK, Black PM. Low rate of venous
25 thromboembolism after craniotomy for brain tumor using multimodality prophylaxis. *Chest*.
26 2002; 122(6):1933-1937
- 27 116. Goldhaber SZ, Hirsch DR, MacDougall RC, Polak JF, Creager MA, Cohn LH. Prevention of
28 venous thrombosis after coronary artery bypass surgery (a randomized trial comparing two
29 mechanical prophylaxis strategies). *American Journal of Cardiology*. 1995; 76(14):993-996
- 30 117. Gomez-Outes A, Avendano-Sola C, Terleira-Fernandez AI, Vargas-Castrillon E.
31 Pharmacoeconomic evaluation of dabigatran, rivaroxaban and apixaban versus enoxaparin
32 for the prevention of venous thromboembolism after total hip or knee replacement in Spain.
33 *Pharmacoeconomics*. 2014; 32(9):919-936
- 34 118. Gonzalez EM, Fontcuberta J, De I. Prophylaxis of thromboembolic disease with RO-11 (ROVI),
35 during abdominal surgery. *Hepato Gastroenterology*. 1996; 43(9):744-747
- 36 119. Gordois A, Posnett J, Borris L, Bossuyt P, Jonsson B, Levy E et al. The cost-effectiveness of
37 fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following
38 major orthopedic surgery. *Journal of Thrombosis and Haemostasis*. 2003; 1(10):2167-2174
- 39 120. Gordon-Smith IC, Le Quesne LP, Grundy DJ, Newcombe JF, Bramble FJ. Controlled trial of two
40 regimens of subcutaneous heparin in prevention of postoperative deep-vein thrombosis.
41 *Lancet*. 1972; 1(7761):1133-1135

- 1 121. Gozzard D, Hutchinson J, Lloyd A, Hutchings A. Economic evaluation of extended and
2 conventional prophylaxis with enoxaparin against venous thromboembolism in patients
3 undergoing surgery for abdominal cancer. *Journal of Medical Economics*. 2004; 7:53-65
- 4 122. Green D, Lee MY, Lim AC. Prevention of thromboembolism after spinal cord injury using low-
5 molecular-weight heparin. *Annals of Internal Medicine*. 1990; 113(8):571-574
- 6 123. Green D, Rossi EC, Yao JS. Deep vein thrombosis in spinal cord injury : effect of prophylaxis
7 with calf compression, aspirin and dipyridamole. *Paraplegia*. 1982; 20:227-234
- 8 124. Haas S, Stemberger A, Fritsche HM, Welzel D, Wolf H, Lechner F et al. Prophylaxis of deep
9 vein thrombosis in high risk patients undergoing total hip replacement with low molecular
10 weight heparin plus dihydroergotamine. *Arzneimittel-Forschung*. 1987; 37(7):839-843
- 11 125. Haas SB, Insall JN, Scuderi GR, Windsor RE, Ghelman B. Pneumatic sequential-compression
12 boots compared with aspirin prophylaxis of deep-vein thrombosis after total knee
13 arthroplasty. *Journal of Bone and Joint Surgery*. 1990; 72(1):27-31
- 14 126. Haentjens P, De Groote K, Annemans L. Prolonged enoxaparin therapy to prevent venous
15 thromboembolism after primary hip or knee replacement. A cost-utility analysis. *Archives of
16 Orthopaedic and Trauma Surgery*. 2004; 124(8):507-517
- 17 127. Halim TA, Chhabra HS, Arora M, Kumar S. Pharmacological prophylaxis for deep vein
18 thrombosis in acute spinal cord injury: an Indian perspective. *Spinal Cord*. 2014; 52(7):547-
19 550
- 20 128. Hamidi V, Ringerike T, Hagen G, Reikvam A, Klemp M. New anticoagulants as
21 thromboprophylaxis after total hip or knee replacement. *International Journal of Technology
22 Assessment in Health Care*. 2013; 29(3):234-243
- 23 129. Hamilton HW, Crawford JS, Gardiner JH, Wiley AM. Venous thrombosis in patients with
24 fracture of the upper end of the femur. A phlebographic study of the effect of prophylactic
25 anticoagulation. *Journal of Bone and Joint Surgery (British Volume)*. 1970; 52(2):268-289
- 26 130. Hampson WG, Harris FC, Lucas HK, Roberts PH, McCall IW, Jackson PC et al. Failure of low-
27 dose heparin to prevent deep-vein thrombosis after hip-replacement arthroplasty. *Lancet*.
28 1974; 2(7884):795-797
- 29 131. Hansberry KL, Thompson IM, Jr., Bauman J, Deppe S, Rodriguez FR. A prospective comparison
30 of thromboembolic stockings, external sequential pneumatic compression stockings and
31 heparin sodium /dihydroergotamine mesylate for the prevention of thromboembolic
32 complications in urological surgery. *Journal of Urology*. 1991; 145(6):1205-1208
- 33 132. Hardwick ME, Pulido PA, Colwell CWJ. A mobile compression device compared with low-
34 molecular-weight heparin for prevention of venous thromboembolism in total hip
35 arthroplasty. *Orthopaedic Nursing*. 2011; 30(5):312-316
- 36 133. Harris WH, Athanasoulis CA, Waltman AC, Salzman EW. Prophylaxis of deep-vein thrombosis
37 after total hip replacement. Dextran and external pneumatic compression compared with 1.2
38 or 0.3 gram of aspirin daily. *Journal of Bone and Joint Surgery*. 1985; 67(1):57-62
- 39 134. Harris WH, Salzman EW, Athanasoulis C, Waltman AC, Baum S, DeSanctis RW. Comparison of
40 warfarin, low-molecular-weight dextran, aspirin, and subcutaneous heparin in prevention of
41 venous thromboembolism following total hip replacement. *Journal of Bone and Joint
42 Surgery*. 1974; 56(8):1552-1562

- 1 135. Harris WH, Salzman EW, Athanasoulis CA, Waltman AC, DeSanctis RW. Aspirin prophylaxis of
2 venous thromboembolism after total hip replacement. *New England Journal of Medicine*.
3 1977; 297(23):1246-1249
- 4 136. Hartl P, Brucke P, Dienstl E, Vinazzer H. Prophylaxis of thromboembolism in general surgery:
5 comparison between standard heparin and fragmin. *Thrombosis Research*. 1990; 57(4):577-
6 584
- 7 137. Hata K, Kimura T, Tsuzuki S, Ishii G, Kido M, Yamamoto T et al. Safety of fondaparinux for
8 prevention of postoperative venous thromboembolism in urological malignancy: A
9 prospective randomized clinical trial. *International Journal of Urology*. 2016; 23(11):923-928
- 10 138. Hauch O, Jorgensen LN, Kolle TR, Nerstrom H, Schebye O, Wille-Jorgensen P et al. Low
11 molecular weight heparin (Logiparin(TM)) as thromboprophylaxis in elective abdominal
12 surgery. A dose finding study. *Acta Chirurgica Scandinavica Supplementum*. 1988; 543:90-95
- 13 139. He ML, Xiao ZM, Lei M, Li TS, Wu H, Liao J. Continuous passive motion for preventing venous
14 thromboembolism after total knee arthroplasty. *Cochrane Database of Systematic Reviews*
15 2014, Issue 7. Art. No.: CD008207. DOI: 10.1002/14651858.CD008207.pub2.
- 16 140. Heit JA, Elliott CG, Trowbridge AA, Morrey BF, Gent M, Hirsh J. Ardeparin sodium for
17 extended out-of-hospital prophylaxis against venous thromboembolism after total hip or
18 knee replacement. A randomized, double-blind, placebo-controlled trial. *Annals of Internal*
19 *Medicine*. 2000; 132(11):853-861
- 20 141. Heit JA, Scott D, Berkowitz SD, Bona R, Cabanas V, Corson JD et al. Efficacy and safety of low
21 molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of
22 venous thromboembolism after total knee replacement surgery: A double- blind dose-
23 ranging study. *Thrombosis and Haemostasis*. 1997; 77(1):32-38
- 24 142. Hendolin H, Tuppurainen T, Lahtinen J. Thoracic epidural analgesia and deep vein thrombosis
25 in cholecystomized patients. *Acta Chirurgica Scandinavica*. 1982; 148(5):405-409
- 26 143. Holford CP. Graded compression for preventing deep venous thrombosis. *British Medical*
27 *Journal*. 1976; 2(6042):969-970
- 28 144. Hull R, Delmore TJ, Hirsch J, Gent M, Armstrong P, Lofthouse R et al. Effectiveness of
29 intermittent pulsative elastic stockings for the prevention of calf and thigh vein thrombosis in
30 patients undergoing elective knee surgery. *Thrombosis Research*. 1979; 16(1-2):37-45
- 31 145. Hull RD, Pineo GF, Francis C, Bergqvist D, Fellenius C, Soderberg K et al. Low-molecular-
32 weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip
33 arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin
34 Trial Investigators. *Archives of Internal Medicine*. 2000; 160(14):2199-2207
- 35 146. Hull RD, Pineo GF, Stein PD, Mah AF, MacIsaac SM, Dahl OE et al. Extended out-of-hospital
36 low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after
37 elective hip arthroplasty: a systematic review. *Annals of Internal Medicine*. 2001;
38 135(10):858-869
- 39 147. Hull RD, Raskob GE, Gent M, McLoughlin D, Julian D, Smith FC et al. Effectiveness of
40 intermittent pneumatic leg compression for preventing deep vein thrombosis after total hip
41 replacement. *JAMA*. 1990; 263(17):2313-2317
- 42 148. Hume M, Kuriakose TX, Zuch L, Turner RH. 125I fibrinogen and the prevention of venous
43 thrombosis. *Archives of Surgery*. 1973; 107(5):803-806

- 1 149. Imberti D, Baldini E, Pierfranceschi MG, Nicolini A, Cartelli C, De Paoli M et al. Prophylaxis of
2 venous thromboembolism with low molecular weight heparin in bariatric surgery: a
3 prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study).
4 *Obesity Surgery*. 2014; 24(2):284-291
- 5 150. Imberti D, Legnani C, Baldini E, Cini M, Nicolini A, Guerra M et al. Pharmacodynamics of low
6 molecular weight heparin in patients undergoing bariatric surgery: a prospective,
7 randomised study comparing two doses of parnaparin (BAFLUX study). *Thrombosis Research*.
8 2009; 124(6):667-671
- 9 151. Intiyanaravut T, Thongpulsawasdi N, Sinthuvanich N, Teavirat S, Kunopart M. Enoxaparin
10 versus no anticoagulation prophylaxis after total knee arthroplasty in Thai patients: A
11 randomized controlled trial. *Journal of the Medical Association of Thailand*. 2017; 100(1):42-
12 49
- 13 152. Jameson SS, Baker PN, Charman SC, Deehan DJ, Reed MR, Gregg PJ et al. The effect of aspirin
14 and low-molecular-weight heparin on venous thromboembolism after knee replacement: a
15 non-randomised comparison using national joint registry data. *Journal of Bone and Joint
16 Surgery (British Volume)*. 2012; 94(7):914-918
- 17 153. Jameson SS, Charman SC, Gregg PJ, Reed MR, Van Der Meulen JH. The effect of aspirin and
18 low-molecular-weight heparin on venous thromboembolism after hip replacement: A non-
19 randomised comparison from information in the National Joint Registry. *Journal of Bone and
20 Joint Surgery - Series B*. 2011; 93 B(11):1465-1470
- 21 154. Jørgensen PS, Knudsen JB, Broeng L, Josephsen L, Bjerregaard P, Hagen K et al. The
22 thromboprophylactic effect of a low-molecular-weight heparin (Fragmin) in hip fracture
23 surgery. A placebo-controlled study. *Clinical Orthopaedics and Related Research*. 1992;
24 278:95-100
- 25 155. Jorgensen PS, Warming T, Hansen K, Paltved C, Vibeke Berg H, Jensen R et al. Low molecular
26 weight heparin (Innohep) as thromboprophylaxis in outpatients with a plaster cast: a
27 venographic controlled study. *Thrombosis Research*. 2002; 105(6):477-480
- 28 156. Kaaja R, Lehtovirta P, Venesmaa P, Kajanoja P, Halonen P, Gummerus M et al. Comparison of
29 enoxaparin, a low-molecular-weight heparin, and unfractionated heparin, with or without
30 dihydroergotamine, in abdominal hysterectomy. *European Journal of Obstetrics, Gynecology,
31 and Reproductive Biology*. 1992; 47(2):141-145
- 32 157. Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J et al. Extended duration
33 rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism
34 after total hip arthroplasty: a double-blind, randomised controlled trial. *Lancet*. 2008;
35 372(9632):31-39
- 36 158. Kakkar VV, Balibrea JL, Martinez-Gonzalez J, Prandoni P, Group CS. Extended prophylaxis with
37 bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery
38 for cancer: the CANBESURE randomized study. *Journal of Thrombosis and Haemostasis*.
39 2010; 8(6):1223-1229
- 40 159. Kakkar VV, Cohen AT, Edmonson RA, Phillips MJ, Cooper DJ, Das SK et al. Low molecular
41 weight versus standard herapin for prevention of venous thromboembolism after major
42 abdominal surgery. *Lancet*. 1993; 341(8840):259-265
- 43 160. Kakkar VV, Corrigan T, Spindler J, Fossard DP, Flute PT, Crellin RQ et al. Efficacy of low doses
44 of heparin in prevention of deep-vein thrombosis after major surgery. A double-blind,
45 randomised trial. *Lancet*. 1972; 2(7768):101-106

- 1 161. Kakkar VV, Howes J, Sharma V, Kadziola Z. A comparative double-blind, randomised trial of a
2 new second generation LMWH (bemiparin) and UFH in the prevention of post-operative
3 venous thromboembolism. The Bemiparin Assessment group. *Thrombosis and Haemostasis*.
4 2000; 83(4):523-529
- 5 162. Kalfarentzos F, Stavropoulou F, Yarmenitis S, Kehagias I, Karamesini M, Dimitrakopoulos A et
6 al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-
7 weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. *Obesity
8 Surgery*. 2001; 11(6):670-676
- 9 163. Kalodiki EP, Hoppensteadt DA, Nicolaidis AN, Fareed J, Gill K, Regan F et al. Deep venous
10 thrombosis prophylaxis with low molecular weight heparin and elastic compression in
11 patients having total hip replacement. A randomised controlled trial. *International Angiology*.
12 1996; 15(2):162-168
- 13 164. Killewich LA, Aswad MA, Sandager GP, Lilly MP, Flinn WR. A randomized, prospective trial of
14 deep venous thrombosis prophylaxis in aortic surgery. *Archives of Surgery*. 1997; 132(5):499-
15 504
- 16 165. Knudson MM, Lewis FR, Clinton A, Atkinson K, Megerman J. Prevention of venous
17 thromboembolism in trauma patients. *Journal of Trauma*. 1994; 37(3):480-487
- 18 166. Knudson MM, Morabito D, Paiement GD. Use of low molecular weight heparin in preventing
19 thromboembolism in trauma patients. *Journal of Trauma*. 1996; 41(3):446-459
- 20 167. Koch A, Bouges S, Ziegler S, Dinkel H, Daures JP, Victor N. Low molecular weight heparin and
21 unfractionated heparin in thrombosis prophylaxis after major surgical intervention: update of
22 previous meta-analyses. *British Journal of Surgery*. 1997; 84(6):750-759
- 23 168. Kock H-J, Schmit-Neuerburg KP, Hanke J, Rudofsky G, Hirche H. Thromboprophylaxis with
24 low-molecular-weight heparin in outpatients with plaster-cast immobilisation of the leg.
25 *Lancet*. 1995; 346(8973):459-461
- 26 169. Koller M, Schoch U, Buchmann P, Largiader F, Von Felten A, Frick PG. Thrombosis prophylaxis
27 in visceral surgery with the low molecular weight heparin fragment Kabi 2165 (7,500 and
28 2,500 anti-Xa IU/day). *Haemostasis*. 1986; 16(Suppl 2):69-70
- 29 170. Koller M, Schoch U, Buchmann P, Largiader F, Von Felten A, Frick PG. Low molecular weight
30 heparin (KABI 2165) as thromboprophylaxis in elective visceral surgery. A randomized,
31 double-blind study versus unfractionated heparin. *Thrombosis and Haemostasis*. 1986;
32 56(3):243-246
- 33 171. Kolluri R, Plessa AL, Sanders MC, Singh NK, Lucore C. A randomized study of the safety and
34 efficacy of fondaparinux versus placebo in the prevention of venous thromboembolism after
35 coronary artery bypass graft surgery. *American Heart Journal*. 2016; 171(1):1-6
- 36 172. Kujath P, Spannagel U, Habscheid W. Incidence and prophylaxis of deep venous thrombosis
37 in outpatients with injury of the lower limb. *Haemostasis*. 1993; 23(Suppl 1):20-26
- 38 173. Kurtoglu M, Yanar H, Bilsel Y, Guloglu R, Kizilirmak S, Buyukkurt D et al. Venous
39 thromboembolism prophylaxis after head and spinal trauma: Intermittent pneumatic
40 compression devices versus low molecular weight heparin. *World Journal of Surgery*. 2004;
41 28(8):807-811
- 42 174. Lahnborg G. Effect of low-dose heparin and dihydroergotamine on frequency of
43 postoperative deep-vein thrombosis in patients undergoing post-traumatic hip surgery. *Acta
44 Chirurgica Scandinavica*. 1980; 146(5):319-322

- 1 175. Lahnborg G, Bergström K. Clinical and haemostatic parameters related to thromboembolism
2 and low-dose heparin prophylaxis in major surgery. *Acta Chirurgica Scandinavica*. 1975;
3 141(7):590-595
- 4 176. Lahnborg G, Bergstrom K, Friman L, Lagergren H. Effect of low dose heparin on incidence of
5 postoperative pulmonary embolism detected by photoscanning. *Lancet*. 1974; 1(7853):329-
6 331
- 7 177. Lahnborg G, Lagergren H, Hedenstierna G. Effect of low-dose heparin prophylaxis on arterial
8 oxygen tension after high laparotomy. *Lancet*. 1976; 1(7950):54-56
- 9 178. Lapidus LJ. Prolonged thromboprophylaxis with dalteparin after surgical treatment of achilles
10 tendon rupture: A randomized, placebo-controlled study. *Journal of Orthopaedic Trauma*.
11 2007; 21(1):52-57
- 12 179. Lapidus LJ. Prolonged thromboprophylaxis with Dalteparin during immobilization after ankle
13 fracture surgery: A randomized placebo-controlled, double-blind study. *Acta Orthopaedica*.
14 2007; 78(4):528-535
- 15 180. Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ et al. Rivaroxaban
16 versus enoxaparin for thromboprophylaxis after total knee arthroplasty. *New England*
17 *Journal of Medicine*. 2008; 358(26):2776-2786
- 18 181. Lassen MR, Bauer KA, Eriksson BI, Turpie AGG. Postoperative fondaparinux versus
19 preoperative enoxaparin for prevention of venous thromboembolism in elective hip-
20 replacement surgery: a randomised double-blind comparison. *Lancet*. 2002; 359(9319):1715-
21 1720
- 22 182. Lassen MR, Borris LC, Anderson BS, Jensen HP, Skejød Bro HP, Andersen G et al. Efficacy and
23 safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin)
24 after total hip arthroplasty--the Danish Prolonged Prophylaxis (DaPP) Study. *Thrombosis*
25 *Research*. 1998; 89(6):281-287
- 26 183. Lassen MR, Borris LC, Christiansen HM, Boll KL, Eiskjaer SP, Nielsen BW et al. Prevention of
27 thromboembolism in 190 hip arthroplasties. Comparison of LMW heparin and placebo. *Acta*
28 *Orthopaedica Scandinavica*. 1991; 62(1):33-38
- 29 184. Lassen MR, Borris LC, Christiansen HM, Møller-Larsen F, Knudsen VE, Boris P et al.
30 Heparin/dihydroergotamine for venous thrombosis prophylaxis: comparison of low-dose
31 heparin and low molecular weight heparin in hip surgery. *British Journal of Surgery*. 1988;
32 75(7):686-689
- 33 185. Lassen MR, Borris LC, Nakov RL. Use of the low-molecular-weight heparin reviparin to
34 prevent deep-vein thrombosis after leg injury requiring immobilization. *New England Journal*
35 *of Medicine*. 2002; 347(10):726-730
- 36 186. Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D. The efficacy and safety of
37 apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total
38 knee replacement. *Journal of Thrombosis and Haemostasis*. 2007; 5(12):2368-2375
- 39 187. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM et al. Apixaban versus
40 enoxaparin for thromboprophylaxis after hip replacement. *New England Journal of Medicine*.
41 2010; 363(26):2487-2498
- 42 188. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P et al. Apixaban versus
43 enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised
44 double-blind trial. *Lancet*. 2010; 375(9717):807-815

- 1 189. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for
2 thromboprophylaxis after knee replacement. *New England Journal of Medicine*. 2009;
3 361(6):594-604
- 4 190. Lastória S, Rollo HA, Yoshida WB, Giannini M, Moura R, Maffei F-HA. Prophylaxis of deep-vein
5 thrombosis after lower extremity amputation. Comparison of low molecular weight heparin
6 with unfractionated heparin. *Acta Cirurgica Brasileira*. 2006; 21(3):184-186
- 7 191. Leclerc JR, Geerts WH, Desjardins L, Jobin F, Laroche F, Delorme F et al. Prevention of deep
8 vein thrombosis after major knee surgery -- a randomized, double-blind trial comparing a low
9 molecular weight heparin fragment (enoxaparin) to placebo. *Thrombosis and Haemostasis*.
10 1992; 67(4):417-423
- 11 192. Leclerc JR, Geerts WH, Desjardins L, Laflamme GH, L'Espérance B, Demers C et al. Prevention
12 of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial
13 comparing enoxaparin with warfarin. *Annals of Internal Medicine*. 1996; 124(7):619-626
- 14 193. Leizorovicz A, Picolet H, Peyrieux JC, Boissel JP. Prevention of perioperative deep vein
15 thrombosis in general surgery: a multicentre double blind study comparing two doses of
16 Logiparin and standard heparin. H.B.P.M. Research Group. *British Journal of Surgery*. 1991;
17 78(4):412-416
- 18 194. Levine MN, Gent M, Hirsh J, Weitz J, Turpie AG, Powers P et al. Ardeparin (low-molecular-
19 weight heparin) vs graduated compression stockings for the prevention of venous
20 thromboembolism. A randomized trial in patients undergoing knee surgery. *Archives of
21 Internal Medicine*. 1996; 156(8):851-856
- 22 195. Levine MN, Hirsh J, Gent M, Turpie AG, Leclerc J, Powers PJ et al. Prevention of deep vein
23 thrombosis after elective hip surgery. A randomized trial comparing low molecular weight
24 heparin with standard unfractionated heparin. *Annals of Internal Medicine*. 1991;
25 114(7):545-551
- 26 196. Lowe LW. Venous thrombosis and embolism. *Journal of Bone and Joint Surgery (British
27 Volume)*. 1981; 63(2):155-167
- 28 197. Lundkvist J, Bergqvist D, Jonsson B. Cost-effectiveness of fondaparinux vs. enoxaparin as
29 venous thromboembolism prophylaxis in Sweden. *European Journal of Health Economics*.
30 2003; 4(4):254-262
- 31 198. Lynd LD, Goeree R, Crowther MA, O'Brien BJ. A probabilistic cost-effectiveness analysis of
32 enoxaparin versus unfractionated heparin for the prophylaxis of deep-vein thrombosis
33 following major trauma. *Canadian Journal of Clinical Pharmacology*. 2007; 14(2):e215-e226
- 34 199. Macdonald RL, Amidei C, Baron J, Weir B, Brown F, Erickson RK et al. Randomized, pilot study
35 of intermittent pneumatic compression devices plus dalteparin versus intermittent
36 pneumatic compression devices plus heparin for prevention of venous thromboembolism in
37 patients undergoing craniotomy. *Surgical Neurology*. 2003; 59(5):363-372
- 38 200. Manganelli D, Pazzagli M, Mazzantini D, Punzi G, Manca M, Vignali C et al. Prolonged
39 prophylaxis with unfractionated heparin is effective to reduce delayed deep vein thrombosis in
40 total hip replacement. *Respiration*. 1998; 65(5):369-374
- 41 201. Mannucci PM, Citterio LE, Panajotopoulos N. Low-dose heparin and deep-vein thrombosis
42 after total hip replacement. *Thrombosis and Haemostasis*. 1976; 36(1):157-164

- 1 202. Marassi A, Balzano G, Mari G, D'Angelo SV, Della Valle P, Di Carlo V et al. Prevention of
2 postoperative deep vein thrombosis in cancer patients. A randomized trial with low
3 molecular weight heparin (CY 216). *International Surgery*. 1993; 78(2):166-170
- 4 203. Marlovits S, Striessnig G, Schuster R, Stocker R, Luxl M, Trattnig S et al. Extended-duration
5 thromboprophylaxis with enoxaparin after arthroscopic surgery of the anterior cruciate
6 ligament: a prospective, randomized, placebo-controlled study. *Arthroscopy*. 2007;
7 23(7):696-702
- 8 204. Maxwell GL, Synan I, Dodge R, Carroll B, Clarke-Pearson DL. Pneumatic compression versus
9 low molecular weight heparin in gynecologic oncology surgery: a randomized trial. *Obstetrics
10 and Gynecology*. 2001; 98(6):989-995
- 11 205. McBride JA, Turpie AG, Kraus V, Hilz C. Failure of aspirin and dipyridamole to influence the
12 incidence of leg scan detected venous thrombosis after elective hip surgery. *Thrombosis et
13 Diathesis Haemorrhagica*. 1975; 34(2):564
- 14 206. McCullagh L, Tilson L, Walsh C, Barry M. A cost-effectiveness model comparing rivaroxaban
15 and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and
16 total knee replacement in the Irish healthcare setting. *Pharmacoeconomics*. 2009;
17 27(10):829-846
- 18 207. McCullagh L, Walsh C, Barry M. Value-of-information analysis to reduce decision uncertainty
19 associated with the choice of thromboprophylaxis after total hip replacement in the Irish
20 healthcare setting. *Pharmacoeconomics*. 2012; 30(10):941-959
- 21 208. McDonald H, Diamantopoulos A, Wells P, Lees M, Folkerts K, Forster F et al. Cost-
22 effectiveness of rivaroxaban in the prevention of venous thromboembolism: a Canadian
23 analysis using the Ontario Ministry of Health perspective. *Journal of Medical Economics*.
24 2012; 15(5):817-828
- 25 209. McKenna R, Galante J, Bachmann F, Wallace DL, Kaushal PS, Meredith P. Prevention of
26 venous thromboembolism after total knee replacement by high-dose aspirin or intermittent
27 calf and thigh compression. *British Medical Journal*. 1980; 280(6213):514-517
- 28 210. McLeod RS, Geerts WH, Sniderman KW, Greenwood C, Gregoire RC, Taylor BM et al.
29 Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in
30 patients undergoing colorectal surgery: results of the canadian colorectal DVT prophylaxis
31 trial: a randomized, double-blind trial. *Annals of Surgery*. 2001; 233(3):438-444
- 32 211. Melon E, Keravel Y, Gaston A, Huet Y, Combes S, Group N. Deep venous thrombosis
33 prophylaxis by low molecular weight heparin in neurosurgical patients. *Anesthesiology*. 1991;
34 75:A214
- 35 212. Merli GJ, Herbison GJ, Ditunno JF. Deep vein thrombosis : prophylaxis in acute spinal cord
36 injured patients. *Archives of Physical Medicine and Rehabilitation*. 1988; 69:661-664
- 37 213. Michota F. Venous thromboembolism: who is at risk and who is being treated. *Journal of
38 Clinical Prevention*. 2004; 2(1):5-10
- 39 214. Migliaccio-Walle K, Rublee D, Simon TA. Anticoagulation prophylaxis in orthopedic surgery:
40 an efficiency frontier approach. *Postgraduate Medicine*. 2012; 124(1):41-49
- 41 215. Mingus ML. Recovery advantages of regional anesthesia compared with general anesthesia:
42 adult patients. *JClinAnesth*. 1995; 7(7):628-633

- 1 216. Mirdamadi A, Dashtkar S, Kaji M, Pazhang F, Haghpanah B, Gharipour M. Dabigatran versus
2 Enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: A
3 randomized clinical trial. *ARYA Atherosclerosis*. 2014; 10(6):292-297
- 4 217. Mismetti P, Laporte S, Darmon JY, Buchmuller A, Decousus H. Meta-analysis of low molecular
5 weight heparin in the prevention of venous thromboembolism in general surgery. *British*
6 *Journal of Surgery*. 2001; 88(7):913-930
- 7 218. Monreal M, Lafoz E, Navarro A, Granero X, Caja V, Caceres E et al. A prospective double-blind
8 trial of a low molecular weight heparin once daily compared with conventional low-dose
9 heparin three times daily to prevent pulmonary embolism and venous thrombosis in patients
10 with hip fracture. *Journal of Trauma*. 1989; 29(6):873-875
- 11 219. Morimoto A, Ueda Y, Yokoi T, Tokizawa Y, Yoshino K, Fujita M et al. Perioperative venous
12 thromboembolism in patients with gynecological malignancies: a lesson from four years of
13 recent clinical experience. *Anticancer Research*. 2014; 34(7):3589-3595
- 14 220. Morris GK, Mitchell JR. Warfarin sodium in prevention of deep venous thrombosis and
15 pulmonary embolism in patients with fractured neck of femur. *Lancet*. 1976; 2(7991):869-
16 872
- 17 221. Moskovitz PA, Ellenberg SS, Feffer HL, Kenmore P, I, Neviasser RJ, Rubin BE et al. Low-dose
18 heparin for prevention of venous thromboembolism in total hip arthroplasty and surgical
19 repair of hip fractures. *Journal of Bone and Joint Surgery*. 1978; 60(8):1065-1070
- 20 222. Myles PS, Smith JA, Forbes A, Silbert B, Jayarajah M, Painter T et al. Stopping vs. Continuing
21 Aspirin before Coronary Artery Surgery. *New England Journal of Medicine*. 2016; 374(8):728-
22 737
- 23 223. Nagata C, Tanabe H, Takakura S, Narui C, Saito M, Yanaihara N et al. Randomized controlled
24 trial of enoxaparin versus intermittent pneumatic compression for venous thromboembolism
25 prevention in Japanese surgical patients with gynecologic malignancy. *Journal of Obstetrics*
26 *and Gynaecology Research*. 2015; 41(9):1440-1448
- 27 224. National Clinical Guideline Centre. Venous thromboembolism: reducing the risk of venous
28 thromboembolism (deep vein thrombosis and pulmonary embolism) inpatients admitted to
29 hospital. NICE clinical guideline 92. London. National Clinical Guideline Centre, 2010.
30 Available from: <http://www.nice.org.uk/CG92>
- 31 225. National Collaborating Centre for Cancer. Metastatic spinal cord compression: diagnosis and
32 management of patients at risk of or with metastatic spinal cord compression. NICE clinical
33 guideline 75. Cardiff. National Collaborating Centre for Cancer at Velindre NHS Trust, 2008.
34 Available from: <http://guidance.nice.org.uk/CG75>
- 35 226. National Collaborating Centre for Acute Care. Reducing the risk of venous thromboembolism
36 (deep vein thrombosis and pulmonary embolism) in inpatients undergoing surgery. NICE
37 clinical guideline CG46. London. National Institute for Health and Clinical Excellence, 2007.
38 Available from: <http://guidance.nice.org.uk/CG46>
- 39 227. National Hip Fracture Database (NHFD). National Hip Fracture Database (NHFD) annual
40 report 2016. Royal college of physicians, 2016. Available from:
41 <http://web1.crownaudit.org/Report2016/NHFD2016Report.pdf>
- 42 228. National Institute for Health and Clinical Excellence. Dabigatran etexilate for the prevention
43 of venous thromboembolism after hip or knee replacement surgery in adults. NICE
44 technology appraisal guidance 157. London. National Institute for Health and Clinical
45 Excellence, 2008. Available from: <http://guidance.nice.org.uk/TA157>

- 1 229. National Institute for Health and Clinical Excellence. Rivaroxaban for the prevention of
2 venous thromboembolism. NICE technology appraisal guidance 170. London. National
3 Institute for Health and Clinical Excellence, 2009. Available from:
4 <http://guidance.nice.org.uk/TA170>
- 5 230. National Institute for Health and Clinical Excellence. Apixaban for the prevention of venous
6 thromboembolism after total hip or knee replacement in adults. NICE technology appraisal
7 guidance 245. London. National Institute for Health and Clinical Excellence, 2012. Available
8 from: <http://guidance.nice.org.uk/TA245>
- 9 231. National Institute for Health and Clinical Excellence. The guidelines manual. London. National
10 Institute for Health and Clinical Excellence. 2012. Available from:
11 <http://www.nice.org.uk/article/pmg6/>
- 12 232. Nicolaides AN, Miles C, Hoare M, Jury P, Helmis E, Venniker R. Intermittent sequential
13 pneumatic compression of the legs and thromboembolism-deterrent stockings in the
14 prevention of postoperative deep venous thrombosis. *Surgery*. 1983; 94(1):21-25
- 15 233. Norgren L, S. T-L, Magyar G, Lindstrand A, Albrechtsson U. Prevention of deep vein
16 thrombosis in knee arthroplasty. Preliminary results from a randomized controlled study of
17 low molecular weight heparin vs foot pump compression. *International Angiology*. 1998;
18 17(2):93-96
- 19 234. Nurmohamed MT, van Riel AM, Henkens CM, Koopman MM, Que GT, d'Azemar P et al. Low
20 molecular weight heparin and compression stockings in the prevention of venous
21 thromboembolism in neurosurgery. *Thrombosis and Haemostasis*. 1996; 75(2):233-238
- 22 235. Nurmohamed MT, van Riel AM, Henkens CMA, Koopman MMW, Que GTH, d'Azemar P et al.
23 Low molecular weight heparin (LMWH) and compression stockings in the prevention of
24 venous thromboembolism (VTE) in neurosurgery. *Thrombosis and Haemostasis*. 1995;
25 73(6):973
- 26 236. Ockelford PA, Patterson J, Johns AS. A double-blind randomized placebo controlled trial of
27 thromboprophylaxis in major elective general surgery using once daily injections of a low
28 molecular weight heparin fragment (Fragmin). *Thrombosis and Haemostasis*. 1989;
29 62(4):1046-1049
- 30 237. Office for National Statistics. 'Average' Briton highlighted on UN World Statistics Day. Office
31 for National Statistics. Available from:
32 <https://www.google.co.uk/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0ahUKEwih1>
33 -
34 [mzv7UAhVBDMAKHcuABxQQFggpMAA&url=https%3A%2F%2Fwww.ons.gov.uk%2Fons%2F](https://www.ons.gov.uk/about-ons/get-involved/events/events/un-world-statistics-day-average-briton-highlighted-on-un-world-statistics-day.pdf)
35 [about-ons%2Fget-involved%2Fevents%2Fevents%2Fun-world-statistics-day%2F-average--](https://www.ons.gov.uk/about-ons/get-involved/events/events/un-world-statistics-day-average-briton-highlighted-on-un-world-statistics-day.pdf)
36 [briton-highlighted-on-un-world-statistics-](https://www.ons.gov.uk/about-ons/get-involved/events/events/un-world-statistics-day-average-briton-highlighted-on-un-world-statistics-day.pdf)
37 [day.pdf&usq=AFQjCNGiyo3NVKsSFZ8tV6sYiYtVWQPd2w](https://www.ons.gov.uk/about-ons/get-involved/events/events/un-world-statistics-day-average-briton-highlighted-on-un-world-statistics-day.pdf)
- 38 238. Onarheim H, Lund T, Heimdal A, Arnesjo B. A low molecular weight heparin (KABI 2165) for
39 prophylaxis of postoperative deep venous thrombosis. *Acta Chirurgica Scandinavica*. 1986;
40 152:593-596
- 41 239. Osman Y, Kamal M, Soliman S, Sheashaa H, Shokeir A, Shehab el-Dein AB. Necessity of
42 routine postoperative heparinization in non-risky live-donor renal transplantation: results of
43 a prospective randomized trial. *Urology*. 2007; 69(4):647-651

- 1 240. Paiement GD, Wessinger SJ, Walter AC, Harris WH. Low dose warfarin versus external
2 pneumatic compression against venous thromboembolism following total hip replacement.
3 *Journal of Arthroplasty*. 1987; 2(1):23-26
- 4 241. Perry JR, Julian JA, Laperriere NJ, Geerts W, Agnelli G, Rogers LR et al. PRODIGE: a
5 randomized placebo-controlled trial of dalteparin low-molecular-weight heparin
6 thromboprophylaxis in patients with newly diagnosed malignant glioma. *Journal of*
7 *Thrombosis and Haemostasis*. 2010; 8(9):1959-1965
- 8 242. Pitto RP, Hamer H, Heiss-Dunlop W, Kuehle J. Mechanical prophylaxis of deep-vein
9 thrombosis after total hip replacement a randomised clinical trial. *Journal of Bone and Joint*
10 *Surgery (British Volume)*. 2004; 86(5):639-642
- 11 243. Planes A, Vochelle N, Darmon JY, Fagola M, Bellaud M, Compan D et al. Efficacy and safety of
12 postdischarge administration of enoxaparin in the prevention of deep venous thrombosis
13 after total hip replacement. A prospective randomised double-blind placebo-controlled trial.
14 *Drugs*. 1996; 52(Suppl 7):47-54
- 15 244. Planès A, Vochelle N, Fagola M, Bellaud M, Feret J, Salzard C et al. Once-daily dosing of
16 enoxaparin (a low molecular weight heparin) in prevention of deep vein thrombosis after
17 total hip replacement. *Acta Chirurgica Scandinavica Supplementum*. 1990; 556:108-115
- 18 245. Porteous MJ, Nicholson EA, Morris LT, James R, Negus D. Thigh length versus knee length
19 stockings in the prevention of deep vein thrombosis. *British Journal of Surgery*. 1989;
20 76(3):296-297
- 21 246. Postma MJ, Kappelhoff BS, Hulst M, Brouwers JR. Economic evaluation of dabigatran
22 etexilate for the primary prevention of venous thromboembolic events following major
23 orthopedic surgery in the Netherlands. *Journal of Medical Economics*. 2012; 15(5):878-886
- 24 247. Prandoni P, Bruchi O, Sabbion P, Tanduo C, Scudeller A, Sardella C et al. Prolonged
25 thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective
26 controlled randomized study. *Archives of Internal Medicine*. 2002; 162(17):1966-1971
- 27 248. Pulmonary Embolism Prevention (PEP) Trial Collaborative Group. Prevention of pulmonary
28 embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention
29 (PEP) trial. *Lancet*. 2000; 355(9212):1295-1302
- 30 249. Ramos R, Salem B, I, De Pawlikowski MP, Coordes C, Eisenberg S, Leidenfrost R. The efficacy
31 of pneumatic compression stockings in the prevention of pulmonary embolism after cardiac
32 surgery. *Chest*. 1996; 109(1):82-85
- 33 250. Rasmussen A, Hansen PT, Lindholt J, Poulsen TD, Toftdahl DB, Gram J et al. Venous
34 thrombosis after abdominal surgery. A comparison between subcutaneous heparin and
35 antithrombotic stockings, or both. *Journal of Medicine*. 1988; 19(3-4):193-201
- 36 251. Rasmussen MS, Jorgensen LN, Wille-Jorgensen P, Nielsen JD, Horn A, Mohn AC et al.
37 Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in
38 patients undergoing major abdominal surgery: a multicenter randomized open-label study.
39 *Journal of Thrombosis and Haemostasis*. 2006; 4(11):2384-2390
- 40 252. RE-MOBILIZE Writing Committee, Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman
41 RJ et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen
42 for prevention of venous thromboembolism after knee arthroplasty surgery. *Journal of*
43 *Arthroplasty*. 2009; 24(1):1-9

- 1 253. Reeves P, Cooke J, Lloyd A, Hutchings A. An economic evaluation of the costs and benefits of
2 heparin rationalisation in a hospital pharmacy. *Pharmacy World and Science*. 2004;
3 26(3):160-168
- 4 254. Revankar N, Patterson J, Kadambi A, Raymond V, El-Hadi W. A Canadian study of the cost-
5 effectiveness of apixaban compared with enoxaparin for post-surgical venous
6 thromboembolism prevention. *Postgraduate Medicine*. 2013; 125(4):141-153
- 7 255. Riemsma R, Joore MA, Armstrong N, Misso K, Noake C. Apixaban for the prevention of
8 venous thromboembolism in people undergoing elective knee and hip replacement surgery.
9 Southampton. NETSCC, 2011. Available from:
10 http://www.nets.nihr.ac.uk/__data/assets/pdf_file/0003/96501/STARReport-09-124-01.pdf
- 11 256. Roderick P, Ferris G, Wilson K, Halls H, Jackson D, Collins R et al. Towards evidence-based
12 guidelines for the prevention of venous thromboembolism: systematic reviews of mechanical
13 methods, oral anticoagulation, dextran and regional anaesthesia as thromboprophylaxis.
14 *Health Technology Assessment*. 2005; 9(49)
- 15 257. Rokito SE, Schwartz MC, Neuwirth MG. Deep vein thrombosis after major reconstructive
16 spinal surgery. *Spine*. 1996; 21(7):853-858
- 17 258. Ryan MG, Westrich GH, Potter HG, Sharrock N, Maun LM, Macaulay W et al. Effect of
18 mechanical compression on the prevalence of proximal deep venous thrombosis as assessed
19 by magnetic resonance venography. *Journal of Bone and Joint Surgery*. 2002; 84-A(11):1998-
20 2004
- 21 259. Rytberg L, Diamantopoulos A, Forster F, Lees M, Fraschke A, Bjorholt I. Cost-effectiveness of
22 rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or
23 knee surgery in Sweden. *Expert Review of Pharmacoeconomics and Outcomes Research*.
24 2011; 11(5):601-615
- 25 260. Sakon M, Kobayashi T, Shimazui T. Efficacy and safety of enoxaparin in Japanese patients
26 undergoing curative abdominal or pelvic cancer surgery: results from a multicenter,
27 randomized, open-label study. *Thrombosis Research*. 2010; 125(3):e65-e70
- 28 261. Salazar CA, Malaga G, Malasquez G. Direct thrombin inhibitors versus vitamin K antagonists
29 or low molecular weight heparins for prevention of venous thromboembolism following total
30 hip or knee replacement. *Cochrane Database of Systematic Reviews* 2010, Issue 4. Art. No.:
31 CD005981. DOI: 10.1002/14651858.CD005981.pub2.
- 32 262. Samama CM, Clergue F, Barre J, Montefiore A, Ill P, Samii K. Low molecular weight heparin
33 associated with spinal anaesthesia and gradual compression stockings in total hip
34 replacement surgery. Arar study group. *British Journal of Anaesthesia*. 1997; 78(6):660-665
- 35 263. Samama CM, Lecoules N, Kierzek G, Claessens YE, Riou B, Rosencher N et al. Comparison of
36 fondaparinux with low molecular weight heparin for venous thromboembolism prevention in
37 patients requiring rigid or semi-rigid immobilization for isolated non-surgical below-knee
38 injury. *Journal of Thrombosis and Haemostasis*. 2013; 11(10):1833-1843
- 39 264. Samama CM, Vray M, Barré J, Fiessinger JN, Rosencher N, Lecompte T et al. Extended venous
40 thromboembolism prophylaxis after total hip replacement: a comparison of low-molecular-
41 weight heparin with oral anticoagulant. *Archives of Internal Medicine*. 2002; 162(19):2191-
42 2196
- 43 265. San Norberto Garcia EM, Merino B, Taylor JH, Vizcaino I, Vaquero C. Low-molecular-weight
44 heparin for prevention of venous thromboembolism after varicose vein surgery in moderate-
45 risk patients: a randomized, controlled trial. *Annals of Vascular Surgery*. 2013; 27(7):940-946

- 1 266. Santori FS, Vitullo A, Stopponi M, Santori N, Ghera S. Prophylaxis against deep-vein
2 thrombosis in total hip replacement. Comparison of heparin and foot impulse pump. *Journal of Bone and Joint Surgery (British Volume)*. 1994; 76(4):579-583
3
- 4 267. Sautter RD, Koch EL, Myers WO, Ray JR, III, Mazza JJ, Larson DE et al. Aspirin-sulfinpyrazone
5 in prophylaxis of deep venous thrombosis in total hip replacement. *JAMA*. 1983;
6 250(19):2649-2654
- 7 268. Scurr JH, Robbe IJ, Ellis H, Goldsmith HS. Simple mechanical method for decreasing the
8 incidence of thromboembolism. *American Journal of Surgery*. 1981; 141(5):582-585
- 9 269. Selby R, Geerts WH, Kreder HJ, Crowther MA, Kaus L, Sealey F et al. A double-blind,
10 randomized controlled trial of the prevention of clinically important venous
11 thromboembolism after isolated lower leg fractures. *Journal of Orthopaedic Trauma*. 2015;
12 29(5):224-230
- 13 270. Siragusa S, Vicentini L, Carbone S, Barone M, Beltrametti C, Piovella F. Intermittent
14 pneumatic leg compression (IPLC) and unfractionated heparin (UFH) in the prevention of
15 post-operative deep vein thrombosis in hip surgery. *Blood*. 1994; 84(10 Suppl 1):70a
- 16 271. Skillman JJ, Collins RE, Coe NP, Goldstein BS, Shapiro RM, Zervas NT et al. Prevention of deep
17 vein thrombosis in neurosurgical patients: a controlled, randomized trial of external
18 pneumatic compression boots. *Surgery*. 1978; 83(3):354-358
- 19 272. Soderdahl DW, Henderson SR, Hansberry KL. A comparison of intermittent pneumatic
20 compression of the calf and whole leg in preventing deep venous thrombosis in urological
21 surgery. *Journal of Urology*. 1997; 157(5):1774-1776
- 22 273. Song KY, Yoo HM, Kim EY, Kim JI, Yim HW, Jeon HM et al. Optimal prophylactic method of
23 venous thromboembolism for gastrectomy in Korean patients: an interim analysis of
24 prospective randomized trial. *Annals of Surgical Oncology*. 2014; 21(13):4232-4238
- 25 274. Soreff J, Johnsson H, Diener L, Goransson L. Acetylsalicylic acid in a trial to diminish
26 thromboembolic complications after elective hip surgery. *Acta Orthopaedica Scandinavica*.
27 1975; 46(2):246-255
- 28 275. Spebar MJ, Collins GJ, Jr., Rich NM, Kang IY, Clagett GP, Salander JM. Perioperative heparin
29 prophylaxis of deep venous thrombosis in patients with peripheral vascular disease.
30 *American Journal of Surgery*. 1981; 142(6):649-650
- 31 276. Spinal Cord Injury Thromboprophylaxis Investigators. Prevention of venous
32 thromboembolism in the acute treatment phase after spinal cord injury : a randomized,
33 multicenter trial comparing low-dose heparin plus intermittent pneumatic compression with
34 enoxaparin. *Journal of Trauma*. 2003; 54(6):1116-1126
- 35 277. Stannard JP, Harris RM, Bucknell AL, Cossi A, Ward J, Arrington ED. Prophylaxis of deep
36 venous thrombosis after total hip arthroplasty by using intermittent compression of the
37 plantar venous plexus. *American Journal of Orthopedics*. 1996; 25(2):127-134
- 38 278. Stannard JP, Lopez BR, Volgas DA, Anderson ER, Busbee M, Karr DK et al. Prophylaxis against
39 deep-vein thrombosis following trauma: a prospective, randomized comparison of
40 mechanical and pharmacologic prophylaxis. *Journal of Bone and Joint Surgery (American
41 Volume)*. 2006; 88(2):261-266
- 42 279. Stannard JP, Riley RS, McClenney MD, Lopez-Ben RR, Volgas DA, Alonso JE. Mechanical
43 prophylaxis against deep-vein thrombosis after pelvic and acetabular fractures. *Journal of
44 Bone and Joint Surgery*. 2001; 83-A(7):1047-1051

- 1 280. Steele KE, Canner J, Prokopowicz G, Verde F, Beselman A, Wyse R et al. The EFFORT trial:
2 Preoperative enoxaparin versus postoperative fondaparinux for thromboprophylaxis in
3 bariatric surgical patients: a randomized double-blind pilot trial. *Surgery for Obesity and
4 Related Diseases*. 2015; 11(3):672-683
- 5 281. Sterne J, Boudalia P, Bryden P, Davies P, Lopez-Lopez A, Okoli GN. Oral anticoagulants for
6 primary prevention, treatment and secondary prevention of venous thromboembolic
7 disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-
8 analysis and cost-effectiveness analysis [unpublished]. 2016.
- 9 282. Stevenson M, Scope A, Holmes M, Rees A, Kaltenthaler E. Rivaroxaban for the prevention of
10 venous thromboembolism: a single technology appraisal. *Health Technology Assessment*.
11 2009; 13(Suppl 3):43-48
- 12 283. Stone MH, Limb D, Campbell P, Stead D, Culleton G. A comparison of intermittent calf
13 compression and enoxaparin for thromboprophylaxis in total hip replacement. A pilot study.
14 *International Orthopaedics*. 1996; 20(6):367-369
- 15 284. Strand L, Bank-Mikkelsen OK, Lindewald H. Small heparin doses as prophylaxis against deep-
16 vein thrombosis in major surgery. *Acta Chirurgica Scandinavica*. 1975; 141(7):624-627
- 17 285. Svend-Hansen H, Bremerskov V, Gotrik J, Ostri P. Low-dose heparin in proximal femoral
18 fractures. Failure to prevent deep-vein thrombosis. *Acta Orthopaedica Scandinavica*. 1981;
19 52(1):77-80
- 20 286. Taberner DA, Poller L, Burslem RW, Jones JB. Oral anticoagulants controlled by the British
21 comparative thromboplastin versus low-dose heparin in prophylaxis of deep vein
22 thrombosis. *British Medical Journal*. 1978; 1(6108):272-274
- 23 287. Tang Y, Wang K, Shi Z, Yang P, Dang X. A RCT study of Rivaroxaban, low-molecular-weight
24 heparin, and sequential medication regimens for the prevention of venous thrombosis after
25 internal fixation of hip fracture. *Biomedicine and Pharmacotherapy*. 2017; 92:982-988
- 26 288. The German Hip Arthroplasty Trial (GHAT) Group. Prevention of deep vein thrombosis with
27 low molecular-weight heparin in patients undergoing total hip replacement. A randomized
28 trial. *Archives of Orthopaedic and Trauma Surgery*. 1992; 111(2):110-120
- 29 289. Tørholm C, Broeng L, Jørgensen PS, Bjerregaard P, Josephsen L, Jørgensen PK et al.
30 Thromboprophylaxis by low-molecular-weight heparin in elective hip surgery. A placebo
31 controlled study. *Journal of Bone and Joint Surgery (British Volume)*. 1991; 73(3):434-438
- 32 290. Törngren S. Prophylaxis of postoperative deep venous thrombosis. Studies on low-dose
33 heparin, blood coagulation, infection as a risk factor and the half-life of fibrinogen in patients
34 after gastrointestinal surgery. *Acta Chirurgica Scandinavica Supplementum*. 1979; 495:1-69
- 35 291. Törngren S, Forsberg K. Concentrated or diluted heparin prophylaxis of postoperative deep
36 venous thrombosis. *Acta Chirurgica Scandinavica*. 1978; 144(5):283-288
- 37 292. Tsapogas MJ, Goussous H, Peabody RA, Karmody AM, Eckert C. Postoperative venous
38 thrombosis and the effectiveness of prophylactic measures. *Archives of Surgery*. 1971;
39 103(5):561-567
- 40 293. Turner GM, Cole SE, Brooks JH. The efficacy of graduated compression stockings in the
41 prevention of deep vein thrombosis after major gynaecological surgery. *British Journal of
42 Obstetrics and Gynaecology*. 1984; 91(6):588-591

- 1 294. Turpie AG, Bauer KA, Caprini JA, Comp PC, Gent M, Muntz JE et al. Fondaparinux combined
2 with intermittent pneumatic compression vs. intermittent pneumatic compression alone for
3 prevention of venous thromboembolism after abdominal surgery: a randomized, double-
4 blind comparison. *Journal of Thrombosis and Haemostasis*. 2007; 5(9):1854-1861
- 5 295. Turpie AG, Delmore T, Hirsh J, Hull R, Genton E, Hiscoe C et al. Prevention of venous
6 thrombosis by intermittent sequential calf compression in patients with intracranial disease.
7 *Thrombosis Research*. 1979; 15(5-6):611-616
- 8 296. Turpie AG, Gallus A, Beattie WS, Hirsh J. Prevention of venous thrombosis in patients with
9 intracranial disease by intermittent pneumatic compression of the calf. *Neurology*. 1977;
10 27(5):435-438
- 11 297. Turpie AG, Hirsh J, Gent M, Julian D, Johnson J. Prevention of deep vein thrombosis in
12 potential neurosurgical patients. A randomized trial comparing graduated compression
13 stockings alone or graduated compression stockings plus intermittent pneumatic
14 compression with control. *Archives of Internal Medicine*. 1989; 149(3):679-681
- 15 298. Turpie AG, Levine MN, Hirsh J, Carter CJ, Jay RM, Powers PJ et al. A randomized controlled
16 trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in
17 patients undergoing elective hip surgery. *New England Journal of Medicine*. 1986;
18 315(15):925-929
- 19 299. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR. Postoperative fondaparinux versus
20 postoperative enoxaparin for prevention of venous thromboembolism after elective hip-
21 replacement surgery: a randomised double-blind trial. *Lancet*. 2002; 359(9319):1721-1726
- 22 300. Turpie AGG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM et al. Rivaroxaban versus
23 enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised
24 trial. *Lancet*. 2009; 373(9676):1673-1680
- 25 301. van Adrichem RA, Nemeth B, Algra A, le Cessie S, Rosendaal FR, Schipper IB et al.
26 Thromboprophylaxis after knee arthroscopy and lower-leg casting. *New England Journal of*
27 *Medicine*. 2017; 376(6):515-525
- 28 302. Van Vroonhoven TJMV, Van Zijl J, Muller H. Low dose subcutaneous heparin versus oral
29 anticoagulants in the prevention of postoperative deep venous thrombosis. A controlled
30 clinical trial. *Lancet*. 1974; 1(7854):375-378
- 31 303. Vandendris M, Kutnowski M, Futeral B, Gianakopoulos X, Kraytman M, Gregoir W. Prevention
32 of postoperative deep-vein thrombosis by low-dose heparin in open prostatectomy.
33 *Urological Research*. 1980; 8(4):219-221
- 34 304. Venous Thrombosis Clinical Study Group. Prevention of fatal postoperative pulmonary
35 embolism by low doses of heparin. An international multicentre trial. *Lancet*. 1975;
36 306(7924):45-51
- 37 305. Wade R, Sideris E, Paton F, Rice S, Palmer S, Fox D et al. Graduated compression stockings for
38 the prevention of deep-vein thrombosis in postoperative surgical patients: a systematic
39 review and economic model with a value of information analysis. *Health Technology*
40 *Assessment*. 2015; 19(98):1-220
- 41 306. Wang H, Sun Z, Jiang W, Zhang Y, Li X, Wu Y. Postoperative prophylaxis of venous
42 thromboembolism (VTE) in patients undergoing high ligation and stripping of the great
43 saphenous vein (GSV). *Vascular Medicine*. 2015; 20(2):117-121

- 1 307. Warwick D, Bannister GC, Glew D, Mitchelmore A, Thornton M, Peters TJ et al. Perioperative
2 low-molecular-weight heparin. Is it effective and safe. *Journal of Bone and Joint Surgery*
3 (British Volume). 1995; 77(5):715-719
- 4 308. Warwick D, Friedman RJ, Agnelli G, Gil-Garay E, Johnson K, Fitzgerald G et al. Insufficient
5 duration of venous thromboembolism prophylaxis after total hip or knee replacement when
6 compared with the time course of thromboembolic events: findings from the global
7 orthopaedic registry. *Journal of Bone and Joint Surgery British Volume*. 2007; 89B(6):799-807
- 8 309. Warwick D, Harrison J, Glew D, Mitchelmore A, Peters TJ, Donovan J. Comparison of the use
9 of a foot pump with the use of low-molecular-weight heparin for the prevention of deep-vein
10 thrombosis after total hip replacement. A prospective, randomized trial. *Journal of Bone and*
11 *Joint Surgery (American Volume)*. 1998; 80(8):1158-1166
- 12 310. Warwick D, Harrison J, Whitehouse S, Mitchelmore A, Thornton M. A randomised
13 comparison of a foot pump and low-molecular-weight heparin in the prevention of deep-vein
14 thrombosis after total knee replacement. *Journal of Bone and Joint Surgery (British Volume)*.
15 2002; 84(3):344-350
- 16 311. Watcha MF, White PF. Economics of anesthetic practice. *Anesthesiology*. 1997; 86(5):1170-
17 1196
- 18 312. Wautrecht JC, Macquaire V, Vandesteene A, Daoud N, Golzarian J, Capel P. Prevention of
19 deep vein thrombosis in neurosurgical patients with brain tumors: a controlled, randomized
20 study comparing graded compression stockings alone and intermittent sequential
21 compression. Correlation with pre- and postoperative fibrinolysis: preliminary results.
22 *International Angiology*. 1996; 15:5-10
- 23 313. Weitz J, Michelsen J, Gold K, Owen J, Carpenter D. Effects of intermittent pneumatic calf
24 compression on postoperative thrombin and plasmin activity. *Thrombosis and Haemostasis*.
25 1986; 56(2):198-201
- 26 314. Welin-Berger T, Bygdeman S, Mebius C. Deep vein thrombosis following hip surgery. Relation
27 to activated factor X inhibitor activity: effect of heparin and dextran. *Acta Orthopaedica*
28 *Scandinavica*. 1982; 53(6):937-945
- 29 315. Westrich GH, Bottner F, Windsor RE, Laskin RS, Haas SB, Sculco TP. VenaFlow plus Lovenox vs
30 VenaFlow plus aspirin for thromboembolic disease prophylaxis in total knee arthroplasty.
31 *Journal of Arthroplasty*. 2006; 21(6 Suppl 2):139-143
- 32 316. Wille-Jørgensen P, Hauch O, Dimo B, Christensen SW, Jensen R, Hansen B. Prophylaxis of
33 deep venous thrombosis after acute abdominal operation. *Surgery, Gynecology and*
34 *Obstetrics*. 1991; 172(1):44-48
- 35 317. Wille-Jørgensen P, Thorup J, Fischer A, Holst-Christensen J, Flamsholt R. Heparin with and
36 without graded compression stockings in the prevention of thromboembolic complications of
37 major abdominal surgery: a randomized trial. *British Journal of Surgery*. 1985; 72(7):579-581
- 38 318. Wilson NV, Das SK, Kakkar VV, Maurice HD, Smibert JG, Thomas EM et al. Thrombo-embolic
39 prophylaxis in total knee replacement. Evaluation of the A-V impulse system. *Journal of Bone*
40 *and Joint Surgery (British Volume)*. 1992; 74(1):50-52
- 41 319. Wirth T, Schneider B, Misselwitz F, Lomb M, Tüylü H, Egbring R et al. Prevention of venous
42 thromboembolism after knee arthroscopy with low-molecular weight heparin (reviparin):
43 Results of a randomized controlled trial. *Arthroscopy*. 2001; 17(4):393-399

- 1 320. Wolowacz SE, Roskell NS, Maciver F, Beard SM, Robinson PA, Plumb JM et al. Economic
2 evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total
3 knee and hip replacement surgery. *Clinical Therapeutics*. 2009; 31(1):194-212
- 4 321. Wolowacz SE, Roskell NS, Plumb JM, Clemens A, Noack H, Robinson PA et al. Economic
5 evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients
6 aged over 75 years or with moderate renal impairment undergoing total knee or hip
7 replacement. *Thrombosis and Haemostasis*. 2010; 103(2):360-371
- 8 322. Wood KB, Kos PB, Abnet JK, Ista C. Prevention of deep-vein thrombosis after major spinal
9 surgery: a comparison study of external devices. *Journal of Spinal Disorders*. 1997; 10(3):209-
10 214
- 11 323. Woolson ST, Watt JM. Intermittent pneumatic compression to prevent proximal deep venous
12 thrombosis during and after total hip replacement. A prospective, randomized study of
13 compression alone, compression and aspirin, and compression and low-dose warfarin.
14 *Journal of Bone and Joint Surgery (American Volume)*. 1991; 73(4):507-512
- 15 324. Xabregas A, Gray L, Ham JM. Heparin prophylaxis of deep vein thrombosis in patients with a
16 fractured neck of the femur. *Medical Journal of Australia*. 1978; 1(11):620-622
- 17 325. Ye K, Wang R, Qin J, Yang X, Yin M, Liu X et al. Post-operative benefit of compression therapy
18 after endovenous laser ablation for uncomplicated varicose veins: a randomised clinical trial.
19 *European Journal of Vascular and Endovascular Surgery*. 2016; 52(6):847-853
- 20 326. Yokote R, Matsubara M, Hirasawa N, Hagio S, Ishii K, Takata C. Is routine chemical
21 thromboprophylaxis after total hip replacement really necessary in a Japanese population?
22 *Journal of Bone and Joint Surgery (British Volume)*. 2011; 93(2):251-256
- 23 327. Yoo MC, Kang CS, Kim YH, Kim SK. A prospective randomized study on the use of nadroparin
24 calcium in the prophylaxis of thromboembolism in Korean patients undergoing elective total
25 hip replacement. *International Orthopaedics*. 1997; 21(6):399-402
- 26 328. Zanasi R, Fioretta G, Ciocia G, Bergonzi M. Prevention of deep venous thrombosis in
27 orthopedic surgery: effects of defibrotide. *Clinical Therapeutics*. 1988; 10(4):350-357
- 28 329. Zindel S, Stock S, Muller D, Stollenwerk B. A multi-perspective cost-effectiveness analysis
29 comparing rivaroxaban with enoxaparin sodium for thromboprophylaxis after total hip and
30 knee replacement in the German healthcare setting. *BMC Health Services Research*. 2012;
31 12:192(2)
- 32 330. Zou Y, Tian S, Wang Y, Sun K. Administering aspirin, rivaroxaban and low-molecular-weight
33 heparin to prevent deep venous thrombosis after total knee arthroplasty. *Blood Coagulation
34 and Fibrinolysis*. 2014; 25(7):660-664
- 35